"Authors","Author full names","Author(s) ID","Title","Year","Source title","Volume","Issue","Art. No.","Page start","Page end","Page count","Cited by","Link","Abstract","Author Keywords","Index Keywords","References","EID"
"Caminiti S.P.; Canessa N.; Cerami C.; Dodich A.; Crespi C.; Iannaccone S.; Marcone A.; Falini A.; Cappa S.F.","Caminiti, Silvia P. (56584243600); Canessa, Nicola (24334215800); Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Crespi, Chiara (57034303800); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132)","56584243600; 24334215800; 25722905400; 56001713900; 57034303800; 7005943171; 6701496511; 7003494994; 7005836132","Affective mentalizing and brain activity at rest in the behavioral variant of frontotemporal dementia","2015","NeuroImage: Clinical","9","","","484","497","13","42","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943779632&doi=10.1016%2fj.nicl.2015.08.012&partnerID=40&md5=e26222ff34d1b8a82e16e3b9de0998d7","Background bvFTD patients display an impairment in the attribution of cognitive and affective states to others, reflecting GM atrophy in brain regions associated with social cognition, such as amygdala, superior temporal cortex and posterior insula. Distinctive patterns of abnormal brain functioning at rest have been reported in bvFTD, but their relationship with defective attribution of affective states has not been investigated. Objective To investigate the relationship among resting-state brain activity, gray matter (GM) atrophy and the attribution of mental states in the behavioral variant of fronto-temporal degeneration (bvFTD). Methods We compared 12 bvFTD patients with 30 age- and education-matched healthy controls on a) performance in a task requiring the attribution of affective vs. cognitive mental states; b) metrics of resting-state activity in known functional networks; and c) the relationship between task-performances and resting-state metrics. In addition, we assessed a connection between abnormal resting-state metrics and GM atrophy. Results Compared with controls, bvFTD patients showed a reduction of intra-network coherent activity in several components, as well as decreased strength of activation in networks related to attentional processing. Anomalous resting-state activity involved networks which also displayed a significant reduction of GM density. In patients, compared with controls, higher affective mentalizing performance correlated with stronger functional connectivity between medial prefrontal sectors of the default-mode and attentional/performance monitoring networks, as well as with increased coherent activity in components of the executive, sensorimotor and fronto-limbic networks. Conclusions Some of the observed effects may reflect specific compensatory mechanisms for the atrophic changes involving regions in charge of affective mentalizing. The analysis of specific resting-state networks thus highlights an intermediate level of analysis between abnormal brain structure and impaired behavioral performance in bvFTD, reflecting both dysfunction and compensation mechanisms. © 2015 Published by Elsevier Inc.","","Aged; Aged, 80 and over; Brain; Brain Mapping; Case-Control Studies; Female; Frontotemporal Dementia; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Mood Disorders; Neuropsychological Tests; Oxygen; Principal Component Analysis; Rest; Theory of Mind; oxygen; adult; amygdaloid nucleus; anterior cingulate; Article; brain function; cerebellum; cingulate gyrus; clinical article; Clinical Dementia Rating; cognition; controlled study; default mode network; dorsomedial prefrontal cortex; executive function; female; frontal variant frontotemporal dementia; functional magnetic resonance imaging; gray matter; human; inferior parietal cortex; inferior temporal cortex; insula; male; mental health; middle aged; Mini Mental State Examination; neuroimaging; nuclear magnetic resonance scanner; perception; positron emission tomography; posterior cingulate; posterior insula; precuneus; priority journal; resting state network; salience network; sensorimotor function; task performance; temporal cortex; voxel based morphometry; aged; blood; brain; brain mapping; case control study; complication; frontotemporal dementia; image processing; metabolism; mood disorder; neuropsychological test; nuclear magnetic resonance imaging; pathology; physiology; principal component analysis; rest; theory of mind; vascularization; very elderly","Allen E., Erhardt E., Eichele T., Mayer A.R., Calhoun V., Comparison of pre-normalization methods on the accuracy and reliability of group ICA results, 16th Annual Meeting of the Organization of Human Brain Mapping, (2010); Allen E.A., Erhardt E.B., Damaraju E., Gruner W., Segall J.M., Silva R.F., Havlicek M., Rachakonda S., Fries J., Kalyanam R., Michael A.M., Caprihan A., Turner J.A., Eichele T., Adelsheim S., Bryan A.D., Bustillo J., Clark V.P., Feldstein Ewing S.W., Filbey F., Ford C.C., Hutchison K., Jung R.E., Kiehl K.A., Kodituwakku P., Komesu Y.M., Mayer A.R., Pearlson G.D., Phillips J.P., Sadek J.R., Stevens M., Teuscher U., Thoma R.J., Calhoun V.D., A baseline for the multivariate comparison of resting-state networks, Front. Syst. Neurosci., 5, FEBRUARY, (2011); Allison T., Social perception from visual cues: Role of the STS region, Trends Cogn. Sci. (Regul. Ed.), 4, 7, pp. 267-278, (2000); Adolphs R., The social brain: Neural basis of social knowledge, Annu. Rev. Psychol., 60, pp. 693-716, (2009); Agosta F., Sala S., Valsasina P., Meani A., Canu E., Magnani G., Cappa S.F., Scola E., Quatto P., Horsfield M.A., Falini A., Comi G., Filippi M., Brain network connectivity assessed using graph theory in frontotemporal dementia, Neurology, 81, 2, pp. 134-143, (2013); Ances B.M., Liang C.L., Leontiev O., Perthen J.E., Fleisher A.S., Lansing A.E., Buxton R.B., Effects of aging on cerebral blood flow, oxygen metabolism, and blood oxygenation level dependent responses to visual stimulation, Hum. Brain Mapp., 30, 4, pp. 1120-1132, (2009); Andrews-Hanna J.R., Reidler J.S., Sepulcre J., Poulin R., Buckner R.L., Functional-anatomic fractionation of the brain's default network, Neuron, 65, 4, pp. 550-562, (2010); Ashburner J., A fast diffeomorphic image registration algorithm, Neuroimage, 38, 1, pp. 95-113, (2007); Ashburner J., Friston K.J., Voxel-based morphometry - The methods, Neuroimage, 11, 6, pp. 805-821, (2000); Baez S., Manes F., Huepe D., Torralva T., Fiorentino N., Richter F., Huepe-Artigas D., Ferrari J., Montanes P., Reyes P., Matallana D., Vigliecca N.S., Decety J., Ibanez A., Primary empathy deficits in frontotemporal dementia, Front. Aging Neurosci., 6, (2014); Barkhof F., Haller S., Rombouts S.A.R.B., Resting-state functional MR imaging: A new window to the brain, Radiology, 272, 1, pp. 29-49, (2014); Bastiaansen J.A.C.J., Thioux M., Keysers C., Evidence for mirror systems in emotions, Philos. Trans. R. Soc. Lond., B, Biol. Sci., 364, 1528, pp. 2391-2404, (2009); Bell A.J., Sejnowski T.J., An information-maximization approach to blind separation and blind deconvolution, Neural Comput., 7, 6, pp. 1129-1159, (1995); Birn R.M., Diamond J.B., Smith M.A., Bandettini P.A., Separating respiratory-variation-related fluctuations from neuronal-activity-related fluctuations in fMRI, Neuroimage, 31, 4, pp. 1536-1548, (2006); Biswal B., Yetkin F.Z., Haughton V.M., Hyde J.S., Functional connectivity in the motor cortex of resting human brain using echo-planar mri, Magn. Reson. Med., 34, 4, pp. 537-541, (1995); Biswal B.B., Mennes M., Zuo X.-N., Gohel S., Kelly C., Smith S.M., Beckmann C.F., Adelstein J.S., Buckner R.L., Colcombe S., Dogonowski A.M., Ernst M., Fair D., Hampson M., Hoptman M.J., Hyde J.S., Kiviniemi V.J., Kotter R., Li S.J., Lin C.P., Lowe M.J., Mackay C., Madden D.J., Madsen K.H., Margulies D.S., Mayberg H.S., McMahon K., Monk C.S., Mostofsky S.H., Nagel B.J., Pekar J.J., Peltier S.J., Toward discovery science of human brain function, Proc. Natl. Acad. Sci. U. S. A., 107, 10, pp. 4734-4739, (2010); Buckner R.L., Andrews-Hanna J.R., Schacter D.L., The brain's default network: Anatomy, function, and relevance to disease, Ann. N. Y. Acad. Sci., 1124, 1, pp. 1-38, (2008); Calhoun V.D., Adali T., Pearlson G.D., Pekar J.J., Spatial and temporal independent component analysis of functional MRI data containing a pair of task-related waveforms, Hum. Brain Mapp., 13, 1, pp. 43-53, (2001); Calhoun V.D., Adali T., Pearlson G.D., Pekar J.J., A method for making group inferences from functional MRI data using independent component analysis, Hum. Brain Mapp., 14, 3, pp. 140-151, (2001); Cauda F., Sacco K., Duca S., Cocito D., D'Agata F., Geminiani G.C., Canavero S., Altered resting state in diabetic neuropathic pain, PLOS One, 4, 2, (2009); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol. Sci., 34, 8, pp. 1267-1274, (2013); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Lunetta C., Consonni M., Scola E., Falini A., Cappa S.F., Emotional empathy in amyotrophic lateral sclerosis: A behavioural and voxel-based morphometry study, Amyotroph. Lateral Scler. Frontotemporal Degener, 15, 1-2, pp. 21-29, (2014); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Chierchia G., Scola E., Falini A., Cappa S.F., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement., 10, 6, pp. 827-834, (2014); Corbetta M., Shulman G.L., Control of goal-directed and stimulus-driven attention in the brain, Nat. Rev. Neurosci., 3, 3, pp. 201-215, (2002); Cordes D., Haughton V.M., Arfanakis K., Wendt G.J., Turski P.A., Moritz C.H., Quigley M.A., Meyerand M.E., Mapping functionally related regions of brain with functional connectivity MR imaging, A.J.N.R. Am. J. Neuroradiol., 21, 9, pp. 1636-1644, (2000); Couto B., Manes F., Montanes P., Matallana D., Reyes P., Velasquez M., Yoris A., Baez S., Ibanez A., Structural neuroimaging of social cognition in progressive non-fluent aphasia and behavioral variant of frontotemporal dementia, Front. Hum. Neurosci., 7, (2013); Craig A.D., How do you feel? Interoception: The sense of the physiological condition of the body, Nat. Rev. Neurosci., 3, 8, pp. 655-666, (2002); Craig A.D., How do you feel - Now? the anterior insula and human awareness, Nat. Rev. Neurosci., 10, 1, pp. 59-70, (2009); D'Esposito M., Deouell L.Y., Gazzaley A., Alterations in the BOLD fMRI signal with ageing and disease: A challenge for neuroimaging, Nat. Rev. Neurosci., 4, 11, pp. 863-872, (2003); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S.F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the story-based empathy task, Neurol. Sci., pp. 1-6, (2015); Dopper E.G.P., Rombouts S.A.R.B., Jiskoot L.C., Den Heijer T.D., De Graaf J.R.A., De Koning I.D., Hammerschlag A.R., Seelaar H., Seeley W.W., Veer I.M., Van Buchem M.A., Rizzu P., Van Swieten J.C., Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia, Neurology, 80, 9, pp. 814-823, (2013); Downey L.E., Mahoney C.J., Buckley A.H., Golden H.L., Henley S.M., Schmitz N., Schott J.M., Simpson I.J., Ourselin S., Fox N.C., Crutch S.J., Warren J.D., White matter tract signatures of impaired social cognition in frontotemporal lobar degeneration, Neuroimage Clin., 8, pp. 640-651, (2015); Eickhoff S.B., Laird A.R., Fox P.T., Bzdok D., Hensel L., Functional segregation of the human dorsomedial prefrontal cortex, Cereb. Cortex, pp. 1-18, (2014); Eickhoff S.B., Stephan K.E., Mohlberg H., Grefkes C., Fink G.R., Amunts K., Zilles K., A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data, Neuroimage, 25, 4, pp. 1325-1335, (2005); Elamin M., Pender N., Hardiman O., Abrahams S., Social cognition in neurodegenerative disorders: A systematic review, J. Neurol. Neurosurg. Psychiatry, 83, 11, pp. 1071-1079, (2012); Erhardt E.B., Rachakonda S., Bedrick E.J., Allen E.A., Adali T., Calhoun V.D., Comparison of multi-subject ICA methods for analysis of fMRI data, Hum. Brain Mapp., 32, 12, pp. 2075-2095, (2011); Fan Y., Duncan N.W., De Greck M., Northoff G., Is there a core neural network in empathy? An fMRI based quantitative meta-analysis, Neurosci. Biobehav. Rev., 35, 3, pp. 903-911, (2011); Filippi M., Agosta F., Scola E., Canu E., Magnani G., Marcone A., Valsasina P., Caso F., Copetti M., Comi G., Cappa S.F., Falini A., Functional network connectivity in the behavioral variant of frontotemporal dementia, Cortex, 49, 9, pp. 2389-2401, (2013); Friston K.J., Holmes A.P., Poline J.B., Grasby P.J., Williams S.C., Frackowiak R.S., Turner R., Analysis of fMRI time-series revisited, Neuroimage, 2, 1, pp. 45-53, (1995); Frith C.D., The social brain?, Philosophical Transactions of the Royal Society B: Biological Sciences, 362, 1480, pp. 671-678, (2007); Garcia-Cordero I., Sedeno L., Fraiman D., Craiem D., De La Fuente L.A., Salamone P., Serrano C., Sposato L., Manes F., Ibanez A., Stroke and neurodegeneration induce different connectivity aberrations in the insula, Stroke, (2015); Garrity A.G., Pearlson G.D., McKiernan K., Lloyd D., Kiehl K.A., Calhoun V.D., Aberrant 'default mode' functional connectivity in schizophrenia, Am J Psychiatry, 164, 3, pp. 450-457, (2007); Genovese C.R., Lazar N.A., Nichols T., Thresholding of statistical maps in functional neuroimaging using the false discovery rate, Neuroimage, 15, 4, pp. 870-878, (2002); Gleichgerrcht E., Ibanez A., Roca M., Torralva T., Manes F., Decision-making cognition in neurodegenerative diseases, Nat. Rev. Neurol., 6, 11, pp. 611-623, (2010); Gleichgerrcht E., Torralva T., Roca M., Pose M., Manes F., The role of social cognition in moral judgment in frontotemporal dementia, Soc. Neurosci., 6, 2, pp. 113-122, (2011); Gregory C., Lough S., Stone V., Erzinclioglu S., Martin L., Baron-Cohen S., Hodges J.R., Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: Theoretical and practical implications, Brain, 125, 4, pp. 752-764, (2002); Greicius M., Resting-state functional connectivity in neuropsychiatric disorders, Curr. Opin. Neurol., 21, 4, pp. 424-430, (2008); Greicius M.D., Kimmel D.L., Neuroimaging insights into network-based neurodegeneration, Curr. Opin. Neurol., 25, 6, pp. 727-734, (2012); Himberg J., Hyvarinen A., Esposito F., Validating the independent components of neuroimaging time series via clustering and visualization, Neuroimage, 22, 3, pp. 1214-1222, (2004); Iacoboni M., Lieberman M.D., Knowlton B.J., Molnar-Szakacs I., Moritz M., Throop C.J., Fiske A.P., Watching social interactions produces dorsomedial prefrontal and medial parietal BOLD fMRI signal increases compared to a resting baseline, Neuroimage, 21, 3, pp. 1167-1173, (2004); Iacoboni M., Molnar-Szakacs I., Gallese V., Buccino G., Mazziotta J.C., Rizzolatti G., Grasping the intentions of others with one's own mirror neuron system, PLOS Biol., 3, 3, (2005); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurol., 78, 17, pp. 1354-1362, (2012); Irish M., Piguet O., Hodges J.R., Self-projection and the default network in frontotemporal dementia, Nat. Rev. Neurol., 8, 3, pp. 152-161, (2011); Khanna N., Altmeyer W., Zhuo J., Steven A., Functional neuroimaging: Fundamental principles and clinical applications, Neuroradiol J, 28, 2, pp. 87-96, (2015); Kim E.J., Sidhu M., Gaus S.E., Huang E.J., Hof P.R., Miller B.L., DeArmond S.J., Seeley W.W., Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia, Cereb. Cortex, 22, 2, pp. 251-259, (2012); Kipps C.M., Hodges J.R., Theory of mind in frontotemporal dementia, Soc. Neurosci., 1, 3-4, pp. 235-244, (2006); Kochiyama T., Morita T., Okada T., Yonekura Y., Matsumura M., Sadato N., Removing the effects of task-related motion using independent-component analysis, Neuroimage, 25, 3, pp. 802-814, (2005); Lamm C., Decety J., Singer T., Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain, Neuroimage, 54, 3, pp. 2492-2502, (2011); Lieberman M.D., Social cognitive neuroscience: A review of core processes, Annu. Rev. Psychol., 58, pp. 259-289, (2007); Lough S., Kipps C.M., Treise C., Watson P., Blair J.R., Hodges J.R., Social reasoning, emotion and empathy in frontotemporal dementia, Neuropsychologia, 44, 6, pp. 950-958, (2006); Mahoney C.J., Ridgway G.R., Malone I.B., Downey L.E., Beck J., Kinnunen K.M., Schmitz N., Golden H.L., Rohrer J.D., Schott J.M., Rossor M.N., Ourselin S., Mead S., Fox N.C., Warren J.D., Profiles of white matter tract pathology in frontotemporal dementia, Hum. Brain Mapp., 35, 8, pp. 4163-4179, (2014); Mahoney C.J., Simpson I.J.A., Nicholas J.M., Fletcher P.D., Downey L.E., Golden H.L., Clark C.N., Schmitz N., Rohrer J.D., Schott J.M., Zhang H., Ourselin S., Warren J.D., Fox N.C., Longitudinal diffusion tensor imaging in frontotemporal dementia, Ann. Neurol., 77, 1, pp. 33-46, (2015); McKeown M.J., Hansen L.K., Sejnowsk T.J., Independent component analysis of functional MRI: What is signal and what is noise?, Curr. Opin. Neurobiol., 13, 5, pp. 620-629, (2003); Mendez M.F., What frontotemporal dementia reveals about the neurobiological basis of morality, Med. Hypotheses, 67, 2, pp. 411-418, (2006); Mendez M.F., Shapira J.S., Altered emotional morality in frontotemporal dementia, Cogn. Neuropsychiatry, 14, 3, pp. 165-179, (2009); Meyer-Lindenberg A., Weinberger D.R., Intermediate phenotypes and genetic mechanisms of psychiatric disorders, Nat. Rev. Neurosci., 7, 10, pp. 818-827, (2006); Neary D., Snowden J., Mann D., Frontotemporal dementia, Lancet Neurol., 4, 11, pp. 771-780, (2005); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M.F., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, 6, pp. 1546-1554, (1998); Ochsner K.N., Beer J.S., Robertson E.R., Cooper J.C., Gabrieli J.D.E., Kihsltrom J.F., D'Esposito M., The neural correlates of direct and reflected self-knowledge, Neuroimage, 28, 4, pp. 797-814, (2005); Ochsner K.N., Knierim K., Ludlow D.H., Hanelin J., Ramachandran T., Glover G., Mackey S.C., Reflecting upon feelings: An fMRI study of neural systems supporting the attribution of emotion to self and other, Cogn. Neurosci. J, 16, 10, pp. 1746-1772, (2004); Olson I.R., Plotzker A., Ezzyat Y., The enigmatic temporal pole: A review of findings on social and emotional processing, Brain, 130, 7, pp. 1718-1731, (2007); Otti A., Guendel H., Wohlschlager A., Zimmer C., Noll-Hussong M., Frequency shifts in the anterior default mode network and the salience network in chronic pain disorder, B.M.C. Psychiatry, 13, 1, (2013); Pasquini L., Scherr M., Tahmasian M., Meng C., Myers N.E., Ortner M., Muhlau M., Kurz A., Forstl H., Zimmer C., Grimmer T., Wohlschlager A.M., Riedl V., Sorg C., Link between hippocampus' raised local and eased global intrinsic connectivity in AD, Alzheimers Dement, 11, 5, pp. 475-484, (2015); Pelphrey K.A., Morris J.P., Michelich C.R., Allison T., McCarthy G., Functional anatomy of biological motion perception in posterior temporal cortex: An fMRI study of Eye, mouth and hand movements, Cereb. Cortex, 15, 12, pp. 1866-1876, (2005); Pievani M., Filippini N., Van Den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases - From phenotype to proteinopathy, Nat. Rev. Neurol., 10, 11, pp. 620-633, (2014); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol., 10, 2, pp. 162-172, (2011); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weiner M.W., Miller B.L., Structural anatomy of empathy in neurodegenerative disease, Brain, 129, 11, pp. 2945-2956, (2006); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Ridderinkhof K.R., Ullsperger M., Crone E.A., Nieuwenhuis S., The role of the medial frontal cortex in cognitive control, Science, 306, 5695, pp. 443-447, (2004); Rosen A.C., Prull M.W., O'Hara R., Race E.A., Desmond J.E., Glover G.H., Yesavage J.A., Gabrieli J.D.E., Variable effects of aging on frontal lobe contributions to memory, Neuroreport, 13, 18, pp. 2425-2428, (2002); Rytty R., Nikkinen J., Paavola L., Abou Elseoud A., Moilanen V., Visuri A., Tervonen O., Renton A.E., Traynor B.J., Kiviniemi V., Remes A.M., Group ICA dual regression analysis of resting state networks in a behavioral variant of frontotemporal dementia, Front. Hum. Neurosci., 7, AUGUST, (2013); Said C.P., Haxby J.V., Todorov A., Brain systems for assessing the affective value of faces, Philos. Trans. R. Soc. Lond., B, Biol. Sci., 366, 1571, pp. 1660-1670, (2011); Scholvinck M.L., Maier A., Ye F.Q., Duyn J.H., Leopold D.A., Neural basis of global resting-state fMRI activity, Proc. Natl. Acad. Sci. U. S. A., 107, 22, pp. 10238-10243, (2010); Seeley W.W., Allman J.M., Carlin D.A., Crawford R.K., Macedo M.N., Greicius M.D., DeArmond S.J., Miller B.L., Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: Reciprocal networks and neuronal evolution, Alzheimer Dis. Assoc. Disord., 21, 4, pp. S50-S57, (2007); Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Gorno-Tempini M.L., Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Arch. Neurol., 65, 2, pp. 249-255, (2008); Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D., Neurodegenerative diseases target large-scale human brain networks, Neuron, 62, 1, pp. 42-52, (2009); Seeley W.W., Menon V., Schatzberg A.F., Keller J., Glover G.H., Kenna H.K., Reiss A.L., Greicius M.D., Dissociable intrinsic connectivity networks for salience processing and executive control, J. Neurosci., 27, 9, pp. 2349-2356, (2007); Smith S.M., Beckmann C.F., Andersson J., Auerbach E.J., Bijsterbosch J., Douaud G., Duff E., Feinberg D.A., Griffanti L., Harms M.P., Kelly M., Laumann T., Miller K.L., Moeller S., Petersen S., Power J., Salimi-Khorshidi G., Snyder A.Z., Vu A.T., Woolrich M.W., Xu J., Yacoub E., Uturbil K., Van Essen D.C., Glasser M.F., Resting-state fMRI in the human connectome project, NeuroImage, 80, pp. 144-168, (2013); Torralva T., Kipps C.M., Hodges J.R., Clark L., Bekinschtein T., Roca M., Calcagno M.L., Manes F., The relationship between affective decision-making and theory of mind in the frontal variant of fronto-temporal dementia, Neuropsychologia, 45, 2, pp. 342-349, (2007); Torralva T., Roca M., Gleichgerrcht E., Bekinschtein T., Manes F., A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia, Brain, 132, 5, pp. 1299-1309, (2009); Van De Riet W.A.C., Grezes J., De Gelder B., Specific and common brain regions involved in the perception of faces and bodies and the representation of their emotional expressions, Soc. Neurosci., 4, 2, pp. 101-120, (2009); Warren J.D., Rohrer J.D., Schott J.M., Fox N.C., Hardy J., Rossor M.N., Molecular nexopathies: A new paradigm of neurodegenerative disease, Trends Neurosci., 36, 10, pp. 561-569, (2013); Whitwell J.L., Josephs K.A., Avula R., Tosakulwong N., Weigand S.D., Senjem M.L., Vemuri P., Jones D.T., Gunter J.L., Baker M., Wszolek Z.K., Knopman D.S., Rademakers R., Petersen R.C., Boeve B.F., Jack C.R., Altered functional connectivity in asymptomatic MAPT subjects: A comparison to bvFTD, Neurology, 77, 9, pp. 866-874, (2011); Worsley K.J., Friston K.J., Analysis of fMRI time-series revisited - Again, Neuroimage, 2, 3, pp. 173-181, (1995); Zhou J., Greicius M.D., Gennatas E.D., Growdon M.E., Jang J.Y., Rabinovici G.D., Kramer J.H., Weiner M., Miller B.L., Seeley W.W., Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease, Brain, 133, 5, pp. 1352-1367, (2010); Zhou J., Seeley W.W., Network dysfunction in Alzheimer's disease and frontotemporal dementia: Implications for psychiatry, Biol. Psychiatry, 75, 7, pp. 565-573, (2014); Zhou Y., Li S., Dunn J., Li H., Qin W., Zhu M., Rao L.-L., Song M., Yu C., Jiang T., The neural correlates of risk propensity in males and females using resting-state fMRI, Front. Behav. Neurosci., 8, (2014); Zilbovicius M., Meresse I., Chabane N., Brunelle F., Samson Y., Boddaert N., Autism, the superior temporal sulcus and social perception, Trends Neurosci., 29, 7, pp. 359-366, (2006)","2-s2.0-84943779632"
"Agosta F.; Scola E.; Canu E.; Marcone A.; Magnani G.; Sarro L.; Copetti M.; Caso F.; Cerami C.; Comi G.; Cappa S.F.; Falini A.; Filippi M.","Agosta, F. (6701687853); Scola, E. (35071979200); Canu, E. (25225458900); Marcone, A. (6701496511); Magnani, G. (24496141800); Sarro, L. (38562146800); Copetti, M. (24474249000); Caso, F. (35785657000); Cerami, C. (25722905400); Comi, G. (7201788288); Cappa, S.F. (7005836132); Falini, A. (7003494994); Filippi, M. (7202268530)","6701687853; 35071979200; 25225458900; 6701496511; 24496141800; 38562146800; 24474249000; 35785657000; 25722905400; 7201788288; 7005836132; 7003494994; 7202268530","White matter damage in frontotemporal lobar degeneration spectrum","2012","Cerebral Cortex","22","12","","2705","2714","9","136","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84869027954&doi=10.1093%2fcercor%2fbhr288&partnerID=40&md5=968b2eeb8d04bc1bc73a809a931386b3","White matter (WM) tract damage was assessed in patients with the behavioral variant frontotemporal dementia (bvFTD) and the 3 primary progressive aphasia (PPA) variants and compared with the corresponding brain atrophy patterns. Thirteen bvFTD and 20 PPA patients were studied. Tract-based spatial statistics and voxel-based morphometry were used. Patients with bvFTD showed widespread diffusion tensor magnetic resonance imaging (DT MRI) abnormalities affecting most of the WM bilaterally. In PPA patients, WM damage was more focal and varied across the 3 syndromes: left frontotemporoparietal in nonfluent, left frontotemporal in semantic, and left frontoparietal in logopenic patients. In each syndrome, DT MRI changes extended beyond the topography of gray matter loss. Left uncinate damage was the best predictor of frontotemporal lobar degeneration diagnosis versus controls. DT MRI measures of the anterior corpus callosum and left superior longitudinal fasciculus differentiated bvFTD from nonfluent cases. The best predictors of semantic PPA compared with both bvFTD and nonfluent cases were diffusivity abnormalities of the left uncinate and inferior longitudinal fasciculus. This study provides insights into the similarities and differences of WM damage in bvFTD and PPA variants. DT MRI metrics hold promise to serve as early markers of WM integrity loss that only at a later stage may be detectable by volumetric measures. © The Author 2011. Published by Oxford University Press. All rights reserved.","diffusion tensor MRI; frontotemporal dementia; frontotemporal lobar degeneration; primary progressive aphasia; white matter","Aged; Aphasia, Primary Progressive; Atrophy; Brain; Diagnosis, Differential; Diffusion Tensor Imaging; Female; Frontotemporal Lobar Degeneration; Humans; Male; Middle Aged; Nerve Fibers, Myelinated; Reproducibility of Results; Sensitivity and Specificity; adult; article; brain atrophy; comparative study; controlled study; corpus callosum; diffusion tensor imaging; disease marker; female; frontotemporal dementia; gray matter; human; major clinical study; male; morphometrics; prediction; predictor variable; primary progressive aphasia; priority journal; semantic dementia; statistics; topography; uncinate fasciculus; volumetry; white matter injury","Agosta F., Henry R.G., Migliaccio R., Neuhaus J., Miller B.L., Dronkers N.F., Brambati S.M., Filippi M., Ogar J.M., Wilson S.M., Et al., Language networks in semantic dementia, Brain, 133, pp. 286-299, (2010); Agosta F., Pievani M., Sala S., Geroldi C., Galluzzi S., Frisoni G.B., Filippi M., White matter damage in Alzheimer disease and its relationship to gray matter atrophy, Radiology, 258, pp. 853-863, (2011); Ashburner J., A fast diffeomorphic image registration algorithm, Neuroimage, 38, pp. 95-113, (2007); Ashburner J., Friston K.J., Unified segmentation, Neuroimage, 26, pp. 839-851, (2005); Basser P.J., Mattiello J., Lebihan D., Estimation of the effective selfdiffusion tensor from the NMR spin echo, J Magn Reson B, 103, pp. 247-254, (1994); Basso A., Capitani E., Laiacona M., Raven's coloured progressive matrices: Normative values on 305 adult normal controls, Funct Neurol, 2, pp. 189-194, (1987); Borroni B., Brambati S.M., Agosti C., Gipponi S., Bellelli G., Gasparotti R., Garibotto V., Di Luca M., Scifo P., Perani D., Et al., Evidence of white matter changes on diffusion tensor imaging in frontotemporal dementia, Arch Neurol, 64, pp. 246-251, (2007); Borroni B., Garibotto V., Agosti C., Brambati S.M., Bellelli G., Gasparotti R., Padovani A., Perani D., White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia, Arch Neurol, 65, pp. 796-801, (2008); Brambati S.M., Rankin K.P., Narvid J., Seeley W.W., Dean D., Rosen H.J., Miller B.L., Ashburner J., Gorno-Tempini M.L., Atrophy progression in semantic dementia with asymmetric temporal involvement: A tensor-based morphometry study, Neurobiol Aging, 30, pp. 103-111, (2009); Brambati S.M., Renda N.C., Rankin K.P., Rosen H.J., Seeley W.W., Ashburner J., Weiner M.W., Miller B.L., Gorno-Tempini M.L., A tensor based morphometry study of longitudinal gray matter contraction in FTD, Neuroimage, 35, pp. 998-1003, (2007); Breiman L., Random forests, Mach Learn, 45, pp. 5-32, (2001); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Rey- Osterrieth complex figure: Normative values in an Italian population sample, Neurol Sci, 22, pp. 443-447, (2002); Canu E., Frisoni G.B., Agosta F., Pievani M., Bonetti M., Filippi M., Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage, Neurobiol Aging, (2011); De Renzi E., Vignolo L.A., The token test: A sensitive test to detect receptive disturbances in aphasics, Brain, 85, pp. 665-678, (1962); Efron B., Tibshirani R.J., Improvements on cross-validation: The .632+ bootstrap method, J Am Stat Assoc, 92, pp. 548-560, (1997); Erbetta A., Mandelli M.L., Savoiardo M., Grisoli M., Bizzi A., Soliveri P., Chiapparini L., Prioni S., Bruzzone M.G., Girotti F., Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration, AJNR Am J Neuroradiol, 30, pp. 1482-1487, (2009); Folstein M.F., Folstein S.E., McHugh P.R., Mini-mental state"". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res., 12, pp. 189-198, (1975); Galantucci S., Tartaglia M.C., Wilson S.M., Henry M.L., Filippi M., Agosta F., Dronkers N.F., Henry R.G., Ogar J.M., Miller B.L., Et al., White matter damage in primary progressive aphasias: A diffusion tensor tractography study, Brain, (2011); Gorno-Tempini M.L., Brambati S.M., Ginex V., Ogar J., Dronkers N.F., Marcone A., Perani D., Garibotto V., Cappa S.F., Miller B.L., The logopenic/phonological variant of primary progressive aphasia, Neurology, 71, pp. 1227-1234, (2008); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Gorno-Tempini M.L., Murray R.C., Rankin K.P., Weiner M.W., Miller B.L., Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: A case report, Neurocase, 10, pp. 426-436, (2004); Hodges J.R., Davies R.R., Xuereb J.H., Casey B., Broe M., Bak T.H., Kril J.J., Halliday G.M., Clinicopathological correlates in frontotemporal dementia, Ann Neurol, 56, pp. 399-406, (2004); Josephs K.A., Duffy J.R., Strand E.A., Whitwell J.L., Layton K.F., Parisi J.E., Hauser M.F., Witte R.J., Boeve B.F., Knopman D.S., Et al., Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech, Brain, 129, pp. 1385-1398, (2006); MacKenzie I.R., Neumann M., Bigio E.H., Cairns N.J., Alafuzoff I., Kril J., Kovacs G.G., Ghetti B., Halliday G., Holm I.E., Et al., Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update, Acta Neuropathol, 119, pp. 1-4, (2010); Matsuo K., Mizuno T., Yamada K., Akazawa K., Kasai T., Kondo M., Mori S., Nishimura T., Nakagawa M., Cerebral white matter damage in frontotemporal dementia assessed by diffusion tensor tractography, Neuroradiology, 50, pp. 605-611, (2008); McCulloch C.E., Searle S.R., Neuhaus J.M., Generalized, Linear, and Mixed Models, (2008); Mesulam M., Wicklund A., Johnson N., Rogalski E., Leger G.C., Rademaker A., Weintraub S., Bigio E.H., Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia, Ann Neurol, 63, pp. 709-719, (2008); Mesulam M.M., Primary progressive aphasia, Ann Neurol, 49, pp. 425-432, (2001); Miceli G., Laudanna A., Burani C., Capasso R., Batteria per l'Analisi Del Deficit Afasico. B.A.D.A. [B.A.D.A. A Battery for the Assessment of Aphasic Disorders], (1994); Migliaccio R., Agosta F., Rascovsky K., Karydas A., Bonasera S., Rabinovici G.D., Miller B.L., Gorno-Tempini M.L., Clinical syndromes associated with posterior atrophy: Early age at onset AD spectrum, Neurology, 73, pp. 1571-1578, (2009); Mummery C.J., Patterson K., Price C.J., Ashburner J., Frackowiak R.S., Hodges J.R., A voxel-based morphometry study of semantic dementia: Relationship between temporal lobe atrophy and semantic memory, Ann Neurol, 47, pp. 36-45, (2000); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Et al., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Neumann M., Kwong L.K., Truax A.C., Vanmassenhove B., Kretzschmar H.A., Van Deerlin V.M., Clark C.M., Grossman M., Miller B.L., Trojanowski J.Q., Et al., TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions, J Neuropathol Exp Neurol, 66, pp. 177-183, (2007); Nichols T.E., Holmes A.P., Nonparametric permutation tests for functional neuroimaging: A primer with examples, Hum Brain Mapp, 15, pp. 1-25, (2002); Novelli G., Papagno C., Capitani E., Laiacona N., Vallar G., Cappa S.F., Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali, Arch Psicol Neurol Psichiatr, 47, pp. 477-506, (1986); Oldfield R.C., The assessment and analysis of handedness: The Edinburgh inventory, Neuropsychologia, 9, pp. 97-113, (1971); Orsini A., Grossi D., Capitani E., Laiacona M., Papagno C., Vallar G., Verbal and spatial immediate memory span: Normative data from 1355 adults and 1112 children, Ital J Neurol Sci, 8, pp. 539-548, (1987); Papagno C., Miracapillo C., Casarotti A., Romero Lauro L.J., Castellano A., Falini A., Casaceli G., Fava E., Bello L., What is the role of the uncinate fasciculus? Surgical removal and proper name retrieval, Brain, 134, pp. 405-414, (2011); Pierpaoli C., Barnett A., Pajevic S., Chen R., Penix L.R., Virta A., Basser P., Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture, Neuroimage, 13, pp. 1174-1185, (2001); Rohrer J.D., Rossor M.N., Warren J.D., Apraxia in progressive nonfluent aphasia, J Neurol, 257, pp. 569-574, (2010); Rohrer J.D., Warren J.D., Phenomenology and anatomy of abnormal behaviours in primary progressive aphasia, J Neurol Sci, 293, pp. 35-38, (2010); Rohrer J.D., Warren J.D., Modat M., Ridgway G.R., Douiri A., Rossor M.N., Ourselin S., Fox N.C., Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration, Neurology, 72, pp. 1562-1569, (2009); Rosen H.J., Gorno-Tempini M.L., Goldman W.P., Perry R.J., Schuff N., Weiner M., Feiwell R., Kramer J.H., Miller B.L., Patterns of brain atrophy in frontotemporal dementia and semantic dementia, Neurology, 58, pp. 198-208, (2002); Schofield E., Kersaitis C., Shepherd C.E., Kril J.J., Halliday G.M., Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: Tau-positive glia differentiate these disorders, Brain, 126, pp. 827-840, (2003); Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., MacKay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Et al., Tract-based spatial statistics: Voxelwise analysis of multisubject diffusion data, Neuroimage, 31, pp. 1487-1505, (2006); Smith S.M., Nichols T.E., Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference, Neuroimage, 44, pp. 83-98, (2009); Spinnler H., Tognoni G., Standardizzazione e taratura italiana di test neuropsicologici, Ital J Neurol Sci, 6, pp. 1-120, (1987); Strobl C., Boulesteix A.L., Kneib T., Augustin T., Zeileis A., Conditional variable importance for random forests, BMC Bioinformatics, 9, (2008); Strobl C., Boulesteix A.L., Zeileis A., Hothorn T., Bias in random forest variable importance measures: Illustrations, sources and a solution, BMC Bioinformatics, 8, (2007); Wechsler D.A., Manual for the Wechsler Adult Intelligence Scalerevised (WAIS-R), (1981); Whitwell J.L., Avula R., Senjem M.L., Kantarci K., Weigand S.D., Samikoglu A., Edmonson H.A., Vemuri P., Knopman D.S., Boeve B.F., Et al., Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia, Neurology, 74, pp. 1279-1287, (2011); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Senjem M.L., Shiung M.M., Boeve B.F., Knopman D.S., Et al., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study, Brain, 132, pp. 2932-2946, (2009); Zhang Y., Schuff N., Du A.T., Rosen H.J., Kramer J.H., Gorno-Tempini M.L., Miller B.L., Weiner M.W., White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI, Brain, 132, pp. 2579-2592, (2009)","2-s2.0-84869027954"
"Malpetti M.; Carli G.; Sala A.; Cerami C.; Marcone A.; Iannaccone S.; Magnani G.; Perani D.","Malpetti, Maura (57193333856); Carli, Giulia (57201314331); Sala, Arianna (9274476600); Cerami, Chiara (25722905400); Marcone, Alessandra (6701496511); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Perani, Daniela (7005630261)","57193333856; 57201314331; 9274476600; 25722905400; 6701496511; 7005943171; 24496141800; 7005630261","Variant-specific vulnerability in metabolic connectivity and resting-state networks in behavioural variant of frontotemporal dementia","2019","Cortex","120","","","483","497","14","16","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071613064&doi=10.1016%2fj.cortex.2019.07.018&partnerID=40&md5=612ab91a7eecfd823d41d0d135c6b7a3","Brain connectivity measures represent candidate biomarkers of neuronal dysfunction in neurodegenerative diseases. Previous findings suggest that the behavioural variant of frontotemporal dementia (bvFTD) and its variants (i.e., frontal and temporo-limbic) may be related to the vulnerability of distinct functional connectivity networks. In this study, 82 bvFTD patients were included, and two patient groups were identified as frontal and temporo-limbic bvFTD variants. Two advanced multivariate analytical approaches were applied to FDG-PET data, i.e., sparse inverse covariance estimation (SICE) method and seed-based interregional correlation analysis (IRCA). These advanced methods allowed the assessment of (i) the whole-brain metabolic connectivity, without any a priori assumption, and (ii) the main brain resting-state networks of crucial relevance for cognitive and behavioural functions. In the whole bvFTD group, we found dysfunctional connectivity patterns in frontal and limbic regions and in all major brain resting-state networks as compared to healthy controls (HC N = 82). In the two bvFTD variants, SICE and IRCA analyses identified variant-specific reconfigurations of whole-brain connectivity and resting-state networks. Specifically, the frontal bvFTD variant was characterised by metabolic connectivity alterations in orbitofrontal regions and anterior resting-state networks, while the temporo-limbic bvFTD variant was characterised by connectivity alterations in the limbic and salience networks. These results highlight different neural vulnerabilities in the two bvFTD variants, as shown by the dysfunctional connectivity patterns, with relevance for the different neuropsychological profiles. This new evidence provides further insight in the variability of bvFTD and may contribute to a more accurate classification of these patients. © 2019 Elsevier Ltd","Behavioural variant of frontotemporal dementia; Brain metabolic connectivity; Fluorine-18-flourodeoxiglucose; Positron emission tomography","Aged; Attention; Brain; Brain Mapping; Cognition; Connectome; Female; Frontotemporal Dementia; Humans; Male; Memory; Middle Aged; Nerve Net; Neuropsychological Tests; Positron-Emission Tomography; fluorodeoxyglucose f 18; aged; Article; cerebellum; controlled study; correlation analysis; disease duration; dorsolateral prefrontal cortex; female; frontal variant frontotemporal dementia; functional connectivity; human; long term memory; major clinical study; male; memory; neuroimaging; positron emission tomography; prosopagnosia; resting state network; superior temporal gyrus; thalamus; attention; brain; brain mapping; cognition; connectome; diagnostic imaging; frontotemporal dementia; middle aged; nerve cell network; neuropsychological test; physiology; psychology","Agosta F., Sala S., Valsasina P., Meani A., Canu E., Magnani G., Et al., Brain network connectivity assessed using graph theory in frontotemporal dementia, Neurology, 81, 2, pp. 134-143, (2013); Amodio D.M., Meeting of minds: The medial frontal cortex and social cognition, Nature Reviews. Neuroscience, 7, 4, pp. 268-277, (2006); Ballarini T., Iaccarino L., Magnani G., Ayakta N., Miller B.L., Jagust W.J., Et al., Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease, Human Brain Mapping, 37, 12, pp. 4234-4247, (2016); Barletta-Rodolfi C., Gasparini F., Ghidoni E., Kit del neuropsicologo italiano, (2011); Caminiti S.P., Tettamanti M., Sala A., Presotto L., Iannaccone S., Cappa S.F., Et al., Metabolic connectomics targeting brain pathology in dementia with Lewy bodies, Journal of Cerebral Blood Flow and Metabolism, 37, 4, pp. 1311-1325, (2017); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurological Sciences, 34, 8, pp. 1267-1274, (2013); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Et al., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimer's & Dementia, 10, 6, pp. 827-834, (2014); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Et al., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Chow T.W., Binns M.A., Cummings J.L., Lam I., Black S.E., Miller B.L., Et al., Apathy symptom profile and behavioral associations in frontotemporal dementia vs dementia of Alzheimer type, Archives of Neurology, 66, 7, pp. 888-893, (2009); Della Rosa P.A., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, 4, pp. 575-593, (2014); Diehl-Schmid J., Grimmer T., Drzezga A., Bornschein S., Riemenschneider M., Forstl H., Et al., Decline of cerebral glucose metabolism in frontotemporal dementia: A longitudinal 18F-FDG-PET-study, Neurobiology of Aging, 28, 1, pp. 42-50, (2007); Euston D.R., Gruber A.J., McNaughton B.L., The role of medial prefrontal cortex in memory and decision making, Neuron, 76, 6, pp. 1057-1070, (2012); Farb N.A.S., Grady C.L., Strother S., Tang-Wai D.F., Masellis M., Black S., Et al., Abnormal network connectivity in frontotemporal dementia: Evidence for prefrontal isolation, Cortex, 49, 7, pp. 1856-1873, (2013); Filippi M., Agosta F., Scola E., Canu E., Magnani G., Marcone A., Et al., Functional network connectivity in the behavioral variant of frontotemporal dementia, Cortex, 49, 9, pp. 2389-2401, (2013); Franceschi M., Pelati O., Raffaele S., Raffaele S., Franceschi M., Anchisi D., Et al., Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration, Annals of Neurology, 57, 2, pp. 216-225, (2005); Gordon E., Rohrer J.D., Fox N.C., Advances in neuroimaging in frontotemporal dementia, Journal of Neurochemistry, 138, S1, pp. 193-210, (2016); Horwitz B., Duara R., Rapoport S.I., Intercorrelations of glucose metabolic rates between brain regions: Application to healthy males in a state of reduced sensory input, Journal of Cerebral Blood Flow and Metabolism, 4, 4, pp. 484-499, (1984); Huang S., Li J., Sun L., Ye J., Fleisher A., Wu T., Et al., Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation, NeuroImage, 50, 3, pp. 935-949, (2010); Iaccarino L., Sala A., Caminiti S.P., Santangelo R., Iannaccone S., Magnani G., Et al., The brain metabolic signature of visual hallucinations in dementia with Lewy bodies, Cortex, 108, pp. 13-24, (2018); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology, 78, 17, pp. 1354-1362, (2012); Ishii K., PET approaches for diagnosis of dementia, American Journal of Neuroradiology, 35, 11, pp. 2030-2038, (2014); Jeong Y., Cho S.S., Park J.M., Kang S.J., Lee J.S., 18F-FDG PET findings in frontotemporal dementia: An SPM analysis of 29 patients, Journal of Nuclear Medicine, 46, 2, pp. 233-240, (2005); Kruschwitz J.D., List D., Waller L., Rubinov M., Walter H., GraphVar: A user-friendly toolbox for comprehensive graph analyses of functional brain connectivity, Journal of Neuroscience Methods, 245, pp. 107-115, (2015); Lamm C., Decety J., Singer T., NeuroImage Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain, NeuroImage, 54, 3, pp. 2492-2502, (2011); Lansdall C.J., Coyle-Gilchrist I.T., Jones P.S., Vazquez Rodriguez P., Wilcox A., Wehmann E., Et al., Apathy and impulsivity in frontotemporal lobar degeneration syndromes, Brain, 140, 6, pp. 1792-1807, (2017); Lee D.S., Kang H., Kim H., Park H., Oh J.S., Lee J.S., Et al., Metabolic connectivity by interregional correlation analysis using statistical parametric mapping (SPM) and FDG brain PET; methodological development and patterns of metabolic connectivity in adults, European Journal of Nuclear Medicine and Molecular Imaging, 35, 9, pp. 1681-1691, (2008); Lezak M.D., Howieson D.B., Loring D.W., Fischer J.S., Neuropsychological assessment, (2004); Liu H., Roeder K., Wasserman L., Stability approach to regularization selection (StARS) for high dimensional graphical models, Advances in Neural Information Processing Systems, pp. 1432-1440, (2010); Malpetti M., Ballarini T., Presotto L., Garibotto V., Tettamanti M., Perani D., Gender differences in healthy aging and Alzheimer's dementia: A 18 F-FDG-PET study of brain and cognitive reserve, Human Brain Mapping, 38, 8, pp. 4212-4227, (2017); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., van Berckel B.N.M., Et al., Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiology of Aging, 33, 11, pp. 2533-2550, (2012); Morbelli S., Ferrara M., Fiz F., Dessi B., Arnaldi D., Picco A., Et al., Mapping brain morphological and functional conversion patterns in predementia late-onset bvFTD, European Journal of Nuclear Medicine and Molecular Imaging, 43, 7, pp. 1337-1347, (2016); Passamonti L., Lansdall C.J., Rowe J.B., The neuroanatomical and neurochemical basis of apathy and impulsivity in frontotemporal lobar degeneration, Current Opinion in Behavioral Sciences, 22, pp. 14-20, (2018); Perani D., FDG PET and cognitive symptoms of dementia, Clinical and Translational Imaging, 1, 4, pp. 247-260, (2013); Perani D., FDG-PET and amyloid-PET imaging: The diverging paths, Current Opinion in Neurology, 27, 4, pp. 405-413, (2014); Perani D., Anthony P., Rosa D., Cerami C., Gallivanone F., Fallanca F., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, NeuroImage: Clinical, 6, pp. 445-454, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Et al., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Journal of Nuclear Medicine and Molecular Imaging, 43, 3, pp. 499-508, (2016); Perani D., Farsad M., Ballarini T., Lubian F., Malpetti M., Fracchetti A., The impact of bilingualism on brain reserve and metabolic connectivity in Alzheimer's dementia, Proceedings of the National Academy of Sciences, 114, 7, pp. 1690-1695, (2017); Pievani M., Filippini N., van den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases-from phenotype to proteinopathy, Nature Reviews. Neurology, 10, 11, pp. 620-633, (2014); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, The Lancet Neurology, 10, 2, pp. 162-172, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Rohrer J.D., Rosen H.J., Neuroimaging in frontotemporal dementia, International Review of Psychiatry, 25, 2, pp. 221-229, (2013); Ruby P., Decety J., How would you feel versus how do you think she would Feel? A neuroimaging study of perspective-taking with social emotions, Journal of Cognitive Neuroscience, 16, 6, pp. 988-999, (2004); Rytty R., Nikkinen J., Paavola L., Elseoud A.A., Moilanen V., Visuri A., Et al., GroupICA dual regression analysis of resting state networks in a behavioral variant of frontotemporal dementia, Frontiers in Human Neuroscience, 7, pp. 1-10, (2013); Sala A., Caminiti S.P., Presotto L., Premi E., Pilotto A., Turrone R., Et al., Altered brain metabolic connectivity at multiscale level in early Parkinson's disease, Scientific Reports, 7, 1, (2017); Sala A., Perani D., Brain molecular connectivity in neurodegenerative diseases: recent advances and new perspectives using Positron Emission Tomography, Front Neurosci, 13, (2019); Salmon E., Kerrouche N., Herholz K., Perani D., Holthoff V., Beuthien-baumann B., Et al., Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia, NeuroImage, 30, 3, pp. 871-878, (2006); Schlaffke L., Shared and nonshared neural networks of cognitive and affective theory-of-mind: A neuroimaging study using cartoon picture stories cognitive and affective theory of mind, Human Brain Mapping, 36, 1, pp. 29-39, (2015); Schroeter M.L., Raczka K., Neumann J., von Cramon D.Y., Neural networks in frontotemporal dementia—a meta-analysis, Neurobiology of Aging, 29, 3, pp. 418-426, (2008); Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Et al., Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Arch Neurol, 65, pp. 249-255, (2008); Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D., Neurodegenerative diseases target large-scale human brain networks, Neuron, 62, 1, pp. 42-52, (2009); Seeley W., Menon V., Schatzberg A., Keller J., Glover G., Kenna H., Et al., Dissociable intrinsic connectivity networks for salience processing and executive control, Journal of Neurosciences, 27, 9, pp. 2349-2356, (2007); Shi J., Li K., Yan H., Ying W., Tong W., Gao Q., Et al., Handbook of medical statistics, (2017); Shirer W.R., Ryali S., Rykhlevskaia E., Menon V., Greicius M.D., Decoding subject-driven cognitive states with whole-brain connectivity patterns, Cerebral Cortex, 22, 1, pp. 158-165, (2012); Sokolov A.A., Miall R.C., Ivry R.B., The cerebellum: Adaptive prediction for movement and cognition, Trends in Cognitive Sciences, 21, 5, pp. 313-332, (2017); Stanley D.A., Adolphs R., Perspective toward a neural basis for social behavior, Neuron, 80, 3, pp. 816-826, (2013); Titov D., Diehl-schmid J., Shi K., Perneczky R., Zou N., Grimmer T., Et al., Metabolic connectivity for differential diagnosis of dementing disorders, Journal of Cerebral Blood Flow and Metabolism, 37, 1, pp. 252-262, (2017); Tomasi D., Volkow N.D., Association between functional connectivity hubs and brain networks, Cerebral Cortex, 21, 9, pp. 2003-2013, (2011); Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Et al., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, NeuroImage, 15, 1, pp. 273-289, (2002); Van Overwalle F., Social cognition and the brain: A meta-analysis, Human Brain Mapping, 30, 3, pp. 829-858, (2009); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Et al., EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, European Journal of Nuclear Medicine and Molecular Imaging, 36, 12, pp. 2103-2110, (2009); Verfaillie S.C.J., Adriaanse S.M., Binnewijzend M.A.A., Boellaard R., Scheltens P., Van Berckel B.N.M., Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: Two sides of the same coin?, European Radiology, 25, 10, pp. 3050-3059, (2015); Warren J.D., Rohrer J.D., Hardy J., Disintegrating brain networks: From syndromes to molecular nexopathies, Neuron, 73, 6, pp. 1060-1062, (2012); Whitwell J.L., Josephs K.A., Weigand S.D., Baker M., Altered functional connectivity in asymptomatic MAPT subjects A comparison to bvFTD, Neurology, 77, 9, pp. 866-874, (2011); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Et al., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study, Brain, 132, 11, pp. 2932-2946, (2009); Xia M., Wang J., He Y., BrainNet viewer: A network visualization tool for human brain connectomics, Plos One, 8, 7, (2013); Zamboni G., Huey E.D., Krueger F., Nichelli P.F., Grafman J., Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates, Neurology, 71, 10, pp. 736-742, (2008); Zhou J., Greicius M.D., Gennatas E.D., Growdon M.E., Jang J.Y., Rabinovici G.D., Et al., Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease, Brain, 133, 5, pp. 1352-1367, (2010)","2-s2.0-85071613064"
"Galimberti D.; Fenoglio C.; Serpente M.; Villa C.; Bonsi R.; Arighi A.; Fumagalli G.G.; Del Bo R.; Bruni A.C.; Anfossi M.; Clodomiro A.; Cupidi C.; Nacmias B.; Sorbi S.; Piaceri I.; Bagnoli S.; Bessi V.; Marcone A.; Cerami C.; Cappa S.F.; Filippi M.; Agosta F.; Magnani G.; Comi G.P.; Franceschi M.; Rainero I.; Giordana M.T.; Rubino E.; Ferrero P.; Rogaeva E.; Xi Z.; Confaloni A.; Piscopo P.; Bruno G.; Talarico G.; Cagnin A.; Clerici F.; Dell'Osso B.; Altamura A.C.; Mariani C.; Scarpini E.","Galimberti, Daniela (6701617660); Fenoglio, Chiara (8661375900); Serpente, Maria (26030684600); Villa, Chiara (57195622956); Bonsi, Rossana (55348007500); Arighi, Andrea (18633586600); Fumagalli, Giorgio G. (35867039500); Del Bo, Roberto (7003531061); Bruni, Amalia C. (7102347222); Anfossi, Maria (16836146900); Clodomiro, Alessandra (13409934900); Cupidi, Chiara (14059856700); Nacmias, Benedetta (7003393435); Sorbi, Sandro (7004417453); Piaceri, Irene (34877329900); Bagnoli, Silvia (6701732258); Bessi, Valentina (6504062551); Marcone, Alessandra (6701496511); Cerami, Chiara (25722905400); Cappa, Stefano F. (7005836132); Filippi, Massimo (7202268530); Agosta, Federica (6701687853); Magnani, Giuseppe (24496141800); Comi, Giacomo P. (7201788293); Franceschi, Massimo (7004351220); Rainero, Innocenzo (7003753505); Giordana, Maria Teresa (7004525027); Rubino, Elisa (8918035400); Ferrero, Patrizia (7003489601); Rogaeva, Ekaterina (35372614800); Xi, Zhengrui (55314003700); Confaloni, Annamaria (6602313189); Piscopo, Paola (6603198847); Bruno, Giuseppe (7202705363); Talarico, Giuseppina (7003637692); Cagnin, Annachiara (12778956300); Clerici, Francesca (56013510400); Dell'Osso, Bernardo (13605549800); Altamura, A. Carlo (6603834887); Mariani, Claudio (55810313900); Scarpini, Elio (57210771033)","6701617660; 8661375900; 26030684600; 57195622956; 55348007500; 18633586600; 35867039500; 7003531061; 7102347222; 16836146900; 13409934900; 14059856700; 7003393435; 7004417453; 34877329900; 6701732258; 6504062551; 6701496511; 25722905400; 7005836132; 7202268530; 6701687853; 24496141800; 7201788293; 7004351220; 7003753505; 7004525027; 8918035400; 7003489601; 35372614800; 55314003700; 6602313189; 6603198847; 7202705363; 7003637692; 12778956300; 56013510400; 13605549800; 6603834887; 55810313900; 57210771033","Autosomal dominant frontotemporal lobar degeneration due to the C9ORF72 hexanucleotide repeat expansion: Late-onset psychotic clinical presentation","2013","Biological Psychiatry","74","5","","384","391","7","102","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882289214&doi=10.1016%2fj.biopsych.2013.01.031&partnerID=40&md5=07ba6ccca6d0d71b1134a1b7a06baf10","Background: A hexanucleotide repeat expansion in the first intron of C9ORF72 has been shown to be responsible for a high number of familial cases of amyotrophic lateral sclerosis or frontotemporal lobar degeneration (FTLD). Atypical presentations have been described, particularly psychosis. Methods: We determined the frequency of the hexanucleotide repeat expansions in a population of 651 FTLD patients and compared the clinical characteristics of carriers and noncarriers. In addition, we genotyped 21 patients with corticobasal syndrome, 31 patients with progressive supranuclear palsy, and 222 control subjects. Results: The pathogenic repeat expansion was detected in 39 (6%) patients with FTLD (17 male and 22 female subjects); however, it was not detected in any corticobasal syndrome and progressive supranuclear palsy patients or controls. Twenty-four of 39 carriers had positive family history for dementia and/or amyotrophic lateral sclerosis (61.5%), whereas only 145 of 612 noncarriers had positive family history (23.7%; p<.000001). Clinical phenotypes of carriers included 29 patients with the behavioral variant frontotemporal dementia (bvFTD; 5.2% of all bvFTD cases), 8 with bvFTD/motor neuron disease (32% bvFTD/motor neuron disease cases), 2 with semantic dementia (5.9% of patients with semantic dementia), and none with progressive nonfluent aphasia. The presentation with late-onset psychosis (median age = 63 years) was more frequent in carriers than noncarriers (10/33 vs. 3/37, p =.029), as well as the presence of cognitive impairment at onset (15/33 vs. 5/37; p =.0039). Conclusions: The repeat expansion in C9ORF72 is a common cause of FTLD and often presents with late-onset psychosis or memory impairment. © 2013 Society of Biological Psychiatry.","C9ORF72; clinical presentation; dementia; frontotemporal lobar degeneration; hexanucleotide repeat expansion; late onset psychosis; phenotype","hexanucleotide; nucleotide derivative; unclassified drug; adult; aged; amyotrophic lateral sclerosis; article; clinical feature; controlled study; corticobasal syndrome; female; frontal variant frontotemporal dementia; frontotemporal dementia; gene frequency; genotype; heterozygote; human; major clinical study; male; motor neuron disease; neurologic disease; nucleotide repeat; priority journal; progressive nonfluent aphasia; progressive supranuclear palsy; psychosis; semantic dementia; syndrome","Dejesus-Hernandez M., MacKenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, pp. 245-256, (2011); Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, pp. 257-268, (2011); Gijselinck I., Van Langenhove T., Van Der Zee J., Sleegers K., Philtjens S., Kleinberger G., A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study, Lancet Neurol, 11, pp. 54-65, (2012); Byrne S., Elamin M., Bede P., Shatunov A., Walsh C., Corr B., Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: A population-based cohort study, Lancet Neurol, 11, pp. 232-240, (2012); Snowden J.S., Rollinson S., Thompson J.C., Harris J.M., Stopford C.L., Richardson A.M., Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations, Brain, 135, pp. 693-708, (2012); Hsiung G.Y., Dejesus-Hernandez M., Feldman H.H., Sengdy P., Bouchard-Kerr P., Dwosh E., Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p, Brain, 135, pp. 709-722, (2012); Simon-Sanchez J., Dopper E.G., Cohn-Hokke P.E., Hukema R.K., Nicolaou N., Seelaar H., The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions, Brain, 135, pp. 723-735, (2012); Mahoney C.J., Beck J., Rohrer J.D., Lashley T., Mok K., Shakespeare T., Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features, Brain, 135, pp. 736-750, (2012); Cooper-Knock J., Hewitt C., Highley J.R., Brockington A., Milano A., Man S., Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72, Brain, 135, pp. 751-764, (2012); Boeve B.F., Boylan K.B., Graff-Radford N.R., Dejesus-Hernandez M., Knopman D.S., Pedraza O., Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72, Brain, 135, pp. 765-783, (2012); Majounie E., Renton A.E., Mok K., Dopper E.G., Waite A., Rollinson S., Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: A cross-sectional study, Lancet Neurol, 11, pp. 323-330, (2012); Chio A., Borghero G., Restagno G., Mora G., Drepper C., Traynor B.J., Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72, Brain, 135, pp. 784-793, (2012); Sabatelli M., Conforti F.L., Zollino M., Mora G., Monsurro M.R., Volanti P., C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population, Neurobiol Aging, 33, (2012); Ratti A., Corrado L., Castellotti B., Del Bo R., Fogh I., Cereda C., C9ORF72 repeat expansion in a large Italian ALS cohort: Evidence of a founder effect, Neurobiol Aging, 33, (2012); Floris G., Borghero G., Cannas A., Di Stefano F., Costantino E., Murru M.R., Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: A peculiar phenotype?, J Neurol, 259, pp. 1749-1751, (2012); Calvo A., Moglia C., Canosa A., Cistaro A., Valentini C., Carrara G., Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the c9orf72 gene, J Neurol, 259, pp. 2723-2725, (2012); Arighi A., Fumagalli G.G., Jacini F., Fenoglio C., Ghezzi L., Pietroboni A.M., Early onset behavioural variant Frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: Psychiatric clinical presentations, J Alzheimers Dis, 31, pp. 447-452, (2012); Murray M.E., Dejesus-Hernandez M., Rutherford N.J., Baker M., Duara R., Graff-Radford N.R., Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72, Acta Neuropathol, 122, pp. 673-690, (2011); First M.B., Spitzer R.L., Gibbon L., Williams J.B.V., Structured Clinical Interview for DSM-IV-TR Axis i Disorders, Research Version, Patient Edition (SCID-I/P), (2002); First M.B., Gibbon M., Spitzer R.L., Jbw W., Benjamin L.S., Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II), (1997); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Litvan I., Bhatia K.P., Burn D.J., Goetz C.G., Lang A.E., McKeith I., Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders, Mov Disord, 18, pp. 467-486, (2003); Dobson-Stone C., Hallupp M., Bartley L., Shepherd C.E., Halliday G.M., Schofield P.R., C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts, Neurology, 79, pp. 995-1001, (2012); Villa C., Ghezzi L., Pietroboni A.M., Fenoglio C., Cortini F., Serpente M., A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia, J Alzheimers Dis, 26, pp. 19-26, (2011); Pietroboni A.M., Fumagalli G.G., Ghezzi L., Fenoglio C., Cortini F., Serpente M., Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred, J Alzheimers Dis, 24, pp. 253-259, (2011); Rainero I., Rubino E., Negro E., Gallone S., Galimberti D., Gentile S., Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene, Biol Psychiatry, 70, (2011); Cerami C., Marcone A., Galimberti D., Villa C., Scarpini E., Cappa S.F., From genotype to phenotype: Two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder, J Alzheimers Dis, 27, pp. 791-797, (2011); Caso F., Villa C., Fenoglio C., Santangelo R., Agosta F., Coppi E., The progranulin (GRN) Cys157LysfsX97 mutation is associated with nonfluent variant of primary progressive aphasia clinical phenotype, J Alzheimers Dis, 28, pp. 759-763, (2012); Bessi V., Bagnoli S., Nacmias B., Tedde A., Sorbi S., Bracco L., Semantic dementia associated with mutation V363I in the tau gene, J Neurol Sci, 296, pp. 112-114, (2010); Bagnoli S., Piaceri I., Tedde A., Piacentini S., Nannucci S., Bracco L., Progranulin genetic screening in frontotemporal lobar degeneration patients from central Italy, Cell Mol Neurobiol, 32, pp. 13-16, (2012); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Benussi L., BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease, J Alzheimers Dis, 23, pp. 701-707, (2011); Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values, Clin Chem, 47, pp. 1776-1781, (2001); Carecchio M., Fenoglio C., Cortini F., Comi C., Benussi L., Ghidoni R., Cerebrospinal fluid biomarkers in Progranulin mutations carriers, J Alzheimers Dis, 27, pp. 781-790, (2011); Pickering-Brown S.M., Rollinson S., Du Plessis D., Morrison K.E., Varma A., Richardson A.M., Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: Comparison with patients with MAPT and no known mutations, Brain, 131, pp. 721-731, (2008); Sha S.J., Takada L.T., Rankin K.P., Yokoyama J.S., Rutherford N.J., Fong J.C., Frontotemporal dementia due to C9ORF72 mutations: Clinical and imaging features, Neurology, 79, pp. 1002-1011, (2012); Ikeuchi T., Imamura T., Kawase Y., Kitade Y., Tsuchiya M., Tokutake T., Evidence for a common founder and clinical characteristics of Japanese families with the MAPT R406W mutation, Dement Geriatr Cogn Dis Extra, 1, pp. 267-275, (2011); Galimberti D., Scarpini E., Clinical phenotypes and genetic biomarkers of FTLD, J Neural Transm, 119, pp. 851-860, (2012); Baborie A., Griffiths T.D., Jaros E., Momeni P., McKeith I.G., Burn D.J., Frontotemporal dementia in elderly individuals, Arch Neurol, 69, pp. 1052-1060, (2012); Lindquist S., Duno M., Batbayli M., Puschmann A., Braendgaard H., Mardosiene S., Et al., Corticobasal and ataxia syndromes widen the spectrum of C9ORF72 hexanucleotide expansion disease, Clin Genet, 83, pp. 279-283, (2013); Xi Z., Zinman L., Grinberg Y., Moreno D., Sato C., Bilbao J.M., Et al., Investigation of C9orf72 in 4 neurodegenerative disorders, Arch Neurol, 69, pp. 1583-1590, (2012); Whitwell J.L., Weigand S.D., Boeve B.F., Senjem M.L., Gunter J.L., Dejesus-Hernandez M., Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics, Brain, 135, pp. 794-806, (2012)","2-s2.0-84882289214"
"Crespi C.; Dodich A.; Cappa S.F.; Canessa N.; Iannaccone S.; Corbo M.; Lunetta C.; Falini A.; Cerami C.","Crespi, Chiara (57034303800); Dodich, Alessandra (56001713900); Cappa, Stefano F. (7005836132); Canessa, Nicola (24334215800); Iannaccone, Sandro (7005943171); Corbo, Massimo (7006723926); Lunetta, Christian (7801365932); Falini, Andrea (7003494994); Cerami, Chiara (25722905400)","57034303800; 56001713900; 7005836132; 24334215800; 7005943171; 7006723926; 7801365932; 7003494994; 25722905400","Multimodal MRI quantification of the common neurostructural bases within the FTD-ALS continuum","2018","Neurobiology of Aging","62","","","95","104","9","14","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033396924&doi=10.1016%2fj.neurobiolaging.2017.09.019&partnerID=40&md5=abdea07b579a766e32e18d42d8c86f6f","The continuum hypothesis linking the behavioral variant of frontotemporal dementia (bvFTD) and amyotrophic lateral sclerosis (ALS) is supported by clinical, pathological, genetic, and neuroimaging evidence. In the present multimodal magnetic resonance study, we characterized the site and extent of shared neurostructural changes in gray and white matter in 20 bvFTD and 19 ALS patients without dementia. We found an overlap of macrostructural and microstructural damage in both patient groups compared with healthy controls, involving the right orbital and the bilateral anterior cingulate cortices, the corticospinal tract and corpus callosum. The quantification of gray and white matter damage within the areas of shared alterations highlighted a higher degree of atrophy in orbitofrontal and frontomedial regions in patients with more severe executive and/or behavioral symptoms, and a higher degree of degeneration in the motor pathway in patients with more severe motor neuron disorders. Our finding provides additional evidence confirming the FTD-ALS continuum hypothesis and supports the notion of a bimodal but convergent pattern of neurostructural changes characterizing bvFTD and ALS. © 2017 Elsevier Inc.","ALS-FTD continuum hypothesis; Amyotrophic lateral sclerosis; Behavioral variant of frontotemporal dementia; Corticospinal tract; Tract-based spatial statistics; Voxel-based morphometry","Aged; Amyotrophic Lateral Sclerosis; Atrophy; Behavior; Efferent Pathways; Executive Function; Female; Frontotemporal Dementia; Gray Matter; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Nerve Degeneration; White Matter; adult; aged; amyotrophic lateral sclerosis; anterior cingulate; Article; behavior disorder; brain atrophy; clinical article; controlled study; corpus callosum; executive function; female; frontal variant frontotemporal dementia; gray matter; human; male; motor neuron disease; nerve degeneration; neuroimaging; nuclear magnetic resonance imaging; orbital cortex; priority journal; pyramidal tract; white matter; amyotrophic lateral sclerosis; atrophy; behavior; diagnostic imaging; efferent nerve; frontotemporal dementia; middle aged; nuclear magnetic resonance imaging; pathology; procedures","Abrahams S., Goldstein L.H., Suckling J., Ng V., Simmons A., Chitnis X., Atkins L., Williams S.C.R., Leigh P.N., Frontotemporal white matter changes in amyotrophic lateral sclerosis, J. Neurol., 252, pp. 321-331, (2005); Agosta F., Ferraro P.M., Riva N., Spinelli E.G., Chio A., Canu E., Valsasina P., Lunetta C., Iannaccone S., Copetti M., Prudente E., Comi G., Falini A., Filippi M., Structural brain correlates of cognitive and behavioral impairment in MND, Hum. Brain Mapp., 37, pp. 1614-1626, (2016); Ahmed R.M., Irish M., Piguet O., Halliday G.M., Ittner L.M., Farooqi S., Hodges J.R., Kiernan M.C., Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism, Lancet Neurol., 15, pp. 332-342, (2016); Ashburner J., A fast diffeomorphic image registration algorithm, Neuroimage, 38, pp. 95-113, (2007); Ashburner J., Computational anatomy with the SPM software, Magn. Reson. Imaging, 27, pp. 1163-1174, (2009); Brettschneider J., Del Tredici K., Irwin D.J., Grossman M., Robinson J.L., Toledo J.B., Fang L., Van Deerlin V.M., Ludolph A.C., Lee V.M.Y., Braak H., Trojanowski J.Q., Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD), Acta Neuropathol., 127, pp. 423-439, (2014); Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Suh E., Van Deerlin V.M., Wood E.M., Baek Y., Kwong L., Lee E.B., Elman L., McCluskey L., Fang L., Feldengut S., Ludolph A.C., Lee V.M.Y., Braak H., Trojanowski J.Q., Stages of pTDP-43 pathology in amyotrophic lateral sclerosis, Ann. Neurol., 74, pp. 20-38, (2013); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph. Lateral Scler. Other Motor Neuron Disord., 1, pp. 293-299, (2000); Burrell J.R., Kiernan M.C., Vucic S., Hodges J.R., Motor neuron dysfunction in frontotemporal dementia, Brain, 134, pp. 2582-2594, (2011); Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A., The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function, J. Neurol. Sci., 169, pp. 13-21, (1999); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Lunetta C., Consonni M., Scola E., Falini A., Cappa S.F., Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study, Amyotroph. Lateral Scler. Frontotemporal Degener., 15, pp. 21-29, (2013); Cerami C., Marcone A., Crespi C., Iannaccone S., Marangoni C., Dodich A., Giusti M.C., Zamboni M., Golzi V., Cappa S.F., Motor neuron dysfunctions in the frontotemporal lobar degeneration spectrum: a clinical and neurophysiological study, J. Neurol. Sci., 351, pp. 72-77, (2015); Christidi F., Karavasilis E., Zalonis I., Ferentinos P., Giavri Z., Wilde E.A., Xirou S., Rentzos M., Zouvelou V., Velonakis G., Toulas P., Efstathopoulos E., Poulou L., Argyropoulos G., Athanasakos A., Zambelis T., Levin H.S., Karandreas N., Kelekis N., Evdokimidis I., Memory-related white matter tract integrity in amyotrophic lateral sclerosis: an advanced neuroimaging and neuropsychological study, Neurobiol. Aging, 49, pp. 69-78, (2017); Consonni M., Iannaccone S., Cerami C., Frasson P., Lacerenza M., Lunetta C., Corbo M., Cappa S.F., The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria, Behav. Neurol., 27, pp. 143-153, (2013); Daianu M., Mendez M.F., Baboyan V.G., Jin Y., Melrose R.J., Jimenez E.E., Thompson P.M., An advanced white matter tract analysis in frontotemporal dementia and early-onset Alzheimer's disease, Brain Imaging Behav., 10, pp. 1038-1053, (2015); Devenney E., Vucic S., Hodges J.R., Kiernan M.C., Motor neuron disease-frontotemporal dementia: a clinical continuum, Expert Rev. Neurother., 15, pp. 509-522, (2015); Douaud G., Filippini N., Knight S., Talbot K., Turner M.R., Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosis, Brain, 134, pp. 3470-3479, (2011); Douaud G., Jbabdi S., Behrens T.E.J., Menke R.A., Gass A., Monsch A.U., Rao A., Whitcher B., Kindlmann G., Matthews P.M., Smith S., DTI measures in crossing-fibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer's disease, Neuroimage, 55, pp. 880-890, (2011); Douaud G., Menke R.A.L., Gass A., Monsch A.U., Rao A., Whitcher B., Zamboni G., Matthews P.M., Sollberger M., Smith S., Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease, J. Neurosci., 33, pp. 2147-2155, (2013); Eickhoff S.B., Stephan K.E., Mohlberg H., Grefkes C., Fink G.R., Amunts K., Zilles K., A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data, Neuroimage, 25, pp. 1325-1335, (2005); Ferrari R., Kapogiannis D., Huey E.D., Momeni P., FTD and ALS: a tale of two diseases, Curr. Alzheimers Res., 8, pp. 273-294, (2011); Filippini N., Douaud G., MacKay C.E., Knight S., Talbot K., Turner M.R., Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis, Neurology, 75, pp. 1645-1652, (2010); Goldstein L.H., Abrahams S., Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment, Lancet Neurol., 12, pp. 368-380, (2013); Hua K., Zhang J., Wakana S., Jiang H., Li X., Reich D.S., Calabresi P.A., Pekar J.J., van Zijl P.C.M., Mori S., Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification, Neuroimage, 39, pp. 336-347, (2008); Lattante S., Ciura S., Rouleau G.A., Kabashi E., Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD), Trends Genet., 31, pp. 263-273, (2015); Lillo P., Hodges J.R., Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders, J. Clin. Neurosci, 16, pp. 1131-1135, (2009); Lillo P., Mioshi E., Burrell J.R., Kiernan M.C., Hodges J.R., Hornberger M., Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum, PLoS One, 7, (2012); Ling S.C., Polymenidou M., Cleveland D.W., Converging mechanisms in als and FTD: disrupted RNA and protein homeostasis, Neuron, 79, pp. 416-438, (2013); Lomen-Hoerth C., Clinical phenomenology and neuroimaging correlates in ALS-FTD, J. Mol. Neurosci., 45, pp. 656-662, (2011); Lomen-Hoerth C., Anderson T., Miller B., The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology, 59, pp. 1077-1079, (2002); Mahoney C.J., Ridgway G.R., Malone I.B., Downey L.E., Beck J., Kinnunen K.M., Schmitz N., Golden H.L., Rohrer J.D., Schott J.M., Rossor M.N., Ourselin S., Mead S., Fox N.C., Warren J.D., Profiles of white matter tract pathology in frontotemporal dementia, Hum. Brain Mapp., 35, pp. 4163-4179, (2014); Muller H.-P., Turner M.R., Grosskreutz J., Abrahams S., Bede P., Govind V., Prudlo J., Ludolph A.C., Filippi M., Kassubek J., A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis, J. Neurol. Neurosurg. Psychiatry, 87, pp. 570-579, (2016); Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M.-Y., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, pp. 130-133, (2006); Nichols T., Brett M., Andersson J., Wager T., Poline J.B., Valid conjunction inference with the minimum statistic, Neuroimage, 25, pp. 653-660, (2005); Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Lynch C., Pender N., Hardiman O., The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study, J. Neurol. Neurosurg. Psychiatry, 83, pp. 102-108, (2012); Piguet O., Hodges J.R., Behavioural-variant frontotemporal dementia: an update, Dement. Neuropsychol., 7, pp. 10-18, (2013); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Ringholz G.M., Appel S.H., Bradshaw M., Cooke N.A., Mosnik D.M., Schulz P.E., Prevalence and patterns of cognitive impairment in sporadic ALS, Neurology, 65, pp. 586-590, (2005); Schulthess I., Gorges M., Muller H.-P., Lule D., Del Tredici K., Ludolph A.C., Kassubek J., Functional connectivity changes resemble patterns of pTDP-43 pathology in amyotrophic lateral sclerosis, Sci. Rep., 6, (2016); Schuster C., Elamin M., Hardiman O., Bede P., The segmental diffusivity profile of amyotrophic lateral sclerosis associated white matter degeneration, Eur. J. Neurol., 23, pp. 1361-1371, (2016); Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Gorno-Tempini M.L., Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Arch. Neurol., 65, pp. 249-255, (2008); Smith M.C., Nerve fibre degeneration in the brain in amyotrophic lateral sclerosis, J. Neurol. Neurosurg. Psychiatry, 23, pp. 269-282, (1960); Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Behrens T.E.J., Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data, Neuroimage, 31, pp. 1487-1505, (2006); Smith S.M., Nichols T.E., Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference, Neuroimage, 44, pp. 83-98, (2009); Strong M.J., Abrahams S., Goldstein L.H., Woolley S., Mclaughlin P., Snowden J., Mioshi E., Roberts-South A., Benatar M., HortobaGyi T., Rosenfeld J., Silani V., Ince P.G., Turner M.R., Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria, Amyotroph. Lateral Scler. Front. Degener., 18, pp. 153-174, (2017); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Murphy J., Shoesmith C., Rosenfeld J., Leigh P.N., Bruijn L., Ince P., Figlewicz D., Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Amyotroph. Lateral Scler., 10, pp. 131-146, (2009); Trojsi F., Esposito F., de Stefano M., Buonanno D., Conforti F.L., Corbo D., Piccirillo G., Cirillo M., Monsurro M.R., Montella P., Tedeschi G., Functional overlap and divergence between ALS and bvFTD, Neurobiol. Aging, 36, pp. 413-423, (2015); Tsermentseli S., Leigh P.N., Goldstein L.H., The anatomy of cognitive impairment in amyotrophic lateral sclerosis: more than frontal lobe dysfunction, Cortex, 48, pp. 166-182, (2012); Turner M.R., Agosta F., Govind V., Bede P., Lule D., Verstraete E., Neuroimaging in amyotrophic lateral sclerosis Review, Biomarkers Med., 6, pp. 319-337, (2012); Turner M.R., Kiernan M.C., Leigh P.N., Talbot K., Biomarkers in amyotrophic lateral sclerosis, Lancet Neurol., 8, pp. 94-109, (2009); Turner M.R., Verstraete E., What does imaging reveal about the pathology of amyotrophic lateral sclerosis?, Curr. Neurol. Neurosci. Rep., 15, (2015); Weishaupt J.H., Hyman T., Dikic I., Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia, Trends Mol. Med., 22, pp. 769-783, (2016); Whitwell J.L., Avula R., Senjem M.L., Kantarci K., Weigand S.D., Samikoglu A., Edmonson H.A., Vemuri P., Knopman D.S., Boeve B.F., Petersen R.C., Josephs K.A., Jack C.R., Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia, Neurology, 74, pp. 1279-1287, (2010); Woolley S.C., Zhang Y., Schuff N., Weiner M.W., Katz J.S., Neuroanatomical correlates of apathy in ALS using 4 Tesla diffusion tensor MRI, Amyotroph. Lateral Scler., 12, pp. 52-58, (2011); Zhang Y., Schuff N., Du A.-T., Rosen H.J., Kramer J.H., Gorno-Tempini M.L., Miller B.L., Weiner M.W., White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI, Brain, 132, pp. 2579-2592, (2009)","2-s2.0-85033396924"
"Tondo G.; Carli G.; Santangelo R.; Mattoli M.V.; Presotto L.; Filippi M.; Magnani G.; Iannaccone S.; Cerami C.; Perani D.","Tondo, Giacomo (55242296300); Carli, Giulia (57201314331); Santangelo, Roberto (57191567809); Mattoli, Maria Vittoria (40461964300); Presotto, Luca (52564081500); Filippi, Massimo (7202268530); Magnani, Giuseppe (24496141800); Iannaccone, Sandro (7005943171); Cerami, Chiara (25722905400); Perani, Daniela (7005630261)","55242296300; 57201314331; 57191567809; 40461964300; 52564081500; 7202268530; 24496141800; 7005943171; 25722905400; 7005630261","Biomarker-based stability in limbic-predominant amnestic mild cognitive impairment","2021","European Journal of Neurology","28","4","","1123","1133","10","9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096961387&doi=10.1111%2fene.14639&partnerID=40&md5=8ae9098de8d76f44ede1dcad8c2d2ba5","Background: The amnestic presentation of mild cognitive impairment (aMCI) represents the most common prodromal stage of Alzheimer's disease (AD) dementia. There is, however, some evidence of aMCI with typical amnestic syndrome but showing long-term clinical stability. The ability to predict stability or progression to dementia in the aMCI condition is important, particularly for the selection of candidates in clinical trials. We aimed to establish the role of in vivo biomarkers, as assessed by cerebrospinal fluid (CSF) measures and [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging, in predicting prognosis in a large aMCI cohort. Methods: We conducted a retrospective study, including 142 aMCI subjects who had a long follow-up (4–19 years), baseline CSF data and [18F]FDG-PET scans individually assessed by validated voxel-based procedures, classifying subjects into either limbic-predominant or AD-like hypometabolism patterns. Results: The two aMCI cohorts were clinically comparable at baseline. At follow-up, the aMCI group with a limbic-predominant [18F]FDG-PET pattern showed clinical stability over a very long follow-up (8.20 ± 3.30 years), no decline in Mini-Mental State Examination score, and only 7% conversion to dementia. Conversely, the aMCI group with an AD-like [18F]FDG-PET pattern had a high rate of dementia progression (86%) over a shorter follow-up (6.47 ± 2.07 years). Individual [18F]FDG-PET hypometabolism patterns predicted stability or conversion with high accuracy (area under the curve = 0.89), sensitivity (0.90) and specificity (0.89). In the limbic-predominant aMCI cohort, CSF biomarkers showed large variability and no prognostic value. Conclusions: In a large series of clinically comparable subjects with aMCI at baseline, the specific [18F]FDG-PET limbic-predominant hypometabolism pattern was associated with clinical stability, making progression to AD very unlikely. The identification of a biomarker-based benign course in aMCI subjects has important implications for prognosis and in planning clinical trials. © 2020 European Academy of Neurology","cerebrospinal fluid; limbic-predominant; mild cognitive impairment; tauopathy; [<sup>18</sup>F]FDG-PET","Alzheimer Disease; Biomarkers; Brain; Cognitive Dysfunction; Fluorodeoxyglucose F18; Humans; Positron-Emission Tomography; Retrospective Studies; amyloid beta protein[1-42]; apolipoprotein E; biological marker; fluorodeoxyglucose f 18; tau protein; biological marker; aged; Alzheimer disease; animal experiment; animal model; Article; cerebrospinal fluid analysis; clinical feature; cohort analysis; controlled study; disease exacerbation; female; follow up; human; limbic cortex; major clinical study; male; measurement accuracy; mild cognitive impairment; Mini Mental State Examination; nerve degeneration; nonhuman; positron emission tomography; predictive value; priority journal; prognosis; retrospective study; sensitivity and specificity; tauopathy; Alzheimer disease; brain; cognitive defect; diagnostic imaging","Albert M.S., DeKosky S.T., Dickson D., Et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s Dement, 7, pp. 270-279, (2011); Petersen R.C., Roberts R.O., Knopman D.S., Et al., Mild cognitive impairment: ten years later, Arch Neurol, 66, pp. 1447-1455, (2009); Iaccarino L., Sala A., Perani D., Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET, Ann Clin Transl Neurol, 6, pp. 1113-1120, (2019); Sperling R.A., Jack C.R., Aisen P.S., Testing the right target and right drug at the right stage, Sci Transl Med, 3, 111, (2011); Petersen R.C., Lundt E.S., Therneau T.M., Et al., Predicting progression to mild cognitive impairment, Ann Neurol, 85, pp. 155-160, (2019); Jack C.R., Bennett D.A., Blennow K., Et al., NIA-AA research framework: toward a biological definition of Alzheimer’s disease, Alzheimer’s Dement, 14, pp. 535-562, (2018); Bittar A., Bhatt N., Kayed R., Advances and considerations in AD tau-targeted immunotherapy, Neurobiol Dis, 134, (2020); Barkhof F., Polvikoski T.M., Van Straaten E.C.W., Et al., The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old, Neurology, 69, pp. 1521-1527, (2007); Raji C.A., Lopez O.L., Kuller L.H., Carmichael O.T., Becker J.T., Age, Alzheimer disease, and brain structure, Neurology, 73, pp. 1899-1905, (2009); Jack C.R., Dickson D.W., Parisi J.E., Et al., Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia, Neurology, 58, pp. 750-757, (2002); Perani D., Cerami C., Caminiti S.P., Et al., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, J Nucl Med Mol Imaging, 43, pp. 499-508, (2016); Cerami C., Della Rosa P.A., Magnani G., Et al., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, NeuroImage Clin, 7, pp. 187-194, (2015); Caminiti S.P., Ballarini T., Sala A., Et al., FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort, NeuroImage Clin, 18, pp. 167-177, (2018); Frisoni G.B., Boccardi M., Barkhof F., Et al., Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers, Lancet Neurol, 16, pp. 661-676, (2017); Schmidtke K., Hermeneit S., High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients, Int Psychogeriatrics, 20, pp. 96-108, (2008); Caffarra P., Venneri A., Isolated degenerative amnesia without dementia: an 8-year longitudinal study, Neurocase, 2, pp. 99-106, (1996); Lucchelli F., De Renzi E., Perani D., Fazio F., Primary amnesia of insidious onset with subsequent stabilisation, J Neurol Neurosurg Psychiatry, 57, pp. 1366-1370, (1994); Miceli G., Colosimo C., Daniele A., Marra C., Perani D., Fazio F., Isolated amnesia with slow onset and stable course, without ensuing dementia: MRI and PET data and a six-year neuropsychological follow-up, Dement Geriatr Cogn Disord, 7, pp. 104-110, (1996); Marra C., Villa G., Quaranta D., Valenza A., Vita M.G., Gainotti G., Probable Alzheimer’s disease patients presenting as “focal temporal lobe dysfunction” show a slow rate of cognitive decline, J Int Neuropsychol Soc, 18, pp. 144-150, (2012); Cerami C., Dodich A., Iannaccone S., Et al., A biomarker study in long-lasting amnestic mild cognitive impairment, Alzheimers Res Ther, 10, (2018); Nelson P.T., Dickson D.W., Trojanowski J.Q., Et al., Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report, Brain, 142, pp. 1503-1527, (2019); Petersen R.C., Mild cognitive impairment as a diagnostic entity, J Intern Med, 256, pp. 183-194, (2004); Della Rosa P.A., Cerami C., Gallivanone F., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Perani D., Della Rosa P.A., Cerami C., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, NeuroImage Clin, 6, pp. 445-454, (2014); Caroli A., Prestia A., Galluzzi S., Et al., Mild cognitive impairment with suspected nonamyloid pathology (SNAP): prediction of progression, Neurology, 84, pp. 508-515, (2015); Varrone A., Asenbaum S., Vander Borght T., Et al., EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, Eur J Nucl Med Mol Imaging, 36, pp. 2103-2110, (2009); Sjogren M., Vanderstichele H., Agren H., Et al., Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values, Clin Chem, 47, pp. 1776-1781, (2001); Shaw L.M., Vanderstichele H., Knapik-Czajka M., Et al., Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects, Ann Neurol, 65, pp. 403-413, (2009); Mattsson N., Insel P.S., Donohue M., Et al., Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer’s disease, Brain, 138, pp. 772-783, (2014); Jack C.R., Bennett D.A., Blennow K., Et al., A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers, Neurology, 87, pp. 539-547, (2016); Presotto L., Ballarini T., Caminiti S.P., Bettinardi V., Gianolli L., Perani D., Validation of 18 F-FDG-PET single-subject optimized SPM procedure with different PET scanners, Neuroinformatics, 15, pp. 151-163, (2017); Duits F.H., Teunissen C.E., Bouwman F.H., Et al., The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean?, Alzheimer’s Dement, 10, pp. 713-723, (2014); Laforce R., Soucy J.-P., Sellami L., Et al., Molecular imaging in dementia: past, present, and future, Alzheimer’s Dement, 14, pp. 1522-1552, (2018); Nobili F., Arbizu J., Bouwman F., Et al., EANM-EAN recommendations for the use of brain 18 F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative cognitive impairment and dementia: Delphi consensus, Eur J Neurol, 25, pp. 1201-1217, (2018); Shaffer J.L., Petrella J.R., Sheldon F.C., Et al., Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers, Radiology, 266, pp. 583-591, (2013); Yuan Y., Gu Z.-X., Wei W.-S., Fluorodeoxyglucose–positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis, Am J Neuroradiol, 30, pp. 404-410, (2009); Dani M., Brooks D.J., Edison P., Suspected non-Alzheimer’s pathology–Is it non-Alzheimer’s or non-amyloid?, Ageing Res Rev, 36, pp. 20-31, (2017); Botha H., Mantyh W.G., Murray M.E., Et al., FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis, Brain, 141, pp. 1201-1217, (2018); ten Kate M., Dicks E., Visser P.J., Et al., Atrophy subtypes in prodromal Alzheimer’s disease are associated with cognitive decline, Brain, 141, pp. 3443-3456, (2018); Abner E.L., Kryscio R.J., Schmitt F.A., Et al., Outcomes after diagnosis of mild cognitive impairment in a large autopsy series, Ann Neurol, 81, pp. 549-559, (2017); Manly J.J., Tang M., Schupf N., Stern Y., Vonsattel J.G., Mayeux R., Frequency and course of mild cognitive impairment in a multiethnic community, Ann Neurol Off J Am Neurol Assoc Child Neurol Soc, 63, pp. 494-506, (2008); Ravaglia G., Forti P., Montesi F., Et al., Mild cognitive impairment: epidemiology and dementia risk in an elderly Italian population, J Am Geriatr Soc, 56, pp. 51-58, (2008); Roberts R.O., Knopman D.S., Mielke M.M., Et al., Higher risk of progression to dementia in mild cognitive impairment cases who revert to normal, Neurology, 82, pp. 317-325, (2014); Sachdev P.S., Lipnicki D.M., Crawford J., Et al., Factors predicting reversion from mild cognitive impairment to normal cognitive functioning: a population-based study, PLoS One, 8, (2013)","2-s2.0-85096961387"
"Caminiti S.P.; Ballarini T.; Sala A.; Cerami C.; Presotto L.; Santangelo R.; Fallanca F.; Vanoli E.G.; Gianolli L.; Iannaccone S.; Magnani G.; Perani D.; Parnetti L.; Eusebi P.; Frisoni G.; Nobili F.; Picco A.; Scarpini E.","Caminiti, Silvia Paola (56584243600); Ballarini, Tommaso (57190231611); Sala, Arianna (9274476600); Cerami, Chiara (25722905400); Presotto, Luca (52564081500); Santangelo, Roberto (57191567809); Fallanca, Federico (23488654900); Vanoli, Emilia Giovanna (56414581300); Gianolli, Luigi (6602754456); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Perani, Daniela (7005630261); Parnetti, Lucilla (35412328100); Eusebi, Paolo (24477129600); Frisoni, Giovanni (56214208300); Nobili, Flavio (57206948479); Picco, Agnese (40462180900); Scarpini, Elio (57210771033)","56584243600; 57190231611; 9274476600; 25722905400; 52564081500; 57191567809; 23488654900; 56414581300; 6602754456; 7005943171; 24496141800; 7005630261; 35412328100; 24477129600; 56214208300; 57206948479; 40462180900; 57210771033","FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort","2018","NeuroImage: Clinical","18","","","167","177","10","89","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85041667601&doi=10.1016%2fj.nicl.2018.01.019&partnerID=40&md5=90dd69e9485cd85c407f598e086f149f","Background/aims: In this multicentre study in clinical settings, we assessed the accuracy of optimized procedures for FDG-PET brain metabolism and CSF classifications in predicting or excluding the conversion to Alzheimer's disease (AD) dementia and non-AD dementias. Methods: We included 80 MCI subjects with neurological and neuropsychological assessments, FDG-PET scan and CSF measures at entry, all with clinical follow-up. FDG-PET data were analysed with a validated voxel-based SPM method. Resulting single-subject SPM maps were classified by five imaging experts according to the disease-specific patterns, as “typical-AD”, “atypical-AD” (i.e. posterior cortical atrophy, asymmetric logopenic AD variant, frontal-AD variant), “non-AD” (i.e. behavioural variant FTD, corticobasal degeneration, semantic variant FTD; dementia with Lewy bodies) or “negative” patterns. To perform the statistical analyses, the individual patterns were grouped either as “AD dementia vs. non-AD dementia (all diseases)” or as “FTD vs. non-FTD (all diseases)”. Aβ42, total and phosphorylated Tau CSF-levels were classified dichotomously, and using the Erlangen Score algorithm. Multivariate logistic models tested the prognostic accuracy of FDG-PET-SPM and CSF dichotomous classifications. Accuracy of Erlangen score and Erlangen Score aided by FDG-PET SPM classification was evaluated. Results: The multivariate logistic model identified FDG-PET “AD” SPM classification (Expβ = 19.35, 95% C.I. 4.8–77.8, p < 0.001) and CSF Aβ42 (Expβ = 6.5, 95% C.I. 1.64–25.43, p < 0.05) as the best predictors of conversion from MCI to AD dementia. The “FTD” SPM pattern significantly predicted conversion to FTD dementias at follow-up (Expβ = 14, 95% C.I. 3.1–63, p < 0.001). Overall, FDG-PET-SPM classification was the most accurate biomarker, able to correctly differentiate either the MCI subjects who converted to AD or FTD dementias, and those who remained stable or reverted to normal cognition (Expβ = 17.9, 95% C.I. 4.55–70.46, p < 0.001). Conclusions: Our results support the relevant role of FDG-PET-SPM classification in predicting progression to different dementia conditions in prodromal MCI phase, and in the exclusion of progression, outperforming CSF biomarkers. © 2018","Alzheimer's disease dementia; Clinical setting; Erlangen Score; Frontotemporal dementia; Prognosis","Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cognitive Dysfunction; Disease Progression; Female; Fluorodeoxyglucose F18; Frontotemporal Dementia; Humans; Male; Middle Aged; Neuropsychological Tests; Phosphorylation; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity; tau Proteins; amyloid beta protein[1-42]; fluorodeoxyglucose f 18; tau protein; amyloid beta protein; biological marker; tau protein; aged; Alzheimer disease; Article; brain cortex atrophy; brain metabolism; cerebrospinal fluid; cohort analysis; corticobasal degeneration; diffuse Lewy body disease; female; follow up; frontal variant frontotemporal dementia; human; major clinical study; male; mild cognitive impairment; multicenter study; neuroimaging; neuropsychological test; positron emission tomography; priority journal; retrospective study; semantic dementia; Alzheimer disease; brain; cerebrospinal fluid; cognitive defect; diagnostic imaging; disease exacerbation; frontotemporal dementia; middle aged; phosphorylation; prognosis; psychology; sensitivity and specificity; very elderly","Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Theis B., Phelps C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on, Alzheimers Dement., 7, pp. 167-177270-279, (2011); Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Cappa S., Lenz O., Ludecke S., Marcone A., Mielke R., Ortelli P., Padovani A., Pelati O., Pupi A., Scarpini E., Weisenbach S., Herholz K., Salmon E., Holthoff V., Sorbi S., Fazio F., Perani D., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Arch. Neurol., 62, pp. 1728-1733, (2005); Arbizu J., Prieto E., Martinez-Lage P., Marti-Climent J.M., Garcia-Granero M., Lamet I., Pastor P., Riverol M., Gomez-Isla M.T., Penuelas I., Richter J.A., Weiner M.W., Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia, Eur. J. Nucl. Med. Mol. Imaging, 40, pp. 1394-1405, (2013); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Boxer A.L., Dickson D.W., Grossman M., Hallett M., Josephs K.A., Kertesz A., Lee S.E., Miller B.L., Reich S.G., Riley D.E., Tolosa E., Troster A.I., Vidailhet M., Weiner W.J., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, pp. 496-503, (2013); Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med., 367, pp. 795-804, (2012); Bittner T., Zetterberg H., Teunissen C.E., Ostlund R.E., Militello M., Andreasson U., Hubeek I., Gibson D., Chu D.C., Eichenlaub U., Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid, Alzheimers Dement., 12, pp. 517-526, (2016); Blennow K., Johansson A., Zetterberg H., Diagnostic value of 14-3-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease, Int. J. Mol. Med., 16, pp. 1147-1149, (2005); Blennow K., Dubois B., Fagan A.M., Lewczuk P., De Leon M.J., Hampel H., Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease, Alzheimers Dement., 11, pp. 58-69, (2015); Bloudek L.M., Spackman D.E., Blankenburg M., Sullivan S.D., Review and Meta-analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease, 26, pp. 1-5, (2011); Bohnen N.I., Djang D.S.W., Herholz K., Anzai Y., Minoshima S., Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature, J. Nucl. Med., 53, pp. 59-71, (2012); Caminiti S.P., Alongi P., Majno L., Volonte M.A., Cerami C., Gianolli L., Comi G., Perani D., Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders, Eur. J. Neurol., 24, pp. 1-8, (2017); Caroli A., Prestia A., Chen K., Ayutyanont N., Landau S.M., Madison C.M., Haense C., Herholz K., Nobili F., Reiman E.M., Jagust W.J., Frisoni G.B., Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison, J. Nucl. Med., 53, pp. 592-600, (2012); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Perani D., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, NeuroImage Clin., 7, pp. 187-194, (2015); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Pelagallo E., Santangelo R., Cappa S.F., Perani D., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia, J. Alzheimers Dis., 55, pp. 183-197, (2017); Chen X., Zhou Y., Wang R., Cao H., Reid S., Gao R., Han D., Initiative A.D.N., Potential clinical value of multiparametric PET in the prediction of Alzheimer's disease progression, PLoS One, 11, (2016); Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.-C., Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?, Neurology, 60, pp. 1374-1377, (2003); Chetelat G., Desgranges B., Landeau B., Mezenge F., Poline J.B., de la Sayette V., Viader F., Eustache F., Baron J.-C., Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease, Brain, 131, pp. 60-71, (2008); Chiba Y., Iseki E., Fujishiro H., Ota K., Kasanuki K., Hirayasu Y., Arai H., Sato K., Early differential diagnostic between Alzheimer's disease and dementia with Lewy bodies: Comparison between FDG-PET and IMP-SPECT, Alzheimers Dement., 9, pp. P374-P375, (2013); Choo I.H., Ni R., Scholl M., Wall A., Almkvist O., Nordberg A., Combination of (18)F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients, J. Alzheimers Dis., 33, pp. 929-939, (2013); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Gilardi M.C., Frisoni G., Friston K., Ashburner J., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); DeLong E.R., DeLong D.M., Clarke-Pearson D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach, Biometrics, pp. 837-845, (1988); Drzezga A., Grimmer T., Henriksen G., Stangier I., Perneczky R., Diehl-Schmid J., Mathis C.A., Klunk W.E., Price J., DeKosky S., Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease, NeuroImage, 39, pp. 619-633, (2008); Dubois B., Feldman H., Jacova C., Dekosky S., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet, 6, pp. 734-746, (2007); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Dekosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., De Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L., Curie-paris P.M., De H., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol., 13, pp. 614-629, (2014); Dukart J., Sambataro F., Bertolino A., Accurate prediction of conversion to Alzheimer's disease using imaging, genetic, and neuropsychological biomarkers, J. Alzheimers Dis., 49, pp. 1143-1159, (2015); Ewers M., Mattsson N., Minthon L., Molinuevo J.L., Antonell A., Popp J., Jessen F., Herukka S.-K., Soininen H., Maetzler W., CSF biomarkers for the differential diagnosis of Alzheimer's disease: a large-scale international multicenter study, Alzheimers Dement., 11, pp. 1306-1315, (2015); Fellgiebel A., Scheurich A., Bartenstein P., Muller M.J., FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment, Psychiatry Res. Neuroimaging, 155, pp. 167-171, (2007); Fischer P., Jungwirth S., Zehetmayer S., Weissgram S., Hoenigschnabl S., Gelpi E., Krampla W., Tragl K.H., Conversion From Subtypes of Mild Cognitive Impairment to Alzheimer Dementia, (2007); Frisoni G.B., Bocchetta M., Chetelat G., Rabinovici G.D., de Leon M.J., Kaye J., Reiman E.M., Scheltens P., Barkhof F., Black S.E., Brooks D.J., Carrillo M.C., Fox N.C., Herholz K., Nordberg A., Jack C.R., Jagust W.J., Johnson K.A., Rowe C.C., Sperling R.A., Thies W., Wahlund L.-O., Weiner M.W., Pasqualetti P., Decarli C., Imaging markers for Alzheimer disease: which vs how, Neurology, 81, pp. 487-500, (2013); Frisoni G.B., Perani D., Bastianello S., Bernardi G., Porteri C., Boccardi M., Cappa S.F., Trabucchi M., Padovani A., Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap, Neurobiol. Aging, 52, pp. 119-131, (2017); Friston K.J., Holmes A.P., Worsley K.J., Poline J., Frith C.D., Frackowiak R.S.J., Statistical parametric maps in functional imaging: a general linear approach, Hum. Brain Mapp., 2, pp. 189-210, (1994); Fujishiro H., Iseki E., Kasanuki K., Chiba Y., Ota K., Murayama N., Sato K., A follow up study of non-demented patients with primary visual cortical hypometabolism: prodromal dementia with Lewy bodies, J. Neurol. Sci., 334, pp. 48-54, (2013); Galluzzi S., Geroldi C., Amicucci G., Bocchio-Chiavetto L., Bonetti M., Bonvicini C., Cotelli M., Ghidoni R., Paghera B., Zanetti O., Frisoni G.B., Archetti S., Benussi L., Binetti G., Canu E., Caobelli F., Cavedo E., Chito E., Costardi D., Gennarelli M., Giubbini R., Guerra U.P., Kuffenschin G., Lussignoli G., Moretti D., Orlandini A., Parapini M., Paternico D., Porteri C., Romano M., Rosini S., Scarpazza C., Villa I., Zanardini R., Supporting evidence for using biomarkers in the diagnosis of MCI due to AD, J. Neurol., 260, pp. 640-650, (2013); Garibotto V., Herholz K., Boccardi M., Picco A., Varrone A., Nordberg A., Nobili F., Ratib O., for the Roadmap, G.T.F, Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol. Aging, 52, pp. 183-195, (2017); Gaugler J.E., Kane R.L., Johnston J.A., Sarsour K., Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence, Am. J. Alzheimers Dis. Other Demen., 28, pp. 337-347, (2013); Gomar J.J., Conejero-Goldberg C., Davies P., Goldberg T.E., Initiative A.D.N., Extension and refinement of the predictive value of different classes of markers in ADNI: four-year follow-up data, Alzheimers Dement., 10, pp. 704-712, (2014); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Guerra U.P., Nobili F.M., Padovani A., Perani D., Pupi A., Sorbi S., Trabucchi M., Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice, Neurol. Sci., 36, pp. 1075-1081, (2015); van Harten A.C., Kester M.I., Visser P.-J., Blankenstein M.A., Pijnenburg Y.A.L., van der Flier W.M., Scheltens P., Tau and p-tau as CSF biomarkers in dementia: a meta-analysis, Clin. Chem. Lab. Med., 49, pp. 353-366, (2011); Heiss W.-D., Herholz K., Bocher-Schwarz H.G., Pawlik G., Wienhard K., Steinbrich W., Friedmann G., PET, CT, and MR imaging in cerebrovascular disease, J. Comput. Assist. Tomogr., 10, pp. 903-911, (1986); Hinrichs C., Singh V., Xu G., Johnson S.C., Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population, NeuroImage, 55, pp. 574-589, (2011); Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R., A new clinical scale for the staging of dementia, Br. J. Psychiatry, 140, pp. 566-572, (1982); Iaccarino L., Crespi C., Della Rosa P.A., Catricala E., Guidi L., Marcone A., Tagliavini F., Magnani G., Cappa S.F., Perani D., The semantic variant of primary progressive aphasia: clinical and neuroimaging evidence in single subjects, PLoS One, 10, (2015); Iaccarino L., Chiotis K., Alongi P., Almkvist O., Wall A., Cerami C., Bettinardi V., Gianolli L., Nordberg A., Perani D., A cross-validation of FDG- and amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer's disease in a clinical setting, J. Alzheimers Dis., pp. 1-12, (2017); Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R.J., Visser P.J., Aalten P., Aarsland D., Alcolea D., Alexander M., Almdahl I.S., Arnold S.E., Baldeiras I., Barthel H., van Berckel B.N.M., Bibeau K., Blennow K., Brooks D.J., van Buchem M.A., Camus V., Cavedo E., Chen K., Chetelat G., Cohen A.D., Drzezga A., Engelborghs S., Fagan A.M., Fladby T., Fleisher A.S., van der Flier W.M., Ford L., Forster S., Fortea J., Foskett N., Frederiksen K.S., Freund-Levi Y., Frisoni G.B., Froelich L., Gabryelewicz T., Gill K.D., Gkatzima O., Gomez-Tortosa E., Gordon M.F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.-K., Hildebrandt H., Ishihara L., Ivanoiu A., Jagust W.J., Johannsen P., Kandimalla R., Kapaki E., Klimkowicz-Mrowiec A., Klunk W.E., Kohler S., Koglin N., Kornhuber J., Kramberger M.G., Van Laere K., Landau S.M., Lee D.Y., de Leon M., Lisetti V., Lleo A., Madsen K., Maier W., Marcusson J., Mattsson N., de Mendonca A., Meulenbroek O., Meyer P.T., Mintun M.A., Mok V., Molinuevo J.L., Mollergard H.M., Morris J.C., Mroczko B., Van der Mussele S., Na D.L., Newberg A., Nordberg A., Nordlund A., Novak G.P., Paraskevas G.P., Parnetti L., Perera G., Peters O., Popp J., Prabhakar S., Rabinovici G.D., Ramakers I.H.G.B., Rami L., Resende de Oliveira C., Rinne J.O., Rodrigue K.M., Rodriguez-Rodriguez E., Roe C.M., Rot U., Rowe C.C., Ruther E., Sabri O., Sanchez-Juan P., Santana I., Sarazin M., Schroder J., Schutte C., Seo S.W., Soetewey F., Soininen H., Spiru L., Struyfs H., Teunissen C.E., Tsolaki M., Vandenberghe R., Verbeek M.M., Villemagne V.L., Vos S.J.B., van Waalwijk van Doorn L.J.C., Waldemar G., Wallin A., Wallin A.K., Wiltfang J., Wolk D.A., Zboch M., Zetterberg H., Prevalence of cerebral amyloid pathology in persons without dementia, JAMA, 313, (2015); Kaerst L., Kuhlmann A., Wedekind D., Stoeck K., Lange P., Zerr I., Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease, J. Alzheimers Dis., 38, pp. 63-73, (2014); Kalpouzos G., Eustache F., de la Sayette V., Viader F., Chetelat G., Desgranges B., Working memory and FDG–PET dissociate early and late onset Alzheimer disease patients, J. Neurol., 252, pp. 548-558, (2005); Kato T., Inui Y., Nakamura A., Ito K., Brain fluorodeoxyglucose (FDG) PET in dementia, Ageing Res. Rev., 30, pp. 73-84, (2016); Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R., Weiner M.W., Jagust W.J., Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, pp. 230-238, (2010); Lewczuk P., Zimmermann R., Wiltfang J., Kornhuber J., Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers, J. Neural Transm., 116, pp. 1163-1167, (2009); Lewczuk P., Kornhuber J., Toledo J.B., Trojanowski J.Q., Knapik-Czajka M., Peters O., Wiltfang J., Shaw L.M., Validation of the erlangen score algorithm for the prediction of the development of dementia due to Alzheimer's disease in pre-dementia subjects, J. Alzheimers Dis., 48, pp. 433-441, (2015); Litvan I., Mangone C.A., McKee A., Verny M., Parsa A., Jellinger K., D'Olhaberriague L., Chaudhuri K.R., Pearce R.K., Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study, J. Neurol. Neurosurg. Psychiatry, 60, pp. 615-620, (1996); Lo R.Y., Hubbard A.E., Shaw L.M., Trojanowski J.Q., Petersen R.C., Aisen P.S., Weiner M.W., Jagust W.J., Longitudinal change of biomarkers in cognitive decline, Arch. Neurol., 68, pp. 1257-1266, (2011); Lopponen M., Raiha I., Isoaho R., Vahlberg T., Kivela S.-L., Diagnosing cognitive impairment and dementia in primary health care–a more active approach is needed, Age Ageing, 32, pp. 606-612, (2003); Mattsson N., Zetterberg H., Lessons from multicenter studies on CSF biomarkers for Alzheimer's disease, Int. J. Alzheimers Dis., 2010, (2010); Mattsson N., Lonneborg A., Boccardi M., Blennow K., Hansson O., for the Roadmap, G.T.F, Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol. Aging, 52, pp. 196-213, (2017); McKeith I.G., Boeve B.F., Dickson D.W., Halliday G., Taylor J.-P., Weintraub D., Aarsland D., Galvin J., Attems J., Ballard C.G., Diagnosis and management of dementia with Lewy bodies Fourth consensus report of the DLB Consortium, Neurology, pp. 10-1212, (2017); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, pp. 263-269, (2011); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, pp. 263-269, (2011); Mitchell A.J., Shiri-Feshki M., Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies, Acta Psychiatr. Scand., 119, pp. 252-265, (2009); Morbelli S., Garibotto V., Van De Giessen E., Arbizu J., Chetelat G., Drezgza A., Hesse S., Lammertsma A.A., Law I., Payoux P., A Cochrane review on brain [18F] FDG PET in dementia: limitations and future perspectives, Eur. J. Nucl. Med. Mol. Imaging, 42, 10, pp. 1487-1491, (2015); Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Reiman E.M., Holthoff V., Kalbe E., Sorbi S., Diehl-Schmid J., Perneczky R., Clerici F., Caselli R., Beuthien-Baumann B., Kurz A., Minoshima S., de Leon M.J., Multicenter standardized 18F–FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias, J. Nucl. Med., 49, pp. 390-398, (2008); Olsson B., Lautner R., Andreasson U., Ohrfelt A., Portelius E., Bjerke M., Holtta M., Rosen C., Olsson C., Strobel G., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol., 15, pp. 673-684, (2016); Ossenkoppele R., Prins N., Pijnenburg Y.A.L., Lemstra A.W., van der Flier W.M., Adriaanse S.F., Windhorst A.D., Handels R.L.H., Wolfs C.A.G., Aalten P., Verhey F.R.J., Verbeek M.M., van Buchem M.A., Hoekstra O.S., Lammertsma A.A., Scheltens P., van Berckel B.N.M., Impact of molecular imaging on the diagnostic process in a memory clinic, Alzheimers Dement., 9, pp. 414-421, (2013); Ossenkoppele R., Mattsson N., Teunissen C.E., Barkhof F., Pijnenburg Y., Scheltens P., van der Flier W.M., Rabinovici G.D., Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease, Neurobiol. Aging, 36, pp. 2340-2347, (2015); Parnetti L., Chiasserini D., Eusebi P., Giannandrea D., Bellomo G., De Carlo C., Padiglioni C., Mastrocola S., Lisetti V., Calabresi P., Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment, J. Alzheimers Dis., 29, pp. 229-238, (2012); Perani D., FDG PET and cognitive symptoms of dementia, Clin. Transl. Imaging, (2013); Perani D., FDG-PET and amyloid-PET imaging: the diverging paths, Curr. Opin. Neurol., 27, pp. 405-413, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Panzacchi A., Nobili F., Pappata S., Marcone A., Garibotto V., Castiglioni I., Magnani G., Cappa S.F., Gianolli L., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, NeuroImage Clin., 6, pp. 445-454, (2014); Perani D., Schillaci O., Padovani A., Nobili F.M., Iaccarino L., Della Rosa P.A., Frisoni G., Caltagirone C., Erratum to “A Survey of FDG-and Amyloid-PET Imaging in Dementia and GRADE Analysis.”, Biomed. Res. Int., 2014, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Pinto P., Passerini G., Falini A., Iannaccone S., Cappa S.F., Comi G., Gianolli L., Magnani G., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur. J. Nucl. Med. Mol. Imaging, 43, pp. 499-508, (2016); Petersen R.C., Roberts R.O., Knopman D.S., Boeve B.F., Geda Y.E., Ivnik R.J., Smith G.E., Jack C.R., Mild cognitive impairment: ten years later, Arch. Neurol., 66, pp. 1447-1455, (2009); Pievani M., Filippini N., van den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy, Nat. Rev. Neurol., 10, pp. 620-633, (2014); Presotto L., Ballarini T., Caminiti S.P., Bettinardi V., Gianolli L., Perani D., Validation of 18F–FDG-PET Single-subject optimized SPM procedure with different PET scanners, Neuroinformatics, 15, pp. 151-163, (2017); Prestia A., Caroli A., Herholz K., Reiman E., Chen K., Jagust W.J., Frisoni G.B., Group, T.O.M.C.W, Initiative, A.D.N, Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series, Alzheimers Dement., 9, pp. 677-686, (2013); Prestia A., Caroli A., van der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Teunissen C.E., Wall A.E., Carter S.F., Scholl M., Choo I.H., Nordberg A., Scheltens P., Frisoni G.B., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease, Neurology, 80, pp. 1048-1056, (2013); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.-L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., Pantieri G., Mariani E., Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors, Dement. Geriatr. Cogn. Disord., 21, pp. 51-58, (2005); Robb C., Udeh-Momoh C., Wagenpfeil S., Schope J., Alexopoulos P., Perneczky R., Biomarkers and functional decline in prodromal Alzheimer's disease, J. Alzheimers Dis., pp. 1-10, (2017); Seguin J., Formaglio M., Perret-Liaudet A., Quadrio I., Tholance Y., Rouaud O., Thomas-Anterion C., Croisile B., Mollion H., Moreaud O., CSF biomarkers in posterior cortical atrophy, Neurology, 76, pp. 1782-1788, (2011); Shaffer J.L., Petrella J.R., Sheldon F.C., Choudhury K.R., Calhoun V.D., Coleman R.E., Doraiswamy P.M., Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined, Radiology, 266, pp. 583-591, (2013); Signorini M., Paulesu E., Friston K., Perani D., Colleluori A., Lucignani G., Grassi F., Bettinardi V., Frackowiak R.S., Fazio F., Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping, NeuroImage, 9, pp. 63-80, (1999); Simonsen A.H., Herukka S.-K., Andreasen N., Baldeiras I., Bjerke M., Blennow K., Engelborghs S., Frisoni G.B., Gabryelewicz T., Galluzzi S., Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia, Alzheimers Dement., 13, pp. 274-284, (2017); Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Skoog I., Wallin A., Wahlund L.-O., Marcusson J., Nagga K., Andreasen N., Davidsson P., Vanmechelen E., Blennow K., Tau and A{beta}42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values, Clin. Chem., 47, pp. 1776-1781, (2001); Smailagic N., Vacante M., Hyde C., Martin S., Ukoumunne O., Sachpekidis C., 18F-FDG PET for the early diagnosis of Alzheimer?s disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst. Rev., 1, (2015); Stefani A., Brusa L., Olivola E., Pierantozzi M., Martorana A., CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD, J. Neural Transm., 119, pp. 861-875, (2012); Storandt M., Morris J.C., Ascertainment bias in the clinical diagnosis of Alzheimer disease, Arch. Neurol., 67, pp. 1364-1369, (2010); Struyfs H., Van Broeck B., Timmers M., Fransen E., Sleegers K., Van Broeckhoven C., De Deyn P.P., Streffer J.R., Mercken M., Engelborghs S., Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis, J. Alzheimers Dis., 45, pp. 813-822, (2015); Tang W., Huang Q., Wang Y., Wang Z.-Y., Yao Y.-Y., Assessment of CSF Aβ 42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies, J. Neurol. Sci., 345, pp. 26-36, (2014); Teipel S., Drzezga A., Grothe M.J., Barthel H., Chetelat G., Schuff N., Skudlarski P., Cavedo E., Frisoni G.B., Hoffmann W., Thyrian J.R., Fox C., Minoshima S., Sabri O., Fellgiebel A., Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection, Lancet Neurol., 14, pp. 1037-1053, (2015); Teune L.K., Bartels A.L., De Jong B.M., Willemsen A.T.M., Eshuis S.A., de Vries J.J., van Oostrom J.C.H., Leenders K.L., Typical cerebral metabolic patterns in neurodegenerative brain diseases, Mov. Disord., 25, pp. 2395-2404, (2010); Torosyan N., Mason K., Dahlbom M., Silverman D.H.S., Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline, Eur. J. Nucl. Med. Mol. Imaging, 44, pp. 1355-1363, (2017); Vanderstichele H., Bibl M., Engelborghs S., Le Bastard N., Lewczuk P., Molinuevo J.L., Parnetti L., Perret-Liaudet A., Shaw L.M., Teunissen C., Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative, Alzheimers Dement., 8, pp. 65-73, (2012); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Darcourt J., Kapucu O.L., Tatsch K., Bartenstein P., EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2, Eur. J. Nucl. Med. Mol. Imaging, 36, pp. 2103-2110, (2009); Vos S.J.B., Verhey F., Frolich L., Kornhuber J., Wiltfang J., Maier W., Peters O., Ruther E., Nobili F., Morbelli S., Frisoni G.B., Drzezga A., Didic M., Van Berckel B.N.M., Simmons A., Soininen H., Kloszewska I., Mecocci P., Tsolaki M., Vellas B., Lovestone S., Muscio C., Herukka S.K., Salmon E., Bastin C., Wallin A., Nordlund A., De Mendonca A., Silva D., Santana I., Lemos R., Engelborghs S., Van Der Mussele S., Freund-Levi Y., Wallin A.K., Hampel H., Van Der Flier W., Scheltens P., Visser P.J., Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage, Brain, 138, pp. 1327-1338, (2015); Walhovd K.B., Fjell A.M., Brewer J., McEvoy L.K., Fennema-Notestine C., Hagler D.J., Jennings R.G., Karow D., Dale A.M., Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease, Am. J. Neuroradiol., 31, pp. 347-354, (2010); Warren J.D., Fletcher P.D., Golden H.L., The paradox of syndromic diversity in Alzheimer disease, Nat. Rev. Neurol., 8, pp. 451-464, (2012); Young J., Modat M., Cardoso M.J., Mendelson A., Cash D., Ourselin S., Initiative A.D.N., Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment, NeuroImage Clin., 2, pp. 735-745, (2013); Yuan Y., Gu Z.-X., Wei W.-S., Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis, AJNR Am. J. Neuroradiol., 30, pp. 404-410, (2009)","2-s2.0-85041667601"
"Cerami C.; Dodich A.; Iannaccone S.; Marcone A.; Lettieri G.; Crespi C.; Gianolli L.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Lettieri, Giada (56680972900); Crespi, Chiara (57034303800); Gianolli, Luigi (6602754456); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 56001713900; 7005943171; 6701496511; 56680972900; 57034303800; 6602754456; 7005836132; 7005630261","Right limbic FDG-PET hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients","2015","PLoS ONE","10","10","e0141672","","","","26","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84949972927&doi=10.1371%2fjournal.pone.0141672&partnerID=40&md5=edd36f683171ebe56248610e9ffb784c","The behavioural variant of frontotemporal dementia (bvFTD) is a rare disease mainly affecting the social brain. FDG-PET fronto-temporal hypometabolism is a supportive feature for the diagnosis. It may also provide specific functional metabolic signatures for altered socioemotional processing. In this study, we evaluated the emotion recognition and attribution deficits and FDG-PET cerebral metabolic patterns at the group and individual levels in a sample of sporadic bvFTD patients, exploring the cognitive-functional correlations. Seventeen probable mild bvFTD patients (10 male and 7 female; age 67.8±9.9) were administered standardized and validated version of social cognition tasks assessing the recognition of basic emotions and the attribution of emotions and intentions (i.e., Ekman 60-Faces test- Ek60F and Story-based Empathy task-SET). FDG-PET was analysed using an optimized voxel-based SPM method at the single-subject and group levels. Severe deficits of emotion recognition and processing characterized the bvFTD condition. At the group level, metabolic dysfunction in the right amygdala, temporal pole, and middle cingulate cortex was highly correlated to the emotional recognition and attribution performances. At the singlesubject level, however, heterogeneous impairments of social cognition tasks emerged, and different metabolic patterns, involving limbic structures and prefrontal cortices, were also observed. The derangement of a right limbic network is associated with altered socio-emotional processing in bvFTD patients, but different hypometabolic FDG-PET patterns and heterogeneous performances on social tasks at an individual level exist. © 2015 Cerami et al.This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","Aged; Emotions; Female; Fluorodeoxyglucose F18; Frontotemporal Dementia; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Reproducibility of Results; Social Behavior; fluorodeoxyglucose; fluorodeoxyglucose f 18; adult; aged; amygdaloid nucleus; Article; attribution; cingulate gyrus; clinical article; computer assisted emission tomography; controlled study; emotion recognition; female; frontal variant frontotemporal dementia; human; image processing; male; middle aged; middle cingulate cortex; prefrontal cortex; recognition; social cognition; statistical parametrical mapping; task performance; temporal lobe; very elderly; diagnostic imaging; emotion; frontotemporal dementia; neuropsychological test; pathophysiology; positron emission tomography; reproducibility; social behavior","Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol., 10, 2, pp. 162-172, (2011); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol Sci., 34, 8, pp. 1267-1274, (2013); Bernhardt B.C., Singer T., The neural basis of empathy, Annu Rev Neurosci., 35, pp. 1-23, (2012); Shamay-Tsoory S.G., The neural bases for empathy, Neuroscientist., 17, 1, pp. 18-24, (2011); Posamentier M.T., Abdi H., Processing faces and facial expressions, Neuropsychol Rev., 13, 3, pp. 113-143, (2003); Pievani M., Filippini N., Van Den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases - from phenotype to proteinopathy, Nat Rev Neurol., 10, 11, pp. 620-633, (2014); Seeley W.W., Zhou J., Kim E.J., Frontotemporal dementia: What can the behavioral variant teach us about human brain organization?, Neuroscientist., 18, 4, pp. 373-385, (2012); Kumfor F., Piguet O., Disturbance of emotion processing in frontotemporal dementia: A synthesis of cognitive and neuroimaging findings, Neuropsychol Rev., 22, 3, pp. 280-297, (2012); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: A meta-analysis, J Neurol Neurosurg Psychiatry., 86, 7, pp. 714-719, (2015); Henry J.D., Phillips L.H., Von Hippel C., A meta-analytic review of theory of mind difficulties in behaviouralvariant frontotemporal dementia, Neuropsychologia., 56, pp. 53-62, (2014); Kamminga J., Kumfor F., Burrell J.R., Piguet O., Hodges J.R., Irish M., Differentiating between right-lateralised semantic dementia and behavioural-variant frontotemporal dementia: An examination of clinical characteristics and emotion processing, J Neurol Neurosurg Psychiatry., 86, 10, pp. 1082-1088, (2015); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Et al., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement., 10, 6, pp. 827-834, (2014); Shany-Ur T., Poorzand P., Grossman S.N., Growdon M.E., Jang J.Y., Ketelle R.S., Et al., Comprehension of insincere communication in neurodegenerative disease: Lies, sarcasm, and theory of mind, Cortex., 48, 10, pp. 1329-1341, (2012); Baez S., Manes F., Huepe D., Torralva T., Fiorentino N., Richter F., Et al., Primary empathy deficits in frontotemporal dementia, Front Aging Neurosci., 6, (2014); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weiner M.W., Et al., Structural anatomy of empathy in neurodegenerative disease, Brain., 129, pp. 2945-2956, (2006); Perry D.C., Sturm V.E., Wood K.A., Miller B.L., Kramer J.H., Divergent processing of monetary and social reward in behavioral variant frontotemporal dementia and Alzheimer disease, Alzheimer Dis Assoc Disord., 29, 2, pp. 161-164, (2015); Freedman M., Binns M.A., Black S.E., Murphy C., Stuss D.T., Theory of mind and recognition of facial emotion in dementia: Challenge to current concepts, Alzheimer Dis Assoc Disord., 27, 1, pp. 56-61, (2013); Kipps C.M., Mioshi E., Hodges J.R., Emotion, social functioning and activities of daily living in frontotemporal dementia, Neurocase., 15, 3, pp. 182-189, (2009); Gregory C., Lough S., Stone V., Erzinclioglu S., Martin L., Baron-Cohen S., Et al., Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: Theoretical and practical implications, Brain., 125, pp. 752-764, (2002); Lee G.J., Lu P.H., Mather M.J., Shapira J., Jimenez E., Leow A.D., Et al., Neuroanatomical correlates of emotional blunting in behavioral variant frontotemporal dementia and early-onset Alzheimer's disease, J Alzheimers Dis., 41, 3, pp. 793-800, (2014); Heitz C., Vogt N., Cretin B., Philippi N., Jung B., Phillipps C., Et al., Cognitive and affective theory of mind in Lewy body dementia: A preliminary study, Rev Neurol (Paris)., 171, 4, pp. 373-381, (2015); O'Keeffe F.M., Murray B., Coen R.F., Dockree P.M., Bellgrove M.A., Garavan H., Et al., Loss of insight in frontotemporal dementia, corticobasal degeneration and progressive supranuclear palsy, Brain., 130, pp. 753-764, (2007); Ghosh B.C., Calder A.J., Peers P.V., Lawrence A.D., Acosta-Cabronero J., Pereira J.M., Et al., Social cognitive deficits and their neural correlates in progressive supranuclear palsy, Brain., 135, pp. 2089-2102, (2012); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain., 134, pp. 2456-2477, (2011); Salmon E., Garraux G., Delbeuck X., Collette F., Kalbe E., Zuendorf G., Et al., Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia, Neuroimage., 20, 1, pp. 435-440, (2003); Jeong Y., Cho S.S., Park J.M., Kang S.J., Lee J.S., Kang E., Et al., 18F-FDG PET findings in frontotemporal dementia: An SPM analysis of 29 patients, J Nucl Med., 46, 2, pp. 233-239, (2005); Ibach B., Poljansky S., Marienhagen J., Sommer M., Manner P., Hajak G., Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease, Neuroimage., 23, 2, pp. 739-743, (2004); Kipps C.M., Hodges J.R., Fryer T.D., Nestor P.J., Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: Refining the clinical phenotype, Brain., 132, pp. 2566-2578, (2009); Ishii K., Sakamoto S., Sasaki M., Kitagaki H., Yamaji S., Hashimoto M., Et al., Cerebral glucose metabolism in patients with frontotemporal dementia, J Nucl Med., 39, 11, pp. 1875-1878, (1998); Grimmer T., Diehl J., Drzezga A., Forstl H., Kurz A., Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: A prospective 18F-FDG-PET study, Dement Geriatr Cogn Disord., 18, 1, pp. 32-36, (2004); Kumfor F., Irish M., Hodges J.R., Piguet O., The orbitofrontal cortex is involved in emotional enhancement of memory: Evidence from the dementias, Brain., 136, pp. 2992-3003, (2013); Grossman M., Eslinger P.J., Troiani V., Anderson C., Avants B., Gee J.C., Et al., The role of ventral medial prefrontal cortex in social decisions: Converging evidence from fMRI and frontotemporal lobar degeneration, Neuropsychologia., 48, 12, pp. 3505-3512, (2010); Eslinger P.J., Moore P., Anderson C., Grossman M., Social cognition, executive functioning, and neuroimaging correlates of empathic deficits in frontotemporal dementia, J Neuropsychiatry Clin Neurosci., 23, 1, pp. 74-82, (2011); Omar R., Rohrer J.D., Hailstone J.C., Warren J.D., Structural neuroanatomy of face processing in frontotemporal lobar degeneration, J Neurol Neurosurg Psychiatry., 82, 12, pp. 1341-1343, (2011); Zahn R., Moll J., Iyengar V., Huey E.D., Tierney M., Krueger F., Et al., Social conceptual impairments in frontotemporal lobar degeneration with right anterior temporal hypometabolism, Brain., 132, pp. 604-616, (2009); Le Bouc R., Lenfant P., Delbeuck X., Ravasi L., Lebert F., Semah F., Et al., My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease, Brain., 135, pp. 3026-3038, (2012); Moll J., Zahn R., De Oliveira-Souza R., Bramati I.E., Krueger F., Tura B., Et al., Impairment of prosocial sentiments is associated with frontopolar and septal damage in frontotemporal dementia, Neuroimage., 54, 2, pp. 1735-1742, (2011); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci., 35, 7, pp. 1015-1021, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol Sci., 36, 10, pp. 1907-1912, (2015); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics., 12, 4, pp. 575-593, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clin., 6, pp. 445-454, (2014); Lamm C., Decety J., Singer T., Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain, Neuroimage., 54, 3, pp. 2492-2502, (2011); Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Et al., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage., 17, 1, pp. 302-316, (2002); Woodward M.C., Rowe C.C., Jones G., Villemagne V.L., Varos T.A., Differentiating the frontal presentation of Alzheimer's disease with FDG-PET, J Alzheimers Dis., 44, 1, pp. 233-242, (2015); Salmon E., Kerrouche N., Herholz K., Perani D., Holthoff V., Beuthien-Baumann B., Et al., Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia, Neuroimage., 30, 3, pp. 871-878, (2006); Warmus B.A., Sekar D.R., McCutchen E., Schellenberg G.D., Roberts R.C., McMahon L.L., Et al., Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia, J Neurosci., 34, 49, pp. 16482-16495, (2014); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology., 78, 17, pp. 1354-1362, (2012); Eckart J.A., Sturm V.E., Miller B.L., Levenson R.W., Diminished disgust reactivity in behavioral variant frontotemporal dementia, Neuropsychologia., 50, 5, pp. 786-790, (2012); Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Et al., Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration, Ann Neurol., 57, 2, pp. 216-225, (2005); Sarazin M., Michon A., Pillon B., Samson Y., Canuto A., Gold G., Et al., Metabolic correlates of behavioral and affective disturbances in frontal lobe pathologies, J Neurol., 250, 7, pp. 827-833, (2003)","2-s2.0-84949972927"
"Cerami C.; Iaccarino L.; Perani D.","Cerami, Chiara (25722905400); Iaccarino, Leonardo (56114773500); Perani, Daniela (7005630261)","25722905400; 56114773500; 7005630261","Molecular imaging of neuroinflammation in neurodegenerative dementias: The role of in vivo PET imaging","2017","International Journal of Molecular Sciences","18","5","993","","","","58","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019121341&doi=10.3390%2fijms18050993&partnerID=40&md5=4e63a551b06a1182a4d8b44d9db654a4","Neurodegeneration elicits neuroinflammatory responses to kill pathogens, clear debris and support tissue repair. Neuroinflammation is a dynamic biological response characterized by the recruitment of innate and adaptive immune system cells in the site of tissue damage. Resident microglia and infiltrating immune cells partake in the restoration of central nervous system homeostasis. Nevertheless, their activation may shift to chronic and aggressive responses, which jeopardize neuron survival and may contribute to the disease process itself. Positron Emission Tomography (PET) molecular imaging represents a unique tool contributing to in vivo investigating of neuroinflammatory processes in patients. In the present review, we first provide an overview on the molecular basis of neuroinflammation in neurodegenerative diseases with emphasis on microglia activation, astrocytosis and the molecular targets for PET imaging. Then, we review the state-of-the-art of in vivo PET imaging for neuroinflammation in dementia conditions associated with different proteinopathies, such as Alzheimer’s disease, frontotemporal lobar degeneration and Parkinsonian spectrum. © 2017 by the authors.Licensee MDPI, Basel, Switzerland.","<sup>11</sup>C-PK11195; Alzheimer’s disease; Astrocytosis; Microglia activation; Molecular imaging; Neurodegenerative disorders; Neuroinflammation; TSPO-PET imaging","Alzheimer Disease; Humans; Inflammation; Microglia; Positron-Emission Tomography; Receptors, GABA; amine oxidase (flavin containing) isoenzyme B; carrier protein; n sec butyl 1 (2 chlorophenyl) n methyl 3 isoquinolinecarboxamide; 4 aminobutyric acid receptor; TSPO protein, human; Alzheimer disease; astrocytosis; cell activation; cell function; cell migration; degenerative disease; dementia; disease association; drug transport; frontotemporal dementia; human; microglia; molecular imaging; nervous system inflammation; neurodegenerative dementia; parkinsonism; positron emission tomography; prodromal symptom; protein binding; protein expression; Review; signal transduction; diagnostic imaging; inflammation; metabolism; pathology; positron emission tomography; procedures","Pievani M., Filippini N., Van Den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases—From phenotype to proteinopathy, Nat. Rev. Neurol, 10, pp. 620-633, (2014); Brettschneider J., Del Tredici K., Lee V.M., Trojanowski J.Q., Spreading of pathology in neurodegenerative diseases: A focus on human studies, Nat. Rev. Neurosci, 16, pp. 109-120, (2015); Heneka M.T., Kummer M.P., Latz E., Innate immune activation in neurodegenerative disease, Nat. Rev. Immunol, 14, pp. 463-477, (2014); Pasqualetti G., Brooks D.J., Edison P., The role of neuroinflammation in dementias, Curr. Neurol. Neurosci. Rep, 15, (2015); Du L., Zhang Y., Chen Y., Zhu J., Yang Y., Zhang H.L., Role of microglia in neurological disorders and their potentials as a therapeutic target, Mol. Neurobiol, (2016); Wyss-Coray T., Mucke L., Inflammation in neurodegenerative disease—A double-edged sword, Neuron, 5, pp. 419-432, (2002); Rivest S., Regulation of innate immune responses in the brain, Nat. Rev. Immunol, 9, pp. 429-439, (2009); Czeh M., Gressens P., Kaindl A.M., The yin and yang of microglia, Dev. Neurosci, 33, pp. 199-209, (2011); Perry V.H., Nicoll J.A., Holmes C., Microglia in neurodegenerative disease, Nat. Rev. Neurol, 6, pp. 193-201, (2010); Stefaniak J., O'Brien J., Imaging of neuroinflammation in dementia: A review, J. Neurol. Neurosurg. Psychiatry, 87, pp. 21-28, (2016); Miyoshi M., Shinotoh H., Wszolek Z.K., Strongosky A.J., Shimada H., Arakawa R., Higuchi M., Ikoma Y., Yasuno F., Fukushi K., Et al., In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study, Park. Relat. Disord, 16, pp. 404-408, (2010); Lant S.B., Robinson A.C., Thompson J.C., Rollinson S., Pickering-Brown S., Snowden J.S., Davidson Y.S., Gerhard A., Mann D.M., Patterns of microglial cell activation in frontotemporal lobar degeneration, Neuropathol. Appl. Neurobiol, 40, pp. 686-696, (2014); Santillo A.F., Gambini J.P., Lannfelt L., Langstrom B., Ulla-Marja L., Kilander L., Engler H., In vivo imaging of astrocytosis in Alzheimer’s disease: An 11C-L-deuteriodeprenyl and PIB PET study, Eur. J. Nucl. Med. Mol. Imaging, 38, pp. 2202-2208, (2011); Carter S.F., Scholl M., Almkvist O., Wall A., Engler H., Langstrom B., Nordberg A., Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG, J. Nucl. Med, 53, pp. 37-46, (2012); Choo I.L., Carter S.F., Scholl M.L., Nordberg A., Astrocytosis measured by 11C-deprenyl PET correlates with decrease in gray matter density in the parahippocampus of prodromal Alzheimer’s patients, Eur. J. Nucl. Med. Mol. Imaging, 41, pp. 2120-2126, (2014); Rodriguez-Vieitez E., Saint-Aubert L., Carter S.F., Almkvist O., Farid K., Scholl M., Chiotis K., Thordardottir S., Graff C., Wall A., Et al., Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease, Brain, 139, pp. 922-936, (2016); Ginhoux F., Greter M., Leboeuf M., Nandi S., See P., Gokhan S., Mehler M.F., Conway S.J., Ng L.G., Stanley E.R., Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science, 330, pp. 841-845, (2010); Prinz M., Priller J., Microglia and brain macrophages in the molecular age: From origin to neuropsychiatric disease, Nat. Rev. Neurosci, 15, pp. 300-312, (2014); Rawji K.S., Mishra M.K., Michaels N.J., Rivest S., Stys P.K., Yong V.W., Immunosenescence of microglia and macrophages: Impact on the ageing central nervous system, Brain, 139, pp. 653-661, (2016); Hanisch U.K., Kettenmann H., Microglia: Active sensor and versatile effector cells in the normal and pathologic brain, Nat. Neurosci, 10, pp. 1387-1394, (2007); Tremblay M.E., Lecours C., Samson L., Sanchez-Zafra V., Sierra A., From the Cajal alumni Achúcarro and Río-Hortega to the rediscovery of never-resting microglia, Front. Neuroanat, 9, (2015); Medzhitov R., Origin and physiological roles of inflammation, Nature, 54, pp. 428-435, (2008); Hickman S.E., Kingery N.D., Ohsumi T.K., Borowsky M.L., Wang L.C., Means T.K., El Khoury J., The microglial sensome revealed by direct RNA sequencing, Nat. Neurosci, 16, pp. 1896-1905, (2013); Ransohoff R.M., Perry V.H., Microglial physiology: Unique stimuli, specialized responses, Annu. Rev. Immunol, 27, pp. 119-145, (2009); Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., Et al., Neuroinflammation in Alzheimer’s disease, Lancet Neurol, 14, pp. 388-405, (2015); Pekny M., Pekna M., Messing A., Steinhauser C., Lee J.M., Parpura V., Hol E.M., Sofroniew M.V., Verkhratsky A., Astrocytes: A central element in neurological diseases, Acta Neuropathol, 131, pp. 323-345, (2016); Mills C.D., M1 and M2 macrophages: Oracles of health and disease, Crit. Rev. Immunol, 32, pp. 463-488, (2012); Ransohoff R.M., A polarizing question: Do M1 and M2 microglia exist?, Nat. Neurosci, 19, pp. 987-991, (2016); Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., Et al., TREM2 variants in Alzheimer’s disease, N. Engl. J. Med, 368, pp. 117-127, (2013); Rosenberg R.N., Lambracht-Washington D., Yu G., Xia W., Genomics of Alzheimer disease: A review, JAMA Neurol, 73, pp. 867-874, (2016); Hickman S.E., El Khoury J., TREM2 and the neuroimmunology of Alzheimer’s disease, Biochem. Pharmacol, 88, pp. 495-498, (2014); Rayaprolu S., Mullen B., Baker M., Lynch T., Finger E., Seeley W.W., Hatanpaa K.J., Lomen-Hoerth C., Kertesz A., Bigio E.H., TREM2 in neurodegeneration: Evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson’s disease, Mol. Neurodegener., 8, (2013); Jacobs A.H., Tavitian B., Noninvasive molecular imaging of neuroinflammation, J. Cereb. Blood Flow Metab, 32, pp. 1393-1415, (2012); Venneti S., Lopresti B.J., Wiley C.A., Molecular imaging of microglia/macrophages in the brain, Glia, 61, pp. 10-23, (2013); Liu G.J., Middleton R.J., Hatty C.R., Kam W.W., Chan R., Pham T., Harrison-Brown M., Dodson E., Veale K., Banati R.B., The 18 kDa translocator protein, microglia and neuroinflammation, Brain Pathol, 24, pp. 631-653, (2014); Venneti S., Lopresti B.J., Wiley C.A., The peripheral benzodiazepine receptor (Translocator protein 18 kDa) in microglia: From pathology to imaging, Prog. Neurobiol, 80, pp. 308-322, (2006); Rupprecht R., Papadopoulos V., Rammes G., Baghai T.C., Fan J., Akula N., Groyer G., Adams D., Schumacher M., Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders, Nat. Rev. Drug Discov, 9, pp. 971-988, (2010); Lavisse S., Guillermier M., Herard A.S., Petit F., Delahaye M., Van Camp N., Ben Haim L., Lebon V., Remy P., Dolle F., Et al., Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging, J. Neurosci, 8, pp. 10809-10818, (2012); Fowler J.S., Logan J., Volkow N.D., Wang G.J., Translational neuroimaging: Positron emission tomography studies of monoamine oxidase, Mol. Imaging Biol, 7, pp. 377-387, (2005); Cosenza-Nashat M., Zhao M.L., Suh H.S., Morgan J., Natividad R., Morgello S., Lee S.C., Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain, Neuropathol. Appl. Neurobiol, 35, pp. 306-328, (2009); Chauveau F., Boutin H., Van Camp N., Dolle F., Tavitian B., Nuclear imaging of neuroinflammation: A comprehensive review of 11C-PK11195 challengers, Eur. J. Nucl. Med. Mol. Imaging, 35, pp. 2304-2319, (2008); Varley J., Brooks D.J., Edison P., Imaging neuroinflammation in Alzheimer’s disease and other dementias: Recent advances and future directions, Alzheimers Dement, 11, pp. 1110-1120, (2015); Ramlackhansingh A.F., Brooks D.J., Greenwood R.J., Bose S.K., Turkheimer F.E., Kinnunen K.M., Gentleman S., Heckemann R.A., Gunanayagam K., Gelosa G., Et al., Inflammation after trauma: Microglial activation and traumatic brain injury, Ann. Neurol, 70, pp. 374-383, (2011); Roncaroli F., Su Z., Herholz K., Gerhard A., Turkheimer F.E., TSPO expression in brain tumours: Is TSPO a target for brain tumour imaging?, Clin. Transl. Imaging, 4, pp. 145-156, (2016); Cerami C., Perani D., Imaging neuroinflammation in ischemic stroke and in the atherosclerotic vascular disease, Curr. Vasc. Pharmacol, 13, pp. 218-222, (2015); Airas L., Rissanen E., Rinne J., Imaging of microglial activation in MS using PET: Research use and potential future clinical application, Mult. Scler., 23, pp. 496-504, (2017); Yokokura M., Terada T., Bunai T., Nakaizumi K., Takebayashi K., Iwata Y., Yoshikawa E., Futatsubashi M., Suzuki K., Mori N., Et al., Depiction of microglial activation in aging and dementia: Positron emission tomography with 11C-DPA713 versus 11C-(R)PK11195, J. Cereb. Blood Flow Metab, 37, pp. 877-889, (2016); Yasuno F., Ota M., Kosaka J., Ito H., Higuchi M., Doronbekov T.K., Nozaki S., Fujimura Y., Koeda M., Asada T., Et al., Increased binding of peripheral benzodiazepine receptor in Alzheimer’s disease measured by positron emission tomography with 11C-DAA1106, Biol. Psychiatry, 64, pp. 835-841, (2008); Kreisl W.C., Lyoo C.H., Liow J.S., Snow J., Page E., Jenko K.J., Morse C.L., Zoghbi S.S., Pike V.W., Turner R.S., Et al., Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer’s disease, Neurobiol. Aging, 51, pp. 132-140, (2017); Kreisl W.C., Lyoo C.H., McGwier M., Snow J., Jenko K.J., Kimura N., Corona W., Morse C.L., Zoghbi S.S., Pike V.W., Et al., In vivo radioligand binding to translocator protein correlates with severity of Alzheimer’s disease, Brain, 136, pp. 2228-2238, (2013); Kreisl W.C., Lyoo C.H., Liow J.S., Wei M., Snow J., Page E., Jenko K.J., Morse C.L., Zoghbi S.S., Pike V.W., Et al., 11C-PBR28 binding to translocator protein increases with progression of Alzheimer’s disease, Neurobiol. Aging, 44, pp. 53-61, (2016); Gulyas B., Vas A., Toth M., Takano A., Varrone A., Cselenyi Z., Schain M., Mattsson P., Halldin C., Age and disease related changes in the translocator protein (TSPO) system in the human brain: Positron emission tomography measurements with 11C-vinpocetine, Neuroimage, 56, pp. 1111-1121, (2011); Hamelin L., Lagarde J., Dorothee G., Leroy C., Labit M., Comley R.A., De Souza L.C., Corne H., Dauphinot L., Bertoux M., Et al., Early and protective microglial activation in Alzheimer’s disease: A prospective study using 18F-DPA-714 PET imaging, Brain, 139, pp. 1252-1264, (2016); Suridjan I., Pollock B.G., Verhoeff N.P., Voineskos A.N., Chow T., Rusjan P.M., Lobaugh N.J., Houle S., Mulsant B.H., Mizrahi R., In vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: A positron emission tomography study with a novel radioligand, 18F-FEPPA, Mol. Psychiatry, 20, pp. 1579-1587, (2015); Varrone A., Oikonen V., Forsberg A., Joutsa J., Takano A., Solin O., Haaparanta-Solin M., Nag S., Nakao R., Al-Tawil N., Et al., Positron emission tomography imaging of the 18 kDa translocator protein (TSPO) with 18F-FEMPA in Alzheimer’s disease patients and control subjects, Eur. J. Nucl. Med. Mol. Imaging, 42, pp. 438-446, (2015); Fujimura Y., Ikoma Y., Yasuno F., Suhara T., Ota M., Matsumoto R., Nozaki S., Takano A., Kosaka J., Zhang M.R., Et al., Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain, J. Nucl. Med, 47, pp. 43-50, (2006); Takano A., Gulyas B., Varrone A., Karlsson P., Sjoholm N., Larsson S., Jonsson C., Odh R., Sparks R., Al Tawil N., Et al., Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand 18F-FEDAA1106: A human whole-body PET study, Eur. J. Nucl. Med. Mol. Imaging, 38, pp. 2058-2065, (2011); Varrone A., Mattsson P., Forsberg A., Takano A., Nag S., Gulyas B., Borg J., Boellaard R., Al-Tawil N., Eriksdotter M., Et al., In vivo imaging of the 18 kDa translocator protein (TSPO) with 18F-FEDAA1106 and PET does not show increased binding in Alzheimer’s disease patients, Eur. J. Nucl. Med. Mol. Imaging, 40, pp. 921-931, (2013); Owen D.R.J., Gunn R.N., Rabiner E.A., Bennacef I., Fujita M., Kreisl W.C., Innis R.B., Pike V.W., Reynolds R., Matthews P.M., Et al., Mixed-affinity binding in humans with 18 kDa translocator protein ligands, J. Nucl. Med. Off. Publ. Soc. Nucl. Med, 52, pp. 24-32, (2011); Dodel R., Spottke A., Gerhard A., Reuss A., Reinecker S., Schimke N., Trenkwalder C., Sixel-Doring F., Herting B., Kamm C., Et al., Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and 11C-(R)-PK11195 PET (MEMSA-trial), Mov. Disord, 25, pp. 97-107, (2010); Owen D.R., Yeo A.J., Gunn R.N., Song K., Wadsworth G., Lewis A., Rhodes C., Pulford D.J., Bennacef I., Parker C.A., Et al., An 18 kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28, J. Cereb. Blood Flow Metab, 32, pp. 1-5, (2012); Turkheimer F.E., Rizzo G., Bloomfield P.S., Howes O., Zanotti-Fregonara P., Bertoldo A., Veronese M., The methodology of TSPO imaging with positron emission tomography, Biochem. Soc. Trans, 43, pp. 586-592, (2015); Turkheimer F.E., Edison P., Pavese N., Roncaroli F., Anderson A.N., Hammers A., Gerhard A., Hinz R., Tai Y.F., Brooks D.J., Reference and target region modeling of 11C-(R)-PK11195 brain studies, J. Nucl. Med, 48, pp. 158-167, (2007); Yaqub M., Van Berckel B.N., Schuitemaker A., Hinz R., Turkheimer F.E., Tomasi G., Lammertsma A.A., Boellaard R., Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-11C-PK11195 brain PET studies, J. Cereb. Blood Flow Metab, 32, pp. 1600-1608, (2012); Anderson A.N., Pavese N., Edison P., Tai Y.F., Hammers A., Gerhard A., Brooks D.J., Turkheimer F.E., A systematic comparison of kinetic modelling methods generating parametric maps for 11C-(R)-PK11195, Neuroimage, 36, pp. 28-37, (2007); Tomasi G., Edison P., Bertoldo A., Roncaroli F., Singh P., Gerhard A., Cobelli C., Brooks D.J., Turkheimer F.E., Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer’s disease, J. Nucl. Med, 49, pp. 1249-1256, (2008); Engler H., Lundberg P.O., Ekbom K., Nennesmo I., Nilsson A., Bergstrom M., Tsukada H., Hartvig P., Langstrom B., Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease, Eur. J. Nucl. Med. Mol. Imaging, 30, pp. 85-95, (2003); Johansson A., Engler H., Blomquist G., Scott B., Wall A., Aquilonius S.M., Langstrom B., Askmark H., Evidence for astrocytosis in ALS demonstrated by 11C-L-deprenyl-D2 PET, J. Neurol. Sci, 255, pp. 17-22, (2007); Kumlien E., Nilsson A., Hagberg G., Langstrom B., Bergstrom M., PET with 11C-deuterium-deprenyl and 18F-FDG in focal epilepsy, Acta Neurol. Scand, 103, pp. 360-366, (2001); Ahmad R., Postnov A., Bormans G., Versijpt J., Vandenbulcke M., Van Laere K., Decreased in vivo availability of the cannabinoid type 2 receptor in Alzheimer’s disease, Eur. J. Nucl. Med. Mol. Imaging, 43, pp. 2219-2227, (2016); Esposito G., Giovacchini G., Liow J.S., Bhattacharjee A.K., Greenstein D., Schapiro M., Hallett M., Herscovitch P., Eckelman W.C., Carson R.E., Et al., Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET, J. Nucl. Med, 49, pp. 1414-1421, (2008); Heppner F.L., Ransohoff R.M., Becher B., Immune attack: The role of inflammation in Alzheimer disease, Nat. Rev. Neurosci, 16, pp. 358-372, (2015); Groom G.N., Junck L., Foster N.L., Frey K.A., Kuhl D.E., PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer’s disease, J. Nucl. Med, 36, pp. 2207-2210, (1995); Kropholler M.A., Boellaard R., Van Berckel B.N., Schuitemaker A., Kloet R.W., Lubberink M.J., Jonker C., Scheltens P., Lammertsma A.A., Evaluation of reference regions for (R)-11C-PK11195 studies in Alzheimer’s disease and mild cognitive impairment, J. Cereb. Blood Flow Metab, 27, pp. 1965-1974, (2007); Wiley C.A., Lopresti B.J., Venneti S., Price J., Klunk W.E., Dekosky S.T., Mathis C.A., Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease, Arch. Neurol, 66, pp. 60-67, (2009); Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., Banati R.B., In vivo measurement of activated microglia in dementia, Lancet, 358, pp. 461-467, (2001); Versijpt J.J., Dumont F., Van Laere K.J., Decoo D., Santens P., Audenaert K., Achten E., Slegers G., Dierckx R.A., Korf J., Assessment of neuroinflammation and microglial activation in Alzheimer’s disease with radiolabelled PK11195 and single photon emission computed tomography, Eur. Neurol, 50, pp. 39-47, (2003); Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Et al., Microglia, amyloid, and cognition in Alzheimer’s disease: An 11C-(R)PK11195-PET and 11C-PIB-PET study, Neurobiol. Dis, 32, pp. 412-419, (2008); Fan Z., Aman Y., Ahmed I., Chetelat G., Landeau B., Ray Chaudhuri K., Brooks D.J., Edison P., Influence of microglial activation on neuronal function in Alzheimer’s and Parkinson’s disease dementia, Alzheimers Dement, 11, pp. 608-621, (2015); Femminella G.D., Ninan S., Atkinson R., Fan Z., Brooks D.J., Edison P., Does microglial activation influence hippocampal volume and neuronal function in Alzheimer’s disease and Parkinson’s disease dementia, J. Alzheimers Dis, 51, pp. 1275-1289, (2016); Fan Z., Okello A.A., Brooks D.J., Edison P., Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer’s disease, Brain, 138, pp. 3685-3698, (2015); Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Et al., Microglial activation and amyloid deposition in mild cognitive impairment: A PET study, Neurology, 72, pp. 56-62, (2009); Schuitemaker A., Kropholler M.A., Boellaard R., Van Der Flier W.M., Kloet R.W., Van Der Doef T.F., Knol D.L., Windhorst A.D., Luurtsema G., Barkhof F., Et al., Microglial activation in Alzheimer’s disease: An (R)-11C-PK11195 positron emission tomography study, Neurobiol. Aging, 34, pp. 128-136, (2013); Yokokura M., Mori N., Yagi S., Yoshikawa E., Kikuchi M., Yoshihara Y., Wakuda T., Sugihara G., Takebayashi K., Suda S., Et al., In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer’s disease, Eur. J. Nucl. Med. Mol. Imaging, 38, pp. 343-351, (2011); Yasuno F., Kosaka J., Ota M., Higuchi M., Ito H., Fujimura Y., Nozaki S., Takahashi S., Mizukami K., Asada T., Et al., Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with 11C-DAA1106, Psychiatry Res, 203, pp. 67-74, (2012); Cerami C., Crespi C., Della Rosa P.A., Dodich A., Marcone A., Magnani G., Coppi E., Falini A., Cappa S.F., Perani D., Brain changes within the visuo-spatial attentional network in posterior cortical atrophy, J. Alzheimers Dis, 43, pp. 385-395, (2015); Cagnin A., Rossor M., Sampson E.L., Mackinnon T., Banati R.B., In vivo detection of microglial activation in frontotemporal dementia, Ann. Neurol, 56, pp. 894-897, (2004); Gerhard A., Watts J., Trender-Gerhard I., Turkheimer F., Banati R.B., Bhatia K., Brooks D.J., In vivo imaging of microglial activation with 11C-(R)-PK11195 PET in corticobasal degeneration, Mov. Disord, 19, pp. 1221-1226, (2004); Gerhard A., Trender-Gerhard I., Turkheimer F., Quinn N.P., Bhatia K.P., Brooks D.J., In vivo imaging of microglial activation with 11C-(R)-PK11195 PET in progressive supranuclear palsy, Mov. Disord, 21, pp. 89-93, (2006); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Et al., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Iannaccone S., Cerami C., Alessio M., Garibotto V., Panzacchi A., Olivieri S., Gelsomino G., Moresco R.M., Perani D., In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease, Parkinsonism Relat. Disord, 19, pp. 47-52, (2013); Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R.B., Brooks D.J., In vivo imaging of microglial activation with 11C-(R)-PK11195 PET in idiopathic Parkinson’s disease, Neurobiol. Dis, 21, pp. 404-412, (2006); Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Torizuka T., Microglial activation and dopamine terminal loss in early Parkinson’s disease, Ann. Neurol, 57, pp. 168-175, (2005); Bartels A.L., Willemsen A.T., Doorduin J., De Vries E.F., Dierckx R.A., Leenders K.L., 11C-PK11195 PET: Quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson’s disease?, Parkinsonism Relat. Disord, 16, pp. 57-59, (2010); Zhou X., Li Y., Shi X., Ma C., An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: Targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels, Am. J. Transl. Res, 8, pp. 246-269, (2016); Budni J., Garcez M.L., De Medeiros J., Cassaro E., Bellettini-Santos T., Mina F., Quevedo J., The anti-inflammatory role of minocycline in Alzheimer’s disease, Curr. Alzheimer Res, 13, pp. 1319-1329, (2016); Venigalla M., Sonego S., Gyengesi E., Sharman M.J., Munch G., Novel promising therapeutics against chronic neuroinflammation and neurodegeneration in Alzheimer’s disease, Neurochem. Int, 95, pp. 63-74, (2016); Ratchford J.N., Endres C.J., Hammoud D.A., Pomper M.G., Shiee N., McGready J., Pham D.L., Calabresi P.A., Decreased microglial activation in MS patients treated with glatiramer acetate, J. Neurol, 259, pp. 1199-1205, (2012); Sucksdorff M., Rissanen E., Tuisku J., Nuutinen S., Paavilainen T., Rokka J., Rinne J., Airas L., Evaluation of the effect of fingolimod treatment on microglial activation using serial PET imaging in multiple sclerosis, J. Nucl. Med, (2017); Vivash L., O'Brien T.J., Imaging microglial activation with TSPO PET: Lighting up neurologic diseases, J. Nucl. Med, 57, pp. 165-168, (2016)","2-s2.0-85019121341"
"Van den Stock J.; Cerami C.; Dodich A.; Cappa S.; Vandenberghe R.; De Winter F.-L.; Vandenbulcke M.","Van den Stock, Jan (21834885100); Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Cappa, Stefano (7005836132); Vandenberghe, Rik (57203039054); De Winter, François-Laurent (55155176800); Vandenbulcke, Mathieu (56998955200)","21834885100; 25722905400; 56001713900; 7005836132; 57203039054; 55155176800; 56998955200","Transdiagnostic overlap in brain correlates of affective and cognitive theory of mind deficits","2023","Brain","146","6","","E39","E42","3","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160965139&doi=10.1093%2fbrain%2fawad023&partnerID=40&md5=6affbec962d400b0c49371bc9b6a1135","[No abstract available]","","Brain; Cognition; Humans; Theory of Mind; amygdala; art; attribution (psychology); brain size; brain tumor; cognition; emotion; emotion attribution; follow up; frontal variant frontotemporal dementia; functional neuroimaging; gray matter; human; intention attribution; Letter; major clinical study; mental task; mentalizing network; neuroimaging; neuropsychological assessment; parietal lobe; rank sum test; regression analysis; reliability; reproducibility; social cognition; story based empathy task; T1 weighted imaging; temporal lobe; theory of mind; valence (emotion); validation study; validity; brain; cognition; diagnostic imaging","Campanella F, West T, Corradi-Dell'Acqua C, Skrap M., Cognitive and affective theory of mind double dissociation after parietal and temporal lobe tumours, Brain, 145, pp. 1818-1829, (2022); Dodich A, Cerami C, Canessa N, Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the story-based empathy task, Neurol Sci, 36, pp. 1907-1912, (2015); Cerami C, Dodich A, Canessa N, Et al., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 10, pp. 827-834, (2014); Schurz M, Radua J, Tholen MG, Et al., Toward a hierarchical model of social cognition: A neuroimaging meta-analysis and integrative review of empathy and theory of mind, Psychol Bull, 147, pp. 293-327, (2021); Marek S, Tervo-Clemmens B, Calabro FJ, Et al., Reproducible brain-wide association studies require thousands of individuals, Nature, 603, pp. 654-660, (2022); Rosenberg MD, Finn ES., How to establish robust brain-behavior relationships without thousands of individuals, Nat Neurosci, 25, pp. 835-837, (2022); Van den Stock J, De Winter FL, Stam D, Et al., Reduced tendency to attribute mental states to abstract shapes in behavioral variant frontotemporal dementia links with cerebellar structural integrity, Neuroimage Clin, 22, (2019); Steerneman P, Meesters C, Muris P., Theory-of-mind-screeningschaal, (2000); Stone VE, Baron-Cohen S, Knight RT., Frontal lobe contributions to theory of mind, J Cogn Neurosci, 10, pp. 640-656, (1998); Spek AA., Faux-pas","2-s2.0-85160965139"
"Perani D.; Della Rosa P.A.; Cerami C.; Gallivanone F.; Fallanca F.; Vanoli E.G.; Panzacchi A.; Nobili F.; Pappatà S.; Marcone A.; Garibotto V.; Castiglioni I.; Magnani G.; Cappa S.F.; Gianolli L.; Drzezga A.; Perneczky R.; Didic M.; Guedj E.; Van Berckel B.N.; Ossenkoppele R.; Morbelli S.; Frisoni G.; Caroli A.","Perani, Daniela (7005630261); Della Rosa, Pasquale Anthony (14420734200); Cerami, Chiara (25722905400); Gallivanone, Francesca (20435500300); Fallanca, Federico (23488654900); Vanoli, Emilia Giovanna (56414581300); Panzacchi, Andrea (6603278442); Nobili, Flavio (57206948479); Pappatà, Sabina (56243181600); Marcone, Alessandra (6701496511); Garibotto, Valentina (24281297800); Castiglioni, Isabella (6603570829); Magnani, Giuseppe (24496141800); Cappa, Stefano F. (7005836132); Gianolli, Luigi (6602754456); Drzezga, Alexander (6603680777); Perneczky, Robert (6506128340); Didic, Mira (55946471200); Guedj, Eric (13604996000); Van Berckel, Bart N. (6603412407); Ossenkoppele, Rik (40462134000); Morbelli, Silvia (24471961700); Frisoni, Giovanni (56214208300); Caroli, Anna (13908172500)","7005630261; 14420734200; 25722905400; 20435500300; 23488654900; 56414581300; 6603278442; 57206948479; 56243181600; 6701496511; 24281297800; 6603570829; 24496141800; 7005836132; 6602754456; 6603680777; 6506128340; 55946471200; 13604996000; 6603412407; 40462134000; 24471961700; 56214208300; 13908172500","Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting","2014","NeuroImage: Clinical","6","","","445","454","9","164","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84910087093&doi=10.1016%2fj.nicl.2014.10.009&partnerID=40&md5=7c9bfab2ed26cd95ecb8cc87adb73f89","Diagnostic accuracy in FDG-PET imaging highly depends on the operating procedures. In this clinical study on dementia, we compared the diagnostic accuracy at a single-subject level of a) Clinical Scenarios, b) Standard FDG Images and c) Statistical Parametrical (SPM) Maps generated via a new optimized SPM procedure. We evaluated the added value of FDG-PET, either Standard FDG Images or SPM Maps, to Clinical Scenarios. In 88 patients with neurodegenerative diseases (Alzheimer's Disease-AD, Frontotemporal Lobar Degeneration-FTLD, Dementia with Lewy bodies-DLB and Mild Cognitive Impairment-MCI), 9 neuroimaging experts made a forced diagnostic decision on the basis of the evaluation of the three types of information. There was also the possibility of a decision of normality on the FDG-PET images. The clinical diagnosis confirmed at a long-term follow-up was used as the gold standard. SPM Maps showed higher sensitivity and specificity (96% and 84%), and better diagnostic positive (6.8) and negative (0.05) likelihood ratios compared to Clinical Scenarios and Standard FDG Images. SPM Maps increased diagnostic accuracy for differential diagnosis (AD vs. FTD; beta 1.414, p = 0.019). The AUC of the ROC curve was 0.67 for SPM Maps, 0.57 for Clinical Scenarios and 0.50 for Standard FDG Images. In the MCI group, SPM Maps showed the highest predictive prognostic value (mean LOC = 2.46), by identifying either normal brain metabolism (exclusionary role) or hypometabolic patterns typical of different neurodegenerative conditions. © 2014, Elsevier Inc. All rights reserved.","Dementia diagnosis; FDG-PET imaging; Statistical parametrical mapping; Voxel-based analysis","Aged; Aged, 80 and over; Brain; Data Interpretation, Statistical; Diagnosis, Computer-Assisted; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neurodegenerative Diseases; Positron-Emission Tomography; Sensitivity and Specificity; fluorodeoxyglucose f 18; fluorodeoxyglucose f 18; adult; aged; Alzheimer disease; anterior cingulate; Article; brain mapping; brain metabolism; controlled study; corticobasal degeneration; dementia; diagnostic accuracy; differential diagnosis; diffuse Lewy body disease; female; follow up; frontal cortex; frontal variant frontotemporal dementia; frontotemporal dementia; human; interrater reliability; major clinical study; male; medial frontal cortex; medical expert; mild cognitive impairment; neuroimaging; PET scanner; positron emission tomography; posterior cingulate; predictive value; primary progressive aphasia; sensitivity and specificity; statistical analysis; statistical parametrical mapping; superior anterior temporal cortex; temporal cortex; validation study; voxel based morphometry; brain; computer assisted diagnosis; diagnostic use; metabolism; middle aged; Neurodegenerative Diseases; positron emission tomography; procedures; statistical analysis; very elderly","Albert M.S., DeKosky S.T., Dickson D., Et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 7, 3, pp. 270-279, (2011); Anchisi D., Borroni B., Franceschi M., Et al., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Archives of Neurology, 62, 11, pp. 1728-1733, (2005); Armstrong M.J., Litvan I., Lang A.E., Et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, 5, pp. 496-503, (2013); Bateman R.J., Xiong C., Benzinger T.L., Et al., Clinical and biomarker changes in dominantly inherited Alzheimer's disease, New England Journal of Medicine, 367, 9, pp. 795-804, (2012); Bohnen N.I., Djang D.S., Herholz K., Anzai Y., Minoshima S., Effectiveness and safety of <sup>18</sup>F-FDG PET in the evaluation of dementia: A review of the recent literature, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 53, 1, pp. 59-71, (2012); Buchert R., Wilke F., Chakrabarti B., Martin B., Brenner W., Mester J., Clausen M., Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patientswith suspected Alzheimer's disease, Journal of Neuroimaging: Official Journal of the American Society of Neuroimaging, 15, 4, pp. 348-355, (2005); Caroli A., Prestia A., Chen K., Et al., Summary metrics to assess Alzheimer diseaserelated hypometabolic pattern with <sup>18</sup>F-FDG PET: Head-to-head comparison, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 53, 4, pp. 592-600, (2012); Chen W.P., Samuraki M., Yanase D., Et al., Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis, Nuclear Medicine Communications, 29, 3, pp. 270-276, (2008); Chetelat G., Desgranges B., Landeau B., Et al., Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease, Brain: A Journal of Neurology, 131, 1, pp. 60-71, (2008); De Souza L.C., Chupin M., Bertoux M., Et al., Is hippocampal volume a good marker to differentiate Alzheimer's disease from frontotemporal dementia?, Journal of Alzheimer's Disease: JAD, 36, 1, pp. 57-66, (2013); Della Rosa P.A., Cerami C., Gallivanone F., Et al., A standardized [<sup>18</sup>F]FDG-PET template for spatial normalization in statistical parametric mapping analysis pf brain images in dementia, Neuroinformatics, (2014); Dubois B., Epelbaum S., Santos A., Et al., Alzheimer disease: From biomarkers to diagnosis, Revue Neurologique, 169, 10, pp. 744-751, (2013); Dubois B., Feldman H.H., Jacova C., Et al., Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria, Lancet. Neurology, 13, 6, pp. 614-629, (2014); Dubois B., Feldman H.H., Jacova C., Et al., Revising the definition of Alzheimer's disease: A new lexicon, Lancet. Neurology, 9, 11, pp. 1118-1127, (2010); Fjell A.M., McEvoy L., Holland D., Dale A.M., Walhovd K.B., Alzheimer's Disease Neuroimaging Initiative, Brain changes in older adults at very low risk for Alzheimer's disease, Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 33, 19, pp. 8237-8242, (2013); Foster N.L., Heidebrink J.L., Clark C.M., Et al., FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease, Brain: A Journal of Neurology, 130, 10, pp. 2616-2635, (2007); Fotuhi M., Do D., Jack C., Modifiable factors that alter the size of the hippocampus with ageing, Nature Reviews. Neurology, 8, 4, pp. 189-202, (2012); Frisoni G.B., Bocchetta M., Chetelat G., Et al., Imaging markers for Alzheimer disease: Which vs how, Neurology, 81, 5, pp. 487-500, (2013); Friston K.J., Holmes A.P., Worsley K.J., Poline J.-P., Frith C.D., Frackowiak R.S.J., Statistical parametric maps in functional imaging: A general linear approach, Human Brain Mapping, 2, 4, pp. 189-210, (1994); Galluzzi S., Geroldi C., Amicucci G., Et al., Supporting evidence for using biomarkers in the diagnosis of MCI due to AD, Journal of Neurology, 260, 2, pp. 640-650, (2013); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, 11, pp. 1006-1114, (2011); Herholz K., Cerebral glucosemetabolismin preclinical and prodromal Alzheimer's disease, Expert Review of Neurotherapeutics, 10, 11, pp. 1667-1673, (2010); Herholz K., Salmon E., Perani D., Et al., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage, 17, 1, pp. 302-306, (2002); Jack C.R., Albert M.S., Knopman D.S., Et al., Introduction to the recommendations from the National Institute on Aging-Alzheimer's Associationworkgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 7, 3, pp. 257-262, (2011); Jack C.R., Knopman D.S., Jagust W.J., Et al., Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade, Lancet. Neurology, 9, 1, pp. 119-128, (2010); McKeith I.G., Dickson D.W., Lowe J., Et al., Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium, Neurology, 65, 12, pp. 1863-1872, (2005); McKhann G.M., Knopman D.S., Chertkow H., Et al., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 7, 3, pp. 263-269, (2011); Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., Kuhl D.E., Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation, Annals of Neurology, 50, 3, pp. 358-365, (2001); Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E., Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease, Annals of Neurology, 42, 1, pp. 85-94, (1997); Morbelli S., Drzezga A., Perneczky R., Et al., Resting metabolic connectivity in prodromal Alzheimer's disease, Neurobiology of Aging, 33, 11, pp. 2533-2550, (2012); Mosconi L., Murray J., Tsui W.H., Et al., Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD, Neurology, 82, 9, pp. 752-760, (2014); Mosconi L., Tsui W.H., Herholz K., Et al., Multicenter standardized <sup>18</sup>F-FDG PET diagnosis ofmild cognitive impairment, Alzheimer's disease, and other dementias, Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, 49, 3, pp. 390-398, (2008); Patterson J.C., Lilien D.L., Takalkar A., Pinkston J.B., Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans, International Journal of Alzheimer's Disease, 2011, (2010); Perani D., FDG-PET and amyloid-PET imaging: The diverging paths, Current Opinion in Neurology, 27, 4, pp. 405-413, (2014); Perani D., Functional Neuroimaging of Cognition, Handbook of Clinical Neurology, 88, pp. 61-111, (2008); Perani D., Schillaci O., Padovani A., Et al., A survey of FDG and amyloid PET imaging in dementia and GRADE analysis, BioMed Research International, 2014, (2014); Petersen R.C., Roberts R.O., Knopman D.S., Et al., Mild cognitive impairment: Ten years later, Archives of Neurology, 66, 12, pp. 1447-1455, (2009); Prestia A., Caroli A., Van Der Flier W.M., Et al., Prediction of dementia in MCI patients based on core diagnosticmarkers for Alzheimer disease, Neurology, 80, 11, pp. 1048-1056, (2013); Rascovsky K., Hodges J.R., Knopman D., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Ridgway G.R., Omar R., Ourselin S., Hill D.L., Warren J.D., Fox N.C., Issues with threshold masking in voxel-based morphometry of atrophied brains, Neuroimage, 44, 1, pp. 99-111, (2009); Salmon E., Garraux G., Delbeuck X., Et al., Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia, Neuroimage, 20, 1, pp. 435-440, (2003); Signorini M., Paulesu E., Friston K., Et al., Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [<sup>18</sup>F]FDG PET: A clinical validation of statistical parametric mapping, Neuroimage, 9, 1, pp. 63-80, (1999); Silverman D.H., Mosconi L., Ercoli L., Chen W., Small G.W., Positron emission tomography scans obtained for the evaluation of cognitive dysfunction, Seminars in Nuclear Medicine, 38, 4, pp. 251-261, (2008); Silverman D.H., Truong C.T., Kim S.K., Et al., Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: Comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET, Molecular Genetics and Metabolism, 80, 3, pp. 350-355, (2003); Spence J.S., Carmack P.S., Gunst R.F., Schucany W.R., Woodward W.A., Haley R.W., Using a white matter reference to remove the dependency of global signal on experimental conditions in SPECT analyses, Neuroimage, 32, 1, pp. 49-53, (2006); Sperling R.A., Aisen P.S., Beckett L.A., Et al., Toward defining the preclinical stage of Alzheimer's disease: Recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 7, 3, pp. 280-292, (2011); Teune L.K., Bartels A.L., De Jong B.M., Et al., Typical cerebralmetabolic patterns in neurodegenerative brain diseases, Movement Disorders: Official Journal of the Movement Disorder Society, 25, 14, pp. 2395-2404, (2010); Varrone A., Asenbaum S., Vander Borght T., Et al., European association of nuclear medicine neuroimaging committee. EANM procedure guidelines for PET brain imaging using [<sup>18</sup> F]FDG, European Journal of Nuclear Medicine and Molecular Imaging, 36, 12, pp. 2103-2110, (2009); Yakushev I., Hammers A., Fellgiebel A., Et al., SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease and amnestic mild cognitive impairment from healthy aging, Neuroimage, 44, 1, pp. 43-50, (2009)","2-s2.0-84910087093"
"Sala A.; Iaccarino L.; Fania P.; Vanoli E.G.; Fallanca F.; Pagnini C.; Cerami C.; Calvo A.; Canosa A.; Pagani M.; Chiò A.; Cistaro A.; Perani D.","Sala, Arianna (9274476600); Iaccarino, Leonardo (56114773500); Fania, Piercarlo (54399746900); Vanoli, Emilia G. (56414581300); Fallanca, Federico (23488654900); Pagnini, Caterina (57205349009); Cerami, Chiara (25722905400); Calvo, Andrea (57208095998); Canosa, Antonio (15838973400); Pagani, Marco (57197175050); Chiò, Adriano (7006225787); Cistaro, Angelina (24366002700); Perani, Daniela (7005630261)","9274476600; 56114773500; 54399746900; 56414581300; 23488654900; 57205349009; 25722905400; 57208095998; 15838973400; 57197175050; 7006225787; 24366002700; 7005630261","Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis","2019","European Journal of Nuclear Medicine and Molecular Imaging","46","5","","1117","1131","14","16","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059703559&doi=10.1007%2fs00259-018-4246-2&partnerID=40&md5=60306937c134fea44bdcc8a95faeb495","Purpose: The role for [18F]FDG-PET in supporting amyotrophic lateral sclerosis (ALS) diagnosis is not fully established. In this study, we aim at evaluating [18F]FDG-PET hypo- and hyper-metabolism patterns in spinal- and bulbar-onset ALS cases, at the single-subject level, testing the diagnostic value in discriminating the two conditions, and the correlations with core clinical symptoms severity. Methods: We included 95 probable-ALS patients with [18F]FDG-PET scan and clinical follow-up. [18F]FDG-PET images were analyzed with an optimized voxel-based-SPM method. The resulting single-subject SPM-t maps were used to: (a) assess brain regional hypo- and hyper-metabolism; (b) evaluate the accuracy of regional hypo- and hyper metabolism in discriminating spinal vs. bulbar-onset ALS; (c) perform correlation analysis with motor symptoms severity, as measured by ALS-FRS-R. Results: Primary motor cortex showed the most frequent hypo-metabolism in both spinal-onset (∼57%) and bulbar-onset (∼64%) ALS; hyper-metabolism was prevalent in the cerebellum in both spinal-onset (∼56.5%) and bulbar-onset (∼55.7%) ALS, and in the occipital cortex in bulbar-onset (∼62.5%) ALS. Regional hypo- and hyper-metabolism yielded a very low accuracy (AUC < 0.63) in discriminating spinal- vs. bulbar-onset ALS, as obtained from single-subject SPM-t-maps. Severity of motor symptoms correlated with hypo-metabolism in sensorimotor cortex in spinal-onset ALS, and with cerebellar hyper-metabolism in bulbar-onset ALS. Conclusions: The high variability in regional hypo- and hyper-metabolism patterns, likely reflecting the heterogeneous pathology and clinical phenotypes, limits the diagnostic potential of [18F]FDG-PET in discriminating spinal and bulbar onset patients. © 2019, Springer-Verlag GmbH Germany, part of Springer Nature.","Amyotrophic lateral sclerosis; Biomarkers; Brain metabolism; Diagnosis; [18F]FDG-PET","Amyotrophic Lateral Sclerosis; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Humans; Male; Medulla Oblongata; Middle Aged; Motor Cortex; Sensitivity and Specificity; Spine; fluorodeoxyglucose f 18; adult; amyotrophic lateral sclerosis; amyotrophic lateral sclerosis functional rating scale; Article; brain metabolism; bulbar paralysis; cerebellum; clinical assessment; clinical evaluation; controlled study; correlation analysis; diagnostic accuracy; diagnostic test; diagnostic value; disease severity; female; follow up; functional status assessment; human; hypermetabolism; image analysis; major clinical study; male; middle aged; motor dysfunction; occipital cortex; positron emission tomography; primary motor cortex; sensorimotor cortex; spine disease; symptom; amyotrophic lateral sclerosis; diagnostic imaging; differential diagnosis; medulla oblongata; metabolism; motor cortex; sensitivity and specificity; spine","Chio A., Pagani M., Agosta F., Calvo A., Cistaro A., Filippi M., Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes, Lancet Neurol, 13, pp. 1228-1240, (2014); Ludolph A., Drory V., Hardiman O., Nakano I., Ravits J., Robberecht W., Et al., A revision of the El Escorial criteria - 2015, Amyotroph Lateral Scler Front Degener, 16, pp. 291-292, (2015); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, pp. 293-299, (2000); Zoccolella S., Beghi E., Palagano G., Fraddosio A., Samarelli V., Lamberti P., Et al., Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study, J Neurol Sci, 250, pp. 45-49, (2006); Turner M.R., Kiernan M.C., Leigh P.N., Talbot K., Biomarkers in amyotrophic lateral sclerosis, Lancet Neurol. Elsevier Ltd, 8, pp. 94-109, (2009); Swinnen B., Robberecht W., The phenotypic variability of amyotrophic lateral sclerosis, Nat. Rev. Neurol. Nature Publishing Group, 10, pp. 661-670, (2014); Chio A.I.S.I.S., Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis, J Neurol, 246, pp. 1-5, (1999); Belsh J.M., Schiffman P.L., The amyotrophic lateral sclerosis (ALS) patient perspective on misdiagnosis and its repercussions, J Neurol Sci, 139, pp. 110-116, (1996); Nzwalo H., De Abreu D., Swash M., Pinto S., De Carvalho M., Delayed diagnosis in ALS: the problem continues, J Neurol Sci, 343, pp. 173-175, (2014); Hardiman O., van den Berg L.H., Kiernan M.C., Clinical diagnosis and management of amyotrophic lateral sclerosis, Nat Rev Neurol Nature Publishing Group, 7, pp. 639-649, (2011); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Et al., Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria, Lancet Neurol, 13, pp. 614-629, (2014); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Et al., The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s dement, Elsevier Ltd, 7, pp. 263-269, (2011); McKeith I., Boeve B., Dickson D., Lowe J., Emre M., Al E., Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium, Neurology, 89, pp. 88-100, (2017); Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging and Alzheimer’s association workgroup, Alzheimers Dement, 7, pp. 270-279, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Stoessl A.J., Glucose utilization: still in the synapse, Nat Neurosci Nature Publishing Group, 20, pp. 382-384, (2017); Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Et al., Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s dement, Elsevier Ltd, 7, pp. 280-292, (2011); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, pp. 496-503, (2013); Caminiti S.P., Alongi P., Majno L., Volonte M.A., Cerami C., Gianolli L., Et al., Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders, Eur J Neurol, 24, pp. 626-687, (2017); Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Et al., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia, J Alzheimers Dis, 55, pp. 183-197, (2016); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. NeuroImage. Clin, Elsevier BV, 6, pp. 445-454, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Et al., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging, 43, pp. 499-508, (2016); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Et al., Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia, NeuroImage Clin Elsevier BV, 7, pp. 187-194, (2015); Caminiti S.P., Ballarini T., Sala A., Cerami C., Presotto L., Santangelo R., Et al., FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort, NeuroImage Clin Elsevier, 18, pp. 167-177, (2018); Pilotto A., Premi E., Caminiti S.P., Presotto L., Alberici A., Paghera B., Et al., Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson’s disease, Neurology, 90, pp. e1029-e1037, (2018); Iaccarino L., Chiotis K., Alongi P., Almkvist O., Wall A., Cerami C., Et al., A cross-validation of FDG- and amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer’s disease in a clinical setting, J Alzheimers Dis, pp. 1-12, (2017); Pagani M., Chio A., Valentini M.C., Oberg J., Nobili F., Calvo A., Et al., Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis, Neurology, 83, pp. 1067-1074, (2014); Cistaro A., Valentini M.C., Chio A., Nobili F., Calvo A., Moglia C., Et al., Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset, Eur J Nucl Med Mol Imaging, 39, pp. 251-259, (2012); Van L.K., Vanhee A., Verschueren J., De C.L., Driesen A., Dupont P., Et al., Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis a prospective study, JAMA Neurol, 71, pp. 553-561, (2014); Matias-Guiu J.A., Pytel V., Cabrera-Martin M.N., Galan L., Valles-Salgado M., Guerrero A., Et al., Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis, Eur J Nucl Med Mol Imaging, 43, pp. 2050-2060, (2016); Canosa A., Pagani M., Cistaro A., Montuschi A., Iazzolino B., Fania P., Et al., 18F-FDG-PET correlates of cognitive impairment in ALS, Neurology, 86, pp. 44-49, (2015); Agosta F., Altomare D., Festari C., Orini S., Gandolfo F., Boccardi M., Et al., Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington disease, Eur J Nucl Med Mol Imaging, 45, pp. 1546-1556, (2018); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Et al., EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2, Eur J Nucl Med Mol Imaging Springer, 36, pp. 2103-2110, (2009); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [(18)F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Gallivanone F., della Rosa P., Perani D., Gilardi M.C., Castiglioni I., The impact of different 18FDG PET healthy subject scans for comparison with single patient in SPM analysis, Q J Nucl Med Mol Imaging, 6, 1, pp. 115-132, (2017); Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Et al., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, NeuroImage, 15, pp. 273-289, (2002); Sallet J., Mars R.B., Noonan M.P., Neubert F.-X., Jbabdi S., O'Reilly J.X., Et al., The organization of dorsal frontal cortex in humans and macaques, J Neurosci, 33, pp. 12255-12274, (2013); Mayka M.A., Corcos D.M., Leurgans S.E., Vaillancourt D.E., Three-dimensional locations and boundaries of motor and premotor cortices as defined by functional brain imaging: a meta-analysis, NeuroImage, 31, pp. 1453-1474, (2006); Tziortzi A.C., Searle G.E., Tzimopoulou S., Salinas C., Beaver J.D., Jenkinson M., Et al., Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy, NeuroImage, 54, pp. 264-277, (2011); Lancaster J., Rainey L., Summerlin J., Freitas C., Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method, Hum Brain Mapp, 5, pp. 238-242, (1997); Lancaster J.L., Woldorff M.G., Parsons L.M., Liotti M., Freitas C.S., Rainey L., Et al., Automated Talairach atlas labels for functional brain mapping, Hum Brain Mapp, 10, pp. 120-131, (2000); Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H., An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets, NeuroImage, 19, pp. 1233-1239, (2003); Diedrichsen J., Maderwald S., Kuper M., Thurling M., Rabe K., Gizewski E.R., Et al., Imaging the deep cerebellar nuclei: a probabilistic atlas and normalization procedure, NeuroImage, 54, pp. 1786-1794, (2011); Pagani M., Oberg J., De Carli F., Calvo A., Moglia C., Canosa A., Et al., Metabolic spatial connectivity in amyotrophic lateral sclerosis as revealed by independent component analysis, Hum Brain Mapp, 37, pp. 942-953, (2016); Cauda F., Giuliano G., Federico D., Sergio D., Katiuscia S., Discovering the somatotopic organization of the motor areas of the medial wall using low-frequency bold fluctuations, Hum Brain Mapp, 32, pp. 1566-1579, (2011); Bennett C.M., Wolford G.L., Miller M.B., The principled control of false positives in neuroimaging, Soc Cogn Affect Neurosci, 4, pp. 417-422, (2009); Endo H., Sekiguchi K., Ueda T., Kowa H., Kanda F., Toda T., Regional glucose hypometabolic spread within the primary motor cortex is associated with amyotrophic lateral sclerosis disease progression: a fluoro-deoxyglucose positron emission tomography study, eNeurologicalSci, 6, pp. 74-79, (2017); Verstraete E., Veldink J.H., Hendrikse J., Schelhaas H.J., Van Den Heuvel M.P., Van Den Berg L.H., Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis, J Neurol Neurosurg Psychiatry, 83, pp. 383-388, (2012); Genc B., Jara J.H., Lagrimas A.K.B., Pytel P., Roos R.P., Mesulam M.M., Et al., Apical dendrite degeneration, a novel cellular pathology for Betz cells in ALS, Sci Rep Nature Publishing Group, 7, (2017); Baker M.R., ALS—dying forward, backward or outward?, Nat Rev Neurol, 10, (2014); Chou S.M., Norris F.H., Amyotrophic lateral sclerosis: lower motor neuron disease spreading to upper motor neurons, Muscle Nerve, 16, pp. 864-869, (1993); Eisen A., Weber M., The motor cortex and amyotrophic lateral sclerosis, Muscle Nerve, 24, pp. 564-573, (2001); Yamanaka K., Chun S.J., Boillee S., Fujimori-Tonou N., Yamashita H., Gutmann D.H., Et al., Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis, Nat Neurosci, 11, pp. 251-253, (2008); Philips T., Robberecht W., Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease, Lancet Neurol Elsevier Ltd, 10, pp. 253-263, (2011); Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Et al., Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study, Neurobiol Dis, 15, pp. 601-609, (2004); Schroeter M., Dennin M.A., Walberer M., Backes H., Neumaier B., Fink G.R., Et al., Neuroinflammation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F]FDG-PET study, J Cereb Blood Flow Metab, 29, pp. 1216-1225, (2009); Turner M.R., Kiernan M.C., Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?, Amyotroph Lateral Scler, 13, pp. 245-250, (2012); Sibson N.R., Dhankhar A., Mason G.F., Rothman D.L., Behar K.L., Shulman R.G., Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal activity, Neurobiology, 95, pp. 316-321, (1998); Schreiber H., Gaigalat T., Wiedemuth-Catrinescu U., Graf M., Uttner I., Muche R., Et al., Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis: a longitudinal study in 52 patients, J Neurol, 252, pp. 772-781, (2005); Iaccarino L., Sala A., Caminiti S.P., Perani D., The emerging role of PET imaging in dementia, F1000Research, 6, (2017); Takeuchi R., Tada M., Shiga A., Toyoshima Y., Konno T., Sato T., Et al., Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: evidence for clinico-pathologic subtypes, Acta Neuropathol Commun Acta Neuropathologica Communications, 4, (2016); Nishihira Y., Tan C.F., Onodera O., Toyoshima Y., Yamada M., Morita T., Et al., Sporadic amyotrophic lateral sclerosis: two pathological patterns shown by analysis of distribution of TDP-43-immunoreactive neuronal and glial cytoplasmic inclusions, Acta Neuropathol, 116, pp. 169-182, (2008); Sabatelli M., Conte A., Zollino M., Clinical and genetic heterogeneity of amyotrophic lateral sclerosis, Clin Genet, 83, pp. 408-416, (2013); Willekens S.M.A., van Weehaeghe D., van Damme P., van Laere K., Positron emission tomography in amyotrophic lateral sclerosis: Towards targeting of molecular pathological hallmarks, Eur J Nucl Med Mol Imaging, pp. 1-15, (2016); Hoffman J.M., Mazziotta J.C., Hawk T.C., Sumida R., Cerebral glucose utilization in motor neuron disease, Arch Neurol, 49, pp. 849-854, (1992); Buckner R.L., The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging, Neuron, 80, pp. 807-815, (2013); Mottolese C., Richard N., Harquel S., Szathmari A., Sirigu A., Desmurget M., Mapping motor representations in the human cerebellum, Brain, 136, pp. 330-342, (2013); Prell T., Grosskreutz J., The involvement of the cerebellum in amyotrophic lateral sclerosis, Amyotroph Lateral Scler Front Degener, 14, pp. 507-515, (2013)","2-s2.0-85059703559"
"Bonanni L.; Cagnin A.; Agosta F.; Babiloni C.; Borroni B.; Bozzali M.; Bruni A.C.; Filippi M.; Galimberti D.; Monastero R.; Muscio C.; Parnetti L.; Perani D.; Serra L.; Silani V.; Tiraboschi P.; Padovani A.; On behalf of DLB-SINdem study group; Alberici A.; Alberoni M.; Amici S.; Appollonio I.; Arena M.G.; Arighi A.; Avanzi S.; Bagella C.F.; Baglio F.; Barocco F.; Belardinelli N.; Bonuccelli U.; Bottini G.; Bruno Bossio R.; Bruno G.; Buccomino D.; Cacchiò G.; Calabrese E.; Campanelli A.; Canevelli M.; Canu E.D.G.; Cappa A.; Capra C.; Carapelle E.; Caratozzolo S.; Carbone G.F.S.; Cattaruzza T.; Cerami C.; Cester A.; Cheldi A.; Cherchi R.; Chiari A.; Cirafisi C.; Colao R.; Confaloni A.; Conti M.Z.; Costa A.; Costa B.; Cotelli M.S.; Cova I.; Cravello L.; Cumbo E.; Cupidi C.; De Togni L.; Del Din G.; Del Re M.L.; Dentizzi C.; Di Lorenzo F.; Di Stefano F.; Dikova N.; Farina E.; Floris G.; Foti A.; Franceschi M.; Fumagalli G.G.; Gabelli C.; Ghidoni E.; Giannandrea D.; Giordana M.T.; Giorelli M.; Giubilei F.; Grimaldi L.; Grimaldi R.; Guglielmi V.; Lanari A.; Le Pira F.; Letteri F.; Levi Minzi G.V.; Lorusso S.; Ludovico L.; Luzzi S.; Maggiore L.; Magnani G.; Mancini G.; Manconi F.M.; Manfredi L.; Maniscalco M.; Marano P.; Marcon M.; Marcone A.; Marra C.; Martorana A.; Mascia M.G.; Mascia V.; Mauri M.; Mazzei B.; Meloni M.; Merlo P.; Messa G.; Milia A.; Monacelli F.; Montecalvo G.; Moschella V.; Mura G.; Nemni R.; Nobili F.; Notarelli A.; Di Giacomo R.; Onofrj M.; Paci C.; Padiglioni C.; Perini M.; Perotta D.; Perri F.A.; Perri R.; Piccininni C.; Piccoli T.; Pilia G.; Pilotto A.; Poli S.; Pomati S.; Pompanin S.; Pucci E.; Puccio G.; Quaranta D.; Rainero I.; Rea G.; Realmuto S.; Riva M.; Rizzetti M.C.; Rolma G.; Rozzini L.; Sacco L.; Saibene F.L.; Scarpini E.; Sensi S.; Seripa D.; Sinforiani E.; Sorbi S.; Sorrentino G.; Spallazzi M.; Stracciari A.; Talarico G.; Tassinari T.; Thomas A.; Tiezzi A.; Tomassini P.F.; Trebbastoni A.; Tremolizzo L.; Tripi G.; Ursini F.; Vaianella L.; Valluzzi F.; Vezzadini G.; Vista M.; Volontè M.A.","Bonanni, L. (6603146272); Cagnin, A. (12778956300); Agosta, F. (6701687853); Babiloni, C. (7006669615); Borroni, B. (6701398657); Bozzali, M. (6701548417); Bruni, A.C. (7102347222); Filippi, M. (7202268530); Galimberti, D. (6701617660); Monastero, R. (6602175887); Muscio, C. (56029401900); Parnetti, L. (35412328100); Perani, D. (7005630261); Serra, L. (8266381200); Silani, V. (7006146949); Tiraboschi, P. (6701774925); Padovani, A. (55996824100); On behalf of DLB-SINdem study group (57193216269); Alberici, A. (6701506634); Alberoni, M. (6602735759); Amici, S. (6602857534); Appollonio, I. (8309607400); Arena, M.G. (55999182100); Arighi, A. (18633586600); Avanzi, S. (6701747731); Bagella, C.F. (56011813100); Baglio, F. (57202514086); Barocco, F. (55228692700); Belardinelli, N. (6507969284); Bonuccelli, U. (55156487000); Bottini, G. (7003788458); Bruno Bossio, R. (57197716359); Bruno, G. (7202705363); Buccomino, D. (57193216343); Cacchiò, G. (23024298600); Calabrese, E. (57193219079); Campanelli, A. (56353634800); Canevelli, M. (37053450300); Canu, E.D.G. (57206033008); Cappa, A. (7005370647); Capra, C. (57195625891); Carapelle, E. (55628882400); Caratozzolo, S. (36467950200); Carbone, G.F.S. (8940106500); Cattaruzza, T. (7801648508); Cerami, C. (25722905400); Cester, A. (23011626800); Cheldi, A. (6603419561); Cherchi, R. (57212413651); Chiari, A. (12792407200); Cirafisi, C. (6603193039); Colao, R. (6506732115); Confaloni, A. (6602313189); Conti, M.Z. (7401876294); Costa, A. (35499758300); Costa, B. (56432303200); Cotelli, M.S. (24343912800); Cova, I. (55455372500); Cravello, L. (7005513919); Cumbo, E. (15023966800); Cupidi, C. (14059856700); De Togni, L. (19033865300); Del Din, G. (6508375991); Del Re, M.L. (6701333097); Dentizzi, C. (57193218828); Di Lorenzo, F. (6603888625); Di Stefano, F. (54953653200); Dikova, N. (57223605151); Farina, E. (7006124237); Floris, G. (35589179800); Foti, A. (57223449740); Franceschi, M. (7004351220); Fumagalli, G.G. (35867039500); Gabelli, C. (6701723117); Ghidoni, E. (6602533869); Giannandrea, D. (36951384000); Giordana, M.T. (7004525027); Giorelli, M. (6602344431); Giubilei, F. (7003924434); Grimaldi, L. (7006655949); Grimaldi, R. (57189597192); Guglielmi, V. (57193220060); Lanari, A. (7006655447); Le Pira, F. (6701852647); Letteri, F. (55614155600); Levi Minzi, G.V. (57193215532); Lorusso, S. (7003271177); Ludovico, L. (57190381391); Luzzi, S. (56264790400); Maggiore, L. (24067645000); Magnani, G. (24496141800); Mancini, G. (57193216687); Manconi, F.M. (56613220000); Manfredi, L. (7003875018); Maniscalco, M. (57193217795); Marano, P. (24394206100); Marcon, M. (57197039438); Marcone, A. (57193216778); Marra, C. (7102675596); Martorana, A. (7005822633); Mascia, M.G. (57222392237); Mascia, V. (6701428294); Mauri, M. (7103045989); Mazzei, B. (57193215862); Meloni, M. (36905554300); Merlo, P. (7003834860); Messa, G. (6603866070); Milia, A. (36765409300); Monacelli, F. (8692938800); Montecalvo, G. (57193216024); Moschella, V. (10039929400); Mura, G. (56045848100); Nemni, R. (7005022543); Nobili, F. (57206948479); Notarelli, A. (56030088300); Di Giacomo, R. (55907231000); Onofrj, M. (7006653830); Paci, C. (6603834356); Padiglioni, C. (23989679400); Perini, M. (57200423475); Perotta, D. (6507945455); Perri, Formenti A. (7003629644); Perri, R. (57200284365); Piccininni, C. (57204444681); Piccoli, T. (6505971622); Pilia, G. (23051690800); Pilotto, A. (45661638400); Poli, S. (55357276800); Pomati, S. (7801639139); Pompanin, S. (37111400300); Pucci, E. (7005611337); Puccio, G. (13006379400); Quaranta, D. (24178705000); Rainero, I. (7003753505); Rea, G. (57194687830); Realmuto, S. (42462180200); Riva, M. (37031805700); Rizzetti, M.C. (35609131500); Rolma, G. (57213844161); Rozzini, L. (6701774589); Sacco, L. (6701668924); Saibene, F.L. (56449452200); Scarpini, E. (57210771033); Sensi, S. (7004346920); Seripa, D. (57223409194); Sinforiani, E. (7004048043); Sorbi, S. (7004417453); Sorrentino, G. (7006224880); Spallazzi, M. (54794493200); Stracciari, A. (7003997181); Talarico, G. (7003637692); Tassinari, T. (6602163316); Thomas, A. (7403883588); Tiezzi, A. (57210653956); Tomassini, P.F. (6701323235); Trebbastoni, A. (24081970200); Tremolizzo, L. (57200719476); Tripi, G. (23994549600); Ursini, F. (35094514900); Vaianella, L. (57193215552); Valluzzi, F. (6508110802); Vezzadini, G. (6506387183); Vista, M. (6602826777); Volontè, M.A. (7003972673)","6603146272; 12778956300; 6701687853; 7006669615; 6701398657; 6701548417; 7102347222; 7202268530; 6701617660; 6602175887; 56029401900; 35412328100; 7005630261; 8266381200; 7006146949; 6701774925; 55996824100; 57193216269; 6701506634; 6602735759; 6602857534; 8309607400; 55999182100; 18633586600; 6701747731; 56011813100; 57202514086; 55228692700; 6507969284; 55156487000; 7003788458; 57197716359; 7202705363; 57193216343; 23024298600; 57193219079; 56353634800; 37053450300; 57206033008; 7005370647; 57195625891; 55628882400; 36467950200; 8940106500; 7801648508; 25722905400; 23011626800; 6603419561; 57212413651; 12792407200; 6603193039; 6506732115; 6602313189; 7401876294; 35499758300; 56432303200; 24343912800; 55455372500; 7005513919; 15023966800; 14059856700; 19033865300; 6508375991; 6701333097; 57193218828; 6603888625; 54953653200; 57223605151; 7006124237; 35589179800; 57223449740; 7004351220; 35867039500; 6701723117; 6602533869; 36951384000; 7004525027; 6602344431; 7003924434; 7006655949; 57189597192; 57193220060; 7006655447; 6701852647; 55614155600; 57193215532; 7003271177; 57190381391; 56264790400; 24067645000; 24496141800; 57193216687; 56613220000; 7003875018; 57193217795; 24394206100; 57197039438; 57193216778; 7102675596; 7005822633; 57222392237; 6701428294; 7103045989; 57193215862; 36905554300; 7003834860; 6603866070; 36765409300; 8692938800; 57193216024; 10039929400; 56045848100; 7005022543; 57206948479; 56030088300; 55907231000; 7006653830; 6603834356; 23989679400; 57200423475; 6507945455; 7003629644; 57200284365; 57204444681; 6505971622; 23051690800; 45661638400; 55357276800; 7801639139; 37111400300; 7005611337; 13006379400; 24178705000; 7003753505; 57194687830; 42462180200; 37031805700; 35609131500; 57213844161; 6701774589; 6701668924; 56449452200; 57210771033; 7004346920; 57223409194; 7004048043; 7004417453; 7006224880; 54794493200; 7003997181; 7003637692; 6602163316; 7403883588; 57210653956; 6701323235; 24081970200; 57200719476; 23994549600; 35094514900; 57193215552; 6508110802; 6506387183; 6602826777; 7003972673","The Italian dementia with Lewy bodies study group (DLB-SINdem): toward a standardization of clinical procedures and multicenter cohort studies design","2017","Neurological Sciences","38","1","","83","91","8","10","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84987660259&doi=10.1007%2fs10072-016-2713-8&partnerID=40&md5=6fc496719dc98cf10e146e72bd494ed8","Dementia with Lewy bodies (DLB) causes elevated outlays for the National Health Systems due to high institutionalization rate and patients’ reduced quality of life and high mortality. Furthermore, DLB is often misdiagnosed as Alzheimer’s disease. These data motivate harmonized multicenter longitudinal cohort studies to improve clinical management and therapy monitoring. The Italian DLB study group of the Italian Neurological Society for dementia (SINdem) developed and emailed a semi-structured questionnaire to 572 national dementia centers (from primary to tertiary) to prepare an Italian large longitudinal cohort. The questionnaire surveyed: (1) prevalence and incidence of DLB; (2) clinical assessment; (3) relevance and availability of diagnostic tools; (4) pharmacological management of cognitive, motor, and behavioural disturbances; (5) causes of hospitalization, with specific focus on delirium and its treatment. Overall, 135 centers (23.6 %) contributed to the survey. Overall, 5624 patients with DLB are currently followed by the 135 centers in a year (2042 of them are new patients). The percentage of DLB patients was lower (27 ± 8 %) than that of Alzheimer’s disease and frontotemporal dementia (56 ± 27 %) patients. The majority of the centers (91 %) considered the clinical and neuropsychological assessments as the most relevant procedure for a DLB diagnosis. Nonetheless, most of the centers has availability of magnetic resonance imaging (MRI; 95 %), electroencephalography (EEG; 93 %), and FP-CIT single photon emission-computerized tomography (SPECT; 75 %) scan for clinical applications. It will be, therefore, possible to recruit a large harmonized Italian cohort of DLB patients for future cross-sectional and longitudinal multicenter studies. © 2016, Springer-Verlag Italia.","Dementia with Lewy bodies; Standardization of diagnostic procedures; Survey","Alzheimer Disease; Cohort Studies; Diagnosis, Differential; Disease Management; Humans; Italy; Lewy Body Disease; Research Design; Surveys and Questionnaires; antidepressant agent; benzodiazepine derivative; cholinesterase inhibitor; clozapine; dopamine receptor stimulating agent; haloperidol; levodopa; melatonin; memantine; neuroleptic agent; olanzapine; quetiapine; risperidone; Alzheimer disease; Article; behavior disorder; cerebrospinal fluid analysis; clinical assessment; cohort analysis; computer assisted tomography; controlled study; delirium; diagnostic accuracy; diagnostic test accuracy study; diffuse Lewy body disease; extrapyramidal symptom; frontotemporal dementia; geographic distribution; hospital admission; hospitalization; human; hyposmia; incidence; Italy; longitudinal study; major clinical study; multicenter study; neuropsychological test; nuclear magnetic resonance imaging; parasomnia; polysomnography; prevalence; single photon emission computed tomography; somatoform disorder; structured questionnaire; Alzheimer disease; differential diagnosis; disease management; Lewy Body Disease; methodology; questionnaire","McKeith I.G., Dickson D.W., Lowe J., Et al., Diagnosis and management of Dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, pp. 1863-1872, (2009); Merdes A.R., Hansen L.A., Jeste D.V., Galasko D., Hofstetter C.R., Ho G.J., Et al., Influence of Alzheimer pathology on clinical diagnostic accuracy in Dementia with Lewy bodies, Neurology, 60, pp. 1586-1590, (2003); Walker Z., Jaros E., Walker R.W.H., Lee L., Costa D.C., Livingston G., Et al., Dementia with Lewy bodies: a comparison of clinical diagnosis, (123)I-FP-CIT SPECT imaging and autopsy, J Neurol Neurosurg Psychiatry, 78, pp. 1176-1181, (2007); Mok W., Chow T.W., Zheng L., Mack W.J., Miller C., Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians, Am J Alzheimers Dis Other Demen, 19, pp. 161-165, (2004); Toledo J.B., Cairns N.J., Da X., Chen K., Carter D., Fleisher A., Clinical and multimodal biomarker correlates of ADNI neuropathological findings, Acta Neuropathol Commun, 1, (2013); Walker Z., Possin K.L., Boeve B.F., Aarsland D., Lewy body dementias, Lancet, 386, pp. 1683-1697, (2015); Ballard C., Grace J., McKeith I., Holmes C., Neuroleptic sensitivity in Dementia with Lewy bodies and Alzheimer’s disease, Lancet, 351, pp. 1032-1033, (1998); Olichney J., Galasko D., Salmon R., Hofstetter C.R., Hansen L.A., Katzman R., Thal L.J., Cognitive decline is faster in the Lewy body variant of Alzheimer’s disease, Neurology, 51, pp. 351-357, (1998); Rongve A., Vossius C., Nore S., Testad I., Aarsland D., Time until nursing home admission in people with mild dementia: comparison of Dementia with Lewy bodies and Alzheimer’s dementia, Int J Geriatr Psychiatry, 29, pp. 392-398, (2014); Levy R., Eagger S., Griffiths M., Perry E., Honavar M., Dean A., Lantos P., Lewy bodies and response to tacrine in Alzheimer’s disease, Lancet, 343, (1994); Garcia-Ptacek S., Farahmand B., Kareholt I., Religa D., Cuadrado M.L., Eriksdotter M., Mortality risk after dementia diagnosis by dementia type and underlying factors: a cohort of 15,209 patients based on the Swedish Dementia Registry, J Alzheimers Dis, 41, pp. 467-477, (2014); O'Brien J.T., McKeith I.G., Walker Z., Tatsch K., Booij J., Darcourt J., Marquardt M., Reininger C., Diagnostic accuracy of 123I-FP-CIT SPECT in possible Dementia with Lewy bodies, Br J Psychiatry, 194, pp. 34-39, (2009); Walker Z., Moreno E., Thomas A., Inglis F., Tabet N., Rainer M., Pizzolato G., Padovani A., Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible Dementia with Lewy bodies: randomised study, Br J Psychiatry, 206, pp. 145-152, (2015); McKeith I., O'Brien J., Walker Z., Tatsch K., Booij J., Darcourt J., Padovani A., Giubbini R., Bonuccelli U., Volterrani D., Holmes C., Kemp P., Tabet N., Meyer I., Reininger C., Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in Dementia with Lewy bodies: a phase III, multicentre study, Lancet Neurol, 6, pp. 305-313, (2007); Breitve M.H., Hynninen M.J., Bronnick K., Chwiszczuk L.J., Auestad B.H., Aarsland D., Rongve A., A longitudinal study of anxiety and cognitive decline in Dementia with Lewy bodies and Alzheimer’s disease, Alzheimers Res Ther, 8, (2016); Yoon J.H., Kim M., Moon S.Y., Yong S.W., Hong J.M., Olfactory function and neuropsychological profile to differentiate Dementia with Lewy bodies from Alzheimer’s disease in patients with mild cognitive impairment: a 5-year follow-up study, J Neurol Sci, 355, pp. 174-179, (2015); Cagnin A., Busse C., Jelcic N., Gnoato F., Mitolo M., Caffarra P., High specificity of MMSE pentagon scoring for diagnosis of prodromal Dementia with Lewy bodies, Parkinsonism Relat Disord, 21, pp. 303-305, (2015); Firbank M.J., Watson R., Mak E., Aribisala B., Barber R., Colloby S.J., He J., Blamire A.M., O'Brien J.T., Longitudinal diffusion tensor imaging in Dementia with Lewy bodies and Alzheimer’s disease, Parkinsonism Relat Disord, 24, pp. 76-80, (2016); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Perani D., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, Neuroimage Clin, 7, pp. 187-194, (2014); Bird T., Knopman D., VanSwieten J., Rosso S., Feldman H., Tanabe H., Et al., Epidemiology and genetics of frontotemporal dementia/Pick’s disease, Ann Neurol, 54, pp. S29-S31, (2003); Borroni B., Turrone R., Galimberti D., Nacmias B., Alberici A., Benussi A., Et al., Italian frontotemporal dementia network (FTD group-SINDEM): sharing clinical and diagnostic procedures in frontotemporal dementia in Italy, Neurol Sci, 36, pp. 751-757, (2015); Tiraboschi P., Salmon D.P., Hansen L.A., Hofstetter R.C., Thal L.J., Corey-Bloom J., What best differentiates Lewy body from Alzheimer’s disease in early-stage dementia?, Brain, 129, pp. 729-735, (2006); McCleery J., Morgan S., Bradley K.M., Noel-Storr A.H., Ansorge O., Hyde C., Dopamine transporter imaging for the diagnosis of Dementia with Lewy bodies, Cochrane Database Syst Rev, 1, (2015); Seppi K., Weintraub D., Coelho M., Perez-Lloret S., Fox S.H., Katzenschlager R., Hametner E.M., Poewe W., Rascol O., Goetz C.G., Sampaio C., The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease, Mov Disord, 26, pp. S42-S80, (2011)","2-s2.0-84987660259"
"Cerami C.; Crespi C.; Della Rosa P.A.; Dodich A.; Marcone A.; Magnani G.; Coppi E.; Falini A.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Crespi, Chiara (57034303800); Della Rosa, Pasquale Anthony (14420734200); Dodich, Alessandra (56001713900); Marcone, Alessandra (6701496511); Magnani, Giuseppe (24496141800); Coppi, Elisabetta (56370374600); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 57034303800; 14420734200; 56001713900; 6701496511; 24496141800; 56370374600; 7003494994; 7005836132; 7005630261","Brain changes within the visuo-spatial attentional network in posterior cortical atrophy","2015","Journal of Alzheimer's Disease","43","2","","385","395","10","43","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911897522&doi=10.3233%2fJAD-141275&partnerID=40&md5=445099902276ebdda971423ea2dce29b","Posterior cortical atrophy (PCA) is characterized by basic visual and high order visual-spatial dysfunctions. In this study, we investigated long-distance deafferentation processes within the frontal-parietal-occipital network in ten PCA patients using a MRI-PET combined approach. Objective voxel-based [18F]FDG-PET imaging measured metabolic changes in single patients. Comprehensive investigation of diffusion tensor imaging (DTI) metrics and grey-matter density with voxel-based morphometry were obtained in a subgroup of 6 patients. Fractional anisotropy in the superior longitudinal fasciculus correlated with the PET metabolic changes within the inferior parietal and frontal eye field regions. [18F]FDG-PET analysis showed in each PCA case the typical bilateral hypometabolic pattern, involving posterior temporal, parietal, and occipital cortex, with additional hypometabolic foci in the frontal eye fields. Voxel-based morphometry showed right-sided atrophy in the parieto-occipital cortex, as well as a limited temporal involvement. DTI revealed extensive degeneration of the major anterior-posterior connecting fiber bundles and of commissural frontal lobe tracts. Microstructural measures in the superior longitudinal fasciculus were correlated with the PET metabolic changes within the inferior parietal and frontal eye field regions. Our results confirmed the predominant occipital-temporal and occipital-parietal degeneration in PCA patients. [18F]FDG-PET and DTI-MRI combined approaches revealed neurodegeneration effects well beyond the classical posterior cortical involvement, most likely as a consequence of deafferentation processes within the occipital-parietal-frontal network that could be at the basis of visuo-perceptual, visuo-spatial integration and attention deficits in PCA. © 2015 IOS Press and the authors. All rights reserved.","Dementia; diffusion tensor imaging; frontal eye field; posterior cortical atrophy; voxel-based morphometry; [${18}^F$]FDG-PET imaging","Aged; Atrophy; Attention Deficit Disorder with Hyperactivity; Cerebral Cortex; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Middle Aged; Neurodegenerative Diseases; Neuropsychological Tests; Perceptual Disorders; Photic Stimulation; Positron-Emission Tomography; Space Perception; fluorodeoxyglucose f 18; fluorodeoxyglucose f 18; adult; aged; Article; attention; brain cortex atrophy; clinical article; deafferentation; depth perception; diffusion tensor imaging; female; fractional anisotropy; frontal eye field; frontal lobe; gray matter; human; male; middle aged; nerve degeneration; occipital cortex; positron emission tomography; voxel based morphometry; atrophy; Attention Deficit Disorder with Hyperactivity; brain cortex; complication; degenerative disease; depth perception; diagnostic use; mental health; neuropsychological test; nuclear magnetic resonance imaging; pathology; Perceptual Disorders; photostimulation; physiology; scintiscanning","Crutch S.J., Lehmann M., Schott J.M., Rabinovici G.D., Rossor M.N., Fox N.C., Posterior cortical atrophy, Lancet Neurol, 11, pp. 170-178, (2012); Formaglio M., Costes N., Seguin J., Tholance Y., Le Bars D., Roullet-Solignac I., Mercier B., Krolak-Salmon P., Vighetto A., In vivo demonstration of amyloid burden in posteriorcortical atrophy: A case series with PET and CSF findings, J Neurol, 258, pp. 1841-1851, (2011); Rosenbloom M.H., Alkalay A., Agarwal N., Baker S.L., O'Neil J.P., Janabi M., Yen I.V., Growdon M., Jang J., Madison C., Mormino E.C., Rosen H.J., Gorno-Tempini M.L., Weiner M.W., Miller B.L., Jagust W.J., Rabinovici G.D., Distinct clinicaland metabolic deficits in PCA and AD are not related toamyloid distribution, Neurology, 76, pp. 1789-1796, (2011); Shakespeare T.J., Yong K.X., Frost C., Kim L.G., Warrington E.K., Crutch S.J., Scene perception in posterior cortical atrophy:Categorization, description and fixation patterns, Front Hum Neurosci, 7, (2013); Crutch S.J., Lehmann M., Warren J.D., Rohrer J.D., The languageprofile of posterior cortical atrophy, J Neurol Neurosurg Psychiatry, 84, pp. 460-466, (2013); Magnin E., Sylvestre G., Lenoir F., Dariel E., Bonnet L., Chopard G., Tio G., Hidalgo J., Ferreira S., Mertz C., Binetruy M., Chamard L., Haffen S., Ryff I., Laurent E., Moulin T., Vandel P., Rumbach L., Logopenic syndrome in posterior corticalatrophy, J Neurol, 260, pp. 528-533, (2013); Lehmann M., Crutch S.J., Ridgway G.R., Ridha B.H., Barnes J., Warrington E.K., Rossor M.N., Fox N.C., Corticalthickness and voxel-based morphometry in posterior corticalatrophy and typical Alzheimer's disease, Neurobiol Aging, 32, pp. 1466-1476, (2011); Lehmann M., Barnes J., Ridgway G.R., Ryan N.S., Warrington E.K., Crutch S.J., Fox N.C., Global gray matter changes inposterior cortical atrophy: A serial imaging study, Alzheimers Dement, 8, pp. 502-512, (2012); Whitwell J.L., Jack C.R., Kantarci K., Weigand S.D., Boeve B.F., Knopman D.S., Drubach D.A., Tang-Wai D.F., Petersen R.C., Josephs K.A., Imaging correlates of posterior corticalatrophy, Neurobiol Aging, 28, pp. 1051-1061, (2007); Migliaccio R., Agosta F., Rascovsky K., Karydas A., Bonasera S., Rabinovici G.D., Miller B.L., Gorno-Tempini M.L., Clinicalsyndromes associated with posterior atrophy: Early ageat onset AD spectrum, Neurology, 73, pp. 1571-1578, (2009); Migliaccio R., Agosta F., Toba M.N., Samri D., Corlier F., Desouza L.C., Chupin M., Sharman M., Gorno-Tempini M.L., Dubois B., Filippi M., Bartolomeo P., Brain networks inposterior cortical atrophy: A single case tractography studyand literature review, Cortex, 48, pp. 1298-1230, (2012); Migliaccio R., Agosta F., Scola E., Magnani G., Cappa S.F., Pagani E., Canu E., Comi G., Falini A., Gorno-Tempini M.L., Bartolomeo P., Filippi M., Ventral and dorsal visual streamsin posterior cortical atrophy: A DT MRI study, NeurobiolAging, 33, pp. 2572-2584, (2012); Duning T., Warnecke T., Mohammadi S., Lohmann H., Schiffbauer H., Kugel H., Knecht S., Ringelstein E.B., Deppe M., Pattern and progression of white-matter changes in a caseof posterior cortical atrophy using diffusion tensor imaging, J Neurol Neurosurg Psychiatry, 80, pp. 432-436, (2009); Schmidtke K., Hull M., Talazko J., Posterior corticalatrophy: Variant of Alzheimer's disease? A case series withPET findings, J Neurol, 252, pp. 27-35, (2005); Kas A., De Souza L.C., Samri D., Bartolomeo P., Lacomblez L., Kalafat M., Migliaccio R., Thiebaut De Schotten M., Cohen L., Dubois B., Habert M.O., Sarazin M., Neural correlates ofcognitive impairment in posterior cortical atrophy, Brain, 134, pp. 1464-1478, (2011); Andrade K., Kas A., Samri D., Sarazin M., Dubois B., Habert M.O., Bartolomeo P., Visuospatial deficits and hemisphericperfusion asymmetries in posterior cortical atrophy, Cortex, 49, pp. 940-947, (2013); Nestor P.J., Caine D., Fryer T.D., Clarker J., Hodges J.R., The topography of metabolic deficits in posterior corticalatrophy (the visual variant of Alzheimer's disease) with FDGPET, J Neurol Neurosurg Psychiatry, 74, pp. 1521-1529, (2003); Andrade K., Kas A., Valabregue R., Samri D., Sarazin M., Habert M.O., Dubois B., Bartolomeo P., Visuospatial deficitsin posterior cortical atrophy: Structural and functional correlates, J Neurol Neurosurg Psychiatry, 83, pp. 860-863, (2012); Alladi S., Xuereb J., Bak T., Nestor P., Knibb J., Patterson K., Hodges J.R., Focal cortical presentations of Alzheimer'sdisease, Brain, 130, pp. 2636-2645, (2007); McMonagle P., Deering F., Berliner Y., Kertesz A., Thecognitive profile of posterior cortical atrophy, Neurology, 66, pp. 331-338, (2006); McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Cummings J., Duda J.E., Lippa C., Perry E.K., Aarsland D., Arai H., Ballard C.G., Boeve B., Burn D.J., Costa D., Del Ser T., Dubois B., Galasko D., Gauthier S., Goetz C.G., Gomez-Tortosa E., Halliday G., Hansen L.A., Hardy J., Iwatsubo T., Kalaria R.N., Kaufer D., Kenny R.A., Korczyn A., Kosaka K., Lee V.M., Lees A., Litvan I., Londos E., Lopez O.L., Minoshima S., Mizuno Y., Molina J.A., Mukaetova-Ladinska E.B., Pasquier F., Perry R.H., Schulz J.B., Trojanowski J.Q., Yamada M., Diagnosis and management of dementia withLewy bodies: Third report of theDLBConsortium, Neurology, 65, pp. 1863-1872, (2005); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Lunetta C., Consonni M., Scola E., Falini A., Cappa S.F., Emotional empathy in amyotrophic lateral sclerosis:Abehavioural and voxel-based morphometry study, AmyotrophLateral Scler Frontotemporal Degener, 15, pp. 21-29, (2013); Ennis D.B., Kindlmann G., Orthogonal tensor invariantsand the analysis of diffusion tensor magnetic resonanceimages, Magn Reson Med, 55, pp. 136-146, (2006); Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., MacKay C.E., Watkins K.E., Ciccarelli O., Cader M.Z., Matthews P.M., Behrens T.E., Tract-based spatialstatistics: Voxelwise analysis of multi-subject diffusion data, Neuroimage, 31, pp. 1487-1505, (2006); Crespi C., Cerami C., Dodich A., Canessa N., Arpone M., Iannaccone S., Corbo M., Lunetta C., Scola E., Falini A., Cappa S.F., Microstructural white matter correlates of emotionrecognition impairment in amyotrophic lateral sclerosis, Cortex, 53, pp. 1-8, (2014); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Castiglioni I., Gilardi M.C., Friston K., Ashburner J., Perani D., A new standardized [18F]-FDG-PET template for spatial normalization in statisticalparametric mapping analysis of brain images in dementia, Neuroinformatics, (2014); Signorini M., Paulesu E., Friston K., Perani D., Colleluori A., Lucignani G., Grassi F., Bettinardi V., Frackowiak R.S., Fazio F., Rapid assessment of regional cerebral metabolicabnormalities in single subjects with quantitative and nonquantitative [18F] FDG PET:Aclinical validation of statisticalparametric mapping, Neuroimage, 9, pp. 63-80, (1999); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., Van Berckel B.N., Ossenkoppele R., Guedj E., Didic M., Brugnolo A., Sambuceti G., Pagani M., Salmon E., Nobili F., Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiol Aging, 33, pp. 2533-2550, (2012); Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E., Metabolic reduction in the posterior cingulatecortex in very early Alzheimer's disease, Ann Neurol, 42, pp. 85-94, (1997); Gagnon D., O'Driscoll G.A., Petrides M., Pike G.B., Theeffect of spatial and temporal information on saccades andneural activity in oculomotor structures, Brain, 125, pp. 123-139, (2002); Doricchi F., Perani D., Incoccia C., Grassi F., Cappa S.F., Bettinardi V., Galati G., Pizzamiglio L., Fazio F., Neuralcontrol of fast-regular saccades and antisaccades: An investigationusing positron emission tomography, Exp Brain Res, 116, pp. 50-62, (1997); Bray S., Arnold A.E., Iaria G., MacQueen G., Structuralconnectivity of visuotopic intraparietal sulcus, Neuroimage, 82, pp. 137-145, (2013); Daw N.D., O'Doherty J.P., Dayan P., Seymour B., Dolan R.J., Cortical substrates for exploratory decisions inhumans, Nature, 441, pp. 876-879, (2006); Yoav B., Hochberg Y., Controlling the false discoveryrate: A practical and powerful approach to multiple testing, J R Stat Soc Series B Stat Methodol, 57, pp. 289-300, (1995); Yoshida T., Shiga K., Yoshikawa K., Yamada K., Nakagawa M., White matter loss in the splenium of the corpuscallosum in a case of posterior cortical atrophy: A diffusiontensor imaging study, Eur Neurol, 52, pp. 77-81, (2004); Teune L.K., Bartels A.L., De Jong B.M., Willemsen A.T., Eshuis S.A., De Vries J.J., Van Oostrom J.C., Leenders K.L., Typicalcerebral metabolic patterns in neurodegenerative braindiseases, Mov Disord, 25, pp. 2395-2404, (2010); Paus T., Location and function of the human frontaleye-field: A selective review, Neuropsychologia, 34, pp. 475-483, (1996); Pierrot-Deseilligny C., Milea D., Muri R.M., Eye movementcontrol by the cerebral cortex, Curr Opin Neurol, 17, pp. 17-25, (2004); Tehovnik E.J., Sommer M.A., Chou I.H., Slocum W.M., Schiller P.H., Eye fields in the frontal lobes of primates, Brain Res Brain Res Rev, 32, pp. 413-448, (2000); Tsai P.H., Teng E., Liu C., Mendez M.F., Posterior corticalatrophy: Evidence for discrete syndromes of early-onsetAlzheimer's disease, Am J Alzheimers Dis Other Demen, 26, pp. 413-418, (2011); Crutch S.J., Schott J.M., Rabinovici G.D., Boeve B.F., Cappa S.F., Dickerson B.C., Dubois B., Graff-Radford N.R., Krolak-Salmon P., Lehmann M., Mendez M.F., Pijnenburg Y., Ryan N.S., Scheltens P., Shakespeare T., Tang-Wai D.F., Van Der Flier W.M., Bain L., Carrillo M.C., Fox N.C., Shining a light on posteriorcortical atrophy, Alzheimers Dement, 9, pp. 463-465, (2013); Ptak R., The frontoparietal attention network of thehuman brain: Action, saliency, and a priority map of theenvironment, Neuroscientist, 18, pp. 502-515, (2012); Beaulieu C., The basis of anisotropic water diffusionin the nervous system-A technical review, NMR Biomed, 15, pp. 435-455, (2002); Bennett I.J., Madden D.J., Vaidya C.J., Howard D.V., Howard J.H., Age-related differences in multiple measures of whitematter integrity: A diffusion tensor imaging study of healthyaging, Hum Brain Mapp, 31, pp. 378-390, (2010); Goodale M.A., Milner A.D., Separate visual pathwaysfor perception and action, Trends Neurosci, 15, pp. 20-25, (1992); Thiebaut De Schotten M., Tomaiuolo F., Aiello M., Merola S., Silvetti M., Lecce F., Bartolomeo P., Doricchi F., Damageto white matter pathways in subacute and chronic spatialneglect: A group study and 2 single-case studies with completevirtual ""in vivo"" tractography dissection, Cereb Cortex, 24, pp. 691-706, (2014); Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., Kuhl D.E., Alzheimer's disease versus dementia with Lewybodies: Cerebral metabolic distinction with autopsy confirmation, Ann Neurol, 50, pp. 358-365, (2001)","2-s2.0-84911897522"
"Dodich A.; Crespi C.; Santi G.C.; Cappa S.F.; Cerami C.","Dodich, Alessandra (56001713900); Crespi, Chiara (57034303800); Santi, Gaia C. (57217289456); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400)","56001713900; 57034303800; 57217289456; 7005836132; 25722905400","Evaluation of Discriminative Detection Abilities of Social Cognition Measures for the Diagnosis of the Behavioral Variant of Frontotemporal Dementia: a Systematic Review","2021","Neuropsychology Review","31","2","","251","266","15","24","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092417547&doi=10.1007%2fs11065-020-09457-1&partnerID=40&md5=09111c97b09a76c10cfb305ae7cb32e9","The use of social tasks in the neuropsychological assessment of the behavioral variant of frontotemporal dementia (bvFTD) is at present not required by diagnostic guidelines, despite extensive literature shows relevant social cognitive dysfunctions in such patients. In this systematic review, we explored the clinical maturity of social cognition measures in the diagnosis of bvFTD. Papers were selected according to the PRISMA guidelines by searching the PubMed and Medline databases. Only papers reporting indices of diagnostic accuracy and/or sensitivity/specificity in classifying bvFTD from controls or from other relevant diseases were considered. Quality of evidence was assessed through QUADAS-2. Among the 663 articles entered in the paper selection only 14 papers were eligible for the scope of the present review and showed an overall moderate-to-low quality. The major risk of bias was the lack of pathological confirmation. The evaluation of the accuracy of social cognition tasks in bvFTD detection compared to normal controls, as well as in the discrimination with Alzheimer’s disease and psychiatric patients, is mainly focused on emotion recognition and theory of mind. However, the use of different cognitive measures, variable task formats and the limited normative data hamper study comparability. Although literature seems to suggest that emotion recognition and ToM tasks could be the best choice to ensure a high diagnostic accuracy in clinical settings, further comparative studies are required and no recommendation concerning the use of a specific social task in bvFTD diagnosis can be currently provided. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.","Accuracy of socio-emotional markers in the bvFTD; Behavioral variant of Frontotemporal dementia; Cognitive assessment in dementia; Cognitive marker of bvFTD; Social cognition disorders","Alzheimer Disease; Cognition; Diagnosis, Differential; Frontotemporal Dementia; Humans; Neuropsychological Tests; Social Cognition; Alzheimer disease; cognition; differential diagnosis; frontotemporal dementia; human; neuropsychological test; social cognition","Baez S., Kanske P., Matallana D., Montanes P., Reyes P., Slachevsky A., Et al., Integration of intention and outcome for moral judgment in Frontotemporal dementia: Brain structural signatures, Neurodegenerative Diseases, 16, 3-4, pp. 206-217, (2016); Baez S., Manes F., Huepe D., Torralva T., Fiorentino N., Richter F., Huepe-Artigas D., Ferrari J., MontaA+/-es P., Reyes P., Matallana D., Vigliecca N.S., Decety J., Ibanez A., Primary empathy deficits in frontotemporal dementia, Frontiers in Aging Neuroscience, 6, (2014); Baez S., Morales J.P., Slachevsky A., Torralva T., Matus C., Manes F., Ibanez A., Orbitofrontal and limbic signatures of empathic concern and intentional harm in the behavioral variant frontotemporal dementia, Cortex, 75, pp. 20-32, (2016); Baez S., Pinasco C., Roca M., Ferrari J., Couto B., Garcia-Cordero I., Et al., Brain structural correlates of executive and social cognition profiles in behavioral variant frontotemporal dementia and elderly bipolar disorder, Neuropsychologia, 126, pp. 159-169, (2019); Baron-Cohen S., Wheelwright S., Hill J., Raste Y., Plumb I., The ""Reading the mind in the eyes"" test revised version: A study with normal adults, and adults with Asperger syndrome or high-functioning autism, Journal of Child Psychology and Psychiatry, 42, 2, pp. 241-251, (2001); Bertoux M., de Souza L.C., O'Callaghan C., Greve A., Sarazin M., Dubois B., Hornberger M., Social cognition deficits: The key to discriminate behavioral variant Frontotemporal dementia from Alzheimer's disease regardless of amnesia?, Journal of Alzheimer's Disease, 49, 4, pp. 1065-1074, (2016); Bertoux M., Delavest M., de Souza L.C., Funkiewiez A., Lepine J.P., Fossati P., Et al., Social cognition and emotional assessment differentiates frontotemporal dementia from depression, Journal of Neurology, Neurosurgery, and Psychiatry, 83, 4, pp. 411-416, (2012); Bertoux M., Funkiewiez A., O'Callaghan C., Dubois B., Hornberger M., Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia, Alzheimers Dement, 9, pp. S84-S94, (2013); Bertoux M., Volle E., de Souza L.C., Funkiewiez A., Dubois B., Habert M.O., Neural correlates of the mini-SEA (social cognition and emotional assessment) in behavioral variant frontotemporal dementia, Brain Imaging and Behavior, 8, 1, pp. 1-6, (2014); Bertoux M., Volle E., Funkiewiez A., de Souza L.C., Leclercq D., Dubois B., Social cognition and emotional assessment (SEA) is a marker of medial and orbital frontal functions: A voxel-based morphometry study in behavioral variant of frontotemporal degeneration, Journal of the International Neuropsychological Society, 18, 6, pp. 972-985, (2012); Bolboaca S.D., Medical diagnostic tests: A review of test anatomy, phases, and statistical treatment of data. Computational and Mathematical Methods in Medicine, eCollection 2019, Doi.Org/10.1155/2019/1891569, (2019); Bora E., Velakoulis D., Walterfang M., Meta-analysis of facial emotion recognition in behavioral variant Frontotemporal dementia: Comparison with Alzheimer disease and healthy controls, Journal of Geriatric Psychiatry and Neurology, 29, 4, pp. 205-211, (2016); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: A meta-analysis, Journal of Neurology, Neurosurgery, and Psychiatry, 86, 7, pp. 714-719, (2015); Buhl C., Stokholm J., Gade A., Clinical utility of short social cognitive tests in early differentiation of behavioral variant frontotemporal dementia from Alzheimer's disease, Dement Geriatr Cogn Dis Extra, 3, 1, pp. 376-385, (2013); Caminiti S.P., Canessa N., Cerami C., Dodich A., Crespi C., Iannaccone S., Marcone A., Falini A., Cappa S.F., Affective mentalizing and brain activity at rest in the behavioral variant of frontotemporal dementia, Neuroimage Clin, 9, pp. 484-497, (2015); Carr A.R., Samimi M.S., Paholpak P., Jimenez E.E., Mendez M.F., Emotional quotient in frontotemporal dementia vs. Alzheimer's disease: The role of socioemotional agnosia, Cognitive Neuropsychiatry, 22, 1, pp. 28-38, (2017); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurological Sciences, 34, 8, pp. 1267-1274, (2013); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Chierchia G., Scola E., Falini A., Cappa S.F., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 10, 6, pp. 827-834, (2014); Cerami C., Dodich A., Iannaccone S., Marcone A., Lettieri G., Crespi C., Gianolli L., Cappa S.F., Perani D., (2015); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Chiu I., Piguet O., Diehl-Schmid J., Riedl L., Beck J., Leyhe T., Holsboer-Trachsler E., Kressig R.W., Berres M., Monsch A.U., Sollberger M., Facial emotion recognition performance differentiates between behavioral variant Frontotemporal dementia and major depressive disorder, The Journal of Clinical Psychiatry, 79, 1, (2018); Couto B., Manes F., Montanes P., Matallana D., Reyes P., Velasquez M., Et al., Structural neuroimaging of social cognition in progressive non-fluent aphasia and behavioral variant of frontotemporal dementia, Frontiers in Human Neuroscience, 7, (2013); Davis M.H., Measuring individual-differences in empathy - evidence for a multidimensional approach, Journal of Personality and Social Psychology, 44, 1, pp. 113-126, (1983); de Souza L.C., Bertoux M., de Faria A.R.V., Corgosinho L.T.S., de Almeida Prado A.C., Barbosa I., G.,.. & Teixeira, A. L, The Effects of Gender, Age, Schooling, and Cultural Background on the Identification of Facial Emotions: A Transcultural Study. International Psychogeriatrics, 30, 12, (2018); de Vignemont F., Singer T., The empathic brain: How, when and why?, Trends in Cognitive Sciences, 10, 10, pp. 435-441, (2006); Decety J., Jackson P.L., The functional architecture of human empathy, Behavioral and Cognitive Neuroscience Reviews, 3, 2, pp. 71-100, (2004); Diehl-Schmid J., Pohl C., Ruprecht C., Wagenpfeil S., Foerstl H., Kurz A., The Ekman 60 faces test as a diagnostic instrument in frontotemporal dementia, Archives of Clinical Neuropsychology, 22, 4, pp. 459-464, (2007); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S.F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the story-based empathy task, Neurological Sciences, 36, 10, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Realmuto S., Cappa S.F., Emotion recognition from facial expressions: A normative study of the Ekman 60-faces test in the Italian population, Neurological Sciences, 35, 7, pp. 1015-1021, (2014); Dodich A., Cerami C., Cappa S.F., Marcone A., Golzi V., Zamboni M., Giusti M.C., Iannaccone S., Combined socio-behavioral evaluation improves the differential diagnosis between the behavioral variant of Frontotemporal dementia and Alzheimer's disease: In search of neuropsychological markers, Journal of Alzheimer's Disease, 61, 2, pp. 761-772, (2018); Dodich A., Cerami C., Crespi C., Canessa N., Lettieri G., Iannaccone S., Marcone A., Cappa S.F., Cacioppo J.T., Differential impairment of cognitive and affective Mentalizing abilities in neurodegenerative dementias: Evidence from behavioral variant of Frontotemporal dementia, Alzheimer's disease, and mild cognitive impairment, Journal of Alzheimer's Disease, 50, 4, pp. 1011-1022, (2016); Downey L.E., Blezat A., Nicholas J., Omar R., Golden H.L., Mahoney C.J., Crutch S.J., Warren J.D., Mentalising music in frontotemporal dementia, Cortex, 49, 7, pp. 1844-1855, (2013); Ekman P., Friesen W.V., O'Sullivan M., Chan A., Diacoyanni-Tarlatzis I., Heider K., Krause R., LeCompte W., Pitcairn T., Ricci-Bitti P.E., Universals and cultural differences in the judgments of facial expressions of emotion, Journal of Personality and Social Psychology, 53, 4, pp. 712-717, (1987); Engelmann J.B., Pogosyan M., Emotion perception across cultures: The role of cognitive mechanisms, Frontiers in Psychology, 4, (2013); Fernandez-Matarrubia M., Matias-Guiu J.A., Cabrera-Martin M.N., Moreno-Ramos T., Valles-Salgado M., Carreras J.L., Et al., Episodic memory dysfunction in behavioral variant Frontotemporal dementia: A clinical and FDG-PET study, Journal of Alzheimer's Disease, 57, 4, pp. 1251-1264, (2017); Ferretti V., Papaleo F., Understanding others: Emotion recognition in humans and other animals, Genes, Brain, and Behavior, 18, 1, (2019); Frisoni G.B., Boccardi M., Barkhof F., Blennow K., Cappa S., Chiotis K., (2017); Frith C.D., Social cognition, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 363, 1499, pp. 2033-2039, (2008); Garcia-Cordero I., Sedeno L., de la Fuente L., Slachevsky A., Forno G., Klein F., Et al., Feeling, learning from and being aware of inner states: Interoceptive dimensions in neurodegeneration and stroke, Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 371, 1708, (2016); Giovagnoli A.R., Bell B., Erbetta A., Paterlini C., Bugiani O., Analyzing theory of mind impairment in patients with behavioral variant frontotemporal dementia, Neurological Sciences, 40, 9, pp. 1893-1900, (2019); Gleichgerrcht E., Torralva T., Roca M., Manes F., Utility of an abbreviated version of the executive and social cognition battery in the detection of executive deficits in early behavioral variant frontotemporal dementia patients, Journal of the International Neuropsychological Society, 16, 4, pp. 687-694, (2010); Gossink F., Schouws S., Krudop W., Scheltens P., Stek M., Pijnenburg Y., Dols A., Social cognition differentiates behavioral variant frontotemporal dementia from other neurodegenerative diseases and psychiatric disorders, The American Journal of Geriatric Psychiatry, 26, 5, pp. 569-579, (2018); Healey M.L., Grossman M., Cognitive and affective perspective-taking: Evidence for shared and dissociable anatomical substrates, Frontiers in Neurology, 9, (2018); Henry J.D., von Hippel W., Molenberghs P., Lee T., Sachdev P.S., Clinical assessment of social cognitive function in neurological disorders, Nature Reviews. Neurology, 12, 1, pp. 28-39, (2016); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology, 78, 17, pp. 1354-1362, (2012); Johnen A., Bertoux M., Psychological and cognitive markers of behavioral variant Frontotemporal dementia-a clinical Neuropsychologist's view on diagnostic criteria and beyond, Frontiers in Neurology, 10, (2019); Kloeters S., Bertoux M., O'Callaghan C., Hodges J.R., Hornberger M., Money for nothing - atrophy correlates of gambling decision making in behavioural variant frontotemporal dementia and Alzheimer's disease, Neuroimage Clin, 2, pp. 263-272, (2013); Kumfor F., Honan C., McDonald S., Hazelton J.L., Hodges J.R., Piguet O., Assessing the ""social brain"" in dementia: Applying TASIT-S, Cortex, 93, pp. 166-177, (2017); Kumfor F., Irish M., Hodges J.R., Piguet O., Discrete neural correlates for the recognition of negative emotions: Insights from Frontotemporal dementia, PLoS One, 8, 6, (2013); McDonald S., Flanagan S., Rollins J., Kinch J., TASIT: A new clinical tool for assessing social perception after traumatic brain injury, The Journal of Head Trauma Rehabilitation, 18, 3, pp. 219-238, (2003); Melloni M., Billeke P., Baez S., Hesse E., de la Fuente L., Forno G., Birba A., Garcia-Cordero I., Serrano C., Plastino A., Slachevsky A., Huepe D., Sigman M., Manes F., Garcia A.M., Sedeno L., Ibanez A., Your perspective and my benefit: Multiple lesion models of self-other integration strategies during social bargaining, Brain, 139, 11, pp. 3022-3040, (2016); Melloni M., Lopez V., Ibanez A., Empathy and contextual social cognition, Cognitive, Affective, & Behavioral Neuroscience, 14, 1, pp. 407-425, (2014); Mendez M.F., Fong S.S., Ashla M.M., Jimenez E.E., Carr A.R., Skin conduction levels differentiate Frontotemporal dementia from Alzheimer's disease, The Journal of Neuropsychiatry and Clinical Neurosciences, 30, 3, pp. 208-213, (2018); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology, 51, 6, pp. 1546-1554, (1998); O'Callaghan C., Bertoux M., Irish M., Shine J.M., Wong S., Spiliopoulos L., Et al., Fair play: Social norm compliance failures in behavioural variant frontotemporal dementia, Brain, 139, pp. 204-216, (2016); Panchal H., Paholpak P., Lee G., Carr A., Barsuglia J.P., Mather M., Jimenez E., Mendez M.F., Neuropsychological and neuroanatomical correlates of the social norms questionnaire in Frontotemporal dementia versus Alzheimer's disease, American Journal of Alzheimer's Disease and Other Dementias, 31, 4, pp. 326-332, (2016); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management, Lancet Neurology, 10, 2, pp. 162-172, (2011); Possin K.L., Feigenbaum D., Rankin K.P., Smith G.E., Boxer A.L., Wood K., Hanna S.M., Miller B.L., Kramer J.H., Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias, Neurology, 80, 24, pp. 2180-2185, (2013); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer H.J., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Schroeter M.L., Laird A.R., Chwiesko C., Deuschl C., Schneider E., Bzdok D., Eickhoff S.B., Neumann J., Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - the case of behavioral variant frontotemporal dementia, Cortex, 57, pp. 22-37, (2014); Schroeter M.L., Pawelke S., Bisenius S., Kynast J., Schuemberg K., Polyakova M., Anderl-Straub S., Danek A., Fassbender K., Jahn H., Jessen F., Kornhuber J., Lauer M., Prudlo J., Schneider A., Uttner I., Thone-Otto A., Otto M., Diehl-Schmid J., A modified Reading the mind in the eyes test predicts behavioral variant Frontotemporal dementia better than executive function tests, Frontiers in Aging Neuroscience, 10, (2018); Seeley W.W., Selective functional, regional, and neuronal vulnerability in frontotemporal dementia, Current Opinion in Neurology, 21, 6, pp. 701-707, (2008); Seeley W.W., Zhou J., Kim E.J., Frontotemporal dementia: What can the behavioral variant teach us about human brain organization?, Neuroscientist, 18, 4, pp. 373-385, (2012); Shamay-Tsoory S.G., The neural bases for empathy, Neuroscientist, 17, 1, pp. 18-24, (2011); Stietz J., Jauk E., Krach S., Kanske P., Dissociating empathy from perspective-taking: Evidence from intra- and inter-individual differences research, Frontiers in Psychiatry, 10, (2019); Torralva T., Roca M., Gleichgerrcht E., Bekinschtein T., Manes F., A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia, Brain, 132, pp. 1299-1309, (2009); Van Overwalle F., Baetens K., Understanding others' actions and goals by mirror and mentalizing systems: A meta-analysis, Neuroimage, 48, 3, pp. 564-584, (2009); Walter H., Social cognitive neuroscience of empathy: Concepts, circuits, and genes, Emotion Review, 4, 1, pp. 9-17, (2012); Whiting P.F., Rutjes A.W., Westwood M.E., Mallett S., Deeks J.J., Reitsma J.B., Leeflang M.M., Sterne J.A., Bossuyt P.M., QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies, Annals of Internal Medicine, 155, 8, pp. 529-536, (2011); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Senjem M.L., Shiung M.M., Boeve B.F., Knopman D.S., Parisi J.E., Dickson D.W., Petersen R.C., Jack C.R., Josephs K.A., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study, Brain, 132, pp. 2932-2946, (2009)","2-s2.0-85092417547"
"Bernini S.; Panzarasa S.; Sinforiani E.; Quaglini S.; Cappa S.F.; Cerami C.; Tassorelli C.; Vecchi T.; Bottiroli S.","Bernini, Sara (55884116400); Panzarasa, Silvia (13907744600); Sinforiani, Elena (7004048043); Quaglini, Silvana (55080856700); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400); Tassorelli, Cristina (7005630887); Vecchi, Tomaso (6603719753); Bottiroli, Sara (24471204500)","55884116400; 13907744600; 7004048043; 55080856700; 7005836132; 25722905400; 7005630887; 6603719753; 24471204500","HomeCoRe for Telerehabilitation in Mild or Major Neurocognitive Disorders: A Study Protocol for a Randomized Controlled Trial","2021","Frontiers in Neurology","12","","752830","","","","7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122439703&doi=10.3389%2ffneur.2021.752830&partnerID=40&md5=a4a8109bb01fb605ec109714abf97cb5","Background: Given the limited effectiveness of pharmacological treatments for cognitive decline, non-pharmacological interventions have gained increasing attention. Evidence exists on the effectiveness of cognitive rehabilitation in preventing elderly subjects at risk of cognitive decline and in reducing the progression of functional disability in cognitively impaired individuals. In recent years, telerehabilitation has enabled a broader application of cognitive rehabilitation programs. The purpose of this study is to test a computer-based intervention administered according to two different modalities (at the hospital and at home) using the tools CoRe and HomeCoRe, respectively, in participants with Mild or Major Neurocognitive Disorders. Methods: Non-inferiority, single-blind randomized controlled trial where 40 participants with Mild or Major Neurocognitive Disorders will be assigned to the intervention group who will receive cognitive telerehabilitation through HomeCoRe or to the control group who will receive in-person cognitive intervention through CoRe, with the therapist administering the same computer-based exercises. The rehabilitative program will last 6 weeks, with 3 sessions/week, each lasting ~45 min. All the participants will be evaluated on an exhaustive neuropsychological battery before (T0) and after (T1) the intervention; follow-up visits will be scheduled after 6 (T2) and 12 months (T3). Discussion: The results of this study will inform about the comparability (non-inferiority trial) of HomeCoRe with CoRe. Their equivalence would support the use of HomeCoRe for at distance treatment, favoring the continuity of care. Ethics and Dissemination: This study has been approved by the Local Ethics Committee and registered in https://clinicaltrials.gov (NCT04889560). The dissemination plan includes the scientific community through publication in open-access peer-reviewed scientific journals and presentations at national and international conferences. Trial Registration: Clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT04889560 (registration date: May 17, 2021). Copyright © 2021 Bernini, Panzarasa, Sinforiani, Quaglini, Cappa, Cerami, Tassorelli, Vecchi and Bottiroli.","cognitive rehabilitation; cognitive training; computer-based telerehabilitation; dementia; mild cognitive impairment; neurocognitive disorder","Article; clinical article; clinical protocol; controlled study; dementia; disorders of higher cerebral function; home; hospital; human; mild cognitive impairment; prospective study; randomized controlled trial; single blind procedure; software; telerehabilitation","Livingston G., Sommerlad A., Orgeta V., Costafreda S.G., Huntley J., Ames D., Et al., Dementia prevention, intervention, and care, Lancet, 390, pp. 2673-2734, (2017); Livingston G., Huntley J., Sommerlad A., Ames D., Ballard C., Banerjee S., Et al., Dementia prevention, intervention, and care: 2020 report of the Lancet Commission, Lancet, 396, pp. 413-446, (2020); Petersen R.C., Lopez O., Armstrong M.J., Getchius T.S.D., Ganguli M., Gloss D., Et al., Practice guideline update summary: mild cognitive impairment, Neurology, 90, pp. 126-135, (2018); Cotelli M., Manenti R., Brambilla M., Gobbi E., Ferrari C., Binetti G., Et al., Cognitive telerehabilitation in mild cognitive impairment, Alzheimer's disease and frontotemporal dementia: a systematic review, J Telemed Telecare, 25, pp. 67-79, (2019); Diagnostic and Statistical Manual of Mental Disorders, (2013); Li H., Li J., Li N., Li B., Wang P., Zhou T., Cognitive intervention for persons with mild cognitive impairment: a meta-analysis, Ageing Res Rev, 10, pp. 285-296, (2011); Hill N.T.M., Mowszowski L., Naismith S.L., Chadwick V.L., Valenzuela M., Lampit A., Computerized cognitive training in older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis, Am J Psychiatry, 174, pp. 329-340, (2017); Maresca G., Maggio M.G., De Luca R., Manuli A., Tonin P., Pignolo L., Et al., Tele-neuro-rehabilitation in italy: state of the art and future perspectives, Front Neurol, 11, (2020); Peel N.M., Russell T.G., Gray L.C., Feasibility of using an in-home video conferencing system ingeriatric rehabilitation, J Rehabil Med, 43, pp. 364-366, (2011); Jeong I.C., Liu J., Finkelstein J., Factors affecting adherence with telerehabilitation in patients with multiple sclerosis, Stud Health Technol Inform, 257, pp. 189-193, (2019); Gil-Pages M., Solana J., Sanchez-Carrion R., Tormos J.M., Ensenat-Cantallops A., Garcia-Molina A., A customized home-based computerized cognitive rehabilitation platform for patients with chronic-stage stroke: study protocol for a randomized controlled trial, Trials, 19, (2018); Haesner M., Steinert A., O'Sullivan J.L., Steinhagen-Thiessen E., Evaluating an accessible web interface for older adults – the impact of mild cognitive impairment (MCI), J Assist Technol, 9, pp. 219-232, (2015); Hattink B., Droes R.-M., Sikkes S., Oostra E., Lemstra A.W., Evaluation of the digital alzheimer center: testing usability and usefulness of an online portal for patients with dementia and their carers, JMIR Res Protoc, 5, (2016); Castilla D., Suso-Ribera C., Zaragoza I., Garcia-Palacios A., Botella C., Designing ICTs for users with mild cognitive impairment: a usability study, Int J Environ Res Public Health, 17, (2020); De Cola M.C., Maresca G., D'Aleo G., Carnazza L., Giliberto S., Maggio M.G., Et al., Teleassistance for frail elderly people: a usability and customer satisfaction study, Geriatr Nurs, 41, pp. 463-467, (2020); Kim H., Lee S.-H., Cho N.-B., You H., Et al., User-dependent usability and feasibility of a swallowing training mhealth app for older adults: mixed methods pilot study, JMIR mHealth uHealth, 8, (2020); Taylor M.E., Close J.C.T., Lord S.R., Kurrle S.E., Webster L., Savage R., Et al., Pilot feasibility study of a home-based fall prevention exercise program (StandingTall) delivered through a tablet computer (iPad) in older people with dementia, Australas J Ageing, 39, pp. e278-e287, (2020); Bloem B.R., Dorsey E.R., Okun M.S., The coronavirus disease 2019 crisis as catalyst for telemedicine for chronic neurological disorders, JAMA Neurol, 77, pp. 927-928, (2020); Mantovani E., Zucchella C., Bottiroli S., Federico A., Giugno R., Sandrini G., Et al., Telemedicine and virtual reality for cognitive rehabilitation: a roadmap for the COVID-19 pandemic, Front Neurol, 11, (2020); Platz T., Sandrini G., Specialty grand challenge for neurorehabilitation research, Front Neurol, 11, (2020); Matamala-Gomez M., Bottiroli S., Realdon O., Riva G., Galvagni L., Platz T., Et al., Telemedicine and virtual reality at time of COVID-19 pandemic: an overview for future perspectives in neurorehabilitation, Front Neurol, 12, (2021); Stasolla F., Matamala-Gomez M., Bernini S., Caff o A.O., Bottiroli S., Virtual reality as a technological-aided solution to support communication in persons with neurodegenerative diseases and acquired brain injury during COVID-19 pandemic, Front Public Heal, 8, (2021); Alloni A., Sinforiani E., Zucchella C., Sandrini G., Bernini S., Cattani B., Et al., Computer-based cognitive rehabilitation: the CoRe system, Disabil Rehabil, 39, pp. 407-417, (2017); Alloni A., Quaglini S., Panzarasa S., Sinforiani E., Bernini S., Evaluation of an ontology-based system for computerized cognitive rehabilitation, Int J Med Inform, 115, pp. 64-72, (2018); Bernini S., Alloni A., Panzarasa S., Picascia M., Quaglini S., Tassorelli C., Et al., A computer-based cognitive training in Mild Cognitive Impairment in Parkinson's Disease, NeuroRehabilitation, 44, pp. 555-567, (2019); Bernini S., Panzarasa S., Barbieri M., Sinforiani E., Quaglini S., Tassorelli C., Et al., A double-blind randomized controlled trial of the efficacy of cognitive training delivered using two different methods in mild cognitive impairment in Parkinson's disease: preliminary report of benefits associated with the use of a computerized tool, Aging Clin Exp Res, 33, pp. 1567-1575, (2021); Rodella C., Bernini S., Panzarasa S., Sinforiani E., Picascia M., Quaglini S., Et al., A double-blind randomized controlled trial combining cognitive training (CoRe) and neurostimulation (tDCS) in the early stages of cognitive impairment, Aging Clin Exp Res, (2021); Quaglini S., Panzarasa S., Alloni A., Sacchi M., Sinforiani E., Bottiroli S., Et al., HomeCore: bringing cognitive rehabilitation at home, Stud Health Technol Inform, 264, pp. 1755-1756, (2019); Bernini S., Stasolla F., Panzarasa S., Quaglini S., Sinforiani E., Sandrini G., Et al., Cognitive telerehabilitation for older adults with neurodegenerative diseases in the COVID-19 era: a perspective study, Front Neurol, 11, (2021); Hughes C.P., Berg L., Danziger W., Coben L.A., Martin R.L., A new clinical scale for the staging of dementia, Br J Psychiatry, 140, pp. 566-572, (1982); Magni E., Binetti G., Bianchetti A., Rozzini R., Trabucchi M., Mini-Mental State Examination: a normative study in Italian elderly population, Eur J Neurol, 3, pp. 198-202, (1996); Conti S., Bonazzi S., Laiacona M., Masina M., Coralli M.V., Montreal Cognitive Assessment (MoCA)-Italian version: regression based norms and equivalent scores, Neurol Sci, 36, pp. 209-214, (2015); Novelli G., Papagno C., Capitani E., Laiacona M., Cappa SF V.G., Tre test clinici di memoria verbale a lungo termine, Taratura su soggetti normali Arch di Psicol Neurol Psychiatry, 47, pp. 278-296, (1986); Spinnler H., [Italian standardization and classification of Neuropsychological tests. The Italian Group on the neuropsychological study of aging], Ital J Neurol Sci Suppl, 8, pp. 1-120, (1987); Carlesimo G.A., Caltagirone C., Gainotti G., Al E., The mental deterioration battery: normative data, diagnositc reliability and qualitative analyses of cognitive impaiment, Eur J Neurol, 36, pp. 378-384, (1996); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Rey-Osterrieth complex figure: normative values in an Italian population sample, Neurol Sci, 22, pp. 443-447, (2002); Appollonio I., Leone M., Isella V., Piamarta F., Consoli T., Villa M.L., Et al., The Frontal Assessment Battery (FAB): normative values in an Italian population sample, Neurol Sci, 26, pp. 108-116, (2005); Giovagnoli A.R., Del Pesce M., Mascheroni S., Simoncelli M., Laiacona M., Capitani E., Trail making test: normative values from 287 normal adult controls, Ital J Neurol Sci, 4, pp. 305-309, (1996); Lawton M., Brody E., Assessment of older people: self-maintaining and instrumental activities of daily living, Gerontologist, 3, pp. 179-186, (1969); Beck A.T., Steer R.A., Brown G., Beck Depression Inventory-IIUSA. NCS Person, Inc., Italian Translation:, Adattamento Ital. Manuale. Giunti O.S. Organ. Spec, (2006); Apolone G., Mosconi P., The italian SF-36 health survey, J Clin Epidemiol, 51, pp. 1025-1036, (1998); Nucci M., Mapelli D., Mondini S., Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve, Aging Clin Exp Res, 24, pp. 218-226, (2012); Marvardi M., Mattioli P., Spazzafumo L., Mastriforti R., Rinaldi P., Polidori M.C., Et al., The Caregiver Burden Inventory in evaluating the burden of caregivers of elderly demented patients: results from a multicenter study, Aging Clin Exp Res, 17, pp. 46-53, (2005); Hurst H., Bolton J., Assessing the clinical significance of change scores recorded on subjective outcome measures, J Manipulative Physiol Ther, 27, pp. 26-35, (2004); Lumsden J., Edwards E.A., Lawrence N.S., Coyle D., Munafo M.R., Gamification of cognitive assessment and cognitive training: a systematic review of applications and efficacy, JMIR Serious Games, 4, (2016); Smith-Ray R.L., Irmiter C., Boulter K., Cognitive Training among cognitively impaired older adults: a feasibility study assessing the potential improvement in balance, Front Public Heal, 4, (2016); Jelcic N., Agostini M., Meneghello F., Buss e C., Parise S., Galano A., Et al., Feasibility and efficacy of cognitive telerehabilitation in early Alzheimer's disease: a pilot study, Clin Interv Aging, 9, pp. 1605-1611, (2014); Global Action Plan on the Public Health Response to Dementia 2017–2025, (2017); Chirra M., Marsili L., Wattley L., Sokol L.L., Keeling E., Maule S., Et al., Telemedicine in neurological disorders: opportunities and challenges, Telemed e-Health, 25, pp. 541-550, (2019); Nesbitt T.S., Hilty D.M., Kuenneth C.A., Siefkin A., Development of a telemedicine program: a review of 1,000 videoconferencing consultations, West J Med, 173, pp. 169-174, (2000); Zampolini M., Todeschini E., Bernabeu Guitart M., Hermens H., Ilsbroukx S., Macellari V., Et al., Tele-rehabilitation: present and future, Ann Ist Super Sanita, 44, pp. 125-134, (2008); Pecina J.L., Vickers K.S., Finnie D.M., Hathaway J.C., Hanson G.J., Takahashi P.Y., Telemonitoring increases patient awareness of health and prompts health-related action: initial evaluation of the TELE-ERA study, Telemed e-Health, 17, pp. 461-466, (2011); Choi H., Kim J., Effectiveness of telemedicine: videoconferencing for low-income elderly with hypertension, Telemed e-Health, 20, pp. 1156-1164, (2014); De Luca R., Bramanti A., De Cola M.C., Trifiletti A., Tomasello P., Torrisi M., Et al., Tele-health-care in the elderly living in nursing home: the first Sicilian multimodal approach, Aging Clin Exp Res, 28, pp. 753-759, (2016); Moo L.R., Gately M.E., Jafri Z., Shirk S.D., Home-based video telemedicine for dementia management, Clin Gerontol, 43, pp. 193-203, (2020); Smith G.E., Lunde A.M., Hathaway J.C., Vickers K.S., Telehealth home monitoring of solitary persons with mild dementia, Am J Alzheimer's Dis Other Dementias®, 22, pp. 20-26, (2007); Nijland N., van Gemert-Pijnen J., Boer H., Steehouder M.F., Seydel E.R., Evaluation of internet-based technology for supporting self-care: problems encountered by patients and caregivers when using self-care applications, J Med Internet Res, 10, (2008); Boutron I., Moher D., Altman D.G., Schulz K.F., Ravaud P., Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration, Ann Intern Med, 148, (2008); Boutron I., Altman D.G., Moher D., Schulz K.F., Ravaud P., CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts, Ann Intern Med, 167, (2017)","2-s2.0-85122439703"
"Borroni B.; Turrone R.; Galimberti D.; Nacmias B.; Alberici A.; Benussi A.; Caffarra P.; Caltagirone C.; Cappa S.F.; Frisoni G.B.; Ghidoni R.; Marra C.; Padovani A.; Rainero I.; Scarpini E.; Silani V.; Sorbi S.; Tagliavini F.; Tremolizzo L.; Bruni A.C.; Agosta F.; Alberoni M.; Appollonio I.; Arighi A.; Avanzi S.; Baglio F.; Benussi L.; Bianchetti A.; Binetti G.; Bonanni L.; Bottacchi E.; Bruno G.; Canevelli M.; Canu E.; Cerami C.; Chiari A.; Conti M.Z.; Costa A.; Costa M.; Cotelli M.; Cupidi C.; Daniele A.; D’Anna S.; de Caro M.F.; De Togni L.; Dell’Osa M.T.; Di Stefano F.; Ferrarese C.; Ferrari C.; Filastro F.; Floris G.; Franceschi M.; Gennuso M.; Ghidoni E.; Giordana M.T.; Gragnaniello D.; Grimaldi L.; Lanari A.; Le Pira F.; Lombardi G.; Lorusso S.; Ludovico L.; Luzzi S.; Magnani G.; Manfredi L.G.; Marano P.; Marcone A.; Marrosu M.G.; Martorana A.; Mascia M.G.; Masullo C.; Mauri M.; Mazzone A.; Mela A.; Merlo P.; Micheli A.; Milia A.; Mina C.; Montella P.; Mura G.; Murru M.R.; Nemni R.; Paci C.; Pantieri R.; Panza F.; Parnetti L.; Perini M.; Pettenati C.; Piccininni M.; Piccoli T.; Pilia G.; Pinessi L.; Piras M.R.; Realmuto S.; Ricca I.; Rizzetti M.C.; Rozzini L.; Rubino E.; Sambati L.; Seripa D.; Siano P.; Sinforiani E.; Sorrentino G.; Specchio L.M.; Stracciari A.; Susani E.; Talarico G.; Tartaglione B.; Tessitore A.; Thomas A.; Tiezzi A.; Tiraboschi P.; Tognoni G.; Tondelli M.; Trebbastoni A.; Turla M.; Ursini F.; Valluzzi F.; Vista M.; Zannino G.; Zanusso G.","Borroni, B. (6701398657); Turrone, R. (56453400300); Galimberti, D. (6701617660); Nacmias, B. (7003393435); Alberici, A. (6701506634); Benussi, A. (56151871000); Caffarra, P. (7003351095); Caltagirone, C. (35228717800); Cappa, S.F. (7005836132); Frisoni, G.B. (56214208300); Ghidoni, R. (7005186567); Marra, C. (7102675596); Padovani, A. (55996824100); Rainero, I. (7003753505); Scarpini, E. (57210771033); Silani, V. (7006146949); Sorbi, S. (7004417453); Tagliavini, F. (7006559302); Tremolizzo, L. (57200719476); Bruni, A.C. (7102347222); Agosta, F. (6701687853); Alberoni, M. (6602735759); Appollonio, I. (8309607400); Arighi, A. (18633586600); Avanzi, S. (6701747731); Baglio, F. (8966898500); Benussi, L. (7004507361); Bianchetti, A. (7006463531); Binetti, G. (35429391100); Bonanni, L. (6603146272); Bottacchi, E. (7003377832); Bruno, G. (7202705363); Canevelli, M. (37053450300); Canu, E. (25225458900); Cerami, C. (25722905400); Chiari, A. (12792407200); Conti, M.Z. (14036842400); Costa, A. (35499758300); Costa, M. (57220736370); Cotelli, M. (24343912800); Cupidi, C. (14059856700); Daniele, A. (7004251623); D’Anna, S. (57190386339); de Caro, M.F. (57216100159); De Togni, L. (19033865300); Dell’Osa, M.T. (57190381930); Di Stefano, F. (54953653200); Ferrarese, C. (7005869087); Ferrari, C. (55176840000); Filastro, F. (57190385986); Floris, G. (35589179800); Franceschi, M. (7004351220); Gennuso, M. (6507069812); Ghidoni, E. (6602533869); Giordana, M.T. (7004525027); Gragnaniello, D. (19434106600); Grimaldi, L. (7006655949); Lanari, A. (7006655447); Le Pira, F. (6701852647); Lombardi, G. (56083119300); Lorusso, S. (7003271177); Ludovico, L. (57190381391); Luzzi, S. (56264790400); Magnani, G. (24496141800); Manfredi, L.G. (7003875018); Marano, P. (24394206100); Marcone, A. (6701496511); Marrosu, M.G. (7006500728); Martorana, A. (7005822633); Mascia, M.G. (57222392237); Masullo, C. (7003422525); Mauri, M. (7103045989); Mazzone, A. (55872766200); Mela, A. (57190370990); Merlo, P. (7003834860); Micheli, A. (7005491423); Milia, A. (36765409300); Mina, C. (6602335528); Montella, P. (6507877161); Mura, G. (56045848100); Murru, M.R. (7003602803); Nemni, R. (7005022543); Paci, C. (6603834356); Pantieri, R. (6602768442); Panza, F. (57190310649); Parnetti, L. (35412328100); Perini, M. (57200423475); Pettenati, C. (6701489663); Piccininni, M. (7801552788); Piccoli, T. (6505971622); Pilia, G. (23051690800); Pinessi, L. (7004379523); Piras, M.R. (7004388483); Realmuto, S. (42462180200); Ricca, I. (25226322800); Rizzetti, M.C. (35609131500); Rozzini, L. (6701774589); Rubino, E. (8918035400); Sambati, L. (35604459700); Seripa, D. (6602180406); Siano, P. (55917454300); Sinforiani, E. (7004048043); Sorrentino, G. (7006224880); Specchio, L.M. (7003551597); Stracciari, A. (7003997181); Susani, E. (6504075396); Talarico, G. (7003637692); Tartaglione, B. (16466089500); Tessitore, A. (8603853500); Thomas, A. (7403882353); Tiezzi, A. (57210653956); Tiraboschi, P. (6701774925); Tognoni, G. (35944149100); Tondelli, M. (23135706200); Trebbastoni, A. (24081970200); Turla, M. (6602470362); Ursini, F. (35094514900); Valluzzi, F. (6508110802); Vista, M. (6602826777); Zannino, G. (6603452217); Zanusso, G. (6701822555)","6701398657; 56453400300; 6701617660; 7003393435; 6701506634; 56151871000; 7003351095; 35228717800; 7005836132; 56214208300; 7005186567; 7102675596; 55996824100; 7003753505; 57210771033; 7006146949; 7004417453; 7006559302; 57200719476; 7102347222; 6701687853; 6602735759; 8309607400; 18633586600; 6701747731; 8966898500; 7004507361; 7006463531; 35429391100; 6603146272; 7003377832; 7202705363; 37053450300; 25225458900; 25722905400; 12792407200; 14036842400; 35499758300; 57220736370; 24343912800; 14059856700; 7004251623; 57190386339; 57216100159; 19033865300; 57190381930; 54953653200; 7005869087; 55176840000; 57190385986; 35589179800; 7004351220; 6507069812; 6602533869; 7004525027; 19434106600; 7006655949; 7006655447; 6701852647; 56083119300; 7003271177; 57190381391; 56264790400; 24496141800; 7003875018; 24394206100; 6701496511; 7006500728; 7005822633; 57222392237; 7003422525; 7103045989; 55872766200; 57190370990; 7003834860; 7005491423; 36765409300; 6602335528; 6507877161; 56045848100; 7003602803; 7005022543; 6603834356; 6602768442; 57190310649; 35412328100; 57200423475; 6701489663; 7801552788; 6505971622; 23051690800; 7004379523; 7004388483; 42462180200; 25226322800; 35609131500; 6701774589; 8918035400; 35604459700; 6602180406; 55917454300; 7004048043; 7006224880; 7003551597; 7003997181; 6504075396; 7003637692; 16466089500; 8603853500; 7403882353; 57210653956; 6701774925; 35944149100; 23135706200; 24081970200; 6602470362; 35094514900; 6508110802; 6602826777; 6603452217; 6701822555","Italian frontotemporal dementia network (FTD group-SINDEM): Sharing clinical and diagnostic procedures in Frontotemporal dementia in Italy","2015","Neurological Sciences","36","5","","751","757","6","8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84939986730&doi=10.1007%2fs10072-014-2033-9&partnerID=40&md5=588345304102b2085c1eddaaad0d1282","In the prospect of improved disease management and future clinical trials in Frontotemporal Dementia, it is desirable to share common diagnostic procedures. To this aim, the Italian FTD Network, under the aegis of the Italian Neurological Society for Dementia, has been established. Currently, 85 Italian Centers involved in dementia care are part of the network. Each Center completed a questionnaire on the local clinical procedures, focused on (1) clinical assessment, (2) use of neuroimaging and genetics; (3) support for patients and caregivers; (4) an opinion about the prevalence of FTD. The analyses of the results documented a comprehensive clinical and instrumental approach to FTD patients and their caregivers in Italy, with about 1,000 newly diagnosed cases per year and 2,500 patients currently followed by the participating Centers. In analogy to other European FTD consortia, future aims will be devoted to collect data on epidemiology of FTD and its subtypes and to provide harmonization of procedures among Centers. © Springer-Verlag Italia 2014.","Counseling; Frontotemporal dementia; Frontotemporal lobar degeneration; Genetics; Network; Survey","Aged; Aged, 80 and over; Caregivers; Community Networks; Female; Frontotemporal Dementia; Humans; Information Dissemination; Italy; Male; Prevalence; aged; caregiver; clinical trial; community care; female; frontotemporal dementia; human; information dissemination; Italy; male; multicenter study; prevalence; psychology; very elderly","Sieben A., van Langenhove T., Engelborghs S., Martin J.J., Boon P., Cras P., de Deyn P.P., Santens P., van Broeckhoven C., Cruts M., The genetics and neuropathology of frontotemporal lobar degeneration, Acta Neuropathol, 124, pp. 353-372, (2012); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration: A consensus of clinical diagnostic criteria, Neurology, 51, 6, pp. 1546-1554, (1998); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011)","2-s2.0-84939986730"
"Sacco L.; Morellini L.; Cerami C.","Sacco, Leonardo (6701668924); Morellini, Lucia (57823819400); Cerami, Chiara (25722905400)","6701668924; 57823819400; 25722905400","Editorial: The diagnosis and the therapy of social cognition deficits in adults affected by ADHD and MCI","2023","Frontiers in Neurology","14","","1162510","","","","1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150357112&doi=10.3389%2ffneur.2023.1162510&partnerID=40&md5=a1d993e7338617860f7b08824370c434","[No abstract available]","ADHD; Alzheimer's disease; empathy; MCI; social cognition (SC)","aducanumab; lecanemab; oxytocin; acupuncture; Alzheimer disease; attention deficit hyperactivity disorder; cognitive rehabilitation; Editorial; emotion; empathy; executive function; exercise; human; mild cognitive impairment; psychiatric diagnosis; psychiatric treatment; psychopharmacology; recognition; social cognition; transcranial direct current stimulation; transcranial magnetic stimulation","Premack D., Woodruff G., Does the chimpanzee have a theory of mind?, Behav Brain Sci, 1, pp. 515-526, (1978); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol Sci, 36, pp. 1907-1912, (2015); Malle B.F., Social robots and the tree of social cognition, Proceedings of the Workshop “Cognition: A bridge between robotics and interaction” at HRI, pp. 13-14, (2015); Decety J., Jackson P.L., The functional architecture of human empathy, Behav Cogn Neurosci Rev, 3, pp. 71-100, (2004); Malle B.F., How the Mind Explains Behavior: Folk Explanation, Meaning and Social Interaction, (2004); American Psychiatric A., DSM-5 Task F., Diagnostic and Statistical Manual of Mental Disorders: DSM-5TM (5th ed.), (2013); Kennedy D.P., Adolphs R., The social brain in psychiatric and neurological disorders, Trends Cogn Sci, 16, pp. 559-572, (2012); Arioli M., Crespi C., Canessa N., Social cognition through the lens of cognitive and clinical neuroscience, Biomed Res Int, 2018, (2018); Dodich A., Crespi C., Santi G.C., Cappa S.F., Cerami C., Evaluation of discriminative detection abilities of social cognition measures for the diagnosis of the behavioral variant of frontotemporal dementia: a systematic review, Neuropsych Rev, 31, pp. 251-266, (2021); Dodich A., Crespi C., Santi G.C., Marcone A., Iannaccone S., Perani D., Et al., Emotion recognition deficits in the differential diagnosis of amnestic mild cognitive impairment: a cognitive marker for the limbic-predominant phenotype, J Int Neuropsychol Soc, 28, pp. 203-209, (2022); Nijmeijer J.S., Minderaa R.B., Buitelaar J.K., Mulligan A., Hartman C.A., Hoekstra P.J., Et al., Attention-deficit/hyperactivity disorder and social dysfunctioning, Clin Psychol Rev, 28, pp. 692-708, (2007); Bora E., Pantelis C., Meta-analysis of social cognition in attention-deficit/hyperactivity disorder (ADHD): comparison with healthy controls and autistic spectrum disorder, Psychol Med, 46, pp. 699-716, (2016); Bora E., Yener G.G., Meta-analysis of social cognition in mild cognitive impairment, J Geriatr Psych Neurol, 30, pp. 206-213, (2017); Garcia-Casal J.A., Martinez-Abad F., Cid-Bartolome T., Smith S.J., Llano-Ordonez K., Perea-Bartolome M.V., Et al., Usability study and pilot validation of a computer-based emotion recognition test for older adults with Alzheimer's disease and amnestic mild cognitive impairment, Aging Ment. Health, 23, pp. 365-375, (2019); Hayashi S., Terada S., Takenoshita S., Kawano Y., Yabe M., Imai N., Et al., Facial expression recognition in mild cognitive impairment and dementia: Is the preservation of happiness recognition hypothesis true?, Psychogeriatrics, 21, pp. 54-61, (2021); Kessels R., Waanders-Oude Elferink M., van Tilborg I., Social cognition and social functioning in patients with amnestic mild cognitive impairment or Alzheimer's dementia, J Neuropsychol, 15, pp. 186-203, (2021); Tsentidou G., Moraitou D., Tsolaki M., Similar theory of mind deficits in community dwelling older adults with vascular risk profile and patients with mild cognitive impairment: the case of paradoxical sarcasm comprehension, Brain Sci, 11, (2021); Orso B., Lorenzini L., Arnaldi D., Girtler N., Brugnolo A., Doglione E., Et al., The role of hub and spoke regions in theory of mind in early Alzheimer's disease and frontotemporal dementia, Biomedicines, 10, (2022); Ekman P., Friesen W., Pictures of Facial Affect, (1976); Baron-Cohen S., Wheelwright S., Hill J., Raste Y., Plumb I., The “reading the mind in theeyes” test revised version: a study with normal adults, and adults with asperger syndrome orhigh-functioning autism, J Child Psychol Psych, 42, pp. 241-251, (2001); McDonald S., Flanagan S., Rollins J., Kinch J., TASIT: a new clinical tool for assessing social perception after traumatic brain injury, J Head Trauma Rehabil, 18, pp. 219-238, (2003); Funkiewiez A., Bertoux M., de Souza L.C., Levy R., Dubois B., The SEA (Social cognition and Emotional Assessment): a clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration, Neuropsychology, 26, pp. 81-90, (2012); Devine R.T., Hughes C., Measuring theory of mind across middle childhood: reliability and validity of the silent films and strange stories tasks, J Exp Child Psychol, 149, pp. 23-40, (2016); Boccardi M., Monsch A.U., Ferrari C., Altomare D., Berres M., Bos I., Et al., Consortium for the harmonization of neuropsychological assessment for neurocognitive disorders. Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe, Alzheimer's Dement, 18, pp. 29-42, (2022); van den Stock J., Social cognition assessment for mild neurocognitive disorders, Alzheimers Dement, 18, pp. 1439-1440, (2022); Dodich A., Boccardi M., Sacco L., Monsch A.U., Demonet J.F., Filardi M., Et al., Consortium for the harmonization of neuropsychological assessment for neurocognitive disorders. Answer to “Social cognition assessment for mild neurocognitive disorders”, Alzheimers Dement, 18, pp. 1441-1442, (2022); Riedijk S., Duivenvoorden H., Rosso S., Van Swieten J., Niermeijer M., Tibben A., Et al., Frontotemporal dementia: change of familial caregiver burden and partner relation in a Dutch cohort of 63 patients, Dement Geriatr Cogn Disord, 26, pp. 398-406, (2008); Mioshi E., Bristow M., Cook R., Hodges J.R., Factors underlying caregiver stress in frontotemporal dementia and Alzheimer's disease, Dement Geriatr Cogn Disord, 27, pp. 76-81, (2009); Riedijk S.R., Vugt D., Duivenvoorden M.E., Niermeijer H.J., van Swieten M.F., Verhey J.C., Et al., Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease, Dement Geriatr Cogn Disord, 22, pp. 405-412, (2006); Spitzer N., Shafir T., Lerman Y., Werner P., The relationship between caregiver burden and emotion recognition deficits in persons with MCI and early AD: the mediating role of caregivers' subjective evaluations, Alzheimer Dis Assoc Disord, 33, pp. 266-271, (2019); Cerami C., Perini G., Panzavolta A., Cotta Ramusino M., Costa A., A call for drug therapies for the treatment of social behavior disorders in dementia: systematic review of evidence and state of the art, Int J Mol Sci, 23, (2022); Budd Haeberlein S., Aisen P.S., Barkhof F., Chalkias S., Chen T., Cohen S., Et al., A two randomized phase 3 studies of aducanumab in early Alzheimer's Disease, J Prev. Alzheimers Dis, 9, pp. 197-210, (2022); van Dyck C.H., Swanson C.J., Aisen P., Bateman R.J., Chen C., Gee M., Et al., Lecanemab in early Alzheimer's disease, N Engl J Med, 388, pp. 9-21, (2023); Perneczky R., Jessen F., Grimmer T., Levin J., Floel A., Peters O., Et al., Anti-amyloid antibody therapies in Alzheimer's disease, Brain, (2023); Stokin G.B., Krell-Roesch J., Petersen R.C., Geda Y.E., Mild neurocognitive disorder: an old wine in a new bottle, Harvard Rev Psychiat, 23, pp. 368-376, (2015); Chen F.T., Etnier J.L., Chan K.H., Chiu P.K., Hung T.M., Chang Y.K., Et al., Effects of exercise training interventions on executive function in older adults: a systematic review and meta-analysis, Sports Med (Auckland, NZ), 50, pp. 1451-1467, (2022); Chu C.S., Li C.T., Brunoni A.R., Yang F.C., Tseng P.T., Tu Y.K., Et al., Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis, J Neurol Neurosurg Psychiatry, 92, pp. 195-203, (2021); Catala-Lopez F., Hutton B., Nunez-Beltran A., Page M.J., Ridao M., Macias Saint-Gerons D., Et al., The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials, PLoS ONE, 12, (2017); Storebo O.J., Krogh H.B., Ramstad E., Moreira-Maia C.R., Holmskov M., Skoog M., Et al., Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials, BMJ, 351, (2015)","2-s2.0-85150357112"
"Picascia M.; Cerami C.; Panzavolta A.; Bernini S.; Calculli A.; Regalbuto S.; Pisani A.","Picascia, Marta (55315018400); Cerami, Chiara (25722905400); Panzavolta, Andrea (57195292184); Bernini, Sara (55884116400); Calculli, Alessandra (57911467700); Regalbuto, Simone (57826531700); Pisani, Antonio (7006447950)","55315018400; 25722905400; 57195292184; 55884116400; 57911467700; 57826531700; 7006447950","Risk factors for post-COVID cognitive dysfunctions: the impact of psychosocial vulnerability","2023","Neurological Sciences","44","8","","2635","2642","7","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85162696482&doi=10.1007%2fs10072-023-06884-9&partnerID=40&md5=4cbd0cc73171379adb15c41cf02266a0","Background: Cognitive dysfunction is a well-established manifestation of the post-COVID syndrome. Psychological vulnerability to stressors can modify disease trajectories, causing long-term risk for negative outcomes. Nonetheless, how premorbid risk factors and response to stressor affect neuropsychological changes is still incompletely understood. In this study, we explored the impact of psychosocial variables on cognitive functioning in a post-COVID sample. Methods: All subjects were submitted to a comprehensive neuropsychological battery and an assessment of perceived loneliness, post-traumatic stress, and changes in anxiety and depression levels. A social vulnerability index was also calculated. The set of psycho-social variables was reduced to two Principal Component Analysis (PCA) components: distress and isolation. Results: Forty-five percent of individuals showed cognitive impairments, with predominant memory and executive deficits. Post-traumatic stress disorder was clinically relevant in 44% of the sample. Social vulnerability scores of the sample were comparable to those of general population. The individual performance in learning and response initiation/suppression was directly related to distress component, encasing anxiety, stress, and depression measures. Conclusion: These findings suggest that psychosocial assessment of post-COVID patients can detect fragile individuals at risk of cognitive impairments. Dedicated psychological support services may play a useful role in the prevention of post-COVID cognitive dysfunction. © 2023, Fondazione Società Italiana di Neurologia.","Cognitive dysfunctions; COVID; Distress; Post-COVID; Social vulnerability","Anxiety; Cognition; Cognitive Dysfunction; COVID-19; Depression; Humans; Risk Factors; adult; Article; cognition; cognitive defect; female; human; long COVID; major clinical study; male; middle aged; Mini Mental State Examination; neuropsychology; population; posttraumatic stress disorder; principal component analysis; psychological care; risk factor; social isolation; social support; social vulnerability; Social Vulnerability Index; trail making test; vulnerability; anxiety; cognitive defect; complication; coronavirus disease 2019; depression; physiology; psychology; risk factor","Kamal M., Abo Omirah M., Hussein A., Saeed H., Assessment and characterisation of post-COVID-19 manifestations, Int J Clin Pract, 75, (2021); Dashboard. World Health Organization., (2023); Diez-Cirarda M., Yus M., Gomez-Ruiz N., Et al., Multimodal neuroimaging in post-COVID syndrome and correlation with cognition, Brain, 146, 5, pp. 2142-2152, (2022); Munipalli B., Paul S., Mohabbat A., Et al., Clinical differences in symptomology, characteristics, and risk factors in patients with post-acute sequelae of COVID-19: an experience from a tertiary-care academic center, J Invest Med, 71, 5, pp. 495-501, (2023); Antar A.A.R., Yu T., Demko Z.O., Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection, Medrxiv Prepr Serv Health Sci, (2023); Huerne K., Filion K.B., Grad R., Et al., Epidemiological and clinical perspectives of long COVID syndrome, Am J Med Open, 9, (2023); Delgado-Alonso C., Valles-Salgado M., Delgado-Alvarez A., Et al., Cognitive dysfunction associated with COVID-19: a comprehensive neuropsychological study, J Psychiatr Res, 150, pp. 40-46, (2022); Prabhakaran D., Day G., Munipalli B., Et al., Neurophenotypes of COVID-19: Risk Factors and Recovery Outcomes, (2023); Matias-Guiu J.A., Herrera E., Gonzalez-Nosti M., Et al., Development of criteria for cognitive dysfunction in post-COVID syndrome: the IC-CoDi-COVID approach, Psychiatry Res, 319, (2023); Miskowiak K., Johnsen S., Sattler S., Et al., Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables, Eur Neuropsychopharmacol, 46, pp. 39-48, (2021); Reza-Zaldivar E.E., Hernandez-Sapiens M.A., Minjarez B., Et al., Infection mechanism of SARS-COV-2 and its implication on the nervous system, Front Immunol, 11, (2020); Schirinzi T., Lattanzi R., Maftei D., Et al., Substance P and Prokineticin-2 are overexpressed in olfactory neurons and play differential roles in persons with persistent post-COVID-19 olfactory dysfunction, Brain Behav Immun, 108, pp. 302-308, (2023); Cerami C., Santi G.C., Galandra C., Et al., COVID-19 outbreak in Italy: are we ready for the psychosocial and the economic crisis? Baseline Findings From the PsyCovid Study, Front Psych, 11, (2020); Cerami C., Canevelli M., Santi G.C., Et al., Identifying frail populations for disease risk prediction and intervention planning in the COVID-19 era: a focus on social isolation and vulnerability, Front Psych, 12, (2021); Cerami C., Crespi C., Bottiroli S., Et al., High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients, Cephalalgia, 41, pp. 1437-1446, (2021); Wei G., Diehl-Schmid J., Matias-Guiu J.A., Et al., The effects of the COVID-19 pandemic on neuropsychiatric symptoms in dementia and carer mental health: an international multicentre study, Sci Rep, 12, (2022); Harrison P.J., Taquet M., Neuropsychiatric disorders following SARS-CoV-2 infection, Brain, 146, pp. 2241-2247, (2023); Rival G., Chalbet S., Dupont C., Et al., Post-traumatic stress among COVID-19 survivors: a descriptive study of hospitalized first-wave survivors, Can J Respir Ther, 59, pp. 20-25, (2023); Sattler D.N., Bishkhorloo B., Lawley K.A., Et al., Stigma, post-traumatic stress, and COVID-19 vaccination intent in Mongolia, India, and the United States, Int J Environ Res Public Health, 20, (2023); Delgado-Alonso C., Valles-Salgado M., Delgado-Alvarez A., Et al., Examining association of personality characteristics and neuropsychiatric symptoms in post-COVID syndrome, Brain Sci, 12, (2022); Measso G., Cavarzeran F., Zappala G., Et al., The Mini-Mental State Examination: normative study of an Italian random sample, Dev Neuropsychol, 9, pp. 77-85, (1993); Caltagirone C., Gainotti G., Carlesimo G.A., Parnetti L., Batteria per la valutazione del deterioramento mentale: I. Descrizione di uno strumento di diagnosi neuropsicologica. [The Mental Deterioration Battery: I. Description of a neuropsychological diagnostic instrument.], Arch Psicol Neurol Psichiatr, 56, pp. 461-470, (1995); Caffarra P., Vezzadini G., Dieci F., Et al., Rey-Osterrieth complex figure: normative values in an Italian population sample, Neurol Sci, 22, pp. 443-447, (2002); Spitoni G.F., Bevacqua S., Cerini C., Et al., Normative data for the Hayling and Brixton tests in an Italian population, Arch Clin Neuropsychol, 33, pp. 466-476, (2018); Giovagnoli A.R., Del Pesce M., Mascheroni S., Et al., Trail making test: normative values from 287 normal adult controls, Ital J Neurol Sci, 17, pp. 305-309, (1996); Appollonio I., Leone M., Isella V., Et al., The Frontal Assessment Battery (FAB): normative values in an Italian population sample, Neurol Sci, 26, pp. 108-116, (2005); Carlesimo G.A., Caltagirone C., Gainotti G., The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery, Eur Neurol, 36, pp. 378-384, (1996); Novelli G., Papagno C., Capitani E., Et al., Tre test clinici di ricerca e produzione lessicale. Taratura su sogetti normali. [Three clinical tests to research and rate the lexical performance of normal subjects.], Arch Psicol Neurol Psichiatr, 47, pp. 477-506, (1986); Chipi E., Montanucci C., Eusebi P., Et al., The Italian version of Cognitive Function Instrument (CFI) for tracking changes in healthy elderly: results at 1-year follow-up, Neurol Sci, 40, pp. 2147-2153, (2019); Zammuner V., Italians’ social and emotional loneliness: the results of five studies, Int J Humanit Soc Sci, 3, pp. 108-120, (2008); Bottesi G., Ghisi M., Altoe G., Et al., The Italian version of the Depression Anxiety Stress Scales-21: factor structure and psychometric properties on community and clinical samples, Compr Psychiatry, 60, pp. 170-181, (2015); Passardi S., Peyk P., Rufer M., Et al., Facial mimicry, facial emotion recognition and alexithymia in post-traumatic stress disorder, Behav Res Ther, 122, (2019); Edwards E.R., Posttraumatic stress and alexithymia: a meta-analysis of presentation and severity, Psychol Trauma Theory Res Pract Policy, 14, pp. 1192-1200, (2022); Brooks S.K., Dunn R., Amlot R., Et al., Social and occupational factors associated with psychological distress and disorder among disaster responders: a systematic review, BMC Psychol, 4, (2016); Brooks S.K., Dunn R., Amlot R., Et al., A systematic, thematic review of social and occupational factors associated with psychological outcomes in healthcare employees during an infectious disease outbreak, J Occup Environ Med, 60, pp. 248-257, (2018); Osman A., Wong J.L., Bagge C.L., Et al., The Depression Anxiety Stress Scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates, J Clin Psychol, 68, pp. 1322-1338, (2012); Weiss D.S., Marmar C.R., The impact of event scale—revised, Assessing psychological trauma and PTSD, pp. 399-411, (1997); Beck J.G., Grant D.M., Read J.P., Et al., The impact of event scale –revised: psychometric properties in a sample of motor vehicle accident survivors, J Anxiety Disord, 22, pp. 187-198, (2008); Capitani E., Laiacona M., Composite neuropsychological batteries and demographic correction: standardization based on equivalent scores, with a review of published data. The Italian Group for the Neuropsychological Study of Ageing, J Clin Exp Neuropsychol, 19, pp. 795-809, (1997); Bryant F.B., Yarnold P.R., Principal-Components Analysis and Exploratory and Confirmatory Factor Analysis. In: Reading and Understanding Multivariate Statistics, pp. 99-136, (1995); Abdi H., Williams L., Principal component analysis, Wiley Interdiscip Rev Comput Stat, 2, pp. 433-459, (2010); For Post COVID Condition (Post COVID-19 CRF), (2021); World Health Organization, (2023); Miskowiak K., Fugledalen L., Jespersen A., Et al., Trajectory of cognitive impairments over 1 year after COVID-19 hospitalisation: pattern, severity, and functional implications, Eur Neuropsychopharmacol, 59, pp. 82-92, (2022); Giurgi-Oncu C., Tudoran C., Pop G.N., Et al., Cardiovascular abnormalities and mental health difficulties result in a reduced quality of life in the post-acute COVID-19 syndrome, Brain Sci, 11, (2021); Taquet M., Geddes J.R., Husain M., Et al., 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records, Lancet Psychiatry, 8, pp. 416-427, (2021); Zigmond A.S., Snaith R.P., The Hospital Anxiety and Depression Scale, Acta Psychiatr Scand, 67, pp. 361-370, (1983); Ferrando S.J., Dornbush R., Lynch S., Et al., Neuropsychological, medical, and psychiatric findings after recovery from acute COVID-19: a cross-sectional study, J Acad Consult Liaison Psychiatry, 63, pp. 474-484, (2022); Calabria M., Garcia-Sanchez C., Grunden N., Et al., Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms, J Neurol, 269, pp. 3990-3999, (2022); Livingston G., Huntley J., Sommerlad A., Et al., Dementia prevention, intervention, and care: 2020 report of the Lancet Commission, Lancet, 396, pp. 413-446, (2020); Lovden M., Fratiglioni L., Glymour M.M., Et al., Education and cognitive functioning across the life span, Psychol Sci Public Interest, 21, pp. 6-41, (2020); Opdebeeck C., Martyr A., Clare L., Cognitive reserve and cognitive function in healthy older people: a meta-analysis, Neuropsychol Dev Cogn B Aging Neuropsychol Cogn, 23, pp. 40-60, (2016); Stern Y., What is cognitive reserve? Theory and research application of the reserve concept, J Int Neuropsychol Soc, 8, 3, pp. 448-460, (2002); Lei L., Huang X., Zhang S., Et al., Comparison of prevalence and associated factors of anxiety and depression among people affected by versus people unaffected by quarantine during the COVID-19 epidemic in Southwestern China, Med Sci Monit, 26, (2020); Panico F., Luciano S.M., Sagliano L., Et al., Cognitive reserve and coping strategies predict the level of perceived stress during COVID-19 pandemic: a cross-sectional study, Personal Individ Differ, 195, (2022)","2-s2.0-85162696482"
"Consonni M.; Rossi S.; Cerami C.; Marcone A.; Iannaccone S.; Francesco Cappa S.; Perani D.","Consonni, Monica (23093832900); Rossi, Stefania (56640594000); Cerami, Chiara (25722905400); Marcone, Alessandra (6701496511); Iannaccone, Sandro (7005943171); Francesco Cappa, Stefano (7005836132); Perani, Daniela (7005630261)","23093832900; 56640594000; 25722905400; 6701496511; 7005943171; 7005836132; 7005630261","Executive dysfunction affects word list recall performance: Evidence from amyotrophic lateral sclerosis and other neurodegenerative diseases","2017","Journal of Neuropsychology","11","1","","74","90","16","18","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929224352&doi=10.1111%2fjnp.12072&partnerID=40&md5=e88de1c840384091bc6b4248dee12d20","The Rey Auditory Verbal Learning Test (RAVLT) is widely used in clinical practice to evaluate verbal episodic memory. While there is evidence that RAVLT performance can be influenced by executive dysfunction, the way executive disorders affect the serial position curve (SPC) has not been yet explored. To this aim, we analysed immediate and delayed recall performances of 13 non-demented amyotrophic lateral sclerosis (ALS) patients with a specific mild executive dysfunction (ALSci) and compared their performances to those of 48 healthy controls (HC) and 13 cognitively normal patients with ALS. Moreover, to control for the impact of a severe dysexecutive syndrome and a genuine episodic memory deficit on the SPC, we enrolled 15 patients with a diagnosis of behavioural variant of frontotemporal dementia (bvFTD) and 18 patients with probable Alzheimer's disease (AD). Results documented that, compared to cognitively normal subjects, ALSci patients had a selective mid-list impairment for immediate recall scores. The bvFTD group obtained low performances with a selectively increased forgetting rate for terminal items, whereas the AD group showed a disproportionately large memory loss on the primary and middle part of the SPC for immediate recall scores and were severely impaired in the delayed recall trial. These results suggested that subtle executive dysfunctions might influence the recall of mid-list items, possibly reflecting deficiency in control strategies at retrieval of word lists, whereas severer dysexecutive syndrome might also affect the recall of terminal items possibly due to attention deficit or retroactive interference. © 2015 The British Psychological Society","Alzheimer's disease; amyotrophic lateral sclerosis; behavioural variant of frontotemporal dementia; Rey auditory verbal learning test; serial position curve","Acoustic Stimulation; Aged; Aged, 80 and over; Amyotrophic Lateral Sclerosis; Analysis of Variance; Cognition Disorders; Executive Function; Female; Humans; Male; Memory Disorders; Mental Recall; Mental Status Schedule; Middle Aged; Neurodegenerative Diseases; Neuropsychological Tests; Verbal Learning; aged; amyotrophic lateral sclerosis; analysis of variance; auditory stimulation; Cognition Disorders; complication; degenerative disease; executive function; female; human; learning; male; Memory Disorders; mental health; middle aged; neuropsychological test; physiology; recall; very elderly","Abdulla S., Machts J., Kaufmann J., Patrick K., Kollewe K., Dengler R., Nestor P.J., Hippocampal degeneration in patients with amyotrophic lateral sclerosis, Neurobiology of Aging, 35, pp. 2639-2645, (2014); Abrahams S., Goldstein L.H., Kew J.J.M., Brooks D.J., Lloyd C.M., Frith C.D., Leigh P.N., Frontal lobe dysfunction in amyotrophic lateral sclerosis: A PET study, Brain, 119, pp. 2105-2120, (1996); Abrahams S., Goldstein L.H., Simmons A., Brammer M., Williams S.C., Giampietro V., Leigh P.N., Word retrieval in amyotrophic lateral sclerosis: A functional magnetic resonance imaging study, Brain, 127, pp. 1507-1517, (2004); Abrahams S., Leigh P.N., Harvey A., Vythelingum G.N., Grise D., Goldstein L.H., Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 38, pp. 734-747, (2000); Atkinson R.C., Shiffrin R.M., Human memory: A proposed system and its control processes, The psychology of learning and motivation, pp. 89-195, (1968); Baddeley A., Working memory, Current Biology, 20, pp. R136-R140, (2010); Baddeley A.D., Warrington E.K., Memory coding and amnesia, Neuropsychologia, 11, pp. 159-165, (1973); Basso A., Capitani E., Laicona M., Raven's coloured progressive matrices: Normative values on 305 adult normal controls, Functional Neurology, 2, pp. 189-194, (1987); Basso A., Spinnler H., Vallar G., Zanobio M.E., Left hemisphere damage and selective impairment of auditory verbal short-term memory. A case study, Neuropsychologia, 20, pp. 263-274, (1982); Bayley P.J., Salmon D.P., Bondi M.W., Bui B.K., Olichney J., Delis D.C., Thal L.J., Comparison of the serial position effect in very mild Alzheimer's disease, mild Alzheimer's disease, and amnesia associated with electroconvulsive therapy, Journal of the International Neuropsychological Society, 6, pp. 290-298, (2000); Bede P., Elamin M., Byrne S., McLaughlin R.L., Kenna K., Vajda A., Hardiman O., Basal ganglia involvement in amyotrophic lateral sclerosis, Neurology, 15, pp. 2107-2115, (2013); Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Trojanowski J.Q., Stages of pTDP-43 pathology in amyotrophic lateral sclerosis, Annals of Neurology, 74, pp. 20-38, (2013); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. World Federation of Neurology Research Group on Motor Neuron Diseases, Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, pp. 293-299, (2000); Brooks B.L., Weaver L.E., Scialfa C.T., Does impaired executive functioning differentially impact verbal memory measures in older adults with suspected dementia?, Clinical Neuropsychology, 20, pp. 230-242, (2006); Buschke H., Cued recall in amnesia, Journal of Clinical Neuropsychology, 6, pp. 433-440, (1984); Carlesimo G.A., Caltagirone C., Gainotti G., The Mental Deterioration Battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment, European Neurology, 36, pp. 378-384, (1996); Carlesimo G.A., Sabbadini M., Fadda L., Caltagirone C., Different components in word-list forgetting of pure amnesics, degenerative demented and healthy subjects, Cortex, 31, pp. 735-745, (1995); Carlesimo G.A., Sabbadini M., Fadda L., Caltagirone C., Word-list forgetting in young and elderly subjects: Evidence for age-related decline in transferring information from transitory to permanent memory condition, Cortex, 33, pp. 155-166, (1997); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Cappa S.F., Emotional empathy in amyotrophic lateral sclerosis: A behavioural and voxel-based morphometry study, Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 15, pp. 21-29, (2014); Chang J.L., Lomen-Hoerth C., Murphy J., Henry R.G., Kramer J.H., Miller B.L., Gorno-Tempini M.L., A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD, Neurology, 65, pp. 75-80, (2005); Christidi F., Zalonis I., Smyrnis N., Evdokimidis I., Selective attention and the three-process memory model for the interpretation of verbal free recall in amyotrophic lateral sclerosis, Journal of the International Neuropsychological Society, 18, pp. 809-818, (2012); Consonni M., Iannaccone S., Cerami C., Frasson P., Lacerenza M., Lunetta C., Cappa S.F., The cognitive and behavioural profile of Amyotrophic Lateral Sclerosis: Application of the consensus criteria, Behavioural Neurology, 27, pp. 143-153, (2012); Crespi C., Cerami C., Dodich A., Canessa N., Arpone M., Iannaccone S., Cappa S.F., Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis, Cortex, 53, pp. 1-8, (2014); Cunha C., Guerreiro M., de Mendonca A., Oliveira P.E., Santana I., Serial position effects in Alzheimer's disease, mild cognitive impairment, and normal aging: Predictive value for conversion to dementia, Journal of Clinical and Experimental Neuropsychology, 34, pp. 841-852, (2012); Davelaar E.J., Goshen-Gottstein Y., Ashkenazi A., Haarmann H.J., Usher M., The demise of short-term memory revisited: Empirical and computational investigations of recency effects, Psychological Review, 112, pp. 3-42, (2005); DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Rademakers R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, pp. 245-256, (2011); Di Paola M., Macaluso E., Carlesimo G.A., Tomaiuolo F., Worsley K.J., Fadda L., Caltagirone C., Episodic memory impairment in patients with Alzheimer's disease is correlated with entorhinal cortex atrophy. A voxel-based morphometry study, Journal of Neurology, 254, pp. 774-781, (2007); Duff K., Schoenberg M.R., Scott J.G., Adams R.L., The relationship between executive functioning and verbal and visual learning and memory, Archives of Clinical Neuropsychology, 20, pp. 111-122, (2005); Elamin M., Pender N., Hardiman O., Abrahams S., Social cognition in neurodegenerative disorders: A systematic review, Journal of Neurology, Neurosurgery, and Psychiatry, 83, pp. 1071-1079, (2012); Eslinger P.J., Grattan L.M., Altered serial position learning after frontal lobe lesion, Neuropsychologia, 32, pp. 729-739, (1994); Folstein M.F., Folstein S.E., McHugh P.R., Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, pp. 189-198, (1975); Frasson G., Ghiretti R., Catricala E., Pomati S., Marcone A., Parisi L., Clerici F., Free and cued selective reminding test: An Italian normative study, Neurological Science, 32, pp. 1057-1062, (2011); Gleichgerrcht E., Torralva T., Martinez D., Roca M., Manes F., Impact of executive dysfunction on verbal memory performance in patients with Alzheimer's disease, Journal of ALzheimer's Disease, 23, pp. 79-85, (2011); Glosser G., Gallo J.L., Clark C.M., Grossman M., Memory encoding and retrieval in frontotemporal dementia and Alzheimer's disease, Neuropsychology, 16, pp. 190-196, (2002); Grober E., Buschke H., Genuine memory deficits in dementia, Developmental Neuropsychology, 3, pp. 13-16, (1987); Hanagasi H.A., Gurvit I.H., Ermutlu N., Kaptanoglu G., Karamursel S., Idrisoglu H.A., Demiralp T., Cognitive impairment in amyotrophic lateral sclerosis: Evidence from neuropsychological investigation and event-related potentials, Cognitive Brain Research, 14, pp. 234-244, (2002); Hashimoto R., Meguro K., Yamaguchi S., Ishizaki J., Ishii H., Meguro M., Sekita Y., Executive dysfunction can explain word-list learning disability in very mild Alzheimer's disease: The Tajiri project, Psychiatry and Clinical Neurosciences, 58, pp. 54-60, (2004); Hornberger M., Piguet O., Episodic memory in frontotemporal dementia: A critical review, Brain, 135, pp. 678-692, (2012); Hornberger M., Piguet O., Graham A.J., Nestor P.J., Hodges J.R., How preserved is episodic memory in behavioral variant frontotemporal dementia?, Neurology, 74, pp. 472-479, (2010); Hornberger M., Wong S., Tan R., Irish M., Piguet O., Kril J., Halliday G., In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease, Brain, 135, pp. 3015-3025, (2012); Kew J.J., Goldstein L.H., Leigh P.N., Abrahams S., Cosgrave N., Passingham R.E., Brooks D.J., The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study, Brain, 116, pp. 1399-1423, (1993); Lillo P., Mioshi E., Burrell J.R., Kiernan M.C., Hodges J.R., Hornberger M., Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum, PLoS ONE, 7, (2012); Machts J., Bittner V., Kasper E., Schuster C., Prudlo J., Abdulla S., Bittner D.M., Memory deficits in amyotrophic lateral sclerosis are not exclusively caused by executive dysfunction: A comparative neuropsychological study of amnestic mild cognitive impairment, BMC Neuroscience, 15, (2014); Mantovan M.C., Baggio L., Dalla B.G., Smith P., Pegoraro E., Soraru' G., Angelini C., Memory deficits and retrieval processes in ALS, European Journal of Neurology, 10, pp. 221-227, (2003); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, 7, pp. 263-269, (2011); Meier S.L., Charleston A.J., Tippett L.J., Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis, Brain, 133, pp. 3444-3457, (2010); Montuschi M., Iazzolino B., Calvo A., Moglia C., Lopiano L., Restagno G., Chio A., Cognitive correlates in amyotrophic lateral sclerosis: A population-based study in Italy, Journal of Neurology, Neurosurgery, and Psychiatry, 86, pp. 168-173, (2014); Murdock J., Bennet B., The serial position effect of free recall, Journal of Experimental Psychology, 64, pp. 482-488, (1962); Neath I., Distinctiveness and serial position effects in recognition, Memory & Cognition, 21, pp. 689-698, (1993); Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Lee V.L., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, pp. 130-133, (2006); Novelli G., Papagno C., Capitani E., Laicona M., Vallar G., Cappa S.F., Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali, Archivio di Psicologia, Neurologia e Psichiatria, 47, pp. 477-506, (1986); Orru G., Sampietro S., Catanzaro S., Girardi A., Najjar M., Giantin V., Coin A., Serial position effect in a free recall task: Differences between probable dementia of Alzheimer type (PDAT), vascular (VaD) and mixed etiology dementia (MED), Archives of Gerontology and Geriatrics, 49, pp. 207-210, (2009); Orsini A., Grossi D., Capitani E., Laicona M., Papagno C., Vallar G., Verbal and spatial immediate memory span: Normative data from 1355 adults and 1112 children, Italian Journal of Neurological Sciences, 8, pp. 539-548, (1987); Pasquier F., Grymonprez L., Lebert F., Van der Linden M., Memory impairment differs in frontotemporal dementia and Alzheimer's disease, Neurocase, 7, pp. 161-171, (2001); Pennington C., Hodges J.R., Hornberger M., Neural correlates of episodic memory in behavioral variant frontotemporal dementia, Journal of ALzheimer's Disease, 24, pp. 261-268, (2011); Pepin E.P., Eslinger P.J., Verbal memory decline in Alzheimer's disease: A multiple-processes deficit, Neurology, 39, pp. 1477-1482, (1989); Perri R., Fadda L., Caltagirone C., Carlesimo G.A., Word list and story recall elicit different patterns of memory deficit in patients with Alzheimer's disease, frontotemporal dementia, subcortical ischemic vascular disease, and lewy body dementia, Journal of Alzheimer's Disease, 37, pp. 99-107, (2013); Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Hardiman O., The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study, Journal of Neurology, Neurosurgery, and Psychiatry, 83, pp. 102-108, (2012); Piguet O., Hodges J.R., Behavioural-variant frontotemporal dementia. An update, Dementia & Neuropsychologia, 7, pp. 10-18, (2013); Quinn C., Elman L., McCluskey L., Hoskins K., Karam C., Woo J.H., Grossman M., Frontal lobe abnormalities on MRS correlate with poor letter fluency in ALS, Neurology, 79, pp. 583-588, (2012); Raaphorst J., de Visser M., Linssen W.H., de Haan R.J., Schmand B., The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis, Amyotrophic Lateral Sclerosis, 11, pp. 27-37, (2010); Raaphorsta J., van Tolc M.J., de Vissera M., van der Kooia A.J., Majoied C.B., van den Berge L.H., Schmanda B., Veltmang D.J., Prose memory impairment in amyotrophic lateral sclerosis patients is related to hippocampus volume, European Journal of Neurology, 22, pp. 547-554, (2015); Ranjith N., Mathuranath P.S., Sharma G., Alexander A., Qualitative aspects of learning, recall, and recognition in dementia, Annals of Indian Academy of Neurology, 13, pp. 117-122, (2010); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Jibbs J.R., Traynor B.J., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, pp. 257-268, (2011); Rey A., L'Examen Clinique en Psychologie, (1958); Rippon G.A., Scarmeas N., Gordon P.H., Murphy P.L., Albert S.M., Mitsumoto H., Stern Y., An observational study of cognitive impairment in amyotrophic lateral sclerosis, Archives of Neurology, 63, pp. 345-352, (2006); Rosen H.J., Gorno-Tempini M.L., Goldman W.P., Perry R.J., Schuff N., Weiner M., Miller B.L., Patterns of brain atrophy in frontotemporal dementia and semantic dementia, Neurology, 58, pp. 198-208, (2002); Rouder J.N., Gomez P., Modelling serial position curves with temporal distinctiveness, Memory, 9, pp. 301-311, (2001); Rundus D., Analysis of rehearsal processes in free recall, Journal of Experimental Psychology, 89, pp. 63-77, (1971); Sage C.A., Peeters R.R., Gorner A., Robberecht W., Sunaert S., Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis, NeuroImage, 34, pp. 486-499, (2007); Schuster C., Kasper E., Dyrba M., Machts J., Bittner D., Kaufmann J., Prudlo J., Cortical thinning and its relation to cognition in amyotrophic lateral sclerosis, Neurobiology of Aging, 35, pp. 240-246, (2014); Shallice T., Warrington E.K., Independent functioning of verbal memory stores: A neuropsychological study, The Quarterly Journal of Experimental Psychology, 22, pp. 261-273, (1970); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Figlewicz D., Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis, 10, pp. 131-146, (2009); Stuss D.T., Alexander M.P., Executive functions and the frontal lobes: A conceptual view, Psychological Research, 63, pp. 289-298, (2000); Stuss D.T., Alexander M.P., Palumbo C.L., Bukle L., Sayer L., Pogue J., Organizational strategies of patients with unilateral or bilateral frontal lobe injury in word list learning tasks, Neuropsychology, 8, pp. 355-373, (1994); Takeda T., Uchihara T., Arai N., Mizutani T., Iwata M., Progression of hippocampal degeneration in amyotrophic lateral sclerosis with or without memory impairment: Distinction from Alzheimer disease, Acta Neuropathologica, 117, pp. 35-44, (2009); Takeda T., Uchihara T., Mochizuki Y., Mizutani T., Iwata M., Memory deficits in amyotrophic lateral sclerosis patients with dementia and degeneration of the perforant pathway A clinicopathological study, Journal of Neurological Science, 260, pp. 225-230, (2007); Taylor L.J., Brown R.G., Tsermentseli S., Al-Chalabi A., Shaw C.E., Ellis C.M., Goldstain L.H., Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis?, Journal of Neurology, Neurosurgery, and Psychiatry, 84, pp. 494-498, (2013); Thapar A., Greene R.L., Evidence against a short-term-store account of long-term recency effects, Memory & Cognition, 21, pp. 329-337, (1993); Tierney M.C., Black S.E., Szalai J.P., Snow W.G., Fisher R.H., Nadon G., Chui H.C., Recognition memory and verbal fluency differentiate probable Alzheimer disease from subcortical ischemic vascular dementia, Archives of Neurology, 58, pp. 1654-1659, (2001); Tsermentseli S., Leigh P.N., Goldstein L.H., The anatomy of cognitive impairment in amyotrophic lateral sclerosis: More than frontal lobe dysfunction, Cortex, 48, pp. 166-182, (2012); Waugh N.C., Norman D.A., Primary memory, Psychological Review, 72, pp. 89-104, (1965); Wechsler D.A., Standardized memory scale for clinical use, Journal of Psychology, 19, pp. 87-95, (1945); Whitwell J.L., Jack C.R., Senjem M.L., Josephs K.A., Patterns of atrophy in pathologically confirmed FTLD with and without motor neuron degeneration, Neurology, 66, pp. 102-104, (2006); Wong S., Flanagan E., Savage G., Hodges J.R., Hornberger M., Contrasting prefrontal cortex contributions to episodic memory dysfunction in behavioural variant frontotemporal dementia and Alzheimer's disease, PLoS ONE, 9, (2014)","2-s2.0-84929224352"
"Fiamingo G.; Capittini C.; De Silvestri A.; Rebuffi C.; Cerami C.; Arnaldi D.; Terzaghi M.","Fiamingo, Giuseppe (57218284917); Capittini, Cristina (26425011200); De Silvestri, Annalisa (6701866631); Rebuffi, Chiara (57213811793); Cerami, Chiara (25722905400); Arnaldi, Dario (35809752900); Terzaghi, Michele (6603662935)","57218284917; 26425011200; 6701866631; 57213811793; 25722905400; 35809752900; 6603662935","Neuropsychological evaluation of phenoconversion risk in REM sleep behaviour disorder: A scoping review","2023","Journal of Sleep Research","32","5","e13873","","","","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85150975586&doi=10.1111%2fjsr.13873&partnerID=40&md5=2041042fbf60bda24142833a1359a9fe","The objective of this study was to assess the role of cognitive evaluation in the prediction of phenoconversion in polysomnography-confirmed idiopathic or isolated rapid eye movement sleep behaviour disorder, through a scoping review focussing on a longitudinal comprehensive neuropsychological assessment of patients with idiopathic REM sleep behaviour disorder. A literature search (2006–2022) yielded 1034 records, and 20 were selected for analysis. The sample included 899 patients from eight different cohorts and five countries. We extracted data on clinical evolution, mild cognitive impairment diagnosis, neuropsychological tests used, and classification of cognitive domains. Tests, cognitive domains, and mild cognitive impairment definitions were heterogeneous across the studies, precluding a meta-analysis. Ten studies (50%) evaluated the presence of mild cognitive impairment; 14 studies (70%) grouped neuropsychological tests into between three (6 studies, 21.4%) and seven (1 study, 7.1%) cognitive domains. The most frequently used tests were semantic fluency, Stroop colour word test, trail making test A and B, digit span, Rey auditory verbal learning test, and Rey-Osterrieth figure. All except digit span showed a role in predicting phenoconversion. The authors did not consistently assign tests to specific cognitive domains. In conclusion, we discuss methodological differences between the studies and highlight the need for a standardised framework for neuropsychological data acquisition and presentation, based on a multilevel approach covering test selection, domain assignment, and mild cognitive impairment diagnostic criteria. © 2023 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.","idiopathic REM sleep behaviour disorder (iRBD); longitudinal assessment; mild cognitive impairment (MCI); neuropsychology; PD-MCI diagnostic criteria; phenoconversion","Cognitive Dysfunction; Humans; Neuropsychological Tests; REM Sleep Behavior Disorder; aged; disease classification; female; human; major clinical study; male; mild cognitive impairment; neuropsychological assessment; parasomnia; polysomnography; Review; Rey auditory verbal learning test; Stroop test; systematic review; trail making test; cognitive defect; neuropsychological assessment; psychology; REM sleep behavior disorder","Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimer's & Dementia, 7, 3, pp. 270-279, (2011); Alotaibi F., Pelletier A., Gagnon J.F., Montplaisir J.Y., Postuma R.B., Prodromal marker progression in idiopathic rapid eye movement sleep behavior disorder: Sample size for clinical trials, Movement Disorders, 34, 12, pp. 1914-1919, (2019); International classification of sleep disorders. Diagnostic and Coding Manual, pp. pp. 148-152), (2005); International classification of sleep disorders, 2014; Diagnostic and statistical manual of mental disorders, 21, pp. 591-643, (2013); Arnaldi D., Chincarini A., De Carli F., Fama F., Girtler N., Brugnolo A., Pardini M., Massa F., Meli R., Schenone C., Bauckneht M., Morbelli S., Nobili F., The fate of patients with REM sleep behavior disorder and mild cognitive impairment, Sleep Medicine, 79, pp. 205-210, (2021); Arnaldi D., Mattioli P., Fama F., Girtler N., Brugnolo A., Pardini M., Donniaquio A., Massa F., Orso B., Raffa S., Bauckneht M., Morbelli S., Nobili F., Stratification tools for disease-modifying trials in prodromal synucleinopathy, Movement Disorders, 37, 1, pp. 52-61, (2022); Biundo R., Weis L., Antonini A., Cognitive decline in Parkinson's disease: The complex picture, Npj Parkinson's Disease, 2, 1, (2016); Boccardi M., Monsch A.U., Ferrari C., Altomare D., Berres M., Bos I., Buchmann A., Cerami C., Didic M., Festari C., Nicolosi V., Sacco L., Aerts L., Albanese E., Annoni J.-M., Ballhausen N., Chicherio C., Demonet J.-F., Descloux V., Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe, Alzheimer's & Dementia, 18, pp. 29-42, (2021); Boeve B.F., Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease, Parkinsonism & Related Disorders, 18, pp. S41-S44, (2012); Bondi M., Neuropsychological criteria for MCI improves diagnostic accuracy, Journal of the Alzheimer's Association, 42, 1, pp. 275-289, (2014); Campabadal A., Inguanzo A., Segura B., Serradell M., Abos A., Uribe C., Gaig C., Santamaria J., Compta Y., Bargallo N., Junque C., Iranzo A., Cortical gray matter progression in idiopathic REM sleep behavior disorder and its relation to cognitive decline, NeuroImage: Clinical, 28, (2020); Carone D.A., Strauss E., Sherman E.M.S., Spreen O., A compendium of neuropsychological tests: Administration, norms, and commentary, Applied Neuropsychology, 14, 1, pp. 62-63, (2007); Fantini M.L., Farini E., Ortelli P., Zucconi M., Manconi M., Cappa S., Ferini-Strambi L., Longitudinal study of cognitive function in idiopathic REM sleep behavior disorder, Sleep, 34, 5, pp. 619-625, (2011); Ferini-Strambi L., Fasiello E., Sforza M., Salsone M., Galbiati A., Neuropsychological, electrophysiological, and neuroimaging biomarkers for REM behavior disorder, Expert Review of Neurotherapeutics, 19, 11, pp. 1069-1087, (2019); Flicker C., Ferris S.H., Reisberg B., Mild cognitive impairment in the elderly: Predictors of dementia, Neurology, 41, 7, pp. 1006-1009, (1991); Gilman S., Wenning G.K., Low P.A., Brooks D.J., Mathias C.J., Trojanowski J.Q., Wood N.W., Colosimo C., Durr A., Fowler C.J., Kaufmann H., Klockgether T., Lees A., Poewe W., Quinn N., Revesz T., Robertson D., Sandroni P., Seppi K., Vidailhet M., Second consensus statement on the diagnosis of multiple system atrophy, Neurology, 71, 9, pp. 670-676, (2008); Gliebus G.P., Memory dysfunction, CONTINUUM Lifelong Learning in Neurology, 24, pp. 727-744, (2018); Harvey P.D., Domains of cognition and their assessment, Dialogues in Clinical Neuroscience, 21, 3, pp. 227-237, (2019); Howell M.J., Rapid eye movement sleep behavior disorder and other rapid eye movement parasomnias, Continuum (Minneapolis, Minn.), 26, 4, pp. 929-945, (2020); Hughes A.J., Daniel S.E., Kilford L., Lees A.J., Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A Clinico-pathological study of 100 cases, Journal of Neurology, Neurosurgery, and Psychiatry, 55, 3, pp. 181-184, (1992); Iranzo A., Marrero-Gonzalez P., Serradell M., Gaig C., Santamaria J., Vilaseca I., Significance of hyposmia in isolated REM sleep behavior disorder, Journal of Neurology, 268, 3, pp. 963-966, (2021); Iranzo A., Molinuevo J.L., Santamaria J., Serradell M., Marti M.J., Valldeoriola F., Tolosa E., Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: A descriptive study, Lancet Neurology, 5, 7, pp. 572-577, (2006); Iranzo A., Santamaria J., Valldeoriola F., Serradell M., Salamero M., Gaig C., Ninerola-Baizan A., Sanchez-Valle R., Llado A., De Marzi R., Stefani A., Seppi K., Pavia J., Hogl B., Poewe W., Tolosa E., Lomena F., Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder, Annals of Neurology, 82, 3, pp. 419-428, (2017); Iranzo A., Tolosa E., Gelpi E., Molinuevo J.L., Valldeoriola F., Serradell M., Sanchez-Valle R., Vilaseca I., Lomena F., Vilas D., Llado A., Gaig C., Santamaria J., Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study, The Lancet Neurology, 12, 5, pp. 443-453, (2013); Jak A.J., Bondi M.W., Delano-Wood L., Wierenga C., Corey-Bloom J., Salmon D.P., Delis D.C., Quantification of five neuropsychological approaches to defining mild cognitive impairment, The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 17, 5, pp. 368-375, (2009); Jak A.J., Urban S., McCauley A., Bangen K.J., Delano-Wood L., Corey-Bloom J., Bondi M.W., Profile of hippocampal volumes and stroke risk varies by neuropsychological definition of mild cognitive impairment, Journal of the International Neuropsychological Society, 15, 6, pp. 890-897, (2009); Li Y., Zhang H., Mao W., Liu X., Hao S., Zhou Y., Ma J., Zhuqin G., Chan P., Visual dysfunction in patients with idiopathic rapid eye movement sleep behavior disorder, Neuroscience Letters, 709, June, (2019); Litvan I., Goldman J.G., Troster A.I., Schmand B.A., Weintraub D., Petersen R.C., Mollenhauer B., Adler C.H., Marder K., Williams-Gray C.H., Aarsland D., Kulisevsky J., Rodriguez-Oroz M.C., Burn D.J., Barker R.A., Emre M., Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines, Movement Disorders, 27, 3, pp. 349-356, (2012); Llinas-Regla J., Vilalta-Franch J., Lopez-Pousa S., Calvo-Perxas L., Rodas D.T., Garre-Olmo J., The trail making test: Association with other neuropsychological measures and normative values for adults aged 55 years and older from a Spanish-speaking population-based sample, Assessment, 24, 2, pp. 183-196, (2017); Marchand D.G., Montplaisir J., Postuma R.B., Rahayel S., Gagnon J.F., Detecting the cognitive prodrome of dementia with Lewy bodies: A prospective study of REM sleep behavior disorder, Sleep, 40, 1, (2017); Marchand G., Daphne R.B., Postuma F.E., De Roy J., Pelletier A., Montplaisir J., Gagnon J.F., How does dementia with Lewy bodies start? Prodromal cognitive changes in REM sleep behavior disorder, Annals of Neurology, 83, 5, pp. 1016-1026, (2018); Martini A., Weis L., Schifano R., Pistonesi F., Fiorenzato E., Antonini A., Biundo R., Differences in cognitive profiles between Lewy body and Parkinson's disease dementia, Journal of Neural Transmission, 127, 3, pp. 323-330, (2020); McKeith I.G., Boeve B.F., Dickson D.W., Halliday G., Taylor J.-P., Weintraub D., Aarsland D., Galvin J., Attems J., Ballard C.G., Bayston A., Beach T.G., Blanc F., Bohnen N., Bonanni L., Bras J., Brundin P., Burn D., Chen-Plotkin A., Kosaka K., Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium, Neurology, 89, 1, pp. 88-100, (2017); Molano J., Boeve B., Ferman T., Smith G., Parisi J., Dickson D., Knopman D., Graff-Radford N., Geda Y., Lucas J., Kantarci K., Shiung M., Jack C., Silber M., Pankratz V.S., Petersen R., Mild cognitive impairment associated with limbic and neocortical Lewy body disease: A clinicopathological study, Brain, 133, 2, pp. 540-556, (2010); Natale E.R.D., Wilson H., Politis M., Predictors of RBD progression and conversion to synucleinopathies, Current Neurology and Neuroscience Reports, 22, 2, pp. 93-104, (2022); Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., Chou R., Glanville J., Grimshaw J.M., Hrobjartsson A., Lalu M.M., Li T., Loder E.W., Mayo-Wilson E., McDonald S., Moher D., The PRISMA 2020 statement: An updated guideline for reporting systematic reviews, BMJ, 29, 372, (2021); Payne S., Shofer J.B., Shutes-David A., Li G., Jankowski A., Dean P., Tsuang D., Correlates of conversion from mild cognitive impairment to dementia with Lewy bodies: Data from the National Alzheimer's coordinating center, Journal of Alzheimer's Disease, 86, 4, pp. 1643-1654, (2022); Perianez J.A., Lubrini G., Garcia-Gutierrez A., Rios-Lago M., Construct validity of the sroop color-word test: Influence of speed of visual search, verbal fluency, working memory, cognitive flexibility, and conflict monitoring, Archives of Clinical Neuropsychology, 36, 1, pp. 99-111, (2021); Petersen R.C., Mild cognitive impairment as a diagnostic entity, Journal of Internal Medicine, 256, 3, pp. 183-194, (2004); Petersen R.C., Morris J.C., Mild cognitive impairment as a clinical entity and treatment target, Archives of Neurology, 62, 7, pp. 1160-1163, (2005); Possin K.L., Visual spatial cognition in neurodegenerative disease, Neurocase, 16, 6, pp. 466-487, (2010); Postuma R.B., Gagnon J.F., Vendette M., Montplaisir J.Y., Idiopathic REM sleep behavior disorder in the transition to degenerative disease, Movement Disorders, 24, 15, pp. 2225-2232, (2009); Postuma R.B., Iranzo A., Michele H., Hogl B., Boeve B.F., Manni R., Oertel W.H., Arnulf I., Ferini-Strambi L., Puligheddu M., Antelmi E., De Cock V.C., Arnaldi D., Mollenhauer B., Videnovic A., Sonka K., Jung K.-Y., Kunz D., Dauvilliers Y., Pelletier A., Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study, Brain, 142, 3, pp. 744-759, (2019); Rey A., L'examen Psychologique Dans Les Cas d'encéphalopathie Traumatique.(Les Problems.), Archives de Psychologie, 28, pp. 215-285, (1941); Richardson J.D., Dalton S.G., Assessment of language impairment and function, Handbook of Clinical Neurology, 185, pp. 175-193, (2022); Roascio M., Canessa A., Tro R., Mattioli P., Fama F., Giorgetti L., Girtler N., Orso B., Morbelli S., Nobili F., Arnaldi D., Arnulfo G., Phase and amplitude electroencephalography correlations change with disease progression in people with idiopathic rapid eye-movement sleep behavior disorder, Sleep, 45, 1, pp. 1-9, (2022); Rocchi C., Placidi F., Liguori C., Del Bianco C., Lauretti B., Diomedi M., Pisani A., Mercuri N.B., Izzi F., Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: A preliminary study, Sleep Medicine, 52, pp. 163-167, (2018); Rofes A., de Aguiar V., Jonkers R., Se Jin O., DeDe G., Sung J.E., What drives task performance during animal fluency in people with Alzheimer's disease?, Frontiers in Psychology, 11, July, pp. 1-11, (2020); Sakurai H., Hanyu H., Inoue Y., Kanetaka H., Nakamura M., Miyamoto T., Sasai T., Iwamoto T., Longitudinal study of regional cerebral blood flow in elderly patients with idiopathic rapid eye movement sleep behavior disorder, Geriatrics and Gerontology International, 14, 1, pp. 115-120, (2014); Shin C., Lee J.Y., Kim Y.K., Nam H., Yoon E.J., Shin S.A., Kim H.J., Jeon B., Cognitive decline in association with hyposmia in idiopathic rapid eye movement sleep behavior disorder: A prospective 2-year follow-up study, European Journal of Neurology, 26, 11, pp. 1417-1420, (2019); Shin J.H., Lee J.Y., Kim Y.K., Yoon E.J., Kim H., Nam H., Jeon B., Parkinson disease-related brain metabolic patterns and neurodegeneration in isolated REM sleep behavior disorder, Neurology, 97, 4, pp. e378-e388, (2021); Shin M.S., Park S.Y., Park S.R., Seol S.H., Kwon J.S., Clinical and empirical applications of the Rey-Osterrieth complex figure test, Nature Protocols, 1, 2, pp. 892-899, (2006); Sumi Y., Ubara A., Ozeki Y., Kadotani H., Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study, Acta Neurologica Scandinavica, 145, 3, pp. 348-359, (2022); Terzaghi M., Pilati L., Ghiotto N., Arnaldi D., Versino M., Rustioni V., Rustioni G., Sartori I., Manni R., Twenty-four-hour blood pressure profile in idiopathic REM sleep behavior disorder, Sleep, 45, 2, (2022); Terzaghi M., Toscano G., Casoni F., Picascia M., Arnaldi D., Rustioni V., Versino M., Sinforiani E., Manni R., Assessment of cognitive profile as a prodromal marker of the evolution of rapid eye movement sleep behavior disorder, Sleep, 42, 8, pp. 1-8, (2019); Terzaghi M., Zucchella C., Rustioni V., Sinforiani E., Manni R., Cognitive performances and mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder: Results of a longitudinal follow-up study, Sleep, 36, 10, pp. 1527-1532, (2013); Wagner S., Sebastian A., Lieb K., Tuscher O., Tadic A., A coordinate-based ALE functional MRI meta-analysis of brain activation during verbal fluency tasks in healthy control subjects, BMC Neuroscience, 15, 1, (2014); Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Backman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Petersen R.C., Mild cognitive impairment - beyond controversies, towards a consensus: Report of the international working group on mild cognitive impairment, Journal of Internal Medicine, 256, 3, pp. 240-246, (2004); Yoo D., Lee J.Y., Kim Y.K., Yoon E.J., Kim H., Kim R., Nam H., Jeon B., Mild cognitive impairment and abnormal brain metabolic expression in idiopathic REM sleep behavior disorder, Parkinsonism and Related Disorders, 90, pp. 1-7, (2021); Yoon E.J., Lee J.-Y., Kim H., Yoo D., Shin J.H., Nam H., Jeon B., Kim Y.K., Brain metabolism related to mild cognitive impairment and Phenoconversion in patients with isolated REM sleep behavior disorder, Neurology, 98, 24, (2022); Youn S., Kim T., Yoon I.Y., Jeong J., Kim H.Y., Han J.W., Kim J.M., Kim K.W., Progression of cognitive impairments in idiopathic REM sleep behaviour disorder, Journal of Neurology, Neurosurgery and Psychiatry, 87, 8, pp. 890-896, (2016)","2-s2.0-85150975586"
"Perani D.; Cerami C.; Caminiti S.P.; Santangelo R.; Coppi E.; Ferrari L.; Pinto P.; Passerini G.; Falini A.; Iannaccone S.; Cappa S.F.; Comi G.; Gianolli L.; Magnani G.","Perani, Daniela (7005630261); Cerami, Chiara (25722905400); Caminiti, Silvia Paola (56584243600); Santangelo, Roberto (57191567809); Coppi, Elisabetta (56370374600); Ferrari, Laura (55937899700); Pinto, Patrizia (33867729800); Passerini, Gabriella (36612171900); Falini, Andrea (7003494994); Iannaccone, Sandro (7005943171); Cappa, Stefano Francesco (7005836132); Comi, Giancarlo (7201788288); Gianolli, Luigi (6602754456); Magnani, Giuseppe (24496141800)","7005630261; 25722905400; 56584243600; 57191567809; 56370374600; 55937899700; 33867729800; 36612171900; 7003494994; 7005943171; 7005836132; 7201788288; 6602754456; 24496141800","Erratum to: Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting (European Journal of Nuclear Medicine and Molecular Imaging, 10.1007/s00259-015-3170-y)","2016","European Journal of Nuclear Medicine and Molecular Imaging","43","1","","202","203","1","3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84951907264&doi=10.1007%2fs00259-015-3205-4&partnerID=40&md5=2ddd50c2b6395b3fcef7ec9c1125b705","[No abstract available]","","Erratum; error","","2-s2.0-84951907264"
"Realmuto S.; Zummo L.; Cerami C.; Agrò L.; Dodich A.; Canessa N.; Zizzo A.; Fierro B.; Daniele O.","Realmuto, Sabrina (42462180200); Zummo, Leila (35739511800); Cerami, Chiara (25722905400); Agrò, Luigi (57193926265); Dodich, Alessandra (56001713900); Canessa, Nicola (24334215800); Zizzo, Andrea (57190030168); Fierro, Brigida (7007039157); Daniele, Ornella (56214566700)","42462180200; 35739511800; 25722905400; 57193926265; 56001713900; 24334215800; 57190030168; 7007039157; 56214566700","Social cognition dysfunctions in patients with epilepsy: Evidence from patients with temporal lobe and idiopathic generalized epilepsies","2015","Epilepsy and Behavior","47","","","98","103","5","49","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937637752&doi=10.1016%2fj.yebeh.2015.04.048&partnerID=40&md5=5abd6e3ebe7ece56d01b8388eaf37632","Background and aim: Despite an extensive literature on cognitive impairments in focal and generalized epilepsy, only a few number of studies specifically explored social cognition disorders in epilepsy syndromes. The aim of our study was to investigate social cognition abilities in patients with temporal lobe epilepsy (TLE) and in patients with idiopathic generalized epilepsy (IGE). Materials and methods: Thirty-nine patients (21 patients with TLE and 18 patients with IGE) and 21 matched healthy controls (HCs) were recruited. All subjects underwent a basic neuropsychological battery plus two experimental tasks evaluating emotion recognition from facial expression (Ekman-60-Faces test, Ek-60F) and mental state attribution (Story-based Empathy Task, SET). In particular, the latter is a newly developed task that assesses the ability to infer others' intentions (i.e., intention attribution - IA) and emotions (i.e., emotion attribution - EA) compared with a control condition of physical causality (i.e., causal inferences - CI). Results: Compared with HCs, patients with TLE showed significantly lower performances on both social cognition tasks. In particular, all SET subconditions as well as the recognition of negative emotions were significantly impaired in patients with TLE vs. HCs. On the contrary, patients with IGE showed impairments on anger recognition only without any deficit at the SET task. Discussion: Emotion recognition deficits occur in patients with epilepsy, possibly because of a global disruption of a pathway involving frontal, temporal, and limbic regions. Impairments of mental state attribution specifically characterize the neuropsychological profile of patients with TLE in the context of the in-depth temporal dysfunction typical of such patients. Conclusion: Impairments of socioemotional processing have to be considered as part of the neuropsychological assessment in both TLE and IGE in view of a correct management and for future therapeutic interventions. © 2015 Elsevier Inc.","Empathy; Idiopathic generalized epilepsy; Neurobehavioral impairment; Social cognition; Temporal lobe epilepsy","Adult; Cognition; Cognition Disorders; Emotions; Empathy; Epilepsy; Epilepsy, Generalized; Epilepsy, Temporal Lobe; Face; Facial Expression; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Social Behavior; Social Perception; Temporal Lobe; adult; anger; Article; clinical article; controlled study; emotion; facial expression; female; generalized epilepsy; human; male; neuropsychological test; recognition; social cognition; temporal lobe epilepsy; cognition; Cognition Disorders; complication; emotion; empathy; epilepsy; face; generalized epilepsy; middle aged; pathophysiology; perception; physiology; psychology; social behavior; temporal lobe; temporal lobe epilepsy","Helmstaedter C., Witt J.A., Clinical neuropsychology in epilepsy: theoretical and practical issues, Handb Clin Neurol, 107, pp. 437-459, (2012); Jones-Gotman M., Smith M.L., Risse G.L., Westerveld M., Swanson S.J., Giovagnoli A.R., Et al., The contribution of neuropsychology to diagnostic assessment in epilepsy, Epilepsy Behav, 18, pp. 3-12, (2010); McCagh J., Fisk J.E., Baker G.A., Epilepsy, psychosocial and cognitive functioning, Epilepsy Res, 86, pp. 1-14, (2009); Hermann B., Seidenberg M., Neuropsychology and temporal lobe epilepsy, CNS Spectr, 7, pp. 343-348, (2002); Saling M.M., Verbal memory in mesial temporal lobe epilepsy: beyond material specificity, Brain, 132, pp. 570-582, (2009); Hommet C., Suerwein H.C., De Toffol B., Lassonde M., Idiopathic epileptic syndromes and cognition, Neurosci Biobehav Rev, 30, pp. 85-96, (2006); Pavone P., Bianchini R., Trifiletti R.R., Incorpora G., Pavone A., Parano E., Neuropsychological assessment in children with absence epilepsy, Neurology, 56, pp. 1047-1051, (2001); Dikson J.M., Wilkinson I.D., Howell S.J.L., Griffiths P.D., Grunewald R.A., Idiopathic generalised epilepsy: a pilot study of memory and neuronal dysfunction in the temporal lobes, assessed by magnetic resonance spectroscopy, J Neurol Neurosurg Psychiatry, 77, pp. 834-840, (2006); Bailet L.L., Turk W.R., The impact of childhood epilepsy on neurocognitive and behavioral performance: a prospective longitudinal study, Epilepsia, 41, pp. 426-431, (2000); Chowdhury F.A., Elwes R.D.C., Koutroumanidis M., Morris R.G., Nashef L., Richardson M.P., Impaired cognitive function in idiopathic generalized epilepsy and unaffected family members: an epilepsy andophenotype, Epilepsia, 55, pp. 835-840, (2014); Van Overwalle F., Social cognition and the brain: a meta-analysis, Hum Brain Mapp, 30, pp. 829-858, (2009); Gomez-Ibanez A., Urrestarazu E., Viteri C., Recognition of facial emotions and identity in patients with mesial temporal lobe and idiopathic generalized epilepsy: an eye-tracking study, Seizure, 23, pp. 892-898, (2014); Reynders H.J., Broks P., Dickson J.M., Lee C.E., Turpin G., Investigation of social and emotion information processing in temporal lobe epilepsy with ictal fear, Epilepsy Behav, 7, pp. 419-429, (2005); Meletti S., Benuzzi F., Cantalupo G., Rubboli G., Tassinari C.A., Nichelli P., Impaired facial emotion recognition impairment in early-onset right mesial temporal lobe epilepsy, Neurology, 60, pp. 426-431, (2003); Schacher M., Winkler R., Grunwald T., Kraemer G., Kurthen M., Reed V., Et al., Mesial temporal lobe epilepsy impairs advanced social cognition, Epilepsia, 47, pp. 2141-2146, (2006); Giovagnoli A.R., Franceschetti S., Reati F., Parente A., Maccagnano C., Villani F., Et al., Theory of mind in frontal and temporal lobe epilepsy: cognitive and neural aspects, Epilepsia, 52, pp. 1995-2002, (2011); Li Y.H., Chiu M.J., Yeh Z.T., Liou H.L., Cheng T.W., Hua M.S., Theory of mind in patients with temporal lobe epilepsy, J Int Neuropsychol, 19, pp. 594-600, (2013); Broicher S.D., Kuchukhidze G., Grunwald T., Kramer G., Kurthen M., Jokeit H., Tell me how do I feel"" - emotion recognition and theory of mind in symptomatic mesial temporal lobe epilepsy, Neuropsychologia, 50, pp. 118-128, (2012); Hennion S., Delbeuck X., Duhamel A., Lopes R., Semah F., Tyvaert L., Et al., Characterization and prediction of theory of mind disorders in temporal lobe epilepsy, Neuropsychology, 29, pp. 485-492, (2015); Cohn M., St-Laurent M., Barnett A., McAndrews M.P., Social inference deficits in temporal lobe epilepsy and lobectomy: risk factors and neural substrates, Soc Cogn Affect Neurosci, 10, pp. 636-644, (2015); Stone V.E., Baron-Cohen S., Calder A., Keane J., Young A., Acquired theory of mind impairments in individuals with bilateral amygdala lesions, Neuropsychologia, 41, pp. 209-220, (2003); Shaw P., Lawrence E., Bramham J., Brierley B., Radbourne C., David A.S., A prospective study of the effects of anterior temporal lobectomy on emotion recognition and theory of mind, Neuropsychologia, 45, pp. 2783-2790, (2007); Brierley B., Medford N., Shaw P., David A.S., Emotional memory and perception in temporal lobectomy patients with amygdala damage, J Neurol Neurosurg Psychiatry, 75, pp. 593-599, (2004); Jiang Y., Hu Y., Wang Y., Zhou N., Zhu L., Wang K., Empathy and emotion recognition in patients with idiopathic generalized epilepsy, Epilepsy Behav, 37C, pp. 139-144, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: a normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci, 35, pp. 1015-1021, (2014); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Et al., Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study, Amyotroph Lateral Scler Frontotemporal Degener, 15, pp. 21-29, (2014); Riederer F., Lanzeberger R., Kaya M., Prayer D., Serles W., Baumgartner C., Network atrophy in temporal lobe epilepsy: a voxel based morphometry study, Neurology, 71, pp. 419-425, (2008); Keller S.S., Mackay C.E., Barrick T.R., Wieshmann U.C., Howard M.A., Roberts N., Voxel based morphometric comparison of hippocampal and extrahippocampal abnormalities in patients with left and right hippocampal atrophy, Neuroimage, 16, pp. 23-31, (2002); Berg A.T., Berkovic S.F., Brodie M.J., Buchhalter J., Cross J.H., van Emde B.W., Et al., Revised terminology and concepts for organization of seizures and epilepsies: report of ILAE Commission on Classification and Terminology, 2005-2009, Epilepsia, 51, pp. 676-685, (2010); Engel J., A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology, Epilepsia, 42, pp. 796-803, (2001); Lezak M., Neuropsychological assessment, (1995); De Renzi E., Vignola L.A., The token test: a sensitive test to detect receptive disturbances in aphasics, Brain, 85, pp. 665-678, (1962); Luzzatti C., Willmes K., De-Bleser R., Bianchi A., Chiesa G., De-Tanti A., Et al., New normative data for the Italian version of the Aachen Aphasia Test A.A.T., Arch Psicol Neurol Psichiatr, 55, pp. 1086-1131, (1994); Beck A.T., Steer R.A., Brown G.H., Manual of the Beck Depression Inventory, (1996); Ekman P., Friesen W., Pictures of Facial Affect, (1976); Zeman A., Jones-Gotman M., Kapur N., Epilepsy and Memory, (2012); Oyegbile T.O., Dow C., Jones J., Bell B., Rutecki P., Sheth R., Et al., The nature and course of neuropsychological morbidity in chronic temporal lobe epilepsy, Neurology, 62, pp. 1736-1742, (2004); Bartha-Doering L., Trinka E., The interictal language profile in adult epilepsy, Epilepsy, 55, pp. 1512-1525, (2014); Giovagnoli A.R., Canafoglia L., Reati F., Et al., The neuropsychological pattern of Unverricht-Lundborg disease, Epilepsy Res, 84, pp. 217-223, (2009); Gauffin H., van Ettinger-Veenstra H., Landtblom A.M., Et al., Impaired language function in generalized epilepsy: inadequate suppression of the default mode network, Epilepsy Behav, 28, pp. 26-35, (2013); Jansen J.F., van der Kruijs S.J., Vlooswijk M.C., Majoie H.M., Hofman P.A., Aldenkamp A.P., Et al., Quantitative MR and cognitive impairment in cryptogenic localisation-related epilepsy, Epileptic Disord, 16, pp. 318-327, (2014); Kakeda S., Korogi Y., The efficacy of a voxel-based morphometry on the analysis of imaging in schizophrenia, temporal lobe epilepsy, and Alzheimer's disease/mild cognitive impairment: a review, Neuroradiology, 52, pp. 711-721, (2010); Amodio D.M., Fricht C.D., Meeting of mind: the medial frontal cortex and social cognition, Nat Rev Neurosci, 7, pp. 268-277, (2006); Gallagher H.L., Frith C.D., Functional imaging of 'theory of mind, Trends Cogn Sci, 7, pp. 77-83, (2003); Carrington S.J., Bailey A.J., Are the theory of mind regions in the brain? A review of the neuroimaging literature, Hum Brain Mapp, 30, pp. 2313-2335, (2009); Van Overwalle F., Baetens K., Understanding other's actions and goals by mirror and mentalizing systems: a meta-analysis, Neuroimage, 48, pp. 564-584, (2009); Alexander R.P., Concha L., Snyder T.J., Beaulieu C., Gross D.W., Correlations between limbic white matter and cognitive functions in temporal lobe epilepsy, preliminary findings, Front Aging Neurosci, 6, (2014); Liu T.T., He Z.G., Tian X.B., Xiang H.B., Neural mechanisms and potential treatment of epilepsy and its complications, Am J Transl Res, 6, pp. 625-630, (2014); Adolphs R., The social brain: neural basis of social knowledge, Annu Rev Psychol, 60, (2009); Fusar-Poli P., Placentino A., Carletti F., Landi P., Allen P., Surguladze S., Et al., Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies, J Psychiatry Neurosci, 34, pp. 418-432, (2009); Morris J.S., Frith C.D., Perret D.I., Rowland D., Young A.W., Calder A.J., Et al., A differential neural response in the human amygdala to fearful and happy facial expression, Nature, 383, pp. 812-815, (1996); Richardson M.P., Current themes in neuroimaging of epilepsy: brain networks, dynamic phenomena, and clinical relevance, Clin Neurophysiol, 121, pp. 1153-1175, (2010); Adolphs R., Neural system for recognizing emotion, Curr Opin Neurobiol, 12, pp. 169-177, (2002); Harmer C.J., Thilo K.V., Rothwell G.J., Goodwin G.M., Transcranial magnetic stimulation of medial-frontal cortex impairs the processing of angry facial expression, Nat Neurosci, 4, pp. 17-18, (2001); Blair R.J.R., Morris J.S., Frith C.D., Perret D.I., Dolan R.J., Dissociable neural responses to facial expression of sadness and anger, Brain, 122, pp. 883-893, (1999); Meletti S., Benuzzi F., Cantalupo G., Rubboli G., Tassinari C.A., Nichelli P., Facial emotion recognition impairment in chronic temporal lobe epilepsy, Epilepsia, 50, pp. 1547-1559, (2009); Walpole P., Isaac C.L., Reynders H.J., A comparison of emotional and cognitive intelligence in people with and without temporal lobe epilepsy, Epilepsia, 49, pp. 1470-1474, (2008); Cristinzio C., N'Diaye K., Seeck M., Vuilleumier P., Sander D., Integration of gaze direction and facial expression in patients with unilateral amygdala damage, Brain, 133, pp. 248-261, (2010); Torralva T., Roca M., Gleichgerrcht E., Bekinschtein T., Manes F., A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia, Brain, 132, pp. 1299-1309, (2009); Langenecker S.A., Bieliauskas L.A., Rapport L.J., Zubieta J.K., Wilde E.A., Berent S., Face emotion perception and executive functioning deficits in depression, J Clin Exp Neuropsychol, 27, pp. 320-333, (2005); Kerns J.G., Cohen J.D., Stenger V.A., Carter C.S., Prefrontal cortex guides context-appropriate responding during language production, Neuron, 43, pp. 283-291, (2004); Miller E.K., Cohen J.D., An integrative theory of prefrontal cortex function, Annu Rev Neurosci, 24, pp. 167-202, (2001); Greene J.D., Nystrom L.E., Engell A.D., Darley J.M., Cohen J.D., The neural bases of cognitive conflict and control in moral judgment, Neuron, 44, pp. 389-400, (2004); Saxe R., Schulz L.E., Jiang Y.V., Reading minds versus following rules: dissociating theory of mind and executive control in the brain, Soc Neurosci, 1, pp. 284-298, (2006); Bodden M.E., Kubler D., Knake S., Menzler K., Heverhagen J.T., Sommer J., Et al., Comparing the neural correlates of affective and cognitive theory of mind using fMRI: involvement of the basal ganglia in affective theory of mind, Adv Cogn Psychol, 9, pp. 32-43, (2013); Vollm B.A., Taylor A.N., Richardson P., Corcoran R., Stirling J., McKie S., Et al., Neural correlates of the theory of mind and empathy: a functional magnetic resonance imaging study in nonverbal task, Neuroimage, 29, pp. 90-98, (2006); Aichhorn M., Perner J., Kronbichler M., Staffen W., Ladurner G., Do visual perspective tasks need theory of mind?, Neuroimage, 30, pp. 1059-1068, (2006); Giovagnoli A.R., Meneses R.F., da Silva A.M., The contribution of spirituality to quality of life in focal epilepsy, Epilepsy Behav, 9, pp. 133-139, (2006); Hermann B.P., Seidenberg M., Bell B., Woodard A., Rutecki P., Sheth R., Comorbid psychiatric symptoms in temporal lobe epilepsy: association with chronicity of epilepsy and impact on quality of life, Epilepsy Behav, 1, pp. 184-190, (2000); Giovagnoli A.R., Parente A., Tarallo A., Casazza M., Franceschetti S., Avanzini G., Self-rated and assessed cognitive functions in epilepsy: impact on quality of life, Epilepsy Res, 108, pp. 1461-1468, (2014); Giovagnoli A.R., Parente A., Villani F., Franceschetti S., Spreafico R., Theory of mind and epilepsy: what clinical implications?, Epilepsia, 54, pp. 1639-1646, (2013)","2-s2.0-84937637752"
"Cerami C.; Dubois B.; Boccardi M.; Monsch A.U.; Demonet J.F.; Cappa S.F.","Cerami, Chiara (25722905400); Dubois, Bruno (7101841106); Boccardi, Marina (6507801629); Monsch, Andreas U. (7003427149); Demonet, Jean Francois (7005727609); Cappa, Stefano F. (7005836132)","25722905400; 7101841106; 6507801629; 7003427149; 7005727609; 7005836132","Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework","2017","Neurobiology of Aging","52","","","153","166","13","48","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85015417329&doi=10.1016%2fj.neurobiolaging.2016.03.034&partnerID=40&md5=4856926e637dff07f73c7f1a1a55529a","Although Alzheimer's disease criteria promote the use of biomarkers, their maturity in clinical routine still needs to be assessed. In the light of the oncology framework, we conducted a literature review on measures used to assess delayed recall impairment due to medial temporal lobe dysfunction (i.e., free and cued word list recall tests). Ample evidence is available for phases 1 (rationale for use), 2 (discriminative ability), and 3 (early detection ability) for many of the tests in routine use. Evidence about phase 4 (performance in real world) and phase 5 (quantify impact and costs) is yet to come. Administration procedures have been standardized and cutoff scores are well validated in large Alzheimer's disease and mild cognitive impaired series. Some aspects (e.g., different task formats), however, hamper the comparability of results among different populations and the reproducibility between laboratories. No definite guideline for their use can thus be proposed at the moment. Accordingly, the maturity of such markers is not yet sufficient and requires future investigation to promote the proper use of memory measures in clinical settings. © 2016 Elsevier Inc.","5-Phases; Alzheimer's disease; Biomarker development; Biomarker-based diagnosis; Cued recall tasks; Delayed recall; Early diagnosis; Episodic memory; Free word list tests; Mild cognitive impairment","Alzheimer Disease; Biomarkers; Cognitive Dysfunction; Cues; Early Diagnosis; Humans; Memory, Episodic; Mental Recall; Neuropsychological Tests; Reproducibility of Results; Temporal Lobe; biological marker; Alzheimer disease; cerebrospinal fluid; cognition; controlled study; differential diagnosis; disease severity; early diagnosis; human; nuclear magnetic resonance imaging; pathophysiology; positron emission tomography; recall; reproducibility; Review; Rey auditory verbal learning test; scoring system; temporal lobe; validity; Alzheimer disease; association; cognitive defect; episodic memory; neuropsychological test; psychology; recall","Abdulrab K., Heun R., Subjective memory impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria, Eur. Psychiatry, 23, pp. 321-330, (2008); Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, pp. 270-279, (2011); Allan C.L., Ebmeier K.P., The influence of ApoE4 on clinical progression of dementia: a meta-analysis, Int. J. Geriatr. Psychiatry, 26, pp. 520-526, (2011); Diagnostic and Statistical Manual of Mental Disorders IV-TR, (2000); Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Cappa S., Lenz O., Ludecke S., Marcone A., Mielke R., Ortelli P., Padovani A., Pelati O., Pupi A., Scarpini E., Weisenbach S., Herholz K., Salmon E., Holthoff V., Sorbi S., Fazio F., Perani D., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Arch. Neurol., 62, pp. 1728-1733, (2005); Auriacombe S., Helmer C., Amieva H., Berr C., Dubois B., Dartigues J.F., Validity of the free and cued selective reminding test in predicting dementia: the 3C study, Neurology, 74, pp. 1760-1777, (2010); Backman L., Jones S., Berger A.K., Laukka E.J., Small B.J., Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis, Neuropsychology, 19, pp. 520-531, (2005); Banerjee S., Willis R., Matthews D., Contell F., Chan J., Murray J., Improving the quality of care for mild to moderate dementia: an evaluation of the Croydon Memory Service Model, Int. J. Geriatr. Psychiatry, 22, pp. 782-788, (2007); Banerjee S., Wittenberg R., Clinical and cost effectiveness of services for early diagnosis and intervention in dementia, Int. J. Geriatr. Psychiatry, 24, pp. 748-754, (2009); Barbeau E., Didic M., Tramoni E., Felician O., Joubert S., Sontheimer A., Ceccaldi M., Poncet M., Evaluation of visual recognition memory in MCI patients, Neurology, 62, pp. 1317-1322, (2004); Barbeau E.J., Ranjeva J.P., Didic M., Confort-Gouny S., Felician O., Soulier E., Cozzone P.J., Ceccaldi M., Poncet M., Profile of memory impairment and gray matter loss in amnestic mild cognitive impairment, Neuropsychologia, 46, pp. 1009-1019, (2008); Beck I.R., Gagneux-Zurbriggen A., Berres M., Taylor K.I., Monsch A.U., Comparison of verbal episodic memory measures: Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT), Arch. Clin. Neuropsychol., 27, pp. 510-519, (2012); Belleville S., Gauthier S., Lepage E., Kergoat M.J., Gilbert B., Predicting decline in mild cognitive impairment: a prospective cognitive study, Neuropsychology, 28, pp. 643-652, (2014); Bennett D.A., Wilson R.S., Schneider J.A., Evans D.A., Beckett L.A., Aggarwal N.T., Barnes L.L., Fox J.H., Bach J., Natural history of mild cognitive impairment in older persons, Neurology, 59, pp. 198-205, (2002); Berrios G.E., Markova I.S., Girala N., Functional memory complaints: hypochondria and disorganization, Memory disorders in psychiatric practice, pp. 384-399, (2000); Boccardi M., Gallo V., Yutaka Y., Vineis P., Padovani A., Mosimann U., Giannakopoulos P., Gold G., Dubois B., Jack C.R., Winblad B., Frisoni G.B., Albanese E., The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers, The Biomarker-based Diagnosis of Alzheimer's Disease, 2 – Lessons From Oncology, Neurobiol. Aging, 52, pp. 141-152, (2017); Braak H., Braak E., Neuropathological staging of Alzheimer-related changes, Acta Neuropathol., 82, pp. 239-259, (1991); Brandt J., Benedict R.H.B., Hopkins Verbal Learning Test—Revised, (2001); Bruscoli M., Lovestone S., Is MCI really just early dementia? a systematic review of conversion studies, Int. Psychogeriatr., 16, pp. 129-140, (2004); Buschke H., Cued recall in amnesia, J. Clin. Neuropsychol., 6, pp. 433-440, (1984); Buschke H., Sliwinski M.J., Kuslansky G., Lipton R.B., Diagnosis of early dementia by the Double Memory Test: encoding specificity improves diagnostic sensitivity and specificity, Neurology, 48, pp. 989-997, (1997); Chang Y.L., Bondi M.W., Fennema-Notestine C., McEvoy L.K., Hagler D.J., Jacobson M.W., Dale A.M., Brain substrates of learning and retention in mild cognitive impairment diagnosis and progression to Alzheimer's disease, Neuropsychologia, 48, pp. 1237-1247, (2010); Chetelat G., Eustache F., Viader F., De La Sayette V., Pelerin A., Mezenge F., Hannequin D., Dupuy B., Baron J.C., Desgranges B., FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment, Neurocase, 11, pp. 14-25, (2005); Chiotis K., Saint-Aubert L., Boccardi M., Gietl A., Picco A., Varrone A., Garibotto V., Herholz K., Nobili F., Nordberg A., The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers, Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol, Aging, 52, pp. 214-227, (2017); Crane P.K., Carle A., Gibbons L.E., Insel P., Mackin R.S., Gross A., Jones R.N., Mukherjee S., Curtis S.M., Harvey D., Weiner M., Mungas D., Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI), Brain Imaging Behav., 6, pp. 502-516, (2012); Crossen J.R., Wiens A.N., Comparison of the Auditory-Verbal Learning Test (AVLT) and California Verbal Learning Test (CVLT) in a sample of normal subjects, J. Clin. Exp. Neuropsychol., 16, pp. 190-194, (1994); Delgado C., Munoz-Neira C., Soto A., Martinez M., Henriquez F., Flores P., Slachevsky A., Comparison of the psychometric properties of the “word” and “picture” versions of the free and cued selective reminding test in a Spanish-speaking cohort of patients with mild Alzheimer's disease and cognitively healthy controls, Arch. Clin. Neuropsychol., 31, pp. 165-175, (2016); Delis D.C., Kramer J.H., Kaplan E., Ober B.A., The California Verbal Learning Test, (1987); Delis D.C., Kramer J.H., Kaplan E., Ober B.A., The California Verbal Learning Test, (2000); Derby C.A., Burns L.C., Wang C., Katz M.J., Zimmerman M.E., L'italien G., Guo Z., Berman R.M., Lipton R.B., Screening for predementia AD: time-dependent operating characteristics of episodic memory tests, Neurology, 80, pp. 1307-1314, (2013); Devanand D.P., Pradhaban G., Liu X., Khandji A., De Santi S., Segal S., Rusinek H., Pelton G.H., Honig L.S., Mayeux R., Stern Y., Tabert M.H., de Leon M.J., Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease, Neurology, 68, pp. 828-836, (2007); Dickerson B.C., Eichenbaum H., The episodic memory system: neurocircuitry and disorders, Neuropsychopharmacology, 35, pp. 86-104, (2010); Dierckx E., Engelborghs S., De Raedt R., Van Buggenhout M., De Deyn P.P., Verte D., Ponjaert-Kristoffersen I., Verbal cued recall as a predictor of conversion to Alzheimer's disease in mild cognitive impairment, Int. J. Geriatr. Psychiatry, 24, pp. 1094-1100, (2009); Dion M., Potvin O., Belleville S., Ferland G., Renaud M., Bherer L., Joubert S., Vallet G.T., Simard M., Rouleau I., Lecomte S., Macoir J., Hudon C., Normative data for the Rappel libre/Rappel indicé à 16 items (16-item Free and Cued Recall) in the elderly Quebec-French population, Clin. Neuropsychol., 28, pp. S1-S19, (2015); Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol., 6, pp. 734-746, (2007); Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P., Revising the definition of Alzheimer's disease: a new lexicon, Lancet Neurol., 9, pp. 1118-1127, (2010); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M.O., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., de Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol., 13, pp. 614-629, (2014); Eckerstrom C., Olsson E., Bjerke M., Malmgren H., Edman A., Wallin A., Nordlund A., A combination of neuropsychological, neuroimaging, and cerebrospinal fluid markers predicts conversion from mild cognitive impairment to dementia, J. Alzheimers Dis., 36, pp. 421-431, (2013); Eichenbaum H., Cohen N.J., From Conditioning to Conscious Recollection: Memory Systems of the Brain, (2001); Elias M.F., Beiser A., Wolf P.A., Au R., White R.F., D'Agostino R.B., The preclinical phase of Alzheimer disease. A 22-year prospective study of the Framingham cohort, Arch. Neurol., 57, pp. 808-813, (2000); Espinosa A., Alegret M., Valero S., Vinyes-Junque G., Hernandez I., Mauleon A., Rosende-Roca M., Ruiz A., Lopez O., Tarraga L., Boada M., A longitudinal follow-up of 550 mild cognitive impairment patients: evidence for large conversion to dementia rates and detection of major risk factors involved, J. Alzheimers Dis., 34, pp. 769-780, (2013); Estevez-Gonzalez A., Kulisevsky J., Boltes A., Otermin P., Garcia-Sanchez C., Rey verbal learning test is a useful tool for differential diagnosis in the preclinical phase of Alzheimer's disease: comparison with mild cognitive impairment and normal aging, Int. J. Geriatr. Psychiatr., 18, pp. 1021-1028, (2003); Ewers M., Walsh C., Trojanowski J.Q., Shaw L.M., Petersen R.C., Jack C.R., Feldman H.H., Bokde A.L., Alexander G.E., Scheltens P., Vellas B., Dubois B., Weiner M., Hampel H., Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance, Neurobiol. Aging, 33, pp. 1203-1214, (2012); Fleisher A.S., Sowell B.B., Taylor C., Gamst A.C., Petersen R.C., Thal L.J., Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment, Neurology, 68, pp. 1588-1595, (2007); Frasson P., Ghiretti R., Catricala E., Pomati S., Marcone A., Parisi L., Rossini P.M., Cappa S.F., Mariani C., Vanacore N., Clerici F., Free and cued selective reminding test: an Italian normative study, Neurol. Sci., 32, pp. 1057-1062, (2011); Frisoni G.B., Perani D., Bastianello S., Bernardi G., Porteri C., Boccardi M., Cappa S.F., Trabucchi M., Padovani A., A roadmap to the use of biomarkers for the diagnosis of Alzheimer's disease in clinical practice: the Italian inter-societal consensus, Neurobiol, Aging, 52, pp. 119-131, (2017); Gainotti G., Quaranta D., Vita M.G., Marra C., Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer's disease, J. Alzheimers Dis., 38, pp. 481-495, (2014); Gallagher D., Mhaolain A.N., Coen R., Walsh C., Kilroy D., Belinski K., Bruce I., Coakley D., Walsh J.B., Cunningham C., Lawlor B.A., Detecting prodromal Alzheimer's disease in mild cognitive impairment: utility of the CAMCOG and other neuropsychological predictors, Int. J. Geriatr. Psychiatry, 25, pp. 1280-1287, (2010); Garibotto V., Herholz K., Boccardi M., Picco A., Varrone A., Nordberg A., Nobili F., Ratib O., The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers, Maturity of FDG-PET as a biomarker for Alzheimer's disease in the context of a structured 5 –phase development framework, Neurobiol, Aging, 52, pp. 183-195, (2017); Geroldi C., Rossi R., Calvagna C., Testa C., Bresciani L., Binetti G., Zanetti O., Frisoni G.B., Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment, J. Neurol. Neurosurg. Psychiatry, 77, pp. 1219-1222, (2006); Grober E., Buschke H., Genuine memory deficits in dementia, Dev. Neuropsychol., 3, pp. 13-36, (1987); Grober E., Kawas C., Learning and retention in preclinical and early Alzheimer's disease, Psychol. Aging, 12, pp. 183-188, (1997); Grober E., Lipton R.B., Katz M., Sliwinski M., Demographic influences on free and cued selective reminding performance in older persons, J. Clin. Exp. Neuropsychol., 20, pp. 221-226, (1998); Grober E., Lipton R.B., Hall C.B., Crystal H., Memory impairment on free and cued selective reminding predicts dementia, Neurology, 54, pp. 827-832, (2000); Grober E., Sanders A.E., Hall C., Lipton R.B., Free and cued selective reminding identifies very mild dementia in primary care, Alzheimer Dis. Assoc. Disord., 24, pp. 284-290, (2010); Guillozet A.L., Weintraub S., Mash D.C., Mesulam M.M., Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment, Arch. Neurol., 60, pp. 729-736, (2003); Hartley T., Bird C.M., Chan D., Cipolotti L., Husain M., Varga-Khadem F., Burgess N., The hippocampus is required for short term topographical memory in humans, Hippocampus, 17, pp. 34-48, (2007); Heister D., Brewer J.B., Magda S., Blennow K., McEvoy L.K., Predicting MCI outcome with clinically available MRI and CSF biomarkers, Neurology, 77, pp. 1619-1628, (2011); Hornberger M., Piguet O., Graham A.J., Nestor P.J., Hodges J.R., How preserved is episodic memory in behavioral variant frontotemporal dementia?, Neurology, 74, pp. 472-479, (2010); Ivanoiu A., Adam S., Van der Linden M., Salmon E., Juillerat A.C., Mulligan R., Seron X., Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease, J. Neurol., 252, pp. 47-55, (2005); Ivnik R.J., Smith G.E., Lucas J.A., Tangalos E.G., Kokmen E., Petersen R.C., Free and cued selective reminding test: MOANS norms, J. Clin. Exp. Neuropsychol., 19, pp. 676-691, (1997); Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C., 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment, Brain, 131, pp. 665-680, (2008); Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Thies B., Phelps C.H., Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, pp. 257-262, (2011); Jain K.K., Biomarkers of neurological disorders, Applications of Biotechnology in Neurology, pp. 49-53, (2012); Jessen F., Amariglio R.E., van Boxtel M., Breteler M., Ceccaldi M., Chetelat G., Dubois B., Dufouil C., Ellis K.A., van der Flier W.M., Glodzik L., van Harten A.C., de Leon M.J., McHugh P., Mielke M.M., Molinuevo J.L., Mosconi L., Osorio R.S., Perrotin A., Petersen R.C., Rabin L.A., Rami L., Reisberg B., Rentz D.M., Sachdev P.S., de la Sayette V., Saykin A.J., Scheltens P., Shulman M.B., Slavin M.J., Sperling R.A., Stewart R., Uspenskaya O., Vellas B., Visser P.J., Wagner M., A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease, Alzheimers Dement., 10, pp. 844-852, (2014); Kaiser N.C., Melrose R.J., Liu C., Sultzer D.L., Jimenez E., Su M., Monserratt L., Mendez M.F., Neuropsychological and neuroimaging markers in early versus late-onset Alzheimer's disease, Am. J. Alzheimers Dis. Other Demen., 27, pp. 520-529, (2012); Kalpouzos G., Eustache F., de la Sayette V., Viader F., Chetelat G., Desgranges B., Working memory and FDG-PET dissociate early and late onset Alzheimer disease patients, J. Neurol., 252, pp. 548-558, (2005); Kim S.H., Seo S.W., Yoon D.S., Chin J., Lee B.H., Cheong H.K., Han S.H., Na D.L., Comparison of neuropsychological and FDG-PET findings between early- versus late-onset mild cognitive impairment: a five-year longitudinal study, Dement. Geriatr. Cogn. Disord., 29, pp. 213-223, (2010); Koric L., Ranjeva J.P., Felician O., Guye M., de Anna F., Soulier E., Didic M., Ceccaldi M., Cued recall measure predicts the progression of gray matter atrophy in patients with amnesic mild cognitive impairment, Dement Geriatr. Cogn. Disord., 36, pp. 197-210, (2013); Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R., Weiner M.W., Jagust W.J., Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, pp. 230-238, (2010); Lekeu F., Van der Linden M., Chicherio C., Collette F., Degueldre C., Franck G., Moonen G., Salmon E., Brain correlates of performance in a free/cued recall task with semantic encoding in Alzheimer disease, Alzheimer Dis. Assoc. Disord., 17, pp. 35-45, (2003); Lemos R., Simoes M.R., Santiago B., Santana I., The free and cued selective reminding test: validation for mild cognitive impairment and Alzheimer's disease, J. Neuropsychol., 9, pp. 242-257, (2015); Li J.Q., Tan L., Wang H.F., Tan M.S., Tan L., Xu W., Zhao Q.F., Wang J., Jiang T., Yu J.T., Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: a systematic review and meta-analysis of cohort studies, J. Neurol. Neurosurg. Psychiatry, 87, pp. 476-484, (2016); Locascio J.J., Growdon J.H., Corkin S., Cognitive test performance in detecting, staging, and tracking Alzheimer's disease, Arch. Neurol., 52, pp. 1087-1099, (1995); Lojo-Seoane C., Facal D., Guardia-Olmos J., Juncos-Rabadan O., Structural model for estimating the influence of cognitive reserve on cognitive performance in adults with subjective memory complaints, Arch. Clin. Neuropsychol., 29, pp. 245-255, (2014); Lowndes G., Savage G., Early detection of memory impairment in Alzheimer's disease: a neurocognitive perspective on assessment, Neuropsychol. Rev., 17, pp. 193-202, (2007); Marra C., Gainotti G., Fadda L., Perri R., Lacidogna G., Scaricamazza E., Piccininni C., Quaranta D., Usefulness of an integrated analysis of different memory tasks to predict the progression from mild cognitive impairment to Alzheimer's disease: the episodic memory score (EMS), J. Alzheimers Dis., 50, pp. 61-70, (2015); Martin S., Kelly S., Khan A., Cullum S., Dening T., Rait G., Fox C., Katona C., Cosco T., Brayne C., Lafortune L., Attitudes and preferences towards screening for dementia: a systematic review of the literature, BMC Geriatr., 15, (2015); Maruta C., Guerreiro M., de Mendonca A., Hort J., Scheltens P., The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia, Eur. J. Neurol., 18, pp. 279-285, (2011); Mattson N., Lonneborg A., Boccardi M., Blennow K., Hansson O., The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers, Maturity of Aβ42, tau, and phospho-tau in the cerebrospinal fluid as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol, Aging, 52, pp. 196-213, (2017); McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, pp. 939-944, (1984); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, pp. 263-269, (2011); Meltzer J.A., Constable R.T., Activation of human hippocampal formation reflects success in both encoding and cued recall of paired associates, Neuroimage, 24, pp. 384-397, (2005); Mistridis P., Egli S.C., Iverson G.L., Berres M., Willmes K., Welsh-Bohmer K.A., Monsch A.U., Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB), Eur. Arch. Psychiatry Clin. Neurosci., 265, pp. 407-417, (2015); Mitchell A.J., A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment, J. Psychiatr. Res., 43, pp. 411-431, (2009); Mitchell J., Arnold R., Dawson K., Nestor P.J., Hodges J.R., Outcome in subgroups of mild cognitive impairment (MCI) is highly predictable using a simple algorithm, J. Neurol., 256, pp. 1500-1509, (2009); Modrego P.J., Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment, Curr. Alzheimer Res., 3, pp. 161-170, (2006); Mohs R.C., Rosen W.G., Davis K.L., The Alzheimer's Disease Assessment Scale: an instrument for assessing treatment efficacy, Psychopharmacol. Bull, 19, pp. 448-450, (1983); Mokri H., Avila-Funes J.A., Meillon C., Gutierrez Robledo L.M., Amieva H., Normative data for the mini-mental state examination, the free and cued selective reminding test and the Isaacs set test for an older adult Mexican population: the Coyoacán cohort study, Clin. Neuropsychol., 27, pp. 1004-1018, (2013); Morris J.C., Mohs R.C., Rogers H., Fillenbaum G., Heyman A., Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease, Psychopharmacol. Bull, 24, pp. 641-652, (1988); Mura T., Proust-Lima C., Jacqmin-Gadda H., Akbaraly T.N., Touchon J., Dubois B., Berr C., Measuring cognitive change in subjects with prodromal Alzheimer's disease, J. Neurol. Neurosurg. Psychiatry, 85, pp. 363-370, (2014); Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study, Lancet Neurol., 10, pp. 785-796, (2011); Nasreddine Z.S., Phillips N.A., Bedirian V., Charbonneau S., Whitehead V., Collin I., Cummings J.L., Chertkow H., The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment, J. Am. Geriatr. Soc., 53, pp. 695-699, (2005); Nelson P.T., Alafuzoff I., Bigio E.H., Bouras C., Braak H., Cairns N.J., Castellani R.J., Crain B.J., Davies P., Del Tredici K., Duyckaerts C., Frosch M.P., Haroutunian V., Hof P.R., Hulette C.M., Hyman B.T., Iwatsubo T., Jellinger K.A., Jicha G.A., Kovari E., Kukull W.A., Leverenz J.B., Love S., Mackenzie I.R., Mann D.M., Masliah E., McKee A.C., Montine T.J., Morris J.C., Schneider J.A., Sonnen J.A., Thal D.R., Trojanowski J.Q., Troncoso J.C., Wisniewski T., Woltjer R.L., Beach T.G., Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature, J. Neuropathol. Exp. Neurol., 71, pp. 362-381, (2012); O'Connell M.E., Tuokko H., The 12-item Buschke memory test: appropriate for use across levels of impairment, Appl. Neuropsychol., 9, pp. 226-233, (2002); Parra M.A., Abrahams S., Fabi K., Logie R., Luzzi S., Della Sala S., Short-term memory binding deficits in Alzheimer's disease, Brain, 132, pp. 1057-1066, (2009); Parra M.A., Abrahams S., Logie R.H., Mendez L.G., Lopera F., Della Sala S., Visual short-term memory binding deficits in familial Alzheimer's disease, Brain, 133, pp. 2702-2713, (2010); Pepe M.S., Etzioni R., Feng Z., Potter J.D., Thompson M.L., Thornquist M., Winget M., Yasui Y., Phases of biomarker development for early detection of cancer, J. Natl. Cancer Inst., 93, pp. 1054-1061, (2001); Petersen R.C., Smith G.E., Ivnik R.J., Kokmen E., Tangalos E.G., Memory function in very early Alzheimer's disease, Neurology, 44, pp. 867-872, (1994); Petersen R.C., Mild cognitive impairment as a diagnostic entity, J. Intern. Med., 256, pp. 183-194, (2004); Porteri C., Albanese E., Scerri C., Carrillo M.C., Snyder H.M., Martensson B., Baker M., Giacobini E., Boccardi M., Winblad B., Frisoni G.B., Hurst S.; Pozueta A., Rodriguez-Rodriguez E., Vazquez-Higuera J.L., Mateo I., Sanchez-Juan P., Gonzalez-Perez S., Berciano J., Combarros O., Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test, BMC Neurol., 11, (2011); Rami L., Sole-Padulles C., Fortea J., Bosch B., Llado A., Antonell A., Olives J., Castellvi M., Bartres-Faz D., Sanchez-Valle R., Molinuevo J.L., Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD, Int. J. Geriatr. Psychiatry, 27, pp. 127-134, (2012); Randolph C., Gold J.M., Kozora E., Cullum M., Hermann B.P., Wyler A.R., Estimating memory function: disparity of Wechsler Memory Scale – Revised and California Verbal Learning Test indices in clinical and normal samples, Clin. Neuropsychologist, 8, pp. 99-108, (1994); Relkin N., Screening and early diagnosis of dementia, Am. J. Manag. Care, 6, pp. S1111-S1118, (2000); Rey A., L'examen psychologique dans les cas d'encéphalopathie traumatique, Arch. de Psychol., 28, (1941); Ricci M., Graef S., Blundo C., Miller L.A., Using the Rey Auditory Verbal Learning Test (RAVLT) to differentiate Alzheimer's dementia and behavioural variant fronto-temporal dementia, Clin. Neuropsychol., 26, pp. 926-941, (2012); Richard E., Schmand B.A., Eikelenboom P., Van Gool W.A., MRI and cerebrospinal fluid biomarkers for predicting progression to Alzheimer's disease in patients with mild cognitive impairment: a diagnostic accuracy study, BMJ Open, 3, (2013); Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, Neurobiol. Aging, 31, pp. 1275-1283, (2010); Salmon D.P., Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease, Curr. Top Behav. Neurosci., 10, pp. 187-212, (2012); Sarazin M., Berr C., De Rotrou J., Fabrigoule C., Pasquier F., Legrain S., Michel B., Puel M., Volteau M., Touchon J., Verny M., Dubois B., Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study, Neurology, 69, pp. 1859-1867, (2007); Sarazin M., Chauvire V., Gerardin E., Colliot O., Kinkingnehun S., de Souza L.C., Hugonot-Diener L., Garnero L., Lehericy S., Chupin M., Dubois B., The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study, J. Alzheimers Dis., 22, pp. 285-294, (2010); Shi J., Han P., Kuniyoshi S.M., Cognitive impairment in neurological diseases: lessons from apolipoprotein E, J. Alzheimers Dis., 38, pp. 1-9, (2014); Small B.J., Fratiglioni L., Viitanen M., Winblad B., Backman L., The course of cognitive impairment in preclinical Alzheimer disease. Three- and 6-year follow-up of a population-based sample, Arch. Neurol., 57, pp. 839-844, (2000); Sonni I., Ratib O., Boccardi M., Picco A., Herholz K., Nobili F., Varrone A., The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers, Maturity of presynaptic dopaminergic imaging with 123I-Ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and Dementia with Lewy bodies in the context of a structured 5–phase development framework, Neurobiol, Aging, 52, pp. 228-242, (2017); Sotaniemi M., Pulliainen V., Hokkanen L., Pirttila T., Hallikainen I., Soininen H., Hanninen T., CERAD-neuropsychological battery in screening mild Alzheimer's disease, Acta Neurol. Scand., 125, pp. 16-23, (2012); Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, pp. 280-292, (2011); Squire L.R., Stark C.E., Clark R.E., The medial temporal lobe, Annu. Rev. Neurosci., 27, pp. 279-306, (2004); Tabert M.H., Manly J.J., Liu X., Pelton G.H., Rosenblum S., Jacobs M., Zamora D., Goodkind M., Bell K., Stern Y., Devanand D.P., Neuropsychological prediction of conversion to Alzheimer disease in patients with mild cognitive impairment, Arch. Gen. Psychiatry, 63, pp. 916-924, (2006); Ten Kate M., Barkhof F., Boccardi M., Visser P.-J., Jack C.R., Lovblad K.-O., Frisoni G.B., Scheltens P., The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers, Maturity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol, Aging, 52, pp. 167-182, (2017); Tierney M.C., Szalai J.P., Snow W.G., Fisher R.H., Nores A., Nadon G., Dunn E., St George-Hyslop P.H., Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study, Neurology, 46, pp. 661-665, (1996); Tounsi H., Deweer B., Ergis A.M., Van der Linden M., Pillon B., Michon A., Dubois B., Sensitivity to semantic cuing: an index of episodic memory dysfunction in early Alzheimer disease, Alzheimer Dis. Assoc. Disord., 13, pp. 38-46, (1999); Tulving E., Episodic memory: from mind to brain, Annu. Rev. Psychol., 53, pp. 1-25, (2002); van der Flier W.M., Pijnenburg Y.A., Fox N.C., Scheltens P., Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele, Lancet Neurol., 10, pp. 280-288, (2011); Visser P.J., Verhey F.R., Hofman P.A., Scheltens P., Jolles J., Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment, J. Neurol. Neurosurg. Psychiatry, 72, pp. 491-497, (2002); Vogel A., Mortensen E.L., Gade A., Waldemar G., The Category Cued Recall test in very mild Alzheimer's disease: discriminative validity and correlation with semantic memory functions, Eur. J. Neurol., 14, pp. 102-108, (2007); Wagner M., Wolf S., Reischies F.M., Daerr M., Wolfsgruber S., Jessen F., Popp J., Maier W., Hull M., Frolich L., Hampel H., Perneczky R., Peters O., Jahn H., Luckhaus C., Gertz H.J., Schroder J., Pantel J., Lewczuk P., Kornhuber J., Wiltfang J., Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, 78, pp. 379-386, (2012); Welsh K., Butters N., Hughes J., Mohs R., Heyman A., Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures, Arch. Neurol., 48, pp. 278-281, (1991); Welsh K.A., Butters N., Hughes J.P., Mohs R.C., Heyman A., Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimers Disease, Arch. Neurol., 49, pp. 448-452, (1992); Wolfsgruber S., Jessen F., Wiese B., Stein J., Bickel H., Mosch E., Weyerer S., Werle J., Pentzek M., Fuchs A., Kohler M., Bachmann C., Riedel-Heller S.G., Scherer M., Maier W., Wagner M., The CERAD neuropsychological assessment battery total score detects and predicts Alzheimer disease dementia with high diagnostic accuracy, Am. J. Geriatr. Psychiatry, 22, pp. 1017-1028, (2014); Xie J., Gabelle A., Dorey A., Garnier-Crussard A., Perret-Liaudet A., Delphin-Combe F., Bathsavanis A., Dauphinot V., Lehmann S., Mercier B., Desestret V., Roullet-Solignac I., Vighetto A., Krolak-Salmon P., Initial memory deficit profiles in patients with a cerebrospinal fluid Alzheimer's disease signature, J. Alzheimers Dis., 41, pp. 1109-1116, (2014); Xu W., Yu J.T., Tan M.S., Tan L., Cognitive reserve and Alzheimer's disease, Mol. Neurobiol., 51, pp. 187-208, (2015)","2-s2.0-85015417329"
"Cerami C.; Marcone A.; Galimberti D.; Zamboni M.; Fenoglio C.; Serpente M.; Scarpini E.; Cappa S.F.","Cerami, Chiara (25722905400); Marcone, Alessandra (6701496511); Galimberti, Daniela (6701617660); Zamboni, Michele (36777386200); Fenoglio, Chiara (8661375900); Serpente, Maria (26030684600); Scarpini, Elio (57210771033); Cappa, Stefano F. (7005836132)","25722905400; 6701496511; 6701617660; 36777386200; 8661375900; 26030684600; 57210771033; 7005836132","Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9","2013","Journal of Alzheimer's Disease","35","3","","455","462","7","16","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84880202372&doi=10.3233%2fJAD-122302&partnerID=40&md5=c26d06fb2f3ee21d7643ae05a39aa561","C9ORF72 repeat expansion is currently considered as a major genetic cause of amyotrophic lateral sclerosis (ALS) and, in particular, of combined frontotemporal dementia-motor neuron disorder (FTD-MND) pedigrees. Studies of large series of patients have indicated that various phenotypic presentations may be observed even in the same family. Here, we describe four patients carrying a C9ORF72 mutation with heterogeneous clinical presentation sharing a rapid disease course. Cases 1 and 2 presented with predominant semantic deficits, accompanied in one patient by clinical signs of ALS. Case 3 showed a phenotype compatible with a diagnosis of behavioral variant of FTD. Case 4 presented with memory impairments, apathy, and social withdrawal, and had negative cerebrospinal fluid markers for Alzheimer's disease. Two patients showed a positive familiar history of MND and dementia (at least one first-degree family member affected). The two other patients were apparently sporadic cases. Our data provide further evidence for the heterogeneity of phenotypes associated with the C9ORF72 mutation and indicate its association with a fluent progressive aphasia phenotype. The present findings confirm the importance of screening for the hexanucleotide repeat expansion in chromosome 9 in the case not only of familial, but also of sporadic FTD, and in the presence of atypical cognitive disorders. © 2013 - IOS Press and the authors. All rights reserved.","C9ORF72 mutation; frontotemporal dementia; frontotemporal lobar degeneration; mild cognitive impairment; motor neuron disorders; semantic dementia","donepezil; fluorodeoxyglucose f 18; technetium 99m; adult; aged; Alzheimer disease; amyotrophic lateral sclerosis; apathy; article; chromosome 9; family history; female; frontal variant frontotemporal dementia; frontotemporal dementia; gene mutation; genetic heterogeneity; genetic variability; heredity; hexanucleotide repeat expansion; human; hyperphagia; major clinical study; male; memory disorder; Mini Mental State Examination; motor neuron disease; neuroimaging; neuropsychological test; nuclear magnetic resonance imaging; nucleotide repeat; open reading frame; phenotype; positron emission tomography; priority journal; psychosocial withdrawal; screening test; semantic dementia; single photon emission computer tomography; symptom","Hosler B.A., Siddique T., Sapp P.C., Sailor W., Huang M.C., Hossain A., Daube J.R., Nance M., Fan C., Kaplan J., Hung W.Y., McKenna-Yasek D., Haines J.L., Pericak-Vance M.A., Horvitz H.R., Brown Jr. R.H., Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22, JAMA, 284, pp. 1664-1669, (2000); Calvo A., Moglia C., Canosa A., Cistaro A., Valentini C., Carrara G., Soldano E., Ilardi A., Bersano E., Bertuzzo D., Brunetti M., Ossola I., Restagno G., Chio A., Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCCexpansion of the c9orf72 gene, J Neurol, 259, pp. 2723-2725, (2012); Ferrari R., Mok K., Moreno J.H., Cosentino S., Goldman J., Pietrini P., Mayeux R., Tierney M.C., Kapogiannis D., Jicha G.A., Murrell J.R., Ghetti B., Wassermann E.M., Grafman J., Hardy J., Huey E.D., Momeni P., Screening for C9ORF72 repeat expansion in FTLD, Neurobiol Aging, 33, (2012); Sabatelli M., Conforti F.L., Zollino M., Mora G., Monsurro M.R., Volanti P., Marinou K., Salvi F., Corbo M., Giannini F., Battistini S., Penco S., Lunetta C., Quattrone A., Gambardella A., Logroscino G., Simone I., Bartolomei I., Pisano F., Tedeschi G., Conte A., Spataro R., La Bella V., Caponnetto C., Mancardi G., Mandich P., Sola P., Mandrioli J., Renton A.E., Majounie E., Abramzon Y., Marrosu F., Marrosu M.G., Murru M.R., Sotgiu M.A., Pugliatti M., Rodolico C., C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population, Neurobiol Aging, 33, (2012); Renton A.E., Majounie E., Waite A., Sim'on-S'anchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., Van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Holtta-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chio A., Restagno G., Borghero G., Sabatelli M., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, pp. 257-268, (2011); DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, pp. 245-256, (2011); Gijselinck I., Van Langenhove T., Van Der Zee J., Sleegers K., Philtjens S., Kleinberger G., Janssens J., Bettens K., Van Cauwenberghe C., Pereson S., Engelborghs S., Sieben A., De Jonghe P., Vandenberghe R., Santens P., De Bleecker J., Maes G., Baumer V., Dillen L., Joris G., Cuijt I., Corsmit E., Elinck E., Van Dongen J., Vermeulen S., Van Den Broeck M., Vaerenberg C., Mattheijssens M., Peeters K., Robberecht W., Cras P., Martin J.J., De Deyn P.P., Cruts M., Van Broeckhoven C., A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study, Lancet Neurol, 11, pp. 54-65, (2012); Dobson-Stone C., Hallupp M., Bartley L., Shepherd C.E., Halliday G.M., Schofield P.R., Hodges J.R., Kwok J.B., C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts, Neurology, 79, pp. 995-1001, (2012); Rademakers R., Baker M., Gass J., Adamson J., Huey E.D., Momeni P., Spina S., Coppola G., Karydas A.M., Stewart H., Johnson N., Hsiung G.Y., Kelley B., Kuntz K., Steinbart E., Wood E.M., Yu C.E., Josephs K., Sorenson E., Womack K.B., Weintraub S., Pickering-Brown S.M., Schofield P.R., Brooks W.S., Van Deerlin V.M., Snowden J., Clark C.M., Kertesz A., Boylan K., Ghetti B., Neary D., Schellenberg G.D., Beach T.G., Mesulam M., Mann D., Grafman J., Mackenzie I.R., Feldman H., Bird T., Petersen R., Knopman D., Boeve B., Geschwind D.H., Miller B., Wszolek Z., Lippa C., Bigio E.H., Dickson D., Graff-Radford N., Hutton M., Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C->T (Arg493X) mutation: An international initiative, Lancet Neurol, 6, pp. 857-868, (2007); Kelley B.J., Haidar W., Boeve B.F., Baker M., Graff-Radford N.R., Krefft T., Frank A.R., Jack Jr. C.R., Shiung M., Knopman D.S., Josephs K.A., Parashos S.A., Rademakers R., Hutton M., Pickering-Brown S., Adamson J., Kuntz K.M., Dickson D.W., Parisi J.E., Smith G.E., Ivnik R.J., Petersen R.C., Prominent phenotypic variability associated with mutations in Progranulin, Neurobiol Aging, 30, pp. 739-751, (2009); Marcon G., Rossi G., Giaccone G., Giovagnoli A.R., Piccoli E., Zanini S., Geatti O., Toso V., Grisoli M., Tagliavini F., Variability of the clinical phenotype in an Italian family with dementia associated with an intronic deletion in the GRN gene, J Alzheimers Dis, 26, pp. 583-590, (2012); Snowden J.S., Rollinson S., Thompson J.C., Harris J.M., Stopford C.L., Richardson A.M., Jones M., Gerhard A., Davidson Y.S., Robinson A., Gibbons L., Hu Q., DuPlessis D., Neary D., Mann D.M., Pickering-Brown S.M., Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations, Brain, 135, PART 3, pp. 693-708, (2012); Floris G., Borghero G., Cannas A., Di Stefano F., Costantino E., Murru M.R., Brunetti M., Restagno G., Traynor B.J., Marrosu M.G., Chio A., Marrosu F., Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: A peculiar phenotype?, J Neurol, 259, pp. 1749-1751, (2012); Arighi A., Fumagalli G.G., Jacini F., Fenoglio C., Ghezzi L., Pietroboni A.M., De Riz M., Serpente M., Ridolfi E., Bonsi R., Bresolin N., Scarpini E., Galimberti D., Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: Psychiatric clinical presentations, J Alzheimers Dis, 31, pp. 447-452, (2012); Khan B.K., Yokoyama J.S., Takada L.T., Sha S.J., Rutherford N.J., Fong J.C., Karydas A.M., Wu T., Ketelle R.S., Baker M.C., Hernandez M.D., Coppola G., Geschwind D.H., Rademakers R., Lee S.E., Rosen H.J., Rabinovici G.D., Seeley W.W., Rankin K.P., Boxer A.L., Miller B.L., Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion, J Neurol Neurosurg Psychiatry, 83, pp. 358-364, (2012); Kipps C.M., Hodges J.R., Fryer T.D., Nestor P.J., Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: Refining the clinical phenotype, Brain, 132, PART 9, pp. 2566-2578, (2009); Majounie E., Abramzon Y., Renton A.E., Perry R., Bassett S.S., Pletnikova O., Troncoso J.C., Hardy J., Singleton A.B., Traynor B.J., Repeat expansion in C9ORF72 in Alzheimer's disease, N Engl J Med, 366, pp. 283-284, (2012); Wallon D., Rovelet-Lecrux A., Deramecourt V., Pariente J., Auriacombe S., Le Ber I., Schraen S., Pasquier F., Campion D., Hannequin D., Definite behavioral variant of frontotemporal dementia with C9ORF72 expansions despite positive Alzheimer's disease cerebrospinal fluid biomarkers, J Alzheimers Dis, 32, pp. 19-22, (2012); Kohli M.A., John-Williams K., Rajbhandary R., Naj A., Whitehead P., Hamilton K., Carney R.M., Wright C., Crocco E., Gwirtzman H.E., Lang R., Beecham G., Martin E.R., Gilbert J., Benatar M., Small G.W., Mash D., Byrd G., Haines J.L., Pericak-Vance M.A., Zuchner S., Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians, Neurobiol Aging, 34, 5, (2013); Carecchio M., Fenoglio C., Cortini F., Comi C., Benussi L., Ghidoni R., Borroni B., De Riz M., Serpente M., Cantoni C., Franceschi M., Albertini V., Monaco F., Rainero I., Binetti G., Padovani A., Bresolin N., Scarpini E., Galimberti D., Cerebrospinal fluid biomarkers in Progranulin mutations carriers, J Alzheimers Dis, 27, pp. 781-790, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, PART 9, pp. 2456-2477, (2011); Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Perry R.H., Trojanowski J.Q., Mann D.M., Lee V.M., A harmonized classification system for FTLDTDP pathology, Acta Neuropathol, 122, pp. 111-113, (2011); Hodges J.R., Mitchell J., Dawson K., Spillantini M.G., Xuereb J.H., McMonagle P., Nestor P.J., Patterson K., Semantic dementia: Demography, familial factors and survival in a consecutive series of 100 cases, Brain, 133, PART 1, pp. 300-306, (2010); Kelley B.J., Haidar W., Boeve B.F., Baker M., Graff-Radford N.R., Krefft T., Frank A.R., Jack Jr. C.R., Shiung M., Knopman D.S., Josephs K.A., Parashos S.A., Rademakers R., Hutton M., Pickering-Brown S., Adamson J., Kuntz K.M., Dickson D.W., Parisi J.E., Smith G.E., Ivnik R.J., Petersen R.C., Prominent phenotypic variability associated with mutations in Progranulin, Neurobiol Aging, 30, pp. 739-751, (2009); Janssen J.C., Warrington E.K., Morris H.R., Lantos P., Brown J., Revesz T., Wood N., Khan M.N., Cipolotti L., Fox N.C., Rossor M.N., Clinical features of frontotemporal dementia due to the intronic tau 10 (+16) mutation, Neurology, 58, pp. 1161-1168, (2002); Whitwell J.L., Weigand S.D., Boeve B.F., Senjem M.L., Gunter J.L., DeJesus-Hernandez M., Rutherford N.J., Baker M., Knopman D.S., Wszolek Z.K., Parisi J.E., Dickson D.W., Petersen R.C., Rademakers R., Jack Jr. C.R., Josephs K.A., Neuroimaging signatures of frontotemporal dementia genetics C9ORF72 tau progranulin and sporadics, Brain, 135, PART 3, pp. 794-806, (2012); Al-Sarraj S., King A., Troakes C., Smith B., Maekawa S., Bodi I., Rogelj B., Al-Chalabi A., Hortob'agyi T., Shaw C.E., P62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS, Acta Neuropathol, 122, pp. 691-702, (2011); Hsiung G.Y., DeJesus-Hernandez M., Feldman H.H., Sengdy P., Bouchard-Kerr P., Dwosh E., Butler R., Leung B., Fok A., Rutherford N.J., Baker M., Rademakers R., Mackenzie I.R., Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p, Brain, 135, PART 3, pp. 709-722, (2012); Mahoney C.J., Beck J., Rohrer J.D., Lashley T., Mok K., Shakespeare T., Yeatman T., Warrington E.K., Schott J.M., Fox N.C., Rossor M.N., Hardy J., Collinge J., Revesz T., Mead S., Warren J.D., Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features, Brain, 135, PART 3, pp. 736-750, (2012)","2-s2.0-84880202372"
"Dodich A.; Cerami C.; Canessa N.; Crespi C.; Marcone A.; Arpone M.; Realmuto S.; Cappa S.F.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400); Canessa, Nicola (24334215800); Crespi, Chiara (57034303800); Marcone, Alessandra (6701496511); Arpone, Marta (56002226300); Realmuto, Sabrina (42462180200); Cappa, Stefano F. (7005836132)","56001713900; 25722905400; 24334215800; 57034303800; 6701496511; 56002226300; 42462180200; 7005836132","Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population","2014","Neurological Sciences","35","7","","1015","1021","6","69","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903397633&doi=10.1007%2fs10072-014-1631-x&partnerID=40&md5=d5e3eebf1eb2fd1bb3ec319386fb8b29","The Ekman 60-Faces (EK-60F) Test is a well-known neuropsychological tool assessing emotion recognition from facial expressions. It is the most employed task for research purposes in psychiatric and neurological disorders, including neurodegenerative diseases, such as the behavioral variant of Frontotemporal Dementia (bvFTD). Despite its remarkable usefulness in the social cognition research field, to date, there are still no normative data for the Italian population, thus limiting its application in a clinical context. In this study, we report procedures and normative data for the Italian version of the test. A hundred and thirty-two healthy Italian participants aged between 20 and 79 years with at least 5 years of education were recruited on a voluntary basis. They were administered the EK-60F Test from the Ekman and Friesen series of Pictures of Facial Affect after a preliminary semantic recognition test of the six basic emotions (i.e., anger, fear, sadness, happiness, disgust, surprise). Data were analyzed according to the Capitani procedure [1]. The regression analysis revealed significant effects of demographic variables, with younger, more educated, female subjects showing higher scores. Normative data were then applied to a sample of 15 bvFTD patients which showed global impaired performance in the task, consistently with the clinical condition. We provided EK-60F Test normative data for the Italian population allowing the investigation of global emotion recognition ability as well as selective impairment of basic emotions recognition, both for clinical and research purposes. © 2014 Springer-Verlag.","Behavioral variant of frontotemporal dementia; Ekman 60-Faces Test; Emotion recognition; Social cognition; Standardization","Adult; Aged; Educational Status; Emotions; Face; Facial Expression; Female; Humans; Italy; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Pattern Recognition, Visual; Photic Stimulation; Reference Values; Young Adult; adult; aged; article; educational status; Ekman 60 Faces Test; emotion; facial expression; female; frontal variant frontotemporal dementia; groups by age; human; human experiment; Italy; male; neuropsychological test; normal human; normal value; population; recognition; semantics; sex difference; task performance; face; mental health; middle aged; neuropsychological test; pattern recognition; photostimulation; physiology; reference value; young adult","Capitani E., Laiacona M., Composite neuropsychological batteries and demographic correction: Standardization based on equivalent scores, with a review of published data, Journal of Clinical and Experimental Neuropsychology, 19, 6, pp. 795-809, (1997); Adolphs R., Cognitive neuroscience of human social behaviour, Nat Rev Neurosci, 4, 3, pp. 165-178, (2003); Phan K.L., Wager T., Taylor S.F., Liberzon I., Functional neuroanatomy of emotion: A meta-analysis of emotion activation studies in PET and fMRI, NeuroImage, 16, 2, pp. 331-348, (2002); Fusar-Poli P., Placentino A., Carletti F., Landi P., Allen P., Surguladze S., Benedetti F., Abbamonte M., Gasparotti R., Barale F., Perez J., McGuire P., Politi P., Functional atlas of emotional faces processing: A voxel-based meta-analysis of 105 functional magnetic resonance imaging studies, J Psychiatry Neurosci, 34, 6, pp. 418-432, (2009); Kohler C.G., Walker J.B., Martin E.A., Healey K.M., Moberg P.J., Facial emotion perception in schizophrenia: A meta-analytic review, Schizophr Bull, 36, 5, pp. 1009-1019, (2010); Unoka Z., Fogd D., Fuzy M., Csukly G., Misreading the facial signs: Specific impairments and error patterns in recognition of facial emotions with negative valence in borderline personality disorder, Psychiatry Res, 189, 3, pp. 419-425, (2011); Poljac E., Montagne B., De Haan E.H., Reduced recognition of fear and sadness in post-traumatic stress disorder, Cortex, 47, 8, pp. 974-980, (2011); Montagne B., Schutters S., Westenberg H.G., Van Honk J., Kessels R.P., De Haan E.H., Reduced sensitivity in the recognition of anger and disgust in social anxiety disorder, Cogn Neuropsychiatry, 11, 4, pp. 389-401, (2006); Croker V., McDonald S., Recognition of emotion from facial expression following traumatic brain injury, Brain Injury, 19, 10, pp. 787-799, (2005); Rapcsak S.Z., Galper S.R., Comer J.F., Reminger S.L., Nielsen L., Kaszniak A.W., Verfaellie M., Laguna J.F., Labiner D.M., Cohen R.A., Fear recognition deficits after focal brain damage: A cautionary note, Neurology, 54, 3, pp. 575-581, (2000); Meletti S., Benuzzi F., Cantalupo G., Rubboli G., Tassinari C.A., Nichelli P., Facial emotion recognition impairment in chronic temporal lobe epilepsy, Epilepsia, 50, 6, pp. 1547-1559, (2009); Ariatti A., Benuzzi F., Nichelli P., Recognition of emotions from visual and prosodic cues in Parkinson's disease, Neurol Sci, 29, 4, pp. 219-227, (2008); Zimmerman E.K., Eslinger P.J., Simmons Z., Barrett A.M., Emotional perception deficits in amyotrophic lateral sclerosis, Cognitive and Behavioral Neurology, 20, 2, pp. 79-82, (2007); Bediou B., Ryff I., Mercier B., Milliery M., Henaff M.A., D'Amato T., Bonnefoy M., Vighetto A., Krolak-Salmon P., Impaired social cognition in mild Alzheimer disease, J Geriatr Psychiatry Neurol, 22, 2, pp. 130-140, (2009); Fernandez-Duque D., Black S.E., Impaired recognition of negative facial emotions in patients with frontotemporal dementia, Neuropsychologia, 43, 11, pp. 1673-1687, (2005); Lough S., Kipps C.M., Treise C., Watson P., Blair J.R., Hodges J.R., Social reasoning, emotion and empathy in frontotemporal dementia, Neuropsychologia, 44, 6, pp. 950-958, (2006); Rosen H.J., Pace-Savitsky K., Perry R.J., Kramer J.H., Miller B.L., Levenson R.W., Recognition of emotion in the frontal and temporal variants of frontotemporal dementia, Dementia and Geriatric Cognitive Disorders, 17, 4, pp. 277-281, (2004); Diehl-Schmid J., Pohl C., Ruprecht C., Wagenpfeil S., Foerstl H., Kurz A., The Ekman 60 Faces Test as a diagnostic instrument in frontotemporal dementia, Arch Clin Neuropsychol, 22, 4, pp. 459-464, (2007); Ghosh B.C., Rowe J.B., Calder A.J., Hodges J.R., Bak T.H., Emotion recognition in progressive supranuclear palsy, J Neurol Neurosurg Psychiatry, 80, 10, pp. 1143-1145, (2009); Rohrer J.D., Sauter D., Scott S., Rossor M.N., Warren J.D., Receptive prosody in nonfluent primary progressive aphasias, Cortex, 48, 3, pp. 308-316, (2012); Calabria M., Cotelli M., Adenzato M., Zanetti O., Miniussi C., Empathy and emotion recognition in semantic dementia: A case report, Brain Cogn, 70, 3, pp. 247-252, (2009); Ekman P., Friesen W., Pictures of Facial Affect, (1976); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, PART 9, pp. 2456-2477, (2011); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, 6, pp. 1546-1554, (1998); Wilks S.S., Determination of sample sizes for setting tolerance limits, Ann Math Stat, 12, pp. 91-96, (1941); McClure E.B., A meta-analytic review of sex differences in facial expression processing and their development in infants, children, and adolescents, Psychol Bull, 126, 3, pp. 424-453, (2000); Lee T.M., Liu H.L., Hoosain R., Liao W.T., Wu C.T., Yuen K.S., Chan C.C., Fox P.T., Gao J.H., Gender differences in neural correlates of recognition of happy and sad faces in humans assessed by functional magnetic resonance imaging, Neurosci Lett, 333, 1, pp. 13-16, (2002); Sullivan S., Ruffman T., Emotion recognition deficits in the elderly, Int J Neurosci, 114, 3, pp. 403-432, (2004); Ruffman T., Henry J.D., Livingstone V., Phillips L.H., A meta-analytic review of emotion recognition and aging: Implications for neuropsychological models of aging, Neurosci Biobehav Rev, 32, 4, pp. 863-881, (2008); Brothers L., The social brain: A project for integrating primate behaviour and neurophysiology in a new domain, Concepts Neurosci, 1, pp. 27-51, (1990); Hedden T., Gabrieli J.D.E., Insights into the ageing mind: A view from cognitive neuroscience, Nature Reviews Neuroscience, 5, 2, pp. 87-96, (2004); Bianchi A., Pra M.D., Twenty years after Spinnler and Tognoni: New instruments in the Italian neuropsychologist's toolbox, Neurolo Sci, 29, 4, pp. 209-217, (2008)","2-s2.0-84903397633"
"Iaccarino L.; Chiotis K.; Alongi P.; Almkvist O.; Wall A.; Cerami C.; Bettinardi V.; Gianolli L.; Nordberg A.; Perani D.","Iaccarino, Leonardo (56114773500); Chiotis, Konstantinos (55552411700); Alongi, Pierpaolo (36192673100); Almkvist, Ove (16071391500); Wall, Anders (7102000770); Cerami, Chiara (25722905400); Bettinardi, Valentino (7003496270); Gianolli, Luigi (6602754456); Nordberg, Agneta (7102413103); Perani, Daniela (7005630261)","56114773500; 55552411700; 36192673100; 16071391500; 7102000770; 25722905400; 7003496270; 6602754456; 7102413103; 7005630261","A Cross-Validation of FDG-and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting","2017","Journal of Alzheimer's Disease","59","2","","603","614","11","44","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85024859079&doi=10.3233%2fJAD-170158&partnerID=40&md5=46c41bb337a6b4d8a9653a2b970e2106","Assessments of brain glucose metabolism (18F-FDG-PET) and cerebral amyloid burden (11C-PiB-PET) in mild cognitive impairment (MCI) have shown highly variable performances when adopted to predict progression to dementia due to Alzheimer's disease (ADD). This study investigates, in a clinical setting, the separate and combined values of 18F-FDG-PET and 11C-PiB-PET in ADD conversion prediction with optimized data analysis procedures. Respectively, we investigate the accuracy of an optimized SPM analysis for 18F-FDG-PET and of standardized uptake value ratio semiquantification for 11C-PiB-PET in predicting ADD conversion in 30 MCI subjects (age 63.57±7.78 years). Fourteen subjects converted to ADD during the follow-up (median 26.5 months, inter-quartile range 30 months). Receiver operating characteristic analyses showed an area under the curve (AUC) of 0.89 and of 0.81 for, respectively, 18F-FDG-PET and 11C-PiB-PET. 18F-FDG-PET, compared to 11C-PiB-PET, showed higher specificity (1.00 versus 0.62, respectively), but lower sensitivity (0.79 versus 1.00). Combining the biomarkers improved classification accuracy (AUC=0.96). During the follow-up time, all the MCI subjects positive for both PET biomarkers converted to ADD, whereas all the subjects negative for both remained stable. The difference in survival distributions was confirmed by a log-rank test (p=0.002). These results indicate a very high accuracy in predicting MCI to ADD conversion of both 18F-FDG-PET and 11C-PiB-PET imaging, the former showing optimal performance based on the SPM optimized parametric assessment. Measures of brain glucose metabolism and amyloid load represent extremely powerful diagnostic and prognostic biomarkers with complementary roles in prodromal dementia phase, particularly when tailored to individual cases in clinical settings. © 2017-IOS Press and the authors. All rights reserved.","<sup>11</sup>C-PiB-PET; <sup>18</sup>F-FDG-PET; Alzheimer's disease; conversion prediction; dementia; early diagnosis; mild cognitive impairment; prognosis","Aged; Alzheimer Disease; Amyloid; Aniline Compounds; Biomarkers; Cognitive Dysfunction; Dementia; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; ROC Curve; Thiazoles; amyloid; fluorodeoxyglucose f 18; Pittsburgh compound B; 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; amyloid; aniline derivative; biological marker; fluorodeoxyglucose f 18; radiopharmaceutical agent; thiazole derivative; adult; aged; Alzheimer disease; Article; attention; brain cortex atrophy; clinical article; diagnostic value; episodic memory; executive function; female; follow up; functional neuroimaging; glucose brain level; gray matter; human; image analysis; image reconstruction; intelligence quotient; male; mild cognitive impairment; Mini Mental State Examination; neuropsychological test; PET-CT scanner; positron emission tomography; posterior cingulate; primary progressive aphasia; priority journal; process optimization; Rey auditory verbal learning test; risk assessment; sensitivity and specificity; short term memory; spatial memory; survival time; trail making test; Wechsler adult intelligence scale; Alzheimer disease; cognitive defect; complication; dementia; diagnostic imaging; disease exacerbation; mental health; metabolism; middle aged; positron emission tomography; predictive value; receiver operating characteristic","Petersen R.C., Caracciolo B., Brayne C., Gauthier S., Jelic V., Fratiglioni L., Mild cognitive impairment: A concept in evolution, J Intern Med, 275, pp. 214-228, (2014); Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L.W., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K., Biomarkers for Alzheimer's disease: Academic, industry and regulatory perspectives, Nat Rev Drug Discov, 9, pp. 560-574, (2010); Shaw L.M., Korecka M., Clark C.M., Lee V.M.Y., Trojanowski J.Q., Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics, Nat Rev Drug Discov, 6, pp. 295-303, (2007); Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 270-279, (2011); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 263-269, (2011); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M.-O., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., De Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L., Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria, Lancet Neurol, 13, pp. 614-629, (2014); Dubois B., Feldman H.H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, pp. 734-746, (2007); Vos S.J.B., Verhey F., Frolich L., Kornhuber J., Wiltfang J., Maier W., Peters O., Ruther E., Nobili F., Morbelli S., Frisoni G.B., Drzezga A., Didic M., Van Berckel B.N.M., Simmons A., Soininen H., Kloszewska I., Mecocci P., Tsolaki M., Vellas B., Lovestone S., Muscio C., Herukka S.-K., Salmon E., Bastin C., Wallin A., Nordlund A., De Mendonca A., Silva D., Santana I., Lemos R., Engelborghs S., Van Der Mussele S., Freund-Levi Y., Wallin A.K., Hampel H., Van Der Flier W., Scheltens P., Visser P.J., Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage, Brain, 138, pp. 1327-1338, (2015); Smailagic N., Vacante M., Hyde C., Martin S., Ukoumunne O., Sachpekidis C., 18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst Rev, 1, (2015); Zhang S., Smailagic N., Hyde C., Noel-Storr A.H., Takwoingi Y., McShane R., Feng J., (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst Rev, 7, (2014); Morbelli S., Garibotto V., Van De Giessen E., Arbizu J., Chetelat G., Drezgza A., Hesse S., Lammertsma A.A., Law I., Pappatà S, Payoux P, Pagani M, European Association of Nuclear, Medicine (2015) A Cochrane review on brain [(18) F]FDG PET in dementia: Limitations and future perspectives, Eur J Nucl Med Mol Imaging, 42, pp. 1487-1491; Ma Y., Zhang S., Li J., Zheng D.-M., Guo Y., Feng J., Ren W.-D., Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: A meta-analysis [Corrected], Medicine (Baltimore), 93, (2014); Frisoni G.B., Bocchetta M., Chetelat G., Rabinovici G.D., De Leon M.J., Kaye J., Reiman E.M., Scheltens P., Barkhof F., Black S.E., Imaging markers for Alzheimer disease Which vs how, Neurology, 81, pp. 487-500, (2013); Perani D., Schillaci O., Padovani A., Nobili F.M., Iaccarino L., Della Rosa P.A., Frisoni G., Caltagirone C., A survey of FDG-and amyloid-PET imaging in dementia and GRADE analysis, Biomed Res Int, 2014, (2014); Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L., Imaging beta-amyloid burden in aging and dementia, Neurology, 68, pp. 1718-1725, (2007); Rabinovici G.D., Furst A.J., O'Neil J.P., Racine C.A., Mormino E.C., Baker S.L., Chetty S., Patel P., Pagliaro T.A., Klunk W.E., Mathis C.A., Rosen H.J., Miller B.L., Jagust W.J., 11CPIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration, Neurology, 68, pp. 1205-1212, (2007); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Perani D., Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia, Neuroimage Clin, 7, pp. 187-194, (2015); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Pinto P., Passerini G., Falini A., Iannaccone S., Cappa S.F., Comi G., Gianolli L., Magnani G., Crossvalidation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging, 43, pp. 499-508, (2016); Rabinovici G.D., Rosen H.J., Alkalay A., Kornak J., Furst A.J., Agarwal N., Mormino E.C., O'Neil J.P., Janabi M., Karydas A., Growdon M.E., Jang J.Y., Huang E.J., DeArmond S.J., Trojanowski J.Q., Grinberg L.T., Gorno-Tempini M.L., Seeley W.W., Miller B.L., Jagust W.J., Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD, Neurology, 77, pp. 2034-2042, (2011); Jagust W., Reed B., Mungas D., Ellis W., DeCarli C., What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?, Neurology, 69, pp. 871-877, (2007); Ng S.Y., Villemagne V.L., Masters C.L., Rowe C.C., Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B, Arch Neurol, 64, pp. 1140-1144, (2007); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Gilardi M.C., Frisoni G., Friston K., Ashburner J., Perani D., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Panzacchi A., Nobili F., Pappata S., Marcone A., Garibotto V., Castiglioni I., Magnani G., Cappa S.F., Gianolli L., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clin, 6, pp. 445-454, (2014); Nordberg A., Carter S.F., Rinne J., Drzezga A., Brooks D.J., Vandenberghe R., Perani D., Forsberg A., Langstrom B., Scheinin N., Karrasch M., Nagren K., Grimmer T., Miederer I., Edison P., Okello A., Van Laere K., Nelissen N., Vandenbulcke M., Garibotto V., Almkvist O., Kalbe E., Hinz R., Herholz K., A European multicentre PET study of fibrillar amyloid in Alzheimer's disease, Eur J Nucl Med Mol Imaging, 40, pp. 104-114, (2013); Bergman I., Blomberg M., Almkvist O., The importance of impaired physical health and age in normal cognitive aging, Scand J Psychol, 48, pp. 115-125, (2007); Cerami C., Crespi C., Della Rosa P.A., Dodich A., Marcone A., Magnani G., Coppi E., Falini A., Cappa S.F., Perani D., Brain changes within the visuo-spatial attentional network in posterior cortical atrophy, J Alzheimers Dis, 43, pp. 385-395, (2015); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Pelagallo E., Santangelo R., Cappa S.F., Perani D., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia, J Alzheimers Dis, 55, pp. 183-197, (2017); Iaccarino L., Crespi C., Della Rosa P.A., Catricala E., Guidi L., Marcone A., Tagliavini F., Magnani G., Cappa S.F., Perani D., The semantic variant of primary progressive aphasia: Clinical and neuroimaging evidence in single subjects, PLoS One, 10, pp. e0120197-e01201917, (2015); Presotto L., Ballarini T., Caminiti S.P., Bettinardi V., Gianolli L., Perani D., Validation of (18)F-FDG-PET singlesubject optimized SPM procedure with different PET scanners, Neuroinformatics, 15, pp. 151-163, (2017); Herholz K., Salmon E., Perani D., Baron J.-C., Holthoff V., Frolich L., Schonknecht P., Ito K., Mielke R., Kalbe E., Zundorf G., Delbeuck X., Pelati O., Anchisi D., Fazio F., Kerrouche N., Desgranges B., Eustache F., Beuthien-Baumann B., Menzel C., Schroder J., Kato T., Arahata Y., Henze M., Heiss W.D., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage, 17, pp. 302-316, (2002); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Crutch S.J., Lehmann M., Schott J.M., Rabinovici G.D., Rossor M.N., Fox N.C., Posterior cortical atrophy, Lancet Neurol, 11, pp. 170-178, (2012); Warren J.D., Fletcher P.D., Golden H.L., The paradox of syndromic diversity in Alzheimer disease, Nat Rev Neurol, 8, pp. 451-464, (2012); Maldjian J.A., Laurienti P.J., Kraft R.A., Burdette J.H., An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets, Neuroimage, 19, pp. 1233-1239, (2003); Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, Neuroimage, 15, pp. 273-289, (2002); Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Langstrom B., Nordberg A., PET imaging of amyloid deposition in patients with mild cognitive impairment, Neurobiol Aging, 29, pp. 1456-1465, (2008); Kato T., Inui Y., Nakamura A., Ito K., Brain fluorodeoxyglucose (FDG) PET in dementia, Ageing Res Rev, 30, pp. 73-84, (2016); Heiss W.-D., Zimmermann-Meinzingen S., PET imaging in the differential diagnosis of vascular dementia, J Neurol Sci, 322, pp. 268-273, (2012); Heiss W.-D., Rosenberg G.A., Thiel A., Berlot R., De Reuck J., Neuroimaging in vascular cognitive impairment: A state-of-the-art review, BMC Med, 14, (2016); Vitali P., Migliaccio R., Agosta F., Rosen H.J., Geschwind M.D., Neuroimaging in dementia, Semin Neurol, 28, pp. 467-483, (2008); Villemagne V.L., Amyloid imaging: Past, present and future perspectives, Ageing Res Rev, 30, pp. 95-106, (2016); Jansen W.J., Ossenkoppele R., Knol D.L., Tijms B.M., Scheltens P., Verhey F.R.J., Visser P.J., Aalten P., Aarsland D., Alcolea D., Alexander M., Almdahl I.S., Arnold S.E., Baldeiras I., Barthel H., Van Berckel B.N.M., Bibeau K., Blennow K., Brooks D.J., Van Buchem M.A., Camus V., Cavedo E., Chen K., Chetelat G., Cohen A.D., Drzezga A., Engelborghs S., Fagan A.M., Fladby T., Fleisher A.S., Van Der Flier W.M., Ford L., Forster S., Fortea J., Foskett N., Frederiksen K.S., Freund-Levi Y., Frisoni G.B., Froelich L., Gabryelewicz T., Gill K.D., Gkatzima O., Gomez-Tortosa E., Gordon M.F., Grimmer T., Hampel H., Hausner L., Hellwig S., Herukka S.-K., Hildebrandt H., Ishihara L., Ivanoiu A., Jagust W.J., Johannsen P., Kandimalla R., Kapaki E., Klimkowicz-Mrowiec A., Klunk W.E., Kohler S., Koglin N., Kornhuber J., Kramberger M.G., Van Laere K., Landau S.M., Lee D.Y., De Leon M., Lisetti V., Lleo A., Madsen K., Maier W., Marcusson J., Mattsson N., De Mendonca A., Meulenbroek O., Meyer P.T., Mintun M.A., Mok V., Molinuevo J.L., Mollergard H.M., Morris J.C., Mroczko B., Van Der Mussele S., Na D.L., Newberg A., Nordberg A., Nordlund A., Novak G.P., Paraskevas G.P., Parnetti L., Perera G., Peters O., Popp J., Prabhakar S., Rabinovici G.D., Ramakers I.H.G.B., Rami L., Resende De Oliveira C., Rinne J.O., Rodrigue K.M., Et al., Prevalence of cerebral amyloid pathology in persons without dementia, JAMA, 313, pp. 1915-1924, (2015); Herrup K., The case for rejecting the amyloid cascade hypothesis, Nat Neurosci, 18, pp. 794-799, (2015); Perani D., FDG-PET and amyloid-PET imaging, Curr Opin Neurol, 27, pp. 405-413, (2014); Bruck A., Virta J.R., Koivunen J., Koikkalainen J., Scheinin N.M., Helenius Nagren H.K., Helin S., Parkkola R., Viitanen M., Rinne J.O., [11C] PIB,[18F]FDG and MR imaging in patients with mild cognitive impairment, Eur J Nucl Med Mol Imaging, 40, pp. 1567-1572, (2013); Trzepacz P.T., Yu P., Sun J., Schuh K., Case M., Witte M.M., Hochstetler H., Hake A., Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia, Neurobiol Aging, 35, pp. 143-151, (2014); Hatashita S., Yamasaki H., Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction, PLoS One, 8, (2013); Grimmer T., Wutz C., Alexopoulos P., Drzezga A., Forster S., Forstl H., Goldhardt O., Ortner M., Sorg C., Kurz A., Visual versus fully automated analyses of 18F-FDG and amyloid PET for prediction of dementia due to Alzheimer disease in mild cognitive impairment, J Nucl Med, 57, pp. 204-207, (2016); Sperling R., Mormino E., Johnson K., The evolution of preclinical Alzheimer's disease: Implications for prevention trials, Neuron, 84, pp. 608-622, (2014)","2-s2.0-85024859079"
"Perani D.; Cerami C.; Caminiti S.P.; Santangelo R.; Coppi E.; Ferrari L.; Pinto P.; Passerini G.; Falini A.; Iannaccone S.; Cappa S.F.; Comi G.; Gianolli L.; Magnani G.","Perani, Daniela (7005630261); Cerami, Chiara (25722905400); Caminiti, Silvia Paola (56584243600); Santangelo, Roberto (57191567809); Coppi, Elisabetta (56370374600); Ferrari, Laura (55937899700); Pinto, Patrizia (33867729800); Passerini, Gabriella (36612171900); Falini, Andrea (7003494994); Iannaccone, Sandro (7005943171); Cappa, Stefano Francesco (7005836132); Comi, Giancarlo (7201788288); Gianolli, Luigi (6602754456); Magnani, Giuseppe (24496141800)","7005630261; 25722905400; 56584243600; 57191567809; 56370374600; 55937899700; 33867729800; 36612171900; 7003494994; 7005943171; 7005836132; 7201788288; 6602754456; 24496141800","Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting","2016","European Journal of Nuclear Medicine and Molecular Imaging","43","3","","499","508","9","59","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84956641655&doi=10.1007%2fs00259-015-3170-y&partnerID=40&md5=56fa82b23be30366d808c4080d2f58ae","Purpose: The aim of this study was to evaluate the supportive role of molecular and structural biomarkers (CSF protein levels, FDG PET and MRI) in the early differential diagnosis of dementia in a large sample of patients with neurodegenerative dementia, and in determining the risk of disease progression in subjects with mild cognitive impairment (MCI). Methods: We evaluated the supportive role of CSF Aβ42, t-Tau, p-Tau levels, conventional brain MRI and visual assessment of FDG PET SPM t-maps in the early diagnosis of dementia and the evaluation of MCI progression. Results: Diagnosis based on molecular biomarkers showed the best fit with the final diagnosis at a long follow-up. FDG PET SPM t-maps had the highest diagnostic accuracy in Alzheimer’s disease and in the differential diagnosis of non-Alzheimer’s disease dementias. The p-tau/Aβ42 ratio was the only CSF biomarker providing a significant classification rate for Alzheimer’s disease. An Alzheimer’s disease-positive metabolic pattern as shown by FDG PET SPM in MCI was the best predictor of conversion to Alzheimer’s disease. Conclusion: In this clinical setting, FDG PET SPM t-maps and the p-tau/Aβ42 ratio improved clinical diagnostic accuracy, supporting the importance of these biomarkers in the emerging diagnostic criteria for Alzheimer’s disease dementia. FDG PET using SPM t-maps had the highest predictive value by identifying hypometabolic patterns in different neurodegenerative dementias and normal brain metabolism in MCI, confirming its additional crucial exclusionary role. © 2015, Springer-Verlag Berlin Heidelberg.","Alzheimer’s Disease; Biomarkers; Clinical setting; Dementia diagnosis; Mild Cognitive Impairment","Aged; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cognitive Dysfunction; Diagnosis, Differential; Disease Progression; Female; Fluorodeoxyglucose F18; Frontotemporal Lobar Degeneration; Humans; Lewy Body Disease; Magnetic Resonance Imaging; Male; Middle Aged; Peptide Fragments; Positron-Emission Tomography; Predictive Value of Tests; Reproducibility of Results; tau Proteins; amyloid beta protein[1-42]; fluorodeoxyglucose f 18; tau protein; amyloid beta protein; amyloid beta-protein (1-42); biological marker; fluorodeoxyglucose f 18; MAPT protein, human; peptide fragment; tau protein; aged; Alzheimer disease; Article; brain atrophy; computed tomography scanner; controlled study; dementia; diagnostic accuracy; diagnostic test accuracy study; differential diagnosis; diffuse Lewy body disease; disease course; early diagnosis; female; follow up; frontotemporal dementia; human; major clinical study; male; mild cognitive impairment; Mini Mental State Examination; neuroimaging; nuclear magnetic resonance imaging; nuclear magnetic resonance scanner; parametric test; PET-CT scanner; positron emission tomography; predictive value; prognosis; protein cerebrospinal fluid level; protein phosphorylation; risk assessment; statistical parametrical mapping; validation study; cerebrospinal fluid; chemistry; Cognitive Dysfunction; differential diagnosis; Frontotemporal Lobar Degeneration; Lewy Body Disease; middle aged; nuclear magnetic resonance imaging; positron emission tomography; reproducibility","Prince M., Bryce R., Ferri C., World Alzheimer report 2011: the benefits of early diagnosis and intervention, (2011); Geldmacher D.S., Kirson N.Y., Birnbaum H.G., Eapen S., Kantor E., Cummings A.K., Et al., Implications of early treatment among Medicaid patients with Alzheimer’s disease, Alzheimers Dement, 10, pp. 214-224, (2014); Gaugler J.E., Ascher-Svanum H., Roth D.L., Fafowora T., Siderowf A., Beach T.G., Characteristics of patients misdiagnosed with Alzheimer’s disease and their medication use: an analysis of the NACC-UDS database, BMC Geriatr, 13, (2013); Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 270-279, (2011); Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Et al., Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 280-292, (2011); McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, pp. 1863-1872, (2005); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, pp. 496-503, (2013); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Et al., Advancing research diagnostic criteria for Alzheimer ’ s disease : the IWG-2 criteria, Lancet Neurol, 13, 6, pp. 614-629, (2014); Shaw L.M., Korecka M., Clark C.M., Lee V.M.-Y., Trojanowski J.Q., Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics, Nat Rev Drug Discov, 6, pp. 295-303, (2007); Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Et al., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage, 17, pp. 302-316, (2002); Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Et al., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Arch Neurol, 62, pp. 1728-1733, (2005); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Et al., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, Neuroimage Clin, 7, pp. 187-194, (2014); Ferreira D., Perestelo-Perez L., Westman E., Wahlund L.O., Sarria A., Serrano-Aguilar P., Meta-review of CSF core biomarkers in Alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria, Front Aging Neurosci, 6, (2014); Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M., The clinical use of structural MRI in Alzheimer disease, Nat Rev Neurol, 6, pp. 67-77, (2010); Nordberg A., Carter S.F., Rinne J., Drzezga A., Brooks D.J., Vandenberghe R., Et al., A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease, Eur J Nucl Med Mol Imaging, 40, pp. 104-114, (2013); Lehmann M., Ghosh P.M., Madison C., Laforce R., Corbetta-Rastelli C., Weiner M.W., Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease, Brain, 136, pp. 844-858, (2013); Murray J., Tsui W.H., Li Y., Mchugh P., Williams S., Pirraglia E., Et al., FDG and amyloid PET in cognitively normal individuals at risk for late-onset Alzheimer’s disease, Adv J Mol Imaging, 4, pp. 15-26, (2014); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 263-269, (2011); Coppi E., Ferrari L., Santangelo R., Caso F., Pinto P., Passerini G., Et al., Further evidence about the crucial role of CSF biomarkers in diagnosis of posterior cortical atrophy, Neurol Sci, 35, pp. 785-787, (2014); Santangelo R., Coppi E., Ferrari L., Bernasconi M.P., Pinto P., Passerini G., Et al., Cerebrospinal fluid biomarkers can play a pivotal role in the diagnostic work up of primary progressive aphasia, J Alzheimers Dis, 43, pp. 1429-1440, (2015); Ferreira D., Rivero-Santana A., Perestelo-Perez L., Westman E., Wahlund L.-O., Sarria A., Improving CSF biomarkers’ performance for predicting progression from mild cognitive impairment to Alzheimer’s disease by considering different confounding factors: a meta-analysis, Front Aging Neurosci, 6, (2014); Blennow K., Dubois B., Fagan A.M., Lewczuk P., de Leon M.J., Hampel H., Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease, Alzheimers Dement, 11, pp. 58-69, (2015); Jack C.R., Dickson D.W., Parisi J.E., Xu Y.C., Cha R.H., O'Brien P.C., Et al., Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia, Neurology, 58, pp. 750-757, (2002); Barkhof F., Polvikoski T.M., Van Straaten E.C., Kalaria R.N., Sulkava R., Aronen H.J., Et al., The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old, Neurology, 69, pp. 1521-1527, (2007); Hodges J.R., Alzheimer’s disease and the frontotemporal dementias: contributions to clinico-pathological studies, diagnosis, and cognitive neuroscience, J Alzheimers Dis, 33, pp. S211-S217, (2013); Raji C.A., Lopez O.L., Kuller L.H., Becker J.T., Age, Alzheimer disease, and brain structure, Neurology, 73, 22, pp. 1899-1905, (2009); Perani D., Functional neuroimaging of cognition, Handb Clin Neurol, 88, pp. 61-111, (2008); Perani D., FDG-PET and amyloid-PET imaging: the diverging paths, Curr Opin Neurol, 27, pp. 405-413, (2014); Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., Et al., The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception, Alzheimers Dement, 9, pp. e111-e194, (2013); Sanchez-Juan P., Ghosh P.M., Hagen J., Gesierich B., Henry M., Grinberg L.T., Et al., Practical utility of amyloid and FDG-PET in an academic dementia center, Neurology, 82, pp. 230-238, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage, 6, pp. 445-454, (2014); Ossenkoppele R., Prins N.D., Pijnenburg Y.A.L., Lemstra A.W., van der Flier W.M., Adriaanse S.F., Et al., Impact of molecular imaging on the diagnostic process in a memory clinic, Alzheimers Dement, 9, pp. 414-421, (2013); Cerami C., Crespi C., Della Rosa P.A., Dodich A., Marcone A., Magnani G., Et al., Brain changes within the visuo-spatial attentional network in posterior cortical atrophy, J Alzheimers Dis, 43, pp. 385-395, (2015); Frisoni G.B., Bocchetta M., Chetelat G., Rabinovici G.D., de Leon M.J., Kaye J., Et al., Imaging markers for Alzheimer disease: which vs how, Neurology, 81, pp. 487-500, (2013); Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Et al., Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer’s disease, Eur J Nucl Med Mol Imaging, 35, pp. 2169-2181, (2008); Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Et al., Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study, Neurology, 68, pp. 501-508, (2007); Kasanuki K., Iseki E., Fujishiro H., Yamamoto R., Higashi S., Minegishi M., Et al., Neuropathological investigation of the hypometabolic regions on positron emission tomography with [18F]fluorodeoxyglucose in patients with dementia with Lewy bodies, J Neurol Sci, 314, pp. 111-119, (2012); Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Et al., Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, pp. 230-238, (2010); Prestia A., Caroli A., van der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Et al., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease, Neurology, 80, pp. 1048-1056, (2013); Zhang D., Wang Y., Zhou L., Yuan H., Shen D., Multimodal classification of Alzheimer’s disease and mild cognitive impairment, Neuroimage, 55, pp. 856-867, (2011); Morinaga A., Ono K., Ikeda T., Ikeda Y., Shima K., Noguchi-Shinohara M., Et al., A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer’s disease in a memory clinic, Dement Geriatr Cogn Disord, 30, pp. 285-292, (2010); Shaffer J.L., Petrella J.R., Sheldon F.C., Choudhury K.R., Calhoun V.D., Coleman R.E., Et al., Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers, Radiology, 266, pp. 583-591, (2013); Choo I.H., Ni R., Scholl M., Wall A., Almkvist O., Nordberg A., Combination of (18)F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer’s disease in mild cognitive impairment patients, J Alzheimers Dis, 33, pp. 929-939, (2013); Alexopoulos P., Kriett L., Haller B., Klupp E., Gray K., Grimmer T., Et al., Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer’s disease, Alzheimers Dement, 10, pp. 684-689, (2014); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Petersen R.C., Roberts R.O., Knopman D.S., Boeve B.F., Geda Y.E., Ivnik R.J., Et al., Mild cognitive impairment: ten years later, Arch Neurol, 66, pp. 1447-1455, (2009); Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H., Et al., Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch Neurol, 66, pp. 382-389, (2009); Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Et al., Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 257-262, (2011); Salmon E., Garraux G., Delbeuck X., Collette F., Kalbe E., Zuendorf G., Et al., Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia, Neuroimage, 20, pp. 435-440, (2003); Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., Et al., FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease, Brain, 130, pp. 2616-2635, (2007); Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M., Phengrasamy L., Rosen H.J., Et al., Cognition and anatomy in three variants of primary progressive aphasia, Ann Neurol, 55, pp. 335-346, (2004); Fellgiebel A., Scheurich A., Bartenstein P., Muller M.J., FDG-PET and CSF phospho-tau for prediction of cognitive decline in mild cognitive impairment, Psychiatry Res Neuroimaging, 155, pp. 167-171, (2007); Walhovd K.B., Fjell A.M., Brewer J., McEvoy L.K., Fennema-Notestine C., Hagler D.J., Et al., Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease, AJNR Am J Neuroradiol, 31, pp. 347-354, (2010); Kaerst L., Kuhlmann A., Wedekind D., Stoeck K., Lange P., Zerr I., Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson’s disease, and Alzheimer's disease, J Alzheimers Dis, 38, pp. 63-73, (2014); Van de Pol L.A., Hensel A., Barkhof F., Gertz H.J., Scheltens P., van der Flier W.M., Hippocampal atrophy in Alzheimer disease: age matters, Neurology, 66, pp. 236-238, (2006)","2-s2.0-84956641655"
"Lalli S.; Piacentini S.; Franzini A.; Panzacchi A.; Cerami C.; Messina G.; Ferré F.; Perani D.; Albanese A.","Lalli, Stefania (6506775584); Piacentini, Sylvie (7003342270); Franzini, Angelo (7006606666); Panzacchi, Andrea (6603278442); Cerami, Chiara (25722905400); Messina, Giuseppe (35325356200); Ferré, Francesca (37161164300); Perani, Daniela (7005630261); Albanese, Alberto (7101798303)","6506775584; 7003342270; 7006606666; 6603278442; 25722905400; 35325356200; 37161164300; 7005630261; 7101798303","Epidural premotor cortical stimulation in primary focal dystonia: Clinical and 18F-fluoro deoxyglucose positron emission tomography open study","2012","Movement Disorders","27","4","","533","538","5","24","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84859420083&doi=10.1002%2fmds.24949&partnerID=40&md5=39ec57b7ba96cd2b631726f3df740f3b","The aim of this study was to evaluate the efficacy and safety of epidural premotor stimulation in patients with primary focal dystonia. Seven patients were selected: 6 had cervical dystonia and 1 had right upper limb dystonia. In 2 patients, sustained muscle contractions led to a prevalently fixed head posture. Patients with cervical dystonia received a bilateral implant, whereas the patient with hand dystonia received a unilateral implant. Neurological and neuropsychological evaluations were performed before surgery (baseline), and 1, 3, 6, and 12 months afterward. The Burke-Fahn-Marsden scale (BFMS) and the Toronto Western spasmodic torticollis rating scale (TWSTRS) were administered at the same time points. Patients underwent resting 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scans, before and 12 months after surgery. No adverse events occurred. An overall improvement was observed on the BFMS and TWSTRS after surgery. Patients with prevalently fixed cervical dystonia had a reduced benefit. Presurgical neuroimaging revealed a significant bilateral metabolic increase in the sensorimotor areas, which was reduced after surgery. © 2012 Movement Disorder Society.","DaTscan; Dystonia; Parkinson's disease; Tremor","fluorodeoxyglucose f 18; adult; article; Burke Fahn Marsden scale; cervical dystonia; clinical article; dystonia; epidural premotor stimulation; focal dystonia; human; nerve stimulation; neuroimaging; positron emission tomography; premotor cortex; priority journal; rating scale; Toronto Western Spasmodic Torticollis Rating Scale; upper limb dystonia","Kupsch A., Benecke R., Muller J., Et al., Pallidal deep-brain stimulation in primary generalized or segmental dystonia, N Engl J Med, 355, pp. 1978-1990, (2006); Albanese A., Asmus F., Bhatia K.P., Et al., EFNS guidelines on diagnosis and treatment of primary dystonias, Eur J Neurol, 18, pp. 5-18, (2011); Vidailhet M., Vercueil L., Houeto J.L., Et al., Bilateral, pallidal, deep-brain stimulation in primary generalised dystonia: a prospective 3 year follow-up study, Lancet Neurol, 6, pp. 223-229, (2007); Woehrle J.C., Blahak C., Kekelia K., Et al., Chronic deep brain stimulation for segmental dystonia, Stereotact Funct Neurosurg, 87, pp. 379-384, (2009); Huang Y.Z., Edwards M.J., Bhatia K.P., Rothwell J.C., One-Hz repetitive transcranial magnetic stimulation of the premotor cortex alters reciprocal inhibition in DYT1 dystonia, Mov Disord, 19, pp. 54-59, (2004); Murase N., Rothwell J.C., Kaji R., Et al., Subthreshold low-frequency repetitive transcranial magnetic stimulation over the premotor cortex modulates writer's cramp, Brain, 128, PART. 1, pp. 104-115, (2005); Huang Y.Z., Rothwell J.C., Lu C.S., Wang J., Chen R.S., Restoration of motor inhibition through an abnormal premotor-motor connection in dystonia, Mov Disord, 25, pp. 689-696, (2010); Priori A., Lefaucheur J.P., Chronic epidural motor cortical stimulation for movement disorders, Lancet Neurol, 6, pp. 279-286, (2007); Kranz G., Shamim E.A., Lin P.T., Kranz G.S., Hallett M., Transcranial magnetic brain stimulation modulates blepharospasm: a randomized controlled study, Neurology, 75, pp. 1465-1471, (2010); Romito L.M., Franzini A., Perani D., Et al., Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation, Neurology, 68, pp. 875-876, (2007); Fahn S., Bressman S.B., Marsden C.D., Classification of dystonia, Adv Neurol, 78, pp. 1-10, (1998); Burke R.E., Fahn S., Marsden C.D., Bressman S.B., Moskowitz C., Friedman J., Validity and reliability of a rating scale for the primary torsion dystonias, Neurology, 35, pp. 73-77, (1985); Consky E.S., Lang A., Clinical assessments of patients with cervical dystonia, Therapy with Botulinum Toxin, pp. 211-237, (1994); Zung W.W., A self-rating depression scale, Arch Gen Psychiatry, 12, pp. 63-70, (1965); Zung W.W., A rating instrument for anxiety disorders, Psychosomatics, 12, pp. 371-379, (1971); Overall J.E., Gorham D.R., The Brief Psychiatric Rating Scale, Psychol Rep, 10, pp. 799-812, (1962); Berger M., Bobbit R.A., Carter W.B., Gislon B.S., Sickness Impact Profile, Med Care, 19, pp. 787-805, (1981); Niethammer M., Carbon M., Argyelan M., Eidelberg D., ereditary dystonia as a neurodevelopmental circuit disorder: evidence from neuroimaging, Neurobiol Dis, 42, pp. 202-209, (2011); Hung S.W., Hamani C., Lozano A.M., Et al., Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia, Neurology, 68, pp. 457-459, (2007); Ibrahim N.M., Martino D., van De Warrenburg B.P., Et al., The prognosis of fixed dystonia: a follow-up study, Parkinsonism Relat Disord, 15, pp. 592-597, (2009); Galardi G., Perani D., Grassi F., Et al., Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis, Acta Neurol Scand, 94, pp. 172-176, (1996)","2-s2.0-84859420083"
"Cerami C.; Santi G.C.; Galandra C.; Dodich A.; Cappa S.F.; Vecchi T.; Crespi C.","Cerami, Chiara (25722905400); Santi, Gaia C. (57217289456); Galandra, Caterina (36806194800); Dodich, Alessandra (56001713900); Cappa, Stefano F. (7005836132); Vecchi, Tomaso (6603719753); Crespi, Chiara (57034303800)","25722905400; 57217289456; 36806194800; 56001713900; 7005836132; 6603719753; 57034303800","Covid-19 Outbreak In Italy: Are We Ready for the Psychosocial and the Economic Crisis? Baseline Findings From the PsyCovid Study","2020","Frontiers in Psychiatry","11","","556","","","","89","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087024497&doi=10.3389%2ffpsyt.2020.00556&partnerID=40&md5=cad06d4241d1f224ed33f9cf8c33e0f6","The Covid-19 pandemic is burning all over the world. National healthcare systems are facing the contagion with incredible strength, but concern regarding the psychosocial and economic effects is growing quickly. The PsyCovid Study assessed the influence of psychosocial variables on individual differences from the perceived impact of the Covid-19 outbreak on the issues of health and economy in the Italian population. Italian volunteers from different regions completed an online anonymous survey. The main outcomes were the perceived impact of the Covid-19 outbreak on health and the economy. A two-way MANOVA evaluated differences in the main outcomes, with geographical area (northern, central, and southern regions) and professional status (healthcare workers or not) as factors. We then tested the relationship linking psychosocial variables (i.e. perceived distress and social isolation, empathy, and coping style) to the main outcomes through two different mediation models. 1163 responders completed the survey (835 females; mean age: 42 ± 13.5 y.o.; age range: 18-81 y.o.) between March 14 and 21, 2020. Healthcare workers and people living in northern Italy reported a significantly worse outbreak impact on health, but not on the economy. In the whole sample, distress and loneliness were key variables influencing the perceived impact of the Covid-19 outbreak on health, while empathy and coping style affected the perceived impact on the economy. The Covid-19 pandemic is a worldwide emergency in terms of psychological, social, and economic consequences. Our data suggests that in the Italian population, actual differences in individual perception of the Covid-19 outbreak severity for health are dramatically modulated by psychosocial frailty (i.e., distress and loneliness). At the same time, problem-oriented coping strategies and enhanced empathic abilities increase people's awareness of the severity of the impact of the Covid-19 emergency on economics. There is an immediate need for consensus guidelines and healthcare policies to support interventions aimed to manage psychosocial distress and increase population resilience towards the imminent crisis. © Copyright © 2020 Cerami, Santi, Galandra, Dodich, Cappa, Vecchi and Crespi.","coping abilities; Covid-19 outbreak; distress; economic crisis; empathy; loneliness; perceived impact on health; psychosocial frailty","adult; aged; Article; awareness; coping behavior; coronavirus disease 2019; disease severity; distress syndrome; economic aspect; economic crisis; empathy; epidemic; female; human; Italian (citizen); Italy; loneliness; major clinical study; male; perception; psychosocial care; risk factor; social isolation; young adult","Zhu N., Zhang D., Wang W., Li X., Yang M.S., Song J., Et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med, 382, 8, (2020); Din M.A.U., Boppana L.K.T., An update on the 2019-nCoV outbreak, American Journal of Infection Control, (2020); Albarello F., Pianura E., Di Stefano F., Cristofaro M., Petrone A., Marchioni L., 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation, Int J Infect Dis, 93, (2020); Giovanetti M., Benvenuto D., Angeletti S., Ciccozzi M., The first two cases of 2019-nCoV in Italy: Where they come from, J Med Virol, 92, 5, (2020); Spina S., Marrazzo F., Migliari M., Stucchi R., Sforza A., Fumagalli R., The response of Milan's Emergency Medical System to the COVID-19 outbreak in Italy, Lancet, 395, 10227, (2020); Remuzzi A., Remuzzi G., COVID-19 and Italy: what next, Lancet, 395, (2020); Sim K., Chua H.C., The psychological impact of SARS: a matter of heart and mind, CMAJ, 170, 5, (2004); Sani G., Janiri D., Di Nicola M., Janiri L., Ferretti S., Chieffo D., Mental health during and after the COVID-19 emergency in Italy, Psychiatry Clin Neurosci, 74, (2020); Brooks S.K., Dunn R., Amlot R., Greenberg N., Rubin G.J., Social and occupational factors associated with psychological distress and disorder among disaster responders: a systematic review, BMC Psychol, 4, (2016); Brooks S.K., Dunn R., Amlot R., Rubin G.J., Greenberg N., A Systematic Thematic Review of Social and Occupational Factors Associated With Psychological Outcomes in Healthcare Employees During an Infectious Disease Outbreak, J Occup Environ Med, 60, 3, (2018); Welch S.J., Twenty years of patient satisfaction research applied to the emergency department: a qualitative review, Am J Med Qual, 25, 1, pp. 64-72, (2010); Wang H., Kline J.A., Jackson B.E., Laureano-Phillips J., Robinson R.D., Cowden C.D., Association between emergency physician self-reported empathy and patient satisfaction, PloS One, 13, 9, (2018); Khalid I., Khalid T.J., Qabajah M.R., Barnard A.G., Qushmaq I.A., Healthcare Workers Emotions, Perceived Stressors and Coping Strategies During a MERS-CoV Outbreak, Clin Med Res, 14, 1, pp. 7-14, (2016); Bottesi G., Ghisi M., Altoe G., Conforti E., Melli G., Sica C., The Italian version of the Depression Anxiety Stress Scales-21: Factor structure and psychometric properties on community and clinical samples, Compr Psychiatry, 60, (2015); Davis M., Measuring individual differences in empathy: Evidence for a multidimensional approach, HJJop Psychol s, 44, 1, (1983); Zammuner V.L., Italians' social and emotional loneliness: The results of five studies, JIJoSS, 3, 2, (2008); Foa C., Tonarelli A., Caricati L., Fruggeri L., COPE-NVI-25: validazione italiana della versione ridotta della Coping Orientation to the Problems Experienced (COPE-NVI), JPdS, 2, (2015); Moccia L., Janiri D., Pepe M., Dattoli L., Molinaro M., De Martin V., Affective temperament, attachment style, and the psychological impact of the COVID-19 outbreak: an early report on the Italian general population, Brain Behav Immun, (2020); Maunder R.G., Was SARS a mental health catastrophe, General Hospital Psychiatry, 31, 4, (2009); Mak I.W.C., Chu C.M., Pan P.C., Yiu M.G.C., Chan V.L., Long-term psychiatric morbidities among SARS survivors, JGhp, 31, 4, (2009); Wang C., Pan R., Wan X., Tan Y., Xu L., Ho C.S., Et al., Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China, Int J Environ Res Public Health, 17, 5, (2020); Li J.-B., Yang A., Dou K., Cheung R.Y., Self-control moderates the association between perceived severity of the coronavirus disease 2019 (COVID-19) and mental health problems among the Chinese public, PsyArXiv, (2020); Tversky A., Kahneman D., Judgment under Uncertainty: Heuristics and Biases, Science, 185, 4157, (1974); Puterman E., Delongis A., Lee-Baggley D., Greenglass E., Coping and health behaviors in times of health crises: Lessons from SARS and West Nile, Global Public Health, 4, pp. 69-81, (2009); Gardiner C., Geldenhuys G., Gott M., Interventions to reduce social isolation and loneliness among older people: an integrative review, Health Soc Care Community, 26, 2, (2018); Falkenberg I., Buchkremer G., Bartels M., Wild B., Implementation of a manual-based training of humor abilities in patients with depression: a pilot study, Psychiatry Res, 186, 2-3, (2011); Masi C.M., Chen H.Y., Hawkley L.C., Cacioppo JT. A meta-analysis of interventions to reduce loneliness, Pers Soc Psychol Rev, 15, 3, (2011); Regehr C., Glancy D., Pitts A., LeBlanc V.R., Interventions to reduce the consequences of stress in physicians: a review and meta-analysis, J Nerv Ment Dis, 202, 5, (2014); Sharma M., Rush S.E., Mindfulness-based stress reduction as a stress management intervention for healthy individuals: a systematic review, J Evid Based Complementary Altern Med, 19, 4, (2014); Weisz E., Zaki J., Empathy building interventions: A review of existing work and suggestions for future directions, Jtohocs, (2017)","2-s2.0-85087024497"
"Dodich A.; Cerami C.; Crespi C.; Canessa N.; Lettieri G.; Iannaccone S.; Marcone A.; Cappa S.F.; Cacioppo J.T.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400); Crespi, Chiara (57034303800); Canessa, Nicola (24334215800); Lettieri, Giada (56680972900); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Cappa, Stefano F. (7005836132); Cacioppo, John T. (35480797500)","56001713900; 25722905400; 57034303800; 24334215800; 56680972900; 7005943171; 6701496511; 7005836132; 35480797500","Differential Impairment of Cognitive and Affective Mentalizing Abilities in Neurodegenerative Dementias: Evidence from Behavioral Variant of Frontotemporal Dementia, Alzheimer's Disease, and Mild Cognitive Impairment","2016","Journal of Alzheimer's Disease","50","4","","1011","1022","11","60","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84959332677&doi=10.3233%2fJAD-150605&partnerID=40&md5=becf4e769c16e4e6edc82b0bca20009b","Cognitive and affective theory of mind (ToM) can be impaired in the course of neurodegenerative dementias. Experimental tests based on different task conditions and/or complexity may fail to capture disease-specific patterns of impairments. In this study, we assessed with a single task both the affective and the cognitive facets of ToM ability in a sample of 47 patients (i.e., 12 AD, 20 bvFTD, and 15 aMCI fulfilling IWG criteria for AD in predementia phase) and 65 healthy controls. Subjects were administered the Story-based Empathy task (SET), a non-verbal task measuring the ability to infer others' intentions (IA) and emotions (EA) compared to a control condition (causal inferences, CI). Global and single sub-condition scores were evaluated with a vectorial method, analyzing the relationship between social abilities and basic cognitive functioning by means of two indices representing the basic ability to perform the task and the balance between basic functions and ToM skills. Dementia (AD and bvFTD) patients showed impaired performances on all SET sub-conditions, whereas aMCI subjects' performance was not different from healthy controls. Vectorial analysis revealed a specific change in the balance between EA and CI conditions only in the bvFTD group, supporting a disproportionate deficit in mental states attribution based on affective cues. The overall deficit in the task in AD appears to be more general and related to the severity of dementia. This latter finding is further supported by the normal performance of the prodromal AD group. © 2016 - IOS Press and the authors. All rights reserved.","Alzheimer's disease; frontotemporal dementia; mild cognitive impairment; neurodegenerative diseases; theory of mind","Aged; Alzheimer Disease; Cognition; Cognitive Dysfunction; Emotions; Female; Frontotemporal Dementia; Humans; Male; Theory of Mind; aged; Alzheimer disease; analysis; Article; assessment of humans; association; clinical article; controlled study; emotion; empathy; executive function; frontal variant frontotemporal dementia; human; mild cognitive impairment; priority journal; skill; social cognition; Story based Empathy task; task performance; theory of mind; vectorial analysis; Alzheimer disease; cognition; cognitive defect; comparative study; emotion; female; frontotemporal dementia; male; psychology; theory of mind","Premack D., Woodruff G., Does the chimpanzee have a theory of mind, Behav Brain Sci, 1, pp. 515-526, (1978); Frith C.D., Frith U., The neural basis of mentalizing, Neuron, 50, pp. 531-534, (2006); Schurz M., Radua J., Aichhorn M., Richlan F., Perner J., Fractionating theory of mind: A meta-analysis of functional brain imaging studies, Neurosci Biobehav Rev, 42, pp. 9-34, (2014); Shamay-Tsoory S.G., Harari H., Aharon-Peretz J., Levkovitz Y., The role of the orbitofrontal cortex in affective theory of mind deficits in criminal offenders with psychopathic tendencies, Cortex, 46, pp. 668-677, (2010); Baron-Cohen S., The autistic child's theory of mind: A case of specific developmental delay, J Child Psychol Psychiatry, 30, pp. 285-297, (1989); Baron-Cohen S., Leslie A.M., Frith U., Does the autistic child have a ""theory of mind, Cognition, 21, pp. 37-46, (1985); Baron-Cohen S., Wheelwright S., Hill J., Raste Y., Plumb I., The ""reading the Mind in the Eyes"" Test revised version: A study with normal adults, and adults with Asperger syndrome or high-functioning autism, J Child Psychol Psychiatry, 42, pp. 241-251, (2001); Kalbe E., Schlegel M., Sack A.T., Nowak D.A., Dafotakis M., Bangard C., Brand M., Shamay-Tsoory S., Onur O.A., Kessler J., Dissociating cognitive from affective theory of mind: A TMS study, Cortex, 46, pp. 769-780, (2010); Shamay-Tsoory S.G., Aharon-Peretz J., Dissociable prefrontal networks for cognitive and affective theory of mind: A lesion study, Neuropsychologia, 45, pp. 3054-3067, (2007); Kramer U.M., Mohammadi B., Donamayor N., Samii A., Munte T.F., Emotional and cognitive aspects of empathy and their relation to social cognition-an fMRI-study, Brain Res, 1311, pp. 110-120, (2010); Sebastian C.L., Fontaine N.M., Bird G., Blakemore S.J., Brito S.A., McCrory E.J., Viding E., Neural processing asso ciated with cognitive and affective Theory of Mind in adolescents and adults, Soc Cogn Affect Neurosci, 7, pp. 53-63, (2012); Vollm B.A., Taylor A.N., Richardson P., Corcoran R., Stirling J., McKie S., Deakin J.F., Elliott R., Neuronal correlates of theory of mind and empathy: A functional magnetic resonance imaging study in a nonverbal task, Neuroimage, 29, pp. 90-98, (2006); Corradi-Dell'Acqua C., Hofstetter C., Vuilleumier P., Cognitive and affective theory of mind share the same local patterns of activity in posterior temporal but not medial prefrontal cortex, Soc Cogn Affect Neurosci, 9, pp. 1175-1184, (2014); Van Overwalle F., Baetens K., Understanding others' actions and goals by mirror and mentalizing systems: A meta-analysis, Neuroimage, 48, pp. 564-584, (2009); Bodden M.E., Kubler D., Knake S., Menzler K., Heverhagen J.T., Sommer J., Kalbe E., Krach S., Dodel R., Comparing the neural correlates of affective and cognitive theory of mind using fMRI: Involvement of the basal ganglia in affective theory of mind, Adv Cogn Psychol, 9, pp. 32-43, (2013); Dal Monte O., Schintu S., Pardini M., Berti A., Wassermann E.M., Grafman J., Krueger F., The left inferior frontal gyrus is crucial for reading the mind in the eyes: Brain lesion evidence, Cortex, 58, pp. 9-17, (2014); Shamay-Tsoory S.G., Tomer R., Berger B.D., Goldsher D., Aharon-Peretz J., Impaired ""affective theory of mind"" is associated with right ventromedial prefrontal damage, Cogn Behav Neurol, 18, pp. 55-67, (2005); Poletti M., Enrici I., Adenzato M., Cognitive and affective Theory of Mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels, Neurosci Biobehav Rev, 36, pp. 2147-2164, (2012); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Lunetta C., Consonni M., Scola E., Falini A., Cappa S.F., Emotional empathy in amyotrophic lateral sclerosis: A behavioural and voxel-based morphometry study, Amyotroph Lateral SclerFrontotemporalDegener, 15, pp. 21-29, (2014); Bodden M.E., Mollenhauer B., Trenkwalder C., Cabanel N., Eggert K.M., Unger M.M., Oertel W.H., Kessler J., Dodel R., Kalbe E., Affective and cognitive Theory of Mind in patients with Parkinson's disease, Parkinsonism Relat Disord, 16, pp. 466-470, (2010); Wang Y.G., Wang Y.Q., Chen S.L., Zhu C.Y., Wang K., Theory of mind disability in major depression with or without psychotic symptoms: A componential view, Psychiatry Res, 161, pp. 153-161, (2008); Bora E., Yucel M., Pantelis C., Theory of mind impairment: A distinct trait-marker for schizophrenia spectrum disorders and bipolar disorder, Acta Psychiatr Scand, 120, pp. 253-264, (2009); Pievani M., Filippini N., Van Den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases-from phenotype to proteinopathy, Nat Rev Neurol, 10, pp. 620-633, (2014); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol, 10, pp. 162-172, (2011); Ratnavalli E., Brayne C., Dawson K., Hodges J.R., The prevalence of frontotemporal dementia, Neurology, 58, pp. 1615-1621, (2002); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol Sci, 34, pp. 1267-1274, (2013); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Chierchia G., Scola E., Falini A., Cappa S.F., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 10, pp. 827-834, (2014); Henry J.D., Phillips L.H., Von Hippel C., Ameta-analytic review of theory of mind difficulties in behavioural-variant frontotemporal dementia, Neuropsychologia, 56, pp. 53-62, (2014); Gainotti G., Is the difference between right and left ATLs due to the distinction between general and social cognition or between verbal and non-verbal representations, Neurosci Biobehav Rev, 51, pp. 296-312, (2015); Stopford C.L., Thompson J.C., Neary D., Richardson A.M., Snowden J.S., Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia, Cortex, 48, pp. 429-446, (2012); Shany-Ur T., Rankin K.P., Personality and social cognition in neurodegenerative disease, Curr Opin Neurol, 24, pp. 550-555, (2011); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: A meta-analysis, J Neurol Neurosurg Psychiatry, 86, pp. 714-719, (2015); Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Schonknecht P., Ito K., Mielke R., Kalbe E., Zundorf G., Delbeuck X., Pelati O., Anchisi D., Fazio F., Kerrouche N., Desgranges B., Eustache F., Beuthien-Baumann B., Menzel C., Schroder J., Kato T., Arahata Y., Henze M., Heiss W.D., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage, 17, pp. 302-316, (2002); Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol, 82, pp. 239-259, (1991); Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A., Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory, J Neurosci, 25, pp. 7709-7717, (2005); Castelli I., Pini A., Alberoni M., Liverta-Sempio O., Baglio F., Massaro D., Marchetti A., Nemni R., Mapping levels of theory of mind in Alzheimer's disease: A preliminary study, Aging Ment Health, 15, pp. 157-168, (2011); Gregory C., Lough S., Stone V., Erzinclioglu S., Martin L., Baron-Cohen S., Hodges J.R., Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: Theoretical and practical implications, Brain, 125, pp. 752-764, (2002); Laisney M., Bon L., Guiziou C., Daluzeau N., Eustache F., Desgranges B., Cognitive and affective Theory of Mind in mild to moderate Alzheimer's disease, J Neuropsychol, 7, pp. 107-120, (2013); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S.F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol Sci, 36, pp. 1907-1912, (2015); Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., De Souza L.C., Stern Y., Visser P.J., Scheltens P., Revising the definition of Alzheimer's disease: A new lexicon, Lancet Neurol, 9, pp. 1118-1127, (2010); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M.O., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., De Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L., Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria, Lancet Neurol, 13, pp. 614-629, (2014); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 263-269, (2011); Petersen R.C., Mild cognitive impairment as a diagnostic entity, J Intern Med, 256, pp. 183-194, (2004); Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J., The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia, Neurology, 44, pp. 2308-2314, (1994); Kertesz A., Davidson W., Fox H., Frontal behavioral inventory: Diagnostic criteria for frontal lobe dementia, Can J Neurol Sci, 24, pp. 29-36, (1997); Davis M.H., Measuring individual differences in empathy: Evidence for a multidimensional approach, J Pers Soc Psychology, 44, pp. 113-126, (1983); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weiner M.W., Miller B.L., Structural anatomy of empathy in neurodegenerative disease, Brain, 129, pp. 2945-2956, (2006); Small G.W., Rabins P.V., Barry P.P., Buckholtz N.S., DeKosky S.T., Ferris S.H., Finkel S.I., Gwyther L.P., Khachaturian Z.S., Lebowitz B.D., McRae T.D., Morris J.C., Oakley F., Schneider L.S., Streim J.E., Sunderland T., Teri L.A., Tune L.E., Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society, JAMA, 278, pp. 1363-1371, (1997); DeCarli C., Mild cognitive impairment: Prevalence, prognosis, aetiology, and treatment, Lancet Neurol, 2, pp. 15-21, (2003); Fernandez-Duque D., Baird J.A., Black S.E., Falsebelief understanding in frontotemporal dementia and Alzheimer's disease, J Clin Exp Neuropsychol, 31, pp. 489-497, (2009); Eslinger P.J., Moore P., Troiani V., Antani S., Cross K., Kwok S., Grossman M., Oops! Resolving social dilemmas in frontotemporal dementia, J Neurol Neurosurg Psychiatry, 78, pp. 457-460, (2007); Hanakawa T., Immisch I., Toma K., Dimyan M.A., Van Gelderen P., Hallett M., Functional properties of brain areas associated with motor execution and imagery, J Neurophysiol, 89, pp. 989-1002, (2003); Schurz M., Aichhorn M., Martin A., Perner J., Common brain areas engaged in false belief reasoning and visual perspective taking: A meta-analysis of functional brain imaging studies, Front Hum Neurosci, 7, (2013); Elamin M., Pender N., Hardiman O., Abrahams S., Social cognition in neurodegenerative disorders: A systematic review, J Neurol Neurosurg Psychiatry, 83, pp. 1071-1079, (2012); Kumfor F., Piguet O., Disturbance of emotion processing in frontotemporal dementia:Asynthesis of cognitive and neuroimaging findings, Neuropsychol Rev, 22, pp. 280-297, (2012); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology, 78, pp. 1354-1362, (2012); Baez S., Manes F., Huepe D., Torralva T., Fiorentino N., Richter F., Huepe-Artigas D., Ferrari J., Montanes P., Reyes P., Matallana D., Vigliecca N.S., Decety J., Ibanez A., Primary empathy deficits in frontotemporal dementia, Front Aging Neurosci, 6, (2014); Seeley W.W., Selective functional, regional, and neuronal vulnerability in frontotemporal dementia, Curr Opin Neurol, 21, pp. 701-707, (2008); Mendez M.F., Fong S.S., Shapira J.S., Jimenez E.E., Kaiser N.C., Kremen S.A., Tsai P.H., Observation of social behavior in frontotemporal dementia, Am J Alzheimers Dis Other Demen, 29, pp. 215-221, (2014); Rankin K.P., Kramer J.H., Miller B.L., Patterns of cognitive and emotional empathy in frontotemporal lobar degeneration, Cogn Behav Neurol, 18, pp. 28-36, (2005); Gleichgerrcht E., Torralva T., Roca M., Pose M., Manes F., The role of social cognition in moral judgment in frontotemporal dementia, Soc Neurosc, 6, pp. 113-122, (2011); Baglio F., Castelli I., Alberoni M., Blasi V., Griffanti L., Falini A., Nemni R., Marchetti A., Theory of mind in amnestic mild cognitive impairment: An FMRI study, J Alzheimers Dis, 29, pp. 25-37, (2012); Maki Y., Yamaguchi T., Koeda T., Yamaguchi H., Communicative competence in Alzheimer's disease: Metaphor and sarcasm comprehension, Am J Alzheimers Dis Other Demen, 28, pp. 69-74, (2013); Poletti M., Bonuccelli U., Alteration of affective Theory of Mind in amnestic mild cognitive impairment, J Neuropsychol, 7, pp. 121-131, (2013); Torralva T., Gleichgerrcht E., Torres Ardila M.J., Roca M., Manes F.F., Differential cognitive and affective theory of mind abilities at mild and moderate stages of behavioral variant frontotemporal dementia, Cogn Behav Neurol, 28, pp. 63-70, (2015)","2-s2.0-84959332677"
"Dodich A.; Cerami C.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400)","56001713900; 25722905400","Answer to ""Current Potential for Clinical Optimization of Social Cognition Assessment for Frontotemporal Dementia and Primary Psychiatric Disorders""","2022","Neuropsychology Review","","","","","","","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137533823&doi=10.1007%2fs11065-022-09556-1&partnerID=40&md5=d7c794e129c73f0423b00ea03928eb0a","[No abstract available]","","","Barker M.S., Gottesman R.T., Manoochehri M., Chapman S., Appleby B.S., Brushaber D., Devick K.L., Dickerson B.C., Domoto-Reilly K., Fields J.A., Forsberg L.K., Proposed research criteria for prodromal behavioural variant frontotemporal dementia, Brain, 145, 3, pp. 1079-1097, (2022); Boccardi M., Monsch A.U., Ferrari C., Altomare D., Berres M., Bos I., Et al., Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe, Alzheimer’s Dement, (2021); Bora E., Yener G.G., Meta-Analysis of Social Cognition in Mild Cognitive Impairment, Journal of Geriatric Psychiatry and Neurology, 30, 4, pp. 206-213, (2017); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer’s disease: A meta-analysis, Journal of Neurology, Neurosurgery and Psychiatry, 86, pp. 714-719, (2015); Dodich A., Boccardi M., Sacco L., Monsch A.U., Demonet J., Filardi M., Answer to “Social cognition assessment for mild neurocognitive disorders.”, Alzheimer’s Dement., (2022); Dodich A., Crespi C., Santi G.C., Cappa S.F., Cerami C., Evaluation of Discriminative Detection Abilities of Social Cognition Measures for the Diagnosis of the Behavioral Variant of Frontotemporal Dementia: A Systematic Review, Neuropsychology Review, 31, 2, pp. 251-266, (2021); Frisoni G.B., Boccardi M., Barkhof F., Blennow K., Cappa S., Chiotis K., Demonet J.F., Garibotto V., Giannakopoulos P., Gietl A., Hansson O., Herholzjack K., Nobili F., Nordberg A., Snyder H.M., Ten Kate M., Varrone A., Albanese E., Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers, The Lancet Neurology, 16, 8, pp. 661-676, (2017); Jarsch M., Semenkova A., Monsch A.U., Kressig R.W., Sollberger M., Eine Lücke, die es zu schliessen gilt: Die Untersuchung sozial-kognitiver Fähigkeiten an deutschsprachigen Memory-Kliniken. Zeitschrift fur Neuropsychol, 33, pp. 129-137, (2022); Quesque F., Nivet M., Etchepare A., Wauquiez G., Prouteau A., Desgranges B., Bertoux M., Social cognition in neuropsychology: A nationwide survey revealing current representations and practices, Applied Neuropsychology: Adult, pp. 1-14, (2022); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Schroeter M.L., Laird A.R., Chwiesko C., Deuschl C., Schneider E., Bzdok D., Neumann J., Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - The case of behavioral variant frontotemporal dementia, Cortex, 57, pp. 22-37, (2014); Toller G., Ranasinghe K., Cobigo Y., Staffaroni A., Appleby B., Brushaber D., Et al., Revised Self-Monitoring Scale: A potential endpoint for frontotemporal dementia clinical trials, Neurology, 94, 22, pp. e2384-e2395, (2020); van Den Stock J., Social cognition assessment for mild neurocognitive disorders, Alzheimer’s Dement, pp. 11-12, (2021)","2-s2.0-85137533823"
"Cerami C.; Dodich A.; Canessa N.; Crespi C.; Marcone A.; Cortese F.; Chierchia G.; Scola E.; Falini A.; Cappa S.F.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Canessa, Nicola (24334215800); Crespi, Chiara (57034303800); Marcone, Alessandra (6701496511); Cortese, Francesca (56046172900); Chierchia, Gabriele (55604128400); Scola, Elisa (35071979200); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132)","25722905400; 56001713900; 24334215800; 57034303800; 6701496511; 56046172900; 55604128400; 35071979200; 7003494994; 7005836132","Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia","2014","Alzheimer's and Dementia","10","6","","827","834","7","65","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84927177565&doi=10.1016%2fj.jalz.2014.01.005&partnerID=40&md5=b90e653cedd1e06acc302044ee6c3959","Objective Loss of empathy is a symptom of the behavioral variant of frontotemporal dementia (bvFTD), constituting a clue for early diagnosis. In this study, we directly compared two empathy components (intention attribution [IA] and emotion attribution [EA]), correlating them with possible specific patterns of gray-matter density reduction within the mentalizing network. Methods We evaluated IA and EA in 18 mild bvFTD patients compared with 36 healthy controls (HCs) using a single nonverbal test. A subgroup entered a voxel-based morphometry study. Results Compared with HC, bvFTD patients showed IA and EA impairments. EA performance correlated with gray-matter reduction in the right amygdala, left insula, and posterior-superior temporal sulcus extending into the temporoparietal junction. Conclusion We proved an empathic impairment, with the ability to infer emotional states showing the most severe deficit. These results provide further evidence of selective disease-specific vulnerability of the limbic and frontoinsular network in bvFTD and highlight the usefulness of empathy assessment in early patients. © 2014 The Alzheimer's Association. All rights reserved.","Behavioral variant of frontotemporal dementia; Empathy; Mentalizing; Social cognition disorders; Voxel-based morphometry","Adult; Aged; Brain; Brain Mapping; Empathy; Female; Frontotemporal Dementia; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Mental Status Schedule; Middle Aged; Mood Disorders; Neuropsychological Tests; Young Adult; adult; affect; amygdaloid nucleus; Article; brain atrophy; brain cortex; clinical article; controlled study; disease severity; emotion; empathy; female; frontal variant frontotemporal dementia; frontotemporal dementia; gray matter; human; insula; male; mental capacity; middle aged; nerve cell; nonverbal communication; priority journal; social cognition; superior temporal sulcus; task performance; voxel based morphometry; aged; brain; brain mapping; complication; empathy; frontotemporal dementia; image processing; mental health; Mood Disorders; neuropsychological test; nuclear magnetic resonance imaging; pathology; physiology; psychology; young adult","Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., Van Swieten J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review, J Neurol Neurosurg Psychiatry, 82, pp. 476-486, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Torralva T., Roca M., Gleichgerrcht E., Bekinschtein T., Manes F., A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia, Brain, 132, pp. 1299-1309, (2009); Preston S.D., De Waal F.B., Empathy: Its ultimate and proximate bases, Behav Brain Sci, 25, pp. 1-20, (2002); De Vignemont F., Singer T., The empathic brain: How, when and why?, Trends Cogn Sci, 10, pp. 435-441, (2006); Shamay-Tsoory S.G., Aharon-Peretz J., Perry D., Two systems for empathy: A double dissociation between emotional and cognitive empathy in inferior frontal gyrus versus ventromedial prefrontal lesions, Brain, 132, pp. 617-627, (2009); Gallese V., The roots of empathy: The shared manifold hypothesis and the neural basis of intersubjectivity, Psychopathology, 36, pp. 171-180, (2003); Frith U., Frith C.D., Development and neurophysiology of mentalizing, Phil Trans Royal Soc B Biol Sci, 358, pp. 459-473, (2003); Van Overwalle F., Baetens K., Understanding others' actions and goals by mirror and mentalizing systems: A meta-analysis, Neuroimage, 48, pp. 564-584, (2009); Singer T., Seymour B., O'Doherty J., Kaube H., Dolan R.J., Frith C.D., Empathy for pain involves the affective but not sensory components of pain, Science, 303, pp. 1157-1162, (2004); Decety J., The neurodevelopment of empathy in humans, Develop Neurosci, 32, pp. 257-267, (2010); Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Arch Neurol, 65, pp. 249-255, (2008); Lough S., Kipps C.M., Treise C., Watson P., Blair J.R., Hodges J.R., Social reasoning, emotion and empathy in frontotemporal dementia, Neuropsychologia, 44, pp. 950-958, (2006); Rosen H.J., Perry R.J., Murphy J., Kramer J.H., Mychack P., Schuff N., Emotion comprehension in the temporal variant of frontotemporal dementia, Brain, 125, pp. 2286-2295, (2002); Gregory C., Lough S., Stone V., Erzinclioglu S., Martin L., Baron-Cohen S., Theory of mind in patients with frontal variant frontotemporal dementia and Alzheimer's disease: Theoretical and practical implications, Brain, 125, pp. 752-764, (2002); Eslinger P.J., Moore P., Anderson C., Grossman M., Social cognition, executive functioning, and neuroimaging correlates of empathic deficits in frontotemporal dementia, J Neuropsych Clin Neurosci, 23, pp. 74-82, (2011); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weiner M.W., Structural anatomy of empathy in neurodegenerative disease, Brain, 129, pp. 2945-2956, (2006); Adenzato M., Cavallo M., Enrici I., Theory of mind ability in the behavioural variant of frontotemporal dementia: An analysis of the neural, cognitive, and social levels, Neuropsychologia, 48, pp. 2-12, (2010); Kipps C.M., Nestor P.J., Acosta-Cabronero J., Arnold R., Hodges J.R., Understanding social dysfunction in the behavioural variant of frontotemporal dementia: The role of emotion and sarcasm processing, Brain, 132, pp. 592-603, (2009); Shany-Ur T., Poorzand P., Grossman S.N., Growdon M.E., Jang J.Y., Ketelle R.S., Comprehension of insincere communication in neurodegenerative disease: Lies, sarcasm, and theory of mind, Cortex, 48, pp. 1329-1341, (2012); Rosen H.J., Pace-Savitsky K., Perry R.J., Kramer J.H., Miller B.L., Levenson R.W., Recognition of emotion in the frontal and temporal variants of frontotemporal dementia, Dement Geriatr Cogn Disord, 17, pp. 277-281, (2004); Sturm V.E., Rosen H.J., Allison S., Miller B.L., Levenson R.W., Self-conscious emotion deficits in frontotemporal lobar degeneration, Brain, 129, pp. 2508-2516, (2006); Kosmidis M.H., Aretouli E., Bozikas V.P., Giannakou M., Ioannidis P., Studying social cognition in patients with schizophrenia and patients with frontotemporal dementia: Theory of mind and the perception of sarcasm, Behav Neurol, 19, pp. 65-69, (2008); Omar R., Henley S.M., Bartlett J.W., Hailstone J.C., Gordon E., Sauter D.A., The structural neuroanatomy of music emotion recognition: Evidence from frontotemporal lobar degeneration, Neuroimage, 56, pp. 1814-1821, (2011); Werner K.H., Roberts N.A., Rosen H.J., Dean D.L., Kramer J.H., Weiner M.W., Emotional reactivity and emotion recognition in frontotemporal lobar degeneration, Neurology, 69, pp. 148-155, (2007); Rankin K.P., Baldwin E., Pace-Savitsky C., Kramer J.H., Miller B.L., Self-awareness and personality change in dementia, J Neurol Neurosurg Psychiatry, 76, pp. 632-639, (2005); Williamson C., Alcantar O., Rothlind J., Cahn-Weiner D., Miller B.L., Rosen H.J., Standardised measurement of self-awareness deficits in FTD and AD, J Neurol Neurosurg Psychiatry, 81, pp. 140-145, (2010); Freedman M., Binns M.A., Black S.E., Murphy C., Stuss D.T., Theory of mind and recognition of facial emotion in dementia: Challenge to current concepts, Alzheimer Dis Assoc Disord, 27, pp. 56-61, (2013); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease, Arch Neurol, 58, pp. 1803-1809, (2001); Sarfati Y., Hardy-Bayle M.C., Besche C., Widlocher D., Attribution of intentions to others in people with schizophrenia: A non-verbal exploration with comic strips, Schizophr Res, 25, pp. 199-209, (1997); Brunet E., Sarfati Y., Hardy-Bayle M.C., Decety J., A PET investigation of the attribution of intentions with a nonverbal task, Neuroimage, 11, pp. 157-166, (2000); Vollm B.A., Taylor A.N., Richardson P., Corcoran R., Stirling J., McKie S., Neuronal correlates of theory of mind and empathy: A functional magnetic resonance imaging study in a nonverbal task, Neuroimage, 29, pp. 90-98, (2006); Eickhoff S.B., Stephan K.E., Mohlberg H., Grefkes C., Fink G.R., Amunts K., A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data, Neuroimage, 25, pp. 1325-1335, (2005); Nichols T., Brett M., Andersson J., Wager T., Poline J.-B., Valid conjunction inference with the minimum statistic, Neuroimage, 25, pp. 653-660, (2005); Hutchinson A.D., Mathias J.L., Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: A meta-analytic review, J Neurol Neurosurg Psychiatry, 78, pp. 917-928, (2007); Kim E.J., Sidhu M., Gaus S.E., Huang E.J., Hof P.R., Miller B.L., Selective frontoinsular von economo neuron and fork cell loss in early behavioral variant frontotemporal dementia, Cerebral Cortex, 22, pp. 251-259, (2012); Olson I.R., Plotzker A., Ezzyat Y., The Enigmatic temporal pole: A review of findings on social and emotional processing, Brain, 130, pp. 1718-1731, (2007); Grossman E.D., Blake R., Brain areas active during visual perception of biological motion, Neuron, 35, pp. 1167-1175, (2002); Corbetta M., Shulman G.L., Control of goal-directed and stimulus-driven attention in the brain, Nat Rev Neurosci, 3, pp. 201-215, (2002); Samson D., Apperly I.A., Chiavarino C., Humphreys G.W., Left temporoparietal junction is necessary for representing someone else's belief, Nat Neurosci, 7, pp. 499-500, (2004); Hamilton A.F., Grafton S.T., Goal representation in human anterior intraparietal sulcus, J Neurosci, 26, pp. 1133-1137, (2006); Mar R.A., The neural bases of social cognition and story comprehension, Annu Rev Psychol, 62, pp. 103-134, (2011); Cavanna A.E., Trimble M.R., The precuneus: A review of its functional anatomy and behavioural correlates, Brain, 129, pp. 564-583, (2006); Jesso S., Morlog D., Ross S., Pell M.D., Pasternak S.H., Mitchell D.G.V., The effects of oxytocin on social cognition and behaviour in frontotemporal dementia, Brain, 134, pp. 2493-2501, (2011)","2-s2.0-84927177565"
"Della Rosa P.A.; Cerami C.; Gallivanone F.; Prestia A.; Caroli A.; Castiglioni I.; Gilardi M.C.; Frisoni G.; Friston K.; Ashburner J.; Perani D.","Della Rosa, Pasquale Anthony (14420734200); Cerami, Chiara (25722905400); Gallivanone, Francesca (20435500300); Prestia, Annapaola (16744236000); Caroli, Anna (13908172500); Castiglioni, Isabella (6603570829); Gilardi, Maria Carla (57226200721); Frisoni, Giovanni (56214208300); Friston, Karl (36080215500); Ashburner, John (7004536701); Perani, Daniela (7005630261)","14420734200; 25722905400; 20435500300; 16744236000; 13908172500; 6603570829; 57226200721; 56214208300; 36080215500; 7004536701; 7005630261","A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia","2014","Neuroinformatics","12","4","","575","593","18","227","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84911007865&doi=10.1007%2fs12021-014-9235-4&partnerID=40&md5=93ac1ffbe1d8e7a462d81ce51deb332a","[18F]-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) is a widely used diagnostic tool that can detect and quantify pathophysiology, as assessed through changes in cerebral glucose metabolism. [18F]-FDG PET scans can be analyzed using voxel-based statistical methods such as Statistical Parametric Mapping (SPM) that provide statistical maps of brain abnormalities in single patients. In order to perform SPM, a “spatial normalization” of an individual’s PET scan is required to match a reference PET template. The PET template currently used for SPM normalization is based on [15O]-H2O images and does not resemble either the specific metabolic features of [18F]-FDG brain scans or the specific morphological characteristics of individual brains affected by neurodegeneration. Thus, our aim was to create a new [18F]-FDG PET aging and dementia-specific template for spatial normalization, based on images derived from both age-matched controls and patients. We hypothesized that this template would increase spatial normalization accuracy and thereby preserve crucial information for research and diagnostic purposes. We investigated the statistical sensitivity and registration accuracy of normalization procedures based on the standard and new template—at the single-subject and group level—independently for subjects with Mild Cognitive Impairment (MCI), probable Alzheimer’s Disease (AD), Frontotemporal lobar degeneration (FTLD) and dementia with Lewy bodies (DLB). We found a significant statistical effect of the population-specific FDG template-based normalisation in key anatomical regions for each dementia subtype, suggesting that spatial normalization with the new template provides more accurate estimates of metabolic abnormalities for single-subject and group analysis, and therefore, a more effective diagnostic measure. © 2014, Springer Science+Business Media New York.","         <sup>18</sup>F-FDG PET; Dementia; Spatial normalization; SPM (RRID:nif-0000-00343); Template","Aged; Aged, 80 and over; Brain; Brain Mapping; Case-Control Studies; Dementia; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Mild Cognitive Impairment; Positron-Emission Tomography; Sensitivity and Specificity; fluorodeoxyglucose f 18; aged; brain; brain mapping; case control study; dementia; female; human; image processing; male; middle aged; mild cognitive impairment; pathophysiology; positron emission tomography; procedures; psychology; scintiscanning; sensitivity and specificity; very elderly","Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s & Dementia, 7, 3, pp. 270-279, (2011); Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Cappa S., Et al., Heterogeneity of brain glucose metaboism in mild cognitive impairment and clinical progression to Alzheimer disease, Archives of Neurology, 62, 11, pp. 1728-1733, (2005); Ashburner J., A fast diffeomorphic image registration algorithm, NeuroImage, 38, 1, pp. 95-113, (2007); Ashburner J., Friston K.J., Nonlinear spatial normalization using basis functions, Human Brain Mapping, 7, 4, pp. 254-266, (1999); Bartenstein P., Asenbaum S., Catafau A., Halldin C., Pilowski L., Pupi A., Et al., European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG, European Journal of Nuclear Medicine and Molecular Imaging, 29, 10, pp. BP43-BP48, (2002); Berti V., Osorio R.S., Mosconi L., Li Y., De Santi S., de Leon M.J., Early detection of Alzheimer’s disease with PET imaging, Neurodegenerative Diseases, 7, 1-3, pp. 131-135, (2010); Bornebroek M., Bretelera M.B., Epidemiology of non-AD dementia, Clinical Neuroscience Reserach, 3, pp. 349-361, (2004); Buchert R., Wilke F., Chakrabarti B., Martin B., Brenner W., Mester J., Clausen M., Adjusted scaling of FDG positron emission tomography images for statistical evaluation in patients with suspected Alzheimer’s disease, Journal of Neuroimaging, 15, pp. 348-355, (2005); Caroli A., Prestia A., Chen K., Ayutyanont N., Landau S.M., Madison C.M., Et al., Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison, Journal of Nuclear Medicine, 53, 4, pp. 592-600, (2012); Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.C., Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease?, Neurology, 60, 8, pp. 1374-1377, (2003); Crivello F., Schormann T., Tzourio-Mazoyer N., Roland P.E., Zilles K., Mazoyer B.M., Comparison of spatial normalization procedures and their impact on functional maps, Human Brain Mapping, 16, 4, pp. 228-250, (2002); Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Et al., Revising the definition of Alzheimer’s disease: a new lexicon, Lancet Neurology, 9, 11, pp. 1118-1127, (2010); Eickhoff S., Stephan K.E., Mohlberg H., Grefkes C., Fink G.R., Amunts K., Et al., A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data, NeuroImage, 25, 4, pp. 1325-1335, (2005); 3D statistical neuroanatomical models from 305 MRI volumes.; Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., Et al., FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease, Brain, 130, 10, pp. 2616-2635, (2007); Friston K.J., Holmes A.P., Worsley K.J., Poline J.P., Frith C.D., Frackowiak R.S., Statistical parametric maps in functional imaging: a general linear approach, Human Brain Mapping, 2, 4, pp. 189-210, (1994); Gispert J.D., Pascau J., Reig S., Martinez-Lazaro R., Molina V., Garcia-Barreno P., Et al., Influence of the normalization template on the outcome of statistical parametric mapping of PET scans, NeuroImage, 19, 3, pp. 601-612, (2003); Good C.D., Johnsrude I.S., Ashburner J., Henson R.N., Friston K.J., Frackowiak R.S., A voxel-based morphometric study of ageing in 465 normal adult human brains, NeuroImage, 14, 1, pp. 21-36, (2001); Herholz K., Salmon E., Perani D., Baron J.-C., Holthoff V., Frolich L., Schonknecht P., Et al., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, NeuroImage, 17, 1, pp. 302-316, (2002); Ishii K., Willoch F., Minoshima S., Drzezga A., Ficaro E.P., Cross D.J., Et al., Statistical brain mapping of 18F-FDG PET in Alzheimer’s disease: validation of anatomic standardization for atrophied brains, Journal of Nuclear Medicine, 42, 4, pp. 548-557, (2001); Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Et al., Introduction to the recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s & Dementia, 7, 3, pp. 257-262, (2011); Kherif F., Poline J.P., Meriaux S., Benali H., Flandin G., Brett M., Group analysis in functional neuroimaging: selecting subjects using similarity measures, NeuroImage, 20, 4, pp. 2197-2208, (2003); Krishnan S., Slavin M.J., Tran T.T., Doraiswamy P.M., Petrella J.R., Accuracy of spatial normalization of the hippocampus: implications for fMRI research in memory disorders, NeuroImage, 31, 2, pp. 560-571, (2006); Magistretti P.J., Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling, Brain Research, 886, 1-2, pp. 108-112, (2000); Markiewicz P.J., Matthews J.C., Declerck J., Herholz K., Robustness of multivariate image analysis assessed by resampling techniques and applied to FDG-PET scans of patients with Alzheimer’s disease, NeuroImage, 46, 2, pp. 472-485, (2009); Martino M.E., Guzman de Villoria J., Lacalle-Aurioles M., Olazaran J., Cruz I., Navarro E., Et al., Comparison of different methods of spatial normalization of FDG-PET brain images in the voxel-wise analysis of MCI patients and controls, Annals of Nuclear Medicine, (2013); McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, 12, pp. 1863-1872, (2005); McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick’s Disease, Archives of Neurology, 58, pp. 1803-1809, (2001); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Et al., The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging– Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s & Dementia, 7, 3, pp. 263-269, (2011); Minoshima S., Frey K.A., Koeppe R.A., Foster N.L., Kuhl D.E., A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET, Journal of Nuclear Medicine, 36, 7, pp. 1238-1248, (1995); Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E., Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease, Annals of Neurology, 42, 1, pp. 85-94, (1997); Minoshima S., Foster N.L., Sima A.A., Frey K.A., Albin R.L., Kuhl D.E., Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation, Annals of Neurology, 50, 3, pp. 358-365, (2001); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., van Berckel B.N., Et al., Resting metabolic connectivity in prodromal Alzheimer’s disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiology of Aging, 33, 11, pp. 2533-2550, (2012); Mori T., Ikeda M., Fukuhara R., Nestor P.J., Tanabe H., Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB, Neurology, 66, 6, pp. 935-937, (2006); Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Et al., Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias, Journal of Nuclear Medicine, 49, 3, pp. 390-398, (2008); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Et al., Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Patterson J.C., Lilien D.L., Takalkar A., Pinkston J.B., Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans, International Journal of Alzheimer’s Disease, (2011); Perani D., Perani D., Functional neuroimaging of cognition, M. J. Aminoff, F. Boller, & D. F. Swaab, pp. 61-111, (2008); Prince M., Bryce R., Ferr C., The benefits of early diagnosis and intervention, Alzheimer’s Disease International World Alzheimer Report, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Ridgway G., Omar R., Ourselin S., Hill D., Warren J., Fox N., Issues with threshold masking in voxel-based morphometry of atrophied brains, NeuroImage, 44, 1, pp. 99-111, (2009); Rorden C., Bonilha L., Fridriksson J., Bender B., Karnath H.O., Age-specific CT and MRI templates for spatial normalization, NeuroImage, 61, 4, pp. 957-965, (2012); Salmon E., Garraux G., Delbeuck X., Collette F., Kalbe E., Zuendorf G., Et al., Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia, NeuroImage, 20, 1, pp. 435-440, (2003); Salmon E., Kerrouche N., Perani D., Lekeu F., Holthoff V., Beuthien- Baumann B., Et al., On the multivariate nature of brain metabolic impairment in Alzheimer’s disease, Neurobiology of Aging, 30, 2, pp. 186-197, (2009); Sestini S., Castagnoli A., Mansi L., The new FDG brain revolution: the neurovascular unit and the default network, European Journal of Nuclear Medicine and Molecular Imaging, 37, 5, pp. 913-916, (2010); Signorini M., Paulesu E., Friston K., Perani D., Colleluori A., Lucignani G., Et al., Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [18F]FDG PET: a clinical validation of statistical parametric mapping, NeuroImage, 9, 1, pp. 63-80, (1999); Spence J.S., Carmack P.S., Gunst R.F., Schucany W.R., Woodward W.A., Haley R.W., Using a white matter reference to remove the dependency of global signal on experimental conditions in SPECT analyses, NeuroImage, 32, 1, pp. 49-53, (2006); Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Towards defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s & Dementia, 7, 3, pp. 280-292, (2011); Teipel S.J., Sabri O., Grothe M., Barthel H., Prvulovic D., Buerger K., Et al., Perspectives for multimodal neurochemical and imaging biomarkers in Alzheimer’s disease, Journal of Alzheimer’s Disease, 33, S1, pp. S329-S347, (2013); Teune L.K., Bartels A.L., de Jong B.M., Willemsen A.T., Eshuis S.A., de Vries J.J., Et al., Typical cerebral metabolic patterns in neurodegenerative brain diseases, Movement Disorders, 25, 14, pp. 2395-2404, (2010); Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Et al., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, NeuroImage, 15, 1, pp. 273-289, (2002); Wenzel F., Young S., Wilke F., Apostolova I., Arlt S., Jahn H., Et al., B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: impact on voxel-based statistical single-subject analysis, NeuroImage, 50, 3, pp. 994-1003, (2010); Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Et al., Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment, Journal of Internal Medicine, 256, 3, pp. 240-246, (2004); Yakushev I., Hammers A., Fellgiebel A., Schmidtmann I., Scheurich A., Buchholz H.G., Et al., SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnesic mild cognitive impairment from healthy aging, NeuroImage, 44, 1, pp. 43-50, (2009)","2-s2.0-84911007865"
"Cerami C.; Cappa S.F.","Cerami, Chiara (25722905400); Cappa, Stefano F. (7005836132)","25722905400; 7005836132","The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition","2013","Neurological Sciences","34","8","","1267","1274","7","24","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883172330&doi=10.1007%2fs10072-013-1317-9&partnerID=40&md5=860f0922a0879a548019b32c3687aa6c","The behavioral variant of frontotemporal dementia (bvFTD) is one of the most frequent neurodegenerative disorders with a presenile onset. It is characterized by a long phase of subclinical behavioral changes and social conduct disorders, associated with a progressive modification of personality. Recently, an international consortium of experts developed revised guidelines for its clinical diagnosis, which highlight the supportive role of biomarkers in the diagnostic process. According to new criteria, bvFTD can be classified in ""possible"" (requiring three of six specific clinical features), ""probable"" (in the presence of functional disability and typical neuroimaging features), and ""with definite frontotemporal lobar degeneration"" (requiring the presence of a known causal mutation or a histopathological confirmation). Familial aggregation is frequently reported in bvFTD and frontotemporal lobar degeneration in general, with an autosomal dominant transmission in about 10 % cases. The aim of this paper is to review and discuss recent advances in the knowledge of clinical, neuropsychological, and imaging features of bvFTD. We also briefly summarize the available genetic information about the frontotemporal lobar degeneration spectrum. © 2013 Springer-Verlag Italia.","[ <sup>18</sup>F]FDG PET imaging; Behavioral variant of frontotemporal dementia; Frontotemporal lobar degeneration; Social cognition disorders; Voxel-based morphometry","Brain; Cognition Disorders; Frontotemporal Dementia; Humans; Social Behavior Disorders; DNA binding protein; fluorodeoxyglucose f 18; fused in sarcoma protein; transactive response DNA binding protein; unclassified drug; valosin containing protein; valosin containing protein 1; antisocial personality disorder; C9ORF72 gene; CHMP2B gene; computer assisted tomography; electroencephalogram; emotion; episodic memory; executive function; frontal variant frontotemporal dementia; functional magnetic resonance imaging; FUS gene; gene; gene identification; gene mutation; genetic association; GRN gene; human; image analysis; knowledge; MAPT gene; memory disorder; neuroimaging; neuropathology; neuropsychology; nuclear magnetic resonance imaging; positron emission tomography; recognition; review; social cognition; TARBDP gene; UBQLN2 gene; VCP 1 gene","Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol, 10, 2, pp. 162-172, (2011); Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., Van Swieten J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review, J Neurol Neurosurg Psychiatry, 82, 5, pp. 476-486, (2011); Borroni B., Alberici A., Grassi M., Et al., Is frontotemporal lobar degeneration a rare disorder? Evidence from a preliminary study in Brescia County, Italy, J Alzheimers Dis, 19, 1, pp. 111-116, (2010); Bernardi L., Frangipani F., Smirne N., Et al., Epidemiology and genetics of frontotemporal dementia: A door-to-door survey in Southern Italy, Neurobiol Aging, 33, 12, (2012); Baker M., Mackenzie I.R., Pickering-Brown S.M., Et al., Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17, Nature, 442, pp. 916-919, (2006); Rosso S.M., Donker Kaat L., Baks T., Et al., Frontotemporal dementia in the Netherlands: Patient characteristics and prevalence estimates from a population-based study, Brain, 126, PART 9, pp. 2016-2022, (2003); Loy C.T., McCusker E., Kril J.J., Et al., Very early-onset frontotemporal dementia with no family history predicts underlying fused in sarcoma pathology, Brain, 133, PART 12, (2010); Halliday G., Bigio E.H., Cairns N.J., Neumann M., Mackenzie I.R., Mann D.M., Mechanisms of disease in frontotemporal lobar degeneration: Gain of function versus loss of function effects, Acta Neuropathol, 124, 3, pp. 373-382, (2012); Whitwell J.L., Weigand S.D., Boeve B.F., Et al., Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics, Brain, 135, PART 3, pp. 794-806, (2012); Alladi S., Xuereb J., Bak T., Et al., Focal cortical presentations of Alzheimer's disease, Brain, 130, PART 10, pp. 2636-2645, (2007); Cerami C., Scarpini E., Cappa S.F., Galimberti D., Frontotemporal lobar degeneration: Current knowledge and future challenges, J Neurol, 259, 11, pp. 2278-2286, (2012); Rascovsky K., Hodges J.R., Knopman D., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, PART 9, pp. 2456-2477, (2011); Neary D., Snowden J.S., Gustafson L., Et al., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, 6, pp. 1546-1554, (1998); Zamboni G., Huey E.D., Krueger F., Nichelli P.F., Grafman J., Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates, Neurology, 71, 10, pp. 736-742, (2008); Manoochehri M., Huey E.D., Diagnosis and management of behavioral issues in frontotemporal dementia, Curr Neurol Neurosci Rep, 12, 5, pp. 528-536, (2012); Piguet O., Petersen A., Yin Ka Lam B., Et al., Eating and hypothalamus changes in behavioral-variant frontotemporal dementia, Ann Neurol, 69, pp. 312-319, (2011); Mahoney C.J., Rohrer J.D., Omar R., Rossor M.N., Warren J.D., Neuroanatomical profiles of personality change in frontotemporal lobar degeneration, Br J Psychiatry, 198, 5, pp. 365-372, (2011); Grossman M., Eslinger P.J., Troiani V., Et al., The role of ventral medial prefrontal cortex in social decisions: Converging evidence from fMRI and frontotemporal lobar degeneration, Neuropsychologia, 48, 12, pp. 3505-3512, (2010); Torralva T., Roca M., Gleichgerrcht E., Bekinschtein T., Manes F., A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia, Brain, 132, PART 5, pp. 1299-1309, (2009); Mendez M.F., The unique predisposition to criminal violations in frontotemporal dementia, J Am Acad Psychiatry Law, 38, pp. 318-323, (2010); Sturm V.E., McCarthy M.E., Yun I., Et al., Mutual gaze in Alzheimer's disease, frontotemporal and semantic dementia couples, Soc Cogn Affect Neurosci, 6, pp. 359-367, (2011); Zanetti O., Vallotti B., Frisoni G.B., Geroldi C., Bianchetti A., Pasqualetti P., Trabucchi M., Insight in dementia: When does it occur? Evidence for a nonlinear relationship between insight and cognitive status, J Gerontol B Psychol Sci Soc Sci, 54, 2, (1999); Kipps C.M., Mioshi E., Hodges J.R., Emotion, social functioning and activities of daily living in frontotemporal dementia, Neurocase, 15, 3, pp. 182-189, (2009); Omar R., Rohrer J.D., Hailstone J.C., Warren J.D., Structural neuroanatomy of face processing in frontotemporal lobar degeneration, J Neurol Neurosurg Psychiatry, 82, 12, pp. 1341-1343, (2011); Eckart J.A., Sturm V.E., Miller B.L., Levenson R.W., Diminished disgust reactivity in behavioral variant frontotemporal dementia, Neuropsychologia, 50, 5, pp. 786-790, (2012); Omar R., Henley S.M., Bartlett J.W., Et al., The structural neuroanatomy of music emotion recognition: Evidence from frontotemporal lobar degeneration, Neuroimage, 56, 3, pp. 1814-1821, (2011); Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D., Neurodegenerative diseases target large-scale human brain networks, Neuron, 62, 1, pp. 42-52, (2009); Seeley W.W., Zhou J., Kim E.J., Frontotemporal dementia: What can the behavioral variant teach us about human brain organization?, Neuroscientist, 18, 4, pp. 373-385, (2012); Zahn R., Moll J., Iyengar V., Et al., Social conceptual impairments in frontotemporal lobar degeneration with right anterior temporal hypometabolism, Brain, 132, pp. 604-616, (2009); Adenzato M., Cavallo M., Enrici I., Theory of mind ability in the behavioural variant of frontotemporal dementia: An analysis of the neural, cognitive, and social levels, Neuropsychologia, 48, 1, pp. 2-12, (2010); Shany-Ur T., Poorzand P., Grossman S.N., Et al., Comprehension of insincere communication in neurodegenerative disease: Lies, sarcasm, and theory of mind, Cortex, 48, 10, pp. 1329-1341, (2012); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Et al., Structural anatomy of empathy in neurodegenerative disease, Brain, 129, PART 11, pp. 2945-2956, (2006); Mendez M.F., Shapira J.S., Altered emotional morality in frontotemporal dementia, Cogn Neuropsychiatry, 14, 3, pp. 165-179, (2009); Gleichgerrcht E., Torralva T., Roca M., Pose M., Manes F., The role of social cognition in moral judgment in frontotemporal dementia, Soc Neurosci, 6, 2, pp. 113-122, (2011); Eslinger P.J., Moore P., Anderson C., Grossman M., Social cognition, executive functioning, and neuroimaging correlates of empathic deficits in frontotemporal dementia, J Neuropsychiatry Clin Neurosci, 23, 1, pp. 74-82, (2011); Krueger C.E., Laluz V., Rosen H.J., Neuhaus J.M., Miller B.L., Kramer J.H., Double dissociation in the anatomy of socioemotional disinhibition and executive functioning in dementia, Neuropsychology, 25, 2, pp. 249-259, (2011); Goodkind M.S., Gyurak A., McCarthy M., Miller B.L., Levenson R.W., Emotion regulation deficits in frontotemporal lobar degeneration and Alzheimer's disease, Psychol Aging, 25, 1, pp. 30-37, (2010); Johns E.K., Phillips N.A., Belleville S., Et al., Executive functions in frontotemporal dementia and Lewy body dementia, Neuropsychology, 23, 6, pp. 765-777, (2009); Laisney M., Matuszewski V., Mezenge F., Belliard S., De La Sayette V., Eustache F., Desgranges B., The underlying mechanisms of verbal fluency deficit in frontotemporal dementia and semantic dementia, J Neurol, 256, 7, pp. 1083-1094, (2009); Huey E.D., Goveia E.N., Paviol S., Pardini M., Krueger F., Zamboni G., Tierney M.C., Wassermann E.M., Grafman J., Executive dysfunction in frontotemporal dementia and corticobasal syndrome, Neurology, 72, 5, pp. 453-459, (2009); Kipps C.M., Hodges J.R., Fryer T.D., Nestor P.J., Combined magnetic resonance imaging and positron emission tomography brain imaging in behavioural variant frontotemporal degeneration: Refining the clinical phenotype, Brain, 132, PART 9, pp. 2566-2578, (2009); Hornberger M., Piguet O., Kipps C., Hodges J.R., Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia, Neurology, 71, 19, pp. 1481-1488, (2008); Hornberger M., Piguet O., Episodic memory in frontotemporal dementia: A critical review, Brain, 135, PART 3, pp. 678-692, (2012); Pennington C., Hodges J.R., Hornberger M., Neural correlates of episodic memory in behavioral variant frontotemporal dementia, J Alzheimers Dis, 24, 2, pp. 261-268, (2011); Frasson P., Ghiretti R., Catricala E., Et al., Free and Cued Selective Reminding Test: An Italian normative study, Neurol Sci, 32, 6, pp. 1057-1062, (2011); Della Sala S., Parra M.A., Fabi K., Luzzi S., Abrahams S., Short-term memory binding is impaired in AD but not in non-AD dementias, Neuropsychologia, 50, 5, pp. 833-840, (2012); McKinnon M.C., Nica E.I., Sengdy P., Et al., Autobiographical memory and patterns of brain atrophy in frontotemporal lobar degeneration, J Cogn Neurosci., 20, 10, pp. 1839-1853, (2008); Irish M., Piguet O., Hodges J.R., Self-projection and the default network in frontotemporal dementia, Nat Rev Neurol, 8, 3, pp. 152-161, (2012); Hornberger M., Wong S., Tan R., Et al., In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease, Brain, 135, PART 10, pp. 3015-3025, (2012); Arighi A., Fumagalli G.G., Jacini F., Et al., Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: Psychiatric clinical presentations, J Alzheimers Dis, 31, 2, pp. 447-452, (2012); Snowden J.S., Rollinson S., Thompson J.C., Et al., Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations, Brain, 135, PART 3, pp. 693-708, (2012); Kipps C.M., Hodges J.R., Hornberger M., Nonprogressive behavioural frontotemporal dementia: Recent developments and clinical implications of the 'bvFTD phenocopy syndrome, Curr Opin Neurol, 23, 6, pp. 628-632, (2010); Khan B.K., Yokoyama J.S., Takada L.T., Et al., Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansion, J Neurol Neurosurg Psychiatry, 83, 4, pp. 358-364, (2012); Seeley W.W., Crawford R., Rascovsky K., Et al., Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Arch Neurol, 65, 2, pp. 249-255, (2008); Pan P.L., Song W., Yang J., Et al., Gray matter atrophy in behavioral variant frontotemporal dementia: A meta-analysis of voxel-based morphometry studies, Dement Geriatr Cogn Disord, 33, 2-3, pp. 141-148, (2012); Kril J.J., Macdonald V., Patel S., Png F., Halliday G.M., Distribution of brain atrophy in behavioral variant frontotemporal dementia, J Neurol Sci, 232, 1-2, pp. 83-90, (2005); Barnes J., Whitwell J.L., Frost C., Josephs K.A., Rossor M., Fox N.C., Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration, Arch Neurol, 63, 10, pp. 1434-1439, (2006); Chan D., Fox N.C., Jenkins R., Scahill R.I., Crum W.R., Rossor M.N., Rates of global and regional cerebral atrophy in AD and frontotemporal dementia, Neurology, 57, 10, pp. 1756-1763, (2001); Whitwell J.L., Przybelski S.A., Weigand S.D., Et al., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study, Brain, 132, PART 11, pp. 2932-2946, (2009); Josephs Jr.K.A., Whitwell J.L., Weigand S.D., Et al., Predicting functional decline in behavioural variant frontotemporal dementia, Brain, 134, PART 2, pp. 432-448, (2011); Whitwell J.L., Xu J., Mandrekar J., Et al., Frontal asymmetry in behavioral variant frontotemporal dementia: Clinicoimaging and pathogenetic correlates, Neurobiol Aging, (2012); Rohrer J.D., Ridgway G.R., Modat M., Et al., Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations, Neuroimage, 53, 3, pp. 1070-1076, (2010); Beck J., Rohrer J.D., Campbell T., Et al., A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series, Brain, 131, pp. 706-720, (2008); Cerami C., Marcone A., Galimberti D., Villa C., Scarpini E., Cappa S.F., From genotype to phenotype: Two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder, J Alzheimers Dis, 27, 4, pp. 791-797, (2011); Sha S.J., Takada L.T., Rankin K.P., Et al., Frontotemporal dementia due to C9ORF72 mutations: Clinical and imaging features, Neurology, 79, 10, pp. 1002-1011, (2012); Mahoney C.J., Downey L.E., Ridgway G.R., Et al., Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions, Alzheimers Res Ther, 4, 5, (2012); Zhou J., Greicius M.D., Gennatas E.D., Et al., Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease, Brain, 133, PART 5, pp. 1352-1367, (2010); Zhang Y., Schuff N., Du A.T., Et al., White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI, Brain, 132, PART 9, pp. 2579-2592, (2009); Whitwell J.L., Avula R., Senjem M.L., Et al., Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia, Neurology, 74, 16, pp. 1279-1287, (2010); Kanda T., Ishii K., Uemura T., Et al., Comparison of grey matter and metabolic reductions in frontotemporal dementia using FDG-PET and voxel-based morphometric MR studies, Eur Nucl Med Mol Imaging, 35, 12, pp. 2227-2234, (2008); Yu C.E., Bird T.D., Bekris L.M., Et al., The spectrum of mutations in progranulin: A collaborative study screening 545 cases of neurodegeneration, Arch Neurol, 67, pp. 161-170, (2010); Chio A., Borghero G., Restagno G., Et al., Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72, Brain, 135, PART 3, pp. 784-793, (2012); Calvo A., Moglia C., Canosa A., Et al., Amyotrophic lateral sclerosis/frontotemporal dementia with predominant manifestations of obsessive-compulsive disorder associated to GGGGCC expansion of the c9orf72 gene, J Neurol, (2012); Floris G., Borghero G., Cannas A., Et al., Frontotemporal dementia with psychosis, parkinsonism, visuo-spatial dysfunction, upper motor neuron involvement associated to expansion of C9ORF72: A peculiar phenotype?, J Neurol, 259, 8, pp. 1749-1751, (2012); Schroeter M.L., Considering the frontomedian cortex in revised criteria for behavioural variant frontotemporal dementia, Brain, 135, PART 4, (2012); Ghidoni R., Stoppani E., Rossi G., Et al., Optimal plasma progranulin cutoff value for predicting null progranulin mutations in neurodegenerative diseases: A multicenter Italian study, Neurodegener Dis, 9, 3, pp. 121-127, (2012); Bossu P., Salani F., Alberici A., Et al., Loss of function mutations in the progranulin gene are related to pro-inflammatory cytokine dysregulation in frontotemporal lobar degeneration patients, J Neuroinflammation, 8, (2011)","2-s2.0-84883172330"
"Valera-Bermejo J.M.; De Marco M.; Mitolo M.; Cerami C.; Dodich A.; Venneri A.","Valera-Bermejo, Jose Manuel (57217080719); De Marco, Matteo (7004975487); Mitolo, Micaela (55655267600); Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Venneri, Annalena (7004430967)","57217080719; 7004975487; 55655267600; 25722905400; 56001713900; 7004430967","Large-Scale Functional Networks, Cognition and Brain Structures Supporting Social Cognition and Theory of Mind Performance in Prodromal to Mild Alzheimer’s Disease","2021","Frontiers in Aging Neuroscience","13","","766703","","","","5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120577513&doi=10.3389%2ffnagi.2021.766703&partnerID=40&md5=1fe83d4438aa4c716e656cfb7ab84cfd","Impairment of social cognition (SC) skills such as recognition and attribution of intentions and affective states of others (Theory of Mind, ToM) has been evidenced in Alzheimer’s Disease (AD). This study investigated the neuropsychological, neuroanatomical and brain-functional underpinnings of SC processing to obtain an understanding of the social neurophenotype in early probable AD. Forty-six patients with mild cognitive impairment and mild probable AD underwent SC assessment including emotion recognition (Ekman-60-faces task) and cognitive and affective ToM (Reading-the-Mind-in-the-Eyes test and Story-based Empathy task). Linear models tested the association between SC scores and neuropsychological measures, grey matter maps and large-scale functional networks activity. The executive domain had the most predominant association with SC scores in the cognitive profile. Grey matter volume of the anterior cingulate, orbitofrontal, temporoparietal junction (TPJ), superior temporal, and cerebellar cortices were associated with ToM. Social cognition scores were associated with lower connectivity of the default-mode network with the prefrontal cortex. The right fronto-parietal network displayed higher inter-network connectivity in the right TPJ and insula while the salience network showed lower inter-network connectivity with the left TPJ and insula. Connectivity coupling alterations of executive-attentional networks may support default mode social-cognitive-associated decline through the recruitment of frontal executive mechanisms. Copyright © 2021 Valera-Bermejo, De Marco, Mitolo, Cerami, Dodich and Venneri.","Alzheimer’s disease; fMRI; mild cognitive impairment; social cognition; theory of mind; VBM","aged; Alzheimer disease; anterior cingulate; Article; cerebellum cortex; clinical article; cognition; controlled study; default mode network; Ekman 60 Faces test; emotion; female; frontoparietal network; functional connectivity; functional magnetic resonance imaging; gray matter; gray matter volume; human; insula; male; mental performance; mental task; mild cognitive impairment; nerve cell network; neuroanatomy; neuropsychological test; neuropsychology; orbital cortex; prefrontal cortex; prodromal symptom; Reading the Mind in the Eyes Test; resting state network; salience network; social cognition; Story based Empathy Task; superior temporal gyrus; temporoparietal junction; theory of mind; voxel based morphometry","Abu-Akel A., Shamay-Tsoory S., Neuroanatomical and neurochemical bases of theory of mind, Neuropsychologia, 49, pp. 2971-2984, (2011); Ahmed F.S., Stephen Miller L., Executive function mechanisms of theory of mind, J. Autism Dev. Dis, 41, pp. 667-678, (2011); Aichhorn M., Perner J., Weiss B., Kronbichler M., Staffen W., Ladurner G., Temporo-parietal junction activity in theory-of-mind tasks: falseness, beliefs, or attention, J. Cogn. Neurosci, 21, pp. 1179-1192, (2009); Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Et al., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Demen, 7, pp. 270-279, (2011); Amanzio M., Torta D.M.E., Sacco K., Cauda F., D'Agata F., Duca S., Et al., Unawareness of deficits in Alzheimer’s disease: role of the cingulate cortex, Brain, 134, pp. 1061-1076, (2011); Amodio D.M., Frith C.D., Meeting of minds: the medial frontal cortex and social cognition, Nat. Rev. Neurosci, 7, 268, (2006); Badhwar A., Tam A., Dansereau C., Orban P., Hoffstaedter F., Bellec P., Resting-state network dysfunction in Alzheimer’s disease: A systematic review and meta-analysis, Alzheimer’s Demen, 8, pp. 73-85, (2017); Baglio F., Castelli I., Alberoni M., Blasi V., Griffanti L., Falini A., Et al., Theory of mind in amnestic mild cognitive impairment: an FMRI study, J. Alzheimers Dis, 29, pp. 25-37, (2012); Baron-Cohen S., Leslie A.M., Frith U., Does the autistic child have a “theory of mind”?, Cognition, 21, pp. 37-46, (1985); Baron-Cohen S., Wheelwright S., Hill J., Raste Y., Plumb I., The “reading the mind in the eyes”. test revised version: a study with normal adults, and adults with asperger syndrome or high-functioning autism, J. Child Psychol. Psychiatry, 42, pp. 241-251, (2001); Beckmann C.F., DeLuca M., Devlin J.T., Smith S.M., Investigations into resting-state connectivity using independent component analysis. Philosophical transactions of the Royal Society of London, Ser. B Biol. Sci, 360, pp. 1001-1013, (2005); Bertoux M., de Souza L.C., O'Callaghan C., Greve A., Sarazin M., Dubois B., Et al., Social cognition deficits: the key to discriminate behavioral variant frontotemporal dementia from Alzheimer’s disease regardless of amnesia?, J. Alzheimers Dis, 49, pp. 1065-1074, (2016); Bird C.M., Castelli F., Malik O., Frith U., Husain M., The impact of extensive medial frontal lobe damage on ‘Theory of Mind’ and cognition, Brain, 127, pp. 914-928, (2004); Bora E., Yener G.G., Meta-Analysis of social cognition in mild cognitive impairment, J. Geriat. Psychiatry Neurol, 30, pp. 206-213, (2017); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer’s disease: a meta-analysis, J. Neurol. Neurosur. Psychiatry, 86, pp. 714-719, (2015); Bressler S.L., Menon V., Large-scale brain networks in cognition: emerging methods and principles, Trends Cogn. Sci, 14, pp. 277-290, (2010); Broyd S.J., Demanuele C., Debener S., Helps S.K., James C.J., Sonuga-Barke E.J., Default-mode brain dysfunction in mental disorders: a systematic review, Neurosci. Biobehav. Rev, 33, pp. 279-296, (2009); Castelli I., Pini A., Alberoni M., Liverta-Sempio O., Baglio F., Massaro D., Et al., Mapping levels of theory of mind in Alzheimer’s disease: A preliminary study, Aging Ment. Health, 15, pp. 157-168, (2011); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Et al., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Demen, 10, pp. 827-834, (2014); Chainay H., Gaubert F., Affective and cognitive theory of mind in Alzheimer’s disease: The role of executive functions, J. Clin. Experimen. Neuropsychol, 42, pp. 371-386, (2020); Chand G.B., Wu J., Hajjar I., Qiu D., Interactions of the salience network and its subsystems with the default-mode and the central-executive networks in normal aging and mild cognitive impairment, Brain Connect, 7, pp. 401-412, (2017); Chen H., Li Y., Liu Q., Shi Q., Wang J., Shen H., Et al., Abnormal interactions of the salience network, central executive network, and default-mode network in patients with different cognitive impairment loads caused by leukoaraiosis, Front. Neural. Circ, 13, 42, (2019); Chiong W., Wilson S.M., D'Esposito M., Kayser A.S., Grossman S.N., Poorzand P., Et al., The salience network causally influences default mode network activity during moral reasoning, Brain, 136, pp. 1929-1941, (2013); Christidi F., Migliaccio R., Santamaria-Garcia H., Santangelo G., Trojsi F., Social cognition dysfunctions in neurodegenerative diseases: neuroanatomical correlates and clinical implications, Behav. Neurol, 2018, (2018); Ciaramelli E., Bernardi F., Moscovitch M., Individualized Theory of Mind (iToM): when memory modulates empathy, Front. Psychol, 4, (2013); Circelli K.S., Clark U.S., Cronin-Golomb A., Visual scanning patterns and executive function in relation to facial emotion recognition in aging, Aging Neuropsychol. Cogn, 20, pp. 148-173, (2013); Corbetta M., Patel G., Shulman G.L., The reorienting system of the human brain: from environment to theory of mind, Neuron, 58, pp. 306-324, (2008); Cotter J., Granger K., Backx R., Hobbs M., Looi C.Y., Barnett J.H., Social cognitive dysfunction as a clinical marker: A systematic review of meta-analyses across 30 clinical conditions, Neurosci. Biobehav. Rev, 84, pp. 92-99, (2018); Cuerva A.G., Sabe L., Kuzis G., Tiberti C., Dorrego F., Starkstein S.E., Theory of mind and pragmatic abilities in dementia, Neuropsy. Neuropsychol. Behav. Neurol, 14, pp. 153-158, (2001); Demetriou A., Makris N., Kazi S., Spanoudis G., Shayer M., The developmental trinity of mind: Cognizance, executive control, and reasoning, Wiley Interdiscip. Rev. Cogn. Sci, 9, e1461, (2018); Dermody N., Wong S., Ahmed R., Piguet O., Hodges J.R., Irish M., Uncovering the neural bases of cognitive and affective empathy deficits in Alzheimer’s disease and the behavioral-variant of frontotemporal dementia, J. Alzheimers Dis, 53, pp. 801-816, (2016); Diamond A., Executive functions, Ann. Rev. Psychol, 64, pp. 135-168, (2013); Dixon M.L., De La Vega A., Mills C., Andrews-Hanna J., Spreng R.N., Cole M.W., Et al., Heterogeneity within the frontoparietal control network and its relationship to the default and dorsal attention networks, Proc. Nat. Acad. Sci. USA, 115, pp. 1598-1607, (2018); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol. Sci, 36, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: a normative study of the Ekman 60-Faces Test in the Italian population, Neurol. Sci, 35, pp. 1015-1021, (2014); Dodich A., Cerami C., Cappa S.F., Marcone A., Golzi V., Zamboni M., Et al., Combined socio-behavioral evaluation improves the differential diagnosis between the behavioral variant of frontotemporal dementia and Alzheimer’s disease: in search of neuropsychological markers, J. Alzheimers Dis, 61, pp. 761-772, (2018); Dodich A., Cerami C., Crespi C., Canessa N., Lettieri G., Iannaccone S., Et al., Differential impairment of cognitive and affective mentalizing abilities in neurodegenerative dementias: evidence from behavioral variant of frontotemporal dementia. Alzheimer’s disease, and mild cognitive impairment, J. Alzheimers Dis, 50, pp. 1011-1022, (2016); Dvash J., Shamay-Tsoory S.G., Theory of Mind and empathy as multidimensional constructs: neurological foundations, Topic Lang. Disord, 34, 40, (2014); Ekman P., Friesen W.V., Consulting Psychologists Press, Pictures of facial affect, (1976); Eyler L.T., Elman J.A., Hatton S.N., Gough S., Mischel A.K., Hagler D.J., Et al., Resting state abnormalities of the default mode network in mild cognitive impairment: a systematic review and meta-analysis, J. Alzheimer’s Dis, 70, pp. 107-120, (2019); Falk E.B., Bassett D.S., Brain and social networks: fundamental building blocks of human experience, Trends Cogn. Sci, 21, pp. 674-690, (2017); Fox N.C., Schott J.M., Imaging cerebral atrophy: normal ageing to Alzheimer’s disease, Lancet, 363, pp. 392-394, (2004); Fratiglioni L., Wang H.X., Brain reserve hypothesis in dementia, J. Alzheimers Dis, 12, pp. 11-22, (2007); Freedman M., Binns M.A., Black S.E., Murphy C., Stuss D.T., Theory of mind and recognition of facial emotion in dementia: challenge to current concepts, Alzheimer Dis. Assoc. Disord, 27, pp. 56-61, (2013); Frith C.D., Frith U., The neural basis of mentalizing, Neuron, 50, pp. 531-534, (2006); Fusar-Poli P., Placentino A., Carletti F., Landi P., Allen P., Surguladze S., Et al., Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies, J. Psychiatry Neurosci, 34, pp. 418-432, (2009); Gallagher H.L., Frith C.D., Functional imaging of ‘theory of mind’, Trends Cogn. Sci, 7, pp. 77-83, (2003); Garcia-Rodriguez B., Vincent C., Casares-Guillen C., Ellgring H., Frank A., The effects of different attentional demands in the identification of emotional facial expressions in Alzheimer’s disease, Am. J. Alzheimers Dis. Demen, 27, pp. 530-536, (2012); Greicius M.D., Srivastava G., Reiss A.L., Menon V., Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI, Proc. Nat. Acad. Sci. USA, 101, pp. 4637-4642, (2004); Habeck C., Risacher S., Lee G.J., Glymour M.M., Mormino E., Mukherjee S., Et al., Relationship between baseline brain metabolism measured using [<sup>18</sup>F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease, Brain Imag. Behav, 6, pp. 568-583, (2012); Heitz C., Noblet V., Phillipps C., Cretin B., Vogt N., Philippi N., Et al., Cognitive and affective theory of mind in dementia with Lewy bodies and Alzheimer’s disease, Alzheimer’s Res. Therap, 8, 10, (2016); Hot P., Klein-Koerkamp Y., Borg C., Richard-Mornas A., Zsoldos I., Paignon Adeline A., Et al., Fear recognition impairment in early-stage Alzheimer’s disease: when focusing on the eyes region improves performance, Brain Cogn, 82, pp. 25-34, (2013); Hughes C., Cassidy B.S., Faskowitz J., Avena-Koenigsberger A., Sporns O., Krendl A.C., Age differences in specific neural connections within the Default Mode Network underlie theory of mind, Neuroimage, 191, pp. 269-277, (2019); Jack C.R., Bennett D.A., Blennow K., Carrillo M.C., Dunn B., Haeberlein S.B., Et al., NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease, Alzheimers Demen, 14, pp. 535-562, (2018); Jonker F., Wattjes M., Scherder E., Impaired behavioural self-awareness and affective Theory of Mind deficits following prefrontal cortex damage, Neuropsychiatry, 7, pp. 750-758, (2017); Jorge Cardoso M., Leung K., Modat M., Keihaninejad S., Cash D., Barnes J., Et al., STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation, Med. Image Anal, 17, pp. 671-684, (2013); Kalbe E., Schlegel M., Sack A.T., Nowak D.A., Dafotakis M., Bangard C., Et al., Dissociating cognitive from affective theory of mind: a TMS study, Cortex, 46, pp. 769-780, (2010); Kessels R.P.C., Waanders-OudeElferink M., van Tilborg I., Social cognition and social functioning in patients with amnestic mild cognitive impairment or Alzheimer’s dementia, J. Neuropsy, 15, 12223, (2021); Krall S.C., Rottschy C., Oberwelland E., Bzdok D., Fox P.T., Eickhoff S.B., Et al., The role of the right temporoparietal junction in attention and social interaction as revealed by ALE meta-analysis, Brain Struct. Funct, 220, pp. 587-604, (2015); Kucyi A., Hodaie M., Davis K.D., Lateralization in intrinsic functional connectivity of the temporoparietal junction with salience- and attention-related brain networks, J. Neurophys, 108, pp. 3382-3392, (2012); Kumfor F., Honan C., McDonald S., Hazelton J.L., Hodges J.R., Piguet O., Assessing the “social brain” in dementia: Applying TASIT-S, Cortex, 93, pp. 166-177, (2017); Kurth F., Zilles K., Fox P.T., Laird A.R., Eickhoff S.B., A link between the systems: functional differentiation and integration within the human insula revealed by meta-analysis, Brain Struct. Funct, 214, pp. 519-534, (2010); Laisney M., Bon L., Guiziou C., Daluzeau N., Eustache F., Desgranges B., Cognitive and affective Theory of Mind in mild to moderate Alzheimer’s disease, J. Neuropsy, 7, pp. 107-120, (2013); Lancaster J.L., Rainey L.H., Summerlin J.L., Freitas C.S., Fox P.T., Evans A.C., Et al., Automated labeling of the human brain: a preliminary report on the development and evaluation of a forward-transform method, Human Brain Map, 5, pp. 238-242, (1997); Lancaster J.L., Woldorff M.G., Parsons L.M., Liotti M., Freitas C.S., Rainey L., Et al., Automated Talairach atlas labels for functional brain mapping, Human Brain Map, 10, pp. 120-131, (2000); Le Bouc R., Lenfant P., Delbeuck X., Ravasi L., Lebert F., Semah F., Et al., My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer’s disease, Brain, 135Pt 10, pp. 3026-3038, (2012); Leslie A.M., Friedman O., German T.P., Core mechanisms in “theory of mind”, Trends Cogn. Sci, 8, pp. 528-533, (2004); Li W., Mai X., Liu C., The default mode network and social understanding of others: what do brain connectivity studies tell us, Front. Human Neurosci, 8, 74, (2014); Lieberman M.D., Social cognitive neuroscience: a review of core processes, Ann. Rev. Psychol, 58, pp. 259-289, (2007); Lucena A.T., Bhalla R.K., Belfort Almeida Dos Santos T.T., Dourado M.C.N., The relationship between theory of mind and cognition in Alzheimer’s disease: A systematic review, J. Clin. Exp. Neuropsychol, 42, pp. 223-239, (2020); Mars R.B., Neubert F.-X., Noonan M.P., Sallet J., Toni I., Rushworth M.F.S., On the relationship between the “default mode network” and the “social brain”, Front. Human Neurosci, 6, (2012); Martinez M., Multani N., Anor C.J., Misquitta K., Tang-Wai D.F., Keren R., Et al., Emotion detection deficits and decreased empathy in patients with Alzheimer’s disease and parkinson’s disease affect caregiver mood and burden, Front. Aging Neurosci, 10, 120, (2018); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Et al., The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s Demen, 7, pp. 263-269, (2011); Mier D., Lis S., Neuthe K., Sauer C., Esslinger C., Gallhofer B., Et al., The involvement of emotion recognition in affective theory of mind, Psychophysiology, 47, pp. 1028-1039, (2010); Miguel F.K., Caramanico R.B., Huss E.Y., Zuanazzi A.C., Validity of the reading the mind in the eyes test in a brazilian sample, Paidéia (Ribeirão Preto), 27, pp. 16-23, (2017); Miller C.A., Developmental relationships between language and theory of mind, Am. J. Speech-Lang. Pathol, 15, pp. 142-154, (2006); Mitchell R.L., Phillips L.H., The overlapping relationship between emotion perception and theory of mind, Neuropsychologia, 70, pp. 1-10, (2015); Moreau N., Rauzy S., Viallet F., Champagne-Lavau M., Theory of mind in Alzheimer disease: Evidence of authentic impairment during social interaction, Neuropsychology, 30, pp. 312-321, (2016); Otti A., Wohlschlaeger A.M., Noll-Hussong M., Is the Medial Prefrontal Cortex Necessary for Theory of Mind?, PLoS One, 10, (2015); Peelle J.E., Cusack R., Henson R.N.A., Adjusting for global effects in voxel-based morphometry: Gray matter decline in normal aging, Neuroimage, 60, pp. 1503-1516, (2012); Perner J., Aichhorn M., Kronbichler M., Staffen W., Ladurner G., Thinking of mental and other representations: The roles of left and right temporo-parietal junction, Soc. Neurosci, 1, pp. 245-258, (2006); Petersen R.C., Mild cognitive impairment as a diagnostic entity, J. Inter. Med, 256, pp. 183-194, (2004); Phillips L.H., Scott C., Henry J.D., Mowat D., Bell J.S., Emotion perception in Alzheimer’s disease and mood disorder in old age, Psychol. Aging, 25, pp. 38-47, (2010); Poletti M., Enrici I., Adenzato M., Cognitive and affective Theory of Mind in neurodegenerative diseases: neuropsychological, neuroanatomical and neurochemical levels, Neurosci. Biobehav. Rev, 36, pp. 2147-2164, (2012); Postema M.C., De Marco M., Colato, Venneri A., A study of within-subject reliability of the brain’s default-mode network, Magn. Reson. Mater. Phy, 32, pp. 391-405, (2019); Ramanan S., de Souza L.C., Moreau N., Sarazin M., Teixeira A.L., Allen Z., Et al., Determinants of theory of mind performance in Alzheimer’s disease: A data-mining study, Cortex, 88, pp. 8-18, (2017); Rowe A.D., Bullock P.R., Polkey C.E., Morris R.G., Theory of mind” impairments and their relationship to executive functioning following frontal lobe excisions, Brain, 124Pt 3, pp. 600-616, (2001); Saltzman J., Strauss E., Hunter M., Archibald S., Theory of mind and executive functions in normal human aging and Parkinson’s disease, J. Int. Neuropsychol. Soc, 6, pp. 781-788, (2000); Samson D., Apperly I.A., Chiavarino C., Humphreys G.W., Left temporoparietal junction is necessary for representing someone else’s belief, Nat. Neurosci, 7, pp. 499-500, (2004); Sapey-Triomphe L.-A., Heckemann R.A., Boublay N., Dorey J.-M., Henaff M.-A., Rouch I., Et al., Neuroanatomical correlates of recognizing face expressions in mild stages of Alzheimer’s disease, PLoS One, 10, (2015); Saxe R., Kanwisher N., People thinking about thinking people. The role of the temporo-parietal junction in “theory of mind”, Neuroimage, 19, pp. 1835-1842, (2003); Saxe R., Wexler A., Making sense of another mind: the role of the right temporo-parietal junction, Neuropsychologia, 43, pp. 1391-1399, (2005); Schilbach L., Eickhoff S.B., Rotarska-Jagiela A., Fink G.R., Vogeley K., Minds at rest? Social cognition as the default mode of cognizing and its putative relationship to the “default system” of the brain, Consciou. Cogn, 17, pp. 457-467, (2008); Schlaffke L., Lissek S., Lenz M., Juckel G., Schultz T., Tegenthoff M., Et al., Shared and nonshared neural networks of cognitive and affective theory-of-mind: a neuroimaging study using cartoon picture stories, Human Brain Map, 36, pp. 29-39, (2015); Schmahmann J.D., The cerebellum and cognition, Neurosci. Lett, 688, pp. 62-75, (2019); Schurz M., Radua J., Aichhorn M., Richlan F., Perner J., Fractionating theory of mind: a meta-analysis of functional brain imaging studies, Neurosci. Biobehav. Rev, 42, pp. 9-34, (2014); Serafin M., Surian F., Il Test degli Occhi: uno strumento per valutare la “teoria della mente”, Giornale Italiano di Psicologia, 4, pp. 839-860, (2004); Synn A., Mothakunnel A., Kumfor F., Chen Y., Piguet O., Hodges J.R., Et al., Mental states in moving shapes: Distinct cortical and subcortical contributions to Theory of Mind impairments in dementia, J. Alzheimers Dis, 61, pp. 521-535, (2018); Takenoshita S., Hayashi S., Shinya T., Miki T., Yokota O., Maki Y., Et al., Sally–Anne test and regional cerebral blood flow in Alzheimer’s disease dementia, Psychogeriatrics, 20, pp. 549-556, (2020); Takenoshita S., Terada S., Yokota O., Kutoku Y., Wakutani Y., Nakashima M., Et al., Sally-Anne test in patients with Alzheimer’s disease dementia, J. Alzheimers Dis, 61, pp. 1029-1036, (2018); Torres B., Santos R.L., Sousa M.F., Simoes Neto J.P., Nogueira M.M., Belfort T.T., Et al., Facial expression recognition in Alzheimer’s disease: a longitudinal study, Arquivos de Neuropsiquiatria, 73, pp. 383-389, (2015); Torres M., De Melo Fadel B., Santos De Carvalho R.L., Belfort A., Dos Santos T.T., Et al., Facial expression recognition in Alzheimer’s disease: A systematic review, J. Clin. Exp. Neuropsy, 41, pp. 192-203, (2019); Valera-Bermejo J.M., De Marco M., Mitolo M., McGeown W.J., Venneri A., Neuroanatomical and cognitive correlates of domain-specific anosognosia in early Alzheimer’s disease, Cortex, 129, pp. 236-246, (2020); Valle A., Massaro D., Castelli I., Marchetti A., Theory of Mind development in adolescence and early adulthood: The growing complexity of recursive thinking ability, Eur. J. Psychol, 11, pp. 112-124, (2015); Van Overwalle F., Baetens K., Marien P., Vandekerckhove M., Social cognition and the cerebellum: a meta-analysis of over 350 fMRI studies, Neuroimage, 86, pp. 554-572, (2014); Vellante M., Baron-Cohen S., Melis M., Marrone M., Petretto D.R., Masala C., Et al., The “Reading the Mind in the Eyes” test: Systematic review of psychometric properties and a validation study in Italy, Cogn. Neuropsy, 18, pp. 326-354, (2013); Wade M., Prime H., Jenkins J.M., Yeates K.O., Williams T., Lee K., On the relation between theory of mind and executive functioning: A developmental cognitive neuroscience perspective, Psychon. Bull. Rev, 25, pp. 2119-2140, (2018); Wakefield S.J., McGeown W.J., Shanks M.F., Venneri A., Differentiating normal from pathological brain ageing using standard neuropsychological tests, Curr. Alzheimer Res, 11, pp. 765-772, (2014); Wang Y., Li T.-Q., Dimensionality of ICA in resting-state fMRI investigated by feature optimized classification of independent components with SVM, Front. Human Neurosci, 9, (2015); Woo B.K., Harwood D.G., Melrose R.J., Mandelkern M.A., Campa O.M., Walston A., Et al., Executive deficits and regional brain metabolism in Alzheimer’s disease, Int. J. Geriat. Psychiatry, 25, pp. 1150-1158, (2010); Yildirim E., Soncu Buyukiscan E., Demirtas-Tatlidede A., Bilgic B., Gurvit H., An investigation of affective theory of mind ability and its relation to neuropsychological functions in Alzheimer’s disease, J. Neuropsychol, 14, pp. 399-415, (2020); Zaitchik D., Koff E., Brownell H., Winner E., Albert M., Inference of mental states in patients with Alzheimer’s disease, Cogn. Neuropsy, 9, pp. 301-313, (2004); Zhang Z., Liu Y., Jiang T., Zhou B., An N., Dai H., Et al., Altered spontaneous activity in Alzheimer’s disease and mild cognitive impairment revealed by Regional Homogeneity, Neuroimage, 59, pp. 1429-1440, (2012)","2-s2.0-85120577513"
"Cerami C.; Della Rosa P.A.; Magnani G.; Santangelo R.; Marcone A.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Della Rosa, Pasquale Anthony (14420734200); Magnani, Giuseppe (24496141800); Santangelo, Roberto (57191567809); Marcone, Alessandra (6701496511); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 14420734200; 24496141800; 57191567809; 6701496511; 7005836132; 7005630261","Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia","2015","NeuroImage: Clinical","7","","","187","194","7","90","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84919708754&doi=10.1016%2fj.nicl.2014.12.004&partnerID=40&md5=ab547d6b2dc555048d2ee5d44434ddeb","[18F]FDG-PET imaging has been recognized as a crucial diagnostic marker in Mild Cognitive Impairment (MCI), supporting the presence or the exclusion of Alzheimer's Disease (AD) pathology. A clinical heterogeneity, however, underlies MCI definition. In this study, we aimed to evaluate the predictive role of single-subject voxel-based maps of [18F]FDG distribution generated through statistical parametric mapping (SPM) in the progression to different dementia subtypes in a sample of 45 MCI. Their scans were compared to a large normal reference dataset developed and validated for comparison at single-subject level. Additionally, Aβ42 and Tau CSF values were available in 34 MCI subjects. Clinical follow-up (mean 28.5 ± 7.8 months) assessed subsequent progression to AD or non-AD dementias. The SPM analysis showed: 1) normal brain metabolism in 14 MCI cases, none of them progressing to dementia; 2) the typical temporo-parietal pattern suggestive for prodromal AD in 15 cases, 11 of them progressing to AD; 3) brain hypometabolism suggestive of frontotemporal lobar degeneration (FTLD) subtypes in 7 and dementia with Lewy bodies (DLB) in 2 subjects (all fulfilled FTLD or DLB clinical criteria at follow-up); and 4) 7 MCI cases showed a selective unilateral or bilateral temporo-medial hypometabolism without the typical AD pattern, and they all remained stable. In our sample, objective voxel-based analysis of [18F]FDG-PET scans showed high predictive prognostic value, by identifying either normal brain metabolism or hypometabolic patterns suggestive of different underlying pathologies, as confirmed by progression at follow-up. These data support the potential usefulness of this SPM [18F]FDG PET analysis in the early dementia diagnosis and for improving subject selection in clinical trials based on MCI definition. © 2014 Published by Elsevier Inc.","Alzheimer's disease; Cognitive; Dementia diagnosis; Impairment [<sup>18</sup>F]FDG; Mild; PET imaging","Aged; Brain; Brain Mapping; Dementia; Disease Progression; Female; Fluorodeoxyglucose F18; Humans; Male; Mild Cognitive Impairment; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; amyloid beta protein[1-42]; fluorodeoxyglucose f 18; tau protein; fluorodeoxyglucose f 18; radiopharmaceutical agent; adult; aged; Article; brain mapping; brain metabolism; brain region; clinical article; controlled study; differential diagnosis; diffuse Lewy body disease; disease classification; disease course; early diagnosis; female; follow up; frontotemporal dementia; human; male; middle aged; mild cognitive impairment; PET-CT scanner; positron emission tomography; predictive value; protein cerebrospinal fluid level; statistical parameters; statistical parametric mapping; very elderly; voxel based morphometry; brain; brain mapping; computer assisted diagnosis; dementia; metabolism; mild cognitive impairment; procedures; scintiscanning","Alberici A., Geroldi C., Cotelli M., Adorni A., Calabria M., Rossi G., The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease, Neurol. Sci., 28, 2, pp. 80-86, (2007); Albert M.S., Dekosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 3, pp. 270-279, (2011); Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease, Arch. Neurol., 62, 11, pp. 1728-1733, (2005); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, 5, pp. 496-503, (2013); Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Clinical and biomarker changes in dominantly inherited Alzheimer's disease, N. Engl. J. Med., 367, 9, pp. 795-804, (2012); Bruck A., Virta J.R., Koivunen J., Koikkalainen J., Scheinin N.M., Helenius H., [<sup>11</sup>C]PIB, [<sup>18</sup>F]FDG and MR imaging in patients with mild cognitive impairment, Eur. J. Nucl. Med. Mol. Imaging, 40, 10, pp. 1567-1572, (2013); Busse A., Hensel A., Guhne U., Angermeyer M.C., Riedel-Heller S.G., Mild cognitive impairment: Long-term course of four clinical subtypes, Neurology, 67, 12, pp. 2176-2185, (2006); Cerami C., Crespi C., Della Rosa P.A., Dodich A., Marcone A., Magnani G., Brain changes within the visuo-spatial attentional network in posterior cortical atrophy, J. Alzheimers Dis., 43, 2, pp. 385-395; Chetelat G., Eustache F., Viader F., De La Sayette V., Pelerin A., Mezenge F., FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment, Neurocase, 11, 1, pp. 14-25, (2005); Crutch S.J., Lehmann M., Schott J.M., Rabinovici G.D., Rossor M.N., Fox N.C., Posterior cortical atrophy, Lancet Neurol., 11, 2, pp. 170-178, (2012); Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J., The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia, Neurology, 44, 12, pp. 2308-2314, (1994); De Renzi E., Vignolo L.A., The token test: A sensitive test to detect receptive disturbances in aphasics, Brain J. Neurol., 85, pp. 665-678, (1962); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Gilardi M.C., A standardized [(18)F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, 4, pp. 575-593, (2014); Dubois B., Feldman H.H., Jacova C., Cummings J.L., Dekosky S.T., Barberger-Gateau P., Revising the definition of Alzheimer's disease: A new lexicon, Lancet Neurol., 9, 11, pp. 1118-1127, (2010); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria, Lancet Neurol., 13, 6, pp. 614-629, (2014); Dukart J., Mueller K., Villringer A., Kherif F., Draganski B., Frackowiak R., Relationship between imaging biomarkers, age, progression and symptom severity in Alzheimer's disease, Neuroimage Clin., 3, pp. 84-94, (2013); Ewers M., Brendel M., Rizk-Jackson A., Rominger A., Bartenstein P., Schuff N., Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects, Neuroimage Clin., 4, pp. 45-52, (2014); Fischer P., Jungwirth S., Zehetmayer S., Weissgram S., Hoenigschnabl S., Gelpi E., Conversion from subtypes of mild cognitive impairment to Alzheimer dementia, Neurol., 68, 4, pp. 288-291, (2007); Fouquet M., Desgranges B., Landeau B., Duchesnay E., Mezenge F., De La Sayette V., Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease, Brain, 132, 8, pp. 2058-2067, (2009); Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration, Ann. Neurol., 57, 2, pp. 216-225, (2005); Gallivanone F., Della Rosa P.A., Perani D., Gilardi M.G., Castiglioni I., The impact of different 18FDG PET healthy subject scans for comparison with single patient in SPM analysis, Q J Nucl Med Mol Imaging, (2014); Galluzzi S., Geroldi C., Amicucci G., Bocchio-Chiavetto L., Bonetti M., Bonvicini C., Supporting evidence for using biomarkers in the diagnosis of MCI due to AD, J. Neurol., 260, 2, pp. 640-650, (2013); Gamboz N., Coluccia E., Iavarone A., Brandimonte M.A., Normative data for the pyramids and Palm trees test in the elderly Italian population, Neurol. Sci., 30, 6, pp. 453-458, (2009); Ganguli M., Snitz B.E., Saxton J.A., Chang C.C., Lee C.W., Vander Bilt J., Outcomes of mild cognitive impairment by definition: A population study, Arch. Neurol., 68, 6, pp. 761-767, (2011); Garibotto V., Borroni B., Kalbe E., Herholz K., Salmon E., Holtoff V., Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence, Neurology, 71, 17, pp. 1342-1349, (2008); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Classification of primary progressive aphasia and its variants, Neurology, 76, 11, pp. 1006-1014, (2011); Han J.W., Kim T.H., Lee S.B., Park J.H., Lee J.J., Huh Y., Predictive validity and diagnostic stability of mild cognitive impairment subtypes, Alzheimers Dement., 8, 6, pp. 553-559, (2012); Hatashita S., Yamasaki H., Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction, PLOS One, 8, 6, (2013); Herholz K., Cerebral glucose metabolism in preclinical and prodromal Alzheimer's disease, Expert Rev. Neurother., 10, 11, pp. 1667-1673, (2010); Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage, 17, 1, pp. 302-316, (2002); Jack Jr.C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 3, pp. 257-262, (2011); Jack Jr.C.R., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V., Vemuri P., Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity, Neurology, 81, pp. 1732-1740, (2013); Juh R., Pae C.U., Kim T.S., Lee C.U., Choe B., Suh T., Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis, Neurosci. Lett., 383, 12, pp. 22-27, (2005); Kawashima S., Ito K., Kato T., Inclusion criteria provide heterogeneity in baseline profiles of patients with mild cognitive impairment: Comparison of two prospective cohort studies, BMJ Open, 2, 2, (2012); Kertesz A., Davidson W., Fox H., Frontal behavioral inventory: Diagnostic criteria for frontal lobe dementia, Can. J. Neurol. Sci., 24, 1, pp. 29-36, (1997); Klunk W.E., Perani D., Amyloid and neurodegeneration: Converging and diverging paths, Neurology, 81, pp. 1728-1729, (2013); Lezak M., Valutazione Neuropsicologica, (2000); Luzzatti C., Willmes K., De-Bleser R., Bianchi A., Chiesa G., De-Tanti A., New normative data for the Italian version of the Aachen aphasia test, Arch. Psicol. Neurol. Psichiatr., 55, 6, pp. 1086-1131, (1994); Marra C., Villa G., Quaranta D., Valenza A., Vita M.G., Gainotti G., Probable Alzheimer's disease patients presenting as ""focal temporal lobe dysfunction"" show a slow rate of cognitive decline, J. Int. Neuropsychol. Soc., 18, 1, pp. 144-150, (2012); McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium, Neurology, 65, 12, pp. 1863-1872, (2005); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack Jr.C.R., Kawas C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 3, pp. 263-269, (2011); Miceli G., Laudanna A., Burani C., Capasso R., Batteria per l'analisi dei Deficit Afasici (BADA), Technical Report, Roma (1994). Università Cattolica Del Sacro Cuore; Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E., Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease, Ann. Neurol., 42, 1, pp. 85-94, (1997); Mitchell A.J., Shiri-Feshki M., Rate of progression of mild cognitive impairment to dementia - Meta-analysis of 41 robust inception cohort studies, Acta Psychiatr. Scand., 119, 4, pp. 252-265, (2009); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., Van Berckel B.N., Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiol. Aging, 33, 11, pp. 2533-2550, (2012); Mosconi L., Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD, Eur. J. Nucl. Med. Mol. Imaging, 32, 4, pp. 486-510, (2005); Mosconi L., Murray J., Tsui W.H., Li Y., Spector N., Goldowsky A., Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD, Neurology, 82, 9, pp. 752-760, (2014); Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias, J. Nucl. Med., 49, 3, pp. 390-398, (2008); Ossenkoppele R., Prins N.D., Pijnenburg Y.A., Lemstra A.W., Van Der Flier W.M., Adriaanse S.F., Impact of molecular imaging on the diagnostic process in a memory clinic, Alzheimers Dement., 9, 4, pp. 414-421, (2013); Pagani M., Dessi B., Morbelli S., Brugnolo A., Salmaso D., Piccini A., MCI patients declining and not-declining at mid-term follow-up: FDG-PET findings, Curr. Alzheimer Res., 7, 4, pp. 287-294, (2010); Patterson J.C., Lilien D.L., Takalkar A., Pinkston J.B., Early detection of brain pathology suggestive of early AD using objective evaluation of FDG-PET scans, Int. J. Alzheimers Dis., 2011, (2010); Perani D., Functional neuroimaging of cognition, Handbook of Clinical Neurology, 88, pp. 61-111, (2008); Perani D., FDG PET and cognitive symptoms of dementia, Clinical and Translational Imaging, 1, 4, pp. 247-260, (2013); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clin., 6, pp. 445-454, (2014); Petersen R.C., Roberts R.O., Knopman D.S., Boeve B.F., Geda Y.E., Ivnik R.J., Mild cognitive impairment: Ten years later, Arch. Neurol., 66, 12, pp. 1447-1455, (2009); Prestia A., Caroli A., Van Der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease, Neurology, 80, 11, pp. 1048-1056, (2013); Rabinovici G.D., Rosen H.J., Alkalay A., Kornak J., Furst A.J., Agarwal N., Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD, Neurol., 77, 23, pp. 2034-2042, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Ridgway G.R., Omar R., Ourselin S., Hill D.L., Warren J.D., Fox N.C., Issues with threshold masking in voxel-based morphometry of atrophied brains, Neuroimage, 44, 1, pp. 99-111, (2009); Salmon E., Garraux G., Delbeuck X., Collette F., Kalbe E., Zuendorf G., Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia, Neuroimage, 20, 1, pp. 435-440, (2003); Sanchez-Juan P., Ghosh P.M., Hagen J., Gesierich B., Henry M., Grinberg L.T., Practical utility of amyloid and FDG-PET in an academic dementia center, Neurology, 82, 3, pp. 230-238, (2014); Schroeter M.L., Stein T., Maslowski N., Neumann J., Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients, Neuroimage, 47, 4, pp. 1196-1206, (2009); Signorini M., Paulesu E., Friston K., Perani D., Colleluori A., Lucignani G., Rapid assessment of regional cerebral metabolic abnormalities in single subjects with quantitative and nonquantitative [<sup>18</sup>F]FDG PET: A clinical validation of statistical parametric mapping, Neuroimage, 9, pp. 63-80, (1999); Silverman D.H., Mosconi L., Ercoli L., Chen W., Small G.W., Positron emission tomography scans obtained for the evaluation of cognitive dysfunction, Semin. Nucl. Med., 38, 4, pp. 251-261, (2008); Spence J.S., Carmack P.S., Gunst R.F., Schucany W.R., Woodward W.A., Haley R.W., Using a white matter reference to remove the dependency of global signal on experimental conditions in SPECT analyses, Neuroimage, 32, 1, pp. 49-53, (2006); Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement., 7, 3, pp. 280-292, (2011); Tapiola T., Alafuzoff I., Herukka S.K., Parkkinen L., Hartikainen P., Soininen H., Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain, Arch. Neurol., 66, 3, pp. 382-389, (2009); Teune L.K., Bartels A.L., De Jong B.M., Willemsen A.T., Eshuis S.A., De Vries J.J., Typical cerebral metabolic patterns in neurodegenerative brain diseases, Mov. Disord., 25, 14, pp. 2395-2404, (2010); Thiele F., Young S., Buchert R., Wenzel F., Voxel-based classification of FDG PET in dementia using inter-scanner normalization, Neuroimage, 77, pp. 62-69, (2013); Ward A., Arrighi H.M., Michels S., Cedarbaum J.M., Mild cognitive impairment: Disparity of incidence and prevalence estimates, Alzheimers Dement., 8, 1, pp. 14-21, (2012); Warrington E.K., James M., The Visual Object and Space Perception Battery, (1991); Whitwell J.L., Dickson D.W., Murray M.E., Weigand S.D., Tosakulwong N., Senjem M.L., Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study, Lancet Neurol., 11, 10, pp. 868-877, (2012); Yaffe K., Petersen R.C., Lindquist K., Kramer J., Miller B., Subtype of mild cognitive impairment and progression to dementia and death, Dement. Geriatr. Cogn. Disord., 22, 4, pp. 312-319, (2006)","2-s2.0-84919708754"
"Van Bavel J.J.; Cichocka A.; Capraro V.; Sjåstad H.; Nezlek J.B.; Pavlović T.; Alfano M.; Gelfand M.J.; Azevedo F.; Birtel M.D.; Cislak A.; Lockwood P.L.; Ross R.M.; Abts K.; Agadullina E.; Aruta J.J.B.; Besharati S.N.; Bor A.; Choma B.L.; Crabtree C.D.; Cunningham W.A.; De K.; Ejaz W.; Elbaek C.T.; Findor A.; Flichtentrei D.; Franc R.; Gjoneska B.; Gruber J.; Gualda E.; Horiuchi Y.; Huynh T.L.D.; Ibanez A.; Imran M.A.; Israelashvili J.; Jasko K.; Kantorowicz J.; Kantorowicz-Reznichenko E.; Krouwel A.; Laakasuo M.; Lamm C.; Leygue C.; Lin M.-J.; Mansoor M.S.; Marie A.; Mayiwar L.; Mazepus H.; McHugh C.; Minda J.P.; Mitkidis P.; Olsson A.; Otterbring T.; Packer D.J.; Perry A.; Petersen M.B.; Puthillam A.; Riaño-Moreno J.C.; Rothmund T.; Santamaría-García H.; Schmid P.C.; Stoyanov D.; Tewari S.; Todosijević B.; Tsakiris M.; Tung H.H.; Umbreș R.G.; Vanags E.; Vlasceanu M.; Vonasch A.; Yucel M.; Zhang Y.; Abad M.; Adler E.; Akrawi N.; Mdarhri H.A.; Amara H.; Amodio D.M.; Antazo B.G.; Apps M.; Ay F.C.; Ba M.H.; Barbosa S.; Bastian B.; Berg A.; Bernal-Zárate M.P.; Bernstein M.; Białek M.; Bilancini E.; Bogatyreva N.; Boncinelli L.; Booth J.E.; Borau S.; Buchel O.; Cameron C.D.; Carvalho C.F.; Celadin T.; Cerami C.; Chalise H.N.; Cheng X.; Cian L.; Cockcroft K.; Conway J.; Córdoba-Delgado M.A.; Crespi C.; Crouzevialle M.; Cutler J.; Cypryańska M.; Dabrowska J.; Daniels M.A.; Davis V.H.; Dayley P.N.; Delouvee S.; Denkovski O.; Dezecache G.; Dhaliwal N.A.; Diato A.B.; Di Paolo R.; Drosinou M.; Dulleck U.; Ekmanis J.; Ertan A.S.; Etienne T.W.; Farhana H.H.; Farkhari F.; Farmer H.; Fenwick A.; Fidanovski K.; Flew T.; Fraser S.; Frempong R.B.; Fugelsang J.A.; Gale J.; Garcia-Navarro E.B.; Garladinne P.; Ghajjou O.; Gkinopoulos T.; Gray K.; Griffin S.M.; Gronfeldt B.; Gümren M.; Gurung R.L.; Halperin E.; Harris E.; Herzon V.; Hruška M.; Huang G.; Hudecek M.F.C.; Isler O.; Jangard S.; Jørgensen F.J.; Kachanoff F.; Kahn J.; Dangol A.K.; Keudel O.; Koppel L.; Koverola M.; Kubin E.; Kunnari A.; Kutiyski Y.; Laguna O.; Leota J.; Lermer E.; Levy J.; Levy N.; Li C.; Long E.U.; Longoni C.; Maglić M.; McCashin D.; Metcalf A.L.; Mikloušić I.; El Mimouni S.; Miura A.; Molina-Paredes J.; Monroy-Fonseca C.; Morales-Marente E.; Moreau D.; Muda R.; Myer A.; Nash K.; Nesh-Nash T.; Nitschke J.P.; Nurse M.S.; Ohtsubo Y.; Oldemburgo de Mello V.; O’Madagain C.; Onderco M.; Palacios-Galvez M.S.; Palomäki J.; Pan Y.; Papp Z.; Pärnamets P.; Paruzel-Czachura M.; Pavlović Z.; Payán-Gómez C.; Perander S.; Pitman M.M.; Prasad R.; Pyrkosz-Pacyna J.; Rathje S.; Raza A.; Rêgo G.G.; Rhee K.; Robertson C.E.; Rodríguez-Pascual I.; Saikkonen T.; Salvador-Ginez O.; Sampaio W.M.; Santi G.C.; Santiago-Tovar N.; Savage D.; Scheffer J.A.; Schönegger P.; Schultner D.T.; Schutte E.M.; Scott A.; Sharma M.; Sharma P.; Skali A.; Stadelmann D.; Stafford C.A.; Stanojević D.; Stefaniak A.; Sternisko A.; Stoica A.; Stoyanova K.K.; Strickland B.; Sundvall J.; Thomas J.P.; Tinghög G.; Torgler B.; Traast I.J.; Tucciarelli R.; Tyrala M.; Ungson N.D.; Uysal M.S.; Van Lange P.A.M.; van Prooijen J.-W.; van Rooy D.; Västfjäll D.; Verkoeijen P.; Vieira J.B.; von Sikorski C.; Walker A.C.; Watermeyer J.; Wetter E.; Whillans A.; Willardt R.; Wohl M.J.A.; Wójcik A.D.; Wu K.; Yamada Y.; Yilmaz O.; Yogeeswaran K.; Ziemer C.-T.; Zwaan R.A.; Boggio P.S.","Van Bavel, Jay J. (22986966200); Cichocka, Aleksandra (35765189600); Capraro, Valerio (49361021300); Sjåstad, Hallgeir (57200691996); Nezlek, John B. (7004481879); Pavlović, Tomislav (57196148151); Alfano, Mark (36762163600); Gelfand, Michele J. (7201803113); Azevedo, Flavio (57202683756); Birtel, Michèle D. (46060910600); Cislak, Aleksandra (23666913300); Lockwood, Patricia L. (55347628400); Ross, Robert Malcolm (23567212800); Abts, Koen (16314964400); Agadullina, Elena (55948104400); Aruta, John Jamir Benzon (57205719637); Besharati, Sahba Nomvula (56221801500); Bor, Alexander (57193896526); Choma, Becky L. (10039110600); Crabtree, Charles David (56669557400); Cunningham, William A. (16065517700); De, Koustav (57432843300); Ejaz, Waqas (57196262755); Elbaek, Christian T. (57219005068); Findor, Andrej (15051465700); Flichtentrei, Daniel (35094029100); Franc, Renata (6701375451); Gjoneska, Biljana (57211203812); Gruber, June (8929220900); Gualda, Estrella (26531164900); Horiuchi, Yusaku (24168107200); Huynh, Toan Luu Duc (57728566100); Ibanez, Agustin (55172691400); Imran, Mostak Ahamed (14008430600); Israelashvili, Jacob (57196217992); Jasko, Katarzyna (35743100000); Kantorowicz, Jaroslaw (56256131200); Kantorowicz-Reznichenko, Elena (56743290300); Krouwel, André (16744097100); Laakasuo, Michael (55209862600); Lamm, Claus (56566285000); Leygue, Caroline (11839543000); Lin, Ming-Jen (34668140100); Mansoor, Mohammad Sabbir (57432843400); Marie, Antoine (57210735692); Mayiwar, Lewend (57210589547); Mazepus, Honorata (57189074265); McHugh, Cillian (57201644809); Minda, John Paul (6603737492); Mitkidis, Panagiotis (55734672700); Olsson, Andreas (8690139600); Otterbring, Tobias (54684879600); Packer, Dominic J. (22986127600); Perry, Anat (26647787400); Petersen, Michael Bang (35761369500); Puthillam, Arathy (57209821598); Riaño-Moreno, Julián C. (57210113671); Rothmund, Tobias (26026109100); Santamaría-García, Hernando (56610290700); Schmid, Petra C. (35778895000); Stoyanov, Drozdstoy (36601257300); Tewari, Shruti (37102876500); Todosijević, Bojan (6507222236); Tsakiris, Manos (8612330500); Tung, Hans H. (57189267860); Umbreș, Radu G. (56121056100); Vanags, Edmunds (57433130100); Vlasceanu, Madalina (57201915022); Vonasch, Andrew (16425076400); Yucel, Meltem (57201461738); Zhang, Yucheng (56605134100); Abad, Mohcine (57433425600); Adler, Eli (57367764100); Akrawi, Narin (57433856600); Mdarhri, Hamza Alaoui (57433566000); Amara, Hanane (57433711700); Amodio, David M. (6603573634); Antazo, Benedict G. (57218632714); Apps, Matthew (37017949200); Ay, F. Ceren (57432990200); Ba, Mouhamadou Hady (57433425700); Barbosa, Sergio (57194429267); Bastian, Brock (7005685014); Berg, Anton (57433130200); Bernal-Zárate, Maria P. (57433425900); Bernstein, Michael (18133581400); Białek, Michał (56333322000); Bilancini, Ennio (24175889200); Bogatyreva, Natalia (57226525097); Boncinelli, Leonardo (24175528900); Booth, Jonathan E. (27567441600); Borau, Sylvie (57192594944); Buchel, Ondrej (57219655063); Cameron, C. Daryl (36551893200); Carvalho, Chrissie F. (55972096100); Celadin, Tatiana (57216634436); Cerami, Chiara (25722905400); Chalise, Hom Nath (14629921400); Cheng, Xiaojun (57206757068); Cian, Luca (37088275700); Cockcroft, Kate (22933698400); Conway, Jane (57188581373); Córdoba-Delgado, Mateo Andres (57408848700); Crespi, Chiara (57034303800); Crouzevialle, Marie (55934830400); Cutler, Jo (57203910287); Cypryańska, Marzena (55078294200); Dabrowska, Justyna (57433711900); Daniels, Michael A. (56189070000); Davis, Victoria H. (57432990300); Dayley, Pamala N. (57433856800); Delouvee, Sylvain (13612418500); Denkovski, Ognjan (57221594660); Dezecache, Guillaume (55151472900); Dhaliwal, Nathan A. (57219911935); Diato, Alelie B. (57433130400); Di Paolo, Roberto (57201116811); Drosinou, Marianna (57193797236); Dulleck, Uwe (55973560500); Ekmanis, Jānis (57433426100); Ertan, Arhan S. (25923852000); Etienne, Tom W. (57302201900); Farhana, Hapsa Hossain (57433130500); Farkhari, Fahima (57432990400); Farmer, Harry (55233381300); Fenwick, Ali (57433566200); Fidanovski, Kristijan (57202704216); Flew, Terry (56341271400); Fraser, Shona (57211455566); Frempong, Raymond Boadi (57194167162); Fugelsang, Jonathan A. (6603080729); Gale, Jessica (57202291651); Garcia-Navarro, E. Begoña (57218316315); Garladinne, Prasad (57433278100); Ghajjou, Oussama (57433856900); Gkinopoulos, Theofilos (55866447200); Gray, Kurt (15520639300); Griffin, Siobhán M. (7201880907); Gronfeldt, Bjarki (57196054646); Gümren, Mert (6504093196); Gurung, Ranju Lama (57433857000); Halperin, Eran (35866830500); Harris, Elizabeth (57215611020); Herzon, Volo (57433857100); Hruška, Matej (57196236805); Huang, Guanxiong (56844125900); Hudecek, Matthias F. C. (56545531900); Isler, Ozan (57200182087); Jangard, Simon (57195595285); Jørgensen, Frederik J. (57222523239); Kachanoff, Frank (56574304400); Kahn, John (57433426300); Dangol, Apsara Katuwal (57433857200); Keudel, Oleksandra (57218936367); Koppel, Lina (57188825958); Koverola, Mika (57204777214); Kubin, Emily (57205631416); Kunnari, Anton (57204772241); Kutiyski, Yordan (56480708400); Laguna, Oscar (57432990500); Leota, Josh (57217061682); Lermer, Eva (55584194600); Levy, Jonathan (56327503700); Levy, Neil (57216429407); Li, Chunyun (57202677751); Long, Elizabeth U. (57217147507); Longoni, Chiara (55899207500); Maglić, Marina (57216147889); McCashin, Darragh (57204609951); Metcalf, Alexander L. (54890112800); Mikloušić, Igor (36859688300); El Mimouni, Soulaimane (57433278200); Miura, Asako (12645856800); Molina-Paredes, Juliana (57408848800); Monroy-Fonseca, César (57433278300); Morales-Marente, Elena (36240826900); Moreau, David (36552994500); Muda, Rafał (57195249015); Myer, Annalisa (57225980689); Nash, Kyle (22135546300); Nesh-Nash, Tarik (57433278400); Nitschke, Jonas P. (57193254318); Nurse, Matthew S. (57209360893); Ohtsubo, Yohsuke (7005112071); Oldemburgo de Mello, Victoria (57433426400); O’Madagain, Cathal (56593233200); Onderco, Michal (50462189600); Palacios-Galvez, M. Soledad (55946309500); Palomäki, Jussi (55177884100); Pan, Yafeng (57191922458); Papp, Zsófia (55383252800); Pärnamets, Philip (55918105000); Paruzel-Czachura, Mariola (55936861100); Pavlović, Zoran (23397554100); Payán-Gómez, César (54896392800); Perander, Silva (57433426600); Pitman, Michael Mark (19337434700); Prasad, Rajib (57433566400); Pyrkosz-Pacyna, Joanna (57218692997); Rathje, Steve (57221697332); Raza, Ali (57548710100); Rêgo, Gabriel G. (56480308400); Rhee, Kasey (57432843500); Robertson, Claire E. (57215603258); Rodríguez-Pascual, Iván (55851219500); Saikkonen, Teemu (55045848200); Salvador-Ginez, Octavio (57433130800); Sampaio, Waldir M. (57200417301); Santi, Gaia C. (57217289456); Santiago-Tovar, Natalia (57433857400); Savage, David (35773679000); Scheffer, Julian A. (57191989558); Schönegger, Philipp (57223426293); Schultner, David T. (57222164240); Schutte, Enid M. (7003944275); Scott, Andy (57219874700); Sharma, Madhavi (57433566500); Sharma, Pujan (57433712200); Skali, Ahmed (56716506400); Stadelmann, David (25634677900); Stafford, Clara Alexandra (57208079952); Stanojević, Dragan (55252365500); Stefaniak, Anna (57103128900); Sternisko, Anni (57197832704); Stoica, Augustin (6603591272); Stoyanova, Kristina K. (57219964963); Strickland, Brent (49962193300); Sundvall, Jukka (57202986641); Thomas, Jeffrey P. (57432844400); Tinghög, Gustav (25224071700); Torgler, Benno (55897871400); Traast, Iris J. (57433567500); Tucciarelli, Raffaele (55901667000); Tyrala, Michael (57432992000); Ungson, Nick D. (57201349000); Uysal, Mete S. (57219744529); Van Lange, Paul A. M. (7004460194); van Prooijen, Jan-Willem (6602472447); van Rooy, Dirk (6603562161); Västfjäll, Daniel (6603904733); Verkoeijen, Peter (6603048790); Vieira, Joana B. (55899486000); von Sikorski, Christian (55543167600); Walker, Alexander Cameron (56735153200); Watermeyer, Jennifer (25824525800); Wetter, Erik (36460458400); Whillans, Ashley (55601702200); Willardt, Robin (57219439920); Wohl, Michael J. A. (7006650468); Wójcik, Adrian Dominik (35243826100); Wu, Kaidi (57196224019); Yamada, Yuki (55375527500); Yilmaz, Onurcan (56498563100); Yogeeswaran, Kumar (36344224800); Ziemer, Carolin-Theresa (57433567700); Zwaan, Rolf A. (7003515240); Boggio, Paulo S. (10340985700)","22986966200; 35765189600; 49361021300; 57200691996; 7004481879; 57196148151; 36762163600; 7201803113; 57202683756; 46060910600; 23666913300; 55347628400; 23567212800; 16314964400; 55948104400; 57205719637; 56221801500; 57193896526; 10039110600; 56669557400; 16065517700; 57432843300; 57196262755; 57219005068; 15051465700; 35094029100; 6701375451; 57211203812; 8929220900; 26531164900; 24168107200; 57728566100; 55172691400; 14008430600; 57196217992; 35743100000; 56256131200; 56743290300; 16744097100; 55209862600; 56566285000; 11839543000; 34668140100; 57432843400; 57210735692; 57210589547; 57189074265; 57201644809; 6603737492; 55734672700; 8690139600; 54684879600; 22986127600; 26647787400; 35761369500; 57209821598; 57210113671; 26026109100; 56610290700; 35778895000; 36601257300; 37102876500; 6507222236; 8612330500; 57189267860; 56121056100; 57433130100; 57201915022; 16425076400; 57201461738; 56605134100; 57433425600; 57367764100; 57433856600; 57433566000; 57433711700; 6603573634; 57218632714; 37017949200; 57432990200; 57433425700; 57194429267; 7005685014; 57433130200; 57433425900; 18133581400; 56333322000; 24175889200; 57226525097; 24175528900; 27567441600; 57192594944; 57219655063; 36551893200; 55972096100; 57216634436; 25722905400; 14629921400; 57206757068; 37088275700; 22933698400; 57188581373; 57408848700; 57034303800; 55934830400; 57203910287; 55078294200; 57433711900; 56189070000; 57432990300; 57433856800; 13612418500; 57221594660; 55151472900; 57219911935; 57433130400; 57201116811; 57193797236; 55973560500; 57433426100; 25923852000; 57302201900; 57433130500; 57432990400; 55233381300; 57433566200; 57202704216; 56341271400; 57211455566; 57194167162; 6603080729; 57202291651; 57218316315; 57433278100; 57433856900; 55866447200; 15520639300; 7201880907; 57196054646; 6504093196; 57433857000; 35866830500; 57215611020; 57433857100; 57196236805; 56844125900; 56545531900; 57200182087; 57195595285; 57222523239; 56574304400; 57433426300; 57433857200; 57218936367; 57188825958; 57204777214; 57205631416; 57204772241; 56480708400; 57432990500; 57217061682; 55584194600; 56327503700; 57216429407; 57202677751; 57217147507; 55899207500; 57216147889; 57204609951; 54890112800; 36859688300; 57433278200; 12645856800; 57408848800; 57433278300; 36240826900; 36552994500; 57195249015; 57225980689; 22135546300; 57433278400; 57193254318; 57209360893; 7005112071; 57433426400; 56593233200; 50462189600; 55946309500; 55177884100; 57191922458; 55383252800; 55918105000; 55936861100; 23397554100; 54896392800; 57433426600; 19337434700; 57433566400; 57218692997; 57221697332; 57548710100; 56480308400; 57432843500; 57215603258; 55851219500; 55045848200; 57433130800; 57200417301; 57217289456; 57433857400; 35773679000; 57191989558; 57223426293; 57222164240; 7003944275; 57219874700; 57433566500; 57433712200; 56716506400; 25634677900; 57208079952; 55252365500; 57103128900; 57197832704; 6603591272; 57219964963; 49962193300; 57202986641; 57432844400; 25224071700; 55897871400; 57433567500; 55901667000; 57432992000; 57201349000; 57219744529; 7004460194; 6602472447; 6603562161; 6603904733; 6603048790; 55899486000; 55543167600; 56735153200; 25824525800; 36460458400; 55601702200; 57219439920; 7006650468; 35243826100; 57196224019; 55375527500; 56498563100; 36344224800; 57433567700; 7003515240; 10340985700","Author Correction: National identity predicts public health support during a global pandemic (Nature Communications, (2022), 13, 1, (517), 10.1038/s41467-021-27668-9)","2022","Nature Communications","13","1","1949","","","","1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85127717333&doi=10.1038%2fs41467-022-29658-x&partnerID=40&md5=147d1355e888873913457bc13ed1bb35","In this article the author name ‘Agustin Ibanez’ was incorrectly written as ‘Augustin Ibanez’. The original article has been corrected. © The Author(s) 2022.","","erratum","","2-s2.0-85127717333"
"Cerami C.; Perini G.; Panzavolta A.; Cotta Ramusino M.; Costa A.","Cerami, Chiara (25722905400); Perini, Giulia (56441151600); Panzavolta, Andrea (57195292184); Cotta Ramusino, Matteo (57211850060); Costa, Alfredo (35499758300)","25722905400; 56441151600; 57195292184; 57211850060; 35499758300","A Call for Drug Therapies for the Treatment of Social Behavior Disorders in Dementia: Systematic Review of Evidence and State of the Art","2022","International Journal of Molecular Sciences","23","19","11550","","","","2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85139974016&doi=10.3390%2fijms231911550&partnerID=40&md5=81e9c66410a9108ed8c34e052962536b","Growing evidence supports the presence of social cognition deficits and social behavior alterations in major and minor neurocognitive disorders (NCDs). Even though the ability to identify socio-emotional changes has significantly improved in recent years, there is still no specific treatment available. Thus, we explored evidence of drug therapies targeting social cognition alterations in NCDs. Papers were selected according to PRISMA guidelines by searching on the PubMed and Scopus databases. Only papers reporting information on pharmacological interventions for the treatment of social cognition and/or social behavioral changes in major and/or minor NCDs were included. Among the 171 articles entered in the paper selection, only 9 papers were eligible for the scope of the review. Trials testing pharmacological treatments for socio-emotional alterations in NCDs are poor and of low-medium quality. A few attempts with neuroprotective, psychoactive, or immunomodulating drugs have been made. Oxytocin is the only drug specifically targeting the social brain that has been tested with promising results in frontotemporal dementia. Its beneficial effects in long-term use have yet to be evaluated. No recommendation can currently be provided. There is a long way to go to identify and test effective targets to treat social cognition changes in NCDs for the ultimate benefit of patients and caregivers. © 2022 by the authors.","Alzheimer’s disease; dementia; frontotemporal dementia; neurocognitive disorder; oxytocin; pharmacological treatments; social cognition","Cognition; Frontotemporal Dementia; Humans; Oxytocin; Social Behavior; Social Behavior Disorders; atorvastatin; cyclandelate; entinostat; memantine; nicotine; oxytocin; placebo; oxytocin; adult; aged; agitation; Alzheimer disease; antisocial personality disorder; behavior change; cognitive defect; dementia; dosage schedule comparison; drug cerebrospinal fluid level; drug dose escalation; drug dose increase; drug efficacy; female; frontal variant frontotemporal dementia; functional magnetic resonance imaging; functional neuroimaging; human; hypersexuality; insomnia; male; mixed dementia; motor activity; mouse; MPTP-induced parkinsonism; multicenter study (topic); multiinfarct dementia; nonhuman; phase 2 clinical trial (topic); Preferred Reporting Items for Systematic Reviews and Meta-Analyses; primary progressive aphasia; psychotherapy; randomized controlled trial (topic); rat; repeated drug dose; restlessness; Review; semantic dementia; side effect; single drug dose; social cognition; systematic review; antisocial personality disorder; cognition; frontotemporal dementia; social behavior","Frith C.D., Social cognition, Philos. Trans. R. Soc. Lond. B Biol. Sci, 363, pp. 2033-2039, (2008); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol. Sci, 34, pp. 1267-1274, (2013); Piguet O., Kumfor F., Frontotemporal dementias: Main syndromes and underlying brain changes, Curr. Opin. Neurol, 33, pp. 215-221, (2020); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer’s disease: A meta-analysis, J. Neurol. Neurosurg. Psychiatry, 86, pp. 714-719, (2015); Bora E., Velakoulis D., Walterfang M., Meta-Analysis of Facial Emotion Recognition in Behavioral variant frontotemporal dementia: Comparison with Alzheimer disease and healthy controls, J. Geriatr. Psychiatry Neurol, 29, pp. 205-211, (2016); Bora E., Yener G.G., Meta-analysis of social cognition in Mild Cognitive Impairment, J. Geriatr. Psychiatry Neurol, 30, pp. 206-213, (2017); Fornaro M., Solmi M., Stubbs B., Veronese N., Monaco F., Novello S., Fusco A., Anastasia A., De Berardis D., Carvalho A.F., Et al., Prevalence and correlates of major depressive disorder, bipolar disorder and schizophrenia among nursing home residents without dementia: Systematic review and meta-analysis, Br. J. Psychiatry J. Ment. Sci, 216, pp. 6-15, (2020); Kim H.K., Nunes P.V., Oliveira K.C., Young L.T., Lafer B., Neuropathological relationship between major depression and dementia: A hypothetical model and review, Prog. Neuropsychopharmacol. Biol. Psychiatry, 67, pp. 51-57, (2016); Porcelli S., Van Der Wee N., van der Werff S., Aghajani M., Glennon J.C., van Heukelum S., Mogavero F., Lobo A., Olivera F.J., Lobo E., Et al., Social brain, social dysfunction and social withdrawal, Neurosci. Biobehav. Rev, 97, pp. 10-33, (2019); Diehl-Schmid J., Pohl C., Perneczky R., Forstl H., Kurz A., Behavioral disturbances in the course of frontotemporal dementia, Dement. Geriatr. Cogn. Disord, 22, pp. 352-357, (2006); Riedijk S., Duivenvoorden H., Rosso S., Van Swieten J., Niermeijer M., Tibben A., Frontotemporal dementia: Change of familial caregiver burden and partner relation in a Dutch cohort of 63 patients, Dement. Geriatr. Cogn. Disord, 26, pp. 398-406, (2008); Johnen A., Bertoux M., Psychological and cognitive markers of behavioral variant frontotemporal dementia-A clinical neuropsychologist’s view on diagnostic criteria and beyond, Front. Neurol, 10, (2019); Boutoleau-Bretonniere C., Vercelletto M., Volteau C., Renou P., Lamy E., Zarit burden inventory and activities of daily living in the behavioral variant of frontotemporal dementia, Dement. Geriatr. Cogn. Disord, 25, pp. 272-277, (2008); Mioshi E., Bristow M., Cook R., Hodges J.R., Factors underlying caregiver stress in frontotemporal dementia and Alzheimer’s disease, Dement. Geriatr. Cogn. Disord, 27, pp. 76-81, (2009); Riedijk S.R., de Vugt M.E., Duivenvoorden H.J., Niermeijer M.F., van Swieten J.C., Verhey F.R.J., Tibben A., Caregiver burden, health-related quality of life and coping in dementia caregivers: A comparison of frontotemporal dementia and Alzheimer’s disease, Dement. Geriatr. Cogn. Disord, 22, pp. 405-412, (2006); Mioshi E., Foxe D., Leslie F., Savage S., Hsieh S., Miller L., Hodges J.R., Piguet O., The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease, Alzheimer Dis. Assoc. Disord, 27, pp. 68-73, (2013); Mourik J.C., Rosso S.M., Niermeijer M.F., Duivenvoorden H.J., Van Swieten J.C., Tibben A., Frontotemporal dementia: Behavioral symptoms and caregiver distress, Dement. Geriatr. Cogn. Disord, 18, pp. 299-306, (2004); Gitlin L.N., Kales H.C., Lyketsos C.G., Nonpharmacologic management of behavioral symptoms in dementia, JAMA, 308, pp. 2020-2029, (2012); Shnall A., Agate A., Grinberg A., Huijbregts M., Nguyen M.Q., Chow T.W., Development of supportive services for frontotemporal dementias through community engagement, Int. Rev. Psychiatry, 25, pp. 246-252, (2013); Pressman P.S., Miller B.L., Diagnosis and management of behavioral variant frontotemporal dementia, Biol. Psychiatry, 75, pp. 574-581, (2014); Bickart K.C., Dickerson B.C., Barrett L.F., The amygdala as a hub in brain networks that support social life, Neuropsychologia, 63, pp. 235-248, (2014); Arioli M., Cattaneo Z., Ricciardi E., Canessa N., Overlapping and specific neural correlates for empathizing, affective mentalizing, and cognitive mentalizing: A coordinate-based meta-analytic study, Hum. Brain Mapp, 42, pp. 4777-4804, (2021); Blakemore C.B., Cyclandelate in the treatment of multi-infarct dementia. Interim findings from a multicentre study in general practice, Drugs, 33, pp. 110-113, (1987); Ditzler K., Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo-controlled trial, Arzneimittelforschung, 41, pp. 773-780, (1991); Jesso S., Morlog D., Ross S., Pell M.D., Pasternak S.H., Mitchell D.G.V., Kertesz A., Finger E.C., The effects of oxytocin on social cognition and behaviour in frontotemporal dementia, Brain, 134, pp. 2493-2501, (2011); Finger E.C., MacKinley J., Blair M., Oliver L.D., Jesso S., Tartaglia M.C., Borrie M., Wells J., Dziobek I., Pasternak S., Et al., Oxytocin for frontotemporal dementia: A randomized dose-finding study of safety and tolerability, Neurology, 84, pp. 174-181, (2015); Finger E., Berry S., Cummings J., Coleman K., Hsiung R., Feldman H.H., Boxer A., Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: A phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY), Alzheimer’s. Res. Ther, 10, (2018); Oliver L.D., Stewart C., Coleman K., Kryklywy J.H., Bartha R., Mitchell D.G.V., Finger E.C., Neural effects of oxytocin and mimicry in frontotemporal dementia: A randomized crossover study, Neurology, 95, pp. e2635-e2647, (2020); Meyer-Lindenberg A., Domes G., Kirsch P., Heinrichs M., Oxytocin and vasopressin in the human brain: Social neuropeptides for translational medicine, Nat. Rev. Neurosci, 12, pp. 524-538, (2011); Kosfeld M., Heinrichs M., Zak P.J., Fischbacher U., Fehr E., Oxytocin increases trust in humans, Nature, 435, pp. 673-676, (2005); Baumgartner T., Heinrichs M., Vonlanthen A., Fischbacher U., Fehr E., Oxytocin shapes the neural circuitry of trust and trust adaptation in humans, Neuron, 58, pp. 639-650, (2008); Domes G., Heinrichs M., Glascher J., Buchel C., Braus D.F., Herpertz S.C., Oxytocin attenuates amygdala responses to emotional faces regardless of valence, Biol. Psychiatry, 62, pp. 1187-1190, (2007); Guastella A.J., Mitchell P.B., Dadds M.R., Oxytocin increases gaze to the eye region of human faces, Biol. Psychiatry, 63, pp. 3-5, (2008); Hurlemann R., Patin A., Onur O.A., Cohen M.X., Baumgartner T., Metzler S., Dziobek I., Gallinat J., Wagner M., Maier W., Et al., Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans, J. Neurosci, 30, pp. 4999-5007, (2010); De Berardis D., Marini S., Iasevoli F., Tomasetti C., De Bartolomeis A., Mazza M., Valchera A., Fornaro M., Cavuto M., Srinivasan V., Et al., The role of intranasal oxytocin in the treatment of patients with schizophrenia: A systematic review, CNS Neurol. Disord. Drug Targets, 12, pp. 252-264, (2013); Winterton A., Westlye L.T., Steen N.E., Andreassen O.A., Quintana D.S., Improving the precision of intranasal oxytocin research, Nat. Hum. Behav, 5, pp. 9-18, (2021); Leng G., Leng R.I., Ludwig M., Oxytocin-a social peptide? Deconstructing the evidence, Philos. Trans. R. Soc. Lond. B Biol. Sci, 377, (2022); Piguet O., Ahmed R.M., Kumfor F., The Role of Oxytocin in Social Circuits and Social Behavior in Dementia, Oxytocin, Methods and Protocols Methods in Molecular Biology, 2384, pp. 67-80, (2022); Ouzzani M., Hammady H., Fedorowicz Z., Elmagarmid A., Rayyan-a web and mobile app for systematic reviews, Syst. Rev, 5, (2016); Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies, (2014); Hooijmans C.R., Rovers M.M., de Vries R.B., Leenaars M., Ritskes-Hoitinga M., Langendam M.W., SYRCLE’s risk of bias tool for animal studies, BMC Med. Res. Methodol, 26, (2014); Zhang Z.Y., Schluesener H.J., Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model, J. Neuropathol. Exp. Neurol, 72, pp. 178-185, (2013); Castro A.A., Wiemes B.P., Matheus F.C., Lapa F.R., Viola G.G., Santos A.R., Tasca C.I., Prediger R.D., Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson’s disease, Brain Res, 1513, pp. 103-116, (2013); Subramaniam S.R., Magen I., Bove N., Zhu C., Lemesre V., Dutta G., Elias C.J., Lester H.A., Chesselet M.F., Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein, Neurobiol. Dis, 117, pp. 170-180, (2018); Abel T., Zukin R.S., Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders, Curr. Opin. Pharmacol, 8, pp. 57-64, (2008); Graff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J.F., Fass D.M., Kao P.F., Kahn M., Et al., An epigenetic blockade of cognitive functions in the neurodegenerating brain, Nature, 483, pp. 222-226, (2012); Wesson D.W., Wilson D.A., Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice, Behav. Brain Res, 216, pp. 408-413, (2011); Bhat A., Dalvi H., Jain H., Rangaraj N., Singh S.B., Srivastava S., Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal, Curr. Res. Pharmacol. Drug Discov, 2, (2020); Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A., Statins and the risk of dementia, Lancet, 356, pp. 1627-1631, (2000); Wolozin B., Wang S.W., Li N.C., Lee A., Lee T.A., Kazis L.E., Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease, BMC Med, 5, (2007); Ludka F.K., Zomkowski A.D.E., Cunha M.P., Dal-Cim T., Zeni A.L.B., Rodrigues A.L.S., Tasca C.I., Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels, Eur. Neuropsychopharmacol, 23, pp. 400-412, (2013); Dantzer R., Bluthe R.M., Koob G.F., Le Moal M., Modulation of social memory in male rats by neurohypophyseal peptides, Psychopharmacology, 91, pp. 363-368, (1987); Wang H.F., Yu J.T., Tang S.W., Jiang T., Tan C.C., Meng X.F., Wang C., Tan M.S., Tan L., Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis, J. Neurol. Neurosurg. Psychiatry, 86, pp. 135-143, (2015); Magen I., Torres E.R., Dinh D., Chung A., Masliah E., Chesselet M.F., Social Cognition Impairments in Mice Overexpressing Alpha-Synuclein Under the Thy1 Promoter, a Model of Pre-manifest Parkinson’s Disease, J. Parkinsons Dis, 5, pp. 669-680, (2015); Weyer G., Eul A., Milde K., Wierich W., Herrmann W.M., Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: Experience from a placebo controlled multi-center study, Pharmacopsychiatry, 33, pp. 89-97, (2000); Blakemore C.B., Improvement in certain aspects of behaviour of elderly patients treated by cyclandelate, Assessment in Cerebrovascular Insufficiency, (1971); Sandoz Clinical Assessment Geriatric Scale, (1986); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Tottenham N., Tanaka J.W., Leon A.C., McCarry T., Nurse M., Hare T.A., Marcus D.J., Westerlund A., Casey B.J., Nelson C., The NimStim set of facial expressions: Judgments from untrained research participants, Psychiatry Res, 168, pp. 242-249, (2009); Pell M.D., Paulmann S., Dara C., Alasseri A., Kotz S.A., Factors in the recognition of vocally expressed emotions: A comparison of four languages, J. Phon, 37, pp. 417-435, (2009); Cummings J.L., The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients, Neurology, 48, pp. S10-S16, (1997); Kertesz A., Davidson W., Fox H., Frontal behavioral inventory: Diagnostic criteria for frontal lobe dementia, Can. J. Neurol. Sci, 24, pp. 29-36, (1997); Davis M.H., A multidimensional approach to individual differences in empathy, JSAS Catalog of Selected Documents in Psychology, 85, (1980); Knopman D.S., Kramer J.H., Boeve B.F., Caselli R.J., Graff-Radford N.R., Mendez M.F., Miller B.L., Mercaldo N., Development of methodology for conducting clinical trials in frontotemporal lobar degeneration, Brain, 131, pp. 2957-2968, (2008); Mioshi E., Hsieh S., Savage S., Hornberger M., Hodges J.R., Clinical staging and disease progression in frontotemporal dementia, Neurology, 74, pp. 1591-1597, (2010); Lennox R.D., Wolfe R.N., Revision of the self-monitoring scale, J. Pers. Soc. Psychol, 46, pp. 1349-1364, (1984); Mendez M.F., Fong S.S., Shapira J.S., Jimenez E.E., Kaiser N.C., Kremen S.A., Tsai P.H., Observation of social behavior in frontotemporal dementia, Am. J. Alzheimer’s Dis. Other Demen, 29, pp. 215-221, (2014); Oliver L.D., Mitchell D.G., Dziobek I., MacKinley J., Coleman K., Rankin K.P., Finger E.C., Parsing cognitive and emotional empathy deficits for negative and positive stimuli in frontotemporal dementia, Neuropsychologia, 67, pp. 14-26, (2015); Dziobek I., Rogers K., Fleck S., Bahnemann M., Heekeren H.R., Wolf O.T., Convit A., Dissociation of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted Empathy Test (MET), J. Autism Dev. Disord, 38, pp. 464-473, (2008); Mozaz M., Rothi L.J., Anderson J.M., Crucian G.P., Heilman K.M., Postural knowledge of transitive pantomimes and intransitive gestures, J. Int. Neuropsychol. Soc, 8, pp. 958-962, (2002); Soleimani M.A.H., Negarandeh R., Bastani F., Grey R., Disrupted social connectedness in people with Parkinson’s disease, Br. J. Community Nurs, 19, pp. 136-141, (2014); Setien-Suero E., Murillo-Garcia N., Sevilla-Ramos M., Abreu-Fernandez G., Pozueta A., Ayesa-Arriola R., Exploring the relationship between deficits in social cognition and neurodegenerative dementia: A systematic review, Front. Aging Neurosci, 14, (2022); PubChem Compound Summary for CID 2893, Cyclandelate; Rammes G., Danysz W., Parsons C.G., Pharmacodynamics of memantine: An update, Curr. Neuropharmacol, 6, pp. 55-78, (2008); Insel T.R., The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior, Neuron, 65, pp. 768-779, (2010); Hollander E., Bartz J., Chaplin W., Phillips A., Sumner J., Soorya L., Anagnostou E., Wasserman S., Oxytocin increases retention of social cognition in autism, Biol. Psychiatry, 61, pp. 498-503, (2007); Marsh A.A., Yu H.H., Pine D.S., Blair R.J., Oxytocin improves specific recognition of positive facial expressions, Psychopharmacology, 209, pp. 225-232, (2010); Diodati D., Cyn-Ang L., Kertesz A., Finger E., Pathologic evaluation of the supraoptic and paraventricular nuclei in dementia, Can. J. Neurol. Sci, 39, pp. 213-219, (2012); Loup F., Tribollet E., Dubois-Dauphin M., Dreifuss J.J., Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study, Brain Res, 555, pp. 220-232, (1991); Boccia M.L., Petrusz P., Suzuki K., Marson L., Pedersen C.A., Immunohistochemical localization of oxytocin receptors in human brain, Neuroscience, 253, pp. 155-164, (2013); Whitwell J.L., Josephs K.A., Recent advances in the imaging of frontotemporal dementia, Curr. Neurol. Neurosci. Rep, 12, pp. 715-723, (2012); Miller J.B., Banks S.J., Leger G.C., Cummings J.L., Randomized controlled trials in frontotemporal dementia: Cognitive and behavioral outcomes, Transl. Neurodegener, 3, (2014); Richardson E., Burnell J., Adams H.R., Bohannon R.W., Bush E.N., Campbell M., Chen W.H., Coons S.J., Papadopoulos E., Reeve B.R., Et al., Developing and implementing performance outcome assessments: Evidentiary, methodologic, and operational considerations, Ther. Innov. Regul. Sci, 53, pp. 146-153, (2019); Kiresuk T.J., Sherman R.E., Goal attainment scaling: A general method for evaluating comprehensive community mental health programs, Community Ment. Health J, 4, pp. 443-453, (1968); Cotta Ramusino M., Perini G., Vaghi G., Dal Fabbro B., Capelli M., Picascia M., Franciotta D., Farina L., Ballante E., Costa A., Correlation of frontal atrophy and CSF tau levels with neuropsychiatric symptoms in patients with cognitive impairment: A memory clinic experience, Front. Aging Neurosci, 13, (2021); Boxer A.L., Gold M., Feldman H., Boeve B.F., Dickinson S.L., Fillit H., Ho C., Paul R., Pearlman R., Sutherland M., Et al., New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures, Alzheimer’s Dement, 16, pp. 131-143, (2020); Insel T.R., Translating Oxytocin Neuroscience to the Clinic: A National Institute of Mental Health perspective, Biol. Psychiatry, 79, pp. 153-154, (2016); Einfeld S.L., Smith E., McGregor I.S., Steinbeck K., Taffe J., Rice L.J., Horstead S.K., Rogers N., Hodge M.A., Guastella A.J., A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome, Am. J. Med. Genet. A, 164, pp. 2232-2239, (2014); Yatawara C.J., Einfeld S.L., Hickie I.B., Davenport T.A., Guastella A.J., The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: A randomized clinical crossover trial, Mol. Psychiatry, 21, pp. 1225-1231, (2016); Cacciotti-Saija C., Langdon R., Ward P.B., Hickie I.B., Scott E.M., Naismith S.L., Moore L., Alvares G.A., Redoblado Hodge M.A., Guastella A.J., A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis, Schizophr. Bull, 41, pp. 483-493, (2015); Gibson C.M., Penn D.L., Smedley K.L., Leserman J., Elliott T., Pedersen C.A., A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia, Schizophr. Res, 156, pp. 261-265, (2014); Anagnostou E., Soorya L., Chaplin W., Bartz J., Halpern D., Wasserman S., Wang A.T., Pepa L., Tanel N., Kushki A., Et al., Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: A randomized controlled trial, Mol. Autism, 3, (2012); Bales K.L., Perkeybile A.M., Conley O.G., Lee M.H., Guoynes C.D., Downing G.M., Yun C.R., Solomon M., Jacob S., Mendoza S.P., Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles, Biol. Psychiatry, 74, pp. 180-188, (2013); Huang H., Michetti C., Busnelli M., Manago F., Sannino S., Scheggia D., Giancardo L., Sona D., Murino V., Chini B., Et al., Chronic and acute intranasal oxytocin produce divergent social effects in mice, Neuropsychopharmacology, 39, pp. 1102-1114, (2014); Conti F., Sertic S., Reversi A., Chini B., Intracellular trafficking of the human oxytocin receptor: Evidence of receptor recycling via a Rab4/Rab5 “short cycle, Am. J. Physiol. Endocrinol. Metab, 296, pp. E532-E542, (2009); Peters S., Slattery D.A., Uschold-Schmidt N., Reber S.O., Neumann I.D., Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice, Psychoneuroendocrinology, 42, pp. 225-236, (2014); Van den Stock J., Social cognition assessment for mild neurocognitive disorders, Alzheimer’s Dement, 18, pp. 1439-1440, (2022); Dodich A., Boccardi M., Sacco L., Monsch A.U., Demonet J.F., Filardi M., Logroscino G., Salmon D.P., Weinbtraub S., Dubois B., Et al., Consortium for the Harmonization of Neuropsychological Assessment for Neurocognitive Disorders. Answer to “Social cognition assessment for mild neurocognitive disorders, Alzheimer’s Dement, 18, pp. 1441-1442, (2022)","2-s2.0-85139974016"
"Dodich A.; Boccardi M.; Sacco L.; Monsch A.U.; Démonet J.-F.; Filardi M.; Logroscino G.; Salmon D.P.; Weinbtraub S.; Dubois B.; Cappa S.F.; Cerami C.","Dodich, Alessandra (56001713900); Boccardi, Marina (6507801629); Sacco, Leonardo (6701668924); Monsch, Andreas U. (7003427149); Démonet, Jean-François (7005727609); Filardi, Marco (7801538050); Logroscino, Giancarlo (7004888005); Salmon, David P. (7202423155); Weinbtraub, Sandra (57713729700); Dubois, Bruno (7101841106); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400)","56001713900; 6507801629; 6701668924; 7003427149; 7005727609; 7801538050; 7004888005; 7202423155; 57713729700; 7101841106; 7005836132; 25722905400","Answer to “Social cognition assessment for mild neurocognitive disorders”","2022","Alzheimer's and Dementia","18","7","","1441","1442","1","3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85130851377&doi=10.1002%2falz.12664&partnerID=40&md5=7cbe0f55c58c18d569bb35e3ac323559","[No abstract available]","","Cognition; Cognitive Dysfunction; Humans; Neurocognitive Disorders; Neuropsychological Tests; Social Cognition; Alzheimer disease; Awareness of Social Inference Test; cognition assessment; cognitive defect; cognitive function test; diagnostic accuracy; disorders of higher cerebral function; DSM-5; early diagnosis; Ekman 60 Faces Test; frontal variant frontotemporal dementia; frontotemporal dementia; human; Letter; mild neurocognitive disorder; mini Social Cognition and Emotional Assessment; neuropsychological test; prodromal symptom; research priority; Revised Self Monitoring Scale; social cognition; social competence; Story Based Empathy Task; cognition; cognitive defect; disorders of higher cerebral function","Boccardi M., Monsch A.U., Ferrari C., Et al., Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe, Alzheimer's Dement, 18, 1, (2021); Diagnostic and Statistical Manual of Mental Disorders, (2013); Dodich A., Cerami C., Canessa N., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the story-based empathy task, Neurol Sci, 36, 10, pp. 1907-1912, (2015); Cerami C., Dodich A., Canessa N., Et al., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimer's Dement, 10, 6, pp. 827-834, (2014); Van den Stock J., Social cognition assessment for mild neurocognitive disorders, Alzheimer's Dement, 18, 7, pp. 1439-1440, (2022); Kumfor F., Hazelton J.L., De Winter F.-L., Cleret de Langavant L., Van den Stock J., Clinical studies of social neuroscience: a lesion model approach, Neuroscience and Social Science: The Missing Link, pp. 255-296, (2017); Bora E., Velakoulis D., Walterfang M., Meta-analysis of facial emotion recognition in behavioral variant frontotemporal dementia: comparison with Alzheimer disease and healthy controls, J Geriatr Psychiatry Neurol, 29, 4, pp. 205-211, (2016); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: a meta-analysis, J Neurol Neurosurg Psychiatry, 86, 7, pp. 714-719, (2015); Campanella F., West T., Corradi Dell'Acqua C., Skrap M., Cognitive and affective theory of mind double dissociation after parietal and temporal lobe tumors, Brain, (2021); Dodich A., Crespi C., Santi G.C., Cappa S.F., Cerami C., Evaluation of discriminative detection abilities of social cognition measures for the diagnosis of the behavioral variant of frontotemporal dementia: a systematic review, Neuropsychol Rev, 31, 3-4, pp. 251-266, (2020); Borroni B., Graff C., Hardiman O., Et al., FRONTIERS. FRONTotemporal dementia Incidence European Research Study-FRONTIERS: rationale and design, Alzheimer's Dement, 18, 3, pp. 498-506, (2022)","2-s2.0-85130851377"
"Dodich A.; Cerami C.; Inguscio E.; Iannaccone S.; Magnani G.; Marcone A.; Guglielmo P.; Vanoli G.; Cappa S.F.; Perani D.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400); Inguscio, Emanuela (57206656574); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Marcone, Alessandra (6701496511); Guglielmo, Priscilla (56919519400); Vanoli, Giovanna (57211798721); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","56001713900; 25722905400; 57206656574; 7005943171; 24496141800; 6701496511; 56919519400; 57211798721; 7005836132; 7005630261","The clinico-metabolic correlates of language impairment in corticobasal syndrome and progressive supranuclear palsy","2019","NeuroImage: Clinical","24","","102009","","","","15","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075038980&doi=10.1016%2fj.nicl.2019.102009&partnerID=40&md5=2f2a208ad5505382749e50dca102a786","Purpose: To assess the clinical-metabolic correlates of language impairment in a large sample of patients clinically diagnosed as corticobasal syndrome (CBS) and progressive supranuclear palsy syndrome (PSPs). Methods: We included 70 patients fulfilling current criteria for CBS (n = 33) or PSPs (n = 37). All subjects underwent clinical-neuropsychological and FDG-PET assessments at the time of diagnosis. The whole patient's cohort was grouped into three subgroups according to the language characteristics, i.e., (a) nfv-PPA; (b) subtle language impairments, LANG-; (c) no language deficits, NOL-. FDG-PET data were analysed using an optimized voxel-based SPM method at the single-subject and group levels in order to evaluate specific hypometabolic patterns and regional dysfunctional FDG-PET commonalities in subgroups. Results: 21 patients had a nfvPPA diagnosis (i.e., nfv-PPA/CBS = 12 and nfv-PPA/PSPs = 9), while 20 patients had a subtle language impairment LANG- (i.e., CBS = 12 and PSPs = 8), not fulfilling the criteria for a nfv-PPA diagnosis. The remaining sample (i.e., 9/33 CBS and 20/37 PSPs patients) did not show any language deficit. FDG-PET results in individuals with a nfv-PPA diagnosis were consistent with the typical nfv-PPA pattern of hypometabolism (i.e., left fronto-insular and superior medial frontal cortex involvement), both in CBS and PSPs. The LANG-CBS and LANG-PSPs subjects had different FDG-PET hypometabolic patterns involving, respectively, parietal and frontal regions. As expected, NOL-CBS and NOL-PSPs showed a predominant right hemisphere involvement, with selective functional metabolic signatures typical of the two syndromes. Conclusions: Language impairments, fulfilling the nfv-PPA criteria, are associated with both CBS and PSPs clinical presentations early in the disease course. Subtle language deficits may be present in an additional proportion of patients not fulfilling the nfv-PPA criteria. The topography of brain hypometabolism is a major dysfunctional signature of language deficits in CBS and PSPs clinical phenotypes. © 2019 The Author(s)","Corticobasal syndrome; FDG-PET; nfv-PPA; Non-fluent variant of primary progressive aphasia; Positron Emission Tomography; Progressive supranuclear palsy","Aged; Aged, 80 and over; Aphasia, Primary Progressive; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Positron-Emission Tomography; Retrospective Studies; Supranuclear Palsy, Progressive; Syndrome; fluorodeoxyglucose; adult; aged; angular gyrus; anomia; Article; cingulate gyrus; cohort analysis; comprehension; corticobasal syndrome; degenerative disease; disease course; executive function; female; frontal lobe; human; ideomotor apraxia; inferior frontal gyrus; inferior parietal cortex; inferior parietal lobule; language disability; long term memory; major clinical study; male; medial frontal cortex; parietal lobe; positron emission tomography; posterior cingulate; precuneus; priority journal; progressive supranuclear palsy; retrospective study; right hemisphere; superior parietal lobule; thalamus; ventromedial prefrontal cortex; verbal memory; diagnostic imaging; metabolism; middle aged; parkinsonism; primary progressive aphasia; progressive supranuclear palsy; syndrome; very elderly","Horvath J., Burkhard P.R., Bouras C., Kovari E., Etiologies of parkinsonism in a century-long autopsy-based cohort, Brain Pathol., 23, pp. 28-33, (2013); Boeve B.F., The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study, J. Mol. Neurosci., 45, pp. 350-353, (2011); Respondek G., Stamelou M., Kurz C., Ferguson L.W., Rajput A., Chiu W.Z., Et al., The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases, Mov. Disord., 29, pp. 1758-1766, (2014); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, pp. 496-503, (2013); Boxer A.L., Yu J.T., Golbe L.I., Litvan I., Lang A.E., Hoglinger G.U., Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches, Lancet Neurol., 16, pp. 552-563, (2017); Coyle-Gilchrist I.T., Dick K.M., Patterson K., Vazquez Rodriquez P., Wehmann E., Wilcox A., Et al., Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes, Neurology, 86, pp. 1736-1743, (2016); Hoglinger G.U., Respondek G., Stamelou M., Kurz C., Josephs K.A., Lang A.E., Et al., Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria, Mov. Disord., 32, pp. 853-864, (2017); Burrell J.R., Hodges J.R., Rowe J.B., Cognition in corticobasal syndrome and progressive supranuclear palsy: a review, Mov. Disord., 29, pp. 684-693, (2014); Oliveira L.M., Barcellos I., Teive H.A.G., Munhoz R.P., Cognitive dysfunction in corticobasal degeneration, Arq. Neuropsiquiatr., 75, pp. 570-579, (2017); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Et al., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia, J. Alzheimers Dis., 55, pp. 183-197, (2017); Santos-Santos M.A., Mandelli M.L., Binney R.J., Ogar J., Wilson S.M., Henry M.L., Et al., Features of patients with nonfluent/agrammatic primary progressive aphasia with underlying progressive supranuclear palsy pathology or corticobasal degeneration, JAMA Neurol., 73, pp. 733-742, (2016); Walker Z., Gandolfo F., Orini S., Garibotto V., Agosta F., Arbizu J., Et al., Clinical utility of FDG pet in Parkinson's disease and atypical parkinsonism associated with dementia, Eur. J. Nucl. Med. Mol. Imaging, 45, pp. 1534-1545, (2018); Caminiti S.P., Alongi P., Majno L., Volonte M.A., Cerami C., Gianolli L., Et al., Evaluation of an optimized [(18) F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders, Eur. J. Neurol., 24, (2017); Niccolini F., Politis M., A systematic review of lessons learned from pet molecular imaging research in atypical Parkinsonism, Eur. J. Nucl. Med. Mol. Imaging, 43, pp. 2244-2254, (2016); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., van Berckel B.N., Et al., Resting metabolic connectivity in prodromal alzheimer's disease. A European alzheimer disease consortium (EADC) project, Neurobiol. Aging., 33, pp. 2533-2550, (2012); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Et al., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur. J. Nucl. Med. Mol. Imaging, 43, pp. 499-508, (2016); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-pet in dementia diagnosis in a clinical setting, Neuroimage Clin., 6, pp. 445-454, (2014); McMonagle P., Blair M., Kertesz A., Corticobasal degeneration and progressive aphasia, Neurology, 67, pp. 1444-1451, (2006); Gorno-Tempini M.L., Brambati S.M., Ginex V., Ogar J., Dronkers N.F., Marcone A., Et al., The logopenic/phonological variant of primary progressive aphasia, Neurology, 71, pp. 1227-1234, (2008); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Et al., Advancing research diagnostic criteria for alzheimer's disease: the IWG-2 criteria, Lancet Neurol., 13, pp. 614-629, (2014); Shelley B.P., Hodges J.R., Kipps C.M., Xuereb J.H., Bak T.H., Is the pathology of corticobasal syndrome predictable in life?, Mov Disord., 24, pp. 1593-1599, (2009); Josephs K.A., Whitwell J.L., Boeve B.F., Knopman D.S., Petersen R.C., Hu W.T., Et al., Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease, Mov. Disord., 25, pp. 1246-1252, (2010); Pardini M., Huey E.D., Spina S., Kreisl W.C., Morbelli S., Wassermann E.M., Et al., FDG-PET patterns associated with underlying pathology in corticobasal syndrome, Neurology, 92, pp. e1121-e1e35, (2019); Josephs K.A., Duffy J.R., Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy, Curr. Opin. Neurol., 21, pp. 688-692, (2008); Burrell J.R., Hornberger M., Villemagne V.L., Rowe C.C., Hodges J.R., Clinical profile of pib-positive corticobasal syndrome, PLoS One, 8, (2013); Hu W.T., Rippon G.W., Boeve B.F., Knopman D.S., Petersen R.C., Parisi J.E., Et al., Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome, Mov. Disord., 24, pp. 1375-1379, (2009); Catricala E., Gobbi E., Battista P., Miozzo A., Polito C., Boschi V., Et al., SAND: a screening for aphasia in neurodegeneration. Development and normative data, Neurol. Sci., 38, pp. 1469-1483, (2017)","2-s2.0-85075038980"
"Cerami C.; Dodich A.; Greco L.; Iannaccone S.; Magnani G.; Marcone A.; Pelagallo E.; Santangelo R.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Greco, Lucia (57196094606); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Marcone, Alessandra (6701496511); Pelagallo, Elisabetta (57191906621); Santangelo, Roberto (57191567809); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 56001713900; 57196094606; 7005943171; 24496141800; 6701496511; 57191906621; 57191567809; 7005836132; 7005630261","The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia","2017","Journal of Alzheimer's Disease","55","1","","183","197","14","51","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84994666240&doi=10.3233%2fJAD-160682&partnerID=40&md5=e574ba22d2eb4ed93ac82468b0d008fb","Background and Objective: Primary progressive aphasia (PPA) is a clinical syndrome due to different neurodegenerative conditions in which an accurate early diagnosis needs to be supported by a reliable diagnostic tool at the individual level. In this study, we investigated in PPA the FDG-PET brain metabolic patterns at the single-subject level, in order to assess the case-to-case variability and its relationship with clinical-neuropsychological findings. Material and Methods: 55 patients (i.e., 11 semantic variant/sv-PPA, 19 non fluent variant/nfv-PPA, 17 logopenic variant/lv-PPA, 3 slowly progressive anarthria/SPA, and 5 mixed PPA/m-PPA) were included. Clinical-neuropsychological information and FDG-PET data were acquired at baseline. A follow-up of 27.4±12.55 months evaluated the clinical progression. Brain metabolism was analyzed using an optimized and validated voxel-based SPM method at the single-subject level. Results: FDG-PET voxel-wise metabolic assessment revealed specific metabolic signatures characterizing each PPA variant at the individual level, reflecting the underlying neurodegeneration in language networks. Notably, additional dysfunctional patterns predicted clinical progression to specific dementia conditions. In the case of nfv-PPA, a metabolic pattern characterized by involvement of parietal, subcortical and brainstem structures predicted progression to a corticobasal degeneration syndrome or to progressive supranuclear palsy. lv-PPA and sv-PPA cases who progressed to Alzheimer's disease and frontotemporal dementia at the follow-up presented with extended bilateral patterns at baseline. Discussion: Our results indicate that FDG-PET voxel-wise imaging is a valid biomarker for the early differential diagnosis of PPAs and for the prediction of progression to specific dementia condition. This study supports the use of FDG-PET imaging quantitative assessment in clinical settings for a better characterization of PPA individuals and prognostic definition of possible endo-phenotypes. © 2017 - IOS Press and the authors.","FDG-PET; logopenic variant of primary progressive aphasia; non fluent variant of primary progressive aphasia; positron emission tomography; primary progressive aphasia; semantic variant of primary progressive aphasia","Aged; Aphasia, Primary Progressive; Brain; Cognition; Dementia; Diagnosis, Differential; Disease Progression; Early Diagnosis; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Neuropsychological Tests; Positron-Emission Tomography; Precision Medicine; Radiopharmaceuticals; Retrospective Studies; biological marker; fluorodeoxyglucose; fluorodeoxyglucose f 18; radiopharmaceutical agent; adult; aged; Alzheimer disease; anarthria; Article; brain dysfunction; brain metabolism; brain stem; computer assisted emission tomography; corticobasal degeneration; dementia; differential diagnosis; disease course; early diagnosis; endophenotype; female; follow up; frontotemporal dementia; human; major clinical study; male; nerve cell network; nerve degeneration; neuropsychological test; parietal cortex; PET scanner; positron emission tomography; predictive value; primary progressive aphasia; priority journal; prognosis; progressive supranuclear palsy; quantitative analysis; reliability; retrospective study; brain; cognition; dementia; diagnostic imaging; disease exacerbation; metabolism; personalized medicine; primary progressive aphasia","Mesulam M.M., Weintraub S., Spectrum of primary progressive aphasia, Baillieres Clin Neurol, 1, pp. 583-609, (1992); Cerami C., Cappa S.F., Primary progressive aphasia, Hodges? Frontotemporal Dementia, (2016); Harris J.M., Gall C., Thompson J.C., Richardson A.M., Neary D., Du Plessis D., Pal P., Mann D.M., Snowden J.S., Jones M., Classification and pathology of primary progressive aphasia, Neurology, 81, pp. 1832-1839, (2013); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M., Phengrasamy L., Rosen H.J., Johnson J.K., Weiner M.W., Miller B.L., Cognition and anatomy in three variants of primary progressive aphasia, Ann Neurol, 55, pp. 335-346, (2004); Josephs K.A., Duffy J.R., Strand E.A., Machulda M.M., Senjem M.L., Master A.V., Lowe V.J., Jack C.R., Whitwell J.L., Characterizing a neurodegenerative syndrome: Primary progressive apraxia of speech, Brain, 135, pp. 1522-1536, (2012); Perez D.L., Dickerson B.C., McGinnis S.M., Sapolsky D., Johnson K., Searl M., Daffner K.R., You don?t say: Dynamic aphasia, another variant of primary progressive aphasia?, J Alzheimers Dis, 34, pp. 139-144, (2013); Mesulam M., Weintraub S., Rogalski E.J., Wieneke C., Geula C., Bigio E.H., Asymmetry and heterogeneity of Alzheimer?s and frontotemporal pathology in primary progressive aphasia, Brain, 137, pp. 1176-1192, (2014); Diehl J., Grimmer T., Drzezga A., Riemenschneider M., Forstl H., Kurz A., Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. A PET study, Neurobiol Aging, 25, pp. 1051-1056, (2004); Nestor P.J., Fryer T.D., Hodges J.R., Declarative memory impairments in Alzheimer?s disease and semantic dementia, Neuroimage, 30, pp. 1010-1020, (2006); Acosta-Cabronero J., Patterson K., Fryer T.D., Hodges J.R., Pengas G., Williams G.B., Nestor P.J., Atrophy, hypometabolism and white matter abnormalities in semantic dementia tell a coherent story, Brain, 134, pp. 2025-2035, (2011); Iaccarino L., Crespi C., Della Rosa P.A., Catricala E., Guidi L., Marcone A., Tagliavini F., Magnani G., Cappa S.F., Perani D., The semantic variant of primary progressive aphasia: Clinical and neuroimaging evidence in single subjects, PLoS One, 10, (2015); Nestor P.J., Graham N.L., Fryer T.D., Williams G.B., Patterson K., Hodges J.R., Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula, Brain, 126, pp. 2406-2418, (2003); Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., O'Neil J.P., Lal R.A., Dronkers N.F., Miller B.L., Gorno-Tempini M.L., Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia, Ann Neurol, 64, pp. 388-401, (2008); Matias-Guiu J.A., Cabrera-Martin M.N., Moreno-Ramos T., Valles-Salgado M., Fernandez-Matarrubia M., Carreras J.L., Matias-Guiu J., Amyloid and FDG-PET study of logopenic primary progressive aphasia: Evidence for the existence of two subtypes, J Neurol, 262, pp. 1463-1472, (2015); Desgranges B., Matuszewski V., Piolino P., Chetelat G., Mezenge F., Landeau B., De La Sayette V., Belliard S., Eustache F., Anatomical and functional alterations in semantic dementia: A voxel-based MRI and PET study, Neurobiol Aging, 28, pp. 1904-1913, (2007); Kim E.J., Kim B.C., Kim S.J., Jung D.S., Sin J.S., Yoon Y.J., Chin J., Lee K.H., Na D.L., Clinical staging of semantic dementia in an FDG-PET study using FTLD-CDR, Dement Geriatr Cogn Disord, 34, pp. 300-306, (2012); Drzezga A., Grimmer T., Henriksen G., Stangier I., Perneczky R., Diehl-Schmid J., Mathis C.A., Klunk W.E., Price J., DeKosky S., Wester H.J., Schwaiger M., Kurz A., Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer?s disease, Neuroimage, 39, pp. 619-633, (2008); Mion M., Patterson K., Acosta-Cabronero J., Pengas G., Izquierdo-Garcia D., Hong Y.T., Fryer T.D., Williams G.B., Hodges J.R., Nestor P.J., What the left and right anterior fusiform gyri tell us about semantic memory, Brain, 133, pp. 3256-3268, (2010); Matias-Guiu J.A., Cabrera-Martin M.N., Moreno-Ramos T., Garcia-Ramos R., Porta-Etessam J., Carreras J.L., Matias-Guiu J., Clinical course of primary progressive aphasia: Clinical and FDG-PET patterns, J Neurol, 262, pp. 570-577, (2015); Whitwell J.L., Duffy J.R., Strand E.A., Machulda M.M., Senjem M.L., Schwarz C.G., Reid R., Baker M.C., Perkerson R.B., Lowe V.J., Rademakers R., Jack C.R., Josephs K.A., Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia, Brain Lang, 142, pp. 45-53, (2015); Josephs K.A., Duffy J.R., Fossett T.R., Strand E.A., Claassen D.O., Whitwell J.L., Peller P.J., Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants, Arch Neurol, 67, pp. 596-605, (2010); Cerami C., Marcone A., Galimberti D., Villa C., Fenoglio C., Scarpini E., Cappa S.F., Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia, J Alzheimers Dis, 36, pp. 415-420, (2013); Broussolle E., Bakchine S., Tommasi M., Laurent B., Bazin B., Cinotti L., Cohen L., Chazot G., Slowly progressive anarthria with late anterior opercular syndrome: A variant form of frontal cortical atrophy syndromes, J Neurol Sci, 144, pp. 44-58, (1996); Mesulam M., Wieneke C., Rogalski E., Cobia D., Thompson C., Weintraub S., Quantitative template for subtyping primary progressive aphasia, Arch Neurol, 66, pp. 1545-1551, (2009); Catricala E., Della Rosa P.A., Ginex V., Mussetti Z., Plebani V., Cappa S.F., An Italian battery for the assessment of semantic memory disorders, Neurol Sci, 34, pp. 985-993, (2013); Miceli G., Laudanna A., Capasso R., Batteria per l?analisi dei deficit afasici (B.A.D.A.), Versione Riveduta e Computerizzata Su CD-ROM. Bologna E.M.S. ID, (2006); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Realmuto S., Cappa S.F., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci, 35, pp. 1015-1021, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S.F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol Sci, 36, pp. 1907-1912, (2015); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., Van Berckel B.N., Ossenkoppele R., Guedj E., Didic M., Brugnolo A., Sambuceti G., Pagani M., Salmon E., Nobili F., Resting metabolic connectivity in prodromal Alzheimer?s disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiol Aging, 33, pp. 2533-2550, (2012); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Darcourt J., Kapucu O.L., Tatsch K., Bartenstein P., Van Laere K., EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, Eur J Nucl Med Mol Imaging, 36, pp. 2103-2110, (2009); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Gilardi M.C., Frisoni G., Friston K., Ashburner J., Perani D., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Panzacchi A., Nobili F., Pappata S., Marcone A., Garibotto V., Castiglioni I., Magnani G., Cappa S.F., Gianolli L., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clin, 6, pp. 445-454, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Pinto P., Passerini G., Falini A., Iannaccone S., Cappa S.F., Comi G., Gianolli L., Magnani G., Crossvalidation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging, 43, pp. 499-508, (2016); Spinnler H., Tognoni G., Standardizzazione e taratura italiana di test neuropsicologici, Masson Italia Periodici, (1987); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Perani D., Brain metabolic maps in mild cognitive impairment predict heterogenity of progression to dementia, Neuroimage Clin, 7, pp. 187-194, (2014); Mesulam M.M., Wieneke C., Thompson C., Rogalski E., Weintraub S., Quantitative classification of primary progressive aphasia at early and mild impairment stages, Brain, 135, pp. 1537-1553, (2012); Matias-Guiu J.A., Cabrera-Martin M.N., Garcia-Ramos R., Moreno-Ramos T., Valles-Salgado M., Carreras J.L., Matias-Guiu J., Evaluation of the new consensus criteria for the diagnosis of primary progressive aphasia using fluorodeoxyglucose positron emission tomography, Dement Geriatr Cogn Disord, 38, pp. 147-152, (2014); Perani D., FDG PET and cognitive symptoms of dementia, Clin Transl Imaging, 1, pp. 247-260, (2013); Taswell C., Yates P., Shimada H., Leyton C.E., Ballard K.J., Piguet O., Burrell J.R., Hodges J.R., Rowe C.C., 18FFDG PET improves diagnosis in patients with focal-onset dementias, J Nucl Med, 56, pp. 1547-1553, (2015); Van Overwalle F., Social cognition and the brain: A meta-Analysis, Hum Brain Mapp, 30, pp. 829-858, (2009); Duval C., Bejanin A., Piolino P., Laisney M., De La Sayette V., Belliard S., Eustache F., Desgranges B., Theory of mind impairments in patients with semantic dementia, Brain, 135, pp. 228-241, (2012); Kumfor F., Piguet O., Disturbance of emotion processing in frontotemporal dementia:Asynthesis of cognitive and neuroimaging findings, Neuropsychol Rev, 22, pp. 280-297, (2012); Couto B., Manes F., Montanes P., Matallana D., Reyes P., Velasquez M., Yoris A., Baez S., Ibanez A., Structural neuroimaging of social cognition in progressive non-fluent aphasia and behavioral variant of frontotemporal dementia, Front Hum Neurosci, 7, (2013); Cerami C., Dodich A., Iannaccone S., Marcone A., Lettieri G., Crespi C., Gianolli L., Cappa S.F., Perani D., Right limbic FDG-PET hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients, PLoS One, 10, (2015); Le Bouc R., Lenfant P., Delbeuck X., Ravasi L., Lebert F., Semah F., Pasquier F., My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer?s disease, Brain, 135, pp. 3026-3038, (2012)","2-s2.0-84994666240"
"Cerami C.; Corbo M.; Piccolo G.; Iannaccone S.","Cerami, Chiara (25722905400); Corbo, Massimo (7006723926); Piccolo, Giovanni (7006696099); Iannaccone, Sandro (7005943171)","25722905400; 7006723926; 7006696099; 7005943171","Autoimmune neuromyotonia following human papilloma virus vaccination","2013","Muscle and Nerve","47","3","","466","467","1","11","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874252606&doi=10.1002%2fmus.23648&partnerID=40&md5=6215d2eef3212b8ae11825e7205d64ac","[No abstract available]","","Adult; Autoimmune Diseases; Channelopathies; Humans; Immunization, Secondary; Immunosuppressive Agents; Isaacs Syndrome; Magnetic Resonance Imaging; Male; Muscle Weakness; Papillomavirus Vaccines; Potassium Channels; Thymus Hyperplasia; Tomography, X-Ray Computed; creatine kinase; voltage gated potassium channel; Wart virus vaccine; adult; adverse outcome; antibody titer; biceps brachii muscle; case report; computer assisted tomography; drug safety; electromyography; fatigue; female; human; human tissue; hyperhidrosis; immunization; immunosuppressive treatment; letter; limb weakness; muscle injury; muscle twitch; myalgia; myokymia; nuclear magnetic resonance imaging; paresthesia; plasmapheresis; potassium channelopathy; priority journal; tachycardia; treatment response; verruca vulgaris; Wart virus","Hart I.K., Maddison P., Newsom-Davis J., Vincent A., Mills K.R., Phenotypic variants of autoimmune peripheral nerve hyperexcitability, Brain, 125, pp. 1887-1895, (2002); Rubio-Agusti I., Perez-Miralles F., Sevilla T., Muelas N., Chumillas M.J., Mayordomo F., Et al., Peripheral nerve hyperexcitability: a clinical and immunologic study of 38 patients, Neurology, 76, pp. 172-178, (2011); Skeie G.O., Apostolski S., Evoli A., Gilhus N.E., Illa I., Harms L., Et al., Guidelines for the treatment of autoimmune neuromuscular transmission disorders, Eur J Neurol, 17, pp. 893-902, (2010); Jaben E.A., Winters J.L., Plasma exchange as a therapeutic option in patients with neurologic symptoms due to antibodies to voltage-gated potassium channels: a report of five cases and review of the literature, J Clin Apher; Tan K.M., Lennon V.A., Klein C.J., Boeve B.F., Pittock S.J., Clinical spectrum of voltage-gated potassium channel autoimmunity, Neurology, 70, pp. 1883-1890, (2008); Debeer P., De Munter P., Bruyninckx F., Devlieger R., Brachial plexus neuritis following HPV vaccination, Vaccine, 26, pp. 4417-4419, (2008); Bomprezzi R., Wildemann B., Vaccination against human papilloma virus, Neurology, 74, pp. 864-865, (2010); Chang J., Campagnolo D., Vollmer T.L., Bomprezzi R., Demyelinating disease and polyvalent human papilloma virus vaccination, J Neurol Neurosurg Psychiatry, 82, pp. 1296-1298, (2011); Sutton I., Lahoria R., Tan I., Clouston P., Barnett M., CNS demyelination and quadrivalent HPV vaccination, Mult Scler, 15, pp. 116-119, (2009); Wildemann B., Jarius S., Hartmann M., Regula J.U., Hametner C., Acute disseminated encephalomyelitis following vaccination against human papilloma virus, Neurology, 72, pp. 2132-2133, (2009); Menge T., Cree B., Saleh A., Waterboer T., Berthele A., Kalluri S.R., Et al., Neuromyelitis optica following human papillomavirus vaccination, Neurology, 79, pp. 285-287, (2012); Myers K.A., Baker S.K., Late-onset seropositive Isaacs' syndrome after Guillain-Barré syndrome, Neuromuscul Disord, 19, pp. 288-290, (2009)","2-s2.0-84874252606"
"Bernini S.; Panzarasa S.; Quaglini S.; Costa A.; Picascia M.; Cappa S.F.; Cerami C.; Tassorelli C.; Vecchi T.; Bottiroli S.","Bernini, Sara (55884116400); Panzarasa, Silvia (13907744600); Quaglini, Silvana (55080856700); Costa, Alfredo (35499758300); Picascia, Marta (55315018400); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400); Tassorelli, Cristina (7005630887); Vecchi, Tomaso (6603719753); Bottiroli, Sara (24471204500)","55884116400; 13907744600; 55080856700; 35499758300; 55315018400; 7005836132; 25722905400; 7005630887; 6603719753; 24471204500","HomeCoRe system for telerehabilitation in individuals at risk of dementia: A usability and user experience study","2023","Frontiers in Medicine","10","","1129914","","","","2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149623445&doi=10.3389%2ffmed.2023.1129914&partnerID=40&md5=cf3a5024065c419591f8453ce6758f0a","Background: Telerehabilitation has enabled a broader application of cognitive rehabilitation programs. We have recently developed HomeCoRe, a system for supporting cognitive intervention remotely with the assistance of a family member. The main goal of the present study was to determine usability and user experience of HomeCoRe in individuals at risk of dementia and in their family members. The association between subjects’ technological skills and main outcome measures was evaluated as well. Methods: Fourteen individuals with subjective cognitive decline (SCD) or mild neurocognitive disorder (mNCD) were recruited to participate in this pilot study. All participants received a touch-screen laptop implemented with the HomeCoRe software. The intervention consisted of 18 sessions and included a patient-tailored adaptive protocol of cognitive exercises. Usability was assessed in terms of treatment adherence and participants’ performance across sessions; user experience via self-reported questionnaires and a descriptive diary. Results: Usability and user experience were overall satisfactory and suggested usability, pleasantness, and high motivation while using HomeCoRe. Technological skills correlated only with the perceived ability to start and/or perform exercises autonomously. Discussion: These results, although preliminary, suggest that the usability and user experience of HomeCoRe are satisfactory and independent of technological skills. These findings encourage wider and more systematic use of HomeCoRe to overcome the current limitations of in-person cognitive rehabilitation programs and to reach more individuals at risk of dementia. Copyright © 2023 Bernini, Panzarasa, Quaglini, Costa, Picascia, Cappa, Cerami, Tassorelli, Vecchi and Bottiroli.","cognitive rehabilitation; neurocognitive disorder; telerehabilitation; usability; user experience","adult; Article; attention; clinical article; clinical outcome; cognitive rehabilitation; controlled study; dementia; episodic memory; exercise; family; female; human; male; manager; middle aged; motivation; neuropsychological assessment; personal experience; pilot study; processing speed; questionnaire; telerehabilitation; usability testing; working memory","Diagnostic and Statistical Manual of Mental Disorders, (2013); Jessen F., Amariglio R.E., Boxtel M., Breteler M., Ceccaldi M., Chetelat G., Et al., A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease, Alzheimers Dement, 10, pp. 844-852, (2014); Jack C.R., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., Et al., Introduction to the recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimers Dement, 7, pp. 257-262, (2011); Li H., Li J., Li N., Li B., Wang P., Zhou T., Cognitive intervention for persons with mild cognitive impairment: a meta-analysis, Ageing Res Rev, 10, pp. 285-296, (2011); Hill N.T.M., Mowszowski L., Naismith S.L., Chadwick V.L., Valenzuela M., Lampit A., Computerized cognitive training in older adults with mild cognitive impairment or dementia: a systematic review and meta-analysis, Am J Psychiatry, 174, pp. 329-340, (2017); Smart C.M., Karr J.E., Areshenkoff C.N., Rabin L.A., Hudon C., Gates N., Et al., Non-pharmacologic interventions for older adults with subjective cognitive decline: systematic review, meta-analysis, and preliminary recommendations, Neuropsychol Rev, 27, pp. 245-257, (2017); Clare L., Woods B., Cognitive rehabilitation and cognitive training for early-stage Alzheimer’s disease and vascular dementia, Cochrane Database Syst Rev, 4, (2003); Garcia-Casal J.A., Loizeau A., Csipke E., Franco-Martin M., Perea-Bartolome M.V., Orrell M., Computer-based cognitive interventions for people living with dementia: a systematic literature review and meta-analysis, Aging Ment Heal, 21, pp. 454-467, (2017); Zokaei N., Mackellar C., Cepukaityte G., Patai E.Z., Nobre A.C., Cognitive training in the elderly: bottlenecks and new avenues, J Cogn Neurosci, 29, pp. 1473-1482, (2017); Stasolla F., Matamala-Gomez M., Bernini S., Caffo A.O., Bottiroli S., Virtual reality as a technological-aided solution to support communication in persons with neurodegenerative diseases and acquired brain injury during COVID-19 pandemic, Front Public Heal, 8, (2021); Matamala-Gomez M., Bottiroli S., Realdon O., Riva G., Galvagni L., Platz T., Et al., Telemedicine and virtual reality at time of COVID-19 pandemic: an overview for future perspectives in neurorehabilitation, Front Neurol, 12, (2021); Irazoki E., Contreras-Somoza L.M., Toribio-Guzman J.M., Jenaro-Rio C., Van Der Roest H., Franco-Martin M.A., Technologies for cognitive training and cognitive rehabilitation for people with mild cognitive impairment and dementia. A systematic review, Front Psychol, 11, (2020); Cotelli M., Manenti R., Brambilla M., Gobbi E., Ferrari C., Binetti G., Et al., Cognitive telerehabilitation in mild cognitive impairment, Alzheimer’s disease and frontotemporal dementia: a systematic review, J Telemed Telecare, 25, pp. 67-79, (2019); Maresca G., Maggio M.G., De Luca R., Manuli A., Tonin P., Pignolo L., Et al., Tele-neuro-rehabilitation in Italy: state of the art and future perspectives, Front Neurol, 11, (2020); ISO 9241-210: Ergonomics of Human–System Interaction - Human-Centred Design for Interactive Systems, (2019); Meiland F., Innes A., Mountain G., Robinson L., van der Roest H., Garcia-Casal J.A., Et al., Technologies to support community-dwelling persons with dementia: a position paper on issues regarding development, usability, effectiveness and cost-effectiveness, deployment, and ethics, JMIR Rehabil Assist Technol, 4, (2017); Castilla D., Suso-Ribera C., Zaragoza I., Garcia-Palacios A., Botella C., Designing ICTs for users with mild cognitive impairment: a usability study, Int J Environ Res Public Health, 17, (2020); Haesner M., Steinert A., O'Sullivan J.L., Steinhagen-Thiessen E., Evaluating an accessible web interface for older adults – the impact of mild cognitive impairment (MCI), J Assist Technol, 9, pp. 219-232, (2015); Hattink B., Droes R.-M., Sikkes S., Oostra E., Lemstra A.W., Evaluation of the digital Alzheimer center: testing usability and usefulness of an online portal for patients with dementia and their Carers, JMIR Res Protoc, 5, (2016); Kim H., Lee S.-H., Cho N.-B., You H., Choi T., Kim J., User-dependent usability and feasibility of a swallowing training mHealth app for older adults: mixed methods pilot study, JMIR Mhealth Uhealth, 8, (2020); De Cola M.C., Maresca G., D'Aleo G., Carnazza L., Giliberto S., Maggio M.G., Et al., Teleassistance for frail elderly people: a usability and customer satisfaction study, Geriatr Nurs (Minneap), 41, pp. 463-467, (2020); Taylor M.E., Close J.C.T., Lord S.R., Kurrle S.E., Webster L., Savage R., Et al., Pilot feasibility study of a home-based fall prevention exercise program (StandingTall) delivered through a tablet computer (iPad) in older people with dementia, Australas J Ageing, 39, pp. e278-e287, (2020); Isernia S., Pagliari C., Jonsdottir J., Castiglioni C., Gindri P., Gramigna C., Et al., Efficiency and patient-reported outcome measures from clinic to home: the human empowerment aging and disability program for digital-health rehabilitation, Front Neurol, 10, pp. 1-13, (2019); Jelcic N., Agostini M., Meneghello F., Busse C., Parise S., Galano A., Et al., Feasibility and efficacy of cognitive telerehabilitation in early Alzheimer’s disease: a pilot study, Clin Interv Aging, 9, pp. 1605-1611, (2014); ISO 9241-220:2019(en), Ergonomics of Human-System Interaction — Part 220: Processes for Enabling, Executing and Assessing Human-Centred Design within Organizations, (2019); Contreras-Somoza L.M., Irazoki E., Toribio-Guzman J.M., de la Torre-Diez I., Diaz-Baquero A.A., Parra-Vidales E., Et al., Usability and user experience of cognitive intervention Technologies for Elderly People with MCI or dementia: a systematic review, Front Psychol, 12, pp. 1-15, (2021); Bowen D.J., Kreuter M., Spring B., Cofta-Woerpel L., Linnan L., Weiner D., Et al., How we design feasibility studies, Am J Prev Med, 36, pp. 452-457, (2009); Peel N.M., Russell T.G., Gray L.C., Feasibility of using an in-home video conferencing system ingeriatric rehabilitation, J Rehabil Med, 43, pp. 364-366, (2011); Ahmad N.A., Mat Ludin A.F., Shahar S., Mohd Noah S.A., Mohd T.N., Willingness, perceived barriers and motivators in adopting mobile applications for health-related interventions among older adults: a scoping review protocol, BMJ Open, 10, (2020); Heinz M., Martin P., Margrett J.A., Yearns M., Franke W., Yang H.-I., Et al., Perceptions of technology among older adults, J Gerontol Nurs, 39, pp. 42-51, (2013); Jeong I.C., Liu J., Finkelstein J., Factors affecting adherence with telerehabilitation in patients with multiple sclerosis, Stud Health Technol Inform, 257, pp. 189-193, (2019); Gil-Pages M., Solana J., Sanchez-Carrion R., Tormos J.M., Ensenat-Cantallops A., Garcia-Molina A., A customized home-based computerized cognitive rehabilitation platform for patients with chronic-stage stroke: study protocol for a randomized controlled trial, Trials, 19, (2018); Alloni A., Quaglini S., Panzarasa S., Sinforiani E., Bernini S., Evaluation of an ontology-based system for computerized cognitive rehabilitation, Int J Med Inform, 115, pp. 64-72, (2018); Alloni A., Sinforiani E., Zucchella C., Sandrini G., Bernini S., Cattani B., Et al., Computer-based cognitive rehabilitation: the CoRe system, Disabil Rehabil, 39, pp. 407-417, (2017); Bernini S., Alloni A., Panzarasa S., Picascia M., Quaglini S., Tassorelli C., Et al., A computer-based cognitive training in mild cognitive impairment in Parkinson’s disease, NeuroRehabilitation, 44, pp. 555-567, (2019); Bernini S., Panzarasa S., Barbieri M., Sinforiani E., Quaglini S., Tassorelli C., Et al., A double-blind randomized controlled trial of the efficacy of cognitive training delivered using two different methods in mild cognitive impairment in Parkinson’s disease: preliminary report of benefits associated with the use of a computerized tool, Aging Clin Exp Res, 33, pp. 1567-1575, (2021); Rodella C., Bernini S., Panzarasa S., Sinforiani E., Picascia M., Quaglini S., Et al., A double-blind randomized controlled trial combining cognitive training (CoRe) and neurostimulation (tDCS) in the early stages of cognitive impairment, Aging Clin Exp Res, 34, pp. 73-83, (2021); Quaglini S., Panzarasa S., Alloni A., Sacchi M., Sinforiani E., Bottiroli S., Et al., HomeCore: bringing cognitive rehabilitation at home, Stud Health Technol Inform, 264, pp. 1755-1756, (2019); Bernini S., Stasolla F., Panzarasa S., Quaglini S., Sinforiani E., Sandrini G., Et al., Cognitive Telerehabilitation for older adults with neurodegenerative diseases in the COVID-19 era: a perspective study, Front Neurol, 11, (2021); Bernini S., Panzarasa S., Sinforiani E., Quaglini S., Cappa S.F., Cerami C., Et al., HomeCoRe for Telerehabilitation in mild or major neurocognitive disorders: a study protocol for a randomized controlled trial, Front Neurol, 12, (2021); Hwang W., Salvendy G., Number of people required for usability evaluation, Commun ACM, 53, pp. 130-133, (2010); Caine K., Local Standards for Sample Size at CHI. Proceedings of the 2016 CHI Conference on Human Factors in Computing Systems, pp. 981-992, (2016); Hughes C.P., Berg L., Danziger W., Coben L.A., Martin R.L., A new clinical scale for the staging of dementia, Br J Psychiatry, 140, pp. 566-572, (1982); Measso G., Cavarzeran F., Zappala G., Lebowitz B.D., Crook T.H., Pirozzolo F.J., Et al., The mini-mental state examination: normative study of an Italian random sample, Dev Neuropsychol, 9, pp. 77-85, (1993); Conti S., Bonazzi S., Laiacona M., Masina M., Coralli M.V., Montreal cognitive assessment (MoCA)-Italian version: regression based norms and equivalent scores, Neurol Sci, 36, pp. 209-214, (2015); Spinnler H., Italian standardization and classification of neuropsychological tests. The Italian group on the neuropsychological study of aging, Ital J Neurol Sci, 8, pp. 1-120, (1987); Carlesimo G.A., Caltagirone C., Gainotti G., Fadda L., Gallassi R., Lorusso S., Et al., The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment, Eur Neurol, 36, pp. 378-384, (1996); Novelli G., Papagno C., Capitani E., Laiacona M., Tre test clinici di ricerca e produzione lessicale. Taratura su sogetti normali./three clinical tests to research and rate the lexical performance of normal subjects, Arch Psicol Neurol Psichiatr, 47, pp. 477-506, (1986); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Rey-Osterrieth complex figure: normative values in an Italian population sample, Neurol Sci, 22, pp. 443-447, (2002); Appollonio I., Leone M., Isella V., Piamarta F., Consoli T., Villa M.L., Et al., The frontal assessment battery (FAB): normative values in an Italian population sample, Neurol Sci, 26, pp. 108-116, (2005); Giovagnoli A.R., Del Pesce M., Mascheroni S., Simoncelli M., Laiacona M., Capitani E., Trail making test: normative values from 287 normal adult controls, Ital J Neurol Sci, 4, pp. 305-309, (1996); Lawton M., Brody E., Assessment of older people: self-maintaining and instrumental activities of daily living, Gerontologist, 3, pp. 179-186, (1969); Beck A.T., Steer R.A., Ball R., Ranieri W.F., Comparison of beck depression inventories -IA and -II in psychiatric outpatients, J. Pers. Assess, 67, pp. 588-597, (1996); Apolone G., Mosconi P., The Italian SF-36 health survey, J Clin Epidemiol, 51, pp. 1025-1036, (1998); Nucci M., Mapelli D., Mondini S., Cognitive reserve index questionnaire (CRIq): a new instrument for measuring cognitive reserve, Aging Clin Exp Res, 24, pp. 218-226, (2012); Schrepp M., Thomaschewski J., Hinderks A., Construction of a benchmark for the user experience questionnaire (UEQ), Int. J. Interact. Multimedia Artif. Intell, 4, pp. 40-44, (2017); Brooke J., SUS - a quick and dirty usability scale, Usability Eval Ind, 189, pp. 4-7, (1996); Hurst H., Bolton J., Assessing the clinical significance of change scores recorded on subjective outcome measures, J Manip Physiol Ther, 27, pp. 26-35, (2004); Lumsden J., Edwards E.A., Lawrence N.S., Coyle D., Munafo M.R., Gamification of cognitive assessment and cognitive training: a systematic review of applications and efficacy, JMIR Serious Games, 4, (2016); Smith-Ray R.L., Irmiter C., Boulter K., Cognitive training among cognitively impaired older adults: a feasibility study assessing the potential improvement in balance, Front Public Health, 4, (2016); Elo S., Kyngas H., The qualitative content analysis process, J Adv Nurs, 62, pp. 107-115, (2008); Hsieh H.-F., Shannon S.E., Three approaches to qualitative content analysis, Qual Health Res, 15, pp. 1277-1288, (2005); Gutenbrunner C., Ward A., Chamberlain M., White book on physical and rehabilitation medicine in Europe (revised November 2009), J Rehabil Med, 39, pp. 1-48, (2007); Martin M., Clare L., Altgassen A.M., Cameron M.H., Zehnder F., Cognition-based interventions for healthy older people and people with mild cognitive impairment, Cochrane Database Syst Rev, 1, (2011); Makai P., Perry M., Robben S.H., Schers H.J., Heinen M.M., Olde Rikkert M.G., Et al., Evaluation of an eHealth intervention in chronic Care for Frail Older People: why adherence is the first target, J Med Internet Res, 16, (2014); Di Lorito C., Bosco A., Booth V., Goldberg S., Harwood R.H., Van der Wardt V., Adherence to exercise interventions in older people with mild cognitive impairment and dementia: a systematic review and meta-analysis, Prev Med Reports, 19, (2020); Cacciante L., Pieta C., Rutkowski S., Cieslik B., Szczepanska-Gieracha J., Agostini M., Et al., Cognitive telerehabilitation in neurological patients: systematic review and meta-analysis, Neurol Sci, 43, pp. 847-862, (2022); Kumar R., Dear K.B.G., Christensen H., Ilschner S., Jorm A.F., Meslin C., Et al., Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: the personality and Total health through life 60+ study, Dement Geriatr Cogn Disord, 19, pp. 67-74, (2005); Kremen W.S., Jak A.J., Panizzon M.S., Spoon K.M., Franz C.E., Thompson W.K., Et al., Early identification and heritability of mild cognitive impairment, Int J Epidemiol, 43, pp. 600-610, (2014); Moo L.R., Gately M.E., Jafri Z., Shirk S.D., Home-based video telemedicine for dementia management, Clin Gerontol, 43, pp. 193-203, (2020); Smith G.E., Lunde A.M., Hathaway J.C., Vickers K.S., Telehealth home monitoring of solitary persons with mild dementia, Am J Alzheimers Dis Other Dement, 22, pp. 20-26, (2007); Li R., Geng J., Yang R., Ge Y., Hesketh T., Effectiveness of computerized cognitive training in delaying cognitive function decline in people with mild cognitive impairment: systematic review and meta-analysis, J Med Internet Res, 24, (2022); Ge S., Zhu Z., Wu B., McConnell E.S., Technology-based cognitive training and rehabilitation interventions for individuals with mild cognitive impairment: a systematic review, BMC Geriatr, 18, (2018)","2-s2.0-85149623445"
"Cerami C.; Scarpini E.; Cappa S.F.; Galimberti D.","Cerami, Chiara (25722905400); Scarpini, Elio (57210771033); Cappa, Stefano F. (7005836132); Galimberti, Daniela (6701617660)","25722905400; 57210771033; 7005836132; 6701617660","Frontotemporal lobar degeneration: Current knowledge and future challenges","2012","Journal of Neurology","259","11","","2278","2286","8","33","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84868204382&doi=10.1007%2fs00415-012-6507-5&partnerID=40&md5=57cdcde290fa57e80aa40868367fc5f7","Frontotemporal lobar degeneration (FTLD) is one of the most frequent neurodegenerative disorders with a presenile onset. It presents with a spectrum of clinical manifestations, ranging from behavioral and executive impairment to language disorders and motor dysfunction. New diagnostic criteria identified two main cognitive syndromes: behavioral variant frontotemporal dementia (bvFTD) and primary progressive aphasia. Regarding bvFTD, new criteria include the use of biomarkers. According to them, bvFTD can be classified in ""possible"" (clinical features only), ""probable"" (inclusion of imaging biomarkers) and ""definite"" (in the presence of a known causal mutation or at autopsy). Familial aggregation is frequently reported in FTLD, and about 10 % of cases have an autosomal dominant transmission. Microtubule-associ-ated protein tau gene mutations have been the first ones identified, and are generally associated with early onset (40-50 years) and with the bvFTD phenotype. More recently, progranulin gene mutations were recognized in association with the familial form of FTLD and a hexa-nucleotide repetition in C9ORF72 has been shown to be responsible for familial FTLD and amyotrophic lateral sclerosis. In addition, other genes are linked to rare cases of familiar FTLD. Lastly, a number of genetic risk factors for sporadic forms have also been identified. © Springer-Verlag 2012.","C9ORF72; Frontotemporal lobar degeneration; Genetics; Progranulin (GRN); Risk factor; Tau","Animals; Forecasting; Frontotemporal Lobar Degeneration; Humans; Microtubules; Mutation; microtubule associated protein; progranulin; tau protein; autopsy; chromosome 9; disease transmission; frontotemporal dementia; gene; gene identification; gene mutation; genetic association; genetic risk; human; onset age; open reading frame; phenotype; primary progressive aphasia; priority journal; review","Rosen H.J., Allison S.C., Ogar J.M., Amici S., Rose K., Dronkers N., Miller B.L., Gorno-Tempini M.L., Behavioral features in semantic dementia vs other forms of progressive aphasias, Neurology, 67, 10, pp. 1752-1756, (2006); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Et al., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol, 10, pp. 162-172, (2011); Scarpini E., Galimberti D., Guidi I., Bresolin N., Scheltens P., Progressive, isolated language disturbance: Its significance in a 65-year-old-man. A case report with implications for treatment and review of literature, Journal of the Neurological Sciences, 240, 1-2, pp. 45-51, (2006); Rankin K.P., Kramer J.H., Miller B.L., Patterns of cognitive and emotional empathy in frontotemporal lobar degeneration, Cognitive and Behavioral Neurology, 18, 1, pp. 28-36, (2005); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weiner M.W., Miller B.L., Structural anatomy of empathy in neurodegenerative disease, Brain, 129, 11, pp. 2945-2956, (2006); Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M., Phengrasamy L., Rosen H.J., Johnson J.K., Weiner M.W., Miller B.L., Cognition and amatomy in three variants of primany progressive aphasia, Annals of Neurology, 55, 3, pp. 335-346, (2004); Gorno-Tempini M.L., Brambati S.M., Ginex V., Ogar J., Dronkers N.F., Marcone A., Et al., The logopenic/phonological variant of primary progressive aphasia, Neurology, 71, pp. 1227-1234, (2008); Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., Et al., Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia, Ann Neurol, 64, pp. 388-401, (2008); Ratnavalli E., Brayne C., Dawson K., Hodges J.R., The prevalence of frontotemporal dementia, Neurology, 58, 11, pp. 1615-1621, (2002); Bird T., Knopman D., VanSwieten J., Rosso S., Feldman H., Tanabe H., Graff-Raford N., Geschwind D., Verpillat P., Hutton M., Epidemiology and genetics of frontotemporal dementia/Pick's Disease, Annals of Neurology, 54, SUPPL. 5, (2003); Goldman J.S., Farmer J.M., Wood E.M., Johnson J.K., Boxer A., Neuhaus J., Et al., Comparison of family histories in FTLD subtypes and related tauopathies, Neurology, 65, pp. 1817-1819, (2005); Snowden J.S., Neary D., Mann D.M.A., Frontotemporal dementia, British Journal of Psychiatry, 180, FEB., pp. 140-143, (2002); Pickering-Brown S.M., Progranulin and frontotemporal lobar degeneration, Acta Neuropathologica, 114, 1, pp. 39-47, (2007); DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Et al., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, pp. 245-256, (2011); Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Et al., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, pp. 257-268, (2011); Gijselinck I., Van Langenhove T., Van Der Zee J., Sleegers K., Philtjens S., Kleinberger G., Et al., A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: A gene identification study, Lancet Neurol, 11, 1, pp. 54-65, (2012); Lynch T., Sano M., Marder K.S., Bell K.L., Foster N.L., Defendini R.F., Sima A.A.F., Keohane C., Nygaard T.G., Fahn S., Mayeux R., Rowland L.P., Wilhelmsen K.C., Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex, Neurology, 44, 10, pp. 1878-1884, (1994); Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Association of missense and 5<sup>0</sup>-splice-site mutations in tau with the inherited dementia FTDP-17, Nature, 393, pp. 702-705, (1998); Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D., Tau is a candidate gene for chromosome 17 frontotemporal dementia, Annals of Neurology, 43, 6, pp. 815-825, (1998); Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B., Mutation in the tau gene in familial multiple system tauopathy with presenile dementia, Proceedings of the National Academy of Sciences of the United States of America, 95, 13, pp. 7737-7741, (1998); Ingram E.M., Spillantini M.G., Tau gene mutations: Dissecting the pathogenesis of FTDP-17, Trends in Molecular Medicine, 8, 12, pp. 555-562, (2002); Rademakers R., Cruts M., Van Broeckhoven C., The role of tau (MAPT) in frontotemporal dementia and related tauopathies, Human Mutation, 24, 4, pp. 277-295, (2004); Rademakers R., Cruts M., Dermaut B., Sleegers K., Rosso S.M., Van Den Broeck M., Backhovens H., Van Swieten J., Van Duijn C.M., Van Broeckhoven C., Tau negative frontal lobe dementia at 17q21: Significant finemapping of the candidate region to a 4.8 cM interval, Molecular Psychiatry, 7, 10, pp. 1064-1074, (2002); Goedert M., Jakes R., Mutations causing neurodegenerative tauopathies, Biochimica et Biophysica Acta - Molecular Basis of Disease, 1739, 2, pp. 240-250, (2005); Buee L., Delacourte A., Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease, Brain Pathology, 9, 4, pp. 681-693, (1999); Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A., Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease, Neuron, 3, pp. 519-526, (1989); Yancopoulou D., Spillantini M.G., Tau protein in familial and sporadic diseases, NeuroMolecular Medicine, 4, 1-2, pp. 37-48, (2003); Villa C., Ghezzi L., Pietroboni A.M., Fenoglio C., Cortini F., Serpente M., Et al., A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia, J Alz-heimers Dis, 26, pp. 19-26, (2011); Van Swieten J., Spillantini M.G., Hereditary frontotemporal dementia caused by Tau gene mutations, Brain Pathol, 17, pp. 63-73, (2007); Van Swieten J.C., Heutink P., Mutations in progranulin (GRN) within the spectrum of clinical and pathological pheno-types of frontotemporal dementia, Lancet Neurol, 7, pp. 965-974, (2008); Boeve B.F., Hutton M., Refining frontotemporal dementia with parkinsonism linked to chromosome 17: Introducing FTDP-17 (MAPT) and FTDP-17 (PGRN), Archives of Neurology, 65, 4, pp. 460-464, (2008); Josephs K.A., Whitwell J.L., Knopman D.S., Boeve B.F., Vemuri P., Senjem M.L., Et al., Two distinct subtypes of right temporal variant frontotemporal dementia, Neurology, 73, pp. 1443-1450, (2009); Lendon C.L., Lynch T., Norton J., McKeel Jr. D.W., Busfield F., Craddock N., Chakraverty S., Gopalakrishnan G., Shears S.D., Grimmett W., Wilhelmsen K.C., Hansen L., Morris J.C., Goate A.M., Hereditary dysphasic disinhibition dementia. A frontotemporal dementia linked to 17q21-22, Neurology, 50, 6, pp. 1546-1555, (1998); Rosso S.M., Kamphorst W., De Graaf B., Willemsen R., Ravid R., Niermeijer M.F., Spillantini M.G., Heutink P., Van Swieten J.C., Familial frontotemporal dementia with ubiquitin-positive inclusions is linked to chromosome 17q21-22, Brain, 124, 10, pp. 1948-1957, (2001); Van Der Zee J., Rademakers R., Engelborghs S., Gijselinck I., Bogaerts V., Vandenberghe R., Et al., A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD, Brain, 129, pp. 841-852, (2006); Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J., Adamson J., Sadovnick A.D., Rollinson S., Cannon A., Dwosh E., Neary D., Melquist S., Richardson A., Dickson D., Berger Z., Eriksen J., Robinson T., Zehr C., Dickey C.A., Crook R., McGowan E., Mann D., Boeve B., Feldman H., Hutton M., Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17, Nature, 442, 7105, pp. 916-919, (2006); Cruts M., Gijselinck I., Van Der Zee J., Engelborghs S., Wils H., Pirici D., Rademakers R., Vandenberghe R., Dermaut B., Martin J.-J., Van Duijn C., Peeters K., Sciot R., Santens P., De Pooter T., Mattheijssens M., Van Den Broeck M., Cuijt I., Vennekens K., De Deyn P.P., Kumar-Singh S., Van Broeckhoven C., Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, Nature, 442, 7105, pp. 920-924, (2006); He Z., Bateman A., Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis, Journal of Molecular Medicine, 81, 10, pp. 600-612, (2003); Zhu J., Nathan C., Jin W., Sim D., Ashcroft G.S., Wahl S.M., Lacomis L., Erdjument-Bromage H., Tempst P., Wright C.D., Ding A., Conversion of proepithelin to epithelins: Roles of SLPI and elastase in host defense and wound repair, Cell, 111, 6, pp. 867-878, (2002); Gass J., Cannon A., Mackenzie I.R., Boeve B., Baker M., Adamson J., Crook R., Melquist S., Kuntz K., Petersen R., Josephs K., Pickering-Brown S.M., Graff-Radford N., Uitti R., Dickson D., Wszolek Z., Gonzalez J., Beach T.G., Bigio E., Johnson N., Weintraub S., Mesulam M., White III C.L., Woodruff B., Caselli R., Hsiung G.-Y., Feldman H., Knopman D., Hutton M., Rademakers R., Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration, Human Molecular Genetics, 15, 20, pp. 2988-3001, (2006); Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., DuPlessis D., Jaros E., Et al., A harmonized classification system for FTLD-TDP pathology, Acta Neuropathol, 122, 1, pp. 111-113, (2011); Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., McCluskey L.F., Miller B.L., Masliah E., Mackenzie I.R., Feldman H., Feiden W., Kretzschmar H.A., Trojanowski J.Q., Lee V.M.-Y., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, 5796, pp. 130-133, (2006); Snowden J.S., Pickering-Brown S.M., Mackenzie I.R., Richardson A.M.T., Varma A., Neary D., Mann D.M.A., Progranulin gene mutations associated with frontotemporal dementia and progressive non-fluent aphasia, Brain, 129, 11, pp. 3091-3102, (2006); Yu C.E., Bird T.D., Bekris L.M., Montine T.J., Leverenz J.B., Steinbart E., Et al., The spectrum of mutations in progranulin: A collaborative study screening 545 cases of neurodegeneration, Arch Neurol, 67, pp. 161-170, (2010); Carecchio M., Fenoglio C., De Riz M., Guidi I., Comi C., Cortini F., Et al., Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic mild cognitive impairment converted to Alzheimer's disease, J Neurol Sci, 287, pp. 291-293, (2009); Carecchio M., Fenoglio C., Cortini F., Comi C., Benussi L., Ghidoni R., Et al., Cerebrospinal fluid biomarkers in progran-ulin mutations carriers, J Alzheimers Dis, 27, 4, pp. 781-790, (2011); Pietroboni A.M., Fumagalli G.G., Ghezzi L., Fenoglio C., Cortini F., Serpente M., Et al., Phenotypic heterogeneity of the GRN Asp22 fs mutation in a large Italian kindred, J Alzheimers Dis, 24, pp. 253-259, (2011); Rainero I., Rubino E., Negro E., Gallone S., Galimberti D., Gentile S., Et al., Heterosexual pedophilia in a frontotemporal dementia patient with a mutation in the progranulin gene, Biol Psychiatry, 70, pp. 43-44, (2011); Cerami C., Marcone A., Galimberti D., Villa C., Scarpini E., Cappa S.F., From genotype to phenotype: Two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder, J Alzheimers Dis, 27, 4, pp. 791-797, (2011); Ghidoni R., Benussi L., Glionna M., Franzoni M., Binetti G., Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration, Neurology, 71, pp. 1235-1239, (2008); Finch N., Baker M., Crook R., Swanson K., Kuntz K., Surtees R., Et al., Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members, Brain, 132, pp. 583-591, (2009); Hosler B.A., Siddique T., Sapp P.C., Sailor W., Huang M.C., Hossain A., Et al., Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22, JAMA, 284, pp. 1664-1669, (2000); Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Et al., Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6, Science, 323, pp. 1208-1211, (2009); Le Ber I., Camuzat A., Hannequin D., Pasquier F., Guedj E., Rovelet-Lecrux A., Hahn-Barma V., Van Der Zee J., Clot F., Bakchine S., Puel M., Ghanim M., Lacomblez L., Mikol J., Deramecourt V., Lejeune P., De La Sayette V., Belliard S., Vercelletto M., Meyrignac C., Van Broeckhoven C., Lambert J.-C., Verpillat P., Campion D., Habert M.-O., Dubois B., Brice A., Clerget-Darpoux F., Didic M., Desnuelle C., Duyckaerts C., Golfier V., Michel B.F., Thomas-Anterion C., Salachas F., Sellal F., Camu W., Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study, Brain, 131, 3, pp. 732-746, (2008); Morita M., Al-Chalabi A., Andersen P.M., Hosler B., Sapp P., Englund E., Mitchell J.E., Habgood J.J., De Belleroche J., Xi J., Jongjaroenprasert W., Horvitz H.R., Gunnarsson L.-G., Brown Jr. R.H., A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia, Neurology, 66, 6, pp. 839-844, (2006); Rollinson S., Mead S., Snowden J., Richardson A., Rohrer J., Halliwell N., Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis, Neurobiol Aging, 32, (2011); Watts G.D.J., Wymer J., Kovach M.J., Mehta S.G., Mumm S., Darvish D., Pestronk A., Whyte M.P., Kimonis V.E., Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein, Nature Genetics, 36, 4, pp. 377-381, (2004); Kimonis V.E., Fulchiero E., Vesa J., Watts G., VCP disease associated with myopathy, Paget disease of bone and fronto-temporal dementia: Review of a unique disorder, Biochim Bio-phys Acta, 1782, pp. 744-748, (2008); Skibinski G., Parkinson N.J., Brown J.M., Chakrabarti L., Lloyd S.L., Hummerich H., Nielsen J.E., Hodges J.R., Spillantini M.G., Thusgaard T., Brandner S., Brun A., Rossor M.N., Gade A., Johannsen P., Sorensen S.A., Gydesen S., Fisher E.M.C., Collinge J., Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia, Nature Genetics, 37, 8, pp. 806-808, (2005); Holm I.E., Englund E., Mackenzie I.R.A., Johannsen P., Isaacs A.M., A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3, Journal of Neuropathology and Experimental Neurology, 66, 10, pp. 884-891, (2007); Gydesen S., Brown J.M., Brun A., Chakrabarti L., Gade A., Johannsen P., Rossor M., Thusgaard T., Grove A., Yancopoulou D., Spillantini M.G., Fisher E.M.C., Collinge J., Sorensen S.A., Chromosome 3 linked frontotemporal dementia (FTD-3), Neurology, 59, 10, pp. 1585-1594, (2002); Parkinson N., Ince P.G., Smith M.O., Highley R., Skibinski G., Andersen P.M., Morrison K.E., Pall H.S., Hardiman O., Collinge J., Shaw P.J., Fisher E.M.C., ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B), Neurology, 67, 6, pp. 1074-1077, (2006); Pesiridis G., Lee V.M.Y., Trojanowski J.Q., Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis, Hum Mol Gen, 18, (2009); Benajiba L., Le Ber I., Camuzat A., Lacoste M., Thomas-Anterion C., Couratier P., Et al., TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration, Ann Neurol, 65, pp. 470-473, (2009); Borroni B., Bonvicini C., Alberici A., Buratti E., Agosti C., Archetti S., Et al., Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease, Human Mutat, 30, (2009); Kwiatkowski Jr. T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Et al., Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis, Science, 323, pp. 1205-1208, (2009); Chio A., Restagno G., Brunetti M., Ossola I., Calvo A., Mora G., Et al., Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation, Neurobiol Aging, 30, pp. 1272-1275, (2009); Groen E.J., Van Es M.A., Van Vught P.W., Spliet W.G., Van Engelen-Lee J., De Visser M., Et al., FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands, Arch Neurol, 67, pp. 224-230, (2010); Van Langenhove T., Van Der Zee J., Sleegers K., Engelborghs S., Vandenberghe R., Gijselinck I., Et al., Genetic contribution of FUS to frontotemporal lobar degeneration, Neurology, 74, pp. 366-371, (2010); Deng H.X., Chen W., Hong S.T., Boycott K.M., Gorrie G.H., Siddique N., Et al., Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia, Nature, 477, pp. 211-215, (2011); Bernardi L., Maletta R.G., Tomaino C., Smirne N., Di Natale M., Perri M., Et al., The effects of APOE and tau gene variability on risk of frontotemporal dementia, Neurobiol Aging, 27, pp. 702-709, (2006); Froelich Fabre S., Forsell C., Viitanen M., Sjogren M., Wallin A., Blennow K., Blomberg M., Andersen C., Wahlund L.-O., Lannfelt L., Clinic-based cases with frontotemporal dementia show increased cerebrospinal fluid tau and high apolipoprotein E ε4 frequency, but no tau gene mutations, Experimental Neurology, 168, 2, pp. 413-418, (2001); Farrer L.A., Abraham C.R., Volicer L., Foley E.J., Kowall N.W., McKee A.C., Wells J.M., Allele epsilon4 of apolipoprotein E shows a dose effect on age at onset of pick disease, Experimental Neurology, 136, 2, pp. 162-170, (1995); Gustafson L., Abrahamson M., Grubb A., Nilson K., Fex G., Apolipoprotein-E genotyping in Alzheimer's disease and frontotemporal dementia, Dementia and Geriatric Cognitive Disorders, 8, 4, pp. 240-243, (1997); Helisalmi S., Linnaranta K., Lehtovirta M., Mannermaa A., Heinonen O., Ryynanen M., Riekkinen Sr. P., Soininen H., Apolipoprotein E polymorphism in patients with different neurodegenerative disorders, Neuroscience Letters, 205, 1, pp. 61-64, (1996); Stevens M., Van Duijn C.M., De Knijff P., Van Broeckhoven C., Heutink P., Oostra B.A., Et al., Apolipoprotein E gene and sporadic frontal lobe dementia, Neurology, 48, pp. 1526-1529, (1997); Geschwind D., Karrim J., Nelson S.F., Miller B., The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementia, Annals of Neurology, 44, 1, pp. 134-138, (1998); Riemenschneider M., Diehl J., Muller U., Forstl H., Kurz A., Apolipoprotein E polymorphism in German patients with frontotemporal degeneration, Journal of Neurology Neurosurgery and Psychiatry, 72, 5, pp. 639-641, (2002); Short R.A., Graff-Radford N.R., Adamson J., Baker M., Hutton M., Differences in tau and apolipoprotein E polymorphism frequencies in sporadic frontotemporal lobar degeneration syndromes, Archives of Neurology, 59, 4, pp. 611-615, (2002); Srinivasan R., Davidson Y., Gibbons L., Payton A., Richardson A.M.T., Varma A., Julien C., Stopford C., Thompson J., Horan M.A., Pendleton N., Pickering-Brown S.M., Neary D., Snowden J.S., Mann D.M.A., The apolipoprotein E ε4 allele selectively increases the risk of frontotemporal lobar degeneration in males, Journal of Neurology, Neurosurgery and Psychiatry, 77, 2, pp. 154-158, (2006); Forman M.S., Farmer J., Johnson J.K., Clark C.M., Arnold S.E., Coslett H.B., Et al., Frontotemporal dementia: Clinicopath-ological correlations, Ann Neurol, 59, 6, pp. 952-962, (2006); Engelborghs S., Dermaut B., Goeman J., Saerens J., Marien P., Pickut B.A., Et al., Prospective Belgian study of neurode-generative and vascular dementia: APOE genotype effects, J Neurol Neurosurg Psychiatry, 74, pp. 1148-1151, (2003); Verpillat P., Camuzat A., Hannequin D., Thomas-Anterion C., Puel M., Belliard S., Et al., Apolipoprotein E gene in fron-totemporal dementia: An association study and meta-analysis, Eur J Hum Genet, 10, pp. 399-405, (2002); Conrad C., Andreadis A., Trojanowski J.Q., Dickson D.W., Kang D., Chen X., Wiederholt W., Hansen L., Masliah E., Thal L.J., Katzman R., Xia Y., Saitoh T., Genetic evidence for the involvement of τ in progressive supranuclear palsy, Annals of Neurology, 41, 2, pp. 277-281, (1997); Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., Hutton M., Association of an extended haplotype in the tau gene with progressive supranuclear palsy, Human Molecular Genetics, 8, 4, pp. 711-715, (1999); Di Maria E., Tabaton M., Vigo T., Abbruzzese G., Bellone E., Donati C., Frasson E., Marchese R., Montagna P., Munoz D.G., Pramstaller P.P., Zanusso G., Ajmar F., Mandich P., Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy, Annals of Neurology, 47, 3, pp. 374-377, (2000); Rademakers R., Eriksen J.L., Baker M., Robinson T., Ahmed Z., Lincoln S.J., Et al., Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP-43-positive frontotemporal dementia, Human Mol Genet, 17, pp. 3631-3642, (2008); Rollinson S., Rohrer J.D., Van Der Zee J., Sleegers K., Mead S., Engelborghs S., Et al., Noassociation of PGRN 3<sup>0</sup>UTR rs5848 in frontotemporal lobar degeneration, Neurobiol Aging, 32, pp. 754-755, (2011); Galimberti D., Fenoglio C., Cortini F., Serpente M., Venturelli E., Villa C., Et al., GRN variability contributes to sporadic fron-totemporal lobar degeneration, J Alzheimers Dis, 19, pp. 171-177, (2010); Galimberti D., Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Et al., MCP-1 A-2518G polymorphism: Effect on susceptibility for frontotemporal lobar degeneration and on cerebrospinal fluid MCP-1 levels, J Alzheimers Dis, 17, pp. 125-133, (2009); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Ghidoni R., Et al., The NOS3 G894T (Glu298Asp) polymorphism is a risk factor for frontotemporal lobar degeneration, Eur J Neurol, 16, pp. 37-42, (2009); Venturelli E., Villa C., Scarpini E., Fenoglio C., Guidi I., Lovati C., Marcone A., Cortini F., Scalabrini D., Clerici F., Bresolin N., Mariani C., Cappa S., Galimberti D., Neuronal nitric oxide synthase C276T polymorphism increases the risk for frontotemporal lobar degeneration, European Journal of Neurology, 15, 1, pp. 77-81, (2008); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Benussi L., Et al., BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease, J Alzheimers Dis, 23, pp. 701-707, (2011); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Benussi L., Et al., Is KIF24 a genetic risk factor for frontotemporal lobar degeneration?, Neurosci Lett, 482, pp. 240-244, (2010); Villa C., Venturelli E., Fenoglio C., Clerici F., Marcone A., Benussi L., Et al., DCUN1D1 is a risk factor for frontotemporal lobar degeneration, Eur J Neurol, 16, pp. 870-873, (2009); Stefani F., Zhang L., Taylor S., Donovan J., Rollinson S., Doyotte A., Et al., UBAP1 is a component of an endosome-specific ESCRT-I complex that is essential for MVB sorting, Curr Biol, 21, 14, pp. 1245-1250, (2011); Van Deerlin V.M., Sleiman P.M., Martinez-Lage M., Chen-Plotkin A., Wang L.S., Graff-Radford N.R., Et al., Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions, Nat Genet, 42, pp. 234-239, (2010); Van Der Zee J., Van Langenhove T., Kleinberger G., Sleegers K., Engelborghs S., Vandenberghe R., Et al., TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort, Brain, 134, pp. 808-815, (2011); Carrasquillo M.M., Nicholson A.M., Finch N., Gibbs J.R., Baker M., Rutherford N.J., Et al., Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma, Am J Hum Genet, 87, pp. 890-897, (2010); Riedijk S.R., Niermeijer M.F.N., Dooijes D., Tibben A., A decade of genetic counseling in frontotemporal dementia affected families: Few counselling requests and much familial opposition to testing, J Genet Counsel, 18, pp. 350-356, (2009)","2-s2.0-84868204382"
"Iannaccone S.; Cerami C.; Alessio M.; Garibotto V.; Panzacchi A.; Olivieri S.; Gelsomino G.; Moresco R.M.; Perani D.","Iannaccone, S. (7005943171); Cerami, C. (25722905400); Alessio, M. (7006667000); Garibotto, V. (24281297800); Panzacchi, A. (6603278442); Olivieri, S. (6701755659); Gelsomino, G. (58334463700); Moresco, R.M. (7003832341); Perani, D. (7005630261)","7005943171; 25722905400; 7006667000; 24281297800; 6603278442; 6701755659; 58334463700; 7003832341; 7005630261","In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease","2013","Parkinsonism and Related Disorders","19","1","","47","52","5","161","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84871529499&doi=10.1016%2fj.parkreldis.2012.07.002&partnerID=40&md5=0fb6cf22ea40db3f299f0c36bbbf4a01","Background: Reactive microgliosis, hallmark of neuroinflammation, may contribute to neuronal degeneration, as shown in several neurodegenerative diseases. We in vivo evaluated microglia activation in early dementia with Lewy bodies, still not reported, and compared with early Parkinson's disease, to assess possible differential pathological patterns. Methods: We measured the [11C]-PK11195 binding potentials with Positron Emission Tomography, using a simplified reference tissue model, as marker of microglia activation, and cerebral spinal fluid protein carbonylation levels, as marker of oxidative stress. Six dementia with Lewy bodies and 6 Parkinson's disease patients within a year from the onset, and eleven healthy controls were included. Clinical diagnosis was confirmed at a 4-year follow-up. Results: In dementia with Lewy bodies as well as in Parkinson's disease, we found significant (p < 0.001) [11C]-PK11195 binding potential increases in the substantia nigra and putamen. Patients with Lewy bodies dementia had extensive additional microglia activation in several associative cortices. This was evident also at a single subject level. Significant increase of Cerebral Spinal Fluid protein carbonylation was shown in both patients' groups. Conclusions: [11C]-PK11195 Positron Emission Tomography imaging revealed neuroinflammation in dementia with Lewy bodies and Parkinson's disease, mirroring, even at a single subject level, the common and the different topographical distribution of neuropathological changes, yet in the earliest stages of the disease process. Focusing on those events that characterize parkinsonisms and Parkinson's disease may be the key to further advancing the understanding of pathogenesis and to taking these mechanisms forward as a means of defining targets for neuroprotection. © 2012.","[<sup>11</sup>C]-PK11195; Early Parkinson disease; Lewy bodies dementia; Microglia activation; PET","Aged; Aged, 80 and over; Brain; Dementia; Diagnosis, Differential; Female; Humans; Lewy Bodies; Male; Microglia; Neurodegenerative Diseases; Neuroimaging; Parkinson Disease; Substantia Nigra; n sec butyl 1 (2 chlorophenyl) n methyl 3 isoquinolinecarboxamide c 11; aged; anterior cingulate; article; basal ganglion; brain region; caudate nucleus; cell activation; cerebellum; clinical article; comparative study; controlled study; corpus striatum; diffuse Lewy body disease; female; human; in vivo study; male; medial prefrontal cortex; microglia; Parkinson disease; pons; positron emission tomography; priority journal; protein carbonylation; protein cerebrospinal fluid level; putamen; substantia nigra; thalamus; brain; degenerative disease; dementia; differential diagnosis; Lewy body; metabolism; methodology; neuroimaging; pathology; very elderly","Bartels A.L., Leenders K.L., Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [<sup>11</sup>C]-PK11195 PET, Mov Disord, 22, 13, pp. 1852-1856, (2007); Schapira A.H., Jenner P., Etiology and pathogenesis of Parkinson's disease, Mov Disord, 26, 6, pp. 1049-1055, (2011); Dawson T.M., Dawson V.L., Molecular pathways of neurodegeneration in Parkinson's disease, Science, 302, 5646, pp. 819-822, (2003); Dalle-Donne I., Giustarini D., Colombo R., Rossi R., Milzani A., Protein carbonylation in human diseases, Trends Mol Med, 9, 4, pp. 169-176, (2003); McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38, 8, pp. 1285-1291, (1988); Imamura K., Hishikawa N., Sawada M., Nagatsu T., Yoshida M., Hashizume Y., Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains, Acta Neuropathol, 106, 6, pp. 518-526, (2003); Mrak R.E., Griffin W.S., Common inflammatory mechanisms in Lewy body disease and Alzheimer disease, J Neuropathol Exp Neurol, 66, 8, pp. 683-686, (2007); Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Et al., Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration, Proc Natl Acad Sci U S A, 100, 9, pp. 5473-5478, (2003); Papadopoulos V., Baraldi M., Guilarte T.R., Knudsen T.B., Lacapere J.-J., Lindemann P., Et al., Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function, Trends Pharmacol Sci, 27, 8, pp. 402-409, (2006); Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Et al., In-vivo measurement of activated microglia in dementia, Lancet, 358, 9280, pp. 461-467, (2001); Chauveau F., Boutin H., Van Camp N., Dolle F., Tavitian B., Nuclear imaging of neuroinflammation: a comprehensive review of [<sup>11</sup>C]-PK11195 challengers, Eur J Nucl Med Mol Imaging, 35, 12, pp. 2304-2319, (2008); Turkheimer F.E., Edison P., Pavese N., Roncaroli F., Anderson A.N., Hammers A., Et al., Reference and target region modelling of [<sup>11</sup>C]-(R)-PK11195 brain studies, J Nucl Med, 48, 1, pp. 158-167, (2007); Cagnin A., Kassiou M., Meikle S.R., Banati R.B., Positron emission tomography imaging of neuroinflammation, Neurotherapeutics, 4, 3, pp. 443-452, (2007); Ouchi Y., Yoshikawa E., Sekine Y., Futatsubashi M., Kanno T., Ogusu T., Et al., Microglial activation and dopamine terminal loss in early Parkinson's disease, Ann Neurol, 57, 2, pp. 168-175, (2005); Bartels A.L., Willemsen A.T., Doorduin J., de Vries E.F., Dierckx R.A., Leenders K.L., [<sup>11</sup>C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?, Parkinsonism Relat Disord, 16, 1, pp. 57-59, (2010); Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Et al., In vivo imaging of microglial activation with [<sup>11</sup>C](R)-PK11195 PET in idiopathic Parkinson's disease, Neurobiol Dis, 21, 2, pp. 404-412, (2006); Gerhard A., Watts J., Trender-Gerhard I., Turkheimer F., Banati R.B., Bhatia K., Et al., In vivo imaging of microglial activation with [<sup>11</sup>C](R)-PK11195 PET in corticobasal degeneration, Mov Disord, 19, 10, pp. 1221-1226, (2004); Gerhard A., Trender-Gerhard I., Turkheimer F., Quinn N.P., Bhatia K.P., Brooks D.J., In vivo imaging of microglial activation with [<sup>11</sup>C](R)-PK11195 PET in progressive supranuclear palsy, Mov Disord, 21, 1, pp. 89-93, (2006); McKeith I.G., Dickson D.W., Lowe J., Emre M., O'Brien J.T., Feldman H., Et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium, Neurology, 65, 12, pp. 1863-1872, (2005); Gelb D.J., Oliver E., Gilman S., Diagnostic criteria for Parkinson disease, Arch Neurol, 56, 1, pp. 33-39, (1999); Muller J., Wenning G.K., Jellinger K., McKee A., Poewe W., Litvan I., Progression of Hoehn and Yahr stages in Parkinsonian disorders: a clinicopathologic study, Neurology, 55, 6, pp. 888-891, (2000); Matarrese M., Moresco R.M., Cappelli A., Anzini M., Vomero S., Simonelli P., Et al., Labeling and evaluation of N-[<sup>11</sup>C]methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors, J Med Chem, 44, 4, pp. 579-585, (2001); Lammertsma A.A., Hume S.P., Simplified reference tissue model for PET receptor studies, Neuroimage, 4, 3 PART 1, pp. 153-158, (1996); Banati R.B., Newcombe J., Gunn R.N., Cagnin A., Turkheimer F., Heppner F., Et al., The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity, Brain, 123, PART 11, pp. 2321-2337, (2000); Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J., Parametric imaging of ligand-receptor binding in PET using a simplified reference region model, Neuroimage, 6, 4, pp. 279-287, (1997); Debruyne J.C., Van Laere K.J., Versijpt J., De Vos F., Eng J.K., Strijckmans K., Et al., Semiquantification of the peripheraltype benzodiazepine ligand [<sup>11</sup>C]-PK11195 in normal human brain and application in multiple sclerosis patients, Acta Neurol Belg, 102, 3, pp. 127-135, (2002); Schuitemaker A., van der Doef T.F., Boellaard R., Van der Flier W.M., Yaqub M., Windhorst A.D., Et al., Microglial activation in healthy aging, Neurobiol Aging, 33, 6, pp. 1067-1072, (2012); Conti A., Iannaccone S., Sferrazza B., De Monte L., Cappa S., Franciotta D., Et al., Differential expression of ceruloplasmin isoforms in the cerebrospinal fluid of amyotrophic lateral sclerosis patients, Proteomics Clin Appl, 2, 12, pp. 1628-1637, (2008); Olivieri S., Conti A., Iannaccone S., Cannistraci C.V., Campanella A., Barbariga M., Et al., Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention, J Neurosci, 31, 50, pp. 18568-18577, (2011); Romero-Calvo I., Ocon B., Martinez-Moya P., Suarez M.D., Zarzuelo A., Martinez-Augustin O., Et al., Reversible Ponceau staining as a loading control alternative to actin in Western blots, Anal Biochem, 401, 2, pp. 318-320, (2010); Cagnin A., Myers R., Gunn R.N., Lawrence A.D., Stevens T., Kreutzberg G.W., Et al., In vivo visualization of activated glia by [<sup>11</sup>C](R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion, Brain, 124, PART 10, pp. 2014-2027, (2001); Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E., Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging; Maetzler W., Liepelt I., Reimold M., Reischl G., Solbach C., Becker C., Et al., Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics, 34, 1, pp. 107-12, (2008); Grimm S., Hoehn A., Davies K.J., Grune T., Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease, 45, 1, pp. 73-88; Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H., Mechanisms, underlying inflammation in neurodegeneration, 140, 6, pp. 918-34","2-s2.0-84871529499"
"Tondo G.; Iaccarino L.; Cerami C.; Vanoli G.E.; Presotto L.; Masiello V.; Coliva A.; Salvi F.; Bartolomei I.; Mosca L.; Lunetta C.; Perani D.","Tondo, Giacomo (55242296300); Iaccarino, Leonardo (56114773500); Cerami, Chiara (25722905400); Vanoli, Giovanna Emilia (57211798721); Presotto, Luca (52564081500); Masiello, Valeria (22835308200); Coliva, Angela (8960892200); Salvi, Fabrizio (7007021445); Bartolomei, Ilaria (57203665167); Mosca, Lorena (37161856900); Lunetta, Christian (7801365932); Perani, Daniela (7005630261)","55242296300; 56114773500; 25722905400; 57211798721; 52564081500; 22835308200; 8960892200; 7007021445; 57203665167; 37161856900; 7801365932; 7005630261","        11C-PK11195 PET–based molecular study of microglia activation in SOD1 amyotrophic lateral sclerosis","2020","Annals of Clinical and Translational Neurology","7","9","","1513","1523","10","19","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089077326&doi=10.1002%2facn3.51112&partnerID=40&md5=5db5cd5127c16a3eed3100e4bbb9e787","Objective: Neuroinflammation is considered a key driver for neurodegeneration in several neurological diseases, including amyotrophic lateral sclerosis (ALS). SOD1 mutations cause about 20% of familial ALS, and related pathology might generate microglial activation triggering neurodegeneration. 11C-PK11195 is the prototypical and most validated PET radiotracer, targeting the 18-kDa translocator protein which is overexpressed in activated microglia. In this study, we investigated microglia activation in asymptomatic (ASYM) and symptomatic (SYM) SOD1 mutated carriers, by using 11C-PK11195 and PET imaging. Methods: We included 20 subjects: 4 ASYM-carriers, neurologically normal, 6 SYM-carriers with probable ALS, and 10 healthy controls. A receptor parametric mapping procedure estimated 11C-PK11195 binding potentials and voxel-wise statistical comparisons were performed at group and single-subject levels. Results: Both the SYM- and ASYM-carriers showed significant microglia activation in cortical and subcortical structures, with variable patterns at individual level. Clusters of activation were present in occipital and temporal regions, cerebellum, thalamus, and medulla oblongata. Notably, SYM-carriers showed microglia activation also in supplementary and primary motor cortices and in the somatosensory regions. Interpretation: In vivo neuroinflammation occurred in all SOD1 mutated cases since the presymptomatic stages, as shown by a significant cortical and subcortical microglia activation. The involvement of sensorimotor cortex became evident at the symptomatic disease stage. Although our data indicate the role of in vivo PET imaging for assessing resident microglia in the investigation of SOD1-ALS pathophysiology, further studies are needed to clarify the temporal and spatial dynamics of microglia activation and its relationship with neurodegeneration. © 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association","","Adult; Aged; Amides; Amyotrophic Lateral Sclerosis; Brain; Female; Heterozygote; Humans; Inflammation; Isoquinolines; Male; Microglia; Middle Aged; Positron-Emission Tomography; Prodromal Symptoms; Superoxide Dismutase-1; copper zinc superoxide dismutase; fluorodeoxyglucose f 18; n sec butyl 1 (2 chlorophenyl) n methyl 3 isoquinolinecarboxamide c 11; (R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; amide; copper zinc superoxide dismutase; isoquinoline derivative; SOD1 protein, human; adult; aged; amyotrophic lateral sclerosis; Article; asymptomatic disease; brain depth stimulation; clinical article; controlled study; electroencephalography; female; fractional anisotropy; functional connectivity; gene mutation; human; image analysis; male; medulla oblongata; microglia; middle aged; Mini Mental State Examination; nerve degeneration; parietal cortex; positron emission tomography; priority journal; sensorimotor cortex; amyotrophic lateral sclerosis; brain; diagnostic imaging; genetics; heterozygote; immunology; inflammation; metabolism; microglia; positron emission tomography; prodromal symptom","Robberecht W., Philips T., The changing scene of amyotrophic lateral sclerosis, Nat Rev Neurosci, 14, pp. 248-264, (2013); Kiernan M.C., Vucic S., Cheah B.C., Et al., Amyotrophic lateral sclerosis, Lancet, 377, pp. 942-955, (2011); Burke T., Pinto-Grau M., Lonergan K., Et al., A cross-sectional population-based investigation into behavioral change in amyotrophic lateral sclerosis: Subphenotypes, staging, cognitive predictors, and survival, Ann Clin Transl Neurol, 4, pp. 305-317, (2017); De Marchi F., Sarnelli M.F., Solara V., Et al., Depression and risk of cognitive dysfunctions in amyotrophic lateral sclerosis, Acta Neurol Scand, 139, pp. 438-445, (2019); Chio A., Mazzini L., Mora G., Disease-modifying therapies in amyotrophic lateral sclerosis, Neuropharmacology, (2020); Talbott E.O., Malek A.M., Lacomis D., The epidemiology of amyotrophic lateral sclerosis, Handb Clin Neurol, 138, pp. 225-238, (2016); Swinnen B., Robberecht W., The phenotypic variability of amyotrophic lateral sclerosis, Nat Rev Neurol, 10, (2014); Andersen P.M., Al-Chalabi A., Clinical genetics of amyotrophic lateral sclerosis: what do we really know?, Nat Rev Neurol., 7, (2011); Rosen D.R., Siddique T., Patterson D., Et al., Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis, Nature, 362, pp. 59-62, (1993); Ghasemi M., Brown R.H., Genetics of amyotrophic lateral sclerosis, Cold Spring Harb Perspect Med., (2017); Renton A.E., Chio A., Traynor B.J., State of play in amyotrophic lateral sclerosis genetics, Nat Neurosci, 17, (2014); Chia R., Chio A., Traynor B.J., Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications, Lancet Neurol, 17, pp. 94-102, (2018); Chen S., Sayana P., Zhang X., Le W., Genetics of amyotrophic lateral sclerosis: an update, Mol Neurodegener, 8, (2013); Wang J., Novel Aspects on Motor Neuron Disease: The Recent Genetic Studies on ALS, (2019); Turner M.R., Al-Chalabi A., Chio A., Et al., Genetic screening in sporadic ALS and FTD, J Neurol Neurosurg Psychiatry, 88, pp. 1042-1044, (2017); Roggenbuck J., Quick A., Kolb S.J., Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians, Genet Med, 19, pp. 267-274, (2017); Chio A., Moglia C., Canosa A., Et al., ALS phenotype is influenced by age, sex, and genetics: a population-based study, Neurology, 94, pp. e802-e810, (2020); Chio A., Mazzini L., D'Alfonso S., Et al., The multistep hypothesis of ALS revisited: the role of genetic mutations, Neurology, 91, pp. e635-e642, (2018); Abel O., Powell J.F., Andersen P.M., Al-Chalabi A., ALSoD: A user-friendly online bioinformatics tool for amyotrophic lateral sclerosis genetics, Hum Mutat, 33, pp. 1345-1351, (2012); Pansarasa O., Bordoni M., Diamanti L., Et al., SOD1 in amyotrophic lateral sclerosis:“ambivalent” behavior connected to the disease, Int J Mol Sci, 19, (2018); Cudkowicz M.E., McKenna-Yasek D., Sapp P.E., Et al., Epidemiology of mutations in superoxide dismutase in amyotrophic lateal sclerosis, Ann Neurol, 41, pp. 210-221, (1997); Kenna K.P., McLaughlin R.L., Byrne S., Et al., Delineating the genetic heterogeneity of ALS using targeted high-throughput sequencing, J Med Genet, 50, pp. 776-783, (2013); Chio A., Calvo A., Mazzini L., Et al., Extensive genetics of ALS: a population-based study in Italy, Neurology, 79, pp. 1983-1989, (2012); Yamashita S., Ando Y., Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis, Transl Neurodegener, 4, (2015); Nowicka N., Juranek J., Juranek J.K., Wojtkiewicz J., Risk factors and emerging therapies in amyotrophic lateral sclerosis, Int J Mol Sci, 20, (2019); McCord J.M., Fridovich I., Superoxide dismutase an enzymic function for erythrocuprein (hemocuprein), J Biol Chem, 244, pp. 6049-6055, (1969); Kaur S.J., McKeown S.R., Rashid S., Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis, Gene, 577, pp. 109-118, (2016); Pasinelli P., Brown R.H., Molecular biology of amyotrophic lateral sclerosis: insights from genetics, Nat Rev Neurosci, 7, pp. 710-723, (2006); Schain M., Kreisl W.C., Neuroinflammation in Neurodegenerative Disorders—a Review, Curr Neurol Neurosci Rep, 17, (2017); Liu J., Wang F., Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications, Front Immunol, 8, (2017); Philips T., Rothstein J.D., Glial cells in amyotrophic lateral sclerosis, Exp Neurol., 262, pp. 111-120, (2014); Kang S.H., Li Y., Fukaya M., Et al., Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis, Nat Neurosci, 16, (2013); Brettschneider J., Toledo J.B., Van Deerlin V.M., Et al., Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis, PLoS One, 7, (2012); Boillee S., Yamanaka K., Lobsiger C.S., Et al., Onset and progression in inherited ALS determined by motor neurons and microglia, Science (80-), 312, pp. 1389-1392, (2006); Werry E.L., Bright F.M., Piguet O., Et al., Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders, Int J Mol Sci, 20, (2019); Passamonti L., Tsvetanov K., Jones P.S., Et al., Neuroinflammation and functional connectivity in Alzheimer’s disease: interactive influences on cognitive performance, bioRxiv, (2019); Surendranathan A., Su L., Mak E., Et al., Early microglial activation and peripheral inflammation in dementia with Lewy bodies, Brain, 141, pp. 3415-3427, (2018); Kang Y., Mozley P.D., Verma A., Et al., Noninvasive PK11195-PET image analysis techniques can detect abnormal cerebral microglial activation in Parkinson’s disease, J Neuroimaging, 28, pp. 496-505, (2018); Turner M.R., Cagnin A., Turkheimer F.E., Et al., Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study, Neurobiol Dis, 15, pp. 601-609, (2004); Cagnin A., Rossor M., Sampson E.L., Et al., In vivo detection of microglial activation in frontotemporal dementia, Ann Neurol, 56, pp. 894-897, (2004); Pavese N., Gerhard A., Tai Y.F., Et al., Microglial activation correlates with severity in Huntington disease: a clinical and PET study, Neurology, 66, pp. 1638-1643, (2006); Iannaccone S., Cerami C., Alessio M., Et al., In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson’s disease, Parkinsonism Relat Disord, 19, pp. 47-52, (2013); Iaccarino L., Presotto L., Bettinardi V., Et al., An in vivo 11C-PK PET study of microglia activation in Fatal Familial Insomnia, Ann Clin Transl Neurol, 5, pp. 11-18, (2018); Iaccarino L., Moresco R.M., Presotto L., Et al., An In Vivo 11 C-(R)-PK11195 PET and in vitro pathology study of microglia activation in Creutzfeldt-Jakob Disease, Mol Neurobiol, 55, pp. 2856-2868, (2018); Tondo G., Iaccarino L., Caminiti S.P., Et al., The combined effects of microglia activation and brain glucose hypometabolism in early-onset Alzheimer’s disease, Alzheimer's Research & Therapy, 12, (2020); Tai Y.F., Pavese N., Gerhard A., Et al., Microglial activation in presymptomatic Huntington’s disease gene carriers, Brain, 130, pp. 1759-1766, (2007); Bevan-Jones W.R., Cope T.E., Jones P.S., Et al., In vivo evidence for pre-symptomatic neuroinflammation in a MAPT mutation carrier, Ann Clin Transl Neurol., 6, pp. 373-378, (2019); Ludolph A., Drory V., Hardiman O., Et al., A revision of the El Escorial criteria-2015, Amyotroph Lateral Scler Front Degener, 16, pp. 291-292, (2015); Presotto L., Iaccarino L., Bettinardi V., Et al., IEEE nuclear science symposium and medical imaging conference (NSS/MIC), IEEE, 2015, pp. 1-3, (2015); Matarrese M., Moresco R.M., Cappelli A., Et al., Labeling and evaluation of N-[11C] methylated quinoline-2-carboxamides as potential radioligands for visualization of peripheral benzodiazepine receptors, J Med Chem, 44, pp. 579-585, (2001); Turkheimer F.E., Rizzo G., Bloomfield P.S., Et al., The methodology of TSPO imaging with positron emission tomography, Biochem Soc Trans, 43, pp. 586-592, (2015); Turkheimer F.E., Edison P., Pavese N., Et al., Reference and target region modeling of [11C]-(R)-PK11195 brain studies, J Nucl Med, 48, pp. 158-167, (2007); Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J., Parametric imaging of ligand-receptor binding in PET using a simplified reference region model, NeuroImage, 6, pp. 279-287, (1997); Lammertsma A.A., Hume S.P., Simplified reference tissue model for PET receptor studies, NeuroImage, 4, pp. 153-158, (1996); Comi C., Tondo G., Insights into the protective role of immunity in neurodegenerative disease, Neural Regen Res, 12, (2017); Sochocka M., Diniz B.S., Leszek J., Inflammatory response in the CNS: friend or foe?, Mol Neurobiol, 54, pp. 8071-8089, (2017); Motataianu A., Barcutean L., Balasa R., Neuroimmunity in amyotrophic lateral sclerosis: focus on microglia, Amyotroph Lateral Scler Front Degener, pp. 1-8, (2020); Gargiulo S., Anzilotti S., Coda A.R.D., Et al., Imaging of brain TSPO expression in a mouse model of amyotrophic lateral sclerosis with 18 F-DPA-714 and micro-PET/CT, Eur J Nucl Med Mol Imaging, 43, pp. 1348-1359, (2016); Keller A.F., Gravel M., Kriz J., Live imaging of amyotrophic lateral sclerosis pathogenesis: disease onset is characterized by marked induction of GFAP in Schwann cells, Glia, 57, pp. 1130-1142, (2009); Beers D.R., Henkel J.S., Xiao Q., Et al., Wild-type microglia extend survival in PU. 1 knockout mice with familial amyotrophic lateral sclerosis, Proc Natl Acad Sci, 103, pp. 16021-16026, (2006); Gravel M., Beland L.-C., Soucy G., Et al., IL-10 controls early microglial phenotypes and disease onset in ALS caused by misfolded superoxide dismutase 1, J Neurosci, 36, pp. 1031-1048, (2016); Corcia P., Tauber C., Vercoullie J., Et al., Molecular imaging of microglial activation in amyotrophic lateral sclerosis, PLoS One, 7, (2012); Zurcher N.R., Loggia M.L., Lawson R., Et al., Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28, NeuroImage Clin, 7, pp. 409-414, (2015); Alshikho M.J., Zurcher N.R., Loggia M.L., Et al., Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis, Neurology, 87, pp. 2554-2561, (2016); Alshikho M.J., Zurcher N.R., Loggia M.L., Et al., Integrated magnetic resonance imaging and [11C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis, Ann Neurol, 83, pp. 1186-1197, (2018); Cerami C., Iaccarino L., Perani D., Molecular imaging of neuroinflammation in neurodegenerative dementias: the role of in vivo PET imaging, Int J Mol Sci, 18, (2017); Brettschneider J., Del Tredici K., Toledo J.B., Et al., Stages of pTDP-43 pathology in amyotrophic lateral sclerosis, Ann Neurol, 74, pp. 20-38, (2013); Agosta F., Valsasina P., Riva N., Et al., The cortical signature of amyotrophic lateral sclerosis, PLoS One, 7, (2012); Verstraete E., Veldink J.H., Hendrikse J., Et al., Structural MRI reveals cortical thinning in amyotrophic lateral sclerosis, J Neurol Neurosurg Psychiatry, 83, pp. 383-388, (2012); Walhout R., Westeneng H.-J., Verstraete E., Et al., Cortical thickness in ALS: towards a marker for upper motor neuron involvement, J Neurol Neurosurg Psychiatry, 86, pp. 288-294, (2015); Menke R.A.L., Korner S., Filippini N., Et al., Widespread grey matter pathology dominates the longitudinal cerebral MRI and clinical landscape of amyotrophic lateral sclerosis, Brain, 137, pp. 2546-2555, (2014); Tan R.H., Devenney E., Dobson-Stone C., Et al., Cerebellar integrity in the amyotrophic lateral sclerosis-frontotemporal dementia continuum, PLoS One, 9, (2014); Bede P., Chipika R.H., Finegan E., Et al., Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: a longitudinal neuroimaging study, NeuroImage Clin, 24, (2019); Agosta F., Spinelli E.G., Marjanovic I.V., Et al., Unraveling ALS due to SOD1 mutation through the combination of brain and cervical cord MRI, Neurology, 90, pp. e707-e716, (2018); Turner M.R., Hammers A., Allsop J., Et al., Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis, Amyotroph Lateral Scler., 8, pp. 343-347, (2007); Turner M.R., Hammers A., Al-Chalabi A., Et al., Distinct cerebral lesions in sporadic and ‘D90A’SOD1 ALS: studies with [11C] flumazenil PET, Brain, 128, pp. 1323-1329, (2005); Cistaro A., Valentini M.C., Chio A., Et al., Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset, Eur J Nucl Med Mol Imaging, 39, pp. 251-259, (2012); Canosa A., Pagani M., Cistaro A., Et al., 18F-FDG-PET correlates of cognitive impairment in ALS, Neurology, 86, pp. 44-49, (2016); Sala A., Iaccarino L., Fania P., Et al., Testing the diagnostic accuracy of [18F] FDG-PET in discriminating spinal-and bulbar-onset amyotrophic lateral sclerosis, Eur J Nucl Med Mol Imaging, 46, pp. 1117-1131, (2019); Cistaro A., Pagani M., Montuschi A., Et al., The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients, Eur J Nucl Med Mol Imaging, 41, pp. 844-852, (2014); Castelnovo V., Caminiti S.P., Riva N., Et al., Heterogeneous brain FDG-PET metabolic patterns in patients with C9orf72 mutation, Neurol Sci, 40, pp. 515-521, (2019); Pagani M., Chio A., Valentini M.C., Et al., Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis, Neurology, 83, pp. 1067-1074, (2014); Van Laere K., Vanhee A., Verschueren J., Et al., Value of 18fluorodeoxyglucose–positron-emission tomography in amyotrophic lateral sclerosis: a prospective study, JAMA Neurol, 71, pp. 553-561, (2014); Yamanaka K., Chun S.J., Boillee S., Et al., Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis, Nat Neurosci, 11, pp. 251-253, (2008); Visani M., De Biase D., Bartolomei I., Et al., A novel T137A SOD1 mutation in an Italian family with two subjects affected by amyotrophic lateral sclerosis, Amyotroph Lateral Scler, 12, pp. 385-388, (2011); Martinelli I., Zucchi E., Gessani A., Et al., A novel p. N66T mutation in exon 3 of the SOD1 gene: report of two families of ALS patients with early cognitive impairment, Amyotroph Lateral Scler Front Degener, 21, pp. 296-300, (2020); Forsberg K., Graffmo K., Pakkenberg B., Et al., Misfolded SOD1 inclusions in patients with mutations in C9orf72 and other ALS/FTD-associated genes, J Neurol Neurosurg Psychiatry, 90, pp. 861-869, (2019); Gellera C., Genetics of ALS in Italian families, Amyotroph Lateral Scler Other Mot Neuron Disord, 2, pp. s43-s46, (2001)","2-s2.0-85089077326"
"Realmuto S.; Dodich A.; Meli R.; Canessa N.; Ragonese P.; Salemi G.; Cerami C.","Realmuto, Sabrina (42462180200); Dodich, Alessandra (56001713900); Meli, Riccardo (57203309454); Canessa, Nicola (24334215800); Ragonese, Paolo (7003673191); Salemi, Giuseppe (57199511299); Cerami, Chiara (25722905400)","42462180200; 56001713900; 57203309454; 24334215800; 7003673191; 57199511299; 25722905400","Moral Cognition and Multiple Sclerosis: A Neuropsychological Study","2019","Archives of Clinical Neuropsychology","34","3","","319","326","7","13","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85064123460&doi=10.1093%2farclin%2facy047&partnerID=40&md5=de030ce548b62968e4fdd4c01ec76fad","Objectives Recent literature proved that social cognition impairments may characterize the neuropsychological profile of Multiple Sclerosis (MS) patients. However, little is still known about moral cognition in MS. In this study, we evaluated non-social, social, and moral cognitive performances in 45 relapsing-remitting MS patients. Methods Patients underwent the Brief International Cognitive Assessment for Multiple Sclerosis battery, the Cognitive Estimation and Stroop tasks, the Ekman-60 Faces test, the Reading the Mind in the Eye and Story-based Empathy task. Additionally, a task of moral dilemmas including both ""instrumental"" and ""incidental"" conditions was administered to patients. Forty-five age-, gender- and education-matched healthy control subjects (HC) were enrolled for comparisons. Results The majority of patients (i.e., 77.6%) showed deficits at non-social tasks, particularly in the executive domains. A subset of MS sample (i.e., 24%) presented with emotion recognition and socio-affective processing impairments. Overall, MS patients showed comparable levels of moral judgment with respect to HC. The rate of yes/no response in resolution of moral dilemmas and scores of attribution of emotional valence were comparable between groups. Nevertheless, lower moral permissibility and emotional arousal, particularly for the instrumental dilemmas, characterized the MS profile. Significant correlations between the attribution of emotional valence to moral actions and mentalizing scores emerged. Conclusions Our findings expand current literature on MS supporting not only deficits in executive and socio-emotional domains but also low levels of permissibility of immoral actions and emotional detachment in the moral judgment process. © The Author(s) 2018. Published by Oxford University Press. All rights reserved.","Emotions/emotional processing; Moral cognition; Moral judgment; Multiple sclerosis","Adult; Case-Control Studies; Cognition; Emotions; Empathy; Female; Humans; Judgment; Male; Morals; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Theory of Mind; Young Adult; adult; case control study; cognition; decision making; emotion; empathy; female; human; male; morality; multiple sclerosis; neuropsychological test; physiology; psychology; theory of mind; young adult","Bora E., Ozakbas S., Velakoulis D., Walterfang M., Social cognition in multiple sclerosis: A meta-analysis, Neuropsychology Review, 26, pp. 160-172, (2016); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Una versione abbreviata del test di Stroop: dati normativi nella popolazione italiana, Nuova Rivista di Neurologia, 12, pp. 111-115, (2002); Calabrese P., Penner I.K., Cognitive dysfunctions in multiple sclerosis - A ""multiple disconnection syndrome""?, Journal of Neurology, 254, pp. II18-II21, (2007); Chalah M.A., Ayache S.S., Deficits in social cognition: An unveiled signature of multiple sclerosis, Journal of the International Neuropsychological Society: JINS, 23, pp. 266-286, (2017); Chiaravalloti N.D., DeLuca J., Cognitive impairment in multiple sclerosis, Lancet Neurology, 7, pp. 1139-1151, (2008); Chiaravalloti N.D., Genova H.M., DeLuca J., Cognitive rehabilitation in multiple sclerosis: The role of plasticity, Frontiers in Neurology, 6, (2015); Cotter J., Firth J., Enzinger C., Kontopantelis E., Yung A.R., Elliott R., Et al., Social cognition in multiple sclerosis: A systematic review and meta-analysis, Neurology, 87, pp. 1727-1736, (2016); Della Sala S., MacPherson S., Phillips L., Sacco L., Spinnler H., How many camels are there in Italy? Cognitive estimates standardised on the Italian population, Neurological Sciences, 24, pp. 10-15, (2003); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 36, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 35, pp. 1015-1021, (2014); Gleichgerrcht E., Tomashitis B., Sinay V., The relationship between alexithymia, empathy and moral judgment in patients with multiple sclerosis, European Journal of Neurology: The Official Journal of the European Federation of Neurological Societies, 22, pp. 1295-1303, (2015); Goretti B., Niccolai C., Hakiki B., Sturchio A., Falautano M., Minacapelli E., Et al., The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population, BMC Neurology, 14, (2014); Greene J.D., Nystrom L.E., Engell A.D., Darley J.M., Cohen J.D., The neural bases of cognitive conflict and control in moral judgment, Neuron, 44, pp. 389-400, (2004); Greene J.D., Sommerville R.B., Nystrom L.E., Darley J.M., Cohen J.D., An fMRI investigation of emotional engagement in moral judgment, Science (New York), 293, pp. 2105-2108, (2001); Kern K.C., Gold S.M., Lee B., Montag M., Horsfall J., O'Connor M.F., Et al., Thalamic-hippocampal-prefrontal disruption in relapsingremitting multiple sclerosis, Neuroimage Clin, 8, pp. 440-447, (2015); Lotto L., Manfrinati A., Sarlo M., A new set of moral dilemmas: Norms for moral acceptability, decision times, and emotional salience, Journal of Behavioral Decision Making, 27, pp. 57-65, (2014); Macniven J.A., Davis C., Ho M.Y., Bradshaw C.M., Szabadi E., Constantinescu C.S., Stroop performance in multiple sclerosis: Information processing, selective attention, or executive functioning?, Journal of the International Neuropsychological Society: JINS, 14, pp. 805-814, (2008); McCabe M.P., Stokes M., McDonald E., Changes in quality of life and coping among people with multiple sclerosis over a 2 year period, Psychology, Health & Medicine, 14, pp. 86-96, (2009); Moll J., Zahn R., De Oliveira-Souza R., Krueger F., Grafman J., Opinion: The neural basis of human moral cognition, Nature Reviews. Neuroscience, 6, pp. 799-809, (2005); Patil I., Young L., Sinay V., Gleichgerrcht E., Elevated moral condemnation of third-party violations in multiple sclerosis patients, Social Neuroscience, 12, pp. 308-329, (2017); Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria, Annals of Neurology, 69, pp. 292-302, (2011); Pottgen J., Dziobek I., Reh S., Heesen C., Gold S.M., Impaired social cognition in multiple sclerosis, Journal of Neurology, Neurosurgery, and Psychiatry, 84, pp. 523-528, (2013); Serafin M., Surian L., Il Test degli Occhi: Uno strumento per valutare la"" teoria della mente, Giornale Italiano di Psicologia, 31, pp. 839-862, (2004); Taylor R., O'Carroll R., Cognitive estimation in neurological disorders, The British Journal of Clinical Psychology/the British Psychological Society, 34, pp. 223-228, (1995); Winecoff A., Clithero J.A., Carter R.M., Bergman S.R., Wang L., Huettel S.A., Ventromedial prefrontal cortex encodes emotional value, The Journal of Neuroscience, 33, pp. 11032-11039, (2013)","2-s2.0-85064123460"
"Dodich A.; Crespi C.; Santi G.C.; Marcone A.; Iannaccone S.; Perani D.; Cappa S.F.; Cerami C.","Dodich, Alessandra (56001713900); Crespi, Chiara (57034303800); Santi, Gaia Chiara (57217289456); Marcone, Alessandra (6701496511); Iannaccone, Sandro (7005943171); Perani, Daniela (7005630261); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400)","56001713900; 57034303800; 57217289456; 6701496511; 7005943171; 7005630261; 7005836132; 25722905400","Emotion Recognition Deficits in the Differential Diagnosis of Amnestic Mild Cognitive Impairment: A Cognitive Marker for the Limbic-Predominant Phenotype","2022","Journal of the International Neuropsychological Society","28","2","","203","209","6","3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102870743&doi=10.1017%2fS1355617721000254&partnerID=40&md5=459045b6760fab83785405bd2cbf900d","Objective: Late-onset amnestic mild cognitive impairment (aMCI) with long disease course and slow progression has been recently recognized as a possible phenotypical expression of a limbic-predominant neurodegenerative disorder. Basic emotion recognition ability crucially depending on temporo-limbic integrity is supposed to be impaired in this group of MCI subjects presenting a selective vulnerability of mediooral and limbic regions. However, no study specifically investigated this issue. Methods: Hereby, we enrolled 30 aMCI with a biomarker-based diagnosis of Alzheimer's disease (i.e., aMCI-AD, n = 16) or a biomarker evidence of selective mediooral and limbic degeneration (aMCI-mTLD, n = 14). Ekman-60 Faces Test (Ek-60F) was administered to each subject, comparing the performance with that of 20 healthy controls (HCs). Results: aMCI-mTLD subjects showed significantly lower Ek-60F global scores compared to HC (p = 0.001), whose performance was comparable to aMCI-AD. Fear (p = 0.02), surprise (p = 0.005), and anger (p = 0.01) recognition deficits characterized the aMCI-mTLD performance. Fear recognition scores were significantly lower in aMCI-mTLD compared to aMCI-AD (p = 0.04), while no differences were found in other emotions. Conclusions: Impaired social cognition, suggested by defective performance in emotion recognition tasks, may be a useful cognitive marker to detect limbic-predominant aMCI subjects among the heterogeneous aMCI population.  Copyright © INS. Published by Cambridge University Press, 2021.","Alzheimer's disease; cognitive marker; differential diagnosis; Ekman 60 Faces test; medial temporal lobe dysfunction; Mild cognitive impairment","Alzheimer Disease; Biomarkers; Cognition; Cognitive Dysfunction; Diagnosis, Differential; Emotions; Humans; Neuropsychological Tests; Phenotype; biological marker; Alzheimer disease; cognition; cognitive defect; differential diagnosis; emotion; human; neuropsychological test; phenotype; psychology","Adams R.B., Gordon H.L., Baird A.A., Ambady N., Kleck R.E., Effects of gaze on amygdala sensitivity to anger and fear faces, Science, 300, 5625, (2003); Albert M.S., Dekosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Phelps C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 3, pp. 270-279, (2011); Besser L.M., Teylan M.A., Nelson P.T., Limbic Predominant Age-Related TDP-43 Encephalopathy (LATE): Clinical and Neuropathological Associations, Journal of Neuropathology and Experimental Neurology, 79, 3, pp. 305-313, (2020); Bora E., Yener G.G., Meta-Analysis of Social Cognition in Mild Cognitive Impairment, Journal of Geriatric Psychiatry and Neurology, 30, 4, pp. 206-213, (2017); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Perani D., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, Neuroimage Clinical, 7, pp. 187-194, (2015); Cerami C., Dodich A., Iannaccone S., Magnani G., Santangelo R., Presotto L., Perani D., A biomarker study in longlasting amnestic mild cognitive impairment, Alzheimers Research & Therapy, 10, 1, (2018); Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Nelson P.T., Primary age-related tauopathy (PART): A common pathology associated with human aging, Acta Neuropathologica, 128, 6, pp. 755-766, (2014); Dalgleish T., The emotional brain, Nature Reviews Neuroscience, 5, 7, pp. 583-589, (2004); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Consortium E.-P., A standardized 18F-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, 4, pp. 575-593, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Cappa S.F., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurological Sciences, 35, 7, pp. 1015-1021, (2014); Dodich A., Cerami C., Iannaccone S., Marcone A., Alongi P., Crespi C., Perani D., Neuropsychological and FDGPET profiles in VGKC autoimmune limbic encephalitis, Brain and Cognition, 108, pp. 81-87, (2016); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Cummings J.L., Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria, The Lancet Neurology, 13, 6, pp. 614-629, (2014); Ferrer I., Santpere G., Van Leeuwen F.W., Argyrophilic grain disease, Brain, 131, pp. 1416-1432, (2008); Frith C.D., The social brain?, Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 362, 1480, pp. 671-678, (2007); Frith C.D., Social cognition, Philosophical Transactions of the Royal Society of London. B, Biological Sciences, 363, 1499, pp. 2033-2039, (2008); Fusar-Poli P., Placentino A., Carletti F., Landi P., Allen P., Surguladze S., Politi P., Functional atlas of emotional faces processing: A voxel-based meta-analysis of 105 functional magnetic resonance imaging studies, Journal of Psychiatry & Neuroscience, 34, 6, pp. 418-432, (2009); Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Comparing predictors of conversion and decline in mild cognitive impairment, Neurology, 75, 3, pp. 230-238, (2010); Marra C., Villa G., Quaranta D., Valenza A., Vita M.G., Gainotti G., Probable Alzheimer's disease patients presenting as ""focal temporal lobe dysfunction"" show a slow rate of cognitive decline, Journal of the International Neuropsychological Society, 18, 1, pp. 144-150, (2012); Nag S., Yu L., Boyle P.A., Leurgans S.E., Bennett D.A., Schneider J.A., TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease, Acta Neuropathologica Communications, 6, (2018); Nag S., Yu L., Wilson R.S., Chen E.Y., Bennett D.A., Schneider J.A., TDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD, Neurology, 88, 7, pp. 653-660, (2017); Nelson P.T., Dickson D.W., Trojanowski J.Q., Jack C.R., Boyle P.A., Arfanakis K., Schneider J.A., Limbic-predominant age-related TDP-43 encephalopathy (LATE): Consensus working group report, Brain, 142, 6, pp. 1503-1527, (2019); Nelson P.T., Trojanowski J.Q., Abner E.L., Al-Janabi O.M., Jicha G.A., Schmitt F.A., Ighodaro E.T., New Old Pathologies"": AD, PART, and Cerebral Age-Related TDP-43 with Sclerosis (CARTS), Journal of Neuropathology and Experimental Neurology, 75, 6, pp. 482-498, (2016); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Consortium E.-P., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clinical, 6, pp. 445-454, (2014); Petersen R.C., Mild cognitive impairment as a diagnostic entity, Journal of Internal Medicine, 256, 3, pp. 183-194, (2004); Phan K.L., Wager T., Taylor S.F., Liberzon I., Functional neuroanatomy of emotion: A meta-analysis of emotion activation studies in PET and fMRI, Neuroimage, 16, 2, pp. 331-348, (2002); Ruffman T., Henry J.D., Livingstone V., Phillips L.H., A meta-analytic review of emotion recognition and aging: Implications for neuropsychological models of aging, Neuroscience and Biobehavioral Reviews, 32, 4, pp. 863-881, (2008); Van Overwalle F., Baetens K., Understanding others' actions and goals by mirror and mentalizing systems: A meta-analysis, Neuroimage, 48, 3, pp. 564-584, (2009); Zhao K., Zhao J., Zhang M., Cui Q., Fu X., Neural Responses to Rapid Facial Expressions of Fear and Surprise, Frontiers in Psychology, 8, (2017)","2-s2.0-85102870743"
"Consonni M.; Iannaccone S.; Cerami C.; Frasson P.; Lacerenza M.; Lunetta C.; Corbo M.; Cappa S.F.","Consonni, Monica (23093832900); Iannaccone, Sandro (7005943171); Cerami, Chiara (25722905400); Frasson, Paola (37461297000); Lacerenza, Marco (6603591258); Lunetta, Christian (7801365932); Corbo, Massimo (7006723926); Cappa, Stefano F. (7005836132)","23093832900; 7005943171; 25722905400; 37461297000; 6603591258; 7801365932; 7006723926; 7005836132","The cognitive and behavioural profile of Amyotrophic Lateral Sclerosis: Application of the consensus criteria","2013","Behavioural Neurology","27","2","","143","153","10","46","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84882424750&doi=10.3233%2fBEN-2012-110202&partnerID=40&md5=273c993bbea2d322a73afa68cc0bed59","OBJECTIVE: The study aims to assess the spectrum of cognitive and behavioural disorders in patients affected by Amyotrophic Lateral Sclerosis (ALS) according to the recent consensus criteria [9]. The study also intends to assess the impact of physical disability on cognitive and behavioural abnormalities. METHODS: Detailed neurological, neuropsychological and neurobehavioral evaluations were administered to 23 ALS patients, 11 Lower Motor Neuron Disease (LMND) patients and 39 healthy controls. Strong et al.'s criteria [9] were applied to diagnose the presence of cognitive/behavioural impairment. Clinical and neuropsychological scores were used for group comparisons and correlation analyses. RESULTS: In comparison with LMND and controls, a subgroup of ALS patients (∼30%) manifested executive dysfunction, which was severe enough to classify them as cognitively impaired. Action naming difficulties and short-term memory deficits were also observed. Aspontaneity, disorganization and mental rigidity reached clinical relevance in 20% of ALS patients. A small percentage of ALS patients (13%) also had comorbid dementia. The cognitive or behavioural status was not related to the clinical features of ALS. CONCLUSION: The use of consensus criteria for cognitive and behavioural impairment and the comparison with the LMND group proved useful in defining the spectrum of non-motor manifestations of ALS. © 2013 - IOS Press and the authors. All rights reserved.","Amyotrophic Lateral Sclerosis; behavioural impairment; cognitive impairment; dysexecutive syndrome; Lower Motor Neuron Disease; motor disability","adult; aged; amyotrophic lateral sclerosis; article; behavior disorder; clinical article; cognitive defect; controlled study; disease severity; disorientation; female; human; male; motor neuron disease; neurologic examination; neuropsychological test; physical disability; priority journal; rigidity; short term memory","Barson F.P., Kinsella G.J., Ong B., Mathers S.E., A neuropsychological investigation of dementia in motor neurone disease (MND), Journal of the Neurological Sciences, 180, 1-2, pp. 107-113, (2000); Lomen-Hoerth C., Murphy J., Langmore S., Kramer J.H., Olney R.K., Miller B.L., Are amyotrophic lateral sclerosis patients cognitively normal?, Neurology, 60, pp. 1094-1097, (2003); Ringholz G.M., Appel S.H., Bradshaw M., Cooke N.A., Mosnik D.M., Schulz P.E., Prevalence and patterns of cognitive impairment in sporadic ALS, Neurology, 65, pp. 586-590, (2005); Gordon P.H., Goetz R.R., Rabkin J.G., Dalton K., McElhiney M., Hays A.P., Et al., A prospective cohort study of neuropsychological test performance in ALS, Amyotroph Lateral Scler, 11, 3, pp. 312-320, (2010); Phukan J., Pender N.P., Hardiman O., Cognitive impairment in amyotrophic lateral sclerosis, Lancet Neurol, 6, pp. 994-1003, (2007); Frank B., Haas J., Heinze H.J., Stark E., Munte T.F., Relation of neuropsychological and magnetic resonance findings in amyotrophic lateral sclerosis: Evidence for subgroups, Clin Neurol Neurosurg, 99, 2, pp. 79-86, (1997); Rippon G.A., Scarmeas N., Gordon P.H., Murphy P.L., Albert S.M., Mitsumoto H., Et al., An observational study of cognitive impairment in amyotrophic lateral sclerosis, Archives of Neurology, 63, 3, pp. 345-352, (2006); Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Et al., The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study, J Neurol Neurosurg Psychiatry, 83, 1, pp. 102-108, (2012); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Et al., Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Amyotroph Lateral Scler, 10, 3, pp. 131-146, (2009); Gibbons Z.C., Richardson A., Neary D., Snowden J.S., Behaviour in amyotrophic lateral sclerosis, Amyotroph Lateral Scler, 9, 2, pp. 67-74, (2008); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Et al., Frontotemporal lobar degeneration, A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Murphy J., Henry R.G., Langmore S., Kramer J.H., Miller B.L., Lomen-Hoerth C., Continuum of frontal lobe impairment in amyotrophic lateral sclerosis, Arch Neurol, 64, pp. 530-534, (2007); Murphy J., Henry R.G., Lomen-Hoerth C., Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis, Archives of Neurology, 64, pp. 330-334, (2007); Grossman A.B., Woolley-Levine S., Bradley W.G., Miller R.G., Detecting neurobehavioral changes in amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis, 8, 1, pp. 56-61, (2007); Woolley S.C., Katz J.S., Cognitive and behavioral impairment in amyotrophic lateral sclerosis, Phys Med Rehabil Clin N Am, 19, 3, pp. 607-617, (2008); Lomen-Hoerth C., Anderson T., Miller B., The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology, 59, 7, pp. 1077-1079, (2002); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. world federation of neurology research group on motor neuron diseases, Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, pp. 293-299, (2000); Andersen P.M., Borasio G.D., Dengler R., Hardiman O., Kollewe K., Leigh P.N., Et al., EFNS task force on management of amyotrophic lateral sclerosis: Guidelines for diagnosing and clinical care of patients and relatives, Eur J Neurol, 12, 12, pp. 921-938, (2005); Hillel A.D., Miller R.M., Yorkston K., McDonald E., Norris F.H., Konikow N., Amyotrophic lateral sclerosis severity scale, Neuroepidemiology, 8, 3, pp. 142-150, (1989); Jablecki C.K., Berry C., Leach J., Survival prediction in amyotrophic lateral sclerosis, Muscle Nerve, 12, 10, pp. 833-841, (1989); Hamilton M., Development of a rating scale for primary depressive illness, British Journal of Social and Clinical Psychology, 6, pp. 278-296, (1967); Folstein M.F., Folstein S.E., McHugh P.R., Mini-mental state"" A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 3, pp. 189-198, (1975); Wechsler D.A., Standardized memory scale for clinical use, Journal of Psychology, 19, pp. 87-95, (1945); Orsini A., Grossi D., Capitani E., Laicona M., Papagno C., Vallar G., Verbal and spatial immediate memory span: Normative data from 1355 adults and 1112 children, Italian Journal of Neurological Sciences, 8, 6, pp. 539-548, (1987); Carlesimo G.A., Caltagirone C., Gainotti G., The mental deterioration battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment, European Neurology, 36, pp. 378-384, (1996); Basso A., Capitani E., Laicona M., Raven's coloured progressive matrices: Normative values on 305 adult normal controls, Functional Neurology, 2, 2, pp. 189-194, (1987); Novelli G., Papagno C., Capitani E., Laicona M., Vallar G., Cappa S.F., Tre test clinici di ricerca e produzione lessicale. Taratura su soggetti normali, Archivio di Psicologia, Neurologia e Psichiatria, 47, 4, pp. 477-506, (1986); Venturini L., Lombardo Radice M., Imperiali M.G., Color-Word Test"" O Test di Stroop, (1981); Laicona M., Inzaghi M.G., De Tanti A., Capitani E., Wisconsin card sorting test: A new global score with Italian norms, and its relationship with theWeigl sorting test, Neurological Sciences, 21, pp. 279-291, (2000); Della Sala S., Macpherson S.E., Phillips L.H., Spinnler H., How many camels are there in Italy?, Cognitive estimates standardised on the Italian population, Neurological Sciences, 24, pp. 10-15, (2003); Miceli G., Laudanna A., Burani C., Capasso R., Batteria per L'Analisi Del Deficit Afasico., (1994); Spinnler H., Tognoni G., Standardizzazione e taratura italiana di test neuropsicologici, Italian Journal of Neurological Sciences, 6, S8, (1987); Abrahams S., Leigh P.N., Harvey A., Vythelingum G.N., Grise D., Goldstein L.H., Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 38, pp. 734-747, (2000); Kertesz A., Davidson W., Fox H., Frontal behavioral inventory: Diagnostic criteria for frontal lobe dementia, Can J Neurol Sci, 24, 1, pp. 29-36, (1997); Alberici A., Geroldi C., Cotelli M., Adorni A., Calabria M., Rossi G., Et al., The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease, Neurol Sci, 28, 2, pp. 80-86, (2007); Gregory C.A., Serra-Mestres J., Hodges J.R., Early diagnosis of the frontal variant of frontotemporal dementia: How sensitive are standard neuroimaging and neuropsychologic tests?, Neuropsychiatry Neuropsychol Behav Neurol, 12, 2, pp. 128-135, (1999); McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 7, pp. 939-944, (1984); Strong M.J., Grace G.M., Orange J.B., Leeper H.A., Menon R.S., Aere C., A prospective study of cognitive impairment in ALS, Neurology, 53, 8, pp. 1665-1670, (1999); Neary D., Snowden J.S., Mann D.M.A., Cognitive change inmotor neurone disease/amyotrophic lateral sclerosis (MND/ALS), Journal of the Neurological Sciences, 180, 1-2, pp. 15-20, (2000); Wicks P., Abrahams S., Papps B., Al Chalabi A., Shaw C.E., Leigh P.N., Et al., SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis, J Neurol, 256, 2, pp. 234-241, (2009); Birn R.M., Kenworthy L., Case L., Caravella R., Jones T.B., Bandettini P.A., Et al., Neural systems supporting lexical search guided by letter and semantic category cues: A self-paced overt response fMRI study of verbal fluency, Neuroimage, 49, 1, pp. 1099-1107, (2010); Abrahams S., Goldstein L.H., Simmons Z., Brammer M., Williams S.C.R., Giampietro V., Et al., Word retrieval in amyotrophic lateral sclerosis: A functional magnetic resonance imaging study, Brain, 127, pp. 1507-1517, (2004); Milner B., Effects of different brain lesions on card sorting, Archives of Neurology, 9, pp. 90-100, (1963); Neary D., Snowden J., Fronto-temporal dementia: Nosology, Neuropsychology and Neuropathology, Brain and Cognition, 31, pp. 176-187, (1996); Bak T.H., Hodges J.R., Noun-verb dissociation in three patients with motor neuron disease and aphasia, Brain and Language, 60, pp. 38-41, (1997); Bak T.H., O'donovan D.G., Xuereb J.H., Boniface S., Hodges J.R., Selective impairment of verb processing associated with pathological changes in Brodmann areas 44 and 45 in the motor neurone disease-dementia- aphasia syndrome, Brain, 124, PART. 1, pp. 103-120, (2001); Grossman M., Anderson C., Khan A., Avants B., Elman L., McCluskey L., Impaired action knowledge in amyotrophic lateral sclerosis, Neurology, 71, 18, pp. 1396-1401, (2008); Cappa S.F., Binetti G., Pezzini A., Padovani A., Rozzini L., Trabucchi M., Object and action naming in Alzheimer's disease and frontotemporal dementia, Neurology, 50, 2, pp. 351-355, (1998); Goldstein L.H., Adamson M., Jeffrey L., Down K., Barby T., Wilson C., Et al., The psychological impact ofMNDon patients and carers, J Neurol Sci, 160, SUPPL. 1, (1998)","2-s2.0-84882424750"
"Lorenzi C.; Marcone A.; Pirovano A.; Marino E.; Cordici F.; Cerami C.; Delmonte D.; Cappa S.F.; Bramanti P.; Smeraldi E.","Lorenzi, Cristina (7006373773); Marcone, Alessandra (6701496511); Pirovano, Adele (8739253900); Marino, Elena (24833444300); Cordici, Francesco (10239372600); Cerami, Chiara (25722905400); Delmonte, Dario (35174189400); Cappa, Stefano F. (7005836132); Bramanti, Placido (7005112597); Smeraldi, Enrico (7101814406)","7006373773; 6701496511; 8739253900; 24833444300; 10239372600; 25722905400; 35174189400; 7005836132; 7005112597; 7101814406","Serotonin transporter and saitohin genes in risk of Alzheimer's disease and frontotemporal lobar dementia: Preliminary findings","2010","Neurological Sciences","31","6","","741","749","8","12","https://www.scopus.com/inward/record.uri?eid=2-s2.0-78650517131&doi=10.1007%2fs10072-010-0400-8&partnerID=40&md5=ab861b2051a5a3debfbe0074bc9bd57a","Serotonergic transmission impairment and abnormal phosphorylation of tau protein have been implicated in the physiopathology of Alzheimer's disease (AD) and frontotemporal lobar dementia (FTLD). Associations between a functional polymorphism (5-HTTLPR), in the promoter region of the serotonin transporter gene, and susceptibility to sporadic AD and FTLD have been reported. A polymorphism (Q7R) in saitohin gene inside the microtubule-associated protein tau gene has also been related to dementia. To determine the possible role of the two polymorphisms in susceptibility to AD and FTLD, we performed a case-control study collecting 218 Italian sporadic dementia patients and 54 controls. We found a significant excess of 5-HTTLPR short alleles and an interaction between 5-HTTLPR and Q7R polymorphisms in demented subjects. Our study confirms the role of 5-HTTLPR as a potential susceptibility factor for sporadic dementia in the Italian population, and suggests a possible interaction between 5-HTTLPR and Q7R polymorphisms in neurodegenerative diseases. © 2010 Springer-Verlag.","Case-control study; Dementia; Genetics; Saitohin; Serotonin; Serotonin transporter","Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Female; Frontotemporal Dementia; Genetic Predisposition to Disease; Humans; Italy; Male; Polymorphism, Genetic; Risk Factors; Serotonin Plasma Membrane Transport Proteins; Signal Transduction; tau Proteins; saitohin; serotonin transporter; tau protein; unclassified drug; adult; aged; Alzheimer disease; amino acid substitution; article; case control study; controlled study; female; frontotemporal dementia; gene frequency; gene interaction; gene location; genetic association; genetic difference; genetic polymorphism; genetic risk; genetic susceptibility; genetic variability; heterozygote; high risk population; human; Italy; major clinical study; male; onset age; promoter region; protein function","Harciarek M., Jodzio K., Neuropsychological differences between frontotemporal dementia and Alzheimer's disease: A review, Neuropsychology Review, 15, 3, pp. 131-145, (2005); Snowden J.S., Neary D., Mann D.M.A., Frontotemporal dementia, British Journal of Psychiatry, 180, FEB., pp. 140-143, (2002); Rosen H.J., Hartikainen K.M., Jagust W., Kramer J.H., Reed B.R., Cummings J.L., Boone K., Ellis W., Miller C., Miller B.L., Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD, Neurology, 58, pp. 1608-1615, (2002); Deutsch S.I., Rosse R.B., Lakshman R.M., Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 30, 8, pp. 1369-1380, (2006); Spillantini M.G., Goedert M., Tau protein pathology in neurodegenerative diseases, Trends in Neurosciences, 21, 10, pp. 428-433, (1998); Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA, 83, pp. 4913-4917, (1986); Hong M., Lee V.M.-Y., Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons, Journal of Biological Chemistry, 272, 31, pp. 19547-19553, (1997); Hong M., Chen D.C.R., Klein P.S., Lee V.M.-Y., Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3, Journal of Biological Chemistry, 272, 40, pp. 25326-25332, (1997); Lee V.M.-Y., Goedert M., Trojanowski J.Q., Neurodegenerative tauopathies, Annual Review of Neuroscience, 24, pp. 1121-1159, (2001); McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease, Arch Neurol, 58, pp. 1803-1809, (2001); Munoz D.G., Dickson D.W., Bergeron C., Mackenzie I.R.A., Delacourte A., Zhukareva V., The neuropathology and biochemistry of frontotemporal dementia, Annals of Neurology, 54, SUPPL. 5, (2003); Bhat R.V., Budd Haeberlein S.L., Avila J., Glycogen synthase kinase 3: A drug target for CNS therapies, Journal of Neurochemistry, 89, 6, pp. 1313-1317, (2004); Kertesz A., McMonagle P., Blair M., Davidson W., Munoz D.G., The evolution and pathology of frontotemporal dementia, Brain, 128, 9, pp. 1996-2005, (2005); Campion D., Dumanchin C., Hannequin D., Dubois B., Belliard S., Puel M., Thomas-Anterion C., Michon A., Martin C., Charbonnier F., Raux G., Camuzat A., Penet C., Mesnage V., Martinez M., Clerget-Darpoux F., Brice A., Frebourg T., Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum, American Journal of Human Genetics, 65, 3, pp. 664-670, (1999); Bertram L., Tanzi R.E., Thirty years of Alzheimer's disease genetics: The implications of systematic meta-analyses, Nat Rev Neurosci, 9, pp. 768-778, (2008); Mackenzie I.R.A., Rademakers R., The molecular genetics and neuropathology of frontotemporal lobar degeneration: Recent developments, Neurogenetics, 8, 4, pp. 237-248, (2007); Bugiani O., Murrell J.R., Giaccone G., Hasegawa M., Ghigo G., Tabaton M., Morbin M., Primavera A., Carella F., Solaro C., Grisoli M., Savoiardo M., Spillantini M.G., Tagliavini F., Goedert M., Ghetti B., Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau, J Neuropathol Exp Neurol, 58, pp. 667-677, (1999); Murrell J.R., Spillantini M.G., Zolo P., Guazzelli M., Smith M.J., Hasegawa M., Redi F., Crowther R.A., Pietrini P., Ghetti B., Goedert M., Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits, J Neuropathol Exp Neurol, 58, pp. 1207-1226, (1999); Morris H.R., Perez-Tur J., Janssen J.C., Brown J., Lees A.J., Wood N.W., Hardy J., Hutton M., Rossor M.N., Mutation in the tau exon 10 splice site region in familial frontotemporal dementia [1], Annals of Neurology, 45, 2, pp. 270-271, (1999); Rizzini C., Goedert M., Hodges J.R., Smith M.J., Jakes R., Hills R., Xuereb J.H., Crowther R.A., Spillantini M.G., Tau gene mutation K257T causes a tauopathy similar to Pick's disease, J Neuropathol Exp Neurol, 59, pp. 990-1001, (2000); Rademakers R., Cruts M., Van Broeckhoven C., The role of tau (MAPT) in frontotemporal dementia and related tauopathies, Human Mutation, 24, 4, pp. 277-295, (2004); Palmer A.M., Stratmann G.C., Procter A.W., Bowen D.M., Possible neurotransmitter basis of behavioral changes in Alzheimer's disease, Ann Neurol, 23, pp. 616-620, (1988); Reinikainen K.J., Soininen H., Riekkinen P.J., Neurotransmitter changes in Alzheimer's disease: Implications to diagnostics and therapy, J Neurosci Res, 27, pp. 576-586, (1990); Mossner R., Schmitt A., Syagailo Y., Gerlach M., Riederer P., Kp L., The serotonin transporter in Alzheimer's and Parkinson's disease, J Neural Transm Suppl, 60, pp. 345-350, (2000); Kumar A.M., Serotonin uptake and its kinetics in platelets of women with Alzheimer's disease, Psychiatry Research, 59, 1-2, pp. 145-150, (1995); Lesch K.P., Balling U., Gross J., Strauss K., Wolozin B.L., Murphy D.L., Riederer P., Organization of the human serotonin transporter gene, J Neural Transm Gen Sect, 95, pp. 157-162, (1994); Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., Lesch P., Allelic variation of human serotonin transporter gene expression, J Neurochem, 66, pp. 2621-2624, (1996); Kunugi H., Ueki A., Otsuka M., Isse K., Hirasawa H., Kato N., Nabika T., Kobayashi S., Nanko S., Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: No evidence for an association, American Journal of Medical Genetics - Neuropsychiatric Genetics, 96, 3, pp. 307-309, (2000); Li T., Holmes C., Sham P.C., Vallada H., Birkett J., Kirov G., Lesch K.P., Powell J., Lovestone S., Collier D., Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimer's disease, Neuroreport, 8, pp. 683-686, (1997); Oliveira J.R.M., Zatz M., The study of genetic polymorphisms related to serotonin in Alzheimer's disease: New perspective in a heterogenic disorder, Braz J Med Biol Res, 32, pp. 463-467, (1999); Oliveira J.R.M., Gallindo R.M., Maia L.G.S., Britomarques P.R., Otto P.A., Passosbueno M.R., Morais M.A., Zatz M., The short variant of the polymorphism within the promoter region of the serotonin transporter gene is a risk factor for late onset Alzheimers-disease, Mol Psychiatry, 3, pp. 438-441, (1998); Zill P., Padberg F., De Jonge S., Hampel H., Burger K., Stubner S., Boetsch T., Jurgen Moller H., Ackenheil M., Bondy B., Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients, Neuroscience Letters, 284, 1-2, pp. 113-115, (2000); Assal F., Alarcon M., Solomon E.C., Masterman D., Geschwind D.H., Cummings J.L., Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease, Archives of Neurology, 61, 8, pp. 1249-1253, (2004); Tae M.H., Deuk M.C., Sung W.P., Myung J.J., Bong J.L., Bo G.K., Jae M.K., Jin S.Y., Young H.K., Evaluating associations between 5-HTTLPR polymorphism and Alzheimer's disease for Korean patients, Dementia and Geriatric Cognitive Disorders, 20, 1, pp. 31-34, (2005); Micheli D., Bonvicini C., Rocchi A., Ceravolo R., Mancuso M., Tognoni G., Gennarelli M., Siciliano G., Murri L., No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease, J Alzheimers Dis, 10, pp. 371-378, (2006); Borroni B., Grassi M., Agosti C., Archetti S., Costanzi C., Cornali C., Caltagirone C., Caimi L., Di Luca M., Padovani A., Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease, Am J Geriatr Psychiatry, 14, pp. 343-351, (2006); Albani D., Prato F., Fenoglio C., Batelli S., Dusi S., De Mauro S., Polito L., Lovati C., Galimberti D., Mariani C., Scarpini E., Forloni G., Association study to evaluate the serotonin transporter and apolipoprotein e genes in frontotemporal lobar degeneration in Italy, J Hum Genet, 53, pp. 1029-1033, (2008); Borroni B., Grassi M., Agosti C., Premi E., Archetti S., Alberici A., Bellelli G., Caimi L., Di Luca M., Padovani A., Establishing short-term prognosis in frontotemporal lobar degeneration spectrum: Role of genetic background and clinical phenotype, Neurobiol Aging, 31, 2, pp. 270-279, (2010); Albani D., Prato F., Tettamanti M., Lovati C., Galimberti D., Restelli I., Mariani C., Quadri P.L., Scarpini E., Lucca U., Forloni G., The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimer's disease related behavioral disturbances, J Alzheimers Dis, 18, pp. 125-130, (2009); Hu M., Retz W., Baader M., Pesold B., Adler G., Henn F.A., Rosler M., Thome J., Promoter polymorphism of the 5-HT transporter and Alzheimer's disease, Neurosci Lett, 294, pp. 63-65, (2000); Serretti A., Artioli P., Quartesan R., De Ronchi D., Genes involved in Alzheimer's disease, a survey of possible candidates, J Alzheimers Dis, 7, pp. 331-353, (2005); Conrad C., Vianna C., Freeman M., Davies P., A polymorphic gene nested within an intron of the tau gene: Implications for Alzheimer's disease, Proceedings of the National Academy of Sciences of the United States of America, 99, 11, pp. 7751-7756, (2002); Buee L., Bussiere T., Buee-Scherrer V., Delacourte A., Hof P.R., Tau protein isoforms, phosphorylation and role in neurodegenerative disorders, Brain Res Brain Res Rev, 33, pp. 95-130, (2000); Cook L., Brayne C.E., Easton D., Evans J.G., Xuereb J., Cairns N.J., Rubinsztein D.C., No evidence for an association between saitohin Q7R polymorphism and Alzheimer's disease, Ann Neurol, 52, pp. 690-691, (2002); Verpillat P., Ricard S., Hannequin D., Dubois B., Bou J., Camuzat A., Pradier L., Frebourg T., Brice A., Clerget-Darpoux F., Deleuze J.-F., Campion D., Belliard S., Didic M., Golfier V., Lacomblez L., Michel B.-F., Moreaud O., Nedelec C., Puel M., Sellal F., Thomas-Anterion C., Vercelletto M., Is the saitohin gene involved in neurodegenerative diseases?, Annals of Neurology, 52, 6, pp. 829-832, (2002); Clark L.N., Levy G., Tang M.-X., Mejia-Santana H., Ciappa A., Tycko B., Cote L.J., Louis E.D., Mayeux R., Marder K., The Saitohin 'Q7R' polymorphism and tau haplotype in multi-ethnic Alzheimer disease and Parkinson's disease cohorts, Neuroscience Letters, 347, 1, pp. 17-20, (2003); Combarros O., Rodero L., Infante J., Palacio E., Llorca J., Fernandez-Viadero C., Pena N., Berciano J., Age-dependent association between the Q7R polymorphism in the Saitohin gene and sporadic Alzheimer's disease, Dementia and Geriatric Cognitive Disorders, 16, 3, pp. 132-135, (2003); Streffer J.R., Papassotiropoulos A., Kurosinski P., Signorell A., Wollmer M.A., Tsolaki M., Iakovidou V., Horndli F., Bosset J., Gotz J., Nitsch R.M., Hock C., Saitohin gene is not associated with Alzheimer's disease, Journal of Neurology Neurosurgery and Psychiatry, 74, 3, pp. 362-363, (2003); Conrad C., Vianna C., Schultz C., Thal D.R., Ghebremedhin E., Lenz J., Braak H., Davies P., Molecular evolution and genetics of the saitohin gene and tau haplotype in Alzheimer's disease and argyrophilic grain disease, J Neurochem, 89, pp. 179-188, (2004); Seripa D., Matera M.G., D'Andrea R.P., Gravina C., Masullo C., Daniele A., Bizzarro A., Rinaldi M., Antuono P., Wekstein D.R., Dal Forno G., Fazio V.M., Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism, Neurology, 62, pp. 1631-1633, (2004); Wang B., Zhou S., Yang Z., Xie Y.C., Wang J., Zhang P., Lv Z., Zheng C., Ma X., Genetic analysis of tumor necrosis factor-alpha (TNF-alpha) G-308A and saitohin Q7R polymorphisms with Alzheimer's disease, J Neurol Sci, 270, pp. 148-151, (2008); Lin K., Tang M., Guo Y., Han H., Lin Y., Ma C., The Q7R polymorphism in the saitohin gene is rare in a southern Chinese population, Neurol Sci, 29, pp. 431-434, (2008); De Silva R., Hope A., Pittman A., Weale M.E., Morris H.R., Wood N.W., Lees A.J., Strong association of the saitohin gene Q7 variant with progressive supranuclear palsy, Neurology, 61, pp. 407-409, (2003); Ezquerra M., Campdelacreu J., Munoz E., Oliva R., Tolosa E., Sequence analysis of tau 3′untranslated region and saitohin gene in sporadic progressive supranuclear palsy, J Neurol Neurosurg Psychiatry, 75, pp. 155-157, (2004); Levecque C., Elbaz A., Clavel J., Vidal J.S., Amouyel P., Alperovitch A., Tzourio C., Chartier-Harlin M.C., Association of polymorphisms in the Tau and Saitohin genes with Parkinson's disease, Journal of Neurology, Neurosurgery and Psychiatry, 75, 3, pp. 478-480, (2004); McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, pp. 939-944, (1984); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised, (2002); Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J., The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia, Neurology, 44, pp. 2308-2314, (1994); Faul F., Erdfelder E., Lang A.G., Buchner A., G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences, Behav Res Methods, 39, pp. 175-191, (2007); Lesch K.-P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L., Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region, Science, 274, 5292, pp. 1527-1531, (1996); Vossel K.A., Miller B.L., New approaches to the treatment of frontotemporal lobar degeneration, Curr Opin Neurol, 21, pp. 708-716, (2008); Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A., Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau, Proc Natl Acad Sci USA, 85, pp. 4051-4055, (1988); Andreadis A., Brown W.M., Kosik K.S., Structure and novel exons of the human tau gene, Biochemistry, 31, pp. 10626-10633, (1992); Goedert M., Spillantini M.G., Jakes R., Rutherford D., Crowther R.A., Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease, Neuron, 3, pp. 519-526, (1989); Goedert M., Spillantini M.G., Potier M.C., Ulrich J., Crowther R.A., Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain, EMBO J, 8, pp. 393-399, (1989); Verpillat P., Camuzat A., Hannequin D., Thomas-Anterion C., Puel M., Belliard S., Dubois B., Didic M., Michel B.F., Lacomblez L., Moreaud O., Sellal F., Golfier V., Campion D., Clerget-Darpoux F., Brice A., Association between the extended tau haplotype and frontotemporal dementia, Arch Neurol, 59, pp. 935-939, (2002); Peplonska B., Zekanowski C., Religa D., Czyzewski K., Styczynska M., Pfeffer A., Gabryelewicz T., Gollebiowski M., Lluczywek E., Wasiak B., Barczak A., Chodakowska M., Barcikowska M., Kuznicki J., Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population, Neuroscience Letters, 348, 3, pp. 163-166, (2003); Zekanowski C., Peplonska B., Styczynska M., Gustaw K., Kuznicki J., Barcikowska M., Mutation screening of the MAPT and STH genes in Polish patients with clinically diagnosed frontotemporal dementia, Dementia and Geriatric Cognitive Disorders, 16, 3, pp. 126-131, (2003); Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., Hutton M., Association of an extended haplotype in the tau gene with progressive supranuclear palsy, Human Molecular Genetics, 8, 4, pp. 711-715, (1999); Conrad C., Andreadis A., Trojanowski J.Q., Dickson D.W., Kang D., Chen X., Wiederholt W., Hansen L., Masliah E., Thal L.J., Katzman R., Xia Y., Saitoh T., Genetic evidence for the involvement of τ in progressive supranuclear palsy, Annals of Neurology, 41, 2, pp. 277-281, (1997); Liu W.-K., Le T.V., Adamson J., Baker M., Cookson N., Hardy J., Hutton M., Yen S.-H., Dickson D.W., Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy, Annals of Neurology, 50, 4, pp. 494-502, (2001); Houlden H., Baker M., Morris H.R., MacDonald N., Pickering-Brown S., Adamson J., Lees A.J., Rossor M.N., Quinn N.P., Kertesz A., Khan M.N., Hardy J., Lantos P.L., St. George-Hyslop P., Munoz D.G., Mann D., Lang A.E., Bergeron C., Bigio E.H., Litvan I., Bhatia K.P., Dickson D., Wood N.W., Hutton M., Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype, Neurology, 56, 12, pp. 1702-1706, (2001); Pittman A.M., Myers A.J., Duckworth J., Bryden L., Hanson M., Abou-Sleiman P., Wood N.W., Hardy J., Lees A., De Silva R., The structure of the tau haplotype in controls and in progressive supranuclear palsy, Human Molecular Genetics, 13, 12, pp. 1267-1274, (2004); Kwok J.B.J., Teber E.T., Loy C., Hallupp M., Nicholson G., Mellick G.D., Buchanan D.D., Silburn P.A., Schofield P.R., Tau Haplotypes Regulate Transcription and Are Associated with Parkinson's Disease, Annals of Neurology, 55, 3, pp. 329-334, (2004); Skipper L., Wilkes K., Toft M., Baker M., Lincoln S., Hulihan M., Ross O.A., Hutton M., Aasly J., Farrer M., Linkage disequilibrium and association of MAPT H1 in Parkinson disease, American Journal of Human Genetics, 75, 4, pp. 669-677, (2004); Zhang J., Song Y., Chen H., Fan D., The tau gene haplotype H1 confers a susceptibility to Parkinson's disease, European Neurology, 53, 1, pp. 15-21, (2005)","2-s2.0-78650517131"
"Dodich A.; Cerami C.; Iannaccone S.; Marcone A.; Alongi P.; Crespi C.; Canessa N.; Andreetta F.; Falini A.; Cappa S.F.; Perani D.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Alongi, Pierpaolo (36192673100); Crespi, Chiara (57034303800); Canessa, Nicola (24334215800); Andreetta, Francesca (6701660100); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","56001713900; 25722905400; 7005943171; 6701496511; 36192673100; 57034303800; 24334215800; 6701660100; 7003494994; 7005836132; 7005630261","Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis","2016","Brain and Cognition","108","","","81","87","6","28","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983542302&doi=10.1016%2fj.bandc.2016.07.010&partnerID=40&md5=09ab7b7cd0e34ee4e95b60afe77576d7","Background Limbic encephalitis (LE) is characterized by an acute or subacute onset with memory impairments, confusional state, behavioral disorders, variably associated with seizures and dystonic movements. It is due to inflammatory processes that selectively affect the medial temporal lobe structures. Voltage-gate potassium channel (VGKC) autoantibodies are frequently observed. In this study, we assessed at the individual level FDG-PET brain metabolic dysfunctions and neuropsychological profiles in three autoimmune LE cases seropositive for neuronal VGKC-complex autoantibodies. Materials and methods LGI1 and CASPR2 potassium channel complex autoantibody subtyping was performed. Cognitive abilities were evaluated with an in-depth neuropsychological battery focused on episodic memory and affective recognition/processing skills. FDG-PET data were analyzed at single-subject level according to a standardized and validated voxel-based Statistical Parametric Mapping (SPM) method. Results Patients showed severe episodic memory and fear recognition deficits at the neuropsychological assessment. No disorder of mentalizing processing was present. Variable patterns of increases and decreases of brain glucose metabolism emerged in the limbic structures, highlighting the pathology-driven selective vulnerability of this system. Additional involvement of cortical and subcortical regions, particularly in the sensorimotor system and basal ganglia, was found. Conclusions Episodic memory and fear recognition deficits characterize the cognitive profile of LE. Commonalities and differences may occur in the brain metabolic patterns. Single-subject voxel-based analysis of FDG-PET imaging could be useful in the early detection of the metabolic correlates of cognitive and non-cognitive deficits characterizing LE condition. © 2016 Elsevier Inc.","Autoimmune limbic encephalitis; Episodic memory impairment; FDG-PET imaging; Fear recognition; VGKC-complex autoantibodies","Aged; Autoantibodies; Autoimmune Diseases; Fear; Female; Fluorodeoxyglucose F18; Humans; Limbic Encephalitis; Male; Memory Disorders; Memory, Episodic; Middle Aged; Neuropsychological Tests; Positron-Emission Tomography; Potassium Channels, Voltage-Gated; Radiopharmaceuticals; Recognition (Psychology); autoantibody; carbamazepine; CASPR2 antibody; fluorodeoxyglucose; glucose; lacosamide; leucine rich glioma inactivated 1 protein antibody; levetiracetam; phenobarbital; unclassified drug; voltage gated potassium channel antibody; autoantibody; fluorodeoxyglucose f 18; radiopharmaceutical agent; voltage gated potassium channel; adult; affect; aged; allergic encephalitis; amnesia; antigen antibody complex; Article; basal ganglion; brain metabolism; case report; cognitive defect; controlled study; disease severity; early diagnosis; embryo; emotional disorder; episodic memory; fear; female; focal epilepsy; generalized epilepsy; glucose brain level; glucose metabolism; human; human cell; limbic system; long term memory; male; middle aged; neuroimaging; neuropsychological test; neuropsychology; paraneoplastic neuropathy; PET-CT scanner; positron emission tomography; priority journal; sensorimotor cortex; short term memory; social cognition; temporal lobe epilepsy; theory of mind; verbal memory; autoimmune disease; blood; complication; diagnostic imaging; episodic memory; immunology; Memory Disorders; neuropsychological test; paraneoplastic neuropathy; pathophysiology; physiology; positron emission tomography; procedures; recognition","Adolphs R., Fear, faces, and the human amygdala, Current Opinion in Neurobiology, 18, 2, pp. 166-172, (2008); Ances B.M., Vitaliani R., Taylor R.A., Liebeskind D.S., Voloschin A., Houghton D.J., Et al., Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates, Brain, 128, pp. 1764-1777, (2005); Baumgartner A., Rauer S., Mader I., Meyer P.T., Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: Correlation with autoantibody types, Journal of Neurology, 260, 11, pp. 2744-2753, (2013); Broks P., Young A.W., Maratos E.J., Coffey P.J., Calder A.J., Isaac C.L., Et al., Face processing impairments after encephalitis: Amygdala damage and recognition of fear, Neuropsychologia, 36, 1, pp. 59-70, (1998); Butler C.R., Miller T.D., Kaur M.S., Baker I.W., Boothroyd G.D., Illman N.A., Et al., Persistent anterograde amnesia following limbic encephalitis associated with antibodies to the voltage-gated potassium channel complex, Journal of Neurology, Neurosurgery and Psychiatry, 85, 4, pp. 387-391, (2014); Chan D., Henley S.M., Rossor M.N., Warrington E.K., Extensive and temporally ungraded retrograde amnesia in encephalitis associated with antibodies to voltage-gated potassium channels, Archives of Neurology, 64, 3, pp. 404-410, (2007); Chatzikonstantinou A., Szabo K., Ottomeyer C., Kern R., Hennerici M.G., Successive affection of bilateral temporomesial structures in a case of non-paraneoplastic limbic encephalitis demonstrated by serial MRI and FDG-PET, Journal of Neurology, 256, 10, pp. 1753-1755, (2009); Chen W.P., Samuraki M., Yanase D., Shima K., Takeda N., Ono K., Et al., Effect of sample size for normal database on diagnostic performance of brain FDG PET for the detection of Alzheimer's disease using automated image analysis, Nuclear Medicine Communications, 29, 3, pp. 270-276, (2008); Cistaro A., Caobelli F., Quartuccio N., Fania P., Pagani M., Uncommon 18F-FDG-PET/CT findings in patients affected by limbic encephalitis: Hyper-hypometabolic pattern with double antibody positivity and migrating foci of hypermetabolism, Clinical Imaging, 39, 2, pp. 329-333, (2015); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, 4, pp. 575-593, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurological Sciences, 36, 10, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurological Sciences, 35, 7, pp. 1015-1021, (2014); Fisher R.E., Patel N.R., Lai E.C., Schulz P.E., Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis, Clinical Nuclear Medicine, 37, 9, pp. e213-e218, (2012); Frisch C., Malter M.P., Elger C.E., Helmstaedter C., Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis, European Journal of Neurology, 20, 9, pp. 1297-1304, (2013); Furie R., Ishikawa T., Dhawan V., Eidelberg D., Alternating hemichorea in primary antiphospholipid syndrome: Evidence for contralateral striatal hypermetabolism, Neurology, 44, 11, pp. 2197-2199, (1994); Goldman S., Amrom D., Szliwowski H.B., Detemmerman D., Bidaut L.M., Stanus E., Et al., Reversible striatal hypermetabolism in a case of Sydenham's chorea, Movement Disorders, 8, 3, pp. 355-358, (1993); Irani S.R., Michell A.W., Lang B., Pettingill P., Waters P., Johnson M.R., Et al., Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis, Annals of Neurology, 69, 5, pp. 892-900, (2011); Kassubek J., Juengling F.D., Nitzsche E.U., Lucking C.H., Limbic encephalitis investigated by (18)FDG-PET and 3D MRI, Journal of Neuroimaging, 11, 1, pp. 55-59, (2001); Leypoldt F., Buchert R., Kleiter I., Marienhagen J., Gelderblom M., Magnus T., Et al., Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: Distinct pattern of disease, Journal of Neurology, Neurosurgery and Psychiatry, 83, 7, pp. 681-686, (2012); Maeder-Ingvar M., Prior J.O., Irani S.R., Rey V., Vincent A., Rossetti A.O., FDG-PET hyperactivity in basal ganglia correlating with clinical course in anti-NDMA-R antibodies encephalitis, Journal of Neurology, Neurosurgery and Psychiatry, 82, 2, pp. 235-236, (2011); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., van Berckel B.N., Et al., Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiology of Aging, 33, 11, pp. 2533-2550, (2012); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, NeuroImage: Clinical, 6, pp. 445-454, (2014); Pertzov Y., Miller T.D., Gorgoraptis N., Caine D., Schott J.M., Butler C., Et al., Binding deficits in memory following medial temporal lobe damage in patients with voltage-gated potassium channel complex antibody-associated limbic encephalitis, Brain, 136, pp. 2474-2485, (2013); Quartuccio N., Caobelli F., Evangelista L., Alongi P., Kirienko M., De Biasi V., Et al., The role of PET/CT in the evaluation of patients affected by limbic encephalitis: A systematic review of the literature, Journal of Neuroimmunology, 284, pp. 44-48, (2015); Rey C., Koric L., Guedj E., Felician O., Kaphan E., Boucraut J., Et al., Striatal hypermetabolism in limbic encephalitis, Journal of Neurology, 259, 6, pp. 1106-1110, (2012); Serafin M., Surian L., Il Test degli Occhi: Uno strumento per valutare la“ teoria della mente”, Giornale Italiano di Psicologia, 31, 4, pp. 839-862, (2004); Sprengelmeyer R., Atkinson A.P., Sprengelmeyer A., Mair-Walther J., Jacobi C., Wildemann B., Et al., Disgust and fear recognition in paraneoplastic limbic encephalitis, Cortex, 46, 5, pp. 650-657, (2010); Tuzun E., Dalmau J., Limbic encephalitis and variants: Classification, diagnosis and treatment, Neurologist, 13, 5, pp. 261-271, (2007); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Et al., EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, European Journal of Nuclear Medicine and Molecular Imaging, 36, 12, pp. 2103-2110, (2009); Vincent A., Bien C.G., Irani S.R., Waters P., Autoantibodies associated with diseases of the CNS: New developments and future challenges, Lancet Neurology, 10, 8, pp. 759-772, (2011); Wegner F., Wilke F., Raab P., Tayeb S.B., Boeck A.L., Haense C., Et al., Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography, BMC Neurology, 14, (2014); Yonelinas A.P., The hippocampus supports high-resolution binding in the service of perception, working memory and long-term memory, Behavioural Brain Research, 254, pp. 34-44, (2013); Zheng Y.M., Sun W., Wang Z.X., Zhang W., Yuan Y., Leucine-rich glioma inactivated-1 protein antibody associated limbic encephalitis: One case report, Beijing Da Xue Xue Bao, 46, 4, pp. 646-649, (2014)","2-s2.0-84983542302"
"Cerami C.; Santi G.C.; Sammartano I.; Borsellino Z.; Cuccia L.; Battista Ruffo G.; Crespi C.","Cerami, Chiara (25722905400); Santi, Gaia Chiara (57217289456); Sammartano, Irene (57212106820); Borsellino, Zelia (6507184266); Cuccia, Liana (6601979555); Battista Ruffo, Giovan (57304091500); Crespi, Chiara (57034303800)","25722905400; 57217289456; 57212106820; 6507184266; 6601979555; 57304091500; 57034303800","Uncertain crisis time affects psychosocial dimensions in beta-thalassemia patients during Covid-19 pandemic: A cross-sectional study","2022","Journal of Health Psychology","27","11","","2529","2538","9","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85117565168&doi=10.1177%2f13591053211049942&partnerID=40&md5=443b90f9795e1e0d1fff7c3baeb8036a","Psychosocial variables are key factors influencing the delicate equilibrium of chronic patients during crisis time. In this study, we explored distress, anxiety, depression, loneliness, coping strategies, and changes in life habits in 43 beta-thalassemia patients and 86 controls during Covid-19 pandemic. Patients showed higher anxiety levels and a predominant transcendent coping profile compared to controls. Patients significantly differed from controls in outdoor habits. Social isolation and habits changes in uncertain life-threaten situations as Covid-19 pandemic are particularly detrimental in fragile beta-thalassemia patients. Structured support interventions are needed to promote well-being in the Covid-19 era. © The Author(s) 2021.","anxiety; beta-thalassemia; Covid-19; psychosocial factors; stress","beta-Thalassemia; COVID-19; Cross-Sectional Studies; Humans; Pandemics; SARS-CoV-2; beta thalassemia; cross-sectional study; human; pandemic","Adib-Hajbaghery M., Ahmadi M., Health related quality of life, depression, anxiety and stress in patients with beta-thalassemia major, Iranian Journal of Pediatric Hematology and Oncology, 5, 4, pp. 193-205, (2015); Ahmadi M., Gheibizadeh M., Rassouli M., Et al., Experience of uncertainty in patients with thalassemia major: A qualitative study, International Journal of Hematology-Oncology and Stem Cell Research, 14, 4, pp. 237-247, (2020); Alsaad A., Psychosocial aspects of thalassemia and patient’s quality of life: A narrative review, Majmaah Journal of Health Sciences, 8, 1, (2020); Anie K.A., Massaglia P., Psychological therapies for thalassaemia, Cochrane Database of Systematic Reviews, 3, (2001); Arbabisarjou A., Karimzaei T., Jamalzaei A., The perception of biological experience in patients with major thalassemia: A qualitative research, Global Journal of Health Science, 7, 1, pp. 79-87, (2014); Aydinok Y., Erermis S., Bukusoglu N., Et al., Psychosocial implications of thalassemia major, Pediatrics International, 47, 1, pp. 84-89, (2005); Baldwin R., Mauro B.W., Economics in the time of COVID-19, (2020); Benz E.J., Angelucci E., Management and prognosis of the thalassemias, (2019); Blanca M., Alarcon R., Arnau J., Et al., Non-normal data: IIs ANOVA still a valid option?, Psicothema, 29, pp. 552-557, (2017); Brooks S.K., Dunn R., Amlot R., Et al., Social and occupational factors associated with psychological distress and disorder among disaster responders: A systematic review, BMC Psychology, 4, 1, (2016); Brooks S.K., Dunn R., Amlot R., Et al., A systematic, thematic review of social and occupational factors associated with psychological outcomes in healthcare employees during an infectious disease outbreak, Journal of Occupational and Environmental Medicine, 60, 3, pp. 248-257, (2018); Canatan D., De Sanctis V., The medical concerns of patients with thalassemias at the time of covid-19 outbreak: The personal experience and the international recommendations, Acta Biomedica, 91, 2, pp. 218-221, (2020); Cerami C., Canevelli M., Santi G.C., Et al., Identifying frail populations for disease risk prediction and intervention planning in the Covid-19 era: A focus on social isolation and vulnerability, Frontiers in Psychiatry, 12, (2021); Cerami C., Santi G.C., Galandra C., Et al., Covid-19 outbreak in Italy: Are we ready for the psychosocial and the economic crisis? Baseline findings from the PsyCovid study, Frontiers in Psychiatry, 11, (2020); Chudasama Y.V., Gillies C.L., Zaccardi F., Et al., Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals, Diabetes & Metabolic Syndrome Clinical Research & Reviews, 14, 5, pp. 965-967, (2020); Consonni M., Telesca A., Grazzi L., Et al., Life with chronic pain during COVID-19 lockdown: The case of patients with small fibre neuropathy and chronic migraine, Neurological Sciences, 42, 2, pp. 389-397, (2021); Crespi C., PsyCOVID study: Exploring psychosocial correlates of the perceived impact of covid-19 emergence on the Italian population, (2020); Cullen W., Gulati G., Kelly B.D., Mental health in the COVID-19 pandemic, QJM : Monthly Journal of the Association of Physicians, 113, 5, pp. 311-312, (2020); Flint J., Harding R.M., Boyce A.J., Et al., The population genetics of the haemoglobinopathies, Bailliere’s Clinical Haematology, 11, 1, pp. 1-51, (1998); Floris F., Comitini F., Leoni G., Et al., Quality of life in Sardinian patients with transfusion-dependent thalassemia: A cross-sectional study, Quality of Life Research, 27, 10, pp. 2533-2539, (2018); Foa C., Caricati L., Fruggeri L., Et al., COPE-NVI-25: validazione italiana della versione ridotta della coping orientation to the problems experienced (COPE-NVI), Psicologia Della Salute, 2, pp. 123-140, (2015); Galanello R., Origa R., Open access REVIEW BioMed central beta-thalassemia, Orphanet Journal of Rare Diseases, 5, (2010); Ghanizadeh A., Khajavian S., Ashkani H., Prevalence of psychiatric disorders, depression, and suicidal behavior in child and adolescent with thalassemia major, Journal of Pediatric Hematology/Oncology, 28, 12, pp. 781-784, (2006); Gharaibeh H., Amarneh B.H., Zamzam S.Z., The psychological burden of patients with beta thalassemia major in Syria, Pediatrics International, 51, pp. 630-636, (2009); Groarke J.M., Berry E., Graham-Wisener L., Et al., Loneliness in the UK during the COVID-19 pandemic: Cross-sectional results from the COVID-19 psychological wellbeing study, PLoS One, 15, 9, (2020); Hossain M.S., Raheem E., Siddiqee M.H., The forgotten people with thalassemia in the time of COVID-19: South Asian perspective, Orphanet Journal of Rare Diseases, 15, 1, (2020); Jabbarifard F., Sharifi T., Solati K., Et al., The effectiveness of acceptance and commitment therapy on perceived stress, resilience, and the quality of life in thalassemia major patients, Journal of Shahrekord University of Medical Sciences, 21, 2, pp. 91-97, (2019); Karimi M., De Sanctis V., Implications of SARSR-COV 2 infection in thalassemias: Do patients fall into the ‘high clinical risk’ category?, Acta Biomedica, 91, 2, pp. 50-56, (2020); Khalid I., Khalid T.J., Qabajah M.R., Et al., Healthcare workers emotions, perceived stressors and coping strategies during a MERS-CoV outbreak, Clinical Medicine Research, 14, 1, pp. 7-14, (2016); Lacasse A., Page M.G., Dassieu L., Et al., Impact of the COVID-19 pandemic on the pharmacological, physical, and psychological treatments of pain: Findings from the chronic pain & COVID-19 Pan-Canadian study, Pain Reports, 6, 1, (2021); Lansiaux E., Pebay P.P., Picard J.L., Et al., COVID-19: Beta-thalassemia subjects immunised?, Medical Hypotheses, 142, (2020); Louvardi M., Pelekasis P., Chrousos G.P., Et al., Mental health in chronic disease patients during the COVID-19 quarantine in Greece, Palliative & Supportive Care, 18, 4, pp. 394-399, (2020); Mattioli A.V., Ballerini Puviani M., Nasi M., Et al., COVID-19 pandemic: The effects of quarantine on cardiovascular risk, European Journal of Clinical Nutrition, 74, pp. 852-855, (2020); Mauro V., Lorenzo M., Paolo C., Et al., Treat all COVID 19-positive patients, but do not forget those negative with chronic diseases, Internal and Emergency Medicine, 15, 5, pp. 787-790, (2020); Messina G., Colombo E., Cassinerio E., Et al., Psychosocial aspects and psychiatric disorders in young adult with thalassemia major, Internal and Emergency Medicine, 3, 4, pp. 339-343, (2008); Mikelli A., Tsiantis J., Brief report: Depressive symptoms and quality of life in adolescents with b-thalassaemia, Journal of Adolescence, 27, 2, pp. 213-216, (2004); Mohamadian F., Bagheri M., Hashemi M.S., Et al., The effects of cognitive behavioral therapy on depression and anxiety among patients with thalassemia: A randomized controlled trial, Journal of Caring Sciences, 7, 4, pp. 219-224, (2018); Moorjani J.D., Issac C., Neurotic manifestations in adolescents with thalassemia major, Indian Journal of Pediatrics, 73, 7, pp. 603-607, (2006); Osman A., Wong J.L., Bagge C.L., Et al., The depression anxiety stress scales-21 (DASS-21): Further examination of dimensions, scale reliability, and correlates, Journal of Clinical Psychology, 68, 12, pp. 1322-1338, (2012); Pakbaz Z., Treadwell M., Kim H.Y., Et al., Education and employment status of children and adults with thalassemia in North America, Pediatric Blood & Cancer, 55, 4, pp. 678-683, (2010); Petitte T., Mallow J., Barnes E., Et al., A systematic review of loneliness and common chronic physical conditions in adults, The Open Psychology Journal, pp. 113-132, (2015); Pouraboli B., Abedi H.A., Abbaszadeh A., Et al., Living in a misty marsh: A qualitative study on the experiences of self-care suffering of patients with thalassemia, Iranian Journal of Nursing and Midwifery Research, pp. S77-S82, (2014); Raman V., Prakash A., D'Souza F., Psychosocial issues in children with thalassemia: From identification to a model for management in a developing country, Journal of Pediatric Hematology/Oncology, 41, 3, pp. 218-221, (2019); Roy N.B.A., Telfer P., Eleftheriou P., Et al., Protecting vulnerable patients with inherited anaemias from unnecessary death during the COVID-19 pandemic, British Journal of Haematology, 189, 4, pp. 635-639, (2020); Sepulveda-Loyola W., Rodriguez-Sanchez I., Perez-Rodriguez P., Et al., Impact of social isolation due to COVID-19 on health in older people: Mental and physical effects and recommendations, The Journal of Nutrition Health & Aging, 24, pp. 938-947, (2020); Serlachius A., Badawy S.M., Thabrew H., Psychosocial challenges and opportunities for youth with chronic health conditions during the COVID-19 pandemic, JMIR Pediatrics and Parenting, 3, (2020); Shaligram D., Girimaji S.C., Chaturvedi S.K., Psychological problems and quality of life in children with thalassemia, Indian Journal of Pediatrics, 74, pp. 727-730, (2007); Tubman V.N., Fung E.B., Vogiatzi M., Et al., Guidelines for the standard monitoring of patients with thalassemia: Report of the thalassemia longitudinal cohort, Journal of Pediatric Hematology/Oncology, 37, 3, pp. e162-e169, (2015); Vitrano A., Calvaruso G., Lai E., Et al., The era of comparable life expectancy between thalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?, British Journal of Haematology, 176, 1, pp. 124-130, (2017); von Elm E., Altman D.G., Egger M., Et al., The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies, International Journal of Surgery, 12, 12, pp. 1495-1499, (2014); Zammuner V.L., Italians’ social and emotional loneliness: The results of five studies, World Academy of Science, Engineering and Technology, 40, pp. 482-494, (2009)","2-s2.0-85117565168"
"Cerami C.; Canevelli M.; Santi G.C.; Galandra C.; Dodich A.; Cappa S.F.; Vecchi T.; Crespi C.","Cerami, Chiara (25722905400); Canevelli, Marco (37053450300); Santi, Gaia Chiara (57217289456); Galandra, Caterina (36806194800); Dodich, Alessandra (56001713900); Cappa, Stefano F. (7005836132); Vecchi, Tomaso (6603719753); Crespi, Chiara (57034303800)","25722905400; 37053450300; 57217289456; 36806194800; 56001713900; 7005836132; 6603719753; 57034303800","Identifying Frail Populations for Disease Risk Prediction and Intervention Planning in the Covid-19 Era: A Focus on Social Isolation and Vulnerability","2021","Frontiers in Psychiatry","12","","626682","","","","7","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114309373&doi=10.3389%2ffpsyt.2021.626682&partnerID=40&md5=fc0281b54233af89da9ddbf620085195","The early identification of fragile populations in the Covid-19 era would help governments to allocate resources and plan strategies to contain consequences of the pandemic. Beyond frailty, social vulnerability to environmental stressors, such as the social distancing enforced to reduce the SARS-CoV2 contagion, can modify long-term disease risk and induce health status changes in the general population. We assessed frailty and social vulnerability indices in 1,258 Italian residents during the first lockdown phase via an on-line survey. We compared indices taking into account age categories and gender. While frailty showed a linear increase with age and was greater in females than in males, social vulnerability was higher in young adults and elders compared to middle aged and older adults, and in males than females. Both frailty and social vulnerability contributed in explaining the individual perception of the impact of Covid-19 emergency on health, which was further influenced by proactive attitudes/behaviors and social isolation. Social isolation and loneliness following the Covid-19 outbreak may exert dramatic psychosocial effects in the general population. The early detection of vulnerable categories, at risk to become ill and develop long-lasting health status changes, would help to prevent consequences on general well-being by allocating resources to targeted interventions managing psychosocial distress and increasing young adults and elderly resilience toward the post-Covid-19 crisis. © Copyright © 2021 Cerami, Canevelli, Santi, Galandra, Dodich, Cappa, Vecchi and Crespi.","COVID-19; frailty; psychosocial variables; social isolation; social vulnerability","adult; age; aged; Article; attitude to illness; coronavirus disease 2019; disease predisposition; distress syndrome; environmental stress; female; frailty; government; health behavior; health care planning; health status; health survey; human; infection control; infection risk; Italian (citizen); lockdown; loneliness; major clinical study; male; middle aged; pandemic; prediction; psychological resilience; psychological well-being; resource allocation; risk assessment; Severe acute respiratory syndrome coronavirus 2; sex difference; social distancing; social isolation; social psychology; Social Vulnerability Index; young adult","Williamson E., Walker A.J., Bhaskaran K., OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic, Psychol Appl to Work An Introd to Ind Organ Psychol Tenth Ed, 53, pp. 1689-1699, (2012); Cdc C.O.V.I.D.R.T., Severe outcomes among patients with coronavirus disease 2019 (COVID-19) – United States, February 12-March 16, 2020, MMWR Morb Mortal Wkly Rep, 69, pp. 343-346, (2020); Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Et al., Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes, J Med Virol, 93, pp. 1449-1458, (2021); Hewitt J., Carter B., Vilches-Moraga A., Quinn T.J., Braude P., Verduri A., Et al., The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study, Lancet Public Heal, 5, pp. e444-e451, (2020); Cesari M., Prince M., Thiyagarajan J.A., Araujo De Carvalho I., Bernabei R., Chan P., Et al., Frailty: an emerging public health priority, J Am Med Dir Assoc, 17, pp. 188-192, (2016); Fried L.P., Tangen C.M., Walston J., Newman A.B., Hirsch C., Gottdiener J., Et al., Frailty in older adults: evidence for a phenotype, J Gerontol Ser A Biol Sci Med Sci, 56, pp. M146-M157, (2001); Morley J.E., Vellas B., Abellan van Kan G., Anker S.D., Bauer J.M., Bernabei R., Et al., Frailty consensus: a call to action, J Am Med Dir Assoc, 14, pp. 392-397, (2013); Darvall J.N., Bellomo R., Paul E., Subramaniam A., Santamaria J.D., Bagshaw S.M., Et al., Frailty in very old critically ill patients in Australia and New Zealand: a population-based cohort study, Med J Aust, 211, pp. 318-323, (2019); Bellelli G., Rebora P., Valsecchi M.G., Bonfanti P., Citerio G., Frailty index predicts poor outcome in COVID-19 patients, Intensive Care Med, 46, pp. 1634-1636, (2020); Hubbard R.E., Maier A.B., Hilmer S.N., Naganathan V., Etherton-Beer C., Rockwood K., Frailty in the face of COVID-19, Age Ageing, 49, pp. 499-500, (2020); Mitnitski A.B., Mogilner A.J., Rockwood K., Accumulation of deficits as a proxy measure of aging, Sci World J, 1, pp. 323-336, (2001); Andrew M.K., Keefe J.M., Social vulnerability from a social ecology perspective: a cohort study of older adults from the National Population Health Survey of Canada, BMC Geriatr, 14, (2014); Nguyen T.N., Ngangue P., Bouhali T., Ryan B.L., Stewart M., Fortin M., Social vulnerability in patients with multimorbidity: a cross-sectional analysis, Int J Environ Res Public Health, 16, (2019); Rockwood K., Andrew M., Mitnitski A., A comparison of two approaches to measuring frailty in elderly people, J Gerontol Ser A Biol Sci Med Sci, 62, pp. 738-743, (2007); Ahrenfeldt L.J., Moller S., Thinggaard M., Christensen K., Lindahl-Jacobsen R., Sex differences in comorbidity and frailty in Europe, Int J Public Health, 64, pp. 1025-1036, (2019); Gordon E.H., Peel N.M., Samanta M., Theou O., Howlett S.E., Hubbard R.E., Sex differences in frailty: a systematic review and meta-analysis, Exp Gerontol, 89, pp. 30-40, (2017); Fulop T., Larbi A., Witkowski J.M., McElhaney J., Loeb M., Mitnitski A., Et al., Aging, frailty and age-related diseases, Biogerontology, 11, pp. 547-563, (2010); Cerami C., Santi G.C., Galandra C., Dodich A., Cappa S.F., Vecchi T., Et al., Covid-19 outbreak in Italy: are we ready for the psychosocial and the economic crisis? Baseline findings from the PsyCovid study, Front Psychiatry, 11, (2020); Jones D.M., Song X., Rockwood K., Operationalizing a frailty index from a standardized comprehensive geriatric assessment, J Am Geriatr Soc, 52, pp. 1929-1933, (2004); Searle S.D., Mitnitski A., Gahbauer E.A., Gill T.M., Rockwood K., A standard procedure for creating a frailty index, BMC Geriatr, 8, (2008); Wang H., Kline J.A., Jackson B.E., Laureano-Phillips J., Robinson R.R., Cowden C.D., Et al., Association between emergency physician self-reported empathy and patient satisfaction, PLoS ONE, 13, (2018); Khalid I., Khalid T.J., Qabajah M.R., Barnard A.G., Qushmaq I.A., Healthcare workers emotions, perceived stressors and coping strategies during a MERS-CoV outbreak, Clin Med Res, 14, pp. 7-14, (2016); Bottesi G., Ghisi M., Altoe G., Conforti E., Melli G., Sica C., The Italian version of the Depression Anxiety Stress Scales-21: factor structure and psychometric properties on community and clinical samples, Compr Psychiatry, 60, pp. 170-181, (2015); Passardi S., Peyk P., Rufer M., Wingenbach T.S.H., Pfaltz M.C., Facial mimicry, facial emotion recognition and alexithymia in post-traumatic stress disorder, Behav Res Ther, 122, (2019); Edwards E.R., Posttraumatic stress and alexithymia: a meta-analysis of presentation and severity, Psychol Trauma, (2019); Zammuner V.L., Italians' social and emotional loneliness: the results of five studies, World Acad Sci Eng Technol, 40, pp. 482-494, (2009); Davis M.H., Measuring individual differences in empathy: evidence for a multidimensional approach, J Pers Soc Psychol, 44, pp. 113-126, (1983); Foa C., Tonarelli A., Caricati L., Fruggeri L., COPE-NVI-25: validazione italiana della versione ridotta della Coping Orientation to the Problems Experienced (COPE-NVI), Psicologia Della Salute, pp. 123-140, (2015); Bressi C., Taylor G., Parker J., Bressi S., Brambilla V., Aguglia E., Et al., Cross validation of the factor structure of the 20-item Toronto Alexithymia Scale: an Italian multicenter study, J Psychosom Res, 41, pp. 551-559, (1996); Abdi H., Williams L.J., Principal component analysis, WIREs Comp Stat, 2, pp. 433-459, (2010); MacKinnon D.P., Krull J.L., Lockwood C.M., Equivalence of the mediation, confounding and suppression effect, Prev Sci, 1, pp. 173-181, (2000); Andrew M.K., Mitnitski A.B., Rockwood K., Social vulnerability, frailty and mortality in elderly people, PLoS ONE, 3, (2008); Cole S.W., Levine M.E., Arevalo J.M.G., Ma J., Weir D.R., Crimmins E.M., Loneliness, eudaimonia, and the human conserved transcriptional response to adversity, Psychoneuroendocrinology, 62, pp. 11-17, (2015); Santini Z.I., Jose P.E., York Cornwell E., Koyanagi A., Nielsen L., Hinrichsen C., Et al., Social disconnectedness, perceived isolation, and symptoms of depression and anxiety among older Americans (NSHAP): a longitudinal mediation analysis, Lancet Public Heal, 5, pp. e62-e70, (2020); Gerst-Emerson K., Jayawardhana J., Loneliness as a public health issue: the impact of loneliness on health care utilization among older adults, Am J Public Health, 105, pp. 1013-1019, (2015); Novotney A., The risks of social isolation, Monit Psychol, (2020)","2-s2.0-85114309373"
"Crespi C.; Dodich A.; Iannaccone S.; Marcone A.; Falini A.; Cappa S.F.; Cerami C.","Crespi, Chiara (57034303800); Dodich, Alessandra (56001713900); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400)","57034303800; 56001713900; 7005943171; 6701496511; 7003494994; 7005836132; 25722905400","Diffusion tensor imaging evidence of corticospinal pathway involvement in frontotemporal lobar degeneration","2020","Cortex","125","","","1","11","10","3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077916325&doi=10.1016%2fj.cortex.2019.11.022&partnerID=40&md5=1644fb345d068eccd04e7cf825956a2a","Motor neuron dysfunctions (MNDys) in Frontotemporal Lobar Degeneration (FTLD) have been consistently reported. Clinical and neurophysiological findings proved a variable range of pathological changes, also affecting the corticospinal tract (CST). This study aims to assess white-matter microstructural alterations in a sample of patients with FTLD, and to evaluate the relationship with MNDys. Fifty-four FTLD patients (21 bvFTD, 16 PPA, 17 CBS) and 36 healthy controls participated in a Diffusion Tensor Imaging (DTI) study. We analyzed distinctive and common microstructural alteration patterns across FTLD subtypes, including those affecting the CST, and performed an association analysis between CST integrity and the presence of clinical and/or neurophysiological signs of MNDys. The majority of FTLD patients showed microstructural changes in the motor pathway with a high prevalence of CST alterations also in patients not displaying clinical and/or neurophysiological signs of MNDys. Our results suggest that subtle CST alterations characterize FTLD patients regardless to the subtype. This may be due to the spread of the pathological process to the motor system, even without a clear clinical manifestation of MNDys. © 2019 Elsevier Ltd","Corticospinal tract; Diffusion tensor imaging; Frontotemporal lobar degeneration; FTD-ALS disease continuum; Motor neuron dysfunction","aged; Article; capsula interna; cerebral peduncle; cingulum (brain); Clinical Dementia Rating; clinical feature; comparative study; controlled study; corpus callosum; corticobasal degeneration; diffusion tensor imaging; disease duration; disease severity; female; frontal variant frontotemporal dementia; human; image processing; major clinical study; male; medical record review; motoneuron; motor system; neuroanatomy; neuroimaging; neurophysiology; neuropsychiatric inventory; prevalence; primary progressive aphasia; pyramidal tract; retrospective study; white matter","Agosta F., Ferraro P.M., Canu E., Copetti M., Galantucci S., Magnani G., Et al., Differentiation between subtypes of primary progressive aphasia by using cortical thickness and diffusion-tensor MR imaging measures, Radiology, (2015); Agosta F., Galantucci S., Magnani G., Marcone A., Martinelli D., Antonietta Volonte M., Et al., MRI signatures of the frontotemporal lobar degeneration continuum, Human Brain Mapping, (2015); Agosta F., Scola E., Canu E., Marcone A., Magnani G., Sarro L., Et al., White matter damage in frontotemporal lobar degeneration spectrum, Cerebral Cortex, (2012); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, 5, pp. 496-503, (2013); Beaulieu C., The basis of anisotropic water diffusion in the nervous system - a technical review, NMR in Biomedicine, (2002); Bennett I.J., Madden D.J., Vaidya C.J., Howard D.V., Howard J.H., Age-related differences in multiple measures of white matter integrity: A diffusion tensor imaging study of healthy aging, Human Brain Mapping, (2010); Boelmans K., Kaufmann J., Bodammer N., Ebersbach G., Behlau G., Heinze H.J., Et al., Involvement of motor pathways in corticobasal syndrome detected by diffusion tensor tractography, Movement Disorders, (2009); Borroni B., Garibotto V., Agosti C., Brambati S.M., Bellelli G., Gasparotti R., Et al., White matter changes in corticobasal degeneration syndrome and correlation with limb apraxia, Archives of Neurology, (2008); Brettschneider J., Del Tredici K., Irwin D.J., Grossman M., Robinson J.L., Toledo J.B., Et al., Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD), Acta Neuropathologica, (2014); Burrell J.R., Kiernan M.C., Vucic S., Hodges J.R., Motor Neuron dysfunction in frontotemporal dementia, Brain, (2011); Cairns N.J., Bigio E.H., Mackenzie I.R.A., Neumann M., Lee V.M.Y., Hatanpaa K.J., Et al., Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: Consensus of the Consortium for Frontotemporal Lobar Degeneration, Acta Neuropathologica, (2007); Cerami C., Marcone A., Crespi C., Iannaccone S., Marangoni C., Dodich A., Et al., Motor neuron dysfunctions in the frontotemporal lobar degeneration spectrum: A clinical and neurophysiological study, Journal of the Neurological Sciences, 351, 1-2, (2015); Clark C.M., Forman M.S., Frontotemporal lobar degeneration with motor neuron disease: A clinical and pathological spectrum, Archives of Neurology, (2006); Coyle-Gilchrist I.T.S., Dick K.M., Patterson K., Rodriquez P.V., Wehmann E., Wilcox A., Et al., Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes, Neurology, (2016); Crespi C., Dodich A., Cappa S.F., Canessa N., Iannaccone S., Corbo M., Et al., Multimodal MRI quantification of the common neurostructural bases within the FTD-ALS continuum, Neurobiology of Aging, 62, (2018); de Carvalho M., Dengler R., Eisen A., England J.D., Kaji R., Kimura J., Et al., Electrodiagnostic criteria for diagnosis of ALS, Clinical Neurophysiology, (2008); Daianu M., Mendez M.F., Baboyan V.G., Jin Y., Melrose R.J., Jimenez E.E., Et al., An advanced white matter tract analysis in frontotemporal dementia and early-onset Alzheimer???s disease, Brain Imaging and Behavior, (2015); Davidson Y.S., Barker H., Robinson A.C., Thompson J.C., Harris J., Troakes C., Et al., Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72, Acta Neuropathologica Communications, (2014); Davidson Y., Robinson A.C., Liu X., Wu D., Troakes C., Rollinson S., Et al., Neurodegeneration in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins, Neuropathology and Applied Neurobiology, (2016); Devenney E., Vucic S., Hodges J.R., Kiernan M.C., Motor neuron disease-frontotemporal dementia: A clinical continuum, Expert Review of Neurotherapeutics, (2015); Douaud G., Menke R.A.L., Gass A., Monsch A.U., Rao A., Whitcher B., Et al., Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease, Journal of Neuroscience, (2013); Eickhoff S.B., Heim S., Zilles K., Amunts K., Testing anatomically specified hypotheses in functional imaging using cytoarchitectonic maps, Neuroimage, (2006); Ellis C.M., Simmons A., Jones D.K., Bland J., Dawson J.M., Horsfield M.A., Et al., Diffusion tensor MRI assesses corticospinal tract damage in ALS, Neurology, (1999); Ferrari R., Kapogiannis D., Huey E.D., Momeni P., FTD and ALS: A tale of two diseases, Current Alzheimer Research, (2011); Filippini N., Douaud G., MacKay C.E., Knight S., Talbot K., Turner M.R., Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis, Neurology, (2010); Geraldo A.F., Pereira J., Nunes P., Reimao S., Sousa R., Castelo-Branco M., Et al., Beyond fractional anisotropy in amyotrophic lateral sclerosis: The value of mean, axial, and radial diffusivity and its correlation with electrophysiological conductivity changes, Neuroradiology, (2018); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, (2011); Hua K., Zhang J., Wakana S., Jiang H., Li X., Reich D.S., Et al., Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification, Neuroimage, (2008); Kassubek J., Muller H.P., Del Tredici K., Lule D., Gorges M., Braak H., Et al., Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: Targeting a propagation-based biological marker, Journal of Neurology, Neurosurgery and Psychiatry, (2018); Kassubek J., Muller H.P., Tredici K.D., Hornberger M., Schroeter M.L., Muller K., Et al., Longitudinal diffusion tensor imaging resembles patterns of pathology progression in behavioral variant frontotemporal dementia (bvFTD), Frontiers in Aging Neuroscience, (2018); Laforce R., Behavioral and language variants of frontotemporal dementia: A review of key symptoms, Clinical Neurology and Neurosurgery, (2013); Lansdall C.J., Coyle-Gilchrist I.T.S., Simon Jones P., Rodriguez P.V., Wilcox A., Wehmann E., Et al., White matter change with apathy and impulsivity in frontotemporal lobar degeneration syndromes, Neurology, (2018); Lattante S., Ciura S., Rouleau G.A., Kabashi E., Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD), Trends in Genetics, (2015); Lillo P., Mioshi E., Burrell J.R., Kiernan M.C., Hodges J.R., Hornberger M., Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum, Plos One, 7, 8, (2012); Ling S.C., Polymenidou M., Cleveland D.W., Converging mechanisms in als and FTD: Disrupted RNA and protein homeostasis, Neuron, (2013); Lomen-Hoerth C., Clinical phenomenology and neuroimaging correlates in ALS-FTD, Journal of Molecular Neuroscience, (2011); Lomen-Hoerth C., Anderson T., Miller B., The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology, (2002); Mackenzie I.R.A., Neumann M., Molecular neuropathology of frontotemporal dementia: Insights into disease mechanisms from postmortem studies, Journal of Neurochemistry, (2016); Mahoney C.J., Malone I.B., Ridgway G.R., Buckley A.H., Downey L.E., Golden H.L., Et al., White matter tract signatures of the progressive aphasias, Neurobiology of Aging, (2013); Mahoney C.J., Ridgway G.R., Malone I.B., Downey L.E., Beck J., Kinnunen K.M., Et al., Profiles of white matter tract pathology in frontotemporal dementia, Human Brain Mapping, (2014); McMillan C.T., Boyd C., Gross R.G., Weinstein J., Firn K., Toledo J.B., Et al., Multimodal imaging evidence of pathology-mediated disease distribution in corticobasal syndrome, Neurology, (2016); Montembeault M., Brambati S.M., Gorno-Tempini M.L., Migliaccio R., Clinical, anatomical, and pathological features in the three variants of primary progressive aphasia: A review, Frontiers in Neurology, (2018); Neumann M., Sampathu D.M., Kwong L.K., True A.C., Micsenyi M.C., Chou T.T., Et al., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, 5796, pp. 130-133, (2006); Omer T., Finegan E., Hutchinson S., Doherty M., Vajda A., McLaughlin R.L., Et al., Neuroimaging patterns along the ALS-FTD spectrum: A multiparametric imaging study, Amyotrophic lateral sclerosis and frontotemporal degeneration, (2017); Piavani M., Filippini N., Van Den Heuvel M.P., Cappa S.F., Frisoni G.B., Brain connectivity in neurodegenerative diseases—from phenotype to proteinopathy, Nature Reviews Neurology, 10, 11, (2014); Rabinovici G.D., Miller B.L., Frontotemporal lobar degeneration: Epidemiology, pathophysiology, diagnosis and management, CNS Drugs, (2010); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain : A Journal of Neurology, (2011); Schwindt G.C., Graham N.L., Rochon E., Tang-Wai D.F., Lobaugh N.J., Chow T.W., Et al., Whole-brain white matter disruption in semantic and nonfluent variants of primary progressive aphasia, Human Brain Mapping, (2013); Seelaar H., Rohrer J.D., Pijnenburg Y.A.L., Fox N.C., Van Swieten J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review, Journal of Neurology, Neurosurgery and Psychiatry, (2011); Seltman R.E., Matthews B.R., Frontotemporal lobar degeneration: Epidemiology, pathology, diagnosis and management, CNS Drugs, (2012); Senda J., Kato S., Kaga T., Ito M., Atsuta N., Nakamura T., Et al., Progressive and widespread brain damage in ALS: MRI voxel-based morphometry and diffusion tensor imaging study, Amyotrophic Lateral Sclerosis, (2011); Shao W., Li X., Zhang J., Yang C., Tao W., Zhang S., Et al., White matter integrity disruption in the pre-dementia stages of Alzheimer's disease: from subjective memory impairment to amnestic mild cognitive impairment, European journal of neurology, 26, 5, pp. 800-807, (2019); Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Et al., Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data, Neuroimage, (2006); Smith S.M., Nichols T.E., Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference, Neuroimage, (2009); Tovar-Moll F., De Oliveira-Souza R., Bramati I.E., Zahn R., Cavanagh A., Tierney M., Et al., White matter tract damage in the behavioral variant of frontotemporal and corticobasal dementia syndromes, Plos One, (2014); Weishaupt J.H., Hyman T., Dikic I., Common molecular pathways in amyotrophic lateral sclerosis and frontotemporal dementia, Trends in Molecular Medicine, (2016); Whitwell J.L., Avula R., Senjem M.L., Kantarci K., Weigand S.D., Samikoglu A., Et al., Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia, Neurology, (2010); Whitwell J.L., Schwarz C.G., Reid R.I., Kantarci K., Jack C.R., Josephs K.A., Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes, Parkinsonism and Related Disorders, (2014); Woollacott I.O.C., Rohrer J.D., The clinical spectrum of sporadic and familial forms of frontotemporal dementia, Journal of Neurochemistry, (2016); Zhang Y., Schuff N., Du A.-T., Rosen H.J., Kramer J.H., Gorno-Tempini M.L., Et al., White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI, Brain : A Journal of Neurology, 132, pp. 2579-2592, (2009)","2-s2.0-85077916325"
"Cerami C.; Dodich A.; Iannaccone S.; Magnani G.; Marcone A.; Guglielmo P.; Vanoli G.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Marcone, Alessandra (6701496511); Guglielmo, Priscilla (56919519400); Vanoli, Giovanna (57211798721); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 56001713900; 7005943171; 24496141800; 6701496511; 56919519400; 57211798721; 7005836132; 7005630261","Individual Brain Metabolic Signatures in Corticobasal Syndrome","2020","Journal of Alzheimer's Disease","76","2","","517","528","11","9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85088848240&doi=10.3233%2fJAD-200153&partnerID=40&md5=4c19fa97d77305f59323f95b47be3c67","Background: Corticobasal syndrome (CBS) is the usual clinical presentation of patients with corticobasal degeneration pathology. Nevertheless, there are CBS individuals with postmortem neuropathology typical of Alzheimer's disease (AD). Objective: In this study, we aim to detect FDG-PET metabolic signatures at the single-subject level in a CBS sample, also evaluated with cerebrospinal fluid (CSF) markers for AD pathology. Methods: 21 patients (68.9+6.4 years; MMSE score = 21.7+6.3) fulfilling current criteria for CBS were enrolled. All underwent a clinical-neuropsychological assessment and an instrumental evaluation for biomarkers of neurodegeneration, amyloid and tau pathology (i.e., FDG-PET imaging and CSF Aβ42 and tau levels) at close intervals. CBS subjects were classified according to the presence or absence of CSF markers of AD pathology (i.e., low Aβ42 and high phosphorylated tau levels). Optimized voxel-based SPM procedures provided FDG-PET metabolic patterns at the single-subject and group levels. Results: Eight CBS had an AD-like CSF profile (CBS-AD), while thirteen were negative (CBS-noAD). The two subgroups did not differ in demographic characteristics or global cognitive impairment. FDG-PET SPM t-maps identified different metabolic signatures. Namely, all CBS-AD patients showed the typical AD-like hypometabolic pattern involving posterior cingulate cortex, precuneus and temporo-parietal cortex, whereas CBS-noAD cases showed bilateral hypometabolism in fronto-insular cortex and basal ganglia that is typical of the frontotemporal lobar degeneration spectrum. Discussion: These results strongly suggest the inclusion of FDG-PET imaging in the diagnostic algorithm of individuals with CBS clinical phenotype in order to early identify functional metabolic signatures due to different neuropathological substrates, thus improving the diagnostic accuracy. © 2020 - IOS Press and the authors. All rights reserved.","Alzheimer's disease; corticobasal degeneration; corticobasal syndrome; FDG-PET; positron emission tomography","Aged; Basal Ganglia; Biomarkers; Brief Psychiatric Rating Scale; Cerebral Cortex; Cognitive Dysfunction; Female; Humans; Male; Middle Aged; Positron-Emission Tomography; Syndrome; amyloid beta protein[1-42]; fluorodeoxyglucose f 18; tau protein; biological marker; adult; aged; Alzheimer disease; apraxia of speech; Article; attention; basal ganglion; behavior change; brain metabolism; cerebrospinal fluid; cingulate gyrus; clinical article; clinical assessment; clinical evaluation; cognitive defect; controlled study; corticobasal degeneration; diagnostic accuracy; executive function; female; follow up; frontotemporal dementia; glucose metabolism; human; ideomotor apraxia; inferior parietal lobule; inferior temporal gyrus; insula; language; language disability; long term memory; male; middle aged; middle frontal gyrus; middle temporal gyrus; Mini Mental State Examination; nerve degeneration; neuropsychological test; parietal cortex; phenotype; positron emission tomography; posterior cingulate; precuneus; priority journal; short term memory; superior parietal lobule; superior temporal gyrus; thalamus; brain cortex; Brief Psychiatric Rating Scale; diagnostic imaging; metabolism; positron emission tomography; procedures; psychology; syndrome","Horvath J., Burkhard P.R., Bouras C., Kovari E., Etiologies of Parkinsonism in a century-long autopsy-based cohort, Brain Pathol, 23, pp. 28-33, (2013); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Boxer A.L., Dickson D.W., Grossman M., Hallett M., Josephs K.A., Kertesz A., Lee S.E., Miller B.L., Reich S.G., Riley D.E., Tolosa E., TRoster A.I., Vidailhet M., Weiner W.J., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, pp. 496-503, (2013); Boeve B.F., Maraganore D.M., Parisi J.E., Ahlskog J.E., Graff-Radford N., Caselli R.J., Dickson D.W., Kokmen E., Petersen R.C., Pathologic heterogeneity in clinically diagnosed corticobasal degeneration, Neurology, 53, pp. 795-800, (1999); Alladi S., Xuereb J., Bak T., Nestor P., Knibb J., Patterson K., Hodges J.R., Focal cortical presentations of Alzheimer's disease, Brain, 130, pp. 2636-2645, (2007); Chand P., Grafman J., Dickson D., Ishizawa K., Litvan I., Alzheimer's disease presenting as corticobasal syndrome, Mov Disord, 21, pp. 2018-2022, (2006); Doran M., Du Plessis D.G., Enevoldson T.P., Fletcher N.A., Ghadiali E., Larner A.J., Pathological heterogeneity of clinically diagnosed corticobasal degeneration, J Neurol Sci, 216, pp. 127-134, (2003); Villain N., Dubois B., Alzheimer's disease including focal presentations, Semin Neurol, 39, pp. 213-226, (2019); Di Stefano F., Kas A., Habert M.O., Decazes P., Lamari F., Lista S., Hampel H., Teichmann M., The phenotypical core of Alzheimer's disease-related and nonrelated variants of the corticobasal syndrome: A systematic clinical, neuropsychological, imaging, and biomarker study, Alzheimers Dement, 12, pp. 786-795, (2016); Kasanuki K., Josephs K.A., Ferman T.J., Murray M.E., Koga S., Konno T., Sakae N., Parks A., Uitti R.J., Van Gerpen J.A., Graff-Radford N.R., Wszolek Z.K., Dickson D.W., Diffuse Lewybody disease manifesting as corticobasal syndrome:A rare form of Lewy body disease, Neurology, 91, pp. e268-e279, (2018); Lee S.E., Rabinovici G.D., Mayo M.C., Wilson S.M., Seeley W.W., DeArmond S.J., Huang E.J., Trojanowski J.Q., Growdon M.E., Jang J.Y., Sidhu M., See T.M., Karydas A.M., Gorno-Tempini M.L., Boxer A.L., Weiner M.W., Geschwind M.D., Rankin K.P., Miller B.L., Clinicopathological correlations in corticobasal degeneration, Ann Neurol, 70, pp. 327-340, (2011); Hu W.T., Rippon G.W., Boeve B.F., Knopman D.S., Petersen R.C., Parisi J.E., Josephs K.A., Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome, Mov Disord, 24, pp. 1375-1379, (2009); Borroni B., Premi E., Agosti C., Alberici A., Cerini C., Archetti S., Lanari A., Paghera B., Lucchini S., Caimi L., Padovani A., CSF Alzheimer's disease-like pattern in corticobasal syndrome: Evidence for a distinct disorder, J Neurol Neurosurg Psychiatry, 82, pp. 834-838, (2011); Josephs K.A., Whitwell J.L., Boeve B.F., Knopman D.S., Petersen R.C., Hu W.T., Parisi J.E., Dickson D.W., Jack C.R., Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease, Mov Disord, 25, pp. 1246-1252, (2010); Shelley B.P., Hodges J.R., Kipps C.M., Xuereb J.H., Bak T.H., Is the pathology of corticobasal syndrome predictable in life, Mov Disord, 24, pp. 1593-1599, (2009); Sha S.J., Ghosh P.M., Lee S.E., Corbetta-Rastelli C., Jagust W.J., Kornak J., Rankin K.P., Grinberg L.T., Vinters H.V., Mendez M.F., Dickson D.W., Seeley W.W., Gorno-Tempini M., Kramer J., Miller B.L., Boxer A.L., Rabinovici G.D., Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography, Alzheimers Res Ther, 7, (2015); Juh R., Pae C.U., Kim T.S., Lee C.U., Choe B., Suh T., Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis, Neurosci Lett, 383, pp. 22-27, (2005); Coulier I.M., De Vries J.J., Leenders K.L., Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration, Mov Disord, 18, pp. 1175-1178, (2003); Eckert T., Barnes A., Dhawan V., Frucht S., Gordon M.F., Feigin A.S., Eidelberg D., FDG PET in the differential diagnosis of parkinsonian disorders, Neuroimage, 26, pp. 912-921, (2005); Tripathi M., Tang C.C., Feigin A., De Lucia I., Nazem A., Dhawan V., Eidelberg D., Automated differential diagnosis of early parkinsonism using metabolic brain networks: A validation study, J Nucl Med, 57, pp. 60-66, (2016); Tripathi M., Dhawan V., Peng S., Kushwaha S., Batla A., Jaimini A., D'Souza M.M., Sharma R., Saw S., Mondal A., Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography, Neuroradiology, 55, pp. 483-492, (2013); Caminiti S.P., Alongi P., Majno L., Volonte M.A., Cerami C., Gianolli L., Comi G., Perani D., Evaluation of an optimized fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders, Eur J Neurol, 24, pp. e26-e687, (2017); Walker Z., Gandolfo F., Orini S., Garibotto V., Agosta F., Arbizu J., Bouwman F., Drzezga A., Nestor P., Boccardi M., Altomare D., Festari C., Nobili F., Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia, Eur J Nucl Med Mol Imaging, 45, pp. 1534-1545, (2018); Eidelberg D., Dhawan V., Moeller J.R., Sidtis J.J., Ginos J.Z., Strother S.C., Cederbaum J., Greene P., Fahn S., Powers J.M., The metabolic landscape of cortico-basal ganglionic degeneration: Regional asymmetries studied with positron emission tomography, J Neurol Neurosurg Psychiatry, 54, pp. 856-862, (1991); Niethammer M., Tang C.C., Feigin A., Allen P.J., Heinen L., Hellwig S., Amtage F., Hanspal E., Vonsattel J.P., Poston K.L., Meyer P.T., Leenders K.L., Eidelberg D., A disease-specific metabolic brain network associated with corticobasal degeneration, Brain, 137, pp. 3036-3046, (2014); Hammesfahr S., Antke C., Mamlins E., Beu M., Wojtecki L., Ferrea S., Dinkelbach L., Moldovan A.S., Schnitzler A., Muller H.W., Sudmeyer M., FP-CIT-andIBZM-SPECTin corticobasal syndrome: Results from a clinical follow-up study, Neurodegener Dis, 16, pp. 342-347, (2016); Pardini M., Huey E.D., Spina S., Kreisl W.C., Morbelli S., Wassermann E.M., Nobili F., Ghetti B., Grafman J., FDG-PET patterns associated with underlying pathology in corticobasal syndrome, Neurology, 92, pp. e1121-e1135, (2019); Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Skoog I., Wallin A., Wahlund L.O., Marcusson J., Nagga K., Andreasen N., Davidsson P., Vanmechelen E., Blennow K., Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values, Clin Chem, 47, pp. 1776-1781, (2001); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., Van Berckel B.N., Ossenkoppele R., Guedj E., Didic M., Brugnolo A., Sambuceti G., Pagani M., Salmon E., Nobili F.R., Resting metabolic connectivity in prodromal Alzheimer's disease, A European Alzheimer Disease Consortium (EADC) Project. Neurobiol Aging, 33, pp. 2533-2550, (2012); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Gilardi M.C., Frisoni G., Friston K., Ashburner J., Perani D., A standardized 18F FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Panzacchi A., Nobili F., Pappata S., Marcone A., Garibotto V., Castiglioni I., Magnani G., Cappa S.F., Gianolli L., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clin, 6, pp. 445-454, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Pinto P., Passerini G., Falini A., Iannaccone S., Cappa S.F., Comi G., Gianolli L., Magnani G., Crossvalidation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging, 43, pp. 499-508, (2016); Iaccarino L., Sala A., Caminiti S.P., Perani D., The emerging role of PET imaging in dementia, F1000Res, 6, (2017); Hassan A., Whitwell J.L., Josephs K.A., The corticobasal syndrome-Alzheimer's disease conundrum, Expert Rev Neurother, 11, pp. 1569-1578, (2011); Boccardi M., Festari C., Altomare D., Gandolfo F., Orini S., Nobili F., Frisoni G.B., Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia, Eur J Nucl Med Mol Imaging, 45, pp. 1470-1486, (2018); Iaccarino L., Chiotis K., Alongi P., Almkvist O., Wall A., Cerami C., Bettinardi V., Gianolli L., Nordberg A., Perani D., A cross-validation of FDG-and amyloid-PET biomarkers in mild cognitive impairment for the risk prediction to dementia due to Alzheimer's disease in a clinical setting, J Alzheimers Dis, 59, pp. 603-614, (2017); Iaccarino L., Sala A., Perani D., Predicting long-term clinical stability in amyloid-positive subjects by FDG-PET, Ann Clin Transl Neurol, 6, pp. 1113-1120, (2019); Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Pelagallo E., Santangelo R., Cappa S.F., Perani D., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia, J Alzheimers Dis, 55, pp. 183-197, (2017); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Pilotto A., Premi E., Paola Caminiti S., Presotto L., Turrone R., Alberici A., Paghera B., Borroni B., Padovani A., Perani D., Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease, Neurology, 90, pp. e1029-e1037, (2018)","2-s2.0-85088848240"
"Frisoni G.B.; Boccardi M.; Barkhof F.; Blennow K.; Cappa S.; Chiotis K.; Démonet J.-F.; Garibotto V.; Giannakopoulos P.; Gietl A.; Hansson O.; Herholz K.; Jack C.R., Jr; Nobili F.; Nordberg A.; Snyder H.M.; Ten Kate M.; Varrone A.; Albanese E.; Becker S.; Bossuyt P.; Carrillo M.C.; Cerami C.; Dubois B.; Gallo V.; Giacobini E.; Gold G.; Hurst S.; Lönneborg A.; Lovblad K.-O.; Mattsson N.; Molinuevo J.-L.; Monsch A.U.; Mosimann U.; Padovani A.; Picco A.; Porteri C.; Ratib O.; Saint-Aubert L.; Scerri C.; Scheltens P.; Schott J.M.; Sonni I.; Teipel S.; Vineis P.; Visser P.J.; Yasui Y.; Winblad B.","Frisoni, Giovanni B (56214208300); Boccardi, Marina (6507801629); Barkhof, Frederik (7102989379); Blennow, Kaj (56415176000); Cappa, Stefano (7005836132); Chiotis, Konstantinos (55552411700); Démonet, Jean-Francois (7005727609); Garibotto, Valentina (24281297800); Giannakopoulos, Panteleimon (25937290200); Gietl, Anton (6506638926); Hansson, Oskar (7006190615); Herholz, Karl (7005425888); Jack, Clifford R (18033457700); Nobili, Flavio (57206948479); Nordberg, Agneta (7102413103); Snyder, Heather M (7102670847); Ten Kate, Mara (57188682958); Varrone, Andrea (6701713624); Albanese, Emiliano (22133359100); Becker, Stefanie (57194834010); Bossuyt, Patrick (36041769200); Carrillo, Maria C (35472816700); Cerami, Chiara (25722905400); Dubois, Bruno (7101841106); Gallo, Valentina (35236753000); Giacobini, Ezio (57204334283); Gold, Gabriel (35547512800); Hurst, Samia (7005848789); Lönneborg, Anders (6602088927); Lovblad, Karl-Olof (57482329300); Mattsson, Niklas (23005631700); Molinuevo, José-Luis (6701588028); Monsch, Andreas U (7003427149); Mosimann, Urs (6603639434); Padovani, Alessandro (55996824100); Picco, Agnese (40462180900); Porteri, Corinna (11439866900); Ratib, Osman (7007144028); Saint-Aubert, Laure (55078223400); Scerri, Charles (36932764200); Scheltens, Philip (7007073571); Schott, Jonathan M (7103177641); Sonni, Ida (38663307300); Teipel, Stefan (7004435774); Vineis, Paolo (7103293037); Visser, Pieter Jelle (7101761148); Yasui, Yutaka (7102135927); Winblad, Bengt (36048831500)","56214208300; 6507801629; 7102989379; 56415176000; 7005836132; 55552411700; 7005727609; 24281297800; 25937290200; 6506638926; 7006190615; 7005425888; 18033457700; 57206948479; 7102413103; 7102670847; 57188682958; 6701713624; 22133359100; 57194834010; 36041769200; 35472816700; 25722905400; 7101841106; 35236753000; 57204334283; 35547512800; 7005848789; 6602088927; 57482329300; 23005631700; 6701588028; 7003427149; 6603639434; 55996824100; 40462180900; 11439866900; 7007144028; 55078223400; 36932764200; 7007073571; 7103177641; 38663307300; 7004435774; 7103293037; 7101761148; 7102135927; 36048831500","Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers","2017","The Lancet Neurology","16","8","","661","676","15","415","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85023199961&doi=10.1016%2fS1474-4422%2817%2930159-X&partnerID=40&md5=b808e2bfe932de0c84ed970181197bd4","The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics. © 2017 Elsevier Ltd","","Alzheimer Disease; Biomarkers; Early Diagnosis; Humans; Validation Studies as Topic; amyloid; biological marker; tau protein; biological marker; Alzheimer disease; brain atrophy; cerebrospinal fluid analysis; clinical practice; diagnostic test; diagnostic test approval; disease course; early diagnosis; human; medial temporal lobe; neuropsychology; phase 4 clinical trial (topic); positron emission tomography; practice guideline; priority journal; research priority; Review; standardization; validation process; Alzheimer disease; validation study","McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, pp. 939-944, (1984); Dubois B., Feldman H.H., Jacova C., Et al., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol, 6, pp. 734-746, (2007); McKhann G.M., Knopman D.S., Chertkow H., Et al., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 263-269, (2011); Dubois B., Hampel H., Feldman H.H., Et al., Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria, Alzheimers Dement, 12, pp. 292-323, (2016); Bennett D.A., Wilson R.S., Boyle P.A., Buchman A.S., Schneider J.A., Relation of neuropathology to cognition in persons without cognitive impairment, Ann Neurol, 72, pp. 599-609, (2012); Rowe C.C., Ellis K.A., Rimajova M., Et al., Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging, Neurobiol Aging, 31, pp. 1275-1283, (2010); Jack C.R., Lowe V.J., Senjem M.L., Et al., 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment, Brain, 131, pp. 665-680, (2008); Dubois B., Feldman H.H., Jacova C., Et al., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria, Lancet Neurol, 13, pp. 614-629, (2014); Albert M.S., DeKosky S.T., Dickson D., Et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 270-279, (2011); Alzheimer A., Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde, Neurologisches Centralblatt, 23, pp. 1129-1136, (1906); Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K., Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc Natl Acad Sci USA, 82, pp. 4245-4249, (1985); Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I., Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology, Proc Natl Acad Sci USA, 83, pp. 4913-4917, (1986); Terry R.D., DeTeresa R., Hansen L.A., Neocortical cell counts in normal human adult aging, Ann Neurol, 21, pp. 530-539, (1987); Giannakopoulos P., Herrmann F.R., Bussiere T., Et al., Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease, Neurology, 60, pp. 1495-1500, (2003); Jack C.R., Albert M.S., Knopman D.S., Et al., Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 257-262, (2011); Sperling R.A., Aisen P.S., Beckett L.A., Et al., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 280-292, (2011); Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E., Mild cognitive impairment: clinical characterization and outcome, Arch Neurol, 56, pp. 303-308, (1999); Petersen R.C., Doody R., Kurz A., Et al., Current concepts in mild cognitive impairment, Arch Neurol, 58, pp. 1985-1992, (2001); Aisen P.S., Petersen R.C., Donohue M.C., Et al., Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans, Alzheimers Dement, 6, pp. 239-246, (2010); Zwan M.D., Bouwman F.H., Konijnenberg E., Et al., Diagnostic impact of [<sup>18</sup>F]flutemetamol PET in early-onset dementia, Alzheimers Res Ther, 9, (2017); Boccardi M., Altomare D., Ferrari C., Et al., Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: the Incremental Diagnostic Value of Amyloid PET With [<sup>18</sup>F]-Florbetapir (INDIA-FBP) study, JAMA Neurol, 73, pp. 1417-1424, (2016); Jessen F., Amariglio R.E., van Boxtel M., Et al., A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease, Alzheimers Dement, 10, pp. 844-852, (2014); Home-brew tests need regulation, Nature, 512, (2014); Geuze E., Vermetten E., Bremner J.D., MR-based in vivo hippocampal volumetrics: 1. Review of methodologies currently employed, Mol Psychiatry, 10, pp. 147-159, (2005); Chen K., Ayutyanont N., Langbaum J.B., Et al., Characterizing Alzheimer's disease using a hypometabolic convergence index, Neuroimage, 56, pp. 52-60, (2011); Landau S.M., Harvey D., Madison C.M., Et al., Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI, Neurobiol Aging, 32, pp. 1207-1218, (2011); Brewer J.B., Magda S., Airriess C., Smith M.E., Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease, AJNR Am J Neuroradiol, 30, pp. 578-580, (2009); Herholz K., Salmon E., Perani D., Et al., Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET, Neuroimage, 17, pp. 302-316, (2002); Vos S., van Rossum I., Burns L., Et al., Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI, Neurobiol Aging, 33, pp. 2272-2281, (2012); Galluzzi S., Geroldi C., Amicucci G., Et al., Supporting evidence for using biomarkers in the diagnosis of MCI due to AD, J Neurol, 260, pp. 640-650, (2013); Hayes D.F., Biomarker validation and testing, Mol Oncol, 9, pp. 960-966, (2015); Frisoni G.B., Bocchetta M., Chetelat G., Et al., Imaging markers for Alzheimer disease: which vs how, Neurology, 81, pp. 487-500, (2013); Insel P.S., Mattsson N., Mackin R.S., Et al., Accelerating rates of cognitive decline and imaging markers associated with beta-amyloid pathology, Neurology, 86, pp. 1887-1896, (2016); Teipel S.J., Keller F., Thyrian J.R., Et al., Hippocampus and basal forebrain volumetry for dementia and mild cognitive impairment ciagnosis: could it be useful in primary care?, J Alzheimers Dis, 55, pp. 1379-1394, (2017); Mattsson N., Andreasson U., Persson S., Et al., The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers, Alzheimers Dement, 7, pp. 386-395.e6, (2011); Frisoni G.B., Jack C.R., Bocchetta M., Et al., The EADC-ADNI Harmonized Protocol for Manual Hippocampal Segmentation on Magnetic Resonance: evidence of validity, Alzheimers Dement, 11, pp. 111-125, (2015); Reijs B.L., Teunissen C.E., Goncharenko N., Et al., The central biobank and virtual biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases, Front Neurol, 6, (2015); Sancesario G.M., Toniolo S., Chiasserini D., Et al., The clinical use of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: the Italian selfie, J Alzheimers Dis, 55, pp. 1659-1666, (2017); Varrone A., Asenbaum S., Vander Borght T., Et al., EANM procedure guidelines for PET brain imaging using <sup>18</sup>FFDG, version 2, Eur J Nucl Med Mol Imaging, 36, pp. 2103-2110, (2009); Morbelli S., Brugnolo A., Bossert I., Et al., Visual versus semi-quantitative analysis of <sup>18</sup>F-FDG-PET in amnestic MCI: an European Alzheimer's Disease Consortium (EADC) project, J Alzheimers Dis, 44, pp. 815-826, (2015); Hort J., Bartos A., Pirttila T., Scheltens P., Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe, Eur J Neurol, 17, pp. 90-96, (2010); Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T., Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology, Neurology, 56, pp. 1133-1142, (2001); Sorbi S., Hort J., Erkinjuntti T., Et al., EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia, Eur J Neurol, 19, pp. 1159-1179, (2012); Johnson K.A., Minoshima S., Bohnen N.I., Et al., Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association, J Nucl Med, 54, pp. 476-490, (2013); Nationell utvärdering—Vård och omsorg vid demenssjukdom 2014: rekommendationer, bedömningar och sammanfattning. Socialstyrelsen, (2014); Deuschl G., Maier W., Leitlinien für Diagnostik und Therapie in der Neurologie. Demenzen. Entwicklungsstufe: S3. Patent AWMF-Register Nummer: 038-013, (2016); Frisoni G.B., Galluzzi S., Riello R., Prescription and choice of diagnostic imaging by physician specialty in Alzheimer's centers (Unita di Valutazione Alzheimer - UVA) in Northern Italy, Aging Clin Exp Res, 17, pp. 14-19, (2005); Blennow K., Mattsson N., Scholl M., Hansson O., Zetterberg H., Amyloid biomarkers in Alzheimer's disease, Trends Pharmacol Sci, 36, pp. 297-309, (2015); Palmqvist S., Mattsson N., Hansson O., Reply: do we still need positron emission tomography for early Alzheimer's disease diagnosis?, Brain, 139, (2016); Recommandation de bonne pratique. Maladie d'Alzheimer et maladies apparentées: diagnostic et prise en charge. Recommendation, (2011); Carlson C., Siemers E., Hake A., Et al., Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease, Alzheimers Dement (Amst), 2, (2016); Sevigny J., Chiao P., Bussiere T., Et al., The antibody aducanumab reduces Aβ plaques in Alzheimer's disease, Nature, 537, (2016); Scheltens P., Blennow K., Breteler M.M., Et al., Alzheimer's disease, Lancet, 388, pp. 505-517, (2016); Porteri C., Albanese E., Scerri C., Et al., The biomarker-based diagnosis of Alzheimer's disease. 1—ethical and societal issues, Neurobiol Aging, 52, pp. 132-140, (2017); Eichler T., Thyrian J.R., Hertel J., Et al., Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial, J Alzheimers Dis, 42, pp. 451-458, (2014); Pepe M.S., Etzioni R., Feng Z., Et al., Phases of biomarker development for early detection of cancer, J Natl Cacner Inst, 93, pp. 1054-1061, (2017); Boccardi M., Gallo V., Yasui Y., Et al., The biomarker-based diagnosis of Alzheimer's disease. 2—lessons from oncology, Neurobiol Aging, 52, pp. 141-152, (2017); Josephs K.A., Whitwell J.L., Tacik P., Et al.,                                      <sup>18</sup>FAV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration, Acta Neuropathol, 132, (2016); Cerami C., Dubois B., Boccardi M., Monsch A., Demonet J., Cappa S., Clinical validity of free and cued wordlist recall as a gateway-biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 153-166, (2017); Garibotto V., Herholtz K., Boccardi M., Et al., Maturity of FDG-PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 183-195, (2017); Ten Kate M., Barkhof F., Boccardi M., Et al., Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 167-182, (2017); Sonni I., Ratib O., Boccardi M., Et al., Clinical validity of presynaptic dopaminergic imaging with <sup>123</sup>I-ioflupane and noradrenergic imaging with <sup>123</sup>I-MIBG SPECT in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 228-242, (2017); Mattsson N., Lonnborg A., Boccardi M., Blennow K., Hansson O., Maturity of Aβ42, tau, and phospho-tau in the cerebrospinal fluid as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 196-213, (2017); Chiotis K., Saint-Aubert L., Boccardi M., Et al., Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 214-227, (2017); Scheltens P., Leys D., Barkhof F., Et al., Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates, J Neurol Neurosurg Psychiatry, 55, pp. 967-972, (1992); Smailagic N., Vacante M., Hyde C., Martin S., Ukoumunne O., Sachpekidis C.,                                      <sup>18</sup>F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI), Cochrane Database Syst Rev, 1, (2015); Bittner T., Zetterberg H., Teunissen C.E., Et al., Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid(1–42) in human cerebrospinal fluid, Alzheimers Dement, 12, pp. 517-526, (2016); Klunk W.E., Koeppe R.A., Price J.C., Et al., The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET, Alzheimers Dement, 11, pp. 115.e1-115.e4, (2015); Jagust W.J., Landau S.M., Koeppe R.A., Et al., The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015, Alzheimers Dement, 11, pp. 757-771, (2015); Maruyama M., Shimada H., Suhara T., Et al., Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls, Neuron, 79, pp. 1094-1108, (2013); Lemoine L., Saint-Aubert L., Marutle A., Et al., Visualization of regional tau deposits using <sup>3</sup>H-THK5117 in Alzheimer brain tissue, Acta Neuropathol Commun, 3, (2015); Marquie M., Normandin M.D., Vanderburg C.R., Et al., Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue, Ann Neurol, 78, pp. 787-800, (2015); Lowe V.J., Curran G., Fang P., Et al., An autoradiographic evaluation of AV-1451 Tau PET in dementia, Acta Neuropathol Commun, 4, (2016); Sander K., Lashley T., Gami P., Et al., Characterization of tau positron emission tomography tracer [<sup>18</sup>F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias, Alzheimers Dement, 12, pp. 1116-1124, (2016); Kimura Y., Ichise M., Ito H., Et al., PET Quantification of tau pathology in human brain with 11C-PBB3, J Nucl Med, 56, pp. 1359-1365, (2015); Jonasson M., Wall A., Chiotis K., Et al., Tracer kinetic analysis of (S)-<sup>18</sup>F-THK5117 as a PET tracer for assessing tau pathology, J Nucl Med, 57, pp. 574-581, (2016); Wooten D., Guehl N.J., Verwer E.E., Et al.; Chiotis K., Saint-Aubert L., Savitcheva I., Et al., Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm, Eur J Nucl Med Mol Imaging, 43, pp. 1686-1699, (2016); Cho H., Choi J.Y., Hwang M.S., Et al., Tau PET in Alzheimer disease and mild cognitive impairment, Neurology, 87, pp. 375-383, (2016); Johnson K.A., Schultz A., Betensky R.A., Et al., Tau positron emission tomographic imaging in aging and early Alzheimer disease, Ann Neurol, 79, pp. 110-119, (2016); Ossenkoppele R., Schonhaut D.R., Scholl M., Et al., Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease, Brain, 139, pp. 1551-1567, (2016); Smith R., Puschmann A., Scholl M., Et al.,                                      <sup>18</sup>F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers, Brain, 139, pp. 2372-2379, (2016); McMillan C.T., Irwin D.J., Nasrallah I., Et al., Multimodal evaluation demonstrates in vivo <sup>18</sup>F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration, Acta Neuropathol, 132, pp. 935-937, (2016); Johnson K.A., Minoshima S., Bohnen N.I., Et al., Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association, Alzheimers Dement, 9, pp. e1-16, (2013); Guerra U.P., Nobili F.M., Padovani A., Perani D., Pupi A., Sorbi S., Trabucchi M., Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice, Neurol Sci, 36, pp. 1075-1081, (2015); Laforce R., Rosa-Neto P., Soucy J.P., Rabinovici G.D., Dubois B., Gauthier S., Canadian consensus guidelines on use of amyloid imaging in Canada: update and future directions from the Specialized Task Force on Amyloid Imaging in Canada, Can J Neurol Sci, 43, pp. 503-512, (2016); Minoshima S., Drzezga A.E., Djekidel M., Et al., SNM MI procedure standard - EANM practice guideline for amyloid PET imaging of the brain, J Nucl Med, 57, pp. 1316-1322, (2016); Evidence-based indications for the use of PET-CT in the United Kingdom 2016, Clin Radiol, 71, pp. e171-e188, (2016); Weston P.S., Paterson R.W., Dickson J., Et al., Diagnosing dementia in the clinical setting: can amyloid PET provide additional value over cerebrospinal fluid?, J Alzheimers Dis, 54, pp. 1297-1302, (2016); Filippi M., Agosta F., Barkhof F., Et al., EFNS task force: the use of neuroimaging in the diagnosis of dementia, Eur J Neurol, 19, pp. e131-e140, (2012); Dani M., Brooks D.J., Edison P., Tau imaging in neurodegenerative diseases, Eur J Nucl Med Mol Imaging, 43, pp. 1139-1150, (2016); Olsson B., Blennow K., Zetterberg H., The clinical value of fluid biomarkers for dementia diagnosis—authors' reply, Lancet Neurol, 15, pp. 1204-1205, (2016); Olsson B., Lautner R., Andreasson U., Et al., CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis, Lancet Neurol, 15, pp. 673-684, (2016); Prescott J.W., Quantitative imaging biomarkers: the application of advanced image processing and analysis to clinical and preclinical decision making, J Digit Imaging, 26, pp. 97-108, (2013); Winblad B., Amouyel P., Andrieu S., Et al., Defeating Alzheimer's disease and other dementias: a priority for European science and society, Lancet Neurol, 15, pp. 455-532, (2016); Franchi C., Lucca U., Tettamanti M., Et al., Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project, Pharmacoepidemiol Drug Saf, 20, pp. 497-505, (2011); Iturria-Medina Y., Sotero R.C., Toussaint P.J., Mateos-Perez J.M., Evans A.C., Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis, Nat Commun, 7, (2016)","2-s2.0-85023199961"
"Cerami C.; Marcone A.; Galimberti D.; Villa C.; Fenoglio C.; Scarpini E.; Cappa S.F.","Cerami, Chiara (25722905400); Marcone, Alessandra (6701496511); Galimberti, Daniela (6701617660); Villa, Chiara (57195622956); Fenoglio, Chiara (8661375900); Scarpini, Elio (57210771033); Cappa, Stefano F. (7005836132)","25722905400; 6701496511; 6701617660; 57195622956; 8661375900; 57210771033; 7005836132","Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia","2013","Journal of Alzheimer's Disease","36","3","","415","420","5","14","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84881436989&doi=10.3233%2fJAD-130317&partnerID=40&md5=6ea026f3f6697b00637f52a710c7f322","Progranulin (GRN) mutations are typically associated with the behavioral variant of frontotemporal dementia and the non-fluent variant of primary progressive aphasia phenotypes. Hereby, we describe a patient affected by semantic variant of primary progressive aphasia (svPPA) with a highly positive family history of dementia, carrying a novel GRN missense variation in exon 11 [g.2897 C > T (p.Thr409Met)], predicted in silico to be damaging to protein structure and function. The variant was absent in 175 frontotemporal lobar degeneration (FTLD) patients and in 38 healthy subjects. This case confirms that GRN represents one of the most frequent FTLD genetic causes, suggesting that a screening is indicated in the case of svPPA presentation. © 2013 - IOS Press and the authors. All rights reserved.","Frontotemporal lobar degeneration; GRN mutation; semantic variant of primary progressive aphasia","fluorodeoxyglucose f 18; progranulin; adult; anomia; article; brain atrophy; brain metabolism; case report; contrast enhancement; controlled study; dementia; exon; family history; follow up; genetic association; genetic conservation; human; male; Mini Mental State Examination; missense mutation; neurologic examination; nuclear magnetic resonance imaging; positron emission tomography; primary progressive aphasia; priority journal; protein function; protein structure; psychologic assessment; semantic variant primary progressive aphasia","Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vanderberghe R., Rascoscvsky K., Patterson K., Mille B.L., Knopman D.S., Hodges S.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Mackenzie I.R., Neumann M., Bigio E.H., Cairns N.J., Alafuzoff I., Kril J., Kovacs G.G., Ghetti B., Halliday G., Holm I.E., Ince P.G., Kamphorst W., Revesz T., Rozemuller A.J.M., Kumar-Singh S., Akiyama H., Baborie A., Spina S., Dickson D.W., Trojanowski J.Q., Mann D.M.A., Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: An update, Acta Neuropathol, 119, pp. 1-4, (2010); Grossman M., Wood E.M., Peachie Moore B.A., Neumann M., Kwong L., Forman M.S., Clark C.M., McCluskey L.F., Miller B.L., Lee V.M.-Y., Trojanowski J.Q., TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions, Arch Neurol, 64, pp. 1449-1454, (2007); Nestor P.J., Balan K., Cheow H.K., Fryer T.D., Knibb J.A., Xueneb J.H., Hodges J.R., Nuclear imaging predict pathologic diagnosis in progressive nonfluent aphasia, Neurology, 4, pp. 455-460, (2007); Mackenzie I.R., Neumann M., Cairns N.J., Munoz D.G., Isaacs A.M., Novel types of frontotemporal lobar degeneration: Beyond tau and TDP-43, J Mol Neurosci, 45, pp. 402-408, (2011); Rohrer J.D., Guerreiro R., Vandrovcova J., Uphill J., Reiman D., Beck J., Isaacs A.M., Authier A., Ferrari R., Fox N.C., Mackenzie I.R.A., Warren J.D., De Silva R., Holton J., Revesz T., Hardy J., Mead S., Rossor M.N., The heritability and genetics of frontotemporal lobar degeneration, Neurology, 73, pp. 1451-1456, (2009); Seelaar H., Kamphorst W., Rosso S.M., Azmani A., Masdjedi R., De Koning I., Maat-Kievit J.A., Anar B., Donker K.L., Breedveld G.J., Doojees D., Rozemuller J.M., Bronner I.F., Rizzu P., Van Swieten J.C., Distinct genetic forms of frontotemporal dementia, Neurology, 71, pp. 1220-1226, (2008); Seelaar H., Rohrer J.D., Pijnenburg Y.A.L., Fox N.C., Van Swieten J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review, J Neurol Neurosurg Psychiatry, 82, pp. 476-486, (2011); Cruts M., Gijselinck I., Van Der Zee J., Et Engelborghs S., Wils H., Pirici D., Rademakers R., Vandenberghe R., Dermaut B., Martin J.J., Van Duijn C., Peeters K., Sciot R., Santens P., De Pooter T., Mattheijssens M., Van Den Broeck M., Cuijt I., Vennekens K., De Deyn P.P., Kumar-Singh S., Van Broeckhoven C., Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q1, Nature, 442, pp. 920-992, (2006); Le Ber I., Van Der Zee J., Hannequin D., Gijselinck I., Campion D., Puel M., Laquerriere A., De Pooter T., Camuzat A., Van Den Broeck M., Dubois B., Sellal F., Lacomblez L., Vercelletto M., Thomas-Anterion C., Michel B.F., GolfierV Didic M., Salachas F., Duyckaerts C., Cruts M., Verpillat P., Van Broeckhoven C., Brice A., Progranulin null mutations in both sporadic and familial frontotemporal dementia, Hum Mutat, 28, pp. 846-855, (2007); Pickering-Brown S.M., Rollinson S., Du Plessis D., Morrison K.E., Varma A., Richardson A.M.T., Neary D., Snowden J.S., Mann D.M.A., Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: Comparison with patients with MAPT and no known mutations, Brain, 131, pp. 721-731, (2008); Gass J., Cannon A., Mackenzie I.R., Boeve B., Baker M., Adamson J., Crook R., Melquist S., Kuntz K., Petersen R., Josephs K., Brown S.P., Graff-Radford N., Uitti R., Dickson D., Wszolek Z., Gonzalez J., Beach T.G., Bigio E., Johnson N., Weintraub S., Mesulam M., White III C.L., Woodruff B., Caselli R., Hsiung G.Y., Feldman H., Knopman D., Hutton M., Rademakers R., Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration, Hum Mol Genet, 15, pp. 2988-3001, (2006); Baker M., Mackenzie I.R.A., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J.S., Adamson J., Sadovnick A.D., Rollinson S., Cannon A., Dwosh E., Neary D., Melquist S., Richardson A., Dickinson D., Berger Z., Eriksen J., Robinson T., Zehr C., Dickey C.A., Crook R., McGowan E., Mann D., Boeve B., Feldman H., Hutton M., Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17, Nature, 442, pp. 916-919, (2006); Snowden J.S., Pickering-Brown S.M., Mackenzie I.R.A., Richardson A.M.T., Varma A., Neary D., Mann D.M., Progranulin gene mutations associated with frontotemporal dementia and progressive non fluent aphasia, Brain, 129, pp. 3091-3102, (2006); Snowden J.S., Pickering-Brown S.M., Du Plessis D., Mckenzie I.R., Varma A., Mann D.M., Neary D., Progressive anomia revisited: Focal degeneration associated with progranulin gene mutation, Neurocase, 13, pp. 366-377, (2007); Mesulam M., Johnson M., Krefft T.A., Gass J.M., Cannon A.D., Adamson J.L., Bigio E.H., Weintraub S., Dickson D.W., Hutton M.L., Graff-Radford N.R., Progranulin mutations in primary progressive aphasia The PPA1 and PPA3 families, Arch Neurol, 64, pp. 43-47, (2007); Huey E.D., Grafman J., Wassermann E.M., Pietrini P., Tierney M.C., Ghetti B., Spina S., Baker M., Hutton M., Elder J.W., Berger S.L., Heflin K.A., Hardy J., Momeni P., Characteristics of frontotemporal dementia patients with a progranulin mutation, Ann Neurol, 60, pp. 374-380, (2006); Yu C.E., Bird T.D., Bekris L.N., Montine T.J., Leverenz J.B., Steinbart E., Galloway N.M., Feldman H., Woltjer R., Miller C.A., McCarty Wood E., Grossman M., McCluskey L., Clark C.M., Neumann M., Danek A., Galasko D.R., Arnold S.E., Chen-Plotkin A., Karydas A., Miller B.L., Trojanowski J.Q., Lee V.M.-Y., Schellenberg G.D., Van Deerlin V.M., The spectrum of mutations in progranulin.Acollaborative study screening 545 cases of neurodegeneration, Arch Neurol, 67, pp. 161-170, (2010); Rohrer J.D., Warren J.D., Barnes J., Mead S., Beck J., Pepple T., Boyes R., Omar R., Collinge J., Stevens S.M., Warrington E.K., Rossor M.N., Fox N.C., Mapping the progression of progranulin-Associated frontotemporal lobar degeneration, Nat Clin Pract Neurol, 4, pp. 455-460, (2008); Van Deerlin V.M., McCartyWood E., Moore P., Yuan W., Forman M.S., Clark C.M., Neuman M., Kwong L.K., Trojanowski J.Q., Lee V.M.-Y., Grossman M., Clinical, genetic, and pathological characteristics of patients with frontotemporal dementia and progranulin mutations, Arch Neurol, 64, pp. 1148-1153, (2007); Goldman J.S., Farmer J.M., Wood E.M., Johnson J.K., Boxer A., Neuhaus J., Lomen-Hoerth C., Wihelmsen K.C., Lee V.M., Grosmann M., Miller B.L., Comparison of family histories in FTLD subtypes and related tauopathies, Neurology, 65, pp. 1817-1819, (2005); Van Der Zee J., Rademakers R., Engelborghs S., Gijselinck I., Bogaerts V., Vandenberghe R., Santens P., Caekebeke J., De Pooter T., Peeters K., Lubke U., Van Den Broeck M., Martin J.J., Cruts M., De Deyn P.P., Van Broeckhoven C., Dermaut B., ABelgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD, Brain, 129, PART 4, pp. 841-852, (2006); Rohrer J.D., Crutch S.J., Warrington E.K., Warren J.D., Progranulin-Associated primary progressive aphasia: A distinct phenotype?, Neuropsychologia, 48, pp. 288-297, (2010); Le Ber I., Camuzat A., Hannequin D., Pasquier F., Guedj E., Rovelet-Lecrux A., Hahn-Barma V., Van Der Zee J., Clot F., Bakchine S., Puel M., Ghanim M., Lacomblez L., Mikol J., Deramecourt V., Lejeune P., De La Sayette V., Belliard S., Vercelletto M., Meyrignac C., Van Broeckhoven C., Lambert J.C., Verpillat P., Campion D., Habert M.O., Dubois B., Brice A., Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study, Brain, 131, pp. 732-746, (2008); Cerami C., Scarpini E., Cappa S.F., Galimberti D., Frontotemporal lobar degeneration: Current knowledge and future challenges, J Neurol, 259, pp. 2278-2286, (2012); Cerami C., Marcone A., Galimberti D., Villa C., Scarpini E., Cappa S.F., From genotype to phenotype: Two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder, J Alzheimers Dis, 27, pp. 791-797, (2011); Pietroboni A.M., Fumagalli G.G., Ghezzi L., Fenoglio C., Cortini F., Serpente M., Cantoni C., Rotondo E., Corti P., Carecchio M., Bassi M., Bresolin N., Galbiati D., Galimberti D., Scarpini E., Phenotypical heterogeneity of the GRN Asp22fs mutation in a large Italian kindred, J Alzheimers Dis, 24, pp. 253-259, (2011); Ng P.C., Henikoff S., SIFT: Predicting amino acid changes that affect protein function, Nucleic Acids Res, 31, pp. 3812-3814, (2003); Xi T., Jones I.M., Mohrenweiser H.W., Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function, Genomics, 8, pp. 970-979, (2004); Ferrer-Costa C., Gelpi J.L., Zamakola L., Parraga I., De Ic X., Orozco M., PMUT: A web-based tool for the annotation of pathological mutations on proteins, Bioinformatics, 21, pp. 3176-3178, (2005); Cerami C., Marcone A., Galimberti D., Zamboni M., Fenoglio C., Serpente M., Scarpini E., Cappa S.F., Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9, J Alzheimers Disease, (2013); Hodges J.R., Mitchell J., Dawson K., Spillantini M.G., Xuereb J.H., McMonagle P., Nestor P.J., Patterson K., Semantic dementia: Demography, familial factors and survival in a consecutive series of 100 cases, Brain, 133, pp. 300-306, (2009); Rosso S.M., Donker Kaat L., Baks T., Joosse M., De Koning I., Pijnenburg Y., De Jong D., Dooijes D., Kamphorst W., Ravid R., Niermeijer M.F., Verheij F., Kremer H.P., Scheltens P., Van Duijn C.M., Heutink P., Van Swieten J.C., Frontotemporal dementia in Netherlands: Patients' characteristics and prevalence estimates from a population-based study, Brain, 126, pp. 2016-2022, (2003); Neary D., Snowden J.S., Mann D.M.A., Frontotemporal dementia, Lancet Neurol, 4, pp. 771-780, (2005); Kelley B.J., Haidar W., Boeve B.F., Baker M., Graff-Radford N.R., Krefft T., Frank A.R., Jack Jr. C.R., Shiung M., Knopman D.S., Josephs K.A., Parashos S.A., Rademakers R., Hutton M., Pickering-Brown S., Adamson J., Kuntz K.M., Dickson D.W., Parisi J.E., Smith G.E., Ivnik R.J., Petersen R.C., Prominent phenotypic variability associated with mutations in Progranulin, Neurobiol Aging, 30, pp. 739-751, (2009); Rademakers R., Baker M., Gass J., Adamson J., Huey E.D., Momeni P., Spina S., Coppola G., Karydas A.M., Stewart H., Johnson N., Hsiung G.Y., Kelley B., Kuntz K., Steinbart E., Wood E.M., Yu C.E., Josephs K., Sorenson E., Womack K.B., Weintraub S., Pickering-Brown S.M., Schofield P.R., Brooks W.S., Van Deerlin V.M., Snowden J., Clark C.M., Kertesz A., Boylan K., Ghetti B., Neary D., Schellenberg G.D., Beach T.G., Mesulam M., Mann D., Grafman J., Mackenzie I.R., Feldman H., Bird T., Petersen R., Knopman D., Boeve B., Geschwind D.H., Miller B., Wszolek Z., Lippa C., Bigio E.H., Dickson D., Graff-Radford N., Hutton M., Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: An international initiative, Lancet Neurol, 6, pp. 857-868, (2007)","2-s2.0-84881436989"
"Villa C.; Ghezzi L.; Fenoglio C.; Clerici F.; Marcone A.; Benussi L.; Ghidoni R.; Gallone S.; Serpente M.; Cantoni C.; Ridolfi E.; Bonsi R.; Cerami C.; Cappa S.; Binetti G.; Franceschi M.; Rainero I.; Mariani C.; Bresolin N.; Scarpini E.; Galimberti D.","Villa, Chiara (57195622956); Ghezzi, Laura (54880204500); Fenoglio, Chiara (8661375900); Clerici, Francesca (56013510400); Marcone, Alessandra (6701496511); Benussi, Luisa (7004507361); Ghidoni, Roberta (7005186567); Gallone, Salvatore (10142709600); Serpente, Maria (26030684600); Cantoni, Claudia (57202539045); Ridolfi, Elisa (22954355100); Bonsi, Rossana (55348007500); Cerami, Chiara (25722905400); Cappa, Stefano (7005836132); Binetti, Giuliano (35429391100); Franceschi, Massimo (7004351220); Rainero, Innocenzo (7003753505); Mariani, Claudio (55810313900); Bresolin, Nereo (7005827082); Scarpini, Elio (57210771033); Galimberti, Daniela (6701617660)","57195622956; 54880204500; 8661375900; 56013510400; 6701496511; 7004507361; 7005186567; 10142709600; 26030684600; 57202539045; 22954355100; 55348007500; 25722905400; 7005836132; 35429391100; 7004351220; 7003753505; 55810313900; 7005827082; 57210771033; 6701617660","Genetics and expression analysis of the specificity protein 4 gene (SP4) in patients with Alzheimer's disease and frontotemporal lobar degeneration","2012","Journal of Alzheimer's Disease","31","3","","537","542","5","8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84865591172&doi=10.3233%2fJAD-2012-120379&partnerID=40&md5=ca074021d35e5e797739cd3409ceeb7e","Transcription factor Sp4 (Specificity protein 4) levels are increased in the brain of patients with Alzheimer's disease (AD), and Sp4 colocalizes with neurofibrillary tangles. Moreover, SP4 is a susceptibility gene for bipolar disorder and schizophrenia, which share many clinical features with frontotemporal lobar degeneration (FTLD). The distribution of three tagging single nucleotide polymorphisms(SNPs)-rs9639379, rs10272006, and rs6461569-has been determined in a population of 352 patients diagnosed clinically with AD, 290 patients with FTLD, and 341 age-matched controls. Expression analysis of SP4 was performed in peripheral blood mononuclear cells (PBMC). No significant differences in either allelic or genotypic frequency of the three SNPs were found (p > 0.05), even stratifying according to gender and to the apolipoprotein E status. Significantly increased SP4 relative expression levels were observed in PBMC from patients with AD as compared with controls (7.132 ± 1.301 versus 3.396 ± 0.829, p < 0.050) and a similar trend was shown in patients with FTLD compared with controls (6.525 ± 1.500 versus 3.396 ± 0.829, p = 0.073). According to these results, SP4 gene does not act as a susceptibility factor either for AD or FTLD. However, Sp4 mRNA levels are upregulated in patients, possibly resulting in an aberrant expression of downstream target genes involved in the pathogenesis of both diseases. © 2012-IOS Press and the authors. All rights reserved.","Alzheimer's disease; expression; frontotemporal lobar degeneration; risk factor; SP4; specificity protein 4","apolipoprotein E; transcription factor Sp4; aged; Alzheimer disease; article; controlled study; female; frontotemporal dementia; gene expression; gene frequency; genetic analysis; genetic association; human; human cell; human tissue; major clinical study; male; peripheral blood mononuclear cell; priority journal; single nucleotide polymorphism","Heisler L.E., Torti D., Boutros P.C., Watson J., Chan C., Winegarden N., Takahashi M., Yau P., Huang T.M.-H., Farnham P.J., Jurisica I., Woodgett J.R., Bremner R., Penn L.Z., Der S.D., CpG Island microarray probe sequences derived from a physical library are representative of CpG Islands annotated on the human genome, Nucleic Acids Research, 33, 9, pp. 2952-2961, (2005); Boutillier S., Lannes B., Buee L., Delacourte A., Rouaux C., Mohr M., Bellocq J.-P., Sellal F., Larmet Y., Boutillier A.-L., Loeffler J.-P., Sp3 and Sp4 transcription factor levels are increased in brains of patients with Alzheimer's disease, Neurodegenerative Diseases, 4, 6, pp. 413-423, (2007); Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., Owen M.J., O'Donovan M.C., Gene-wide analyses of genomewide association data sets: Evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk, Mol Psych, 14, pp. 252-260, (2009); Detera-Wadleigh S.D., Badner J.A., Yoshikawa T., Sanders A.R., Goldin L.R., Turner G., Rolling D.Y., Moses T., Guroff J.J., Kazuba D., Maxwell M.E., Edenberg H.J., Foroud T., Lahiri D., Nurnberger Jr. J.I., Stine O.C., McMahon F., Meyers D.A., MacKinnon D., Simpson S., McInnis M., DePaulo J.R., Rice J., Goate A., Reich T., Blehar M.C., Gershon E.S., Initial genome scan of the NIMH genetics initiative bipolar pedigrees: Chromosomes 4, 7, 9, 18, 19, 20, and 21q, American Journal of Medical Genetics - Neuropsychiatric Genetics, 74, 3, pp. 254-262, (1997); Zhou X., Tang W., Greenwood T.A., Guo S., He L., Geyer M.A., Kelsoe J.R., Transcription factor Sp4 is a susceptibility gene for bipolar disorder, PlosOne, 4, (2009); Schoder D., Hannequin D., Martinaud O., Opolczynski G., Guyant- Marechal L., Le Ber I., Campion D., Morbid risk for schizophrenia in first-degree relatives of people with frontotemporal dementia, BJ Psych, 197, pp. 28-35, (2010); Momeni P., Detucci K., Straub R.E., Weinberger D.R., Davies P., Grafman J., Hardy J., Huey E.D., Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia, Neurocase, 16, pp. 273-279, (2010); McKhann G., Drachman D., Folstein M., Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, 34, 7, pp. 939-944, (1984); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia, Arch Neurol, 58, pp. 1803-1809, (2001); Villa C., Ghezzi L., Pietroboni A.M., Fenoglio C., Cortini F., Serpente M., Cantoni C., Ridolfi E., Marcone A., Benussi L., Ghidoni R., Jacini F., Arighi A., Fumagalli G.G., Mandelli A., Binetti G., Cappa S., Bresolin N., Scarpini E., Galimberti D., A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia, J Alzheimers Dis, 26, pp. 19-26, (2011); Carecchio M., Fenoglio C., Cortini F., Comi C., Benussi L., Ghidoni R., Borroni B., De Riz M., Serpente M., Cantoni C., Franceschi M., Albertini V., Monaco F., Rainero I., Binetti G., Padovani A., Bresolin N., Scarpini E., Galimberti D., Cerebrospinal fluid biomarkers in progranulin mutations carriers, J Alzheimers Dis, 27, pp. 781-790, (2011); Pietroboni A.M., Fumagalli G.G., Ghezzi L., Fenoglio C., Cortini F., Serpente M., Cantoni C., Rotondo E., Corti P., Carecchio M., Bassi M., Bresolin N., Galbiati D., Galimberti D., Scarpini E., Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred, J Alzheimers Dis, 24, pp. 253-259, (2011); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Benussi L., Ghidoni R., Gallone S., Cortini F., Serpente M., Cantoni C., Fumagalli G., Ridolfi E., Cappa S., Binetti G., Franceschi M., Rainero I., Giordana M.T., Mariani C., Bresolin N., Scarpini E., Galimberti D., BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease, J Alzheimers Dis, 23, pp. 701-707, (2011); Dejesus-Hernandez M., MacKenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, pp. 245-256, (2011); Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., Van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Holtta-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chio A., Restagno G., Borghero G., Sabatelli M., Italsgen C., Heckerman D., Rogaeva E., Zinman L., Rothstein J.D., Sendtner M., Drepper C., Eichler E.E., Alkan C., Abdullaev Z., Pack S.D., Dutra A., Pak E., Hardy J., Singleton A., Williams N.M., Heutink P., Pickering-Brown S., Morris H.R., Tienari P.J., Traynor B.J., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, pp. 257-268, (2011); Del Bo R., Comi G.P., Bresolin N., Castelli E., Conti E., Degiuli A., Ausenda C.D., Scarlato G., The apolipoprotein E ε4 allele causes a faster decline of cognitive performances in Down's syndrome subjects, Journal of the Neurological Sciences, 145, 1, pp. 87-91, (1997); Livak K.J., Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC</sup>T method, Methods, 25, 4, pp. 402-408, (2001); Mao X., Yang S.H., Simpkins J.W., Barger S.W., Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons, J Neurochem, 100, pp. 1300-1314, (2007); Saito K.-I., Elce J.S., Hamos J.E., Nixon R.A., Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration, Proceedings of the National Academy of Sciences of the United States of America, 90, 7, pp. 2628-2632, (1993); Barger S.W., Basile A.S., Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function, Journal of Neurochemistry, 76, 3, pp. 846-854, (2001); Maes O.C., Schipper H.M., Chertkow H.M., Wang E., Methodology for discovery of Alzheimer's disease bloodbased biomarkers, J Gerontol A Biol Sci Med Sci, 64, pp. 636-645, (2009)","2-s2.0-84865591172"
"Van Bavel J.J.; Cichocka A.; Capraro V.; Sjåstad H.; Nezlek J.B.; Pavlović T.; Alfano M.; Gelfand M.J.; Azevedo F.; Birtel M.D.; Cislak A.; Lockwood P.L.; Ross R.M.; Abts K.; Agadullina E.; Aruta J.J.B.; Besharati S.N.; Bor A.; Choma B.L.; Crabtree C.D.; Cunningham W.A.; De K.; Ejaz W.; Elbaek C.T.; Findor A.; Flichtentrei D.; Franc R.; Gjoneska B.; Gruber J.; Gualda E.; Horiuchi Y.; Huynh T.L.D.; Ibanez A.; Imran M.A.; Israelashvili J.; Jasko K.; Kantorowicz J.; Kantorowicz-Reznichenko E.; Krouwel A.; Laakasuo M.; Lamm C.; Leygue C.; Lin M.-J.; Mansoor M.S.; Marie A.; Mayiwar L.; Mazepus H.; McHugh C.; Minda J.P.; Mitkidis P.; Olsson A.; Otterbring T.; Packer D.J.; Perry A.; Petersen M.B.; Puthillam A.; Riaño-Moreno J.C.; Rothmund T.; Santamaría-García H.; Schmid P.C.; Stoyanov D.; Tewari S.; Todosijević B.; Tsakiris M.; Tung H.H.; Umbreș R.G.; Vanags E.; Vlasceanu M.; Vonasch A.; Yucel M.; Zhang Y.; Abad M.; Adler E.; Akrawi N.; Mdarhri H.A.; Amara H.; Amodio D.M.; Antazo B.G.; Apps M.; Ay F.C.; Ba M.H.; Barbosa S.; Bastian B.; Berg A.; Bernal-Zárate M.P.; Bernstein M.; Białek M.; Bilancini E.; Bogatyreva N.; Boncinelli L.; Booth J.E.; Borau S.; Buchel O.; Cameron C.D.; Carvalho C.F.; Celadin T.; Cerami C.; Chalise H.N.; Cheng X.; Cian L.; Cockcroft K.; Conway J.; Córdoba-Delgado M.A.; Crespi C.; Crouzevialle M.; Cutler J.; Cypryańska M.; Dabrowska J.; Daniels M.A.; Davis V.H.; Dayley P.N.; Delouvee S.; Denkovski O.; Dezecache G.; Dhaliwal N.A.; Diato A.B.; Di Paolo R.; Drosinou M.; Dulleck U.; Ekmanis J.; Ertan A.S.; Etienne T.W.; Farhana H.H.; Farkhari F.; Farmer H.; Fenwick A.; Fidanovski K.; Flew T.; Fraser S.; Frempong R.B.; Fugelsang J.A.; Gale J.; Garcia-Navarro E.B.; Garladinne P.; Ghajjou O.; Gkinopoulos T.; Gray K.; Griffin S.M.; Gronfeldt B.; Gümren M.; Gurung R.L.; Halperin E.; Harris E.; Herzon V.; Hruška M.; Huang G.; Hudecek M.F.C.; Isler O.; Jangard S.; Jørgensen F.J.; Kachanoff F.; Kahn J.; Dangol A.K.; Keudel O.; Koppel L.; Koverola M.; Kubin E.; Kunnari A.; Kutiyski Y.; Laguna O.; Leota J.; Lermer E.; Levy J.; Levy N.; Li C.; Long E.U.; Longoni C.; Maglić M.; McCashin D.; Metcalf A.L.; Mikloušić I.; El Mimouni S.; Miura A.; Molina-Paredes J.; Monroy-Fonseca C.; Morales-Marente E.; Moreau D.; Muda R.; Myer A.; Nash K.; Nesh-Nash T.; Nitschke J.P.; Nurse M.S.; Ohtsubo Y.; Oldemburgo de Mello V.; O’Madagain C.; Onderco M.; Palacios-Galvez M.S.; Palomäki J.; Pan Y.; Papp Z.; Pärnamets P.; Paruzel-Czachura M.; Pavlović Z.; Payán-Gómez C.; Perander S.; Pitman M.M.; Prasad R.; Pyrkosz-Pacyna J.; Rathje S.; Raza A.; Rêgo G.G.; Rhee K.; Robertson C.E.; Rodríguez-Pascual I.; Saikkonen T.; Salvador-Ginez O.; Sampaio W.M.; Santi G.C.; Santiago-Tovar N.; Savage D.; Scheffer J.A.; Schönegger P.; Schultner D.T.; Schutte E.M.; Scott A.; Sharma M.; Sharma P.; Skali A.; Stadelmann D.; Stafford C.A.; Stanojević D.; Stefaniak A.; Sternisko A.; Stoica A.; Stoyanova K.K.; Strickland B.; Sundvall J.; Thomas J.P.; Tinghög G.; Torgler B.; Traast I.J.; Tucciarelli R.; Tyrala M.; Ungson N.D.; Uysal M.S.; Van Lange P.A.M.; van Prooijen J.-W.; van Rooy D.; Västfjäll D.; Verkoeijen P.; Vieira J.B.; von Sikorski C.; Walker A.C.; Watermeyer J.; Wetter E.; Whillans A.; Willardt R.; Wohl M.J.A.; Wójcik A.D.; Wu K.; Yamada Y.; Yilmaz O.; Yogeeswaran K.; Ziemer C.-T.; Zwaan R.A.; Boggio P.S.","Van Bavel, Jay J. (22986966200); Cichocka, Aleksandra (35765189600); Capraro, Valerio (49361021300); Sjåstad, Hallgeir (57200691996); Nezlek, John B. (7004481879); Pavlović, Tomislav (57196148151); Alfano, Mark (36762163600); Gelfand, Michele J. (7201803113); Azevedo, Flavio (57202683756); Birtel, Michèle D. (46060910600); Cislak, Aleksandra (23666913300); Lockwood, Patricia L. (55347628400); Ross, Robert Malcolm (23567212800); Abts, Koen (16314964400); Agadullina, Elena (55948104400); Aruta, John Jamir Benzon (57205719637); Besharati, Sahba Nomvula (56221801500); Bor, Alexander (57193896526); Choma, Becky L. (10039110600); Crabtree, Charles David (56669557400); Cunningham, William A. (16065517700); De, Koustav (57432843300); Ejaz, Waqas (57196262755); Elbaek, Christian T. (57219005068); Findor, Andrej (15051465700); Flichtentrei, Daniel (35094029100); Franc, Renata (6701375451); Gjoneska, Biljana (57211203812); Gruber, June (8929220900); Gualda, Estrella (26531164900); Horiuchi, Yusaku (24168107200); Huynh, Toan Luu Duc (57728566100); Ibanez, Augustin (55172691400); Imran, Mostak Ahamed (14008430600); Israelashvili, Jacob (57196217992); Jasko, Katarzyna (35743100000); Kantorowicz, Jaroslaw (56256131200); Kantorowicz-Reznichenko, Elena (56743290300); Krouwel, André (16744097100); Laakasuo, Michael (55209862600); Lamm, Claus (56566285000); Leygue, Caroline (11839543000); Lin, Ming-Jen (34668140100); Mansoor, Mohammad Sabbir (57432843400); Marie, Antoine (57210735692); Mayiwar, Lewend (57210589547); Mazepus, Honorata (57189074265); McHugh, Cillian (57201644809); Minda, John Paul (6603737492); Mitkidis, Panagiotis (55734672700); Olsson, Andreas (8690139600); Otterbring, Tobias (54684879600); Packer, Dominic J. (22986127600); Perry, Anat (26647787400); Petersen, Michael Bang (35761369500); Puthillam, Arathy (57209821598); Riaño-Moreno, Julián C. (57210113671); Rothmund, Tobias (26026109100); Santamaría-García, Hernando (56610290700); Schmid, Petra C. (35778895000); Stoyanov, Drozdstoy (36601257300); Tewari, Shruti (37102876500); Todosijević, Bojan (6507222236); Tsakiris, Manos (8612330500); Tung, Hans H. (57189267860); Umbreș, Radu G. (56121056100); Vanags, Edmunds (57433130100); Vlasceanu, Madalina (57201915022); Vonasch, Andrew (16425076400); Yucel, Meltem (57201461738); Zhang, Yucheng (56605134100); Abad, Mohcine (57433425600); Adler, Eli (57367764100); Akrawi, Narin (57433856600); Mdarhri, Hamza Alaoui (57433566000); Amara, Hanane (57433711700); Amodio, David M. (6603573634); Antazo, Benedict G. (57218632714); Apps, Matthew (37017949200); Ay, F. Ceren (57432990200); Ba, Mouhamadou Hady (57433425700); Barbosa, Sergio (57194429267); Bastian, Brock (7005685014); Berg, Anton (57433130200); Bernal-Zárate, Maria P. (57433425900); Bernstein, Michael (18133581400); Białek, Michał (56333322000); Bilancini, Ennio (24175889200); Bogatyreva, Natalia (57226525097); Boncinelli, Leonardo (24175528900); Booth, Jonathan E. (27567441600); Borau, Sylvie (57192594944); Buchel, Ondrej (57219655063); Cameron, C. Daryl (36551893200); Carvalho, Chrissie F. (55972096100); Celadin, Tatiana (57216634436); Cerami, Chiara (25722905400); Chalise, Hom Nath (14629921400); Cheng, Xiaojun (57206757068); Cian, Luca (37088275700); Cockcroft, Kate (22933698400); Conway, Jane (57188581373); Córdoba-Delgado, Mateo Andres (57408848700); Crespi, Chiara (57034303800); Crouzevialle, Marie (55934830400); Cutler, Jo (57203910287); Cypryańska, Marzena (55078294200); Dabrowska, Justyna (57433711900); Daniels, Michael A. (56189070000); Davis, Victoria H. (57432990300); Dayley, Pamala N. (57433856800); Delouvee, Sylvain (13612418500); Denkovski, Ognjan (57221594660); Dezecache, Guillaume (55151472900); Dhaliwal, Nathan A. (57219911935); Diato, Alelie B. (57433130400); Di Paolo, Roberto (57201116811); Drosinou, Marianna (57193797236); Dulleck, Uwe (55973560500); Ekmanis, Jānis (57433426100); Ertan, Arhan S. (25923852000); Etienne, Tom W. (57302201900); Farhana, Hapsa Hossain (57433130500); Farkhari, Fahima (57432990400); Farmer, Harry (55233381300); Fenwick, Ali (57433566200); Fidanovski, Kristijan (57202704216); Flew, Terry (56341271400); Fraser, Shona (57211455566); Frempong, Raymond Boadi (57194167162); Fugelsang, Jonathan A. (6603080729); Gale, Jessica (57202291651); Garcia-Navarro, E. Begoña (57218316315); Garladinne, Prasad (57433278100); Ghajjou, Oussama (57433856900); Gkinopoulos, Theofilos (55866447200); Gray, Kurt (15520639300); Griffin, Siobhán M. (7201880907); Gronfeldt, Bjarki (57196054646); Gümren, Mert (6504093196); Gurung, Ranju Lama (57433857000); Halperin, Eran (35866830500); Harris, Elizabeth (57215611020); Herzon, Volo (57433857100); Hruška, Matej (57196236805); Huang, Guanxiong (56844125900); Hudecek, Matthias F. C. (56545531900); Isler, Ozan (57200182087); Jangard, Simon (57195595285); Jørgensen, Frederik J. (57222523239); Kachanoff, Frank (56574304400); Kahn, John (57433426300); Dangol, Apsara Katuwal (57433857200); Keudel, Oleksandra (57218936367); Koppel, Lina (57188825958); Koverola, Mika (57204777214); Kubin, Emily (57205631416); Kunnari, Anton (57204772241); Kutiyski, Yordan (56480708400); Laguna, Oscar (57432990500); Leota, Josh (57217061682); Lermer, Eva (55584194600); Levy, Jonathan (56327503700); Levy, Neil (57216429407); Li, Chunyun (57202677751); Long, Elizabeth U. (57217147507); Longoni, Chiara (55899207500); Maglić, Marina (57216147889); McCashin, Darragh (57204609951); Metcalf, Alexander L. (54890112800); Mikloušić, Igor (36859688300); El Mimouni, Soulaimane (57433278200); Miura, Asako (12645856800); Molina-Paredes, Juliana (57408848800); Monroy-Fonseca, César (57433278300); Morales-Marente, Elena (36240826900); Moreau, David (36552994500); Muda, Rafał (57195249015); Myer, Annalisa (57225980689); Nash, Kyle (22135546300); Nesh-Nash, Tarik (57433278400); Nitschke, Jonas P. (57193254318); Nurse, Matthew S. (57209360893); Ohtsubo, Yohsuke (7005112071); Oldemburgo de Mello, Victoria (57433426400); O’Madagain, Cathal (56593233200); Onderco, Michal (50462189600); Palacios-Galvez, M. Soledad (55946309500); Palomäki, Jussi (55177884100); Pan, Yafeng (57191922458); Papp, Zsófia (55383252800); Pärnamets, Philip (55918105000); Paruzel-Czachura, Mariola (55936861100); Pavlović, Zoran (23397554100); Payán-Gómez, César (54896392800); Perander, Silva (57433426600); Pitman, Michael Mark (19337434700); Prasad, Rajib (57433566400); Pyrkosz-Pacyna, Joanna (57218692997); Rathje, Steve (57221697332); Raza, Ali (57548710100); Rêgo, Gabriel G. (56480308400); Rhee, Kasey (57432843500); Robertson, Claire E. (57215603258); Rodríguez-Pascual, Iván (55851219500); Saikkonen, Teemu (55045848200); Salvador-Ginez, Octavio (57433130800); Sampaio, Waldir M. (57200417301); Santi, Gaia C. (57217289456); Santiago-Tovar, Natalia (57433857400); Savage, David (35773679000); Scheffer, Julian A. (57191989558); Schönegger, Philipp (57223426293); Schultner, David T. (57222164240); Schutte, Enid M. (7003944275); Scott, Andy (57219874700); Sharma, Madhavi (57433566500); Sharma, Pujan (57433712200); Skali, Ahmed (56716506400); Stadelmann, David (25634677900); Stafford, Clara Alexandra (57208079952); Stanojević, Dragan (55252365500); Stefaniak, Anna (57103128900); Sternisko, Anni (57197832704); Stoica, Augustin (6603591272); Stoyanova, Kristina K. (57219964963); Strickland, Brent (49962193300); Sundvall, Jukka (57202986641); Thomas, Jeffrey P. (57432844400); Tinghög, Gustav (25224071700); Torgler, Benno (55897871400); Traast, Iris J. (57433567500); Tucciarelli, Raffaele (55901667000); Tyrala, Michael (57432992000); Ungson, Nick D. (57201349000); Uysal, Mete S. (57219744529); Van Lange, Paul A. M. (7004460194); van Prooijen, Jan-Willem (6602472447); van Rooy, Dirk (6603562161); Västfjäll, Daniel (6603904733); Verkoeijen, Peter (6603048790); Vieira, Joana B. (55899486000); von Sikorski, Christian (55543167600); Walker, Alexander Cameron (56735153200); Watermeyer, Jennifer (25824525800); Wetter, Erik (36460458400); Whillans, Ashley (55601702200); Willardt, Robin (57219439920); Wohl, Michael J. A. (7006650468); Wójcik, Adrian Dominik (35243826100); Wu, Kaidi (57196224019); Yamada, Yuki (55375527500); Yilmaz, Onurcan (56498563100); Yogeeswaran, Kumar (36344224800); Ziemer, Carolin-Theresa (57433567700); Zwaan, Rolf A. (7003515240); Boggio, Paulo S. (10340985700)","22986966200; 35765189600; 49361021300; 57200691996; 7004481879; 57196148151; 36762163600; 7201803113; 57202683756; 46060910600; 23666913300; 55347628400; 23567212800; 16314964400; 55948104400; 57205719637; 56221801500; 57193896526; 10039110600; 56669557400; 16065517700; 57432843300; 57196262755; 57219005068; 15051465700; 35094029100; 6701375451; 57211203812; 8929220900; 26531164900; 24168107200; 57728566100; 55172691400; 14008430600; 57196217992; 35743100000; 56256131200; 56743290300; 16744097100; 55209862600; 56566285000; 11839543000; 34668140100; 57432843400; 57210735692; 57210589547; 57189074265; 57201644809; 6603737492; 55734672700; 8690139600; 54684879600; 22986127600; 26647787400; 35761369500; 57209821598; 57210113671; 26026109100; 56610290700; 35778895000; 36601257300; 37102876500; 6507222236; 8612330500; 57189267860; 56121056100; 57433130100; 57201915022; 16425076400; 57201461738; 56605134100; 57433425600; 57367764100; 57433856600; 57433566000; 57433711700; 6603573634; 57218632714; 37017949200; 57432990200; 57433425700; 57194429267; 7005685014; 57433130200; 57433425900; 18133581400; 56333322000; 24175889200; 57226525097; 24175528900; 27567441600; 57192594944; 57219655063; 36551893200; 55972096100; 57216634436; 25722905400; 14629921400; 57206757068; 37088275700; 22933698400; 57188581373; 57408848700; 57034303800; 55934830400; 57203910287; 55078294200; 57433711900; 56189070000; 57432990300; 57433856800; 13612418500; 57221594660; 55151472900; 57219911935; 57433130400; 57201116811; 57193797236; 55973560500; 57433426100; 25923852000; 57302201900; 57433130500; 57432990400; 55233381300; 57433566200; 57202704216; 56341271400; 57211455566; 57194167162; 6603080729; 57202291651; 57218316315; 57433278100; 57433856900; 55866447200; 15520639300; 7201880907; 57196054646; 6504093196; 57433857000; 35866830500; 57215611020; 57433857100; 57196236805; 56844125900; 56545531900; 57200182087; 57195595285; 57222523239; 56574304400; 57433426300; 57433857200; 57218936367; 57188825958; 57204777214; 57205631416; 57204772241; 56480708400; 57432990500; 57217061682; 55584194600; 56327503700; 57216429407; 57202677751; 57217147507; 55899207500; 57216147889; 57204609951; 54890112800; 36859688300; 57433278200; 12645856800; 57408848800; 57433278300; 36240826900; 36552994500; 57195249015; 57225980689; 22135546300; 57433278400; 57193254318; 57209360893; 7005112071; 57433426400; 56593233200; 50462189600; 55946309500; 55177884100; 57191922458; 55383252800; 55918105000; 55936861100; 23397554100; 54896392800; 57433426600; 19337434700; 57433566400; 57218692997; 57221697332; 57548710100; 56480308400; 57432843500; 57215603258; 55851219500; 55045848200; 57433130800; 57200417301; 57217289456; 57433857400; 35773679000; 57191989558; 57223426293; 57222164240; 7003944275; 57219874700; 57433566500; 57433712200; 56716506400; 25634677900; 57208079952; 55252365500; 57103128900; 57197832704; 6603591272; 57219964963; 49962193300; 57202986641; 57432844400; 25224071700; 55897871400; 57433567500; 55901667000; 57432992000; 57201349000; 57219744529; 7004460194; 6602472447; 6603562161; 6603904733; 6603048790; 55899486000; 55543167600; 56735153200; 25824525800; 36460458400; 55601702200; 57219439920; 7006650468; 35243826100; 57196224019; 55375527500; 56498563100; 36344224800; 57433567700; 7003515240; 10340985700","National identity predicts public health support during a global pandemic","2022","Nature Communications","13","1","517","","","","182","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122654063&doi=10.1038%2fs41467-021-27668-9&partnerID=40&md5=dc0ee9ee38a5d0328574e8bf660d0599","Changing collective behaviour and supporting non-pharmaceutical interventions is an important component in mitigating virus transmission during a pandemic. In a large international collaboration (Study 1, N = 49,968 across 67 countries), we investigated self-reported factors associated with public health behaviours (e.g., spatial distancing and stricter hygiene) and endorsed public policy interventions (e.g., closing bars and restaurants) during the early stage of the COVID-19 pandemic (April-May 2020). Respondents who reported identifying more strongly with their nation consistently reported greater engagement in public health behaviours and support for public health policies. Results were similar for representative and non-representative national samples. Study 2 (N = 42 countries) conceptually replicated the central finding using aggregate indices of national identity (obtained using the World Values Survey) and a measure of actual behaviour change during the pandemic (obtained from Google mobility reports). Higher levels of national identification prior to the pandemic predicted lower mobility during the early stage of the pandemic (r = −0.40). We discuss the potential implications of links between national identity, leadership, and public health for managing COVID-19 and future pandemics. © 2022, The Author(s).","","COVID-19; Cross-Cultural Comparison; Health Behavior; Humans; Leadership; Pandemics; Public Health; SARS-CoV-2; Self Report; Social Conformity; Social Identification; COVID-19; disease transmission; global perspective; health policy; health survey; public health; Article; behavior; coronavirus disease 2019; health behavior; health care policy; human; hygiene; ideology; narcissism; national identity; pandemic; prediction; public health; virus transmission; cultural factor; epidemiology; leadership; legislation and jurisprudence; pandemic; prevention and control; psychology; public health; self report; social behavior; social psychology","Coronavirus Disease (COVID-19) Pandemic., (2021); Lewnard J.A., Lo N.C., Scientific and ethical basis for social-distancing interventions against COVID-19, Lancet, 20, pp. 631-633, (2020); WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19 - 30 July 2020, (2021); Biddlestone M., Green R., Douglas K., Cultural orientation, powerlessness, belief in conspiracy theories, and intentions to reduce the spread of COVID-19, Br. J. Soc. Psychol., 59, pp. 663-673, (2020); Haslam S.A., Reicher S.D., Platow M.J., The New Psychology of Leadership, (2011); Martinez-Brawley E., Gualda E., Transnational social implications of the use of the “war metaphor” concerning coronavirus: a birds’ eye view, Cult. e Stud. del. Soc., 5, pp. 259-272, (2020); Leach C.W., Et al., Group-level self-definition and self-investment: a hierarchical (multicomponent) model of in-group identification, J. Personal. Soc. Psychol., 95, pp. 144-165, (2008); Cameron J.E., A three-factor model of social identity, Self Identity, 3, pp. 239-262, (2004); Postmes T., Haslam S.A., Jans L., A single‐item measure of social identification: reliability, validity, and utility, Br. J. Soc. Psychol., 52, pp. 597-617, (2012); Tajfel H., Differentiation between Social Groups: Studies in the Social Psychology of Intergroup Relations, (1978); Brewer M.B., The psychology of prejudice: ingroup love and outgroup hate?, J. Soc. Issues, 55, pp. 429-444, (1999); Buchan N.R., Et al., Global social identity and global cooperation, Psychol. Sci., 22, pp. 821-828, (2011); De Cremer D., Van Vugt M., Social identification effects in social dilemmas: a transformation of motives, Eur. J. Soc. Psychol., 29, pp. 871-893, (1999); Ellemers N., Spears R., Doosje B., Social Identity: Context, (1999); Levine M., Prosser A., Evans D., Reicher S., Identity and emergency intervention: how social group membership and inclusiveness of group boundaries shape helping behaviour, Pers. Soc. Psychol. Bull., 31, pp. 443-453, (2005); Bilewicz M., Wojcik A., Does identification predict community involvement? Exploring consequences of social identification among the Jewish minority in Poland, J. Community Appl. Soc. Psychol., 20, pp. 72-79, (2010); Klandermans B., How group identification helps to overcome the dilemma of collective action, Am. Behav. Sci., 45, pp. 887-900, (2002); Van Zomeren M., Postmes T., Spears R., Toward an integrative social identity model of collective action: a quantitative research synthesis of three socio-psychological perspectives, Psychol. Bull., 134, pp. 504-535, (2008); Van Bavel J.J., Et al., Using social and behavioural science to support COVID-19 pandemic response, Nat. Hum. Behav., 4, pp. 460-471, (2020); Huddy L., Khatib N., American patriotism, national identity, and political involvement, Am. J. Pol. Sci., 51, pp. 63-77, (2007); Kalin M., Sambanis N., How to think about social identity, Ann. Rev. Polit. Sci., 21, pp. 239-257, (2018); Common identity and humanity, Together Apart: The Psychology of COVID-19, pp. 142-146, (2020); Bieber F., Global nationalism in times of the COVID-19 pandemic, Natl. Pap., pp. 1-13, (2020); Gkinopoulos T., Hegarty P., Commemoration in crisis: a discursive analysis of who ‘we’ and ‘they’ have been or become in ceremonial political speeches before and during the Greek financial downturn, Br. J. Soc. Psychol., 57, pp. 591-609, (2018); Gadarian S.K., Goodman S.W., Pepinsky T.B., Partisanship, health behaviour, and policy attitudes in the early stages of the COVID-19 pandemic, PLoS ONE, 16, (2020); Gollwitzer A., Et al., Partisan differences in spatial distancing predict infections and mortality, Nat. Hum. Behav., 4, pp. 1186-1197, (2020); Haslam S.A., Leadership, Together Apart: The Psychology of COVID-19, pp. 40-47, (2020); Haslam S.A., Reicher S., Stressing the group: social identity and the unfolding dynamics of responses to stress, J. Appl. Psychol., 91, pp. 1037-1052, (2006); Together Apart: The Psychology of COVID-19, (2020); Block P., Et al., Social network-based distancing strategies to flatten the COVID-19 curve in a post-lockdown world, Nat. Hum. Behav., 4, pp. 588-596, (2020); Ferguson N.M., Strategies for mitigating an influenza pandemic, Nature, 442, pp. 448-452, (2006); Koo J.R., Et al., Interventions to mitigate early spread of SARS-CoV-2, Lancet, 20, pp. 678-688, (2020); Liberal Nationalism and Its Critics: Normative and Empirical Questions, (2019); Kosterman R., Feshbach S., Toward a measure of patriotic and nationalistic attitudes, Polit. Psychol., 10, pp. 257-274, (1989); Roccas S., Klar Y., Liviatan I., The paradox of group-based guilt: modes of national identification, conflict vehemence, and reactions to the in-group’s moral violations, J. Personal. Soc. Psychol., 91, pp. 698-711, (2006); Golec de Zavala A., Cichocka A., Eidelson R., Jayawickreme N., Collective narcissism and its social consequences, J. Personal. Soc. Psychol., 97, pp. 1074-1096, (2009); Golec de Zavala A., Cichocka A., Iskra-Golec I., Collective narcissism moderates the effect of in-group image threat on intergroup hostility, J. Personal. Soc. Psychol., 104, pp. 1019-1039, (2013); Cichocka A., Understanding defensive and secure in-group positivity: the role of collective narcissism, Eur. Rev. Soc. Psychol., 27, pp. 283-317, (2016); Cislak A., Wojcik A.D., Cichocka A., Cutting the forest down to save your face: narcissistic national identification predicts support for anti-conservation policies, J. Environ. Psychol., 59, pp. 65-73, (2018); Marchlewska M., Cichocka A., Jaworska M., Golec de Zavala A., Bilewicz M., Superficial ingroup love? Collective narcissism predicts ingroup image defense, outgroup prejudice, and lower ingroup loyalty, Br. J. Soc. Psychol., 59, pp. 857-875, (2020); Cislak A., Cichocka A., Wojcik A., Milfont T., Words not deeds: national narcissism, national identification, and support for greenwashing versus genuine proenvironmental campaigns, J. Environ. Psychol., 74, (2021); Nowak B., Et al., Adaptive and maladaptive behaviour during the COVID-19 pandemic: the roles of dark triad traits, collective narcissism, and health beliefs, Pers. Individ. Differ., 167, (2020); Lincoln M., Study the role of hubris in nations’ COVID-19 response, Nature, 585, (2020); Van der Toorn J., Nail P.R., Liviatan I., Jost J.T., My country, right or wrong: does activating system justification motivation eliminate the liberal-conservative gap in patriotism?, J. Exp. Soc. Psychol., 54, pp. 50-60, (2014); Cichocka A., Marchlewska M., Golec de Zavala A., Olechowski M., ‘They will not control us’: in-group positivity and belief in intergroup conspiracies, Br. J. Soc. Psychol., 107, pp. 556-576, (2016); Marchlewska M., Cichocka A., Panayiotou O., Castellanos K., Batayneh J., Populism as identity politics: perceived in-group disadvantage, collective narcissism, and support for populism, Soc. Psychol. Pers. Sci., 9, pp. 151-162, (2018); Calvillo D.P., Ross B.J., Garcia R.J.B., Smelter T.J., Rutchick A.M., Political ideology predicts perceptions of the threat of COVID-19 (and susceptibility to fake news about it), Soc. Psychol. Pers. Sci., 11, pp. 1119-1128, (2020); Capraro V., Barcelo H., The effect of messaging and gender on intentions to wear a face covering to slow down COVID-19 transmission, J. Behav. Econ. Pol., 4, pp. 45-55, (2020); The best-case heuristic: Relative optimism in a global health pandemic, Pre-Print At, (2021); Choma B.L., Hodson G., Sumantry D., Hanoch Y., Gummerum M., Ideological and psychological predictors of COVID-19-related collective action, opinions, and health compliance across three nations, J. Soc. Political Psychol., 9, pp. 123-143, (2021); Nezlek J.B., Cross-Cultural Research Methods in Psychology, pp. 299-347, (2010); Haerpfer C., Et al., World Values Survey: Round Seven – Country-Pooled Datafile (JD Systems Institute & WVSA Secretariat, (2020); Google, COVID-19 Community Mobility Reports, (2020); Milgram S., Behavioural study of obedience, J. Abnorm. Soc. Psychol., 67, pp. 371-378, (1963); Asch S.E., Studies of independence and conformity: I. a minority of one against a unanimous majority, Psychological Monogr.Gen. Appl., 70, pp. 1-70, (1956); Jetten J., Haslam C., Haslam S.A., The Social Cure, (2011); Kachanoff F.J., Bigman Y.E., Kapsaskis K., Gray K., Measuring realistic and symbolic threats of COVID-19 and their unique impacts on well-being and adherence to public health behaviours, Soc. Psychol. Personal. Sci., 12, pp. 603-616, (2020); Allcott H., Et al., Polarization and public health: partisan differences in social distancing during the coronavirus pandemic, J. Public Econ., 191, (2020); Ponce D., The impact of coronavirus in Brazil: politics and the pandemic, Nat. Rev. Nephrol., 16, (2020); Cichocka A., Cislak A., Nationalism as collective narcissism, Curr. Opin. Behav. Sci., 34, pp. 69-74, (2020); Merkley E., Et al., A rare moment of cross-partisan consensus: elite and public responses to the COVID-19 pandemic in Canada, Can. J. Polit. Sci., 53, pp. 311-318, (2020); Gaertner S., In the Social Developmental Construction of Violence and Intergroup Conflict, pp. 105-120, (2016); Harari Y.N., The World after Coronavirus, (2020); Gorska P., Et al., Too great to act in solidarity: the negative relationship between collective narcissism and solidarity‐based collective action, Eur. J. Soc. Psychol., 50, pp. 561-578, (2020); Liu J.H., Et al., Empirical correlates of cosmopolitan orientation: etiology and functions in a worldwide representative sample, Polit. Psychol., 41, pp. 661-678, (2020); Henrich J., Heine S.J., Norenzayan A., The weirdest people in the world?, Behav. Brain Sci., 33, pp. 61-83, (2010); Op-Ed: How to Convince Republicans to Get Vaccinated., (2021); Jost J.T., The end of the end of ideology, Am. Psychol., 61, pp. 651-670, (2006); United Nations Human Development Programme, Human Development Report, (2019); Dong E., Du H., Gardner L., An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis., 20, pp. 533-534, (2020); Raudenbush S.W., Bryk A.S., Cheong Y.F., Congdon R.T., du Toit M.H.L.M., 7: Linear and Nonlinear Modeling, (2011); Nezlek J.B., A practical guide to understanding reliability in studies of within-person variability, J. Res. Personal., 69, pp. 149-155, (2017); Raudenbush S.W., Bryk A.S., Hierarchical Linear Models: Applications and Data Analysis Methods (2Nd Ed.) (Sage Publications, (2002); Shrout P.E., Measurement reliability and agreement in psychiatry, Stat. Methods Med. Res., 7, pp. 301-317, (1998); Muthen L.K., Muthen B., 0. Mplus User’s Guide (8Th Ed.) (Muthén &, (2017); Human Development Index (HDI), (2020)","2-s2.0-85122654063"
"Boccardi M.; Monsch A.U.; Ferrari C.; Altomare D.; Berres M.; Bos I.; Buchmann A.; Cerami C.; Didic M.; Festari C.; Nicolosi V.; Sacco L.; Aerts L.; Albanese E.; Annoni J.-M.; Ballhausen N.; Chicherio C.; Démonet J.-F.; Descloux V.; Diener S.; Ferreira D.; Georges J.; Gietl A.; Girtler N.; Kilimann I.; Klöppel S.; Kustyniuk N.; Mecocci P.; Mella N.; Pigliautile M.; Seeher K.; Shirk S.D.; Toraldo A.; Brioschi-Guevara A.; Chan K.C.G.; Crane P.K.; Dodich A.; Grazia A.; Kochan N.A.; de Oliveira F.F.; Nobili F.; Kukull W.; Peters O.; Ramakers I.; Sachdev P.S.; Teipel S.; Visser P.J.; Wagner M.; Weintraub S.; Westman E.; Froelich L.; Brodaty H.; Dubois B.; Cappa S.F.; Salmon D.; Winblad B.; Frisoni G.B.; Kliegel M.","Boccardi, Marina (6507801629); Monsch, Andreas U. (7003427149); Ferrari, Clarissa (57866310100); Altomare, Daniele (57191225963); Berres, Manfred (6602588903); Bos, Isabelle (57194101601); Buchmann, Andreas (15043794200); Cerami, Chiara (25722905400); Didic, Mira (55946471200); Festari, Cristina (57194078503); Nicolosi, Valentina (57210908614); Sacco, Leonardo (6701668924); Aerts, Liesbeth (57508672700); Albanese, Emiliano (22133359100); Annoni, Jean-Marie (7004285983); Ballhausen, Nicola (56073131900); Chicherio, Christian (8435082800); Démonet, Jean-François (7005727609); Descloux, Virginie (40261285400); Diener, Suzie (57200381581); Ferreira, Daniel (55356608800); Georges, Jean (7102484391); Gietl, Anton (6506638926); Girtler, Nicola (6602982284); Kilimann, Ingo (55129257000); Klöppel, Stefan (23100462800); Kustyniuk, Nicole (57223367243); Mecocci, Patrizia (7006313835); Mella, Nathalie (23398111200); Pigliautile, Martina (36646755800); Seeher, Katrin (34067802300); Shirk, Steven D. (54780582200); Toraldo, Alessio (6603569410); Brioschi-Guevara, Andrea (57188953849); Chan, Kwun C. G. (55477596700); Crane, Paul K. (57202041242); Dodich, Alessandra (56001713900); Grazia, Alice (57223357783); Kochan, Nicole A (6507145158); de Oliveira, Fabricio Ferreira (57222416869); Nobili, Flavio (57206948479); Kukull, Walter (57218928260); Peters, Oliver (57204202580); Ramakers, Inez (23475540400); Sachdev, Perminder S. (7102284091); Teipel, Stefan (7004435774); Visser, Pieter Jelle (7101761148); Wagner, Michael (57211900353); Weintraub, Sandra (7102082264); Westman, Eric (35070775000); Froelich, Lutz (56820309600); Brodaty, Henry (7005329283); Dubois, Bruno (7101841106); Cappa, Stefano F. (7005836132); Salmon, David (7202423155); Winblad, Bengt (36048831500); Frisoni, Giovanni B. (56214208300); Kliegel, Matthias (6603740686)","6507801629; 7003427149; 57866310100; 57191225963; 6602588903; 57194101601; 15043794200; 25722905400; 55946471200; 57194078503; 57210908614; 6701668924; 57508672700; 22133359100; 7004285983; 56073131900; 8435082800; 7005727609; 40261285400; 57200381581; 55356608800; 7102484391; 6506638926; 6602982284; 55129257000; 23100462800; 57223367243; 7006313835; 23398111200; 36646755800; 34067802300; 54780582200; 6603569410; 57188953849; 55477596700; 57202041242; 56001713900; 57223357783; 6507145158; 57222416869; 57206948479; 57218928260; 57204202580; 23475540400; 7102284091; 7004435774; 7101761148; 57211900353; 7102082264; 35070775000; 56820309600; 7005329283; 7101841106; 7005836132; 7202423155; 36048831500; 56214208300; 6603740686","Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe","2022","Alzheimer's and Dementia","18","1","","29","42","13","20","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105700631&doi=10.1002%2falz.12365&partnerID=40&md5=a2bc891cab7d3aa8f79f82cc4cca4f19","Introduction: Harmonized neuropsychological assessment for neurocognitive disorders, an international priority for valid and reliable diagnostic procedures, has been achieved only in specific countries or research contexts. Methods: To harmonize the assessment of mild cognitive impairment in Europe, a workshop (Geneva, May 2018) convened stakeholders, methodologists, academic, and non-academic clinicians and experts from European, US, and Australian harmonization initiatives. Results: With formal presentations and thematic working-groups we defined a standard battery consistent with the U.S. Uniform DataSet, version 3, and homogeneous methodology to obtain consistent normative data across tests and languages. Adaptations consist of including two tests specific to typical Alzheimer's disease and behavioral variant frontotemporal dementia. The methodology for harmonized normative data includes consensus definition of cognitively normal controls, classification of confounding factors (age, sex, and education), and calculation of minimum sample sizes. Discussion: This expert consensus allows harmonizing the diagnosis of neurocognitive disorders across European countries and possibly beyond. © 2021 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association","Alzheimer's disease; cognitive assessment; diagnosis; mild cognitive impairment; mild neurocognitive disorders; standard neuropsychological assessment","Age Factors; Cognition; Cognitive Dysfunction; Consensus Development Conferences as Topic; Datasets as Topic; Educational Status; Europe; Expert Testimony; Humans; Language; Neuropsychological Tests; Sex Factors; adaptation; Alzheimer disease; Article; Australian; calculation; clinician; consensus; disorders of higher cerebral function; educational status; Europe; European; frontal variant frontotemporal dementia; human; language; medical expert; mild cognitive impairment; neuropsychological test; United States; workshop; age; classification; cognition; cognitive defect; consensus development; expert witness; information processing; neuropsychological test; sex factor","Diagnostic and Statistical Manual of Mental Disorders. 5th, (2013); Albert M.S., DeKosky S.T., Dickson D., Et al., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, 3, pp. 270-279, (2011); Cerami C., Dubois B., Boccardi M., Monsch A.U., Demonet J.F., Cappa S.F., Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework, Neurobiol Aging, 52, pp. 153-166, (2017); Frisoni G.B., Boccardi M., Barkhof F., Et al., Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers, Lancet Neurol, 16, 8, pp. 661-676, (2017); Gibbons L.E., Carle A.C., Mackin R.S., Et al., A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment, Brain Imaging Behav, 6, 4, pp. 517-527, (2012); Mukherjee S., Mez J., Trittschuh E.H., Et al., Genetic data and cognitively defined late-onset Alzheimer's disease subgroups, Mol Psychiatry, (2018); Weintraub S., Besser L., Dodge H.H., Et al., Version 3 of the Alzheimer Disease Centers' Neuropsychological Test Battery in the Uniform Data Set (UDS), 32, 1, pp. 10-17, (2018); Wang H., Fan Z., Shi C., Et al., Consensus statement on the neurocognitive outcomes for early detection of mild cognitive impairment and Alzheimer dementia from the Chinese Neuropsychological Normative (CN-NORM) Project, J Glob Health, 9, 2, (2019); Boccardi M., Gallo V., Yasui Y., Et al., The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology, Neurobiol Aging, 52, pp. 141-152, (2017); Jennen-Steinmetz C., Wellek S., A new approach to sample size calculation for reference interval studies, Stat Med, 24, 20, pp. 3199-3212, (2005); Shirk S.D., Mitchell M.B., Shaughnessy L.W., Et al., A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery. Alzheimer's, Research Therapy, 3, 6, (2011); Grober E., Buschke H., Genuine memory deficits in dementia, Dev Neuropsychol, 3, 1, pp. 13-36, (1987); Dodich A., Cerami C., Cappa S.F., Et al., Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: in Search of Neuropsychological Markers, J Alzheimers Dis, 61, 2, pp. 761-772, (2018); Buschke H., Cued recall in amnesia, J Clin Neuropsychol, 6, 4, pp. 433-440, (1984); Rami L., Sole-Padulles C., Fortea J., Et al., Applying the new research diagnostic criteria: mRI findings and neuropsychological correlations of prodromal AD, Int J Geriatr Psychiatry, 27, 2, pp. 127-134, (2012); Derby C.A., Burns L.C., Wang C., Et al., Screening for predementia AD: time-dependent operating characteristics of episodic memory tests, Neurology, 80, 14, pp. 1307-1314, (2013); Wagner M., Wolf S., Reischies F.M., Et al., Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease, Neurology, 78, 6, pp. 379-386, (2012); Sarazin M., Chauvire V., Gerardin E., Et al., The amnestic syndrome of hippocampal type in Alzheimer's disease: an MRI study, J Alzheimers Dis, 22, 1, pp. 285-294, (2010); Sarazin M., Berr C., Rotrou J., Et al., Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study, Neurology, 69, 19, pp. 1859-1867, (2007); Grande G., Vanacore N., Vetrano D.L., Et al., Free and cued selective reminding test predicts progression to Alzheimer's disease in people with mild cognitive impairment, Neurol Sci, 39, 11, pp. 1867-1875, (2018); Small B.J., Rosnick C.B., Fratiglioni L., Backman L., Apolipoprotein E and cognitive performance: a meta-analysis, Psychol Aging, 19, 4, pp. 592-600, (2004); Teichmann M., Epelbaum S., Samri D., Et al., Free and Cued Selective Reminding Test - accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: a large-scale biomarker-characterized monocenter cohort study (ClinAD), Alzheimers Dement, 13, 8, pp. 913-923, (2017); Zimmerman M.E., Katz M.J., Wang C., Et al., Comparison of “Word” vs. “Picture” Version of the Free and Cued Selective Reminding Test (FCSRT) in Older Adults, Alzheimer's & Dementia (Amsterdam, Netherlands), 1, 1, pp. 94-100, (2015); Delgado C., Munoz-Neira C., Soto A., Et al., Comparison of the Psychometric Properties of the “Word” and “Picture” Versions of the Free and Cued Selective Reminding Test in a Spanish-Speaking Cohort of Patients with Mild Alzheimer's Disease and Cognitively Healthy Controls, Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists, 31, 2, pp. 165-175, (2016); Bertoux M., Funkiewiez A., O'Callaghan C., Dubois B., Hornberger M., Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia, Alzheimers Dement, 9, 5, pp. 84-94, (2013); Caminiti S.P., Canessa N., Cerami C., Et al., Affective mentalizing and brain activity at rest in the behavioral variant of frontotemporal dementia, NeuroImage Clinical, 9, pp. 484-497, (2015); Strauss E., Sherman E., Spreen O., A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary, (2006); Wolf E.J., Kelly M., Harrington K.M., Clark S.L., Miller M.W., Sample Size Requirements for Structural Equation Models: an Evaluation of Power, Bias, and Solution Propriety, Educ Psychol Meas, 76, 6, pp. 913-934, (2013); Muthen L.K., Muthen B.O., How To Use A Monte Carlo Study To Decide On Sample Size and Determine Power, Structural Equation Modeling: A Multidisciplinary Journal, 9, 4, pp. 599-620, (2002); Myers N.D., Ahn S., Jin Y., Sample Size and Power Estimates for a Confirmatory Factor Analytic Model in Exercise and Sport: a Monte Carlo Approach, Res Q Exerc Sport, 82, 3, pp. 412-423, (2011); Morris J.C., Weintraub S., Chui H.C., Et al., The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers, Alzheimer Dis Assoc Disord, 20, 4, pp. 210-216, (2006); Nieuwenhuis-Mark R.E., The death knoll for the MMSE: has it outlived its purpose?, J Geriatr Psychiatry Neurol, 23, 3, pp. 151-157, (2010); Beck I.R., Gagneux-Zurbriggen A., Berres M., Taylor K.I., Monsch A.U., Comparison of verbal episodic memory measures: consortium to establish a registry for Alzheimer's disease–Neuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT), Archives of Clinical Neuropsychology: The Official Journal of the National Academy of Neuropsychologists, 27, 5, pp. 510-519, (2012); Sala I., Illan-Gala I., Alcolea D., Et al., Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease, Journal of Alzheimer's disease: JAD, 58, 3, pp. 909-918, (2017); Buschke H., Mowrey W.B., Ramratan W.S., Et al., Memory Binding Test Distinguishes Amnestic Mild Cognitive Impairment and Dementia from Cognitively Normal Elderly, Arch Clin Neuropsychol, 32, 8, pp. 1037-1038, (2017); Ritchie K., Ropacki M., Albala B., Et al., Recommended cognitive outcomes in preclinical Alzheimer's disease: consensus statement from the European Prevention of Alzheimer's Dementia project, Alzheimers Dement, 13, 2, pp. 186-195, (2017); Donohue M.C., Sperling R.A., Salmon D.P., Et al., The preclinical Alzheimer cognitive composite: measuring amyloid-related decline, JAMA Neurol, 71, 8, pp. 961-970, (2014); Burnham S.C., Coloma P.M., Li Q.-X., Et al., Application of the NIA-AA Research Framework: towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study, J Prev Alzheimers Dis, 6, 4, pp. 248-255, (2019); Lim Y.Y., Snyder P.J., Pietrzak R.H., Et al., Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score, Alzheimers Dement (Amst), 2, pp. 19-26, (2016); Papp K.V., Rentz D.M., Orlovsky I., Sperling R.A., Mormino E.C., Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: the PACC5, Alzheimer's & dementia (New York, N Y), 3, 4, pp. 668-677, (2017); Bahar-Fuchs A., Martyr A., Goh A.M., Sabates J., Clare L., Cognitive training for people with mild to moderate dementia, Cochrane Database Syst Rev, 3, (2019)","2-s2.0-85105700631"
"Cerami C.; Perani D.","Cerami, Chiara (25722905400); Perani, Daniela (7005630261)","25722905400; 7005630261","Imaging neuroinflammation in ischemic stroke and in the atherosclerotic vascular disease","2015","Current Vascular Pharmacology","13","2","","218","222","4","16","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929722038&doi=10.2174%2f15701611113116660168&partnerID=40&md5=5e86a4cf0d532ead2fb1a30105cf9541","Neuroinflammation is a complex biological response to any injury occurring to the central nervous system. It is mainly characterized by the recruitment of immune system cells, namely the microglial cells, in the site of injury. Once activated, microglia expresses a cholesterol transporter protein (TSPO), previously also known as peripheral type benzodiazepine receptor. PK11195 is a ligand for TSPO and, labelled with a positron emitter, it is also the most used tracer for PET molecular imaging to in vivo map the microglia activation in various neurological disorders, including ischemic stroke. Recent [11C]PK11195 PET studies proved activated microglia both locally in the area of the infarct and at distance along the affected fibre tracts, suggesting the presence of two different microglia subtypes with peculiar functions in disease progression. The aim of this review is to discuss the most recent knowledge about imaging neuroinflammation in ischemic stroke and in the atherosclerotic and vascular inflammatory disorders, trying to elucidate the interplay between the clinical course and the activation of a microglial response. © 2015 Bentham Science Publishers","Activated microglia; Ischemic stroke; Neuroinflammation; PET imaging; [<sup>11</sup>C]PK11195","Amides; Animals; Atherosclerosis; Brain; Brain Ischemia; Humans; Inflammation; Isoquinolines; Microglia; Positron-Emission Tomography; Predictive Value of Tests; Prognosis; Radionuclide Angiography; Radiopharmaceuticals; Risk Factors; Stroke; (R)-(11C)1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; amide; isoquinoline derivative; radiopharmaceutical agent; Article; brain ischemia; cerebrovascular accident; coronary artery atherosclerosis; disease course; human; immune system; inflammation; microglia; nervous system inflammation; positron emission tomography; receptor upregulation; animal; atherosclerosis; brain; brain ischemia; positron emission tomography; predictive value; procedures; prognosis; radionuclide ventriculography; risk factor; scintiscanning","Medzhitov R., Origin and physiological roles of inflammation, Nature, 454, pp. 428-435, (2008); Davalos D., Grutzendler J., Yang G., Et al., ATP mediates rapid microglial response to local brain injury in vivo, Nat Neurosci, 8, pp. 752-758, (2005); Jacobs A.H., Tavitian B., INMiND consortium. Noninvasive molecular imaging of neuroinflammation, J Cereb Blood Flow Metab, 32, pp. 1393-1415, (2012); Rivest S., Regulation of innate immune responses in the brain, Nat Rev Immunol, 9, pp. 429-439, (2009); Czeh M., Gressens P., Kaindl A.M., The yin and yang of microglia, Dev Neurosci, 33, pp. 199-209, (2011); Lloyd-Jones D., Adams R., Carnethon M., Et al., Heart disease and stroke statistics—2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 119, pp. 480-486, (2009); Yong V.W., Rivest S., Taking advantage of the systemic immune system to cure brain diseases, Neuron, 64, pp. 55-60, (2009); Perry V.H., Nicoll J.A., Holmes C., Microglia in neurodegenerative disease, Nat Rev Neurol, 6, pp. 193-201, (2010); Dirnagl U., Iadecola C., Moskowitz M.A., Pathobiology of ischemic stroke: An integrated view, Trends Neurosci, 22, pp. 391-397, (1999); Macrez R., Ali C., Toutirais O., Et al., Stroke and the immune system: From pathophysiology to new therapeutic strategies, Lancet Neurol, 10, pp. 471-480, (2011); Rupprecht R., Papadopoulos V., Rammes G., Et al., Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders, Nat Rev Drug Discov, 9, pp. 971-988, (2010); Chauveau F., Boutin H., Van Camp N., Dolle F., Tavitian B., Nuclear imaging of neuroinflammation: A comprehensive review of [11C]PK11195 challengers, Eur J Nucl Med Mol Imaging, 35, pp. 2304-2319, (2008); Ikoma Y., Yasuno F., Ito H., Et al., Quantitative analysis for estimating binding potential of the peripheral benzodiazepine receptor with [(11)C]DAA1106, J Cereb Blood Flow Metab, 27, pp. 173-184, (2007); Fujimura Y., Ikoma Y., Yasuno F., Et al., Quantitative analyses of 18F-FEDAA1106 binding to peripheral benzodiazepine receptors in living human brain, J Nucl Med, 47, pp. 43-50, (2006); Takano A., Gulyas B., Varrone A., Et al., Biodistribution and radiation dosimetry of the 18 kDa translocator protein (TSPO) radioligand [(18)F]FEDAA1106: A human whole-body PET study, Eur J Nucl Med Mol Imaging, 38, pp. 2058-2065, (2011); Imaizumi M., Kim H.J., Zoghbi S.S., Et al., PET imaging with [11C]PBR28 can localize and quantify upregulated peripheral benzodiazepine receptors associated with cerebral ischemia in rat, Neurosci Lett, 411, pp. 200-205, (2007); Fujita M., Imaizumi M., Zoghbi S.S., Et al., Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation, Neuroimage, 40, pp. 43-52, (2008); Ramlackhansingh A.F., Brooks D.J., Greenwood R.J., Et al., Inflammation after trauma: Microglial activation and traumatic brain injury, Ann Neurol, 70, pp. 374-383, (2011); Cagnin A., Brooks D.J., Kennedy A.M., Et al., In-vivo, Lancet, 358, pp. 461-467, (2001); Iannaccone S., Cerami C., Alessio M., Et al., In vivo, Parkinsonism Relat Disord, 19, pp. 47-52, (2013); Pappata S., Levasseur M., Gunn R.N., Et al., Thalamic microglial activation in ischemic stroke detected in vivo by PET and [11C]PK1195, Neurology, 55, pp. 1052-1054, (2000); Gerhard A., Neumaier B., Elitok E., Et al., In vivo, Neuroreport, 11, pp. 2957-2960, (2000); Gerhard A., Schwarz J., Myers R., Et al., Evolution of microglial activation in patients after ischemic stroke: A [11C](R)-PK11195 PET study, Neuroimage, 24, pp. 591-595, (2005); Price C.J., Wang D., Menon D.K., Et al., Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke, Stroke, 37, pp. 1749-1753, (2006); Radlinska B.A., Ghinani S.A., Lyon P., Et al., Multimodal microglia imaging of fibre tracts in acute subcortical stroke, Ann Neurol, 66, pp. 825-832, (2009); Thiel A., Radlinska B.A., Paquette C., Et al., The temporal dynamics of poststroke neuroinflammation: A longitudinal diffusion tensor imaging-guided PET study with 11C-PK11195 in acute subcortical stroke, J Nucl Med, 51, pp. 1404-1412, (2010); Schroeter M., Jander S., Witte O.W., Stoll G., Heterogeneity of the microglial response in photochemically induced focal ischemia of the rat cerebral cortex, Neuroscience, 89, pp. 1367-1377, (1999); Schmitt A.B., Brook G.A., Buss A., Nacimiento W., Noth J., Kreutzberg G.W., Dynamics of microglial activation in the spinal cord after cerebral infarction are revealed by expression of MHC class II antigen, Neuropathol Appl Neurobiol, 24, pp. 167-176, (1998); Lee M.Y., Kuan Y.H., Chen H.Y., Et al., Intravenous administration of melatonin reduces the intracerebral cellular inflammatory response following transient focal cerebral ischemia in rats, J Pineal Res, 42, pp. 297-309, (2007); Streit W.J., Microglial response to brain injury: A brief synopsis, Toxicol Pathol, 28, pp. 28-30, (2000); Gulyas B., Toth M., Schain M., Et al., Evolution of microglial activation in ischemic core and peri-infarct regions after stroke: A PET study with the TSPO molecular imaging biomarker [((11))C]vinpocetine, J Neurol Sci, 320, pp. 110-117, (2012); Van Der Wal A.C., Becker A.E., Van Der Loos C.M., Das P.K., Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology, Circulation, 89, pp. 36-44, (1994); Peeters W., Hellings W.E., De Kleijn D.P., Et al., Carotid atherosclerotic plaques stabilize after stroke: Insights into the natural process of atherosclerotic plaque stabilization, Arterioscler Thromb Vasc Biol, 29, pp. 128-133, (2009); Sanz J., Fayad Z.A., Imaging of atherosclerotic cardiovascular disease, Nature, 451, pp. 953-957, (2008); Thiel A., Heiss W.D., Imaging of microglia activation in stroke, Stroke, 42, pp. 507-512, (2011); Camici P.G., Rimoldi O.E., Gaemperli O., Libby P., Non-invasive anatomic and functional imaging of vascular inflammation and unstable plaque, Eur Heart J, 33, pp. 1309-1317, (2012); Pugliese F., Gaemperli O., Kinderlerer A.R., Et al., Imaging of vascular inflammation with [11C]-PK11195 and PET/CT angiography, J am Coll Cardiol, 56, pp. 653-661, (2010); Lamare F., Hinz R., Gaemperli O., Et al., Detection and quantification of large vessel inflammation with [11C]-(R)-PK11195 PET/CT, J Nucl Med, 52, pp. 33-39, (2011); Gaemperli O., Shalhoub J., Owen D.R., Et al., Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography, Eur Heart J, 33, pp. 1902-1910, (2012); Drake C., Boutin H., Jones M.S., Et al., Brain inflammation is induced by co-morbidities and risk factors for stroke, Brain Behav Immun, 25, pp. 1113-1122, (2011); Gunn R.N., Gunn S.R., Cunningham V.J., Positron emission tomography compartmental models, J Cereb Blood Flow Metab, 21, pp. 635-652, (2001); Turkheimer F.E., Edison P., Pavese N., Et al., Reference and target region modeling of [11C]-(R)-PK11195 brain studies, J Nucl Med, 48, pp. 158-167, (2007); Yaqub M., Van Berckel B.N., Schuitemaker A., Et al., Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies, J Cereb Blood Flow Metab, 32, pp. 1600-1608, (2012); Dodel R., Spottke A., Gerhard A., Et al., Minocycline 1-year therapy in multiple-system-atrophy: Effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial), Mov Disord, 25, pp. 97-107, (2010); Jordan J., Segura T., Brea D., Et al., Inflammation as therapeutic objective in stroke, Curr Pharm Des, 14, pp. 3549-3564, (2008)","2-s2.0-84929722038"
"Crespi C.; Santi G.C.; Dodich A.; Lupo F.; Greco L.C.; Piccoli T.; Lunetta C.; Cerami C.","Crespi, Chiara (57034303800); Santi, Gaia Chiara (57217289456); Dodich, Alessandra (56001713900); Lupo, Federica (57522139700); Greco, Lucia Catherine (57196094606); Piccoli, Tommaso (6505971622); Lunetta, Christian (7801365932); Cerami, Chiara (25722905400)","57034303800; 57217289456; 56001713900; 57522139700; 57196094606; 6505971622; 7801365932; 25722905400","Unraveling Moral Reasoning in Amyotrophic Lateral Sclerosis: How Emotional Detachment Modifies Moral Judgment","2020","Frontiers in Psychology","11","","2083","","","","2","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85090287281&doi=10.3389%2ffpsyg.2020.02083&partnerID=40&md5=9d6e85925c1293f1ab566d7e17f6f918","In the last decade, scientific literature provided solid evidence of cognitive deficits in amyotrophic lateral sclerosis (ALS) patients and their effects on end-life choices. However, moral cognition and judgment are still poorly investigated in this population. Here we aimed at evaluating both socio-cognitive and socio-affective components of moral reasoning in a sample of 28 ALS patients. Patients underwent clinical and neuropsychological evaluation including basic cognitive and social cognition measures. Additionally, we administered an experimental task including moral dilemmas, with instrumental and incidental conditions. Patients’ performances were compared with a control group [healthy control (HC)], including 36 age-, gender-, and education-matched healthy subjects. Despite that the judgment pattern was comparable in ALS and HC, patients resulted less prone to carry out a moral transgression compared to HC. Additionally, ALS patients displayed higher levels of moral permissibility and lower emotional arousal, with similar levels of engagement in both instrumental and incidental conditions. Our findings expanded the current literature about cognitive deficits in ALS, showing that in judging moral actions, patients may present non-utilitarian choices and emotion flattening. Such a decision-making profile may have relevant implications in applying moral principles in real-life situations and for the judgment of end-of-life treatments and care in clinical settings. © Copyright © 2020 Crespi, Santi, Dodich, Lupo, Greco, Piccoli, Lunetta and Cerami.","amyotrophic lateral sclerosis; emotion detachment; moral cognition; moral judgment; social cognition","","Alberici A., Geroldi C., Cotelli M., Adorni A., Calabria M., Rossi G., Et al., The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer’s disease, Neurol. Sci, 28, pp. 80-86, (2007); Beeldman E., Raaphorst J., Klein Twennaar M., de Visser M., Schmand B.A., de Haan R.J., The cognitive profile of ALS: a systematic review and meta-analysis update, J. Neurol. Neurosurg. Psychiatry, 87, pp. 611-619, (2016); Blanca M., Alarcon R., Arnau J., Bono R., Bendayan R., Non-normal data: is ANOVA still a valid option?, Psicothema, 29, pp. 552-557, (2017); Bohm S., Aho-Ozhan H.E.A., Keller J., Dorst J., Uttner I., Ludolph A.C., Et al., Medical decisions are independent of cognitive impairment in amyotrophic lateral sclerosis, Neurology, 87, pp. 1737-1738, (2016); Bretz S., Sun R., Two models of moral judgment, Cogn. Sci, 42, pp. 4-37, (2018); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph. Lateral Scler. Other Motor Neuron Disord, 1, pp. 293-299, (2000); Bzdok D., Schilbach L., Vogeley K., Schneider K., Laird A.R., Langner R., Et al., Parsing the neural correlates of moral cognition: ALE meta-analysis on morality, theory of mind, and empathy, Brain Struct. Funct, 217, pp. 783-796, (2012); Cavallo M., Adenzato M., MacPherson S.E., Karwig G., Enrici I., Abrahams S., Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis, PLoS One, 6, e25948, (2011); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Et al., Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study, Amyotroph. Lateral Scler. Frontotemporal Degener, 15, pp. 21-29, (2014); Consonni M., Iannaccone S., Cerami C., Frasson P., Lacerenza M., Lunetta C., Et al., The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria, Behav. Neurol, 27, pp. 143-153, (2013); Crespi C., Cerami C., Dodich A., Canessa N., Arpone M., Iannaccone S., Et al., Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis, Cortex, 53, pp. 1-8, (2014); Crespi C., Cerami C., Dodich A., Canessa N., Iannaccone S., Corbo M., Et al., Microstructural correlates of emotional attribution impairment in non-demented patients with amyotrophic lateral sclerosis, PLoS One, 11, e0161034, (2016); Diniz B.S., Yassuda M.S., Nunes P.V., Radanovic M., Forlenza O.V., Mini-mental state examination performance in mild cognitive impairment subtypes, Int. Psychogeriatr, 19, pp. 647-656, (2007); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol. Sci, 36, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: a normative study of the Ekman 60-Faces Test in the Italian population, Neurol. Sci, 35, pp. 1015-1021, (2014); Duchesne S., Caroli A., Geroldi C., Frisoni G.B., Collins D.L., Predicting clinical variable from MRI features: application to MMSE in MCI, International Conference on Medical Image Computing and Computer-Assisted Intervention, pp. 392-399, (2005); Folstein M.F., Folstein S.E., McHug H.P.R., Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res, 12, pp. 189-198, (1975); Gibbons Z.C., Snowden J.S., Thompson J.C., Happe F., Richardson A., Neary D., Inferring thought and action in motor neurone disease, Neuropsychologia, 45, pp. 1196-1207, (2007); Girardi A., MacPherson S.E., Abrahams S., Deficits in emotional and social cognition in amyotrophic lateral sclerosis, Neuropsychology, 25, pp. 53-65, (2011); Gleichgerrcht E., Torralva T., Roca M., Pose M., Manes F., The role of social cognition in moral judgment in frontotemporal dementia, Soc. Neurosci, 6, pp. 113-122, (2011); Haidt J., The emotional dog and its rational tail: a social intuitionist approach to moral judgment, Psychol. Rev, 108, pp. 814-834, (2001); Hardiman O., Al-Chalabi A., Chio A., Corr E.M., Logroscino G., Robberecht W., Et al., Amyotrophic lateral sclerosis, Nat. Rev. Dis. Primers, 3, 17071, (2017); Kertesz A., Davidson W., Fox H., Frontal behavioral inventory: diagnostic criteria for frontal lobe dementia, Can. J. Neurol. Sci, 24, pp. 29-36, (1997); Khin Khin E., Minor D., Holloway A., Pelleg A., Decisional capacity in amyotrophic lateral sclerosis, J. Am. Acad. Psychiatry Law, 43, pp. 210-217, (2015); Lillo P., Mioshi E., Zoing M.C., Kiernan M.C., Hodges J.R., How common are behavioural changes in amyotrophic lateral sclerosis?, Amyotroph. Lateral Scler, 12, pp. 45-51, (2011); Lotto L., Manfrinati A., Sarlo M., A new set of moral dilemmas: norms for moral acceptability, decision times, and emotional salience, J. Behav. Decis. Mak, 27, pp. 57-65, (2014); Lule D., Kurt A., Jurgens R., Kassubek J., Diekmann V., Kraft E., Et al., Emotional responding in amyotrophic lateral sclerosis, J. Neurol, 252, pp. 1517-1524, (2005); McNair S., Okan Y., Hadjichristidis C., de Bruin W.B., Age differences in moral judgment: older adults are more deontological than younger adults, J. Behav. Decis. Mak, 32, pp. 47-60, (2018); Measso G., Cavarzeran F., Zappala G., Lebowitz B.D., Crook T.H., Pirozzolo F.J., Et al., The mini-mental state examination: normative study of an Italian random sample, Dev. Neuropsychol, 9, pp. 77-85, (1993); Meier S.L., Charleston A.J., Tippett L.J., Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis, Brain, 133, pp. 3444-3457, (2010); Mendez M.F., Anderson E., Shapira J.S., An investigation of moral judgement in frontotemporal dementia, Cogn. Behav. Neurol, 18, pp. 193-197, (2005); Mendez M.F., Shapira J.S., Altered emotional morality in frontotemporal dementia, Cogn. Neuropsychiatry, 14, pp. 165-179, (2009); Mitchell A.J., The Mini-Mental State Examination (MMSE): update on its diagnostic accuracy and clinical utility for cognitive disorders, Cognitive Screening Instruments, pp. 37-48, (2017); Moll J., Zahn R., de Oliveira-Souza R., Krueger F., Grafman J., Opinion: the neural basis of human moral cognition, Nat. Rev. Neurosci, 6, pp. 799-809, (2005); Palmieri A., Naccarato M., Abrahams S., Bonato M., D'Ascenzo C., Balestreri S., Et al., Right hemisphere dysfunction and emotional processing in ALS: an fMRI study, J. Neurol, 257, pp. 1970-1978, (2010); Papps B., Abrahams S., Wicks P., Leigh P.N., Goldstein L.H., Changes in memory for emotional material in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 43, pp. 1107-1114, (2005); Phukan J., Pender N.P., Hardiman O., Cognitive impairment in amyotrophic lateral sclerosis, Lancet Neurol, 6, pp. 994-1003, (2007); Pletti C., Lotto L., Buodo G., Sarlo M., It’s immoral, but I’d do it! Psychopathy traits affect decision-making in sacrificial dilemmas and in everyday moral situations, Br. J. Psychol, 108, pp. 351-368, (2017); Poletti B., Solca F., Carelli L., Madotto F., Lafronza A., Faini A., Et al., The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS), Amyotroph. Lateral Scler. Frontotemporal Degener, 17, pp. 489-498, (2016); Semler E., Petersdorff L., Anderl-Straub S., Bohm S., Lule D., Fangerau H., Et al., Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution, Amyotroph. Lateral Scler Frontotemporal Degener, 20, pp. 12-18, (2019); Strong M.J., Abrahams S., Goldstein L.H., Woolley S., Mclaughlin P., Snowden J., Et al., Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria, Amyotroph. Lateral Scler. Frontotemporal Degener, 18, pp. 153-174, (2017); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Et al., Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Amyotroph. Lateral. Scler, 10, pp. 131-146, (2009); Van Patten R., Britton K., Tremont G., Comparing the Mini-Mental State Examination and the modified Mini-Mental State Examination in the detection of mild cognitive impairment in older adults, Int. Psychogeriatr, 31, pp. 693-701, (2019); Zimmerman E.K., Zachary Simmons M.D., Barrett A.M., Emotional perception deficits in amyotrophic lateral sclerosis, Cogn. Behav. Neurol, 20, pp. 79-82, (2007)","2-s2.0-85090287281"
"Cerami C.; Tarantino P.; Cupidi C.; Annesi G.; Lo Re V.; Gagliardi M.; Piccoli T.; Quattrone A.","Cerami, Chiara (25722905400); Tarantino, Patrizia (9038096400); Cupidi, Chiara (14059856700); Annesi, Grazia (6603944174); Lo Re, Vincenzina (57192342864); Gagliardi, Monica (54388054200); Piccoli, Tommaso (6505971622); Quattrone, Aldo (7102299459)","25722905400; 9038096400; 14059856700; 6603944174; 57192342864; 54388054200; 6505971622; 7102299459","Marinesco-Sjögren syndrome caused by a new SIL1 frameshift mutation","2015","Journal of the Neurological Sciences","354","1-2","13755","112","113","1","4","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937515974&doi=10.1016%2fj.jns.2015.04.026&partnerID=40&md5=be22648498d787787b10ce4e40600dd0","[No abstract available]","Autosomal recessive cerebellar ataxias; Cerebellar atrophy; Early-onset cataracts; Marinesco-Sjögren Syndrome; Mental retardation; SIL1 gene","Adult; Female; Frameshift Mutation; Guanine Nucleotide Exchange Factors; Humans; Male; Pedigree; Spinocerebellar Degenerations; aminotransferase; creatine kinase; gamma glutamyltransferase; genomic DNA; serine; valine; guanine nucleotide exchange factor; SIL1 protein, human; Article; balance disorder; body growth; bone disease; case report; cataract; cerebellum atrophy; cerebellum disease; Darier disease; exon; failure to thrive; frameshift mutation; gait disorder; gene; genotype phenotype correlation; human; human tissue; hypergonadotropic hypogonadism; Italy; male; Marinesco Sjogren syndrome; mental deficiency; motor unit potential; muscle biopsy; muscle hypotonia; nuclear magnetic resonance imaging; polythelia; priority journal; scoliosis; short stature; SIL1 gene; stop codon; adult; female; frameshift mutation; genetics; pedigree; Spinocerebellar Degenerations","Anttonen A.K., Mahjneh I., Hamalainen R.H., Lagier-Tourenne C., Kopra O., Waris L., Et al., The gene disrupted in Marinesco-Sjögren syndrome encodes SIL1, an HSPA5 cochaperone, Nat Genet, 37, pp. 1309-1311, (2005); Senderek J., Krieger M., Stendel C., Bergmann C., Moser M., Breitbach-Faller N., Et al., Mutations in SIL1 cause Marinesco-Sjögren syndrome, a cerebellar ataxia with cataract and myopathy, Nat Genet, 37, pp. 1312-1314, (2005); Krieger M., Roos A., Stendel C., Claeys K.G., Sonmez F.M., Baudis M., Et al., SIL1 mutations and clinical spectrum in patients with Marinesco-Sjögren syndrome, Brain, 136, pp. 3634-3644, (2013); Goto M., Okada M., Komaki H., Sugai K., Sasaki M., Noguchi S., Et al., A nationwide survey on Marinesco-Sjögren syndrome in Japan, Orphanet J Rare Dis, 23, pp. 9-58, (2014); Anttonen A.K., Siintola E., Tranebjaerg L., Iwata N.K., Bijlsma E.K., Meguro H., Et al., Novel SIL1 mutations and exclusion of functional candidate genes in Marinesco-Sjögren syndrome, Eur J Hum Genet, 16, pp. 961-969, (2008); Annesi G., Aguglia U., Tarantino P., Annesi F., De Marco E.V., Civitelli D., Et al., SIL1 and SARA2 mutations in Marinesco-Sjögren and chylomicron retention diseases, Clin Genet, 71, pp. 288-289, (2007); Eriguchi M., Mizuta H., Kurohara K., Fujitake J., Kuroda Y., Identification of a new homozygous frameshift insertion mutation in the SIL1 gene in 3 Japanese patients with Marinesco-Sjögren syndrome, J Neurol Sci, 270, 1-2, pp. 197-200, (2008); Ezgu F., Krejci P., Li S., De Sousa C., Graham J.M., Hansmann I., Et al., Phenotype-genotype correlations in patients with Marinesco-Sjögren syndrome, Clin Genet, 86, 1, pp. 74-84, (2014); Horvers M., Anttonen A.K., Lehesjoki A.E., Morava E., Wortmann S., Vermeer S., Et al., Marinesco-Sjögren syndrome due to SIL1 mutations with a comment on the clinical phenotype, Eur J Paediatr Neurol, 17, 2, pp. 199-203, (2013); Chung K.T., Shen Y., Hendershot L.M., BAP, a mammalian BiP-associated protein, is a nucleotide exchange factor that regulates the ATPase activity of BiP, J Biol Chem, 277, pp. 47557-47563, (2002); Howes J., Shimizu Y., Feige M.J., Hendershot L.M., C-terminal mutations destabilize SIL1/BAP and can cause Marinesco-Sjögren syndrome, J Biol Chem, 287, 11, pp. 8552-8560, (2012)","2-s2.0-84937515974"
"Cerami C.; Crespi C.; Bottiroli S.; Santi G.C.; Sances G.; Allena M.; Vecchi T.; Tassorelli C.","Cerami, Chiara (25722905400); Crespi, Chiara (57034303800); Bottiroli, Sara (24471204500); Santi, Gaia Chiara (57217289456); Sances, Grazia (7003265739); Allena, Marta (24340031200); Vecchi, Tomaso (6603719753); Tassorelli, Cristina (7005630887)","25722905400; 57034303800; 24471204500; 57217289456; 7003265739; 24340031200; 6603719753; 7005630887","High perceived isolation and reduced social support affect headache impact levels in migraine after the Covid-19 outbreak: A cross sectional survey on chronic and episodic patients","2021","Cephalalgia","41","14","","1437","1446","9","8","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85110127539&doi=10.1177%2f03331024211027568&partnerID=40&md5=9957c4695be60c0b6a26efcf02c6704f","Background: Psychosocial variables are key factors influencing psycho-physical equilibrium in migraine patients. Social isolation and vulnerability to stressors may prevent efficient psychological adjustment negatively affecting adaptation to life changes, as that imposed during Covid-19 lockdown. Here, we explored psychosocial dimensions and changes in clinical condition during Covid-19 lockdown in migraine patients, with regard to migraine type and headache impact. Methods: Sixty-four migraine patients (32 episodic and 32 chronic) and 64 healthy control subjects were included in a case-control cross-sectional study. A two-step clustering procedure split patients into two clusters, based on the Headache Impact Test. Perceived global distress, loneliness, empathy, and coping levels were compared in groups, as well as changes in clinical condition. Results: Migraine patients reported higher general loneliness and lower social support compared to healthy control subjects. Emotional loneliness was more marked in patients with higher headache impact. This subgroup of patients more frequently reported changes in the therapeutic and care paths as the perceived cause of the occurrence of motor or extra-motor symptomatology. Conclusions: Migraine patients, especially those more severely affected, proved more vulnerable than healthy control subjects to Covid-19 lockdown. Long-lasting interruption of social interactions may be detrimental in fragile patients that are in need of structured support interventions to maintain psycho-physical wellbeing. © International Headache Society 2021.","chronic migraine; Covid-19; episodic migraine; headache impact; loneliness; perceived isolation","Adult; Anxiety; Case-Control Studies; Communicable Disease Control; COVID-19; Cross-Sectional Studies; Disease Outbreaks; Female; Headache; Humans; Loneliness; Male; Middle Aged; Migraine Disorders; Quarantine; SARS-CoV-2; Social Isolation; Social Support; adult; Article; controlled study; coping behavior; coronavirus disease 2019; cross-sectional study; distress syndrome; empathy; female; headache; human; lockdown; loneliness; major clinical study; male; migraine; nonhuman; anxiety; case control study; communicable disease control; complication; epidemic; headache; middle aged; migraine; psychology; quarantine; social isolation; social support","Bigal M.E., Lipton R.B., The Epidemiology, Burden, and Comorbidities of Migraine, Neurol Clin, 27, pp. 321-334, (2009); The International Classification of Headache Disorders, 3rd edition, Cephalalgia, 33, pp. 629-808, (2018); Bottiroli S., Galli F., Viana M., Et al., Negative short-term outcome of detoxification therapy in chronic migraine with medication overuse headache: role for early life traumatic experiences and recent stressful events, Front Neurol, 10, (2019); Dodick D.W., Loder E.W., Manack Adams A., Et al., assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study, Headache, 56, pp. 821-834, (2016); Scher A.I., Bigal M.E., Lipton R.B., Comorbidity of migraine, Curr Opin Neurol, 18, pp. 305-310, (2008); Goulart A.C., Santos I.S., Brunoni A.R., Et al., Migraine headaches and mood/anxiety disorders in the ELSA Brazil, Headache, 54, pp. 1310-1319, (2014); Parodi I.C., Poeta M.G., Assini A., Et al., Impact of quarantine due to COVID infection on migraine: a survey in Genova,, Neurol Sci, 41, pp. 2025-2027, (2020); Delussi M., Gentile E., Coppola G., Et al., Investigating the effects of COVID-19 quarantine in migraine: an observational cross-sectional study from the Italian National Headache Registry, RICe). Front Neurol, 11, (2020); Al-Hashel J.Y., Ismail I.I., Impact of coronavirus disease 2019 (COVID-19) pandemic on patients with migraine: A web-based survey study, J Headache Pain, 21, (2020); Ma M., Bao J., Fang J., Et al., . Impact of headache frequency and sleep during the COVID-19 pandemic among migraine patients; Gonzalez-Martinez A., Planchuelo-Gomez A., Guerrero A.L., Et al.; Papetti L., Loro P.A., Di Tarantino S., Et al., I stay at home with headache. A survey to investigate how the lockdown for COVID-19 impacted on headache in Italian children, Cephalalgia, 40, pp. 1459-1473, (2020); Crespi C.; Cerami C., Santi G.C., Galandra C., Et al., Covid-19 outbreak in Italy: are we ready for the psychosocial and the economic crisis? Baseline findings from the PsyCovid study, Front Psychiatry, 11, (2020); Rossi R., Socci V., Talevi D., Et al., COVID-19 pandemic and lockdown measures impact on mental health among the general population in Italy, Front Psychiatry, 11, (2020); Sepulveda-Loyola W., Rodriguez-Sanchez I., Perez-Rodriguez P., Et al., Impact of social isolation due to COVID-19 on health in older people: mental and physical effects and recommendations, J Nutr Health Aging, 24, pp. 938-947, (2020); Silvestro M., Tessitore A., Tedeschi G., Et al., Migraine in the Time of COVID-19, Headache, 60, pp. 988-989, (2020); Seiler A., Fagundes C.P., Christian L.M., . The impact of everyday stressors on the immune system and health, Stress Challenges and Immunity in Space, pp. 71-92, (2020); Martin M., Blaisdell B., Kwong J.W., Et al., The Short-Form Headache Impact Test (HIT-6) was psychometrically equivalent in nine languages, J Clin Epidemiol, 57, pp. 1271-1278, (2004); Cerami C., Canevelli M., Santi G.C., Et al.; Brooks S.K., Dunn R., Amlot R., Et al., Social and occupational factors associated with psychological distress and disorder among disaster responders: a systematic review, BMC Psychol, 4, (2016); Wang H., Kline J.A., Jackson B.E., Et al., Association between emergency physician self-reported empathy and patient satisfaction, PLOS ONE, 13, (2018); Khalid I., Khalid T.J., Qabajah M.R., Et al., Healthcare workers emotions, perceived stressors and coping strategies during a MERS-CoV outbreak, Clin Med Res, 14, pp. 7-14, (2016); Osman A., Wong J.L., Bagge C.L., Et al., The Depression Anxiety Stress Scales—21 (DASS‐21): further examination of dimensions, scale reliability, and correlates, J Clin Psychol, 68, pp. 1322-1338, (2012); Davis M.H., Measuring individual differences in empathy: Evidence for a multidimensional approach, J Personality Soc Psychol, 44, pp. 113-126, (1983); Galang C.M., Johnson D., Obhi S.S., Exploring the relationship between empathy, self-construal style, and self-reported social distancing tendencies during the COVID-19 pandemic, Front Psychol, (2021); Zammuner V., Italians’ social and emotional loneliness: the results of five studies, World Academy of Science, Engineering and Technology, International Journal of Social, Behavioral, Educational, Economic, Business and Industrial Engineering, 2, pp. 416-428, (2008); Foa C., Tonarelli A., Caricati, Et al., COPE-NVI-25: validazione italiana della versione ridotta della Coping Orientation to the Problems Experienced (COPE-NVI, Psicologia della Salute, pp. 123-140, (2015); Blanca M., Alarcon R., Arnau J., Et al., Non-normal data: is ANOVA still a valid option?, Psicothema, 29, pp. 552-557, (2017); Vos T., Abajobir A.A., Abate K.H., Et al., Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet, 390, pp. 1211-1259, (2016); Mosley T.H., Penzien D.B., Johnson C.A., Et al., Time-series analysis of stress and headache, Cephalalgia, 11, pp. 306-307, (1991); Martin P.R., Theunissen C., The role of life event stress, coping and social support in chronic headaches, Headache, 33, pp. 301-306, (1993); Ma M., Fang J., Li C., Et al., The status and high-risk factors of severe psychological distress in migraine patients during nCOV-2019 outbreak in Southwest China: A cross-sectional study, J Headache Pain, 21, pp. 1-7, (2020); Zheng H.T., Huang X.M., Absence and presence of human interaction: The relationship between loneliness and empathy, Front Psychol, 11, (2020); Blazer D., Social isolation and loneliness in older adults—a mental health/public health challenge, JAMA Psychiatry, 77, pp. 990-991, (2020); Lui J.Z., Young N.P., Ebbert J.O., Et al., Loneliness and migraine self-management: a cross-sectional assessment, J Prim Care Community Health, 11, (2020); Consonni M., Telesca A., Grazzi L., Et al., Life with chronic pain during COVID-19 lockdown: the case of patients with small fibre neuropathy and chronic migraine, Neurological Sciences, 42, pp. 389-397, (2021); Clemente-Suarez V.J., Dalamitros A.A., Beltran-Velasco A.I., Et al., Social and psychophysiological consequences of the COVID-19 pandemic: an extensive literature review, Front Psychol, 11, (2020); Giordano G., Blanchini F., Bruno R., Et al., Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy, Nat Med, 26, pp. 855-860, (2020); Szperka C.L., Ailani J., Barmherzig R., Et al., Migraine care in the era of COVID-19: Clinical pearls and plea to insurers, Headache, 60, pp. 833-842, (2020); Grazzi L., Rizzoli P., Andrasik F., Effectiveness of mindfulness by smartphone, for patients with chronic migraine and medication overuse during the Covid-19 emergency, Neurol Sci, 41, pp. 461-462, (2020)","2-s2.0-85110127539"
"Galandra C.; Cerami C.; Santi G.C.; Dodich A.; Cappa S.F.; Vecchi T.; Crespi C.","Galandra, Caterina (36806194800); Cerami, Chiara (25722905400); Santi, Gaia Chiara (57217289456); Dodich, Alessandra (56001713900); Cappa, Stefano F. (7005836132); Vecchi, Tomaso (6603719753); Crespi, Chiara (57034303800)","36806194800; 25722905400; 57217289456; 56001713900; 7005836132; 6603719753; 57034303800","Job loss and health threatening events modulate risk-taking behaviours in the Covid-19 emergency","2020","Scientific Reports","10","1","22236","","","","11","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85097666892&doi=10.1038%2fs41598-020-78992-x&partnerID=40&md5=f8a0bbe95ed1573064945992aced451b","Covid-19 pandemic is exerting a tragic impact all around the world. First-person experience of life-threatening and stressful events can modify individuals’ risk perception, and, consequently, risk-taking behaviours. Here we investigated risk-taking profiles in 130 Italian residents, and compared healthcare to non-healthcare workers, during the lockdown phase. We ad hoc developed the “Covid-19 Risk Task”, including the classic monetary Holt-Laury Paired Lottery Task (Monetary Condition, MC) and two new ecological conditions exploring Covid-19 related risk-taking aptitudes in relation to different health (Health Status Condition, HsC) and employment (Employment Status Condition, EsC) outcomes. Results showed that, in the whole sample, individuals were more risk-averse in MC than in HsC and EsC. Moreover, a payoff increase produced a shift toward more risk-averse behaviours in MC, but not in HsC and EsC, where we found an opposite trend suggesting a more risk-loving behaviour. Finally, we found that healthcare workers were significantly less risk-averse compared to non-healthcare workers in EsC, but not in MC and HsC. These findings provided evidence of the possible effects of Covid-19 outbreak on risk-taking aptitudes. The negative impact on human choices and, consequently, on the whole world economy of this catastrophic life event must not be underestimated. © 2020, The Author(s).","","Adult; Aged; COVID-19; Disease Outbreaks; Female; Health Personnel; Humans; Italy; Male; Middle Aged; Pandemics; Risk-Taking; SARS-CoV-2; Unemployment; adult; aged; epidemic; female; health care personnel; high risk behavior; human; Italy; male; middle aged; pandemic; pathogenicity; psychology; unemployment","Cassar A., Healy A., von Kessler C., Trust, risk, and time preferences after a natural disaster: experimental evidence from Thailand, World Dev., 94, pp. 90-105, (2017); Cameron L., Shah M., Risk-Taking Behavior in the Wake of Natural Disasters, (2013); Voors M.J., Et al., Violent conflict and behavior: A field experiment in Burundi, Am. Econ. Rev., 102, pp. 941-964, (2012); Kahneman D., Tversky A., Prospect theory: an analysis of decision under risk, Econometrica, 47, pp. 263-292, (1979); Jakiela P., Ozier O., The impact of violence on individual risk preferences: evidence from a natural experiment, Rev. Econ. Stat., 101, pp. 547-559, (2019); Eckel C.C., El-Gamal M.A., Wilson R.K., Risk loving after the storm: a Bayesian-network study of hurricane Katrina evacuees, J. Econ. Behav. Organ., 69, pp. 110-124, (2009); Holt C.A., Laury S.K., Risk aversion and incentive effects, Am. Econ. Rev., 92, 5, pp. 1644-1655, (2002); Cerami C., Et al., Covid-19 outbreak in Italy: are we ready for the psychosocial and the economic crisis? Baseline findings from the psycovid study, Front. Psychiatry, 11, (2020); Albert S., Duffy J., Differences in risk aversion between young and older adults, Neurosci. Neuroeconomics, 202, (2012); Shupp R., Loveridge S., Skidmore M., Lim J., Rogers C., Risk, loss, and ambiguity aversion after a natural disaster, Econ. Disasters Clim. Chang., 1, pp. 121-142, (2017); Zamanzadeh V., Ghahramanian A., Rassouli M., Abbaszadeh A., Alavi-Majd H., Nikanfar A.R., Design and implementation content validity study: development of an instrument for measuring patient-centered communication, J. Caring Sci., 4, 2, (2015)","2-s2.0-85097666892"
"Dodich A.; Cerami C.; Cappa S.F.; Marcone A.; Golzi V.; Zamboni M.; Giusti M.C.; Iannaccone S.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400); Cappa, Stefano F. (7005836132); Marcone, Alessandra (6701496511); Golzi, Valeria (6508258301); Zamboni, Michele (36777386200); Giusti, Maria Cristina (57200972115); Iannaccone, Sandro (7005943171)","56001713900; 25722905400; 7005836132; 6701496511; 6508258301; 36777386200; 57200972115; 7005943171","Combined socio-behavioral evaluation improves the differential diagnosis between the behavioral variant of frontotemporal dementia and Alzheimer's disease: In search of neuropsychological markers","2018","Journal of Alzheimer's Disease","61","2","","761","772","11","20","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85038820624&doi=10.3233%2fJAD-170650&partnerID=40&md5=06a25c187c8a76495c133ac5e604e2dd","Background: Current diagnostic criteria for behavioral variant of frontotemporal dementia (bvFTD) and typical Alzheimer's disease (AD) include a differential pattern of neuropsychological impairments (episodic memory deficit in typical AD and dysexecutive syndrome in bvFTD). There is, however, large evidence of a frequent overlap in neuropsychological features, making the differential diagnosis extremely difficult. Objectives: In this retrospective study, we evaluated the diagnostic value of different cognitive and neurobehavioral markers in bvFTD and AD patient groups. Methods:We included 95 dementia patients with a clinical and biomarker evidence of bvFTD (n = 48) or typical AD (n = 47) pathology. A clinical 2-year follow-up confirmed clinical classification. Performances at basic cognitive tasks (memory, executive functions, visuo-spatial, language) as well as social cognition skills and neurobehavioral profiles have been recorded. A stepwise logistic regression model compared the neuropsychological profiles between groups and assessed the accuracy of cognitive and neurobehavioral markers in discriminating bvFTD from AD. Results: Statistical comparison between patient groups proved social cognition and episodic memory impairments as main cognitive signatures of bvFTD and AD neuropsychological profiles, respectively. Only half of bvFTD patients showed attentive/executive deficits, questioning their role as cognitive marker of bvFTD. Notably, the large majority of bvFTD sample (i.e., 70%) poorly performed at delayed recall tasks. Logistic regression analysis identified social cognition performances, Frontal Behavioral Inventory and Mini-Mental State Examination scores as the best combination in distinguishing bvFTD from AD. Conclusion: Social cognition tasks and socio-behavioral questionnaires are recommended in clinical settings to improve the accuracy of early diagnosis of bvFTD. © 2018 - IOS Press and the authors. All rights reserved.","Alzheimer's disease; Frontotemporal dementia; Neurodegenerative disease; Neuropsychology; Social skills","Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Cognition; Diagnosis, Differential; Female; Frontotemporal Dementia; Humans; Logistic Models; Male; Memory, Episodic; Mental Recall; Middle Aged; Neuropsychological Tests; Retrospective Studies; Social Skills; biological marker; biological marker; aged; Alzheimer disease; Article; attention; behavior assessment; Clinical Dementia Rating; cognition assessment; diagnostic accuracy; diagnostic value; differential diagnosis; disease duration; emotion assessment; Empathic Concern subscale of Interpersonal Reactivity Index Questionnaire; episodic memory; executive function; female; Frontal Behavioral Inventory; frontal variant frontotemporal dementia; human; Interpersonal Reactivity Index; language ability; long term memory; major clinical study; male; Mini Mental State Examination; neuropathology; neuropsychological test; neuropsychology; Perspective Taking subscale of Interpersonal Reactivity Index Questionnaire; priority journal; recall; retrospective study; short term memory; social behavior; social cognition; social competence; spatial orientation; task performance; time perception; Alzheimer disease; cognition; differential diagnosis; frontotemporal dementia; middle aged; psychology; statistical model; very elderly; comparative study; depth perception; disease classification; disease marker; evaluation study; follow up; language; logistic regression analysis; neuropsychology","Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration:Aconsensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Hornberger M., Piguet O., Episodic memory in frontotemporal dementia: A critical review, Brain, 135, pp. 678-692, (2012); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol, 10, pp. 162-172, (2011); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol Sci, 34, pp. 1267-1274, (2013); Bertoux M., De Souza L.C., O'Callaghan C., Greve A., Sarazin M., Dubois B., Hornberger M., Social cognition deficits: The key to discriminate behavioral variant frontotemporal dementia from Alzheimer's disease regardless of amnesia?, J Alzheimers Dis, 49, pp. 1065-1074, (2016); Hutchinson A.D., Mathias J.L., Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: A meta-Analytic review, J Neurol Neurosurg Psychiatry, 78, pp. 917-928, (2007); Taragano F.E., Allegri R.F., Krupitzki H., Sarasola D.R., Serrano C.M., Lon L., Lyketsos C.G., Mild behavioral impairment and risk of dementia: A prospective cohort study of 358 patients, J Clin Psychiatry, 70, pp. 584-592, (2009); Irish M., Graham A., Graham K.S., Hodges J.R., Hornberger M., Differential impairment of source memory in progressive versus non-progressive behavioral variant frontotemporal dementia, Arch Clin Neuropsychol, 27, pp. 338-347, (2012); Irish M., Piguet O., Hodges J.R., Hornberger M., Common and unique gray matter correlates of episodic memory dysfunction in frontotemporal dementia and Alzheimer's disease, Hum Brain Mapp, 35, pp. 1422-1435, (2014); Schubert S., Leyton C.E., Hodges J.R., Piguet O., Longitudinal memory profiles in behavioral-variant frontotemporal dementia and Alzheimer's disease, J Alzheimers Dis, 51, pp. 775-782, (2016); Ramanan S., Bertoux M., Flanagan E., Irish M., Piguet O., Hodges J.R., Hornberger M., Longitudinal executive function and episodic memory profiles in behavioral-variant frontotemporal dementia and Alzheimer's disease, J Int Neuropsychol Soc, 23, pp. 34-43, (2017); Fernandez-Matarrubia M., Matias-Guiu J.A., Cabrera-Martin M.N., Moreno-Ramos T., Valles-Salgado M., Carreras J.L., Matias-Guiu J., Episodic memory dysfunction in behavioral variant frontotemporal dementia: A clinical and FDG-PET study, J Alzheimers Dis, 57, pp. 1251-1264, (2017); Bertoux M., De Souza L.C., Corlier F., Lamari F., Bottlaender M., Dubois B., Sarazin M., Two distinct amnesic profiles in behavioral variant frontotemporal dementia, Biol Psychiatry, 75, pp. 582-588, (2014); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., DeKosky S.T., Gauthier S., Selkoe D., Bateman R., Cappa S., Crutch S., Engelborghs S., Frisoni G.B., Fox N.C., Galasko D., Habert M.O., Jicha G.A., Nordberg A., Pasquier F., Rabinovici G., Robert P., Rowe C., Salloway S., Sarazin M., Epelbaum S., De Souza L.C., Vellas B., Visser P.J., Schneider L., Stern Y., Scheltens P., Cummings J.L., Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria, Lancet Neurol, 13, pp. 614-629, (2014); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 263-269, (2011); Ossenkoppele R., Pijnenburg Y.A., Perry D.C., Cohn-Sheehy B.I., Scheltens N.M., Vogel J.W., Kramer J.H., Van Der Vlies A.E., La Joie R., Rosen H.J., Van Der Flier W.M., Grinberg L.T., Rozemuller A.J., Huang E.J., Van Berckel B.N., Miller B.L., Barkhof F., Jagust W.J., Scheltens P., Seeley W.W., Rabinovici G.D., The behavioural/dysexecutive variant of Alzheimer's disease: Clinical, neuroimaging and pathological features, Brain, 138, pp. 2732-2749, (2015); Possin K.L., Feigenbaum D., Rankin K.P., Smith G.E., Boxer A.L., Wood K., Hanna S.M., Miller B.L., Kramer J.H., Dissociable executive functions in behavioral variant frontotemporal and Alzheimer dementias, Neurology, 80, pp. 2180-2185, (2013); Stopford C.L., Thompson J.C., Neary D., Richardson A.M., Snowden J.S., Working memory, attention, and executive function in Alzheimer's disease and frontotemporal dementia, Cortex, 48, pp. 429-446, (2012); Wong S., Bertoux M., Savage G., Hodges J.R., Piguet O., Hornberger M., Comparison of prefrontal atrophy and episodic memory performance in dysexecutive Alzheimer's disease and behavioral-variant frontotemporal dementia, J Alzheimers Dis, 51, pp. 889-903, (2016); Hornberger M., Savage S., Hsieh S., Mioshi E., Piguet O., Hodges J.R., Orbitofrontal dysfunction discriminates behavioral variant frontotemporal dementia from Alzheimer's disease, Dement Geriatr Cogn Disord, 30, pp. 547-552, (2010); Blennerhassett R., Lillo P., Halliday G.M., Hodges J.R., Kril J.J., Distribution of pathology in frontal variant Alzheimer's disease, J Alzheimers Dis, 39, pp. 63-70, (2014); Bertoux M., Funkiewiez A., O'Callaghan C., Dubois B.H., Sensitivity and specificity of ventromedial prefrontal cortex tests in behavioral variant frontotemporal dementia, Alzheimers Dement, 9, pp. S84-94, (2013); Funkiewiez A., Bertoux M., De Souza L.C., Levy R., Dubois B., The SEA (Social cognition and Emotional Assessment): A clinical neuropsychological tool for early diagnosis of frontal variant of frontotemporal lobar degeneration, Neuropsychology, 26, pp. 81-90, (2012); Torralva T., Roca M., Gleichgerrcht E., Bekinschtein T., Manes F., A neuropsychological battery to detect specific executive and social cognitive impairments in early frontotemporal dementia, Brain, 132, pp. 1299-1309, (2009); Poletti M., Enrici I., Adenzato M., Cognitive and affective theory of mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels, Neurosci Biobehav Rev, 36, pp. 2147-2164, (2012); Schroeter M.L., Considering the frontomedian cortex in revised criteria for behavioural variant frontotemporal dementia, Brain, 135, (2012); Adenzato M., Poletti M., Theory of Mind abilities in neurodegenerative diseases: An update and a call to introduce mentalizing tasks in standard neuropsychological assessments, Clin Neuropsychiatry, 10, pp. 226-234, (2013); Eslinger P.J., Moore P., Anderson C., Grossman M., Social cognition, executive functioning, and neuroimaging correlates of empathic deficits in frontotemporal dementia, J Neuropsychiatry Clin Neurosci, 23, pp. 74-82, (2011); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology, 78, pp. 1354-1362, (2012); Schroeter M.L., Laird A.R., Chwiesko C., Deuschl C., Schneider E., Bzdok D., Eickhoff S.B., Neumann J., Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-Analyses-The case of behavioral variant frontotemporal dementia, Cortex, 57, pp. 22-37, (2014); Dodich A., Cerami C., Crespi C., Canessa N., Lettieri G., Iannaccone S., Marcone A., Cappa S.F., Cacioppo J.T., Differential impairment of cognitive and affective mentalizing abilities in neurodegenerative dementias: Evidence from behavioral variant of frontotemporal dementia, Alzheimer's disease, and mild cognitive impairment, J Alzheimers Dis, 50, pp. 1011-1022, (2016); Hutchings R., Hodges J.R., Piguet O., Kumfor F., Boutoleau-Bretonniere C., Why should i care? Dimensions of socio-emotional cognition in younger-onset dementia, J Alzheimers Dis, 48, pp. 135-147, (2015); Lezak M.D., Neuropsychological Assessment, Oxford, (2004); Catricala E., Della Rosa P.A., Ginex V., Mussetti Z., Plebani V., Cappa S.F., An Italian battery for the assessment of semantic memory disorders, Neurol Sci, 34, pp. 985-993, (2013); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Realmuto S., Cappa S.F., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci, 35, pp. 1015-1021, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S.F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol Sci, 36, pp. 1907-1912, (2015); Baez S., Herrera E., Villarin L., Theil D., Gonzalez-Gadea M.L., Gomez P., Mosquera M., Huepe D., Strejilevich S., Vigliecca N.S., Matthaus F., Decety J., Manes F., Ibanez A.M., Contextual social cognition impairments in schizophrenia and bipolar disorder, PLoS One, 8, (2013); Alberici A., Geroldi C., Cotelli M., Adorni A., Calabria M., Rossi G., Borroni B., Padovani A., Zanetti O., Kertesz A., The frontal behavioural inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease, Neurol Sci, 28, pp. 80-86, (2007); Davis M.H., Measuring individual differences in empathy: Evidence for a multidimensional approach, J Pers Soc Psychol, 44, pp. 113-126, (1983); Rankin K.P., Kramer J.H., Miller B.L., Patterns of cognitive and emotional empathy in frontotemporal lobar degeneration, Cogn Behav Neurol, 18, pp. 28-36, (2005); Lennox R.D., Wolfe R.N., Revision of the selfmonitoring scale, J Pers Soc Psychol, 46, pp. 1349-1364, (1984); Rascovsky K., Grossman M., Clinical diagnostic criteria and classification controversies in frontotemporal lobar degeneration, Int Rev Psychiatry, 25, pp. 145-158, (2013); Mendez M.F., Shapira J.S., McMurtray A., Licht E., Miller B.L., Accuracy of the clinical evaluation for frontotemporal dementia, Arch Neurol, 64, pp. 830-835, (2007); Leslie F.V., Foxe D., Daveson N., Flannagan E., Hodges J.R., Piguet O., Frontier executive screen: A brief executive battery to differentiate frontotemporal dementia and Alzheimer's disease, J Neurol Neurosurg Psychiatry, 87, pp. 831-835, (2016); Burke T., Pinto-Grau M., Lonergan K., Elamin M., Bede P., Costello E., Hardiman O., Pender N., Measurement of social cognition in amyotrophic lateral sclerosis: A population based study, PLoS One, 11, (2016); Pardini M., Emberti Gialloreti L., Mascolo M., Benassi F., Abate L., Guida S., Viani E., Dal Monte O., Schintu S., Krueger F., Cocito L., Isolated theory of mind deficits and risk for frontotemporal dementia: A longitudinal pilot study, J Neurol Neurosurg Psychiatry, 84, pp. 818-821, (2013); Serafin M., Surian L., Il test degli occhi: Uno strumento per valutare la"" teoria della mente, G Ital Psicol, 31, pp. 839-862, (2004); Hutchings R., Palermo R., Piguet O., Kumfor F., Disrupted face processing in frontotemporal dementia: A review of the clinical and neuroanatomical evidence, Neuropsychol Rev, 27, pp. 18-30, (2017); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weinermw Miller B.L., Structural anatomy of empathy in neurodegenerative disease, Brain, 129, pp. 2945-2956, (2006); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: A meta-Analysis, J Neurol Neurosurg Psychiatry, 86, pp. 714-719, (2015); Castelli I., Pini A., Alberoni M., Liverta-Sempio O., Baglio F., Massaro D., Marchetti A., Nemni R., Mapping levels of theory of mind in Alzheimer's disease: A preliminary study, Aging Ment Health, 15, pp. 157-168, (2011); Kertesz A., Davidson W., McCabe P., Munoz D., Behavioral quantitation is more sensitive than cognitive testing in frontotemporal dementia, Alzheimer Dis Assoc Disord, 17, pp. 223-229, (2003); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-Temporal dementia, Cortex, 83, pp. 101-112, (2016); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Senjem M.L., Shiung M.M., Boeve B.F., Knopman D.S., Parisi J.E., Dickson D.W., Petersen R.C., Jack C.R., Josephs K.A., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study, Brain, 132, pp. 2932-2946, (2009); Tombaugh T.N., McIntyre N.J., The mini-mental state examination: A comprehensive review, J Am Geriatr Soc, 40, pp. 922-935, (1992); Trzepacz P.T., Hochstetler H., Wang S., Walker B., Saykin A.J., Relationship between the montreal cognitive assessment and mini-mental state examination for assessment of mild cognitive impairment in older adults, BMC Geriatr, 15, (2015); Pasquier F., Richard F., Lebert F., Natural history of frontotemporal dementia: Comparison with Alzheimer's disease, Dement Geriatr Cogn Disord, 17, pp. 253-257, (2004); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Pinto P., Passerini G., Falini A., Iannaccone S., Cappa S.F., Comi G., Gianolli L., Magnani G., Crossvalidation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging, 43, pp. 499-508, (2016); Seeley W.W., Selective functional, regional, and neuronal vulnerability in frontotemporal dementia, Curr Opin Neurol, 21, pp. 701-707, (2008); Woodward M.C., Rowe C.C., Jones G., Villemagne V.L., Varos T.A., Differentiating the frontal presentation of Alzheimer's disease with FDG-PET, J Alzheimers Dis, 44, pp. 233-242, (2015); Nelson H.E., A modified card sorting test sensitive to frontal lobe defects, Cortex, 12, pp. 313-324, (1976); Burgess P., Shallice T., The Hayling and Brixton Tests, (1997); Siri S., Benaglio I., Frigerio A., Binetti G., Cappa S.F., A brief neuropsychological assessment for the differential diagnosis between frontotemporal dementia and Alzheimer's disease, Eur J Neurol, 8, pp. 125-132, (2001); Nardell M., Tampi R.R., Pharmacological treatments for frontotemporal dementias: A systematic review of randomized controlled trials, Am J Alzheimers Dis Other Demen, 29, pp. 123-132, (2014); Sevigny J., Chiao P., Bussiere T., Weinreb P.H., Williams L., Maier M., Dunstan R., Salloway S., Chen T., Ling Y., O'Gorman J., Qian F., Arastu M., Li M., Chollate S., Brennan M.S., Quintero-Monzon O., Scannevin R.H., Arnold H.M., Engber T., Rhodes K., Ferrero J., Hang Y., Mikulskis A., Grimm J., Hock C., Nitsch R.M., Sandrock A., The antibody aducanumab reduces Abeta plaques in Alzheimer's disease, Nature, 537, pp. 50-56, (2016)","2-s2.0-85038820624"
"Crespi C.; Cerami C.; Dodich A.; Canessa N.; Arpone M.; Iannaccone S.; Corbo M.; Lunetta C.; Scola E.; Falini A.; Cappa S.F.","Crespi, Chiara (57034303800); Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Canessa, Nicola (24334215800); Arpone, Marta (56002226300); Iannaccone, Sandro (7005943171); Corbo, Massimo (7006723926); Lunetta, Christian (7801365932); Scola, Elisa (35071979200); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132)","57034303800; 25722905400; 56001713900; 24334215800; 56002226300; 7005943171; 7006723926; 7801365932; 35071979200; 7003494994; 7005836132","Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis","2014","Cortex","53","1","","1","8","7","64","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893984599&doi=10.1016%2fj.cortex.2014.01.002&partnerID=40&md5=fb75a999b20b8666c49ac05195527b59","Amyotrophic Lateral Sclerosis (ALS) is associated in about half of the cases with behavioral and cognitive disorders, including impairments in socio-emotional processing, considered as key-features for the diagnosis of the behavioral variant of frontotemporal dementia (bv-FTD). The neurostructural bases of emotional deficits in ALS, however, still remain largely unexplored. Here we aim to assess emotion recognition in non-demented sporadic ALS patients compared with healthy controls, and to explore for the first time its microstructural white-matter correlates. Twenty-two subjects with either probable or definite diagnosis of ALS and 55 age-, gender-, and education-matched healthy controls were recruited in the study. All participants performed the Ekman 60-Faces Test, assessing the recognition of six basic emotions (i.e., anger, disgust, fear, sadness, surprise and happiness). A subgroup of subjects, comprising 19 patients and 20 healthy controls, also underwent a Diffusion Tensor Imaging scanning. Behavioral analysis highlighted a significant decline of emotion recognition skills in patients compared to controls, particularly affecting the identification of negative emotions. Moreover, the Diffusion Tensor Imaging analyses revealed a correlation between this impairment and the alteration of white-matter integrity along the right inferior longitudinal fasciculus and inferior fronto-occipital fasciculus. Our findings indicate the presence of an early emotion recognition deficit in non-demented sporadic ALS patients, associated with microstructural changes in ventral associative bundles connecting occipital, temporo-limbic and orbitofrontal regions in the right hemisphere. These changes may represent a frontotemporal-limbic microstructural marker of socio-emotional impairment in ALS. © 2014 Elsevier Ltd.","ALS-FTD continuum hypothesis; Amyotrophic Lateral Sclerosis; Diffusion Tensor Imaging; Emotion recognition impairment; Inferior Longitudinal Fasciculus and Inferior Fronto-occipital Fasciculus","Aged; Amyotrophic Lateral Sclerosis; Brain; Cognition Disorders; Diffusion Tensor Imaging; Emotions; Facial Expression; Female; Humans; Male; Middle Aged; Psychomotor Performance; Recognition (Psychology); Social Perception; ALS-FTD continuum hypothesis; Amyotrophic Lateral Sclerosis; Diffusion Tensor Imaging; Emotion recognition impairment; Inferior Longitudinal Fasciculus and Inferior Fronto-occipital Fasciculus; adult; aged; amyotrophic lateral sclerosis; anger; article; brain cortex; clinical article; cognitive defect; controlled study; corpus callosum; correlation analysis; diffusion tensor imaging; disgust; ekman 60 faces test; emotion; emotion recognition impairment; emotional disorder; facial expression; fear; female; fractional anisotropy; happiness; human; inferior fronto occipital fasciculus; inferior longitudinal bundle; male; middle aged; named inventories, questionnaires and rating scales; neuropathology; pyramidal tract; sadness; surprise; white matter","Abrahams S., Goldstein L.H., Lloyd C.M., Brooks D.J., Leigh P.N., Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: a neuropsychological investigation, Journal of Neurological Sciences, 129 SUPPL, pp. 54-55, (1995); Abrahams S., Goldstein L.H., Suckling J., Ng V., Simmons A., Chitnis X., Frontotemporal white matter changes in amyotrophic lateral sclerosis, Journal of Neurology, 252, 3, pp. 321-331, (2005); Benjamini Y., Hochberg Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society., Series B (Methodological), pp. 289-300, (1995); Boeve B.F., Boylan K.B., Graff-Radford N.R., DeJesus-Hernandez M., Knopman D.S., Pedraza O., Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72, Brain, 135, PART 3, pp. 765-783, (2012); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 1, 5, pp. 293-299, (2000); Catani M., Thiebaut de Schotten M., A diffusion tensor imaging tractography atlas for virtual invivo dissections, Cortex, 44, 8, pp. 1105-1132, (2008); Cavallo M., Adenzato M., Macpherson S.E., Karwig G., Enrici I., Abrahams S., Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis, PLoS One, 6, 10, (2011); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study, Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, pp. 1-9, (2013); Chen Z., Ma L., Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: a voxel-wise meta-analysis of voxel based morphometry studies, Amyotrophic Lateral Sclerosis, 11, 6, pp. 549-554, (2010); Consonni M., Iannaccone S., Cerami C., Frasson P., Lacerenza M., Lunetta C., The cognitive and behavioural profile of amyotrophic lateral sclerosis: application of the consensus criteria, Behavioural Neurology, 27, 2, pp. 143-153, (2013); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: a normative study of the Ekman 60-Faces Test in the Italian population, Neurological Sciences, pp. 1-7, (2014); Ekman P., Friesen W.V., Measuring facial movement, Environmental Psychology and Nonverbal Behavior, 1, pp. 56-57, (1976); Elamin M., Pender N., Hardiman O., Abrahams S., Social cognition in neurodegenerative disorders: a systematic review, Journal of Neurology, Neurosurgery and Psychiatry, 83, 11, pp. 1071-1079, (2012); Ellis C.M., Suckling J., Amaro E., Bullmore E.T., Simmons A., Williams S.C., Volumetric analysis reveals corticospinal tract degeneration and extramotor involvement in ALS, Neurology, 57, 9, pp. 1571-1578, (2001); Ennis D.B., Kindlmann G., Orthogonal tensor invariants and the analysis of diffusion tensor magnetic resonance images, Magnetic Resonance in Medicine, 55, 1, pp. 136-146, (2006); Filippini N., Douaud G., Mackay C.E., Knight S., Talbot K., Turner M.R., Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis, Neurology, 75, 18, pp. 1645-1652, (2010); Girardi A., Macpherson S.E., Abrahams S., Deficits in emotional and social cognition in amyotrophic lateral sclerosis, Neuropsychology, 25, 1, pp. 53-65, (2011); Gschwind M., Pourtois G., Schwartz S., Van De Ville D., Vuilleumier P., White-matter connectivity between face-responsive regions in the human brain, Cerebral Cortex, 22, 7, pp. 1564-1576, (2012); Gur R.C., Skolnick B.E., Gur R.E., Effects of emotional discrimination tasks on cerebral blood flow: regional activation and its relation to performance, Brain and Cognition, 25, 2, pp. 271-286, (1994); Hua K., Zhang J., Wakana S., Jiang H., Li X., Reich D.S., Tract probability maps in stereotaxic spaces: analyses of white matter anatomy and tract-specific quantification, NeuroImage, 39, 1, pp. 336-347, (2008); Kumfor F., Irish M., Hodges J.R., Piguet O., Discrete neural correlates for the recognition of negative emotions: insights from frontotemporal dementia, PLoS One, 8, 6, (2013); Lillo P., Garcin B., Hornberger M., Bak T.H., Hodges J.R., Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis, Archives of Neurology, 67, 7, pp. 826-830, (2010); Lillo P., Mioshi E., Burrell J.R., Kiernan M.C., Hodges J.R., Hornberger M., Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum, PLoS One, 7, 8, (2012); Lillo P., Mioshi E., Zoing M.C., Kiernan M.C., Hodges J.R., How common are behavioural changes in amyotrophic lateral sclerosis?, Amyotrophic Lateral Sclerosis, 12, 1, pp. 45-51, (2011); Lule D., Kurt A., Jurgens R., Kassubek J., Diekmann V., Kraft E., Emotional responding in amyotrophic lateral sclerosis, Journal of Neurology, 252, 12, pp. 1517-1524, (2005); Omar R., Rohrer J.D., Hailstone J.C., Warren J.D., Structural neuroanatomy of face processing in frontotemporal lobar degeneration, Journal of Neurology, Neurosurgery and Psychiatry, 82, 12, pp. 1341-1343, (2011); Palmieri A., Naccarato M., Abrahams S., Bonato M., D'Ascenzo C., Balestreri S., Right hemisphere dysfunction and emotional processing in ALS: an fMRI study, Journal of Neurology, 257, 12, pp. 1970-1978, (2010); Papps B., Abrahams S., Wicks P., Leigh P.N., Goldstein L.H., Changes in memory for emotional material in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 43, 8, pp. 1107-1114, (2005); Philippi C.L., Mehta S., Grabowski T., Adolphs R., Rudrauf D., Damage to association fiber tracts impairs recognition of the facial expression of emotion, Journal of Neuroscience, 29, 48, pp. 15089-15099, (2009); Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study, Journal of Neurology, Neurosurgery and Psychiatry, 83, 1, pp. 102-108, (2012); Phukan J., Pender N.P., Hardiman O., Cognitive impairment in amyotrophic lateral sclerosis, Lancet Neurology, 6, 11, pp. 994-1003, (2007); Savage S.A., Lillo P., Kumfor F., Kiernan M.C., Piguet O., Hodges J.R., Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia, Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, pp. 1-8, (2013); Seelaar H., Rohrer J.D., Pijnenburg Y.A., Fox N.C., van Swieten J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review, Journal of Neurology, Neurosurgery and Psychiatry, 82, 5, pp. 476-486, (2011); Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data, NeuroImage, 31, 4, pp. 1487-1505, (2006); Smith S.M., Nichols T.E., Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference, NeuroImage, 44, 1, pp. 83-98, (2009); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Et al., Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Amyotrophic Lateral Sclerosis, 10, 3, pp. 131-146, (2009); Thiebaut de Schotten M., Dell'Acqua F., Valabregue R., Catani M., Monkey to human comparative anatomy of the frontal lobe association tracts, Cortex, 48, 1, pp. 82-96, (2012); Tsermentseli S., Leigh P.N., Goldstein L.H., The anatomy of cognitive impairment in amyotrophic lateral sclerosis: more than frontal lobe dysfunction, Cortex, 48, 2, pp. 166-182, (2012); Zimmerman E.K., Eslinger P.J., Simmons Z., Barrett A.M., Emotional perception deficits in amyotrophic lateral sclerosis, Cognitive and Behavioural Neurology, 20, 2, pp. 79-82, (2007)","2-s2.0-84893984599"
"Cerami C.; Perdixi E.; Meli C.; Marcone A.; Zamboni M.; Iannaccone S.; Dodich A.","Cerami, Chiara (25722905400); Perdixi, Elena (57422209200); Meli, Claudia (57222759961); Marcone, Alessandra (6701496511); Zamboni, Michele (36777386200); Iannaccone, Sandro (7005943171); Dodich, Alessandra (56001713900)","25722905400; 57422209200; 57222759961; 6701496511; 36777386200; 7005943171; 56001713900","Early Identification of Different Behavioral Phenotypes in the Behavioral Variant of Frontotemporal Dementia with the Aid of the Mini-Frontal Behavioral Inventory (mini-FBI)","2022","Journal of Alzheimer's Disease","89","1","","299","308","9","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85137162185&doi=10.3233%2fJAD-220173&partnerID=40&md5=7dc9e1b78b09c6025f5850813a1d92a7","Background: The Frontal Behavioral Inventory (FBI) is a questionnaire designed to quantify behavioral changes in frontotemporal dementia (FTD). Literature showed heterogeneous FBI profiles in FTD versus Alzheimer's disease (AD) with variable occurrence of positive and negative symptoms. Objective: In this study, we constructed a short FBI version (i.e., mini-FBI) with the aim to provide clinicians with a brief tool for the identification of early behavioral changes in behavioral variant of FTD (bvFTD), also facilitating the differential diagnosis with AD. Methods: 40 bvFTD and 33 AD patients were enrolled. FBI items were selected based on internal consistency and exploratory factor analysis. Convergent validity of mini-FBI was also assessed. A behavioral index (i.e., B-index) representing the balance between positive and negative mini-FBI symptoms was computed in order to analyze its distribution in bvFTD through a cluster analysis and to compare performance among patient groups. Results: The final version of the mini-FBI included 12 items, showing a significant convergent validity with the Neuropsychiatric Inventory scores (rp = 0.61, p < 0.001). Cluster analysis split patients in four clusters. bvFTD were included in three different clusters characterized by prevalent positive symptoms, both positive and negative symptoms, or prevalent negative behavioral alterations, similar to a subset of AD patients. A fourth cluster included only AD patients showing no positive symptoms. Conclusion: The mini-FBI is a valuable easily administrable questionnaire able to early identify symptoms effectively contributing to the bvFTD behavioral syndrome, aiding clinician in diagnosis and management.  © 2022 - IOS Press. All rights reserved.","Accuracy; Alzheimer's disease; behavioral disorders; behavioral variant of frontotemporal dementia; diagnosis; frontal syndrome; frontotemporal dementia","accuracy; aged; Article; behavior assessment; behavior change; cognition; controlled study; convergent validity; differential diagnosis; exploratory factor analysis; female; frontal variant frontotemporal dementia; human; internal consistency; major clinical study; male; mini frontal behavioral inventory; Mini Mental State Examination; negative syndrome; neuropsychiatric inventory; positive syndrome; sensitivity and specificity","Karageorgiou E., Miller B.L., Frontotemporal lobar degeneration: A clinical approach, Semin Neurol, 34, pp. 189-201, (2014); Rosness T.A., Engedal K., Chemali Z., Frontotemporal dementia: An updated clinicians guide, J Geriatr Psychiatry Neurol, 29, pp. 271-280, (2016); Seelaar H., Rohrer J.D., Pijnenburg Y.A.L., Fox N.C., Van Swieten J.C., Clinical, genetic and pathological heterogeneity of frontotemporal dementia: A review, J Neurol Neurosurg Psychiatry, 82, pp. 476-486, (2011); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol Sci, 34, pp. 1267-1274, (2013); Barber R., Snowden J.S., Craufurd D., Frontotemporal dementia and Alzheimer's disease: Retrospective differentiation using information from informants, J Neurol Neurosurg Psychiatry, 59, pp. 61-70, (1995); Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J., The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia, Neurology, 44, pp. 2308-2314, (1994); De Deyn P.P., Engelborghs S., Saerens J., Goeman J., Marien P., Maertens K., Nagels G., Martin J.-J., Pickut B.A., The Middelheim Frontality Score: A behavioural assessment scale that discriminates frontotemporal dementia from Alzheimer's disease, Int J Geriatr Psychiatry, 20, pp. 70-79, (2005); Gregory C.A., Frontal variant of frontotemporal dementia: A cross-sectional and longitudinal study of neuropsychiatric features, Psychol Med, 29, pp. 1205-1217, (1999); Lennox R.D., Wolfe R.N., Revision of the Self-Monitoring Scale, J Pers Soc Psychol, 46, pp. 1349-1364, (1984); Kertesz A., Davidson W., Fox H., Frontal behavioral inventory: Diagnostic criteria for frontal lobe dementia, Can J Neurol Sci, 24, pp. 29-36, (1997); Kertesz A., Nadkarni N., Davidson W., Thomas A.W., The Frontal Behavioral Inventory in the differential diagnosis of frontotemporal dementia, J Int Neuropsychol Soc, 6, pp. 460-468, (2000); Alberici A., Geroldi C., Cotelli M., Adorni A., Calabria M., Rossi G., Borroni B., Padovani A., Zanetti O., Kertesz A., The Frontal Behavioural Inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease, Neurol Sci, 28, pp. 80-86, (2007); Blair M., Kertesz A., Davis-Faroque N., Hsiung G.Y.R., Black S.E., Bouchard R.W., Gauthier S., Guzman D.A., Hogan D.B., Rockwood K., Feldman H., Behavioural measures in frontotemporal lobar dementia and other dementias: The utility of the frontal behavioural inventory and the neuropsychiatric inventory in a national cohort study, Dement Geriatr Cogn Disord, 23, pp. 406-415, (2007); Boutoleau-Bretonniere C., Lebouvier T., Volteau C., Jaulin P., Lacomblez L., Damier P., Thomas-Anterion C., Vercelletto M., Prospective evaluation of behavioral scales in the behavioral variant of frontotemporal dementia, Dement Geriatr Cogn Disord, 34, pp. 75-82, (2012); Konstantinopoulou E., Aretouli E., Ioannidis P., Karacostas D., Kosmidis M.H., Behavioral disturbances differentiate frontotemporal lobar degeneration subtypes and Alzheimer's disease: Evidence from the Frontal Behavioral Inventory, Int J Geriatr Psychiatry, 28, pp. 939-946, (2013); Milan G., Lamenza F., Iavarone A., Galeone F., Lore E., De Falco C., Sorrentino P., Postiglione A., Frontal Behavioural Inventory in the differential diagnosis of dementia, Acta Neurol Scand, 117, pp. 260-265, (2008); Pachalska M., Bidzan L., Ukowicz M., Bidzan M., Markiewicz K., Jastrzebowska G., Talar J., Differential diagnosis of behavioral variant of fronto-temporal dementia (bvFTD), Med Sci Monit, 17, pp. 311-321, (2011); Lund T., Groups M., Lund T., Groups M., Lund T., Groups M., Clinical and neuropathological criteria for frontotemporal dementia, J Neurol Neurosurg Psychiatry, 57, pp. 416-418, (1994); Dodich A., Cerami C., Cappa S.F., Marcone A., Golzi V., Zamboni M., Giusti M.C., Iannaccone S., Combined socio-behavioral evaluation improves the differential diagnosis between the behavioral variant of frontotemporal dementia and Alzheimer's disease: In search of neuropsychological markers, J Alzheimers Dis, 61, pp. 761-772, (2018); Hutchinson A.D., Mathias J.L., Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: A meta-analytic review, J Neurol Neurosurg Psychiatry, 78, pp. 917-928, (2007); Hornberger M., Wong S., Tan R., Irish M., Piguet O., Kril J., Hodges J.R., Halliday G., In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease, Brain, 135, pp. 3015-3025, (2012); Hornberger M., Piguet O., Episodic memory in frontotemporal dementia: A critical review, Brain, 135, pp. 678-692; Musa G., Slachevsky A., Munoz-Neira C., Mendez-Orellana C., Villagra R., Gonzalez-Billault C., Ibanez A., Hornberger M., Lillo P., Alzheimer's disease or behavioral variant frontotemporal dementia? Review of key points toward an accurate clinical and neuropsychological diagnosis, J Alzheimers Dis, 73, pp. 833-848, (2020); Whitwell J.L., Alzheimer's disease neuroimaging, Curr Opin Neurol, 31, pp. 396-404, (2018); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Bertoux M., De Souza Lc L.C., O'Callaghan C., Greve A., Sarazin M., Dubois B., Hornberger M., Social cognition deficits: The key to discriminate behavioral variant frontotemporal dementia from Alzheimer's disease regardless of amnesia?, J Alzheimers Dis, 49, pp. 1065-1074, (2015); Johnen A., Bertoux M., Psychological and cognitive markers of behavioral variant frontotemporal dementia-A clinical neuropsychologist's view on diagnostic criteria and beyond, Front Neurol, 10, (2019); Dodich A., Crespi C., Santi G.C., Cappa S.F., Cerami C., Evaluation of discriminative detection abilities of social cognition measures for the diagnosis of the behavioral variant of frontotemporal dementia: A systematic review, Neuropsychol Rev, 31, pp. 251-266, (2021); Gregory C.A., Orrell M., Sahakian B., Hodges J.R., Can frontotemporal dementia and Alzheimer's disease be differentiated using a brief battery of tests?, Int J Geriatr Psychiatry, 12, pp. 375-383, (1997); Suhonen N.M., Hallikainen I., Hanninen T., Jokelainen J., Kruger J., Hall A., Pikkarainen M., Soininen H., Remes A.M., The Modified Frontal Behavioral Inventory (FBI-mod) for patients with frontotemporal lobar degeneration, Alzheimer's disease, and mild cognitive impairment, J Alzheimers Dis, 56, pp. 1241-1251, (2017); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G.P., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T.C.R.J., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 7, pp. 263-269, (2012); Panza F., Lozupone M., Seripa D., Daniele A., Watling M., Giannelli G., Imbimbo B.P., Development of diseasemodifying drugs for frontotemporal dementia spectrum disorders, Nat Rev Neurol, 16, pp. 213-228, (2020); Boxer A.L., Lipton A.M., Womack K., Merrilees J., Neuhaus J., Pavlic D., Gandhi A., Red D., Martin-Cook K., Svetlik D., Miller B.L., An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration, Alzheimer Dis Assoc Disord, 23, pp. 211-217, (2009); Diehl-Schmid J., Forstl H., Perneczky R., Pohl C., Kurz A., A 6-month, open-label study of memantine in patients with frontotemporal dementia, Int J Geriatr Psychiatry, 23, pp. 754-759, (2008); Finger E.C., MacKinley J., Blair M., Oliver L.D., Jesso S., Tartaglia M.C., Borrie M., Wells J., Dziobek I., Pasternak S., Mitchell D.G.V., Rankin K., Kertesz A., Boxer A., Oxytocin for frontotemporal dementia:Arandomized dosefinding study of safety and tolerability, Neurology, 84, pp. 174-181, (2015); Kertesz A., Davidson W., McCabe P., Munoz D., Behavioral quantitation is more sensitive than cognitive testing in frontotemporal dementia, Alzheimer Dis Assoc Disord, 17, pp. 223-229, (2003); Heidler-Gary J., Gottesman R., Newhart M., Chang S., Ken L., Hillis A.E., Utility of behavioral versus cognitive measures in differentiating between subtypes of frontotemporal lobar degeneration and Alzheimer's disease, Dement Geriatr Cogn Disord, 23, pp. 184-193, (2007); Ramanan S., Bertoux M., Flanagan E., Irish M., Piguet O., Hodges J.R., Hornberger M., Longitudinal executive function and episodic memory profiles in behavioral-variant frontotemporal dementia and Alzheimer's disease, J Int Neuropsychol Soc, 23, pp. 34-43, (2017); Wong S., Bertoux M., Savage G., Hodges J.R., Piguet O., Hornberger M., Comparison of prefrontal atrophy and episodic memory performance in dysexecutive Alzheimer's disease and behavioral-variant frontotemporal dementia, J Alzheimers Dis, 51, pp. 889-903, (2016); Catricala E., Gobbi E., Battista P., Miozzo A., Polito C., Boschi V., Esposito V., Cuoco S., Barone P., Sorbi S., Cappa S.F., Garrard P., SAND: A Screening for Aphasia in NeuroDegeneration. Development and normative data, Neurol Sci, 38, pp. 1469-1483, (2017); Peterson K.A., Jones P.S., Patel N., Tsvetanov K.A., Ingram R., Cappa S.F., Lambon Ralph M.A., Patterson K., Garrard P., Rowe J.B., Language disorder in progressive supranuclear palsy and corticobasal syndrome: Neural correlates and detection by the MLSE screening tool, Front Aging Neurosci, 13, pp. 1-11, (2021); Matias-Guiu J.A., Pytel V., Hernandez-Lorenzo L., Patel N., Peterson K.A., Matias-Guiu J., Garrard P., Cuetos F., Spanish version of the Mini-Linguistic State Examination for the diagnosis of primary progressive aphasia, J Alzheimers Dis, 83, pp. 771-778, (2021); Hardy C.J.D., Buckley A.H., Downey L.E., Lehmann M., Zimmerer V.C., Varley R.A., Crutch S.J., Rohrer J.D., Warrington E.K., Warren J.D., The language profile of behavioral variant frontotemporal dementia, J Alzheimers Dis, 50, pp. 359-371, (2016); Geraudie A., Diaz Rivera M., Montembeault M., Garcia A.M., Language in behavioral variant frontotemporal dementia: Another stone to be turned in Latin America, Front Neurol, 12, (2021); Liu W., Miller B.L., Kramer J.H., Rankin K., Wyss-Coray C., Gearhart R., Phengrasamy L., Weiner M., Rosen H.J., Behavioral disorders in the frontal and temporal variants of frontotemporal dementia, Neurology, 62, pp. 742-748, (2004); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Senjem M.L., Shiung M.M., Boeve B.F., Knopman D.S., Parisi J.E., Dickson D.W., Petersen R.C., Jack C.R., Josephs K.A., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia:Acluster analysis study, Brain, 132, pp. 2932-2946, (2009); Borroni B., Grassi M., Premi E., Gazzina S., Alberici A., Cosseddu M., Paghera B., Padovani A., Neuroanatomical correlates of behavioural phenotypes in behavioural variant of frontotemporal dementia, Behav Brain Res, 235, pp. 124-129, (2012); Sheelakumari R., Bineesh C., Varghese T., Kesavadas C., Verghese J., Mathuranath P.S., Neuroanatomical correlates of apathy and disinhibition in behavioural variant frontotemporal dementia, Brain Imaging Behav, 14, pp. 2004-2011, (2020); Tranel D., Bechara A., Denburg N.L., Asymmetric functional roles of right and left ventromedial prefrontal cortices in social conduct, decision-making, and emotional processing, Cortex, 38, pp. 589-612, (2002); Benussi A., Premi E., Gazzina S., Brattini C., Bonomi E., Alberici A., Jiskoot L., Van Swieten J.C., Sanchez-Valle R., Moreno F., Laforce R., Graff C., Synofzik M., Galimberti D., Masellis M., Tartaglia C., Rowe J.B., Finger E., Vandenberghe R., De Mendonca A., Tagliavini F., Santana I., Ducharme S., Butler C.R., Gerhard A., Levin J., Danek A., Otto M., Frisoni G., Ghidoni R., Sorbi S., Le Ber I., Pasquier F., Peakman G., Todd E., Bocchetta M., Rohrer J.D., Borroni B., Progression of behavioral disturbances and neuropsychiatric symptoms in patients with genetic frontotemporal dementia, JAMA Netw Open, 4, (2021); Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Fazio F., Perani D., Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration, Ann Neurol, 57, pp. 216-225, (2005); Van Langenhove T., Leyton C.E., Piguet O., Hodges J.R., Comparing longitudinal behavior changes in the primary progressive aphasias, J Alzheimers Dis, 53, pp. 1033-1042, (2016); Dodich A., Crespi C., Santi G.C., Luzzi S., Ranaldi V., Iannaccone S., Marcone A., Zamboni M., Cappa S.F., Cerami C., Diagnostic accuracy of affective social tasks in the clinical classification between the behavioral variant of frontotemporal dementia and other neurodegenerative disease, J Alzheimers Dis, 80, pp. 1401-1411, (2021); Davis M., Measuring individual differences in empathy: Evidence for a multidimensional approach, J Personal Soc Psycholoy, 44, pp. 113-126, (1983); Morris R.G., Mograbi D.C., Anosognosia, autobiographical memory and self knowledge in Alzheimer's disease, Cortex, 49, pp. 1553-1565, (2013)","2-s2.0-85137162185"
"Cerami C.; Galandra C.; Santi G.C.; Dodich A.; Cappa S.F.; Vecchi T.; Crespi C.","Cerami, Chiara (25722905400); Galandra, Caterina (36806194800); Santi, Gaia Chiara (57217289456); Dodich, Alessandra (56001713900); Cappa, Stefano Francesco (7005836132); Vecchi, Tomaso (6603719753); Crespi, Chiara (57034303800)","25722905400; 36806194800; 57217289456; 56001713900; 7005836132; 6603719753; 57034303800","Risk-Aversion for Negative Health Outcomes May Promote Individual Compliance to Containment Measures in Covid-19 Pandemic","2021","Frontiers in Psychology","12","","666454","","","","9","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109125829&doi=10.3389%2ffpsyg.2021.666454&partnerID=40&md5=156e829ee8aee1ca6ba5eb68fb2fbce0","First-person experience of stressful life events can change individuals' risk attitudes, driving to increased or decreased risk perception. This shift to more risk-averse or risk-loving behaviors may find a correlate in the individual psycho-socio-emotional profile. To this purpose, we aimed to estimate the relationship between differences in risk-taking attitudes toward possible negative health outcomes and psycho-socio-emotional dimensions modulating the experience of life-threatening situations, in the context of the Covid-19 pandemic. In March 2020, we launched the PsyCovid Study (https://wprn.org/item/428452) to assess psycho-socio-emotional changes due to Covid-19 pandemic in the Italian population. Additionally, we distributed to 130 participants the Covid-19 Risk Task, including monetary and health-related stimuli, estimating a measure of risk-aversion toward health and classifying participants on the basis of their risk-attitude profiles. The set of psycho-socio-emotional variables was reduced to three PCA components: Proactivity, Isolation, Inactivity. The individual degree of risk-aversion toward negative health outcomes was directly related to Proactivity, encasing empathic, social support and positive coping strategies, which may prompt individuals to put in place self-protection strategies toward possible negative health consequences. These findings indicate that a risk-averse profile toward possible negative health outcomes may be associated to higher levels of individual prosocial and proactive dispositions, possibly making individuals' more compliant with the social and hygienic guidelines and, thus, reducing their exposure to the SARS-CoV-2 infection. © Copyright © 2021 Cerami, Galandra, Santi, Dodich, Cappa, Vecchi and Crespi.","coping styles; COVID-19; empathy; loneliness; negative health outcomes; risk aversion","","Abdi H., Williams L.J., Principal component analysis, WIREs Comp. Stat, 2, pp. 433-459, (2010); Albert S.M., Duffy J., Differences in risk aversion between young and older adults, Neurosci. Neuroecon, 2012, (2012); AlHumaid J., Ali S., Farooq I., The psychological effects of the COVID-19 pandemic and coping with them in Saudi Arabia, Psychol. Trauma, 12, pp. 505-507, (2020); Blum S., Dobrotic I., Childcare-policy responses in the COVID-19 pandemic: unpacking cross-country variation, Eur. Soc, 23, pp. S545-S563, (2021); Bressi C., Taylor G., Parker J., Bressi S., Brambilla V., Aguglia E., Et al., Cross validation of the factor structure of the 20-item Toronto alexithymia scale: an Italian multicenter study, J. Psychosom. Res, 41, pp. 551-559, (1996); Brooks S.K., Dunn R., Amlot R., Rubin G.J., Running title: infectious disease outbreaks, J. Occup. Environ. Med, 60, pp. 248-257, (2018); Cellini N., Canale N., Mioni G., Costa S., Changes in sleep pattern, sense of time and digital media use during COVID-19 lockdown in Italy, J. Sleep Res, 29, (2020); Cerami C., Canevelli M., Santi G., Galandra C., Dodich A., Cappa S., Et al., Identifying frail populations for disease risk prediction and intervention planning in the Covid-19 era: a focus on social isolation and psychosocial vulnerability, PsyArXiv [preprint], (2020); Cerami C., Santi G.C., Galandra C., Dodich A., Cappa S.F., Vecchi T., Et al., Covid-19 outbreak in Italy: are we ready for the psychosocial and the economic crisis? Baseline findings from the psycovid study, Front. Psychiatry, 11, (2020); Charpentier C.J., Aylward J., Roiser J.P., Robinson O.J., Enhanced risk aversion, but not loss aversion, in unmedicated pathological anxiety, Biol. Psychiatry, 81, pp. 1014-1022, (2017); Chew Q.H., Wei K.C., Vasoo S., Chua H.C., Sim K., Narrative synthesis of psychological and coping responses towards emerging infectious disease outbreaks in the general population: practical considerations for the COVID-19 pandemic, Singapore Med. J, 61, pp. 350-356, (2020); Commodari E., La Rosa V.L., Adolescents in quarantine during COVID-19 pandemic in Italy: perceived health risk, beliefs, psychological experiences and expectations for the future, Front. Psychol, 11, (2020); Commodari E., La Rosa V.L., Coniglio M.A., Health risk perceptions in the era of the new coronavirus: are the Italian people ready for a novel virus? A cross-sectional study on perceived personal and comparative susceptibility for infectious diseases, Public Health, 187, pp. 8-14, (2020); Davis M.H., Measuring individual differences in empathy: evidence for a multidimensional approach, J. Pers. Soc. Psychol, 44, pp. 113-126, (1983); Dawson D.L., Golijani-Moghaddam N., COVID-19: psychological flexibility, coping, mental health, and wellbeing in the UK during the pandemic, J. Contextual Behav. Sci, 17, pp. 126-134, (2020); Del Boca D., Oggero N., Profeta P., Rossi M., Women's and men's work, housework and childcare, before and during COVID-19, Rev. Econ. Household, 18, pp. 1001-1017, (2020); Del Boca D., Oggero N., Profeta P., Rossi M., Women's Work, Housework and Childcare, Before and During COVID-19, (2020); Ding Y., Xu J., Huang S., Xie S., Risk perception and depression in public health crises: evidence from the COVID-19 crisis in China, Int. J. Environ. Res. Public Health, 17, (2020); Foa C., Tonarelli A., Caricati L., Fruggeri L., COPE-NVI-25: validazione italiana della versione ridotta della coping orientation to the problems experienced (COPE-NVI), Psicol. Salute, 2, pp. 123-140, (2015); Galandra C., Cerami C., Santi G., Dodich A., Cappa S., Vecchi T., Et al., Job loss and health threatening events modulate risk-taking behaviours in the Covid-19 emergency, Sci. Rep, 10, (2020); Godinic D., Obrenovic B., Khudaykulov A., Effects of economic uncertainty on mental health in the COVID-19 pandemic context: social identity disturbance, job uncertainty and psychological well-being model, Int. J. Innov. Econ. Dev, 6, pp. 61-74, (2020); Holt C.A., Laury S.K., Risk aversion and incentive effects, Am. Econ. Rev, 92, pp. 1644-1655, (2002); Jakiela P., Ozier O., The impact of violence on individual risk preferences: evidence from a natural experiment, Rev. Econ. Stat, 101, pp. 547-559, (2018); Kesavayuth D., Poyago-Theotoky J., Tran D.B., Zikos V., Locus of control, health and healthcare utilization, Econ. Model, 86, pp. 227-238, (2020); Leduc S., Liu Z., The uncertainty channel of the coronavirus, Fed. Reserve Bank San Francisco Econ. Lett, 7, pp. 1-05, (2020); Leon-Zarceno E., Moreno-Tenas A., Boix Vilella S., Garcia-Naveira A., Serrano-Rosa M.A., Habits and psychological factors associated with changes in physical activity due to COVID-19 confinement, Front. Psychol, 12, (2021); Mazza C., Ricci E., Biondi S., Colasanti M., Ferracuti S., Napoli C., Et al., A nationwide survey of psychological distress among italian people during the covid-19 pandemic: immediate psychological responses and associated factors, Int. J. Environ. Res. Public Health, 17, pp. 1-14, (2020); Orri Stefansson H., Bradley R., What is risk aversion?, Br. J. Philos. Sci, 70, pp. 77-102, (2019); Rodriguez-Rey R., Garrido-Hernansaiz H., Collado S., Psychological impact and associated factors during the initial stage of the coronavirus (COVID-19) pandemic among the general population in Spain, Front. Psychol, 11, (2020); Ruffolo M., Price D., Schoultz M., Leung J., Bonsaksen T., Thygesen H., Et al., Employment uncertainty and mental health during the COVID-19 pandemic initial social distancing implementation: a cross-national study, Glob. Soc. Welfare, 1, (2021); Rutter H., Wolpert M., Greenhalgh T., Managing uncertainty in the covid-19 era, BMJ, 370, (2020); Safi-Keykaleh M., Khorasani-Zavareh D., Bohm K., Factors affecting emergency medical technicians' on-scene decision-making in emergency situations: a qualitative study, Front. Emerg. Med, 4, (2020); Sani G., Janiri D., Di Nicola M., Janiri L., Ferretti S., Chieffo D., Mental health during and after the COVID-19 emergency in Italy, Psychiatry Clin. Neurosci, 74, (2020); Serafini G., Parmigiani B., Amerio A., Aguglia A., Sher L., Amore M., The psychological impact of COVID-19 on the mental health in the general population, Qjm, 113, pp. 229-235, (2020); Shupp R., Loveridge S., Skidmore M., Lim J., Rogers C., Risk, loss, and ambiguity aversion after a natural disaster, Econ. Disas. Clim. Change, 1, pp. 121-142, (2017); Taylor B.J., Risk-managing decision-making: a psycho-social rationality model, Br. J. Soc. Work, (2020); Torales J., O'Higgins M., Castaldelli-Maia J.M., Ventriglio A., The outbreak of COVID-19 coronavirus and its impact on global mental health, Int. J. Soc. Psychiatry, 66, pp. 317-320, (2020); Wallston K.A., Strudler Wallston B., DeVellis R., Development of the multidimensional health locus of control (MHLC) scales, Health Educ. Monogr, 6, pp. 160-170, (1978); Xiong J., Lipsitz O., Nasri F., Lui L.M.W., Gill H., Phan L., Et al., Impact of COVID-19 pandemic on mental health in the general population: a systematic review, J. Affect. Disord, 277, pp. 55-64, (2020); Xu S., Pan Y., Wang Y., Spaeth A.M., Qu Z., Rao H., Real and hypothetical monetary rewards modulate risk taking in the brain, Sci. Rep, 6, pp. 1-7, (2016); Yang X.Y., Gong R.N., Sassine S., Jantchou P., Risk perception of COVID-19 infection and adherence to preventive measures among adolescents and young adults, Children, 7, (2020); Zammuner V., Italians-social and emotional loneliness: the results of five studies, World Acad. Sci. Eng. Technol. Int. J. Soc. Behav. Educ. Econ. Bus. Indus. Eng, 2, pp. 416-428, (2008); Zhu Y., Wang C., The lonelier, the more conservative? A research about loneliness and risky decision-making, Psychology, 8, pp. 1570-1585, (2017)","2-s2.0-85109125829"
"Crespi C.; Cerami C.; Dodich A.; Canessa N.; Iannaccone S.; Corbo M.; Lunetta C.; Falini A.; Cappa S.F.","Crespi, Chiara (57034303800); Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Canessa, Nicola (24334215800); Iannaccone, Sandro (7005943171); Corbo, Massimo (7006723926); Lunetta, Christian (7801365932); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132)","57034303800; 25722905400; 56001713900; 24334215800; 7005943171; 7006723926; 7801365932; 7003494994; 7005836132","Microstructural correlates of emotional attribution impairment in non-demented patients with amyotrophic lateral sclerosis","2016","PLoS ONE","11","8","e0161034","","","","16","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84983438340&doi=10.1371%2fjournal.pone.0161034&partnerID=40&md5=85b6df12fac3ff709e1f909c9b4dc758","Impairments in the ability to recognize and attribute emotional states to others have been described in amyotrophic lateral sclerosis patients and linked to the dysfunction of key nodes of the emotional empathy network. Microstructural correlates of such disorders are still unexplored. We investigated the white-matter substrates of emotional attribution deficits in a sample of amyotrophic lateral sclerosis patients without cognitive decline. Thirteen individuals with either probable or definite amyotrophic lateral sclerosis and 14 healthy controls were enrolled in a Diffusion Tensor Imaging study and administered the Story-based Empathy Task, assessing the ability to attribute mental states to others (i.e., Intention and Emotion attribution conditions). As already reported, a significant global reduction of empathic skills, mainly driven by a failure in Emotion Attribution condition, was found in amyotrophic lateral sclerosis patients compared to healthy subjects. The severity of this deficit was significantly correlated with fractional anisotropy along the forceps minor, genu of corpus callosum, right uncinate and inferior fronto-occipital fasciculi. The involvement of frontal commissural fiber tracts and right ventral associative fronto-limbic pathways is the microstructural hallmark of the impairment of high-order processing of socio-emotional stimuli in amyotrophic lateral sclerosis. These results support the notion of the neurofunctional and neuroanatomical continuum between amyotrophic lateral sclerosis and frontotemporal dementia. © 2016 Crespi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","","Amyotrophic Lateral Sclerosis; Brain; Case-Control Studies; Cognition Disorders; Diffusion Tensor Imaging; Emotions; Empathy; Facial Expression; Female; Humans; Male; Middle Aged; Neuropsychological Tests; adult; amyotrophic lateral sclerosis; Article; brain commissure; clinical article; controlled study; corpus callosum; diffusion tensor imaging; disease severity; emotion assessment; emotional attribution impairment; emotional disorder; empathy; female; forceps minor; fractional anisotropy; frontal commissural fiber tract; genu of corpus callosum; human; inferior frontooccipital fasciculus; limbic system; male; nerve tract; nuclear magnetic resonance scanner; story based empathy task; uncinate fasciculus; ventral associative frontolimbic pathway; white matter lesion; amyotrophic lateral sclerosis; brain; case control study; Cognition Disorders; comparative study; complication; diagnostic imaging; emotion; facial expression; middle aged; neuropsychological test; pathophysiology; physiology; procedures; psychology","Goldstein L.H., Abrahams S., Changes in cognition and behaviour in amyotrophic lateral sclerosis: Nature of impairment and implications for assessmentt, Lancet Neurol, 12, 4, pp. 368-380, (2013); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S.A., Et al., Frontotemporal lobar degeneration A consensus on clinical diagnostic criteria, Neurology, 51, 6, pp. 1546-1554, (1998); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Consonni M., Iannaccone S., Cerami C., Frasson P., Lacerenza M., Lunetta C., Et al., The cognitive and behavioural profile of amyotrophic lateral sclerosis: Application of the consensus criteria, Behav Neurol, 27, 2, pp. 143-153, (2013); Lomen-Hoerth C., Clinical phenomenology and neuroimaging correlates in ALS-FTD, J Mol Neurosci, 45, 3, pp. 656-662, (2011); Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Et al., The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study, J Neurol Neurosurg Psychiatry, 83, 1, pp. 102-108, (2012); Boeve B.F., Boylan K.B., Graff-Radford N.R., DeJesus-Hernandez M., Knopman D.S., Pedraza O., Et al., Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72, Brain, 135, 3, pp. 765-783, (2012); Callister J.B., Pickering-Brown S.M., Pathogenesis/genetics of frontotemporal dementia and how it relates to ALS, Exp Neurol, 262, pp. 84-90, (2014); Ling S.C., Polymenidou M., Cleveland D.W., Converging mechanisms in ALS and FTD: Disrupted RNA and protein homeostasis, Neuron, 79, 3, pp. 416-438, (2013); Renton A.E., Chio A., Traynor B.J., State of play in amyotrophic lateral sclerosis genetics, Nat Neurosci, 17, 1, pp. 17-23, (2014); Abrahams S., Goldstein L.H., Suckling J., Ng V., Simmons A., Chitnis X., Et al., Frontotemporal white matter changes in amyotrophic lateral sclerosis, J Neurol, 252, 3, pp. 321-331, (2005); Lillo P., Mioshi E., Burrell J.R., Kiernan M.C., Hodges J.R., Hornberger M., Grey and white matter changes across the amyotrophic lateral sclerosis-frontotemporal dementia continuum, PLoS One, 7, 8, (2012); Tsermentseli S., Leigh P.N., Goldstein L., The anatomy of cognitive impairment in amyotrophic lateral sclerosis: More than frontal lobe dysfunction, Cortex, 48, 2, pp. 166-182, (2012); Consonni M., Rossi S., Cerami C., Marcone A., Iannaccone S., Cappa S.F., Executive dysfunction affects word list recall performance: Evidence from amyotrophic lateral sclerosis and other neurodegenerative diseases, J Neuropsychol, (2015); Lillo P., Mioshi E., Zoing M.C., Kiernan M.C., Hodges J.R., How common are behavioural changes in amyotrophic lateral sclerosis?, Amyotroph Lateral Sc, 12, 1, pp. 45-51, (2011); Tsujimoto M., Senda J., Ishihara T., Niimi Y., Kawai Y., Atsuta N., Et al., Behavioral changes in early ALS correlate with voxel-based morphometry and diffusion tensor imaging, J Neurol Sci, 307, 1, pp. 34-40, (2011); Woolley S.C., Zhang Y., Schuff N., Weiner M.W., Katz J.S., Neuroanatomical correlates of apathy in ALS using 4 Tesla diffusion tensor MRI, Amyotroph Lateral Sc, 12, 1, pp. 52-58, (2011); Beeldman E., Raaphorst J., Twennaar M.K., De Visser M., Schmand B.A., De Haan R.J., The cognitive profile of ALS: A systematic review and meta-analysis update, J Neurol Neurosurg Psychiatry, 87, 6, pp. 611-619, (2016); Crespi C., Cerami C., Dodich A., Canessa N., Arpone M., Iannaccone S., Et al., Microstructural white matter correlates of emotion recognition impairment in Amyotrophic Lateral Sclerosis, Cortex, 53, pp. 1-8, (2014); Zimmerman E.K., Zachary Simmons M.D., Barrett A.M., Emotional perception deficits in amyotrophic lateral sclerosis, Cogn Behav Neurol, 2007, 20, (2007); Lule D., Kurt A., Jurgens R., Kassubek J., Diekmann V., Kraft E., Et al., Emotional responding in amyotrophic lateral sclerosis, J Neurol, 252, 12, pp. 1517-1524, (2005); Palmieri A., Naccarato M., Abrahams S., Bonato M., D'Ascenzo C., Balestreri S., Et al., Right hemisphere dysfunction and emotional processing in ALS: An fMRI study, J Neurol, 257, 12, pp. 1970-1978, (2010); Papps B., Abrahams S., Wicks P., Leigh P.N., Goldstein L.H., Changes in memory for emotional material in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 43, 8, pp. 1107-1114, (2005); Girardi A., MacPherson S.E., Abrahams S., Deficits in emotional and social cognition in amyotrophic lateral sclerosis, Neuropsychology, 25, 1, (2011); Meier S.L., Charleston A.J., Tippett L.J., Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis, Brain, 133, 11, pp. 3444-3457, (2010); Cavallo M., Adenzato M., MacPherson S.E., Karwig G., Enrici I., Abrahams S., Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis, PLoS One, 6, 10, pp. e25948-e25948, (2011); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Et al., Emotional empathy in amyotrophic lateral sclerosis: A behavioural and voxel-based morphometry study, Amyotroph Lateral Scler Frontotemporal Degener, 15, 1-2, pp. 21-29, (2014); Gibbons Z.C., Snowden J.S., Thompson J.C., Happe F., Richardson A., Neary D., Inferring thought and action in motor neurone disease, Neuropsychologia, 45, 6, pp. 1196-1207, (2007); Shamay-Tsoory S.G., Aharon-Peretz J., Perry D., Two systems for empathy: A double dissociation between emotional and cognitive empathy in inferior frontal gyrus versus ventromedial prefrontal lesions, Brain, 132, 3, pp. 617-627, (2009); Shamay-Tsoory S.G., The neural bases for empathy, Neuroscientist, 17, 1, pp. 18-24, (2011); Raz G., Jacob Y., Gonen T., Winetraub Y., Flash T., Soreq E., Hendler T., Cry for her or cry with her: Context-dependent dissociation of two modes of cinematic empathy reflected in network cohesion dynamics, Oc Cogn Affect Neurosci, 9, 1, pp. 30-38, (2014); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, linical staging, and management, Lancet Neurol, 10, 2, pp. 162-172, (2011); Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Gorno-Tempini M.L., Frontal aralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Arch Neurol, 5, 2, pp. 249-255, (2008); Adenzato M., Cavallo M., Enrici I., Theory of mind ability in the behavioural variant of frontotemporal ementia: An analysis of the neural, cognitive, and social levels, Neuropsychologia, 48, 1, pp. 2-12, (2010); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to ocial cognition, Neurol Sci, 34, 8, pp. 1267-1274, (2013); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Et al., Neural correlates of empathic mpairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 10, 6, pp. 27-834, (2014); Kipps C.M., Nestor P.J., Acosta-Cabronero J., Arnold R., Hodges J.R., Understanding social dysfunction in he behavioural variant of frontotemporal dementia: The role of emotion and sarcasm processing, Brain, 9, 3, pp. 592-603; Kumfor F., Piguet O., Disturbance of emotion processing in frontotemporal dementia: A synthesis of cognitive nd neuroimaging findings, Neuropsychol Review, 22, 3, pp. 280-297, (2012); Caminiti S.P., Canessa N., Cerami C., Dodich A., Crespi C., Iannaccone S., Et al., Affective mentalizing and rain activity at rest in the behavioral variant of frontotemporal dementia, NeuroImage Clin, 9, pp. 84-497, (2015); Brooks B.R., Miller R.G., Swash M., Munsat T.L., El Escorial revisited: Revised criteria for the diagnosis of myotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 5, pp. 293-299, (2000); Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Et al., The ALSFRS-R: R revised LS functional rating scale that incorporates assessments of respiratory function, J Neurol Sci, 69, 1, pp. 13-21, (1999); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Et al., Consensus criteria or the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Myotroph Lateral Sc, 10, 3, pp. 131-146, (2009); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing ntention and emotion attribution: Italian standardization and normative data of the Story-based Empathy ask, Neurol Sci, 36, 10, pp. 1907-1912, (2015); Brunet E., Sarfati Y., Hardy-Bayle M.C., Decety J., A PET investigation of the attribution of intentions with nonverbal task, Neuroimage, 11, 2, pp. 157-166, (2000); Sarfati Y., Hardy-Bayle M.C., Besche C., Widlocher D., Attribution of intentions to others in people with chizophrenia: A non-verbal exploration with comic strips, Schizophr Res, 25, 3, pp. 199-209, (1997); Vollm B.A., Taylor A.N., Richardson P., Corcoran R., Stirling J., McKie S., Et al., Neuronal correlates of theory of mind and empathy: A functional magnetic resonance imaging study in a nonverbal task, Neuroimage, 29, 1, pp. 90-98, (2006); Smith S.M., Jenkinson M., Johansen-Berg H., Rueckert D., Nichols T.E., Mackay C.E., Et al., Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data, Neuroimage, 31, 4, pp. 1487-1505, (2006); Smith S.M., Nichols T.E., Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference, Neuroimage, 44, 1, pp. 83-98, (2009); Hua K., Zhang J., Wakana S., Jiang H., Li X., Reich D.S., Et al., Tract probability maps in stereotaxic spaces: Analyses of white matter anatomy and tract-specific quantification, Neuroimage, 39, 1, pp. 336-347, (2008); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, J R Stat Soc Series B, pp. 289-300, (1995); Watermeyer T.J., Brown R.G., Sidle K.C., Oliver D.J., Allen C., Karlsson J., Et al., Executive dysfunction predicts social cognition impairment in amyotrophic lateral sclerosis, J Neurol, pp. 1-10, (2015); Canu E., Agosta F., Riva N., Sala S., Prelle A., Caputo D., Et al., The topography of brain microstructural damage in amyotrophic lateral sclerosis assessed using diffusion tensor MR imaging, AJNR Am J Neuroradiol, 32, 7, pp. 1307-1314, (2011); Filippini N., Douaud G., Mackay C.E., Knight S., Talbot K., Turner M.R., Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis, Neurology, 75, 18, pp. 1645-1652, (2010); Kim M.J., Loucks R.A., Palmer A.L., Brown A.C., Solomon K.M., Marchante A.N., Whalen P.J., The structural and functional connectivity of the amygdala: From normal emotion to pathological anxiety, Behav Brain Res, 223, 2, pp. 403-410, (2011); Von Heide D., Rj Skipper L.M., Klobusicky E., Olson I.R., Dissecting the uncinate fasciculus: Disorders, controversies and a hypothesis, Brain, 136, 6, pp. 1692-1707, (2013); Gallese V., Embodied simulation: From neurons to phenomenal experience, Phenomenol Cogn Sci, 4, 1, pp. 23-48, (2005); Tamietto M., Adenzato M., Geminiani G., De Gelder B., Fast recognition of social emotions takes the whole brain: Interhemispheric cooperation in the absence of cerebral asymmetry, Neuropsychologia, 45, 4, pp. 836-843, (2007); Parkinson C., Wheatley T., Relating anatomical and social connectivity: White matter microstructure predicts emotional empathy, Cereb Cortex, 24, 3, pp. 614-625, (2014); Iacoboni M., Dapretto M., The mirror neuron system and the consequences of its dysfunction, Nat Rev Neurosci, 7, 12, pp. 942-951, (2006); Bridgman M.W., Brown W.S., Spezio M.L., Leonard M.K., Adolphs R., Paul L.K., Facial emotion recognition in agenesis of the corpus callosum, J Neurodev Disord, 6, 1, pp. 1-14, (2014); Fujino J., Takahashi H., Miyata J., Sugihara G., Kubota M., Sasamoto A., Et al., Impaired empathic abilities and reduced white matter integrity in schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry, 48, pp. 117-123, (2014); Hinkley L.B., Marco E.J., Findlay A.M., Honma S., Jeremy R.J., Strominger Z., Et al., The role of corpus callosum development in functional connectivity and cognitive processing, PLoS One, 7, 8, (2012); Miyata J., Yamada M., Namiki C., Hirao K., Saze T., Fujiwara H., Et al., Reduced white matter integrity as a neural correlate of social cognition deficits in schizophrenia, Schizophr Res, 119, 1, pp. 232-239, (2010); Paul L.K., Brown W.S., Adolphs R., Tyszka J.M., Richards L.J., Mukherjee P., Sherr E.H., Agenesis of the corpus callosum: Genetic, developmental and functional aspects of connectivity, Nat Rev Neurosci., 4, pp. 287-299, (2007); Paul L.K., Corsello C., Kennedy D.P., Adolphs R., Agenesis of the corpus callosum and autism: A comprehensive omparison, Brain, (2014); Matsuo K., Mizuno T., Yamada K., Akazawa K., Kasai T., Kondo M., Et al., Cerebral white matter damage in rontotemporal dementia assessed by diffusion tensor tractography, Neuroradiology, 50, 7, pp. 05-611, (2008); Whitwell J.L., Avula R., Senjem M.L., Kantarci K., Weigand S.D., Samikoglu A., Et al., Gray and white matter ater diffusion in the syndromic variants of frontotemporal dementia, Neurology, 74, 16, pp. 1279-1287, (2010); Zhang Y., Schuff N., Du A.T., Rosen H.J., Kramer J.H., Gorno-Tempini M.L., Et al., White matter damage in rontotemporal dementia and Alzheimer's disease measured by diffusion MRI, Brain, 132, 9, pp. 579-2592, (2009); Eisen A., Lemon R., Kiernan M.C., Hornberger M., Turner M.R., Does dysfunction of the mirror neuron system ontribute to symptoms in amyotrophic lateral sclerosis?, Clin Neurophysiol, 126, 7, pp. 1288-1294, (2015); Craig A.D., How do you feel-now? The anterior insula and human awareness, Nat Rev Neurosci, 1, (2009); Craig A.D., Interoception and emotion: A neuroanatomical perspective, Handbook of emotions, pp. 272-288, (2008); Meyer M.L., Masten C.L., Ma Y., Wang C., Shi Z., Eisenberger N.I., Han S., Empathy for the social suffering f friends and strangers recruits distinct patterns of brain activation, Soc Cogn Affect Neurosci, (2012)","2-s2.0-84983438340"
"Iannaccone S.; Cerami C.; Alessio M.; Garibotto V.; Panzacchi A.; Olivieri S.; Gelsomino G.; Moresco R.M.; Perani D.","Iannaccone, S. (7005943171); Cerami, C. (25722905400); Alessio, M. (7006667000); Garibotto, V. (24281297800); Panzacchi, A. (6603278442); Olivieri, S. (6701755659); Gelsomino, G. (58334463700); Moresco, R.M. (7003832341); Perani, D. (7005630261)","7005943171; 25722905400; 7006667000; 24281297800; 6603278442; 6701755659; 58334463700; 7003832341; 7005630261","Corrigendum to Invivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease [Parkinsonism Relat Disord 19 (2013) 47-52]","2013","Parkinsonism and Related Disorders","19","10","","921","","","1","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883266573&doi=10.1016%2fj.parkreldis.2013.06.013&partnerID=40&md5=fcb1a0f6ee49b56ddf790f75362cfff6","[No abstract available]","","erratum; error; priority journal","","2-s2.0-84883266573"
"Cerami C.; Marcone A.; Galimberti D.; Villa C.; Scarpini E.; Cappa S.F.","Cerami, Chiara (25722905400); Marcone, Alessandra (6701496511); Galimberti, Daniela (6701617660); Villa, Chiara (57195622956); Scarpini, Elio (57210771033); Cappa, Stefano F. (7005836132)","25722905400; 6701496511; 6701617660; 57195622956; 57210771033; 7005836132","From genotype to phenotype: Two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder","2011","Journal of Alzheimer's Disease","27","4","","791","797","6","58","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84455193367&doi=10.3233%2fJAD-2011-110788&partnerID=40&md5=1e4c37c50b109e1ff3361537325a4d12","Frontotemporal lobar degeneration (FTLD) is a common early-onset dementia, which shows highly heterogeneous phenotypic presentations. Although an autosomal dominant transmission can be found only in about 10% cases, familial aggregation is frequently observed in FTLD. Recently, the progranulin gene (GRN) was reported to be involved in the disease pathogenesis. We describe two clinically different, apparently sporadic FTLD cases, sharing the previously described GRN mutation g.11019-11022delCACT (relative to nt1, NCBI NG-007886.1), alias Thr272fs, with a premorbid psychiatric history. Both patients are males and were in their sixties when diagnosed clinically with, respectively, the behavioral variant of frontotemporal dementia (bvFTD) and progressive nonfluent aphasia (PNFA). In both cases, the medical history revealed the presence of bipolar spectrum disorders. Mutations in GRN are considered to be a major cause of FTLD. However, the phenotypes associated with these mutations are highly variable. Our description of two novel FTLD genetic cases confirms the high frequency of the g.11019-11022delCACT mutation in Northern Italy. On this basis, we recommend to consider the presence of this mutation as a possible cause of the disease, particularly in patients with premorbid psychiatric symptoms. © 2011-IOS Press and the authors. All rights reserved.","Bipolar disorder; dementia; frontotemporal dementia; frontotemporal lobar degeneration; GRN mutation; primary progressive nonfluent aphasia","duloxetine; lithium; progranulin; risperidone; adult; aggression; aphasia; apraxia; article; bipolar disorder; bipolar II disorder; brain atrophy; clinical article; depression; drug withdrawal; echolalia; fluency disorder; frontal variant frontotemporal dementia; gene mutation; genotype phenotype correlation; human; human tissue; hyperactivity; impulsiveness; insomnia; male; medical history; memory disorder; nuclear magnetic resonance imaging; nucleotide sequence; pathogenesis; priority journal; progressive nonfluent aphasia; sleep disorder; speech disorder; stereotypy","Ratnavalli E., Brayne C., Dawson K., Hodges J.R., The prevalence of frontotemporal dementia, Neurology, 58, 11, pp. 1615-1621, (2002); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (1998); Gorno-Tempini M.L., Dronkers N.F., Rankin K.P., Ogar J.M., Phengrasamy L., Rosen H.J., Johnson J.K., Weiner M.W., Miller B.L., Cognition and Amatomy in Three Variants of Primany Progressive Aphasia, Annals of Neurology, 55, 3, pp. 335-346, (2004); Bird T., Knopman D., VanSwieten J., Rosso S., Feldman H., Tanabe H., Graff-Raford N., Geschwind D., Verpillat P., Hutton M., Epidemiology and genetics of frontotemporal dementia/Pick's Disease, Annals of Neurology, 54, SUPPL. 5, (2003); Goldman J.S., Farmer J.M., Wood E.M., Johnson J.K., Boxer A., Neuhaus J., Lomen-Hoerth C., Wilhelmsen K.C., Lee V.M., Grossman M., Miller B.L., Comparison of family histories in FTLD subtypes and related tauopathies, Neurology, 65, pp. 1817-1819, (2005); Spillantini M.G., Murrell J.R., Goedert M., Farlow M.R., Klug A., Ghetti B., Mutation in the tau gene in familial multiple system tauopathy with presenile dementia, Proceedings of the National Academy of Sciences of the United States of America, 95, 13, pp. 7737-7741, (1998); Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., De Graaff E., Wauters E., Van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Che L.K., Norton J., Morris J.C., Reed L.A., Trojanowski J., Basun H., Lannfelt L., Neystat M., Fahn S., Dark F., Tannenberg T., Dodd P.R., Hayward N., Kwok J.B., Schofield P.R., Andreadis A., Snowden J., Craufurd D., Neary D., Owen F., Oostra B.A., Hardy J., Goate A., Van Swieten J., Mann D., Lynch T., Heutink P., Association of missense and 5β-splicesite mutations in tau with the inherited dementia FTDP-17, Nature, 393, pp. 702-705, (1998); Baker M., Mackenzie I.R., Pickering-Brown S.M., Gass J., Rademakers R., Lindholm C., Snowden J., Adamson J., Sadovnick A.D., Rollinson S., Cannon A., Dwosh E., Neary D., Melquist S., Richardson A., Dickson D., Berger Z., Eriksen J., Robinson T., Zehr C., Dickey C.A., Crook R., McGowan E., Mann D., Boeve B., Feldman H., Hutton M., Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17, Nature, 442, 7105, pp. 916-919, (2006); Cruts M., Gijselinck I., Van Der Zee J., Engelborghs S., Wils H., Pirici D., Rademakers R., Vandenberghe R., Dermaut B., Martin J.-J., Van Duijn C., Peeters K., Sciot R., Santens P., De Pooter T., Mattheijssens M., Van Den Broeck M., Cuijt I., Vennekens K., De Deyn P.P., Kumar-Singh S., Van Broeckhoven C., Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21, Nature, 442, 7105, pp. 920-924, (2006); Buee L., Delacourte A., Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease, Brain Pathology, 9, 4, pp. 681-693, (1999); Eriksen J.L., Mackenzie I.R.A., Progranulin: Normal function and role in neurodegeneration, Journal of Neurochemistry, 104, 2, pp. 287-297, (2008); Gass J., Cannon A., Mackenzie I.R., Boeve B., Baker M., Adamson J., Crook R., Melquist S., Kuntz K., Petersen R., Josephs K., Pickering-Brown S.M., Graff-Radford N., Uitti R., Dickson D., Wszolek Z., Gonzalez J., Beach T.G., Bigio E., Johnson N., Weintraub S., Mesulam M., White III C.L., Woodruff B., Caselli R., Hsiung G.-Y., Feldman H., Knopman D., Hutton M., Rademakers R., Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration, Human Molecular Genetics, 15, 20, pp. 2988-3001, (2006); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurol, 10, pp. 162-172, (2011); Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H.A., MacKenzie I.R., A new subtype of frontotemporal lobar degeneration with FUS pathology, Brain, 132, pp. 2922-2931, (2009); Rademakers R., Cruts M., Van Broeckhoven C., The role of tau (MAPT) in frontotemporal dementia and related tauopathies, Human Mutation, 24, 4, pp. 277-295, (2004); Bruni A.C., Momeni P., Bernardi L., Tomaino C., Frangipane F., Elder J., Kawarai T., Sato C., Pradella S., Wakutani Y., Anfossi M., Gallo M., Geracitano S., Costanzo A., Smirne N., Curcio S.A.M., Mirabelli M., Puccio G., Colao R., Maletta R.G., Kertesz A., St. George-Hyslop P., Hardy J., Rogaeva E., Heterogeneity within a large kindred with frontotemporal dementia: A novel progranulin mutation, Neurology, 69, 2, pp. 140-147, (2007); Borroni B., Archetti S., Alberici A., Agosti C., Gennarelli M., Bigni B., Bonvicini C., Ferrari M., Bellelli G., Galimberti D., Scarpini E., Di Lorenzo D., Caimi L., Caltagirone C., Di Luca M., Padovani A., Progranulin genetic variations in frontotemporal lobar degeneration: Evidence for low mutation frequency in an Italian clinical series, Neurogenetics, 9, pp. 197-205, (2008); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Benussi L., Ghidoni R., Gallone S., Cortini F., Serpente M., Cantoni C., Fumagalli G., Ridolfi E., Cappa S., Binetti G., Franceschi M., Rainero I., Giordana M.T., Mariani C., Bresolin N., Scarpini E., Galimberti D., BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimers disease, J Alzheimers Dis, 23, pp. 701-707, (2011); Josephs K.A., Ahmed Z., Katsuse O., Parisi J.F., Boeve B.F., Knopman D.S., Petersen R.C., Davies P., Duara R., Graff-Radford N.R., Uitti R.J., Rademakers R., Adamson J., Baker M., Hutton M.L., Dickson D.W., Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations, Journal of Neuropathology and Experimental Neurology, 66, 2, pp. 142-151, (2007); Cortini F., Fenoglio C., Guidi I., Venturelli E., Pomati S., Marcone A., Scalabrini Dvilla C., Clerici F., Dallavalle E., Mariani C., Cappa S., Bresolin N., Scarpini E., Galimberti D., Novel exon 1 progranulin gene variant in Alzheimers disease, Eur J Neurol, 15, pp. 1111-1117, (2008); Benussi L., Binetti G., Sina E., Gigola L., Bettecken T., Meitinger T., Ghidoni R., A novel deletion in progranulin gene is associated with FTDP-17 and CBS, Neurobiology of Aging, 29, 3, pp. 427-435, (2008); Borroni B., Bonvicini C., Galimberti D., Tremolizzo L., Papetti A., Archetti S., Turla M., Alberici A., Agosti C., Premi E., Appollonio I., Rainero I., Ferrarese C., Gennarelli M., Scarpini E., Padovani A., Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration, Neurobiol Aging, 32, (2011); Giovagnoli A.R., Del Pesce M., Mascheroni S., Simoncelli M., Laiacona M., Capitani E., Trail Making Test: Normative values from287 normal adult controls, Italian Journal of Neurological Sciences, 17, 4, pp. 305-309, (1996); Spinnler H., Tognoni G., Standardizzazione e taratura italiana di test neuropsicologici, Ital J Neurol Sci, 8, pp. 1-120, (1987); Carlesimo G.A., Caltagirone C., Gainotti G., The mental deterioration battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment, European Neurology, 36, 6, pp. 378-384, (1996); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Rey-Osterrieth complex figure: Normative values in an Italian population sample, Neurological Sciences, 22, 6, pp. 443-447, (2002); McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia: Report of the work group on Frontotemporal Dementia and Pick's Disease, Archives of Neurology, 58, 11, pp. 1803-1809, (2001); Ketter T.A., Nosology, diagnostic challenges, and unmet needs in managing bipolar disorder, J Clin Psychiatry, 71, (2010); Pickering-Brown S.M., Rollinson S., Du Plessis D., Morrison K.E., Varma A., Richardson A.M.T., Neary D., Snowden J.S., Mann D.M.A., Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: Comparison with patients with MAPT and no known mutations, Brain, 131, 3, pp. 721-731, (2008); Rademakers R., Baker M., Gass J., Adamson J., Huey E.D., Momeni P., Spina S., Coppola G., Karydas A.M., Stewart H., Johnson N., Hsiung G.-Y., Kelley B., Kuntz K., Steinbart E., Wood E.M., Yu C.-E., Josephs K., Sorenson E., Womack K.B., Weintraub S., Pickering-Brown S.M., Schofield P.R., Brooks W.S., Van Deerlin V.M., Snowden J., Clark C.M., Kertesz A., Boylan K., Ghetti B., Neary D., Schellenberg G.D., Beach T.G., Mesulam M., Mann D., Grafman J., Mackenzie I.R., Feldman H., Bird T., Petersen R., Knopman D., Boeve B., Geschwind D.H., Miller B., Wszolek Z., Lippa C., Bigio E.H., Dickson D., Graff-Radford N., Hutton M., Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C→T (Arg493X) mutation: An international initiative, Lancet Neurology, 6, 10, pp. 857-868, (2007); Kelley B.J., Haidar W., Boeve B.F., Baker M., Graff-Radford N.R., Krefft T., Frank A.R., Jack Jr. C.R., Shiung M., Knopman D.S., Josephs K.A., Parashos S.A., Rademakers R., Hutton M., Pickering-Brown S., Adamson J., Kuntz K.M., Dickson D.W., Parisi J.E., Smith G.E., Ivnik R.J., Petersen R.C., Prominent phenotypic variability associated with mutations in Progranulin, Neurobiol Aging, 30, pp. 739-751, (2009); Le Ber I., Camuzat A., Hannequin D., Pasquier F., Guedj E., Rovelet-Lecrux A., Hahn-Barma V., Van Der Zee J., Clot F., Bakchine S., Puel M., Ghanim M., Lacomblez L., Mikol J., Deramecourt V., Lejeune P., De La Sayette V., Belliard S., Vercelletto M., Meyrignac C., Van Broeckhoven C., Lambert J.-C., Verpillat P., Campion D., Habert M.-O., Dubois B., Brice A., Clerget-Darpoux F., Didic M., Desnuelle C., Duyckaerts C., Golfier V., Michel B.F., Thomas-Anterion C., Salachas F., Sellal F., Camu W., Phenotype variability in progranulin mutation carriers: A clinical, neuropsychological, imaging and genetic study, Brain, 131, 3, pp. 732-746, (2008); Beck J., Rohrer J.D., Campbell T., Isaacs A., Morrison K.E., Goodall E.F., Warrington E.K., Stevens J., Revesz T., Holton J., Al-Sarraj S., King A., Scahill R., Warren J.D., Fox N.C., Rossor M.N., Collinge J., Mead S., A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series, Brain, 131, 3, pp. 706-720, (2008); Pietroboni A.M., Fumagalli G.G., Ghezzi L., Fenoglio C., Cortini F., Serpente M., Cantoni C., Rotondo E., Corti P., Carecchio M., Bassi M., Bresolin N., Galbiati D., Galimberti D., Scarpini E., Phenotypic heterogeneity of the GRN Asp22fs mutation in a large Italian kindred, J Alzheimers Dis, 24, pp. 253-259, (2011); Benussi L., Binetti G., Sina E., Gigola L., Bettecken T., Meitinger T., Ghidoni R., A novel deletion in progranulin gene is associated with FTDP-17 and CBS, Neurobiology of Aging, 29, 3, pp. 427-435, (2008); Borroni B., Bonvicini C., Galimberti D., Tremolizzo L., Papetti A., Archetti S., Turla M., Alberici A., Agosti C., Premi E., Appollonio I., Rainero I., Ferrarese C., Gennarelli M., Scarpini E., Padovani A., Founder effect and estimation of the age of the Progranulin Thr272fs mutation in 14 Italian pedigrees with frontotemporal lobar degeneration, Neurobiol Aging, 32, (2011); Momeni P., Detucci K., Straub R.E., Weinberger D.R., Davies P., Grafman J., Hardy J., Huey E.D., Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia, Neurocase, 16, pp. 273-279, (2010); Velakoulis D., Walterfang M., Mocellin R., Pantelis C., McLean C., Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: Clinicopathological series and review of cases, Br J Psychiatry, 194, pp. 298-305, (2009)","2-s2.0-84455193367"
"Cerami C.; Dodich A.; Iannaccone S.; Magnani G.; Santangelo R.; Presotto L.; Marcone A.; Gianolli L.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Santangelo, Roberto (57191567809); Presotto, Luca (52564081500); Marcone, Alessandra (6701496511); Gianolli, Luigi (6602754456); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 56001713900; 7005943171; 24496141800; 57191567809; 52564081500; 6701496511; 6602754456; 7005836132; 7005630261","A biomarker study in long-lasting amnestic mild cognitive impairment","2019","Alzheimer's Research and Therapy","10","1","42","","","","19","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060519698&doi=10.1186%2fs13195-018-0369-8&partnerID=40&md5=4fd93f220467624b6f41c5794338980d","Background: Mild cognitive impairment (MCI) is a heterogeneous syndrome resulting from Alzheimer's disease (AD) as well as to non-AD and non-neurodegenerative conditions. A subset of patients with amnestic MCI (aMCI) present with an unusually long-lasting course, a slow rate of clinical neuropsychological progression, and evidence of focal involvement of medial temporal lobe structures. In the present study, we explored positron emission tomography (PET) and cerebrospinal fluid (CSF) biomarkers in a sample of subjects with aMCI with such clinical features in order to provide in vivo evidence to improve disease characterisation in this subgroup. Methods: Thirty consecutive subjects with aMCI who had long-lasting memory impairment (more than 4 years from symptom onset) and a very slow rate of cognitive progression were included. All subjects underwent fluorodeoxyglucose-positron emission tomography (FDG-PET) metabolic imaging. A measure of cerebral amyloid load, by PET and/or CSF, was obtained in 26 of 30 subjects. The mean clinical follow-up was 58.3 ± 10.1 months. Results: No patient progressed to dementia during the follow-up. The typical AD FDG-PET pattern of temporoparietal hypometabolism was not present in any of the subjects. In contrast, a selective medial temporal lobe hypometabolism was present in all subjects, with an extension to frontolimbic regions in some subjects. PET imaging showed absent or low amyloid load in the majority of samples. The values were well below those reported in prodromal AD, and they were slightly elevated in only two subjects, consistent with the CSF β-amyloid (1-42) protein values. Notably, no amyloid load was present in the hippocampal structures. Conclusions: FDG-PET and amyloid-PET together with CSF findings questioned AD pathology as a unique neuropathological substrate in this aMCI subgroup with long-lasting disease course. The possibility of alternative pathological conditions, such as argyrophilic grain disease, primary age-related tauopathy or age-related TDP-43 proteinopathy, known to spread throughout the medial temporal lobe and limbic system structures should be considered in these patients with MCI. © 2018 The Author(s).","Alzheimer's disease; Amyloid-PET; FDG-PET; Medial temporal lobe dysfunction; Mild cognitive impairment; Positron emission tomography","Aged; Aged, 80 and over; Amyloid beta-Peptides; Cognitive Dysfunction; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Longitudinal Studies; Magnetic Resonance Imaging; Male; Mental Status Schedule; Neuropsychological Tests; Peptide Fragments; Positron-Emission Tomography; tau Proteins; amyloid beta protein[1-42]; florbetaben; fluorodeoxyglucose f 18; amyloid beta protein; amyloid beta-protein (1-42); fluorodeoxyglucose f 18; peptide fragment; tau protein; aged; amygdala; Article; cerebrospinal fluid; clinical article; controlled study; episodic memory; female; hippocampus; human; insula; limbic system; lumbar puncture; male; medial temporal lobe; mild cognitive impairment; parietal operculum; positron emission tomography; posterior cingulate; priority journal; standardized uptake value; standardized uptake value ratio; superior temporal gyrus; very elderly; cerebrospinal fluid; cognitive defect; diagnostic imaging; image processing; longitudinal study; mental health; neuropsychological test; nuclear magnetic resonance imaging","Petersen R.C., Mild cognitive impairment as a diagnostic entity, J Intern Med., 256, 3, pp. 183-194, (2004); Sarazin M., Berr C., De Rotrou J., Fabrigoule C., Pasquier F., Legrain S., Et al., Amnestic syndrome of the medial temporal type identifies prodromal ad: A longitudinal study, Neurology., 69, pp. 1859-1867, (2007); Dubois B., Feldman H.H., Jacova C., Hampel H., Molinuevo J.L., Blennow K., Et al., Advancing research diagnostic criteria for Alzheimer's disease: The iwg-2 criteria, Lancet Neurol., 13, 6, pp. 614-629, (2014); Hornberger M., Piguet O., Graham A.J., Nestor P.J., Hodges J.R., How preserved is episodic memory in behavioral variant frontotemporal dementia?, Neurology., 74, 6, pp. 472-479, (2010); Ferrer I., Santpere G., Van Leeuwen F.W., Argyrophilic grain disease, Brain., 131, 6, pp. 1416-1432, (2008); Tolnay M., Probst A., Argyrophilic grain disease, Handb Clin Neurol., 89, pp. 553-563, (2008); Jack C.R., Knopman D.S., Weigand S.D., Wiste H.J., Vemuri P., Lowe V., Et al., An operational approach to national institute on aging-Alzheimer's association criteria for preclinical Alzheimer disease, Ann Neurol., 71, 6, pp. 765-775, (2012); Wisse L.E., Butala N., Das S.R., Davatzikos C., Dickerson B.C., Vaishnavi S.N., Et al., Suspected non-ad pathology in mild cognitive impairment, Neurobiol Aging., 36, 12, pp. 3152-3162, (2015); Jack C.R., Knopman D.S., Chetelat G., Dickson D., Fagan A.M., Frisoni G.B., Et al., Suspected non-Alzheimer disease pathophysiology-concept and controversy, Nat Rev Neurol., 12, 2, pp. 117-124, (2016); Marra C., Villa G., Quaranta D., Valenza A., Vita M.G., Gainotti G., Probable Alzheimer's disease patients presenting as focal temporal lobe dysfunction"" show a slow rate of cognitive decline, J Int Neuropsychol Soc., 18, 1, pp. 144-150, (2012); Cappa A., Calcagni M.L., Villa G., Giordano A., Marra C., De Rossi G., Brain perfusion abnormalities in Alzheimer's disease: Comparison between patients with focal temporal lobe dysfunction and patients with diffuse cognitive impairment, J Neurol Neurosurg Psychiatry., 70, 1, pp. 22-27, (2001); Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: A retrospective study, Lancet Neurol., 10, 9, pp. 785-796, (2011); Whitwell J.L., Dickson D.W., Murray M.E., Weigand S.D., Tosakulwong N., Senjem M.L., Et al., Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study, Lancet Neurol., 11, 10, pp. 868-877, (2012); Prestia A., Caroli A., Van Der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Et al., Prediction of dementia in mci patients based on core diagnostic markers for Alzheimer disease, Neurology., 80, 11, pp. 1048-1056, (2013); Petersen R.C., Aisen P., Boeve B.F., Geda Y.E., Ivnik R.J., Knopman D.S., Et al., Mild cognitive impairment due to Alzheimer disease in the community, Ann Neurol., 74, 2, pp. 199-208, (2013); Duara R., Loewenstein D.A., Shen Q., Barker W., Potter E., Varon D., Et al., Amyloid positron emission tomography with 18f-flutemetamol and structural magnetic resonance imaging in the classification of mild cognitive impairment and Alzheimer's disease, Alzheimers Dement., 9, 3, pp. 295-301, (2013); Caroli A., Prestia A., Galluzzi S., Ferrari C., Van Der Flier W.M., Ossenkoppele R., Et al., Mild cognitive impairment with suspected non-amyloid pathology (snap): Prediction of progression, Neurology., 84, 5, pp. 508-515, (2015); Coan A.C., Kubota B., Bergo F.P., Campos B.M., Cendes F., 3t mri quantification of hippocampal volume and signal in mesial temporal lobe epilepsy improves detection of hippocampal sclerosis, AJNR Am J Neuroradiol., 35, 1, pp. 77-83, (2014); Sjogren M., Vanderstichele H., Agren H., Zachrisson O., Edsbagge M., Wikkelso C., Et al., Tau and aß42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values, Clin Chem., 47, 10, pp. 1776-1781, (2001); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Et al., Eanm procedure guidelines for pet brain imaging using [18f]fdg, version 2, Eur J Nucl Med Mol Imaging., 36, 12, pp. 2103-2110, (2009); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18f]-fdg-pet template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics., 12, 4, pp. 575-593, (2014); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized spm procedure for fdg-pet in dementia diagnosis in a clinical setting, Neuroimage Clin., 6, pp. 445-454, (2014); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Et al., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging., 43, 3, pp. 499-508, (2016); Cerami C., Della Rosa P.A., Magnani G., Santangelo R., Marcone A., Cappa S.F., Et al., Brain metabolic maps in mild cognitive impairment predict heterogeneity of progression to dementia, Neuroimage Clin., 7, pp. 187-194, (2014); Presotto L., Ballarini T., Caminiti S.P., Bettinardi V., Gianolli L., Perani D., Validation of 18f-fdg-pet single-subject optimized spm procedure with different pet scanners, Neuroinformatics., 15, 2, pp. 151-163, (2017); Bettinardi V., Presotto L., Rapisarda E., Picchio M., Gianolli L., Gilardi M.C., Physical performance of the new hybrid pet/ct discovery-690, Med Phys., 38, pp. 5394-5411, (2011); Villemagne V.L., Ong K., Mulligan R.S., Holl G., Pejoska S., Jones G., Et al., Amyloid imaging with 18f-florbetaben in Alzheimer disease and other dementias, J Nucl Med., 52, 8, pp. 1210-1217, (2011); Lewczuk P., Zimmermann R., Wiltfang J., Kornhuber J., Neurochemical dementia diagnostics: A simple algorithm for interpretation of the csf biomarkers, J Neural Transm., 116, 9, pp. 1163-1167, (2009); Lewczuk P., Kornhuber J., Network G.D.C., Toledo J.B., Trojanowski J.Q., Knapik-Czajka M., Et al., Validation of the erlangen score algorithm for the prediction of the development of dementia due to Alzheimer's disease in pre-dementia subjects, J Alzheimers Dis., 48, 2, pp. 433-441, (2015); Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Et al., Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects, Ann Neurol., 65, 4, pp. 403-413, (2009); Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., Et al., Imaging of amyloid ß in Alzheimer's disease with 18f-bay94-9172, a novel pet tracer: Proof of mechanism, Lancet Neurol., 7, 2, pp. 129-135, (2008); Villemagne V.L., Mulligan R.S., Pejoska S., Ong K., Jones G., O'Keefe G., Et al., Comparison of 11c-pib and 18f-florbetaben for aß imaging in ageing and Alzheimer's disease, Eur J Nucl Med Mol Imaging., 39, 6, pp. 983-989, (2012); Ong K.T., Villemagne V.L., Bahar-Fuchs A., Lamb F., Chetelat G., Raniga P., Et al., 18F-florbetaben Aß imaging in mild cognitive impairment, Alzheimers Res Ther., 5, 1, (2013); Ong K.T., Villemagne V.L., Bahar-Fuchs A., Lamb F., Langdon N., Catafau A.M., Et al., Aß imaging with 18f-florbetaben in prodromal Alzheimer's disease: A prospective outcome study, J Neurol Neurosurg Psychiatry., 86, 4, pp. 431-436, (2015); Becker G.A., Ichise M., Barthel H., Luthardt J., Patt M., Seese A., Et al., Pet quantification of 18f-florbetaben binding to ß-amyloid deposits in human brains, J Nucl Med., 54, 5, pp. 723-731, (2013); Teipel S., Grothe M.J., Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease?, Eur J Nucl Med Mol Imaging., 43, 3, pp. 526-536, (2016); Cerami C., Dodich A., Iannaccone S., Marcone A., Lettieri G., Crespi C., Et al., Right limbic fdg-pet hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients, PLoS One., 10, 10, (2015); Cerami C., Dodich A., Lettieri G., Marcone A., Lettieri G., Crespi C., Et al., Different fdg-pet metabolic patterns at single-subject level in the behavioral variant of frontotemporal dementia, Cortex., 83, pp. 101-112, (2016); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain., 134, 9, pp. 2456-2477, (2011); Chetelat G., La Joie R., Villain N., Et al., Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease, Neuroimage Clin., 2, pp. 356-365, (2013); Braak H., Braak E., Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia, Neuropathol Appl Neurobiol., 15, pp. 13-26, (1989); Abner E.L., Kryscio R.J., Schmitt F.A., Fardo D.W., Moga D.C., Ighodaro E.T., Et al., Outcomes after diagnosis of mild cognitive impairment in a large autopsy series, Ann Neurol., 81, 4, pp. 549-559, (2017); Thal D.R., Schultz C., Botez G., Del Tredici K., Mrak R.E., Griffin W.S., Et al., The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology, Neuropathol Appl Neurobiol., 31, 3, pp. 270-279, (2005); Togo T., Isojima D., Akatsu H., Suzuki K., Uchikado H., Katsuse O., Et al., Clinical features of argyrophilic grain disease: A retrospective survey of cases with neuropsychiatric symptoms, Am J Geriatr Psychiatry., 13, 12, pp. 1083-1091, (2005); Saito Y., Yamazaki M., Kanazawa I., Murayama S., Severe involvement of the ambient gyrus in a case of dementia with argyrophilic grain disease, J Neurol Sci., 196, 1-2, pp. 71-75, (2002); Adachi T., Saito Y., Hatsuta H., Funabe S., Tokumaru A.M., Ishii K., Et al., Neuropathological asymmetry in argyrophilic grain disease, J Neuropathol Exp Neurol., 69, 7, pp. 737-744, (2010); Crary J.F., Trojanowski J.Q., Schneider J.A., Abisambra J.F., Abner E.L., Alafuzoff I., Et al., Primary age-related tauopathy (part): A common pathology associated with human aging, Acta Neuropathol., 128, 6, pp. 755-766, (2014); Nag S., Yu L., Wilson R.S., Chen E.Y., Bennett D.A., Schneider J.A., Tdp-43 pathology and memory impairment in elders without pathologic diagnoses of ad or ftld, Neurology., 88, 7, pp. 653-660, (2017); Bien C.G., Helmstaedter C., Elger C.E., Is it really Alzheimer's disease?, J Neurol Neurosurg Psychiatry., 71, 3, pp. 416-417, (2001)","2-s2.0-85060519698"
"Dodich A.; Cerami C.; Canessa N.; Crespi C.; Iannaccone S.; Marcone A.; Realmuto S.; Lettieri G.; Perani D.; Cappa S.F.","Dodich, Alessandra (56001713900); Cerami, Chiara (25722905400); Canessa, Nicola (24334215800); Crespi, Chiara (57034303800); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Realmuto, Sabrina (42462180200); Lettieri, Giada (56680972900); Perani, Daniela (7005630261); Cappa, Stefano F. (7005836132)","56001713900; 25722905400; 24334215800; 57034303800; 7005943171; 6701496511; 42462180200; 56680972900; 7005630261; 7005836132","A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task","2015","Neurological Sciences","36","10","","1907","1912","5","63","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942504255&doi=10.1007%2fs10072-015-2281-3&partnerID=40&md5=f0959576c804b0b2e36137c083b7acc2","Theory of Mind (ToM), the process by which an individual imputes mental states to himself and others, is presently considered as a multidimensional cognitive domain, with two main facets (i.e., cognitive and affective ToM) accounting, respectively, for the ability to understand others’ intention (intention attribution-IA) and emotions (emotion attribution-EA). Despite the large amount of literature investigating the behavioural and neural bases of mentalizing abilities in neurological conditions, there is still a lack of validated neuropsychological tools specifically designed to assess such skills. Here, we report the normative data of the Story-Based Empathy Task (SET), a non-verbal test developed for the assessment of intention and emotion attribution in the neurodegenerative conditions characterized by the impairment of social–emotional abilities. It is an easy-to-administer task including 18 stimuli, sub-grouped into two experimental conditions assessing, respectively, the ability to infer others’ intentions (SET-IA) and emotions (SET-EA), compared to a control condition of causal inference (SET-CI). Normative data were collected in 136 Italian subjects pooled across subgroups homogenous for age (range 20–79 years), sex, and education (at least 5 years). The results show a detrimental effect of age and a beneficial effect of education on both the global score and each subscale, for which we provide correction grids. This new task could be a useful tool to investigate both affective and cognitive aspects of ToM in the course of disorders of socio-emotional behaviour, such as the fronto-temporal dementia spectrum. © 2015, Springer-Verlag Italia.","Affective ToM; Cognitive ToM; Empathy; Italian standardization; Mentalizing; Social cognition","Adult; Age Factors; Aged; Emotions; Empathy; Female; Humans; Intention; Italy; Male; Middle Aged; Neuropsychological Tests; Reference Values; Theory of Mind; Young Adult; adult; aged; Article; behavior assessment; Clinical Dementia Rating; controlled study; educational status; emotion; emotion assessment; emotion attribution; empathy; female; human; intention attribution; Italy; major clinical study; male; mental performance; middle aged; Mini Mental State Examination; standardization; Story Based Empathy Task; task performance; age; behavior; emotion; neuropsychological test; physiology; reference value; standards; theory of mind; young adult","Premack D., Woodruff G., Does the chimpanzee have a theory of mind?, Behav Brain Sci, 1, pp. 515-526, (1978); Frith C.D., Frith U., The neural basis of mentalizing, Neuron, 50, 4, pp. 531-534, (2006); Poletti M., Enrici I., Adenzato M., Cognitive and affective theory of mind in neurodegenerative diseases: neuropsychological, neuroanatomical and neurochemical levels, Neurosci Biobehav Rev, 36, 9, pp. 2147-2164, (2012); Shamay-Tsoory S.G., Harari H., Aharon-Peretz J., Levkovitz Y., The role of the orbitofrontal cortex in affective theory of mind deficits in criminal offenders with psychopathic tendencies, Cortex, 46, 5, pp. 668-677, (2010); Shamay-Tsoory S.G., Aharon-Peretz J., Perry D., Two systems for empathy: a double dissociation between emotional and cognitive empathy in inferior frontal gyrus versus ventromedial prefrontal lesions, Brain, 132, pp. 617-627, (2009); Sebastian C.L., Fontaine N.M., Bird G., Blakemore S.J., Brito S.A., McCrory E.J., Viding E., Neural processing associated with cognitive and affective theory of mind in adolescents and adults, Soc Cogn Affect Neurosci, 7, 1, pp. 53-63, (2012); Shamay-Tsoory S.G., Aharon-Peretz J., Dissociable prefrontal networks for cognitive and affective theory of mind: a lesion study, Neuropsychologia, 45, 13, pp. 3054-3067, (2007); Brune M., ”Theory of mind” in schizophrenia: a review of the literature, Schizophr Bull, 31, 1, pp. 21-42, (2005); Bodden M.E., Mollenhauer B., Trenkwalder C., Cabanel N., Eggert K.M., Unger M.M., Oertel W.H., Kessler J., Dodel R., Kalbe E., Affective and cognitive theory of mind in patients with Parkinson’s disease, Parkinsonism Relat Disord, 16, 7, pp. 466-470, (2010); Cerami C., Dodich A., Canessa N., Crespi C., Iannaccone S., Corbo M., Lunetta C., Consonni M., Scola E., Falini A., Cappa S.F., Emotional empathy in amyotrophic lateral sclerosis: a behavioural and voxel-based morphometry study, Amyotroph Lateral Scler Frontotemporal Degener, 15, 1-2, pp. 21-29, (2014); Wang Y.G., Wang Y.Q., Chen S.L., Zhu C.Y., Wang K., Theory of mind disability in major depression with or without psychotic symptoms: a componential view, Psychiatry Res, 161, 2, pp. 153-161, (2008); Bora E., Yucel M., Pantelis C., Theory of mind impairment: a distinct trait-marker for schizophrenia spectrum disorders and bipolar disorder?, Acta Psychiatr Scand, 120, 4, pp. 253-264, (2009); Sarfati Y., Hardy-Bayle M.C., Besche C., Widlocher D., Attribution of intentions to others in people with schizophrenia: a non-verbal exploration with comic strips, Schizophr Res, 25, 3, pp. 199-209, (1997); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Chierchia G., Scola E., Falini A., Cappa S.F., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 10, 6, pp. 827-834, (2014); Baron-Cohen S., The autistic child’s theory of mind: a case of specific developmental delay, J Child Psychol Psychiatry, 30, 2, pp. 285-297, (1989); Baron-Cohen S., Wheelwright S., Hill J., Raste Y., Plumb I., The “reading the mind in the eyes” test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism, J Child Psychol Psychiatry, 42, 2, pp. 241-251, (2001); Baron-Cohen S., O'Riordan M., Stone V., Jones R., Plaisted K., Recognition of faux pas by normally developing children and children with Asperger syndrome or high-functioning autism, J Autism Dev Disord, 29, 5, pp. 407-418, (1999); Blair M., Marczinski C.A., Davis-Faroque N., Kertesz A., A longitudinal study of language decline in Alzheimer’s disease and frontotemporal dementia, J Int Neuropsychol Soc, 13, 2, pp. 237-245, (2007); Li X., Branch C.A., DeLisi L.E., Language pathway abnormalities in schizophrenia: a review of fMRI and other imaging studies, Curr Opin Psychiatry, 22, 2, pp. 131-139, (2009); Serafin M., Surian L., Il Test degli Occhi: uno strumento per valutare la” teoria della mente, Giornale italiano di psicologia, 31, 4, pp. 839-862, (2004); Prior M., Sartori G., Marchi S., Cognizione sociale e comportamento: uno strumento per la misurazione, (2003); Brunet E., Sarfati Y., Hardy-Bayle M.C., Decety J., A PET investigation of the attribution of intentions with a nonverbal task, Neuroimage, 11, 2, pp. 157-166, (2000); Vollm B.A., Taylor A.N., Richardson P., Corcoran R., Stirling J., McKie S., Deakin J.F., Elliott R., Neuronal correlates of theory of mind and empathy: a functional magnetic resonance imaging study in a nonverbal task, Neuroimage, 29, 1, pp. 90-98, (2006); Capitani E., Laiacona M., Composite neuropsychological batteries and demographic correction: standardization based on equivalent scores, with a review of published data. The Italian Group for the Neuropsychological Study of Ageing, J Clin Exp Neuropsychol, 19, 6, pp. 795-809, (1997); Wilks S., Determination of sample sizes for setting tolerance limits, Ann Math Stat, 12, 1, pp. 91-96, (1941); Bernstein D.M., Thornton W.L., Sommerville J.A., Theory of mind through the ages: older and middle-aged adults exhibit more errors than do younger adults on a continuous false belief task, Exp Aging Res, 37, 5, pp. 481-502, (2011); Li X., Wang K., Wang F., Tao Q., Xie Y., Cheng Q., Aging of theory of mind: the influence of educational level and cognitive processing, Int J Psychol, 48, 4, pp. 715-727, (2013); Thakkar K.N., Brugger P., Park S., Exploring empathic space: correlates of perspective transformation ability and biases in spatial attention, PLoS One, 4, 6, (2009); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Realmuto S., Cappa S.F., Emotion recognition from facial expressions: a normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci, 35, 7, pp. 1015-1021, (2014); Manfrinati A., Sarlo M., Lotto L., Un nuovo set di 60 dilemmi morali: dati normativi italiani per giudizi di accettabilità morale, tempi di decisione e valutazioni emozionali, Giornale italiano di psicologia, 40, 1, pp. 211-230, (2013); Adenzato M., Poletti M., Theory of mind abilities in neurodegenerative diseases: an update and a call to introduce mentalizing tasks in standard neuropsychological assessments Clinical, Neuropsychiatry, 10, pp. 226-234, (2013); Campanella F., Shallice T., Ius T., Fabbro F., Skrap M., Impact of brain tumour location on emotion and personality: a voxel-based lesion-symptom mapping study on mentalization processes, Brain, 137, pp. 2532-2545, (2014); McDonald S., Flanagan S., Social perception deficits after traumatic brain injury: interaction between emotion recognition, mentalizing ability, and social communication, Neuropsychology, 18, 3, pp. 572-579, (2004); Pardini M., Emberti Gialloreti L., Mascolo M., Benassi F., Abate L., Guida S., Viani E., Dal Monte O., Schintu S., Krueger F., Cocito L., Isolated theory of mind deficits and risk for frontotemporal dementia: a longitudinal pilot study, J Neurol Neurosurg Psychiatry, 84, 7, pp. 818-821, (2013)","2-s2.0-84942504255"
"Cerami C.; Valentino F.; Piccoli F.; La Bella V.","Cerami, Chiara (25722905400); Valentino, Francesca (16305344700); Piccoli, Federico (7004620305); La Bella, Vincenzo (57190369466)","25722905400; 16305344700; 7004620305; 57190369466","A cervical myelopathy with a Hirayama disease-like phenotype","2008","Neurological Sciences","29","6","","451","454","3","13","https://www.scopus.com/inward/record.uri?eid=2-s2.0-58149087615&doi=10.1007%2fs10072-008-1058-3&partnerID=40&md5=e092aa38b67e4e4454f2a61f0117a509","A 21-year-old man with a muscular atrophy of the left distal upper extremity is presented. The disorder had been progressive over a few years, showing an exacerbation of the hand's weakness when the patient worked in a chilled environment (i.e., in a cold room). The patient's diagnostic work-up was extensive and the MRI documented the presence of a cervical myelopathy, associated to an inversion of the physiological lordosis at the C5-C6 level, with a phenotype highly resembling Hirayama disease. This case indirectly supports the debated hypothesis that juvenile amyotrophy of the upper limb (Hirayama disease) is actually a type of cervical myelopathy, with a likely ischaemic pathogenesis of the ventral horns. © Springer-Verlag 2008.","Cervical myelopathy; Hirayama disease; MRI; Muscular atrophy","Arm; Cervical Vertebrae; Cold Temperature; Cumulative Trauma Disorders; Disease Progression; Functional Laterality; Humans; Ischemia; Kyphosis; Magnetic Resonance Imaging; Male; Muscle Weakness; Muscle, Skeletal; Muscular Atrophy, Spinal; Neural Pathways; Occupational Diseases; Spinal Cord; Spinal Cord Compression; Syndrome; Young Adult; adult; anamnesis; arm; article; case report; Caucasian; cervical myelopathy; disease course; electromyogram; evoked somatosensory response; hand tremor; Hirayama disease; human; lordosis; male; muscle atrophy; muscle strength; nuclear magnetic resonance imaging; pathogenesis; patient referral; phenotype; weakness","Hirayama K., Tsubaki T., Toyokura Y., Okinaka S., Juvenile muscular atrophy of unilateral upper extremity, Neurology, 13, pp. 373-380, (1963); Schroder R., Keller E., Flacke S., Et al., MRI findings in Hirayama's disease: Flexion-induced cervical myelopathy or intrinsic motor neuron disease?, J Neurol, 246, pp. 1069-1074, (1999); Tataroglu C., Bagdatoglu C., Apaydin F.D., Et al., Hirayama's disease: A case report, Amyotroph Lateral Scler Other Motor Neuron Disord, 4, pp. 264-265, (2003); Chen C.J., Chen C.M., Wu C.H., Et al., Hirayama disease: MR diagnosis, AJNR Am J Neuroradiol, 19, pp. 365-368, (1998); Hirayama K., Tokumaru Y., Cervical dural sac and spinal cord in juvenile muscular atrophy of distal upper extremity, Neurology, 54, pp. 1922-1926, (2000); Robberecht W., Aguirre T., Van den Bosch, Et al., Familial juvenile focal amyotrophy of the upper extremity (Hirayama disease). Superoxide dismutase 1 genotype and activity, Arch Neurol, 54, pp. 46-50, (1996); Suyama C., Suzuki T., Sugimoto Y., Et al., Efficacy of short-latency somatosensory evoked potential (S-SEP) in cases of Hirayama disease, Igaku Kensa, 43, pp. 1717-1723, (1994); Hirayama K., Juvenile muscular atrophy of distal upper extremity (Hirayama disease), Intern Med, 39, pp. 283-290, (2000); Hirayama K., Juvenile muscular atrophy of distal upper extremity (Hirayama disease): Focal cervical ischaemic polyomyelopathy, Neuropathology, 20, (2000); Misra U.K., Kalita J., Central motor conduction in Hirayama disease, Electroenceph Clin Neurophysiol, 97, pp. 73-76, (1995); Misra U.K., Kalita J., Mishra V.N., Et al., Effect of neck flexion on F wave, somatosensory evoked potentials, and magnetic resonance imaging in Hirayama disease, J Neurol Neurosurg Psychiatry, 77, pp. 695-698, (2006); Nezu A., Kimura S., Uehara S., Et al., Magnetic stimulation of motor cortex in children: Maturity of corticospinal pathway and problem of clinical application, Brain Dev, 19, pp. 176-180, (1997); Paus T., Zijdenbos A., Worsley K., Et al., Structural maturation of neural pathways in children and adolescents: In vivo study, Science, 283, pp. 1908-1911, (1999); Yoshimura K., Kurashige T., Age-related changes in the posterior limb of the internal capsule revealed by magnetic resonance imaging, Brain Dev, 22, pp. 118-122, (2000)","2-s2.0-58149087615"
"Cerami C.; Marcone A.; Crespi C.; Iannaccone S.; Marangoni C.; Dodich A.; Giusti M.C.; Zamboni M.; Golzi V.; Cappa S.F.","Cerami, C. (25722905400); Marcone, A. (6701496511); Crespi, C. (57034303800); Iannaccone, S. (7005943171); Marangoni, C. (6701501470); Dodich, A. (56001713900); Giusti, M.C. (57200972115); Zamboni, M. (36777386200); Golzi, V. (6508258301); Cappa, S.F. (7005836132)","25722905400; 6701496511; 57034303800; 7005943171; 6701501470; 56001713900; 57200972115; 36777386200; 6508258301; 7005836132","Motor neuron dysfunctions in the frontotemporal lobar degeneration spectrum: A clinical and neurophysiological study","2015","Journal of the Neurological Sciences","351","1-2","","72","77","5","19","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84926407860&doi=10.1016%2fj.jns.2015.02.039&partnerID=40&md5=34af3254f09b0b2d84660ab9dcb3e443","Background Although only a few frontotemporal lobar degeneration (FTLD) patients develop frank amyotrophic lateral sclerosis (ALS), motor neuron dysfunctions (MNDys) occur in a larger proportion of patients. The aim of this study is to evaluate MNDys and ALS in a sample of consecutively enrolled sporadic FTLD patients. Methods Clinical and neurophysiological evaluations (i.e. needle electromyography) assessed lower (LMN) and upper (UMN) motor neuron function at the baseline in 70 probable FTLD patients (i.e., 26 behavioural variant-bvFTD, 20 primary progressive aphasias-PPAs and 24 corticobasal syndrome-CBS). To obtain a more accurate estimation, quantitative scales were also applied (i.e. ALSFRS-r and UMN scale). Patients were screened for MAPT, GRN and C9orf72 mutations. A mean clinical follow-up of 27.8 ± 22.4 months assessed MNDys progression and the clinical presentation of ALS. Results Five genetic cases were identified. Within the sample of sporadic patients, a relative low rate of FTLD patients was diagnosed as probable ALS (5%), while a higher proportion of patients (17%) showed clinical and neurophysiological MNDys. Thirteen patients (20%) presented with isolated clinical signs of LMN and/or UMN dysfunction, and 8 patients (12%) showed neurogenic changes at the electromyography. No differences in FTLD phenotype and disease duration were found between MNDys positive and negative patients. Clinical MNDys were highly associated with positive electromyographic findings. At follow-up, no MNDys positive patient developed ALS. Conclusion Neurophysiological and clinical examinations revealed mild MNDys in FTLD patients not fulfilling criteria for ALS. This condition did not evolve at a mean follow-up of two years. These results, indicating a subclinical degeneration of corticospinal tracts and lower motor neurons, suggest that FTLD patients may be more at risk of MNDys than the general population. © 2015 Elsevier B.V.","Amyotrophic lateral sclerosis; Electromyography; Frontotemporal dementia; Frontotemporal lobar degeneration; Motor neuron dysfunction; Pyramidal signs","Aged; Amyotrophic Lateral Sclerosis; Comorbidity; Female; Follow-Up Studies; Frontotemporal Lobar Degeneration; Humans; Male; Middle Aged; Motor Neuron Disease; adult; aged; ALS Functional Rating Scale Revised; Article; C9orf72 gene; clinical examination; corticobasal degeneration; disease severity; electromyography; female; frontotemporal dementia; gene mutation; genetic screening; GRN gene; high risk patient; human; major clinical study; male; MAPT gene; middle aged; motoneuron; motor neuron disease; neurophysiology; phenotype; primary progressive aphasia; priority journal; pyramidal tract; rating scale; UMN scale; amyotrophic lateral sclerosis; comorbidity; follow up; Frontotemporal Lobar Degeneration; motor neuron disease; pathophysiology","Morris H.R., Waite A.J., Williams N.M., Neal J.W., Blake D.J., Recent advances in the genetics of the ALS-FTLD complex, Curr Neurol Neurosci Rep, 12, 3, pp. 243-250, (2012); Van Langenhove T., Van Der Zee J., Van Broeckhoven C., The molecular basis of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum, Ann Med, 44, 8, pp. 817-828, (2012); Lomen-Hoerth C., Clinical phenomenology and neuroimaging correlates in ALS-FTD, J Mol Neurosci, 45, 3, pp. 656-662, (2011); Ferrari R., Kapogiannis D., Huey E.D., Momeni P., FTD and ALS: A tale of two diseases, Curr Alzheimer Res, 8, 3, pp. 273-294, (2011); Neumann M., Sampathu D.M., Kwong L.K., Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis, Science, 314, pp. 130-133, (2006); Kwong L.K., Neumann M., Sampathu D.M., Lee V.M., Trojanowski J.Q., TDP-43 proteinopathy: The neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease, Acta Neuropathol, 114, pp. 63-70, (2007); Josephs K.A., Petersen R.C., Knopman D.S., Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP, Neurology, 66, 1, pp. 41-48, (2006); Brenton A.E., Majounie E., Waite A., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, 2, pp. 257-268, (2011); Dejesus-Hernandez M., Mackenzie I.R., Boeve B.F., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, 2, pp. 245-256, (2011); Lillo P., Hodges J.R., Frontotemporal dementia and motor neuron disease: Overlapping clinic-pathological disorders, J Clin Neurosci, 16, 9, pp. 1131-1135, (2009); Lillo P., Savage S., Mioshi E., Kiernan M.C., Hodges J.R., Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum, Amyotroph Lateral Scler, 13, 1, pp. 102-109, (2012); Murphy J.M., Henry R.G., Langmore S., Kramer J.H., Miller B.L., Lomen-Hoerth C., Continuum of frontal lobe impairment in amyotrophic lateral sclerosis, Arch Neurol, 64, 4, pp. 530-534, (2007); Abrahams S., Leigh P.N., Harvey A., Vythelingum G.N., Grise D., Goldstein L.H., Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 38, 6, pp. 734-747, (2000); Consonni M., Iannaccone S., Cerami C., The cognitive and behavioural profile of amyotrophic lateral sclerosis: Application of the consensus criteria, Behav Neurol, 27, 2, pp. 143-153, (2013); Phukan J., Elamin M., Bede P., The syndrome of cognitive impairment in amyotrophic lateral sclerosis: A population-based study, J Neurol Neurosurg Psychiatry, 83, 1, pp. 102-108, (2012); Cerami C., Dodich A., Canessa N., Emotional empathy in amyotrophic lateral sclerosis: A behavioural and voxel-based morphometry study, Amyotroph Lateral Scler Frontotemporal Degener, 15, 12, pp. 21-29, (2014); Lomen-Hoerth C., Murphy J., Langmore S., Kramer J.H., Olney R.K., Miller B., Are amyotrophic lateral sclerosis patients cognitively normal?, Neurology, 60, pp. 1094-1097, (2003); Lomen-Hoerth C., Anderson T., Miller B., The overlap of amyotrophic lateral sclerosis and frontotemporal dementia, Neurology, 59, pp. 1077-1079, (2002); Hodges J.R., Davies R., Xuereb J., Kril J., Halliday G., Survival in frontotemporal dementia, Neurology, 61, pp. 349-354, (2003); Roberson E.D., Hesse J.H., Rose K.D., Frontotemporal dementia progresses to death faster than Alzheimer disease, Neurology, 65, 5, pp. 719-725, (2005); Mitsuyama Y., Takamiya S., Presenile dementia with motor neuron disease in Japan. A new entity?, Arch Neurol, 36, pp. 592-593, (1979); Burrell J.R., Kiernan M.C., Vucic S., Hodges J.R., Motor neuron dysfunction in frontotemporal dementia, Brain, 134, pp. 2582-2594, (2011); Bak T.H., Hodges J.R., Motor neuron disease, dementia and aphasia: Coincidence, co-occurrence or continuum?, J Neurol, 248, pp. 260-270, (2001); Bak T.H., Hodges J.R., The effects of motor neuron disease on language: Further evidence, Brain Lang, 89, pp. 354-361, (2004); De Carvalho M., Dengler R., Eisen A., Electrodiagnostic criteria for diagnosis of ALS, Clin Neurophysiol, 119, 3, pp. 497-503, (2008); Ekman P., Friesen W., Pictures of Facial Affect, (1976); Dodich A., Cerami C., Canessa N., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci, 35, 7, pp. 1015-1021, (2014); Cerami C., Dodich A., Canessa N., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 10, 6, pp. 827-834, (2014); Davis M.H., Measuring individual differences in empathy: Evidence for a multidimensional approach, J Pers Soc Psychol, 44, pp. 113-126, (1983); Cerami C., Marcone A., Galimberti D., Villa C., Scarpini E., Cappa S.F., From genotype to phenotype: Two cases of genetic frontotemporal lobar degeneration with premorbid bipolar disorder, J Alzheimers Dis, 27, 4, pp. 791-797, (2011); Cerami C., Marcone A., Galimberti D., Novel evidence of phenotypical variability in the hexanucleotide repeat expansion in chromosome 9, J Alzheimers Dis, 35, 3, pp. 455-462, (2013); Rascovsky K., Hodges J.R., Knopman D., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Armstrong M.J., Litvan I., Lang A.E., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, 5, pp. 496-503, (2013); Ellis C.M., Simmons A., Jones D.K., Diffusion tensor MRI assesses corticospinal tract damage in ALS, Neurology, 53, 5, pp. 1051-1058, (1999); Cedarbaum J.M., Stambler N., Malta E., The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III), J Neurol Sci, 169, 12, pp. 13-21, (1999); Brooks B.R., Miller R.G., Swash M., Munsat T.L., World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord, 1, 5, pp. 293-299, (2000); Cerami C., Marcone A., Galimberti D., Novel missense progranulin gene mutation associated with the semantic variant of primary progressive aphasia, J Alzheimers Dis, 36, 3, pp. 415-420, (2013); Ferrari R., Hernandez D.G., Nalls M.A., Frontotemporal dementia and its subtypes: A genome-wide association study, Lancet Neurol, 13, 7, pp. 686-699, (2014); Tsuchiya K., Murayama S., Mitani K., Constant and severe involvement of Betz cells in corticobasal degeneration is not consistent with pyramidal signs: A clinicopathological study of ten autopsy cases, Acta Neuropathol, 109, 4, pp. 353-366, (2005); Josephs K.A., Katsuse O., Beccano-Kelly D.A., Atypical progressive supranuclear palsy with corticospinal tract degeneration, J Neuropathol Exp Neurol, 65, 4, pp. 396-405, (2006)","2-s2.0-84926407860"
"Cerami C.; Dodich A.; Canessa N.; Crespi C.; Iannaccone S.; Corbo M.; Lunetta C.; Consonni M.; Scola E.; Falini A.; Cappa S.F.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Canessa, Nicola (24334215800); Crespi, Chiara (57034303800); Iannaccone, Sandro (7005943171); Corbo, Massimo (7006723926); Lunetta, Christian (7801365932); Consonni, Monica (23093832900); Scola, Elisa (35071979200); Falini, Andrea (7003494994); Cappa, Stefano F. (7005836132)","25722905400; 56001713900; 24334215800; 57034303800; 7005943171; 7006723926; 7801365932; 23093832900; 35071979200; 7003494994; 7005836132","Emotional empathy in amyotrophic lateral sclerosis: A behavioural and voxel-based morphometry study","2014","Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","15","1-2","","21","29","8","84","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903366012&doi=10.3109%2f21678421.2013.785568&partnerID=40&md5=a1d2d228aacbad16cad839e1d8cb2058","Amyotrophic lateral sclerosis (ALS) is a multisystem condition, in which executive and/or behavioural symptoms can occur. Deficits of social cognition, including defective cognitive and emotional empathy, have been recently reported in ALS subjects. The neurostructural correlates of these disorders in ALS are still unknown. The aims of this study were to evaluate two components of empathy in non-demented ALS subjects, and to associate performance with regional grey-matter density using voxel-based morphometry (VBM). Twenty non-demented sporadic probable or definite ALS patients and 56 matched healthy controls (HC) participated in a non-verbal task requiring the attribution of emotional versus cognitive states to identify the correct ending of comic strips, compared with a control condition requiring identifying causal relationships devoid of social components. A subgroup of 14 ALS and 20 HC joined the VBM study. Results demonstrated that, compared with controls, ALS patients showed defective emotional empathy attribution, related with reduced grey-matter density in the anterior cingulate cortex and right inferior frontal gyrus. Our study provided evidence of a specific impairment of emotional empathy in ALS patients, reflecting neural damage in a limbic prefrontal network involved in emotional processing. Social cognition disorders may represent a marker of cognitive dysfunction in ALS. © 2014 Informa Healthcare.","Anterior cingulate cortex; Biomarker; Dementia; Empathy; Imaging; Social cognition","Affective Symptoms; Aged; Amyotrophic Lateral Sclerosis; Brain; Cognition Disorders; Empathy; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Psychiatric Status Rating Scales; Statistics as Topic; adult; aged; amyotrophic lateral sclerosis; anterior cingulate; article; controlled study; default mode network; empathy; female; gray matter; human; inferior frontal gyrus; major clinical study; male; middle aged; neuroimaging; nuclear magnetic resonance imaging; nuclear magnetic resonance scanner; priority journal; social cognition; task performance; voxel based morphometry","Strong M.J., The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis, Amyotroph Lateral Scler., 9, pp. 323-328, (2008); Phukan J., Elamin M., Bede P., Jordan N., Gallagher L., Byrne S., Et al., The syndrome of cognitive impairment in amyo-trophic lateral sclerosis: A population based study, J Neurol Neurosurg Psychiatry., 83, pp. 102-108, (2012); Murphy J., Henry R., Lomen-Hoerth C., Establishing subtypes of the continuum of frontal lobe impairment in amyotrophic lateral sclerosis, Archives of Neurology, 64, 3, pp. 330-334, (2007); Taylor L.J., Brown R.G., Tsermentseli S., Al-Chalabi A., Shaw C.E., Ellis C.M., Et al., Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis?, J Neurol Neurosurg Psychiatry, (2012); Elamin M., Pender N., Hardiman O., Abrahams S., Social cognition in neurodegenerative disorders: A systematic review, J Neurol Neurosurg Psychiatry., 83, pp. 1071-1079, (2012); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain., 134, pp. 2456-2477, (2011); Tsermentseli S., Leigh P.N., Goldstein L.H., The anatomy of cognitive impairment in amyotrophic lateral sclerosis: More than frontal lobe dysfunction, Cortex., 48, pp. 166-182, (2012); Mezzapesa D.M., Ceccarelli A., Dicuonzo F., Carella A., De Caro M.F., Lopez M., Samarelli V., Livrea P., Simone I.L., Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis, American Journal of Neuroradiology, 28, 2, pp. 255-259, (2007); Chio A., Borghero G., Restagno G., Mora G., Drepper C., Traynor B.J., Et al., Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9orf72, Brain., 135, pp. 784-793, (2012); Sabatelli M., Conforti F.L., Zollino M., Mora G., Monsurro M.R., Volanti P., Et al., C9orf72 hexanucleotide repeat expansions in the Italian sporadic ALS population, Neurobiol Aging., 33, pp. 15-20, (2012); Zimmerman E.K., Eslinger P.J., Simmons Z., Barrett A.M., Emotional perception deficits in amyotrophic lateral sclerosis, Cognitive and Behavioral Neurology, 20, 2, pp. 79-82, (2007); Palmieri A., Naccarato M., Abrahams S., Bonato M., D'Ascenzo C., Balestreri S., Et al., Right hemisphere dysfunction and emotional processing in ALS: An fMRI study, J Neurol ., 257, pp. 1970-1978, (2010); Papps B., Abrahams S., Wicks P., Leigh P.N., Goldstein L.H., Changes in memory for emotional material in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 43, 8, pp. 1107-1114, (2005); Schmolck H., Mosnik D., Schulz P., Rating the approachabil-ity of faces in ALS, Neurology., 69, pp. 2232-2235, (2007); Gibbons Z.C., Snowden J.S., Thompson J.C., Happe F., Richardson A., Neary D., Inferring thought and action in motor neurone disease, Neuropsychologia, 45, 6, pp. 1196-1207, (2007); Snowden J.S., Gibbons Z.C., Blackshaw A., Doubleday E., Thompson J., Craufurd D., Foster J., Happe F., Neary D., Social cognition in frontotemporal dementia and Huntington's disease, Neuropsychologia, 41, 6, pp. 688-701, (2003); Cavallo M., Adenzato M., Macpherson S.E., Karwig G., Enrici I., Abrahams S., Evidence of social understanding impairment in patients with amyotrophic lateral sclerosis, PLoS One., 6, (2011); Meier S.L., Charleston A.J., Tippett L.J., Cognitive and behavioural deficits associated with the orbitomedial prefrontal cortex in amyotrophic lateral sclerosis, Brain., 133, pp. 3444-3457, (2010); De Vignemont F., Singer T., The empathic brain: How, when and why?, Trends in Cognitive Sciences, 10, 10, pp. 435-441, (2006); Shamay-Tsoory S.G., The neural bases for empathy, Neuro-scientist., 17, pp. 18-24, (2011); Vollm B.A., Taylor A.N.W., Richardson P., Corcoran R., Stirling J., McKie S., Deakin J.F.W., Elliott R., Neuronal correlates of theory of mind and empathy: A functional magnetic resonance imaging study in a nonverbal task, NeuroImage, 29, 1, pp. 90-98, (2006); Frith U., Frith C.D., Development and neurophysiology of mentalizing, Philosophical Transactions of the Royal Society B: Biological Sciences, 358, 1431, pp. 459-473, (2003); Van Overwalle F., Baetens K., Understanding others' actions and goals by mirror and mentalizing systems: A meta-analy-sis, Neuroimage., 48, pp. 564-584, (2009); Gallese V., Keysers C., Rizzolatti G., A unifying view of the basis of social cognition, Trends in Cognitive Sciences, 8, 9, pp. 396-403, (2004); Singer T., Seymour B., O'Doherty J., Kaube H., Dolan R.J., Frith C.D., Empathy for Pain Involves the Affective but not Sensory Components of Pain, Science, 303, 5661, pp. 1157-1162, (2004); Brooks B.R., Miller R.G., Swash M., Munsat T.L., World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis, Amyotroph Lateral Scler Other Motor Neuron Disord ., 1, pp. 293-299, (2000); Vignatelli L., Plazzi G., Barbato A., Ferini-Strambi L., Manni R., Pompei F., D'Alessandro R., Brancasi B., Misceo S., Puca F., Savarese M., Servalli C., Ubiali E., Viscardi M., Vetrugno R., Buzzi G., Cirignotta F., Mostacci B., Sancisi E., Fassari V., Scrofani A., Beelke M., Ferrillo F., Nobili L., Costa C., Di Perri R., Raffaele M., Landi C., Rossi M., Spaggiari C., Terzano M.G., Manni R., Sartori I., Zanotta N., Bonnani E., Indice A., Murri L., Guazzelli M., Palagini L., Panicucci P., Antonini G., Bruni O., Ceschini V., Gragnani F., Miano S., Della Marca G., Farina B., Mennuni G.F., Cosentino F., Ferri R., Bergonzi P., Marinig R., Pauletto G., Dolso P.L., Gigli G.L., Italian version of the Epworth sleepiness scale: External validity, Neurological Sciences, 23, 6, pp. 295-300, (2003); Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., Nakanishi A., The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function, Journal of the Neurological Sciences, 169, 1-2, pp. 13-21, (1999); Lezak M., Neuropsychological Assessment., (1995); Abrahams S., Leigh P.N., Harvey A., Vythelingum G.N., Grise D., Goldstein L.H., Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS), Neuropsychologia, 38, 6, pp. 734-747, (2000); Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Et al., Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis, Amyotroph Lateral Scler., 10, pp. 131-146, (2009); Sarfati Y., Hardy-Bayle M.-C., Besche C., Widlocher D., Attribution of intentions to others in people with schizophrenia: A non- verbal exploration with comic strips, Schizophrenia Research, 25, 3, pp. 199-209, (1997); Brunet E., Sarfati Y., Hardy-Bayle M.-C., Decety J., A PET investigation of the attribution of intentions with a nonverbal task, NeuroImage, 11, 2, pp. 157-166, (2000); Hayasaka S., Nichols T.E., Combining voxel intensity and cluster extent with permutation test framework, NeuroImage, 23, 1, pp. 54-63, (2004); Thivard L., Pradat P.-F., Lehericy S., Lacomblez L., Dormont D., Chiras J., Benali H., Meininger V., Diffusion tensor imaging and voxel based morphometry study in amyotrophic lateral sclerosis: Relationships with motor disability, Journal of Neurology, Neurosurgery and Psychiatry, 78, 8, pp. 889-892, (2007); Bernhardt B.C., Singer T., The neural basis of empathy, Annu Rev Neurosci., 35, pp. 1-23, (2012); Lillo P., Mioshi E., Burrell J.R., Kiernan M.C., Hodges J.R., Hornberger M., Grey and white matter changes across the amyotrophic lateral sclerosis/frontotemporal dementia continuum, PLoS One, 7, (2012); Girardi A., Macpherson S.E., Abrahams S., Deficits in emotional and social cognition in amyotrophic lateral sclerosis, Neuropsychology., 25, pp. 53-65, (2011); Consonni M., Iannaccone S., Cerami C., Frasson P., Lacerenza M., Lunetta C., Et al., The cognitive and behavioural profile of amyotrophic lateral sclerosis: Application of the consensus criteria, Behav Neurol., (2012); Cerami C., Scarpini E., Cappa S.F., Galimberti D., Frontotem-poral lobar degeneration: Current knowledge and future challenges, J Neurol ., 259, pp. 2278-2286, (2012); Rademakers R., Neumann M., Mackenzie I.R., Advances in understanding the molecular basis of frontotemporal dementia, Nat Rev Neurol., 8, pp. 423-434, (2012); Burrell J.R., Kiernan M.C., Vucic S., Hodges J.R., Motor neuron dysfunction in frontotemporal dementia, Brain., 134, pp. 2582-2594, (2011); Lillo P., Savage S., Mioshi E., Kiernan M.C., Hodges J.R., Amyo-trophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum, Amyotroph Lateral Scler., 13, pp. 102-109, (2012); Mackenzie I.R.A., Feldman H., The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease, Acta Neuropathologica, 105, 2, pp. 98-102, (2003); Stewart H., Rutherford N.J., Briemberg H., Krieger C., Cashman N., Fabros M., Et al., Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9orf72 gene on chromosome 9p, Acta Neuropathol., 123, pp. 409-417, (2012); Mackenzie I.R., Neumann M., Baborie A., Sampathu D.M., Du Plessis D., Jaros E., Et al., A harmonized classification system for FTLD-TDP pathology, Acta Neuropathol., 122, pp. 111-113, (2011)","2-s2.0-84903366012"
"Rolandi E.; Dodich A.; Galluzzi S.; Ferrari C.; Mandelli S.; Ribaldi F.; Munaretto G.; Ambrosi C.; Gasparotti R.; Violi D.; Canessa N.; Iannaccone S.; Marcone A.; Falini A.; Hampel H.; Frisoni G.B.; Cerami C.; Cavedo E.","Rolandi, Elena (57159270700); Dodich, Alessandra (56001713900); Galluzzi, Samantha (6602161538); Ferrari, Clarissa (57866310100); Mandelli, Sara (55959393800); Ribaldi, Federica (57196097366); Munaretto, Giulio (57211917063); Ambrosi, Claudia (8300324100); Gasparotti, Roberto (6603885440); Violi, Davide (57211914188); Canessa, Nicola (24334215800); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Falini, Andrea (7003494994); Hampel, Harald (56820298200); Frisoni, Giovanni B. (56214208300); Cerami, Chiara (25722905400); Cavedo, Enrica (37037012100)","57159270700; 56001713900; 6602161538; 57866310100; 55959393800; 57196097366; 57211917063; 8300324100; 6603885440; 57211914188; 24334215800; 7005943171; 6701496511; 7003494994; 56820298200; 56214208300; 25722905400; 37037012100","Randomized controlled trial on the efficacy of a multilevel non-pharmacologic intervention in older adults with subjective memory decline: design and baseline findings of the E.Mu.N.I. study","2020","Aging Clinical and Experimental Research","32","5","","817","826","9","5","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075335052&doi=10.1007%2fs40520-019-01403-3&partnerID=40&md5=036fd6c7a2a3b56946833556f0fefa72","Background: Alzheimer’s Disease (AD) is a multifactorial disorder driven by genetic and modifiable lifestyle risk factors. Lifestyle primary prevention initiatives may reduce the prevalence and incidence of dementia in older adults. Objectives: The E.Mu.N.I study is a randomized controlled trial investigating the effect of multilevel non-pharmacologic interventions on cognitive performances (primary outcome) and structural and vascular brain MRI markers (secondary outcome), as well as markers of brain functional connectivity change (exploratory outcome), in older adults with subjective memory decline (SMD). Here, we present the study design and the baseline features of the sample. Methods: Cognitively intact older adults with SMD, enrolled between February 2016 and June 2017, were randomly assigned to one of the 3 interventions for 1 year: Active Control Intervention (ACI), i.e., educational lessons; Partial Intervention (PI), i.e., homotaurine administration (100 mg/die) and lessons on the Mediterranean diet; Multilevel Intervention (MI), i.e., PI plus computerized cognitive training and physical exercise training. Results: One-hundred and twenty-eight eligible participants were enrolled (66% female; age: 68 ± 5 years). Eighty-two percent of the sample was composed of volunteers with SMD from the community. Participants were randomly allocated to the interventions as follows: ACI (N = 40), PI (N = 44), MI (N = 44). No significant differences among groups emerged on socio-demographic, clinical–neuropsychological variables and MRI markers at baseline. Conclusions: The outcomes obtained from the E.Mu.N.I. study will clarify the efficacy of multilevel non-pharmacologic interventions on cognitive and neuroimaging markers in SMD individuals. This is a crucial step forward for the development of cost-effective non-pharmacologic primary prevention initiatives for AD. © 2019, Springer Nature Switzerland AG.","Alzheimer’s disease; Neuroimaging; Non-pharmacologic interventions; Primary prevention; Subjective cognitive decline","Aged; Brain; Dementia; Exercise; Female; Humans; Life Style; Magnetic Resonance Imaging; Male; Memory; Memory Disorders; Middle Aged; biological marker; homotaurine; olive oil; saturated fatty acid; active control intervention; aged; aged hospital patient; Alzheimer disease; amnesia; Article; brain; claustrophobia; cognitive therapy; community; computer assisted therapy; controlled study; dementia; demography; exercise; female; functional connectivity; human; intervention study; major clinical study; male; Mediterranean diet; memory; mental deterioration; multicenter study; multilevel analysis; neuroimaging; neuropsychological test; nuclear magnetic resonance imaging; outcome assessment; patient education; randomized controlled trial; risk factor; social aspect; study design; therapy effect; dementia; exercise; lifestyle; memory; memory disorder; middle aged; pathophysiology","Wimo A., Jonsson L., Bond J., Et al., The worldwide economic impact of dementia 2010, Alzheimer’s Dement, 9, (2013); Rahimi J., Kovacs G.G., Prevalence of mixed pathologies in the aging brain, Alzheimer’s Res Ther, 6, pp. 1-11, (2014); Boyle P.A., Yu L., Wilson R.S., Et al., Person-specific contribution of neuropathologies to cognitive loss in old age, Ann Neurol, 83, pp. 74-83, (2018); Norton S., Matthews F.E., Barnes D.E., Et al., Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data, Lancet Neurol, 13, pp. 788-794, (2014); Livingston G., Sommerlad A., Orgeta V., Et al., Dementia prevention, intervention, and care, Lancet, 390, pp. 2673-2734, (2017); Vemuri P., Lesnick T.G., Przybelski S.A., Et al., Association of lifetime intellectual enrichment with cognitive decline in the older population, JAMA Neurol, 71, (2014); Singh B., Parsaik A.K., Mielke M.M., Et al., Association of Mediterranean diet with mild cognitive impairment and Alzheimer’s disease: a systematic review and meta-analysis, J Alzheimer’s Dis, 39, pp. 271-282, (2014); Sofi F., Valecchi D., Bacci D., Et al., Physical activity and risk of cognitive decline: a meta-analysis of prospective studies, J Intern Med, 269, pp. 107-117, (2011); Kivipelto M., Mangialasche F., Ngandu T., Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease, Nat Rev Neurol, 14, pp. 653-666, (2018); Ngandu T., Lehtisalo J., Solomon A., Et al., A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial, Lancet, 385, pp. 2255-2263, (2015); Andrieu S., Guyonnet S., Coley N., Et al., Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial, Lancet Neurol, 16, pp. 377-389, (2017); Rolandi E., Frisoni G.B., Cavedo E., Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly, Ageing Res Rev, (2016); Jessen F., Amariglio R.E., van Boxtel M., Et al., A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease, Alzheimer’s Dement, 10, pp. 844-852, (2014); Calabria M., Manenti R., Rosini S., Et al., Objective and subjective memory impairment in elderly adults: a revised version of the everyday memory questionnaire, Aging Clin Exp Res, 23, pp. 67-73, (2011); Galluzzi S., Marizzoni M., Babiloni C., Et al., Clinical and biomarker profiling of prodromal Alzheimer’s disease in workpackage 5 of the innovative medicines initiative PharmaCog project: a “European ADNI study, J Intern Med, 279, pp. 576-591, (2016); Sherif T., Rioux P., Rousseau M.-E., Et al., CBRAIN: a web-based, distributed computing platform for collaborative neuroimaging research, Front Neuroinform, (2014); Caltagirone C., Ferrannini L., Marchionni N., The potential protective effect of tramiprosate (homotaurine) against Alzheimer’s disease: a review, Aging Clin Exp Res, 24, pp. 580-587, (2012); Balducci S., Zanuso S., Massarini M., Et al., The Italian Diabetes and Exercise Study (IDES): design and methods for a prospective Italian multicentre trial of intensive lifestyle intervention in people with type 2 diabetes and the metabolic syndrome, Nutr Metab Cardiovasc Dis, 18, pp. 585-595, (2008); Mahncke H.W., Connor B.B., Appelman J., Et al., Memory enhancement in healthy older adults using a brain plasticity-based training program: a randomized, controlled study, Proc Natl Acad Sci USA, 103, pp. 12523-12528, (2006); Lampit A., Hallock H., Valenzuela M., Computerized cognitive training in cognitively healthy older adults: a systematic review and meta-analysis of effect modifiers, PLoS Med, (2014); Perrotin A., La Joie R., de La Sayette V., Et al., Subjective cognitive decline in cognitively normal elders from the community or from a memory clinic: differential affective and imaging correlates, Alzheimer’s Dement, 13, pp. 550-560, (2017); Snitz B.E., Wang T., Cloonan Y.K., Et al., Risk of progression from subjective cognitive decline to mild cognitive impairment: the role of study setting, Alzheimer’s Dement, 14, pp. 734-742, (2018); Rabin L.A., Smart C.M., Amariglio R.E., Subjective Cognitive Decline in Preclinical Alzheimer’ s Disease, Annu Rev Clin Psychol, 13, pp. 369-396, (2017); Ferretti M., Iulita M., Cavedo E., Et al., Sex differences in Alzheimer disease—the gateway to precision medicine, Nat Rev Neurol, (2018); Cavedo E., Chiesa P.A., Houot M., Et al., Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer’s disease in a monocenter cohort of cognitively normal older adults with subjective memory complaints, Alzheimer’s Dement, (2018); Erickson K.I., Leckie R.L., Weinstein A.M., Physical activity, fitness, and gray matter volume, Neurobiol Aging, 35, pp. S20-S28, (2014); Erickson K.I., Voss M.W., Prakash R.S., Et al., Exercise training increases size of hippocampus and improves memory, Proc Natl Acad Sci, 108, pp. 3017-3022, (2011); Sink K.M., Espeland M.A., Castro C.M., Et al., Effect of a 24-month physical activity intervention vs health education on cognitive outcomes in sedentary older adults, JAMA, 314, (2015); Lautenschlager N.T., Cox K.L., Flicker L., Et al., Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial, JAMA, 300, pp. 1027-1037, (2015); Edwards J.D., Xu H., Clark D.O., Et al., Speed of processing training results in lower risk of dementia, Alzheimer’s Dement Transl Res Clin Interv, 3, pp. 603-611, (2017); Lampit A., Hallock H., Suo C., Et al., Cognitive training-induced short-term functional and long-term structural plastic change is related to gains in global cognition in healthy older adults: a pilot study, Front Aging Neurosci, 7, pp. 1-13, (2015); Suo C., Singh M.F., Gates N., Et al., Therapeutically relevant structural and functional mechanisms triggered by physical and cognitive exercise, Mol Psychiatry, 21, pp. 1633-1642, (2016); Valls-Pedret C., Sala-Vila A., Serra-Mir M., Et al., Mediterranean diet and age-related cognitive decline, JAMA Intern Med, 175, (2015); Aisen P.S., Gauthier S., Ferris S.H., Et al., Tramiprosate in mild-to-moderate Alzheimer’s disease—a randomized, double-blind, placebo-controlled, multi-centre study (the alphase study), Arch Med Sci, 7, pp. 102-111, (2011); Barnes D.E., Santos-Modesitt W., Poelke G., Et al., The mental activity and eXercise (MAX) Trial, JAMA Intern Med, 173, (2013); Cash D.M., Rohrer J.D., Ryan N.S., Et al., Imaging endpoints for clinical trials in Alzheimer’s disease, Alzheimer’s Res Ther, 6, pp. 1-10, (2014)","2-s2.0-85075335052"
"Caminiti S.P.; Alongi P.; Majno L.; Volontè M.A.; Cerami C.; Gianolli L.; Comi G.; Perani D.","Caminiti, S.P. (56584243600); Alongi, P. (36192673100); Majno, L. (57193435356); Volontè, M.A. (7003972673); Cerami, C. (25722905400); Gianolli, L. (6602754456); Comi, G. (7201788288); Perani, D. (7005630261)","56584243600; 36192673100; 57193435356; 7003972673; 25722905400; 6602754456; 7201788288; 7005630261","Evaluation of an optimized [18F]fluoro-deoxy-glucose positron emission tomography voxel-wise method to early support differential diagnosis in atypical Parkinsonian disorders","2017","European Journal of Neurology","24","5","","687,e26","","","38","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85013968050&doi=10.1111%2fene.13269&partnerID=40&md5=9c72617e57deb5326087ed0c5e3b4ff3","Background and purpose: Atypical Parkinsonian disorders (APD) frequently overlap in clinical presentations, making the differential diagnosis challenging in the early stages. The present study aimed to evaluate the accuracy of the [18F]fluoro-deoxy-glucose positron emission tomography Statistical Parametric Mapping (SPM) optimized procedure in supporting the early and differential diagnosis of APD. Methods: Seventy patients with possible APD were retrospectively included from a large clinical cohort. The included patients underwent [18F]fluoro-deoxy-glucose positron emission tomography within 3 months of the first clinical assessment and a diagnostic follow-up. An optimized SPM voxel-wise procedure was used to produce t-maps of brain hypometabolism in single subjects, which were classified by experts blinded to any clinical information. We compared the accuracy of both the first clinical diagnosis and the SPM t-map classifications with the diagnosis at follow-up as the reference standard. Results: At first diagnosis, 60% of patients were classified as possible APD (progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy) and about 40% as APD with uncertain diagnosis, providing 52% sensitivity, 97% specificity and 86% accuracy with respect to the reference standard. SPM t-map classification showed 98% sensitivity, 99% specificity and 99% accuracy, and a significant agreement with the diagnosis at follow-up (P < 0.001). Conclusions: The SPM t-map classification at entry predicted the second diagnosis at follow-up. This indicates its significantly superior role for an early identification of APD subtypes, particularly in cases of uncertain diagnosis. The use of a metabolic biomarker at entry in the instrumental work-up of APD may shorten the diagnostic time, producing benefits for treatment options and support to the patients. © 2017 EAN","biomarkers; corticobasal degeneration; dementia with Lewy bodies; hypometabolism; multiple system atrophy; progressive supranuclear palsy; single subject; Statistical Parametric Mapping","Aged; Aged, 80 and over; Basal Ganglia Diseases; Diagnosis, Differential; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Male; Middle Aged; Neurodegenerative Diseases; Parkinsonian Disorders; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Sensitivity and Specificity; fluorodeoxyglucose f 18; radiopharmaceutical agent; aged; Article; atypical Parkinsonian disorder; brain mapping; brain metabolism; controlled study; corticobasal degeneration; diagnostic accuracy; diagnostic test accuracy study; differential diagnosis; diffuse Lewy body disease; disease classification; early diagnosis; female; follow up; human; major clinical study; male; parametric test; parkinsonism; PET scanner; positron emission tomography; predictive value; priority journal; progressive supranuclear palsy; retrospective study; sensitivity and specificity; Shy Drager syndrome; statistical parametric mapping; uncertainty; voxel based morphometry; degenerative disease; diagnostic imaging; extrapyramidal syndrome; metabolism; middle aged; parkinsonism; positron emission tomography; procedures; very elderly","Wenning G.K., Litvan I., Tolosa E., Milestones in atypical and secondary parkinsonisms advances in the past 25 years, Mov Disord, 26, pp. 1083-1095, (2011); Tolosa E., Wenning G., Poewe W., The diagnosis of Parkinson's disease, Lancet Neurol, 5, pp. 75-86, (2006); Joutsa J., Gardberg M., Roytta M., Kaasinen V., Diagnostic accuracy of parkinsonism syndromes by general neurologists, Parkinsonism Relat Disord, 20, pp. 840-844, (2014); Shih L.C., Tarsy D., Deep brain stimulation for the treatment of atypical parkinsonism, Mov Disord, 22, pp. 2149-2155, (2007); Litvan I., Mangone C.A., McKee A., Et al., Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study, J Neurol Neurosurg Psychiatry, 60, pp. 615-620, (1996); Wenning G.K., Litvan I., Jankovic J., Et al., Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination, J Neurol Neurosurg Psychiatry, 64, pp. 184-189, (1998); Litvan I., Grimes D.A., Lang A.E., Phenotypes and prognosis: clinicopathologic studies of corticobasal degeneration, Adv Neurol, 82, (2000); Hughes A.J., Daniel S.E., Ben-Shlomo Y., Lees A.J., The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, Brain, 125, pp. 861-870, (2002); Mosconi L., Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies, Clin Transl Imaging, 1, pp. 217-233, (2013); Magistretti P.J., Cellular bases of functional brain imaging: insights from neuron-glia metabolic coupling, Brain Res, 886, pp. 108-112, (2000); Perani D., FDG PET and cognitive symptoms of dementia, Clin Transl Imaging, 1, pp. 247-260, (2013); Teune L.K., Bartels A.L., De Jong B.M., Et al., Typical cerebral metabolic patterns in neurodegenerative brain diseases, Mov Disord, 25, pp. 2395-2404, (2010); Teune L.K., Renken R.J., Mudali D., Et al., Validation of parkinsonian disease-related metabolic brain patterns, Mov Disord, 28, pp. 547-551, (2013); Meyer P.T., Hellwig S., Update on SPECT and PET in parkinsonism - part 1: imaging for differential diagnosis, Curr Opin Neurol, 27, pp. 390-397, (2014); McKeith I.G., Dickson D.W., Lowe J., Et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium, Neurology, 65, pp. 1863-1872, (2005); Gilman S., Wenning G.K., Low P.A., Et al., Second consensus statement on the diagnosis of multiple system atrophy, Neurology, 71, pp. 670-676, (2008); Armstrong M.J., Litvan I., Lang A.E., Et al., Criteria for the diagnosis of corticobasal degeneration, Neurology, 80, pp. 496-503, (2013); Juh R., Kim J., Moon D., Choe B., Suh T., Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET, Eur J Radiol, 51, pp. 223-233, (2004); Zhao P., Zhang B., Gao S., 18F-FDG PET study on the idiopathic Parkinson's disease from several parkinsonian-plus syndromes, Parkinsonism Relat Disord, 18, pp. S60-S62, (2012); Hellwig S., Amtage F., Buchert R., Et al., [18 F] FDG-PET is superior to [123 I] IBZM-SPECT for the differential diagnosis of parkinsonism, Neurology, 79, pp. 1314-1322, (2012); Tang C.C., Poston K.L., Eckert T., Et al., Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis, Lancet Neurol, 9, pp. 149-158, (2010); Eckert T., Barnes A., Dhawan V., Et al., FDG PET in the differential diagnosis of parkinsonian disorders, NeuroImage, 26, pp. 912-921, (2005); Tripathi M., Tang C.C., Feigin A., Et al., Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study, J Nucl Med, 57, pp. 60-66, (2016); Tripathi M., Dhawan V., Peng S., Et al., Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography, Neuroradiology, 55, pp. 483-492, (2013); Perani D., Della Rosa P.A., Cerami C., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, Neuroimage Clin, 6, pp. 445-454, (2014); Cerami C., Della Rosa P.A., Magnani G., Et al., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, Neuroimage Clin, 7, pp. 187-194, (2014); Perani D., Cerami C., Paola S., Et al., Cross-validation of biomarkers to early differential diagnosis and prognosis of dementia in a clinical setting, Eur J Nucl Med Mol Imaging, 43, pp. 499-508, (2015); Cerami C., Dodich A., Lettieri G., Et al., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Della Rosa P.A., Cerami C., Gallivanone F., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, pp. 575-593, (2014); Cerami C., Della Rosa P.A., Magnani G., Et al., Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia, Neuroimage Clin, 7, pp. 187-194, (2015); Juh R., Pae C.-U., Kim T.-S., Lee C.-U., Choe B., Suh T., Cerebral glucose metabolism in corticobasal degeneration comparison with progressive supranuclear palsy using statistical mapping analysis, Neurosci Lett, 383, pp. 22-27, (2005); Magistretti P.J., Pellerin L., Rothman D.L., Shulman R.G., Energy on demand, Science, 283, pp. 496-497, (1999); Borghammer P., Perfusion and metabolism imaging studies in Parkinson's disease, Dan Med J, 59, pp. 1-24, (2012); Teras M., Tolvanen T., Johansson J.J., Williams J.J., Knuuti J., Performance of the new generation of whole-body PET/CT scanners: discovery STE and Discovery VCT, Eur J Nucl Med Mol Imaging, 34, pp. 1683-1692, (2007); Varrone A., Asenbaum S., Vander Borght T., Et al., EANM procedure guidelines for PET brain imaging using [18F] FDG, version 2, Eur J Nucl Med Mol Imaging, 36, pp. 2103-2110, (2009); Friston K.J., Holmes A.P., Worsley K.J., Poline J., Frith C.D., Frackowiak R.S.J., Statistical parametric maps in functional imaging: a general linear approach, Hum Brain Mapp, 2, pp. 189-210, (1994); Beaulieu-Boire I., Lang A.E., Behavioral effects of levodopa, Mov Disord, 30, pp. 90-102, (2015); Tripathi M., Tang C.C., Feigin A., Et al., Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study, J Nucl Med, 57, pp. 60-66, (2015)","2-s2.0-85013968050"
"Dodich A.; Carli G.; Cerami C.; Iannaccone S.; Magnani G.; Perani D.","Dodich, Alessandra (56001713900); Carli, Giulia (57201314331); Cerami, Chiara (25722905400); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Perani, Daniela (7005630261)","56001713900; 57201314331; 25722905400; 7005943171; 24496141800; 7005630261","Social and cognitive control skills in long-life occupation activities modulate the brain reserve in the behavioural variant of frontotemporal dementia","2018","Cortex","99","","","311","318","7","17","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044267992&doi=10.1016%2fj.cortex.2017.12.006&partnerID=40&md5=14dfbf8c293389c5dca1ab62e9311ad8","Background: Cognitive reserve may delay disease onset and mitigate symptoms presentation in neurodegenerative dementias. Although high occupation levels can be associated with higher cognitive reserve in the behavioural variant of frontotemporal dementia (bvFTD), it was never addressed how specific occupation profiles involving social interaction, executive and attention abilities can modulate neural reserve in bvFTD. Materials and methods: We retrospectively included thirty-seven bvFTD patients with clinical-neuropsychological and FDG-PET brain metabolic data. We considered occupation levels according to 1) a 5-point scale and 2) the specific cognitive dimensions from the O*Net network database. We used the Principal Component Analysis (PCA) with the O*Net variables most representative of “worker” and “occupation” socio-cognitive skills to merge the best components describing such occupation profiles. We then performed regression analyses with brain metabolism using either 5-level occupation scale or the PCA specific profiles as independent variables, controlling for education and disease severity. Results: According to the brain reserve hypothesis, higher occupation levels were associated with a more severe hypometabolism in the dorsolateral prefrontal cortex. In addition, among the identified PCA profiles, social skills were associated with severe hypometabolism in medial and dorsolateral prefrontal regions, and cognitive control in the left fronto-insular cortex. Discussion: This study contributes to define the role of specific occupation profiles as proxy of cognitive reserve in bvFTD, providing the first evidence for social interaction and cognitive control skills in life-occupation activities as influencing factors of neural reserve against neurodegeneration in bvFTD. Jobs placing high demand on such abilities seem to act as protective factors in bvFTD. © 2017 Elsevier Ltd","Behavioural variant of frontotemporal dementia; Brain functional reserve; FDG-PET imaging; Occupation profiles","Aged; Attention; Brain; Cerebral Cortex; Cognition; Cognitive Reserve; Executive Function; Female; Fluorodeoxyglucose F18; Frontal Lobe; Frontotemporal Dementia; Humans; Interpersonal Relations; Male; Middle Aged; Occupations; Positron-Emission Tomography; Prefrontal Cortex; Principal Component Analysis; Protective Factors; Radiopharmaceuticals; Regression Analysis; Retrospective Studies; fluorodeoxyglucose f 18; glucose; radiopharmaceutical agent; aged; Article; attention; brain metabolism; clinical article; cognitive reserve; controlled study; disease duration; disease severity; dorsolateral prefrontal cortex; executive function; female; frontal variant frontotemporal dementia; glucose blood level; human; image processing; insula; job experience; male; Mini Mental State Examination; neuropsychiatric inventory; occupation; personal experience; positron emission tomography; salience network; social competence; social interaction; social network; attention; brain; brain cortex; cognition; diagnostic imaging; frontal lobe; frontotemporal dementia; human relation; metabolism; middle aged; pathophysiology; prefrontal cortex; principal component analysis; protection; regression analysis; retrospective study","Amodio D.M., Frith C.D., Meeting of minds: The medial frontal cortex and social cognition, Nature Reviews Neuroscience, 7, 4, pp. 268-277, (2006); Barulli D., Stern Y., Efficiency, capacity, compensation, maintenance, plasticity: Emerging concepts in cognitive reserve, Trends in Cognitive Sciences, 17, 10, pp. 502-509, (2013); Bickart K.C., Wright C.I., Dautoff R.J., Dickerson B.C., Barrett L.F., Amygdala volume and social network size in humans, Nature Neuroscience, 14, 2, pp. 163-164, (2011); Borroni B., Premi E., Agosti C., Alberici A., Garibotto V., Bellelli G., Et al., Revisiting brain reserve hypothesis in frontotemporal dementia: Evidence from a brain perfusion study, Dementia and Geriatric Cognitive Disorders, 28, 2, pp. 130-135, (2009); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurological Sciences, 34, 8, pp. 1267-1274, (2013); Cerami C., Dodich A., Iannaccone S., Marcone A., Lettieri G., Crespi C., Et al., Right limbic FDG-PET hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients, PLoS One, 10, 10, (2015); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, 4, pp. 575-593, (2014); Devenney E., Bartley L., Hoon C., O'Callaghan C., Kumfor F., Hornberger M., Et al., Progression in behavioral variant frontotemporal dementia: A longitudinal study, JAMA Neurology, 72, 12, pp. 1501-1509, (2015); Dosenbach N.U., Fair D.A., Cohen A.L., Schlaggar B.L., Petersen S.E., A dual-networks architecture of top–down control, Trends in Cognitive Sciences, 12, 3, pp. 99-105, (2008); Frith C.D., The social brain?, Philosophical Transactions of the Royal Society London B: Biological Sciences, 362, 1480, pp. 671-678, (2007); Gansler D.A., Huey E.D., Pan J.J., Wasserman E., Grafman J.H., Assessing the dysexecutive syndrome in dementia, Journal of Neurology Neurosurgery and Psychiatry, 88, 3, pp. 254-261, (2017); Garibotto V., Borroni B., Kalbe E., Herholz K., Salmon E., Holtoff V., Et al., Education and occupation as proxies for reserve in aMCI converters and AD: FDG-PET evidence, Neurology, 71, 17, pp. 1342-1349, (2008); Garibotto V., Borroni B., Sorbi S., Cappa S.F., Padovani A., Perani D., Education and occupation provide reserve in both ApoE epsilon4 carrier and noncarrier patients with probable Alzheimer's disease, Neurological Sciences, 33, 5, pp. 1037-1042, (2012); Garibotto V., Tettamanti M., Marcone A., Florea I., Panzacchi A., Moresco R., Et al., Cholinergic activity correlates with reserve proxies in Alzheimer's disease, Neurobiology of Aging, 34, 11, (2013); Helzner E.P., Scarmeas N., Cosentino S., Portet F., Stern Y., Leisure activity and cognitive decline in incident Alzheimer disease, Archives of Neurology, 64, 12, pp. 1749-1754, (2007); Hornberger M., Piguet O., Kipps C., Hodges J.R., Executive function in progressive and nonprogressive behavioral variant frontotemporal dementia, Neurology, 71, 19, pp. 1481-1488, (2008); Kemppainen N.M., Aalto S., Karrasch M., Nagren K., Savisto N., Oikonen V., Et al., Cognitive reserve hypothesis: Pittsburgh compound B and fluorodeoxyglucose positron emission tomography in relation to education in mild Alzheimer's disease, Annals of Neurology, 63, 1, pp. 112-118, (2008); Lamm C., Decety J., Singer T., Meta-analytic evidence for common and distinct neural networks associated with directly experienced pain and empathy for pain, NeuroImage, 54, 3, pp. 2492-2502, (2011); Le Bouc R., Lenfant P., Delbeuck X., Ravasi L., Lebert F., Semah F., Pasquier F., My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease, Brain, 135, pp. 3026-3038, (2012); Massimo L., Powers J.P., Evans L.K., McMillan C.T., Rascovsky K., Eslinger P., Et al., Apathy in frontotemporal Degeneration: Neuroanatomical evidence of impaired goal-directed behavior, Frontiers in Human Neuroscience, 9, (2015); Massimo L., Zee J., Xie S.X., McMillan C.T., Rascovsky K., Irwin D.J., Et al., Occupational attainment influences survival in autopsy-confirmed frontotemporal degeneration, Neurology, 84, 20, pp. 2070-2075, (2015); Meng X., D'Arcy C., Education and dementia in the context of the cognitive reserve hypothesis: A systematic review with meta-analyses and qualitative analyses, PLoS One, 7, 6, (2012); Moheb N., Mendez M.F., Kremen S.A., Teng E., Executive dysfunction and behavioral symptoms are associated with deficits in instrumental activities of daily living in frontotemporal dementia, Dementia and Geriatric Cognitive Disorders, 43, 1-2, pp. 89-99, (2017); Morbelli S., Perneczky R., Drzezga A., Frisoni G.B., Caroli A., van Berckel B.N., Et al., Metabolic networks underlying cognitive reserve in prodromal Alzheimer disease: A European Alzheimer disease consortium project, Journal of Nuclear Medicine, 54, 6, pp. 894-902, (2013); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, NeuroImage Clinical, 6, pp. 445-454, (2014); Perneczky R., Diehl-Schmid J., Drzezga A., Kurz A., Brain reserve capacity in frontotemporal dementia: A voxel-based 18F-FDG PET study, European Journal of Nuclear Medicine and Molecular Imaging, 34, 7, pp. 1082-1087, (2007); Perneczky R., Wagenpfeil S., Lunetta K.L., Cupples L.A., Green R.C., Decarli C., Et al., Head circumference, atrophy, and cognition: Implications for brain reserve in Alzheimer disease, Neurology, 75, 2, pp. 137-142, (2010); Placek K., Massimo L., Olm C., Ternes K., Firn K., Van Deerlin V., Et al., Cognitive reserve in frontotemporal degeneration: Neuroanatomic and neuropsychological evidence, Neurology, 87, 17, pp. 1813-1819, (2016); Premi E., Garibotto V., Gazzina S., Grassi M., Cosseddu M., Paghera B., Et al., Beyond cognitive reserve: Behavioural reserve hypothesis in frontotemporal dementia, Behavioural Brain Research, 245, pp. 58-62, (2013); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, pp. 2456-2477, (2011); Ruby P., Decety J., How would you feel versus how do you think she would feel? A neuroimaging study of perspective-taking with social emotions, Journal of Cognitive Neuroscience, 16, 6, pp. 988-999, (2004); Scarmeas N., Albert S.M., Manly J.J., Stern Y., Education and rates of cognitive decline in incident Alzheimer's disease, Journal of Neurology, Neurosurgery and Psychiatry, 77, 3, pp. 308-316, (2006); Schlaffke L., Lissek S., Lenz M., Juckel G., Schultz T., Tegenthoff M., Et al., Shared and nonshared neural networks of cognitive and affective theory-of-mind: A neuroimaging study using cartoon picture stories, Human Brain Mapping, 36, 1, pp. 29-39, (2015); Seeley W.W., Allman J.M., Carlin D.A., Crawford R.K., Macedo M.N., Greicius M.D., Et al., Divergent social functioning in behavioral variant frontotemporal dementia and Alzheimer disease: Reciprocal networks and neuronal evolution, Alzheimer Disease and Associated Disorders, 21, 4, pp. S50-S57, (2007); Seeley W.W., Menon V., Schatzberg A.F., Keller J., Glover G.H., Kenna H., Et al., Dissociable intrinsic connectivity networks for salience processing and executive control, Journal of Neuroscience, 27, 9, pp. 2349-2356, (2007); Spreng R.N., Rosen H.J., Strother S., Chow T.W., Diehl-Schmid J., Freedman M., Et al., Occupation attributes relate to location of atrophy in frontotemporal lobar degeneration, Neuropsychologia, 48, 12, pp. 3634-3641, (2010); Spreng R.N., Drzezga A., Diehl-Schmid J., Kurz A., Levine B., Perneczky R., Relationship between occupation attributes and brain metabolism in frontotemporal dementia, Neuropsychologia, 49, 13, pp. 3699-3703, (2011); Steffener J., Stern Y., Exploring the neural basis of cognitive reserve in aging, Biochimica et Biophysica Acta, 1822, 3, pp. 467-473, (2012); Stern Y., What is cognitive reserve? Theory and research application of the reserve concept, Journal of the International Neuropsychological Society, 8, 3, pp. 448-460, (2002); Valenzuela M.J., Sachdev P., Brain reserve and dementia: A systematic review, Psychological Medicine, 36, 4, pp. 441-454, (2006); Von Der Heide R., Vyas G., Olson I.R., The social network-network: Size is predicted by brain structure and function in the amygdala and paralimbic regions, Social Cognitive and Affective Neuroscience, 9, 12, pp. 1962-1972, (2014); Wong S., Flanagan E., Savage G., Hodges J.R., Hornberger M., Contrasting prefrontal cortex contributions to episodic memory dysfunction in behavioural variant frontotemporal dementia and Alzheimer's disease, PLoS One, 9, 2, (2014); Zhou J., Greicius M.D., Gennatas E.D., Growdon M.E., Jang J.Y., Rabinovici G.D., Et al., Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease, Brain, 133, pp. 1352-1367, (2010)","2-s2.0-85044267992"
"Quaranta D.; Cerami C.; Caraglia N.; Costantini E.M.; Di Tella S.; Silveri M.C.; Cappa S.; Gaudino S.; Marra C.; Dodich A.","Quaranta, Davide (24178705000); Cerami, Chiara (25722905400); Caraglia, Naike (58130890300); Costantini, Emanuele Maria (56290212800); Di Tella, Sonia (57031948600); Silveri, Maria Caterina (7005924852); Cappa, Stefano (7005836132); Gaudino, Simona (6602454002); Marra, Camillo (7102675596); Dodich, Alessandra (56001713900)","24178705000; 25722905400; 58130890300; 56290212800; 57031948600; 7005924852; 7005836132; 6602454002; 7102675596; 56001713900","Self-Assessment of Empathy Uncovers Defective Self-Awareness in Mild Cognitive Impairment","2023","Neuropsychology","","","","","","","0","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85158108291&doi=10.1037%2fneu0000896&partnerID=40&md5=d9cf3b903a16c27ce39a780c67639af2","Objective: Self-assessment scales are broadly used to evaluate empathy in neurological patients, but it is conceivable that some discrepancy with caregiver evaluation may emerge as consequence of reduced selfawareness. The aim of the present study was to verify the presence of discrepancies in the self-assessment of empathy in subjects with mild cognitive impairment (MCI) and to explore their neural correlates. Method: Twenty MCI patients and 38 healthy controls (HCs) underwent the Interpersonal Reactivity Index (IRI), exploring the following four aspects of empathy: perspective taking (PT), fantasy, empathic concern, and personal distress. The questionnaire was administered in two modalities: self-administered, and administered to an informant, and the scores were compared. The correlation between discrepancies and regional cortical thickness was assessed. Results: The self-administered version of IRI showed higher PT scores in MCI as compared to HC (p =.017), with no differences detected in the other subscales. The difference between the scores obtained in the self-administered and in the informant-administered IRI-PT was significantly higher in MCI than in HCs (p =.006). Conclusion: The self-assessment of empathy in subjects with MCI may be misleading because of a tendency toward an overestimation of the PT ability, typically considered as a cognitive component of empathy. Our results may reflect a particular aspect of reduced self-awareness in MCI subjects © 2023 American Psychological Association","Alzheimer’s disease; empathy; mild cognitive impairment; self-awareness; social cognition","Cognitive Dysfunction; Empathy; Humans; Perception; Self-Assessment; Surveys and Questionnaires; cognitive defect; empathy; human; perception; questionnaire; self evaluation","Abu-Akel A., Shamay-Tsoory S., Neuroanatomical and neurochemical bases of theory of mind, Neuropsychologia, 49, 11, pp. 2971-2984, (2011); Albert M. S., DeKosky S. T., Dickson D., Dubois B., Feldman H. H., Fox N. C., Gamst A., Holtzman D. M., Jagust W. J., Petersen R. C., Snyder P. J., Carrillo M. C., Thies B., Phelps C. H., The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease, Alzheimer’s & Dementia, 7, 3, pp. 270-279, (2011); Amanzio M., Torta D. M. E., Sacco K., Cauda F., D'Agata F., Duca S., Leotta D., Palermo S., Geminiani G. C., Unawareness of deficits in Alzheimer’s disease: Role of the cingulate cortex, Brain: A Journal of Neurology, 134, pp. 1061-1076, (2011); Anderson J. W., Schmitter-Edgecombe M., Mild cognitive impairment and feeling-of-knowing in episodic memory, Journal of Clinical and Experimental Neuropsychology, 32, 5, pp. 505-514, (2010); Baron-Cohen S., Wheelwright S., The empathy quotient: An investigation of adults with Asperger syndrome or high functioning autism, and normal sex differences, Journal of Autism and Developmental Disorders, 34, 2, pp. 163-175, (2004); Bastin C., Giacomelli F., Mievis F., Lemaire C., Guillaume B., Salmon E., Anosognosia in mild cognitive impairment: Lack of awareness of memory difficulties characterizes prodromal Alzheimer’s disease, Frontiers in Psychiatry, 12, (2021); Benjamini Y., Hochberg Y., Controlling the false discovery rate: A practical and powerful approach to multiple testing, Journal of the Royal Statistical Society. Series B. Methodological, 57, 1, pp. 289-300, (1995); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer’s disease: A meta-analysis, Journal of Neurology, Neurosurgery, and Psychiatry, 86, 7, pp. 714-719, (2015); Bora E., Yener G. G., Meta-analysis of social cognition in mild cognitive impairment, Journal of Geriatric Psychiatry and Neurology, 30, 4, pp. 206-213, (2017); Bruce J. M., Bhalla R., Westervelt H. J., Davis J., Williams V., Tremont G., Neuropsychological correlates of self-reported depression and self-reported cognition among patients with mild cognitive impairment, Journal ofGeriatric Psychiatry andNeurology, 21, 1, pp. 34-40, (2008); Cacciamani F., Houot M., Gagliardi G., Dubois B., Sikkes S., Sanchez-Benavides G., Denicolo E., Molinuevo J. L., Vannini P., Epelbaum S., Awareness of cognitive decline in patients with Alzheimer’s disease: A systematic review and meta-analysis, Frontiers in Aging Neuroscience, 13, (2021); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Una versione abbreviata del test di Stroop: Dati normativi nella popolazione italiana, Nuova Rivista di Neurologia, 12, 4, pp. 111-115, (2002); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Rey-Osterrieth complex figure: Normative values in an Italian population sample, Neurological Sciences, 22, 6, pp. 443-447, (2002); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Modified card sorting test: Normative data, Journal of Clinical and Experimental Neuropsychology, 26, 2, pp. 246-250, (2004); Carlesimo G. A., Caltagirone C., Gainotti G., Fadda L., Gallassi R., Lorusso S., Marfia G., Marra C., Nocentini U., Parnetti L., The mental deterioration battery: Normative data, diagnostic reliability and qualitative analyses of cognitive impairment, European Neurology, 36, 6, pp. 378-384, (1996); Changeux J.-P., Lou H. C., Emergent pharmacology of conscious experience: New perspectives in substance addiction, The FASEB Journal, 25, 7, pp. 2098-2108, (2011); Chavoix C., Insausti R., Self-awareness and the medial temporal lobe in neurodegenerative diseases, Neuroscience and Biobehavioral Reviews, 78, pp. 1-12, (2017); Chung J. C., Man D. W., Self-appraised, informant-reported, and objective memory and cognitive function in mild cognitive impairment, Dementia and Geriatric Cognitive Disorders, 27, 2, pp. 187-193, (2009); Clare L., Markova I. S., Roth I., Morris R. G., Awareness in Alzheimer’s disease and associated dementias: Theoretical framework and clinical implications, Aging & Mental Health, 15, 8, pp. 936-944, (2011); Clement F., Belleville S., Gauthier S., Cognitive complaint in mild cognitive impairment and Alzheimer’s disease, Journal of the International Neuropsychological Society, 14, 2, pp. 222-232, (2008); Coco A. L., Ingoglia S., Contributo all’adattamento italiano dell’Interpersonal Reactivity Index, Testing Psicometria Metodologia, 13, 2, pp. 107-125, (2006); Cohen J., The effect size, Statistical power analysis for the behavioral sciences, pp. 77-83, (1988); Davis M. H., Measuring individual differences in empathy: Evidence for a multidimensional approach, Journal of Personality and Social Psychology, 44, 1, pp. 113-126, (1983); Davis M. H., Empathy: A social psychological approach, (2018); Decety J., Jackson P. L., The functional architecture of human empathy, Behavioral and Cognitive Neuroscience Reviews, 3, 2, pp. 71-100, (2004); Decety J., Lamm C., The role of the right temporoparietal junction in social interaction: How low-level computational processes contribute to meta-cognition, The Neuroscientist, 13, 6, pp. 580-593, (2007); Decety J., Meyer M., From emotion resonance to empathic understanding: A social developmental neuroscience account, Development and Psychopathology, 20, 4, pp. 1053-1080, (2008); Desikan R. S., Segonne F., Fischl B., Quinn B. T., Dickerson B. C., Blacker D., Buckner R. L., Dale A. M., Maguire R. P., Hyman B. T., Albert M. S., Killiany R. J., An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest, Neuroimage, 31, 2, pp. 968-980, (2006); Destrieux C., Fischl B., Dale A., Halgren E., Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature, Neuroimage, 53, 1, pp. 1-15, (2010); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S. F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the story-based empathy task, Neurological Sciences, 36, 10, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Realmuto S., Cappa S. F., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurological Sciences, 35, 7, pp. 1015-1021, (2014); Eisenberg N., Eggum N. D., Empathic responding: Sympathy and personal distress, The social neuroscience of empathy, pp. 71-83, (2009); Fischer A., Landeira-Fernandez J., Sollero de Campos F., Mograbi D. C., Empathy in Alzheimer’s disease: Review of findings and proposed model, Journal of Alzheimer’s Disease, 69, 4, pp. 921-933, (2019); Folstein M. F., Folstein S. E., McHugh P. R., Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 2, pp. 189-198, (1975); Gagliardi G., Houot M., Cacciamani F., Habert M.-O., Dubois B., Epel-baum S., The meta-memory ratio: A new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease, Alzheimer’s Research & Therapy, 12, 1, (2020); Hannesdottir K., Morris R. G., Primary and secondary anosognosia for memory impairment in patients with Alzheimer’s disease, Cortex, 43, 1, pp. 1020-1030, (2007); Hodges S. D., Klein K. J. K., Regulating the costs of empathy: The price of being human, Journal of Socio-Economics, 30, 5, pp. 437-452, (2001); Hornberger M., Yew B., Gilardoni S., Mioshi E., Gleichgerrcht E., Manes F., Hodges J. R., Ventromedial-frontopolar prefrontal cortex atrophy correlates with insight loss in frontotemporal dementia and Alzheimer’s disease, Human Brain Mapping, 35, 2, pp. 616-626, (2014); Kalbe E., Salmon E., Perani D., Holthoff V., Sorbi S., Elsner A., Weisenbach S., Brand M., Lenz O., Kessler J., Luedecke S., Ortelli P., Herholz K., Anosognosia in very mild Alzheimer’s disease but not in mild cognitive impairment, Dementia and Geriatric Cognitive Disorders, 19, 5-6, pp. 349-356, (2005); Le Bouc R., Lenfant P., Delbeuck X., Ravasi L., Lebert F., Semah F., Pasquier F., My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer’s disease, Brain: A Journal of Neurology, 135, 10, pp. 3026-3038, (2012); Leiberg S., Anders S., The multiple facets of empathy: A survey of theory and evidence, Progress in Brain Research, 156, pp. 419-440, (2006); Lenzi D., Serra L., Perri R., Pantano P., Lenzi G. L., Paulesu E., Caltagirone C., Bozzali M., Macaluso E., Single domain amnestic MCI: A multiple cognitive domains fMRI investigation, (2011); Neurobiology of Aging, 32, 9, pp. 1542-1557; Lou H. C., Changeux J.-P., Rosenstand A., Towards a cognitive neuroscience of self-awareness, Neuroscience and Biobehavioral Reviews, 83, pp. 765-773, (2017); Marra C., Gainotti G., Scaricamazza E., Piccininni C., Ferraccioli M., Quaranta D., The Multiple Features Target Cancellation (MFTC): An attentional visual conjunction search test. Normative values for the Italian population, Neurological Sciences, 34, 2, pp. 173-180, (2013); Mars R. B., Sallet J., Schuffelgen U., Jbabdi S., Toni I., Rushworth M. F. S., Connectivity-based subdivisions of the human right «temporoparietaljunction area»: Evidence for different areas participating in different cortical networks, Cerebral Cortex, 22, 8, (2012); Miceli G., Laudanna A., Burani C., Capasso R., Batteria per l’Analisi del Deficit Afasico, (1994); Monaco M., Costa A., Caltagirone C., Carlesimo G. A., Forward and backward span for verbal and visuo-spatial data: Standardization and normative data from an Italian adult population, Neurological Sciences, 34, 5, pp. 749-754, (2013); Morris R. G., Mograbi D. C., Anosognosia, autobiographical memory and self knowledge in Alzheimer’s disease, Cortex, 49, 6, (2013); Okonkwo O. C., Wadley V. G., Griffith H. R., Belue K., Lanza S., Zamrini E. Y., Harrell L. E., Brockington J. C., Clark D., Raman R., Marson D. C., Awareness of deficits in financial abilities in patients with mild cognitive impairment: Going beyond self-informant discrepancy, The American Journal of Geriatric Psychiatry, 16, 8, (2008); Orfei M. D., Varsi A. E., Blundo C., Celia E., Casini A. R., Caltagirone C., Spalletta G., Anosognosia in mild cognitive impairment and mild Alzheimer’s disease: Frequency and neuropsychological correlates, The American Journal of Geriatric Psychiatry, 18, 12, pp. 1133-1140, (2010); Pernigo S., Gambina G., Valbusa V., Condoleo M. T., Broggio E., Beltramello A., Moretto G., Moro V., Behavioral and neural correlates of visual emotion discrimination and empathy in mild cognitive impairment, Behavioural Brain Research, 294, pp. 111-122, (2015); Perrotin A., Tournelle L., Isingrini M., Executive functioning and memory as potential mediators of the episodic feeling-of-knowing accuracy, Brain and Cognition, 67, 1, pp. 76-87, (2008); Piras F., Piras F., Orfei M. D., Caltagirone C., Spalletta G., Selfawareness in Mild Cognitive Impairment: Quantitative evidence from systematic review and meta-analysis, Neuroscience and Biobehavioral Reviews, 61, pp. 90-107, (2016); Quaranta D., Caprara A., Piccininni C., Vita M. G., Gainotti G., Marra C., Standardization, clinical validation, and typicality norms of a new test assessing semantic verbal fluency, Archives of Clinical Neuropsychology, 31, 5, pp. 434-445, (2016); Quesque F., Brass M., The role of the temporoparietal junction in self-other distinction, Brain Topography, 32, 6, pp. 943-955, (2019); Rankin K. P., Gorno-Tempini M. L., Allison S. C., Stanley C. M., Glenn S., Weiner M. W., Miller B. L., Structural anatomy of empathy in neurodegenerative disease, Brain: A Journal of Neurology, 129, pp. 2945-2956, (2006); Rankin K. P., Kramer J. H., Miller B. L., Patterns of cognitive and emotional empathy in frontotemporal lobar degeneration, Cognitive and Behavioral Neurology, 18, 1, pp. 28-36, (2005); Rascovsky K., Hodges J. R., Knopman D., Mendez M. F., Kramer J. H., Neuhaus J., van Swieten J. C., Seelaar H., Dopper E. G., Onyike C. U., Hillis A. E., Josephs K. A., Boeve B. F., Kertesz A., Seeley W. W., Rankin K. P., Johnson J. K., Gorno-Tempini M. L., Rosen H., Miller B. L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain: A Journal of Neurology, 134, pp. 2456-2477, (2011); Roberts J. L., Clare L., Woods R. T., Subjective memory complaints and awareness of memory functioning in mild cognitive impairment: A systematic review, Dementia and Geriatric Cognitive Disorders, 28, 2, pp. 95-109, (2009); Salmon E., Perani D., Collette F., Feyers D., Kalbe E., Holthoff V., Sorbi S., Herholz K., A comparison of unawareness in frontotemporal dementia and Alzheimer’s disease, Journal of Neurology, Neurosurgery, and Psychiatry, 79, 2, pp. 176-179, (2008); Salmon E., Perani D., Herholz K., Marique P., Kalbe E., Holthoff V., Delbeuck X., Beuthien-Baumann B., Pelati O., Lespagnard S., Collette F., Garraux G., Neural correlates of anosognosia for cognitive impairment in Alzheimer’s disease, Human Brain Mapping, 27, 7, (2006); Shany-Ur T., Lin N., Rosen H. J., Sollberger M., Miller B. L., Rankin K. P., Self-awareness in neurodegenerative disease relies on neural structures mediating reward-driven attention, Brain: A Journal of Neurology, 137, pp. 2368-2381, (2014); Sturm V. E., Yokoyama J. S., Seeley W. W., Kramer J. H., Miller B. L., Rankin K. P., Heightened emotional contagion in mild cognitive impairment and Alzheimer’s disease is associated with temporal lobe degeneration, Proceedings of the National Academy of Sciences of the United States of America, 110, 24, pp. 9944-9949, (2013); Vogel A., Stokholm J., Gade A., Andersen B. B., Hejl A.-M., Waldemar G., Awareness of deficits in mild cognitive impairment and Alzheimer’sdisease: Do MCI patients have impaired insight?, Dementia and Geriatric Cognitive Disorders, 17, 2, pp. 181-187, (2004); Walter H., Social cognitive neuroscience of empathy: Concepts, circuits, and genes, Emotion Review, 4, 1, pp. 9-17, (2012); Wang Y., Li Y., Xiao W., Fu Y., Jie J., Investigation on the rationality of the extant ways of scoring the interpersonal reactivity index based on confirmatory factor analysis, Frontiers in Psychology, 11, (2020); Yamada M., Decety J., Unconscious affective processing and empathy: An investigation of subliminal priming on the detection of painful facial expressions, Pain, 143, 1-2, pp. 71-75, (2009); Zamboni G., Drazich E., McCulloch E., Filippini N., Mackay C. E., Jenkinson M., Tracey I., Wilcock G. K., Neuroanatomy of impaired self-awareness in Alzheimer’s disease and mild cognitive impairment, Cortex, 49, 3, pp. 668-678, (2013)","2-s2.0-85158108291"
"Azevedo F.; Pavlović T.; Rêgo G.G.; Ay F.C.; Gjoneska B.; Etienne T.W.; Ross R.M.; Schönegger P.; Riaño-Moreno J.C.; Cichocka A.; Capraro V.; Cian L.; Longoni C.; Chan H.F.; Van Bavel J.J.; Sjåstad H.; Nezlek J.B.; Alfano M.; Gelfand M.J.; Birtel M.D.; Cislak A.; Lockwood P.L.; Abts K.; Agadullina E.; Aruta J.J.B.; Besharati S.N.; Bor A.; Choma B.L.; Crabtree C.D.; Cunningham W.A.; De K.; Ejaz W.; Elbaek C.T.; Findor A.; Flichtentrei D.; Franc R.; Gruber J.; Gualda E.; Horiuchi Y.; Huynh T.L.D.; Ibanez A.; Imran M.A.; Israelashvili J.; Jasko K.; Kantorowicz J.; Kantorowicz-Reznichenko E.; Krouwel A.; Laakasuo M.; Lamm C.; Leygue C.; Lin M.-J.; Mansoor M.S.; Marie A.; Mayiwar L.; Mazepus H.; McHugh C.; Minda J.P.; Mitkidis P.; Olsson A.; Otterbring T.; Packer D.J.; Perry A.; Petersen M.B.; Puthillam A.; Rothmund T.; Santamaría-García H.; Schmid P.C.; Stoyanov D.; Tewari S.; Todosijević B.; Tsakiris M.; Tung H.H.; Umbres R.G.; Vanags E.; Vlasceanu M.; Vonasch A.; Yucel M.; Zhang Y.; Abad M.; Adler E.; Akrawi N.; Mdarhri H.A.; Amara H.; Amodio D.M.; Antazo B.G.; Apps M.; Ba M.H.; Barbosa S.; Bastian B.; Berg A.; Bernal-Zárate M.P.; Bernstein M.; Białek M.; Bilancini E.; Bogatyreva N.; Boncinelli L.; Booth J.E.; Borau S.; Buchel O.; Cameron C.D.; Carvalho C.F.; Celadin T.; Cerami C.; Chalise H.N.; Cheng X.; Cockcroft K.; Conway J.; Córdoba-Delgado M.A.; Crespi C.; Crouzevialle M.; Cutler J.; Cypryańska M.; Dabrowska J.; Daniels M.A.; Davis V.H.; Dayley P.N.; Delouvée S.; Denkovski O.; Dezecache G.; Dhaliwal N.A.; Diato A.B.; Di Paolo R.; Drosinou M.; Dulleck U.; Ekmanis J.; Ertan A.S.; Farhana H.H.; Farkhari F.; Farmer H.; Fenwick A.; Fidanovski K.; Flew T.; Fraser S.; Frempong R.B.; Fugelsang J.A.; Gale J.; Garcia-Navarro E.B.; Garladinne P.; Ghajjou O.; Gkinopoulos T.; Gray K.; Griffin S.M.; Gronfeldt B.; Gümren M.; Gurung R.L.; Halperin E.; Harris E.; Herzon V.; Hruška M.; Huang G.; Hudecek M.F.C.; Isler O.; Jangard S.; Jorgensen F.J.; Kachanoff F.; Kahn J.; Dangol A.K.; Keudel O.; Koppel L.; Koverola M.; Kubin E.; Kunnari A.; Kutiyski Y.; Laguna O.M.; Leota J.; Lermer E.; Levy J.; Levy N.; Li C.; Long E.U.; Maglić M.; McCashin D.; Metcalf A.L.; Mikloušić I.; El Mimouni S.; Miura A.; Molina-Paredes J.; Monroy-Fonseca C.; Morales-Marente E.; Moreau D.; Muda R.; Myer A.; Nash K.; Nesh-Nash T.; Nitschke J.P.; Nurse M.S.; Ohtsubo Y.; de Mello V.O.; O’Madagain C.; Onderco M.; Palacios-Galvez M.S.; Palomöki J.; Pan Y.; Papp Z.; Pärnamets P.; Paruzel-Czachura M.; Pavlović Z.; Payán-Gómez C.; Perander S.; Pitman M.M.; Prasad R.; Pyrkosz-Pacyna J.; Rathje S.; Raza A.; Rhee K.; Robertson C.E.; Rodríguez-Pascual I.; Saikkonen T.; Salvador-Ginez O.; Santi G.C.; Santiago-Tovar N.; Savage D.; Scheffer J.A.; Schultner D.T.; Schutte E.M.; Scott A.; Sharma M.; Sharma P.; Skali A.; Stadelmann D.; Stafford C.A.; Stanojević D.; Stefaniak A.; Sternisko A.; Stoica A.; Stoyanova K.K.; Strickland B.; Sundvall J.; Thomas J.P.; Tinghög G.; Torgler B.; Traast I.J.; Tucciarelli R.; Tyrala M.; Ungson N.D.; Uysal M.S.; Van Lange P.A.M.; van Prooijen J.-W.; van Rooy D.; Västfjäll D.; Verkoeijen P.; Vieira J.B.; von Sikorski C.; Walker A.C.; Watermeyer J.; Wetter E.; Whillans A.; White K.; Habib R.; Willardt R.; Wohl M.J.A.; Wójcik A.D.; Wu K.; Yamada Y.; Yilmaz O.; Yogeeswaran K.; Ziemer C.-T.; Zwaan R.A.; Boggio P.S.; Sampaio W.M.","Azevedo, Flavio (57202683756); Pavlović, Tomislav (57196148151); Rêgo, Gabriel G. (56480308400); Ay, F. Ceren (57432990200); Gjoneska, Biljana (57211203812); Etienne, Tom W. (57302201900); Ross, Robert M. (23567212800); Schönegger, Philipp (57223426293); Riaño-Moreno, Julián C. (57210113671); Cichocka, Aleksandra (35765189600); Capraro, Valerio (49361021300); Cian, Luca (37088275700); Longoni, Chiara (55899207500); Chan, Ho Fai (55582588800); Van Bavel, Jay J. (22986966200); Sjåstad, Hallgeir (57200691996); Nezlek, John B. (7004481879); Alfano, Mark (36762163600); Gelfand, Michele J. (7201803113); Birtel, Michèle D. (46060910600); Cislak, Aleksandra (23666913300); Lockwood, Patricia L. (55347628400); Abts, Koen (16314964400); Agadullina, Elena (55948104400); Aruta, John Jamir Benzon (57205719637); Besharati, Sahba Nomvula (56221801500); Bor, Alexander (57193896526); Choma, Becky L. (10039110600); Crabtree, Charles David (56669557400); Cunningham, William A. (16065517700); De, Koustav (57432843300); Ejaz, Waqas (57196262755); Elbaek, Christian T. (57219005068); Findor, Andrej (15051465700); Flichtentrei, Daniel (35094029100); Franc, Renata (6701375451); Gruber, June (8929220900); Gualda, Estrella (26531164900); Horiuchi, Yusaku (24168107200); Huynh, Toan Luu Duc (57728566100); Ibanez, Agustin (55172691400); Imran, Mostak Ahamed (14008430600); Israelashvili, Jacob (57196217992); Jasko, Katarzyna (35743100000); Kantorowicz, Jaroslaw (56256131200); Kantorowicz-Reznichenko, Elena (56743290300); Krouwel, André (16744097100); Laakasuo, Michael (55209862600); Lamm, Claus (56566285000); Leygue, Caroline (11839543000); Lin, Ming-Jen (34668140100); Mansoor, Mohammad Sabbir (57432843400); Marie, Antoine (57210735692); Mayiwar, Lewend (57210589547); Mazepus, Honorata (57189074265); McHugh, Cillian (57201644809); Minda, John Paul (6603737492); Mitkidis, Panagiotis (55734672700); Olsson, Andreas (8690139600); Otterbring, Tobias (54684879600); Packer, Dominic J. (22986127600); Perry, Anat (26647787400); Petersen, Michael Bang (35761369500); Puthillam, Arathy (57209821598); Rothmund, Tobias (26026109100); Santamaría-García, Hernando (56610290700); Schmid, Petra C. (35778895000); Stoyanov, Drozdstoy (36601257300); Tewari, Shruti (37102876500); Todosijević, Bojan (6507222236); Tsakiris, Manos (8612330500); Tung, Hans H. (57189267860); Umbres, Radu G. (56121056100); Vanags, Edmunds (57433130100); Vlasceanu, Madalina (57201915022); Vonasch, Andrew (16425076400); Yucel, Meltem (57201461738); Zhang, Yucheng (56605134100); Abad, Mohcine (57433425600); Adler, Eli (57367764100); Akrawi, Narin (57433856600); Mdarhri, Hamza Alaoui (57433566000); Amara, Hanane (57433711700); Amodio, David M. (6603573634); Antazo, Benedict G. (57218632714); Apps, Matthew (37017949200); Ba, Mouhamadou Hady (57433425700); Barbosa, Sergio (57194429267); Bastian, Brock (7005685014); Berg, Anton (57433130200); Bernal-Zárate, Maria P. (57433425900); Bernstein, Michael (18133581400); Białek, Michał (56333322000); Bilancini, Ennio (24175889200); Bogatyreva, Natalia (57226525097); Boncinelli, Leonardo (24175528900); Booth, Jonathan E. (27567441600); Borau, Sylvie (57192594944); Buchel, Ondrej (57219655063); Cameron, C. Daryl (36551893200); Carvalho, Chrissie F. (55972096100); Celadin, Tatiana (57216634436); Cerami, Chiara (25722905400); Chalise, Hom Nath (14629921400); Cheng, Xiaojun (57206757068); Cockcroft, Kate (22933698400); Conway, Jane (57188581373); Córdoba-Delgado, Mateo Andres (57408848700); Crespi, Chiara (57034303800); Crouzevialle, Marie (55934830400); Cutler, Jo (57203910287); Cypryańska, Marzena (55078294200); Dabrowska, Justyna (57433711900); Daniels, Michael A. (56189070000); Davis, Victoria H. (57432990300); Dayley, Pamala N. (57433856800); Delouvée, Sylvain (13612418500); Denkovski, Ognjan (57221594660); Dezecache, Guillaume (55151472900); Dhaliwal, Nathan A. (57219911935); Diato, Alelie B. (57433130400); Di Paolo, Roberto (57201116811); Drosinou, Marianna (57193797236); Dulleck, Uwe (55973560500); Ekmanis, Jānis (57433426100); Ertan, Arhan S. (25923852000); Farhana, Hapsa Hossain (57433130500); Farkhari, Fahima (57432990400); Farmer, Harry (55233381300); Fenwick, Ali (57433566200); Fidanovski, Kristijan (57202704216); Flew, Terry (56341271400); Fraser, Shona (57211455566); Frempong, Raymond Boadi (57194167162); Fugelsang, Jonathan A. (6603080729); Gale, Jessica (57202291651); Garcia-Navarro, E. Begoña (57218316315); Garladinne, Prasad (57433278100); Ghajjou, Oussama (57433856900); Gkinopoulos, Theofilos (55866447200); Gray, Kurt (15520639300); Griffin, Siobhán M. (7201880907); Gronfeldt, Bjarki (57196054646); Gümren, Mert (6504093196); Gurung, Ranju Lama (57433857000); Halperin, Eran (35866830500); Harris, Elizabeth (57215611020); Herzon, Volo (57433857100); Hruška, Matej (57196236805); Huang, Guanxiong (56844125900); Hudecek, Matthias F. C. (56545531900); Isler, Ozan (57200182087); Jangard, Simon (57195595285); Jorgensen, Frederik J. (57222523239); Kachanoff, Frank (56574304400); Kahn, John (57433426300); Dangol, Apsara Katuwal (57433857200); Keudel, Oleksandra (57218936367); Koppel, Lina (57188825958); Koverola, Mika (57204777214); Kubin, Emily (57205631416); Kunnari, Anton (57204772241); Kutiyski, Yordan (56480708400); Laguna, Oscar Moreda (57432990500); Leota, Josh (57217061682); Lermer, Eva (55584194600); Levy, Jonathan (56327503700); Levy, Neil (57216429407); Li, Chunyun (57202677751); Long, Elizabeth U. (57217147507); Maglić, Marina (57216147889); McCashin, Darragh (57204609951); Metcalf, Alexander L. (54890112800); Mikloušić, Igor (36859688300); El Mimouni, Soulaimane (57433278200); Miura, Asako (12645856800); Molina-Paredes, Juliana (57408848800); Monroy-Fonseca, César (57433278300); Morales-Marente, Elena (36240826900); Moreau, David (36552994500); Muda, Rafał (57195249015); Myer, Annalisa (57225980689); Nash, Kyle (22135546300); Nesh-Nash, Tarik (57433278400); Nitschke, Jonas P. (57193254318); Nurse, Matthew S. (57209360893); Ohtsubo, Yohsuke (7005112071); de Mello, Victoria Oldemburgo (58263198000); O’Madagain, Cathal (56593233200); Onderco, Michal (50462189600); Palacios-Galvez, M. Soledad (55946309500); Palomöki, Jussi (58263147400); Pan, Yafeng (57191922458); Papp, Zsófia (55383252800); Pärnamets, Philip (55918105000); Paruzel-Czachura, Mariola (55936861100); Pavlović, Zoran (23397554100); Payán-Gómez, César (54896392800); Perander, Silva (57433426600); Pitman, Michael Mark (19337434700); Prasad, Rajib (57433566400); Pyrkosz-Pacyna, Joanna (57218692997); Rathje, Steve (57221697332); Raza, Ali (57548710100); Rhee, Kasey (57432843500); Robertson, Claire E. (57215603258); Rodríguez-Pascual, Iván (55851219500); Saikkonen, Teemu (55045848200); Salvador-Ginez, Octavio (57433130800); Santi, Gaia C. (57217289456); Santiago-Tovar, Natalia (57433857400); Savage, David (35773679000); Scheffer, Julian A. (57191989558); Schultner, David T. (57222164240); Schutte, Enid M. (7003944275); Scott, Andy (57219874700); Sharma, Madhavi (57433566500); Sharma, Pujan (57433712200); Skali, Ahmed (56716506400); Stadelmann, David (25634677900); Stafford, Clara Alexandra (57208079952); Stanojević, Dragan (55252365500); Stefaniak, Anna (57103128900); Sternisko, Anni (57197832704); Stoica, Augustin (58263247800); Stoyanova, Kristina K. (57219964963); Strickland, Brent (49962193300); Sundvall, Jukka (57202986641); Thomas, Jeffrey P. (57432844400); Tinghög, Gustav (25224071700); Torgler, Benno (55897871400); Traast, Iris J. (57433567500); Tucciarelli, Raffaele (55901667000); Tyrala, Michael (57432992000); Ungson, Nick D. (57201349000); Uysal, Mete S. (57219744529); Van Lange, Paul A. M. (7004460194); van Prooijen, Jan-Willem (6602472447); van Rooy, Dirk (6603562161); Västfjäll, Daniel (6603904733); Verkoeijen, Peter (6603048790); Vieira, Joana B. (55899486000); von Sikorski, Christian (55543167600); Walker, Alexander Cameron (56735153200); Watermeyer, Jennifer (25824525800); Wetter, Erik (36460458400); Whillans, Ashley (55601702200); White, Katherine (7402808087); Habib, Rishad (57209252660); Willardt, Robin (57219439920); Wohl, Michael J. A. (7006650468); Wójcik, Adrian Dominik (35243826100); Wu, Kaidi (57196224019); Yamada, Yuki (55375527500); Yilmaz, Onurcan (56498563100); Yogeeswaran, Kumar (36344224800); Ziemer, Carolin-Theresa (57433567700); Zwaan, Rolf A. (7003515240); Boggio, Paulo S. (10340985700); Sampaio, Waldir M. (57200417301)","57202683756; 57196148151; 56480308400; 57432990200; 57211203812; 57302201900; 23567212800; 57223426293; 57210113671; 35765189600; 49361021300; 37088275700; 55899207500; 55582588800; 22986966200; 57200691996; 7004481879; 36762163600; 7201803113; 46060910600; 23666913300; 55347628400; 16314964400; 55948104400; 57205719637; 56221801500; 57193896526; 10039110600; 56669557400; 16065517700; 57432843300; 57196262755; 57219005068; 15051465700; 35094029100; 6701375451; 8929220900; 26531164900; 24168107200; 57728566100; 55172691400; 14008430600; 57196217992; 35743100000; 56256131200; 56743290300; 16744097100; 55209862600; 56566285000; 11839543000; 34668140100; 57432843400; 57210735692; 57210589547; 57189074265; 57201644809; 6603737492; 55734672700; 8690139600; 54684879600; 22986127600; 26647787400; 35761369500; 57209821598; 26026109100; 56610290700; 35778895000; 36601257300; 37102876500; 6507222236; 8612330500; 57189267860; 56121056100; 57433130100; 57201915022; 16425076400; 57201461738; 56605134100; 57433425600; 57367764100; 57433856600; 57433566000; 57433711700; 6603573634; 57218632714; 37017949200; 57433425700; 57194429267; 7005685014; 57433130200; 57433425900; 18133581400; 56333322000; 24175889200; 57226525097; 24175528900; 27567441600; 57192594944; 57219655063; 36551893200; 55972096100; 57216634436; 25722905400; 14629921400; 57206757068; 22933698400; 57188581373; 57408848700; 57034303800; 55934830400; 57203910287; 55078294200; 57433711900; 56189070000; 57432990300; 57433856800; 13612418500; 57221594660; 55151472900; 57219911935; 57433130400; 57201116811; 57193797236; 55973560500; 57433426100; 25923852000; 57433130500; 57432990400; 55233381300; 57433566200; 57202704216; 56341271400; 57211455566; 57194167162; 6603080729; 57202291651; 57218316315; 57433278100; 57433856900; 55866447200; 15520639300; 7201880907; 57196054646; 6504093196; 57433857000; 35866830500; 57215611020; 57433857100; 57196236805; 56844125900; 56545531900; 57200182087; 57195595285; 57222523239; 56574304400; 57433426300; 57433857200; 57218936367; 57188825958; 57204777214; 57205631416; 57204772241; 56480708400; 57432990500; 57217061682; 55584194600; 56327503700; 57216429407; 57202677751; 57217147507; 57216147889; 57204609951; 54890112800; 36859688300; 57433278200; 12645856800; 57408848800; 57433278300; 36240826900; 36552994500; 57195249015; 57225980689; 22135546300; 57433278400; 57193254318; 57209360893; 7005112071; 58263198000; 56593233200; 50462189600; 55946309500; 58263147400; 57191922458; 55383252800; 55918105000; 55936861100; 23397554100; 54896392800; 57433426600; 19337434700; 57433566400; 57218692997; 57221697332; 57548710100; 57432843500; 57215603258; 55851219500; 55045848200; 57433130800; 57217289456; 57433857400; 35773679000; 57191989558; 57222164240; 7003944275; 57219874700; 57433566500; 57433712200; 56716506400; 25634677900; 57208079952; 55252365500; 57103128900; 57197832704; 58263247800; 57219964963; 49962193300; 57202986641; 57432844400; 25224071700; 55897871400; 57433567500; 55901667000; 57432992000; 57201349000; 57219744529; 7004460194; 6602472447; 6603562161; 6603904733; 6603048790; 55899486000; 55543167600; 56735153200; 25824525800; 36460458400; 55601702200; 7402808087; 57209252660; 57219439920; 7006650468; 35243826100; 57196224019; 55375527500; 56498563100; 36344224800; 57433567700; 7003515240; 10340985700; 57200417301","Social and moral psychology of COVID-19 across 69 countries","2023","Scientific Data","10","1","272","","","","6","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85159738666&doi=10.1038%2fs41597-023-02080-8&partnerID=40&md5=b682bc7695138f2918e6779df40076a4","The COVID-19 pandemic has affected all domains of human life, including the economic and social fabric of societies. One of the central strategies for managing public health throughout the pandemic has been through persuasive messaging and collective behaviour change. To help scholars better understand the social and moral psychology behind public health behaviour, we present a dataset comprising of 51,404 individuals from 69 countries. This dataset was collected for the International Collaboration on Social & Moral Psychology of COVID-19 project (ICSMP COVID-19). This social science survey invited participants around the world to complete a series of moral and psychological measures and public health attitudes about COVID-19 during an early phase of the COVID-19 pandemic (between April and June 2020). The survey included seven broad categories of questions: COVID-19 beliefs and compliance behaviours; identity and social attitudes; ideology; health and well-being; moral beliefs and motivation; personality traits; and demographic variables. We report both raw and cleaned data, along with all survey materials, data visualisations, and psychometric evaluations of key variables. © 2023, The Author(s).","","Attitude; COVID-19; Humans; Morals; Pandemics; Social Change; Socioeconomic Factors; Surveys and Questionnaires; attitude; coronavirus disease 2019; human; morality; pandemic; psychology; questionnaire; social change; socioeconomics","Cucinotta D., Vanelli M., Who declares COVID-19 a pandemic, Acta Biomed., 91, (2020); Nicola M., Et al., The socio-economic implications of the coronavirus and COVID-19 pandemic: A review, Int. J. Surg., (2020); Holmes E.A., Et al., Multidisciplinary research priorities for the COVID-19 pandemic: A call for action for mental health science, The Lancet Psychiatry, (2020); Adam D., Et al., Covid’s true death toll: Much higher than official records, Nature, 603, (2022); Yamada Y., Et al., COVIDiSTRESS global survey dataset on psychological and behavioural consequences of the COVID-19 outbreak, Sci. Data., 8, pp. 1-23, (2021); John A., Et al., The impact of the COVID-19 pandemic on self-harm and suicidal behaviour: A living systematic review, F1000Research, 9, (2020); Serafini G., Et al., The psychological impact of COVID-19 on the mental health in the general population, QJM, 113, pp. 531-537, (2020); Taylor S., The Psychology of Pandemics: Preparing for the Next Global Outbreak of Infectious Disease, (2019); Haug N., Et al., Ranking the effectiveness of worldwide COVID-19 government interventions, Nat. Hum. Behav., 4, pp. 1303-1312, (2020); Van Bavel J.J., Et al., Using social and behavioural science to support COVID-19 pandemic response, Nature Human Behaviour, 4, pp. 460-471, (2020); Van Bavel J.J., Et al., National identity predicts public health support during a global pandemic, Nature Communications, 13, (2022); Pavlovic T., Predicting attitudinal and behavioral responses to COVID-19 pandemic using machine learning, PNAS Nexus, 1, (2022); National Narcissism Predicts the Belief in and the Dissemination of Conspiracy Theories during the COVID-19 Pandemic: Evidence from 56 Countries., (2021); Cichocka A., Globalization is associated with lower levels of national narcissism: Evidence from 56 countries, Social Psychological and Personality Science, (2022); Nurse M.S., Ross R.M., Isler O., Van Rooy D., Analytic thinking predicts accuracy ratings and willingness to share covid-19 misinformation in Australia, Memory & Cognition, 50, pp. 425-434, (2022); McHugh C., Moral identity predicts adherence to COVID-19 mitigation procedures depending on political ideology: A comparison between the USA and New Zealand, Political Psychology. ahead of Print, (2022); Maglic M., Pavlovic T., Franc R., Analytic thinking and political orientation in the corona crisis, Frontiers in Psychology, 2711, (2021); Gkinopoulos T., Elbaek C.T., Mitkidis P., Morality in the echo chamber: The relationship between belief in COVID-19 conspiracy theories and public health support and the mediating role of moral identity and morality-as-cooperation across 67 countries, PLOS ONE, 17, (2022); Borau S., Couprie H., Hopfensitz A., The prosociality of married people: Evidence from a large multinational sample, Journal of Economic Psychology, 92, (2022); Bonetto E., Delouvee S., Mahfud Y., Adam-Troian J., National identification, a social cure for COVID-19? Evidence from 67 countries, International Journal of Social Psychiatry, 68, pp. 1116-1126, (2022); Cutler J., Nitschke J.P., Lamm C., Lockwood P.L., Older adults across the globe exhibit increased prosocial behavior but also greater in-group preferences, Nature Aging, 1, pp. 880-888, (2021); Gualda E., Et al., Social distancing and COVID-19: Factors associated with compliance with social distancing norms in Spain, Frontiers in Psychology, 12, (2021); Pan Y., Psychological well-being is associated with prosociality during the COVID-19 pandemic: A comparison of Swedish and Chinese samples, Emotion., (2022); Wilkinson M.D., Et al., The fair guiding principles for scientific data management and stewardship, Scientific data, 3, pp. 1-9, (2016); Parsons S., Et al., A community-sourced glossary of open scholarship terms, Nature human behaviour, 6, pp. 312-318, (2022); Pownall M., Et al., Embedding open and reproducible science into teaching: A bank of lesson plans and resources, Scholarship of Teaching and Learning in Psychology., (2021); Pownall M., Teaching Open and Reproducible Scholarship: A Critical Review of the Evidence Base for Current Pedagogical Methods and Their Outcomes, (2022); Azevedo F., Et al., Introducing a Framework for Open and Reproducible Research Training (FORRT), (2019); Jong J., Et al., Traumatic life experiences and religiosity in eight countries, Scientific data, 7, pp. 1-8, (2020); Azevedo F., An international investigation of the psychology of COVID-19, Behavioural and Social Sciences at Nature Portfolio. Blog Post At, (2021); Postmes T., Haslam S.A., Jans L., A single-item measure of social identification: Reliability, validity, and utility, Br. J. Soc. Psychol., 52, pp. 597-617, (2013); de Zavala A.G., Cichocka A., Eidelson R., Jayawickreme N., Collective narcissism and its social consequences, Journal of Personality and Social Psychology, 97, pp. 1074-1096, (2009); Malone G.P., Pillow D.R., Osman A., The general belongingness scale (GBS): Assessing achieved belongingness, Personality and Individual Differences, 52, pp. 311-316, (2012); Jost J.T., The end of the end of ideology, American Psychologist, 61, pp. 651-670, (2006); Azevedo F., Jost J.T., Rothmund T., Sterling J., Neoliberal ideology and the justification of inequality in capitalist societies: Why social and economic dimensions of ideology are intertwined, Journal of Social Issues, 75, pp. 49-88, (2019); Azevedo F., Jost J.T., Rothmund T., making america great again”: System justification in the us presidential election of 2016, Translational Issues in Psychological Science, 3, (2017); Azevedo F., Jost J.T., The ideological basis of antiscientific attitudes: Effects of authoritarianism, conservatism, religiosity, social dominance, and system justification, Group Processes & Intergroup Relations, 24, pp. 518-549, (2021); Imhoff R., Et al., Conspiracy mentality and political orientation across 26 countries, Nature Human Behaviour, 6, pp. 392-403, (2022); Van der Linden S., Panagopoulos C., Azevedo F., Jost J.T., The paranoid style in american politics revisited: An ideological asymmetry in conspiratorial thinking, Political Psychology, 42, pp. 23-51, (2021); Measuring ideology: Current practices, consequences, and recommendations, Manuscript in Preparation; Azevedo F., Marques T., Micheli L., In pursuit of racial equality: Identifying the determinants of support for the black lives matter movement with a systematic review and multiple meta-analyses, pp. 1-23, (2022); Azevedo F., Bolesta D., Micheli L., Does stereotype threat contribute to the political knowledge gender gap? A preregistered replication study of ihme and tausendpfund, Journal of Experimental Political Science (In Press), (2018); Pinquart M., Correlates of subjective health in older adults: a meta-analysis, Psychology and Aging, 16, pp. 414-426, (2001); Adler N.E., Epel E.S., Castellazzo G., Ickovics J.R., Relationship of subjective and objective social status with psychological and physiological functioning: Preliminary data in healthy, white women, Health psychology, 19, (2000); Bjornskov C., How comparable are the gallup world poll life satisfaction data?, J. Happiness Stud., 11, pp. 41-60, (2010); Sjastad H., Short-sighted greed? focusing on the future promotes reputation-based generosity, Judgm. Decis. Mak, 14, pp. 199-213, (2019); Curry O.S., Chesters M.J., Van Lissa C.J., Mapping morality with a compass: Testing the theory of ‘morality-as-cooperation’ with a new questionnaire, J. Res. Pers., 78, pp. 106-124, (2019); Aquino K., Reed A., The self-importance of moral identity, J. Pers. Soc. Psychol., 83, (2002); Waytz A., Iyer R., Young L., Haidt J., Graham J., Ideological differences in the expanse of the moral circle, Nat. Commun., 10, pp. 1-12, (2019); Alfano M., Et al., Development and validation of a multi-dimensional measure of intellectual humility, PloS ONE, 12, (2017); Scheier M.F., Carver C.S., Bridges M.W., Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): A reevaluation of the life orientation test, J. Pers. Soc. Psychol., 67, (1994); Robins R.W., Hendin H.M., Trzesniewski K.H., Measuring global self-esteem: Construct validation of a single-item measure and the rosenberg self-esteem scale, Personality and Social Psychology Bulletin, 27, pp. 151-161, (2001); Tangney J.P., Baumeister R.F., Boone A.L., High self-control predicts good adjustment, less pathology, better grades, and interpersonal success, J. Pers., 72, pp. 271-324, (2004); Back M.D., Et al., Narcissistic admiration and rivalry: Disentangling the bright and dark sides of narcissism, J. Pers. Soc. Psychol., 105, (2013); Primi C., Morsanyi K., Chiesi F., Donati M.A., Hamilton J., The development and testing of a new version of the cognitive reflection test applying item response theory (IRT), Journal of Behavioral Decision Making, 29, pp. 453-469, (2016); Azevedo F., Et al., Social amp; Moral Psychology of COVID-19, Open Science Framework, (2022); Azevedo F., Et al., Social and moral psychology of covid-19 across 69 countries, (2022); Graul C.L., Interactive Web-Maps Based on the Leaflet Javascript Library. R Package Version 0, pp. 4-0, (2016); Ggplot2: Elegant Graphics for Data Analysis (, (2016); Ghai S., It’s time to reimagine sample diversity and retire the weird dichotomy, Nature Human Behaviour, 5, pp. 971-972, (2021); Kretzschmar A., Gignac G.E., At what sample size do latent variable correlations stabilize?, Journal of Research in Personality, 80, pp. 17-22, (2019); (2019); Readr: Read Rectangular Text Data, R Package Version 1.4.0, (2020); Wickham H., Miller E., (2021); Readxl: Read Excel Files. R Package Version 1.3.1, (2019); Dplyr: A Grammar of Data Manipulation. R Package Version 1.0.6 (2021).; Psych: Procedures for Psychological, Psychometric, and Personality Research, R Package Version 2.1.6, (2021); Htmltools: Tools for HTML. R Package Version 0.5.1, (2021); Xie Y.M., Map Filenames to MIME Types, R Package Version, (2021); Xie Y.X., Supporting Functions for Packages Maintained by Yihui Xie. R Package Version 0, (2021); Larmarange J., Labelled: Manipulating Labelled Data., (2021); Ludecke D., Sjlabelled: Labelled Data Utility Functions, (2020); Codebook: Automatic Codebooks from Metadata Encoded in Dataset Attributes., (2020); Lubridate: Make Dealing with Dates a Little Easier, R Package Version 1.7.10, (2021)","2-s2.0-85159738666"
"Galbiati A.; Carli G.; Dodich A.; Marelli S.; Caterina P.; Cerami C.; Zucconi M.; Ferini-Strambi L.","Galbiati, Andrea (55667631700); Carli, Giulia (57201314331); Dodich, Alessandra (56001713900); Marelli, Sara (12806232700); Caterina, Pagnini (57211653818); Cerami, Chiara (25722905400); Zucconi, Marco (7007136770); Ferini-Strambi, Luigi (7006625831)","55667631700; 57201314331; 56001713900; 12806232700; 57211653818; 25722905400; 7007136770; 7006625831","Qualitative scoring of the pentagon test: A tool for the identification of subtle cognitive deficits in isolated rem sleep behavior disorder patients","2019","Archives of Clinical Neuropsychology","34","7","","1113","1120","7","3","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85074742681&doi=10.1093%2farclin%2facz024&partnerID=40&md5=6c76029603a81145acb76ef7600948d3","Objective: Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) frequently represents the prodromal stage of alpha-synucleinopathies, and similar to these pathologies, iRBD patients show neuropsychological deficits, particularly in the domain of visuospatial abilities and executive functions. We hypothesized that the qualitative scoring of the Mini-Mental State Examination pentagon test (QSPT) may detect subtle visuospatial deficits in these subjects, and we evaluated its relationship with indexes of sleep quality, as measured by polysomnography. Methods: A total of 80 polysomnography-confirmed iRBD patients and 40 healthy controls (HCs) were retrospectively recruited. Global and specific qualitative performances were evaluated according to QSPT procedure. Comparisons between iRBD and HC regarding all QSPT parameters, neuropsychological tests, and polysomnographic recordings were performed. Results: Patients displayed significantly lower scores in both ""closing-in"" and total score parameters in comparison to HC. The QSPT total score exhibited significant positive correlations with verbal comprehension, fluency, visuospatial abilities, and executive functions. Notably, iRBD patients with impaired performance at QSPT showed decreased neuropsychological performances and higher percentages of slow wave sleep (SWS). In addition, SWS percentages negatively correlated with verbal comprehension, fluency, visuospatial abilities, executive functions, and QSPT total score. Conclusion: QSPT may represent a brief and easy to administer tool for the detection of subtle visuospatial changes in iRBD patients. Furthermore, polysomnographic findings suggest a possible slowdown of electroencephalographic pattern during non- REM sleep in iRBD patients in line with the presence of cognitive decline. © The Author(s) 2019.","Assessment of cognitive disorders/dementia; Cognitive aging; Executive function; Neuropsychological assessment; Parasomnias","Aged; Case-Control Studies; Cognition Disorders; Electroencephalography; Executive Function; Female; Humans; Male; Mental Status and Dementia Tests; Polysomnography; Prodromal Symptoms; REM Sleep Behavior Disorder; Retrospective Studies; aged; case control study; cognitive defect; complication; dementia assessment; electroencephalography; executive function; female; human; male; parasomnia; polysomnography; prodromal symptom; psychology; retrospective study","Alves L., Cardoso S., Maroco J., De Mendonca A., Guerreiro M., Silva D., Neuropsychological predictors of long-term (10 years) mild cognitive impairment stability, Journal of Alzheimer's Disease, 62, 4, pp. 1703-1711, (2018); International Classification of Sleep Disorders (3rd Ed.), (2014); Braak H., Ghebremedhin E., Rub U., Bratzke H., Del Tredici K., Stages in the development of Parkinson's disease-related pathology, Cell and Tissue Research, 318, 1, pp. 121-134, (2004); Caffarra P., Gardini S., Dieci F., Copelli S., Maset L., Concari L., Et al., The qualitative scoring MMSE pentagon test (QSPT): A new method for differentiating dementia with Lewy body from Alzheimer's disease, Behavioural Neurology, 27, 2, pp. 213-220, (2013); Cagnin A., Busse C., Jelcic N., Gnoato F., Mitolo M., Caffarra P., High specificity of MMSE pentagon scoring for diagnosis of prodromal dementia with Lewy bodies, Parkinsonism & Related Disorders, 21, 3, pp. 303-305, (2015); Edmonds E.C., Delano-Wood L., Galasko D.R., Salmon D.P., Bondi M.W., Subtle cognitive decline and biomarker staging in preclinical Alzheimer's disease, Journal of Alzheimer's Disease, 47, 1, pp. 231-242, (2015); Ferini-Strambi L., Marelli S., Galbiati A., Rinaldi F., Giora E., REM sleep behavior disorder (RBD) as a marker of neurodegenerative disorders, Archives Italiennes de Biologie, 152, 2-3, pp. 129-146, (2014); Gagnon J.F., Vendette M., Postuma R.B., Desjardins C., Massicotte-Marquez J., Panisset M., Et al., Mild cognitive impairment in rapid eyemovement sleep behavior disorder and Parkinson's disease, Annals of Neurology, 66, 1, pp. 39-47, (2009); Galbiati A., Verga L., Giora E., Zucconi M., Ferini-Strambi L., The risk of neurodegeneration in REM sleep behavior disorder: A systematic review and meta-analysis of longitudinal studies, Sleep Medicine Reviews, 43, pp. 37-46, (2019); Genier Marchand D., Montplaisir J., Postuma R.B., Rahayel S., Gagnon J.F., Detecting the cognitive prodrome of dementia with Lewy bodies: A prospective study of REM sleep behavior disorder, Sleep, 40, 1, (2016); Genier Marchand D., Postuma R.B., Escudier F., De Roy J., Pelletier A., Montplaisir J., Et al., How does dementia with Lewy bodies start? Prodromal cognitive changes in REM sleep behavior disorder, Annals of Neurology, 83, 5, pp. 1016-1026, (2018); Geraedts V.J., Boon L.I., Marinus J., Gouw A.A., Van Hilten J.J., Stam C.J., Et al., Clinical correlates of quantitative EEG in Parkinson disease: A systematic review, Neurology, 91, 19, pp. 871-883, (2018); Gouw A.A., Alsema A.M., Tijms B.M., Borta A., Scheltens P., Stam C.J., Et al., EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects, Neurobiology of Aging, 57, pp. 133-142, (2017); Heller J., Brcina N., Dogan I., Holtbernd F., Romanzetti S., Schulz J.B., Et al., Brain imaging findings in idiopathic REM sleep behavior disorder (RBD)-A systematic review on potential biomarkers for neurodegeneration, Sleep Medicine Reviews, 34, pp. 23-33, (2017); Hogl B., Stefani A., Videnovic A., Idiopathic REM sleep behaviour disorder and neurodegeneration-An update, Nature Reviews Neurology, 14, 1, (2018); Iranzo A., Isetta V., Molinuevo J.L., Serradell M., Navajas D., Farre R., Et al., Electroencephalographic slowing heralds mild cognitive impairment in idiopathic REM sleep behavior disorder, Sleep Medicine, 11, 6, pp. 534-539, (2010); Iranzo A., Santamaria J., Tolosa E., Idiopathic rapid eye movement sleep behaviour disorder: Diagnosis, management, and the need for neuroprotective interventions, The Lancet Neurology, 15, 4, pp. 405-419, (2016); Kondo D., Ota K., Kasanuki K., Fujishiro H., Chiba Y., Murayama N., Et al., Characteristics of mild cognitive impairment tending to convert into Alzheimer's disease or dementia with Lewy bodies: A follow-up study in a memory clinic, Journal of the Neurological Sciences, 369, pp. 102-108, (2016); Massicotte-Marquez J., Carrier J., Decary A., Mathieu A., Vendette M., Petit D., Et al., Slow-wave sleep and delta power in rapid eye movement sleep behavior disorder, Annals of Neurology, 57, 2, pp. 277-282, (2005); Mitolo M., Salmon D.P., Gardini S., Galasko D., Grossi E., Caffarra P., The new qualitative scoring MMSE pentagon test (QSPT) as a valid screening tool between autopsy-confirmed dementia with Lewy bodies and Alzheimer's disease, Journal of Alzheimer's Disease, 39, 4, pp. 823-832, (2014); Monastero R., Cicero C.E., Baschi R., Davi M., Luca A., Restivo V., Et al., Mild cognitive impairment in Parkinson's disease: The Parkinson's disease cognitive study (PACOS), Journal of Neurology, 265, 5, pp. 1050-1058, (2018); Petersen R.C., Caracciolo B., Brayne C., Gauthier S., Jelic V., Fratiglioni L., Mild cognitive impairment: A concept in evolution, Journal of Internal Medicine, 275, 3, pp. 214-228, (2014); Petersen R.C., Lopez O., Armstrong M.J., Getchius T.S., Ganguli M., Gloss D., Et al., Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology, Neurology, 90, 3, pp. 126-135, (2018); Quade D., Rank analysis of covariance, Journal of the American Statistical Association, 62, 320, pp. 1187-1200, (1967); Rahayel S., Postuma R.B., Montplaisir J., Marchand D.G., Escudier F., Gaubert M., Et al., Cortical and subcortical gray matter bases of cognitive deficits in REM sleep behavior disorder, Neurology, 90, 20, pp. e1759-e1770, (2018); Rodrigues Brazete J.R., Gagnon J.F., Postuma R.B., Bertrand J.A., Petit D., Montplaisir J., Electroencephalogram slowing predicts neurodegeneration in rapid eye movement sleep behavior disorder, Neurobiology of Aging, 37, pp. 74-81, (2016); Sasai T., Matsuura M., Inoue Y., Electroencephalographic findings related with mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder, Sleep, 36, 12, pp. 1893-1899, (2013); Schinka J.A., Loewenstein D.A., Raj A., Schoenberg M.R., Banko J.L., Potter H., Et al., Defining mild cognitive impairment: Impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates, The American Journal of Geriatric Psychiatry, 18, 8, pp. 684-691, (2010); Terzaghi M., Zucchella C., Rustioni V., Sinforiani E., Manni R., Cognitive performances and mild cognitive impairment in idiopathic rapid eye movement sleep behavior disorder: Results of a longitudinal follow-up study, Sleep, 36, 10, pp. 1527-1532, (2013); Zhang J.R., Chen J., Yang Z.J., Zhang H.J., Fu Y.T., Shen Y., Et al., Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in Parkinson's disease, Chinese Medical Journal, 129, 4, pp. 379-385, (2016)","2-s2.0-85074742681"
"Cerami C.; Dodich A.; Lettieri G.; Iannaccone S.; Magnani G.; Marcone A.; Gianolli L.; Cappa S.F.; Perani D.","Cerami, Chiara (25722905400); Dodich, Alessandra (56001713900); Lettieri, Giada (56680972900); Iannaccone, Sandro (7005943171); Magnani, Giuseppe (24496141800); Marcone, Alessandra (6701496511); Gianolli, Luigi (6602754456); Cappa, Stefano F. (7005836132); Perani, Daniela (7005630261)","25722905400; 56001713900; 56680972900; 7005943171; 24496141800; 6701496511; 6602754456; 7005836132; 7005630261","Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia","2016","Cortex","83","","","101","112","11","52","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84982187234&doi=10.1016%2fj.cortex.2016.07.008&partnerID=40&md5=cd04a50bd9e153af4802094c2d41afb6","Background The diagnosis of probable behavioral variant of fronto-temporal dementia (bvFTD) according to current criteria requires the imaging evidence of frontal and/or anterior temporal atrophy or hypoperfusion/hypometabolism. Different variants of this pattern of brain involvement may, however, be found in individual cases, supporting the presence of heterogeneous phenotypes. Objective We examined in a case-by-case approach the FDG-PET metabolic patterns of patients fulfilling clinical criteria for probable bvFTD, assessing the presence and frequency of specific FDG-PET features. Materials and methods Fifty two FDG-PET scans of probable bvFTD patients were retrospectively analyzed together with clinical and neuropsychological data. Neuroimaging experts rated the FDG-PET hypometabolism maps obtained at the single-subject level with optimized voxel-based Statistical Parametric Mapping (SPM). The functional metabolic heterogeneity was further tested by hierarchical cluster analysis and principal component analysis (PCA). Results Both the SPM maps and cluster analysis identified two major variants of cerebral hypometabolism, namely the “frontal” and the “temporo-limbic”, which were correlated with different cognitive profiles. Executive and language deficits were the cognitive hallmark in the “frontal” subgroup, while poor encoding and recall on long-term memory tasks was typical of the “temporo-limbic” subgroup. Discussion SPM single-subject analysis indicates distinct patterns of brain dysfunction in bvFTD, coupled with specific clinical features, suggesting different profiles of neurodegenerative vulnerability. These findings have important implications for the early diagnosis of bvFTD and for the application of the recent international consensus criteria. © 2016 Elsevier Ltd","Behavioral variant of fronto-temporal dementia; FDG positron emission tomography; Frontal variant of fronto-temporal dementia; Temporal variant of fronto-temporal dementia","Brain; Cognition; Executive Function; Fluorodeoxyglucose F18; Frontotemporal Dementia; Humans; Language; Male; Memory, Long-Term; Neuropsychological Tests; Positron-Emission Tomography; fluorodeoxyglucose f 18; fluorodeoxyglucose f 18; adult; aged; amyotrophic lateral sclerosis; Article; behavior; brain mapping; Clinical Dementia Rating; cluster analysis; disease duration; female; follow up; frontal variant frontotemporal dementia; human; long term memory; major clinical study; male; medical history; mental patient; Mini Mental State Examination; neuroimaging; neuropsychology; nuclear magnetic resonance imaging; PET scanner; positron emission tomography; principal component analysis; recall; retrospective study; Rey auditory verbal learning test; Rey Osterrieth complex figure test; Stroop test; token test; Wisconsin Card Sorting Test; brain; cognition; diagnostic imaging; executive function; frontotemporal dementia; language; metabolism; neuropsychological test; physiology; positron emission tomography; procedures; psychology","Alberici A., Geroldi C., Cotelli M., Adorni A., Calabria M., Rossi G., Et al., The frontal behavioural inventory (Italian version) differentiates frontotemporal lobar degeneration variants from Alzheimer's disease, Neurological Sciences, 28, 2, pp. 80-86, (2007); Aleman-Gomez Y., Melie-Garcia L., Valdes-Hernandez P., IBASPM: Toolbox for automatic parcellation of brain structures, Presented at the 12th Annual Meeting of the Organization for Human Brain Mapping, June 11–15, 2006, Florence, Italy, 27, (2006); Bertoux M., de Souza L.C., Corlier F., Lamari F., Bottlaender M., Dubois B., Et al., Two distinct amnesic profiles in behavioral variant frontotemporal dementia, Biological Psychiatry, 75, 7, pp. 582-588, (2014); Bertoux M., de Souza L.C., O'Callaghan C., Greve A., Sarazin M., Dubois B., Et al., Social cognition deficits: The key to discriminate behavioral variant frontotemporal dementia from Alzheimer's disease Regardless of amnesia?, Journal of Alzheimer's Disease, 49, 4, pp. 1065-1074, (2015); Caffarra P., Vezzadini G., Dieci F., Zonato F., Venneri A., Modified card sorting test: Normative data, Journal of Clinical and Experimental Neuropsychology, 26, 2, pp. 246-250, (2004); Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurological Sciences, 34, 8, pp. 1267-1274, (2013); Cerami C., Cappa S.F., Integration of imaging in cortical dementia diagnosis, The neuropsychology of cortical dementia, (2015); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Et al., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimer's & Dementia, 10, 6, pp. 827-834, (2014); Cerami C., Dodich A., Iannaccone S., Marcone A., Lettieri G., Crespi C., Et al., Right limbic FDG-PET hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients, PLoS One, 10, 10, (2015); Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J., The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia, Neurology, 44, 12, pp. 2308-2314, (1994); Della Rosa P.A., Cerami C., Gallivanone F., Prestia A., Caroli A., Castiglioni I., Et al., A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia, Neuroinformatics, 12, 4, pp. 575-593, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Et al., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the story-based empathy task, Neurological Sciences, 36, 10, pp. 1907-1912, (2015); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Et al., Emotion recognition from facial expressions: A normative study of the Ekman 60-faces test in the Italian population, Neurological Sciences, 35, 7, pp. 1015-1021, (2014); Eslinger P.J., Moore P., Anderson C., Grossman M., Social cognition, executive functioning, and neuroimaging correlates of empathic deficits in frontotemporal dementia, The Journal of Neuropsychiatry and Clinical Neurosciences, 23, 1, pp. 74-82, (2011); Franceschi M., Anchisi D., Pelati O., Zuffi M., Matarrese M., Moresco R.M., Et al., Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration, Annals of Neurology, 57, 2, pp. 216-225, (2005); Frisoni G.B., Bocchetta M., Chetelat G., Rabinovici G.D., de Leon M.J., Kaye J., Et al., Imaging markers for Alzheimer disease: Which vs how, Neurology, 81, 5, pp. 487-500, (2013); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Et al., Classification of primary progressive aphasia and its variants, Neurology, 76, pp. 1006-1014, (2011); Grimmer T., Diehl J., Drzezga A., Forstl H., Kurz A., Region-specific decline of cerebral glucose metabolism in patients with frontotemporal dementia: A prospective 18F-FDG-PET study, Dementia and Geriatric Cognitive Disorders, 18, 1, pp. 32-36, (2004); Hornberger M., Geng J., Hodges J.R., Convergent grey and white matter evidence of orbitofrontal cortex changes related to disinhibition in behavioural variant frontotemporal dementia, Brain, 134, pp. 2502-2512, (2011); Hornberger M., Piguet O., Episodic memory in frontotemporal dementia: A critical review, Brain, 135, pp. 678-692, (2012); Hornberger M., Wong S., Tan R., Irish M., Piguet O., Kril J., Et al., In vivo and post-mortem memory circuit integrity in frontotemporal dementia and Alzheimer's disease, Brain, 135, pp. 3015-3025, (2012); Huey E.D., Goveia E.N., Paviol S., Pardini M., Krueger F., Zamboni G., Et al., Executive dysfunction in frontotemporal dementia and corticobasal syndrome, Neurology, 72, 5, pp. 453-459, (2009); Ibach B., Poljansky S., Marienhagen J., Sommer M., Manner P., Hajak G., Contrasting metabolic impairment in frontotemporal degeneration and early onset Alzheimer's disease, NeuroImage, 23, 2, pp. 739-743, (2004); Ibanez A., Manes F., Contextual social cognition and the behavioral variant of frontotemporal dementia, Neurology, 78, 17, pp. 1354-1362, (2012); Irish M., Devenney E., Wong S., Dobson-Stone C., Kwok J.B., Piguet O., Et al., Neural substrates of episodic memory dysfunction in behavioural variant frontotemporal dementia with and without C9ORF72 expansions, NeuroImage: Clinical, 2, pp. 836-843, (2013); Irish M., Piguet O., Hodges J.R., Hornberger M., Common and unique gray matter correlates of episodic memory dysfunction in frontotemporal dementia and Alzheimer's disease, Human Brain Mapping, 35, 4, pp. 1422-1435, (2014); Jacova C., Hsiung G.Y., Tawankanjanachot I., Dinelle K., McCormick S., Gonzalez M., Et al., Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers, Neurology, 81, pp. 1322-1331, (2013); Jeong Y., Cho S.S., Park J.M., Kang S.J., Lee J.S., Kang E., Et al., 18F-FDG PET findings in frontotemporal dementia: An SPM analysis of 29 patients, Journal of Nuclear Medicine, 46, 2, pp. 233-239, (2005); Josephs K.A., Whitwell J.L., Knopman D.S., Boeve B.F., Vemuri P., Senjem M.L., Et al., Two distinct subtypes of right temporal variant frontotemporal dementia, Neurology, 73, pp. 1443-1450, (2009); Josephs K.A., Whitwell J.L., Weigand S.D., Senjem M.L., Boeve B.F., Knopman D.S., Et al., Predicting functional decline in behavioural variant frontotemporal dementia, Brain, 134, pp. 432-448, (2011); Kerklaan B.J., van Berckel B.N., Herholz K., Dols A., van der Flier W.M., Scheltens P., Et al., The added value of 18-fluorodeoxyglucose-positron emission tomography in the diagnosis of the behavioral variant of frontotemporal dementia, American Journal of Alzheimer's Disease and Other Dementias, 29, 7, pp. 607-613, (2014); Kipps C.M., Davies R.R., Mitchell J., Kril J.J., Halliday G.M., Hodges J.R., Clinical significance of lobar atrophy in frontotemporal dementia: Application of an MRI visual rating scale, Dementia and Geriatric Cognitive Disorders, 23, pp. 334-342, (2007); Laisney M., Matuszewski V., Mezenge F., Belliard S., de la Sayette V., Eustache F., Et al., The underlying mechanisms of verbal fluency deficit in frontotemporal dementia and semantic dementia, Journal of Neurology, 256, 7, pp. 1083-1094, (2009); Lee G.J., Lu P.H., Mather M.J., Shapira J., Jimenez E., Leow A.D., Et al., Neuroanatomical correlates of emotional blunting in behavioral variant frontotemporal dementia and early-onset Alzheimer's disease, Journal of Alzheimer's Disease, 41, 3, pp. 793-800, (2014); Massimo L., Powers C., Moore P., Vesely L., Avants B., Gee J., Et al., Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration, Dementia and Geriatric Cognitive Disorders, 27, pp. 96-104, (2009); Morbelli S., Drzezga A., Perneczky R., Frisoni G.B., Caroli A., van Berckel B.N., Et al., Resting metabolic connectivity in prodromal Alzheimer's disease. A European Alzheimer Disease Consortium (EADC) project, Neurobiology of Aging, 33, 11, pp. 2533-2550, (2012); Nichols T., Brett M., Andersson J., Wager T., Poline J.B., Valid conjunction inference with the minimum statistic, NeuroImage, 25, 3, pp. 653-660, (2005); Perani D., Functional neuroimaging of cognition, Handbook of clinical Neurology, 88, pp. 61-111, (2008); Perani D., Cerami C., Caminiti S.P., Santangelo R., Coppi E., Ferrari L., Et al., Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting, European Journal of Nuclear Medicine and Molecular Imaging, 43, 3, pp. 499-508, (2016); Perani D., Della Rosa P.A., Cerami C., Gallivanone F., Fallanca F., Vanoli E.G., Et al., Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting, NeuroImage: Clinical, 6, pp. 445-454, (2014); Perani D., Schillaci O., Padovani A., Nobili F.M., Iaccarino L., Della Rosa P.A., Et al., A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis, Biomed Research International, (2014); Peters F., Perani D., Herholz K., Holthoff V., Beuthien-Baumann B., Sorbi S., Et al., Orbitofrontal dysfunction related to both apathy and disinhibition in frontotemporal dementia, Dementia and Geriatric Cognitive Disorders, 21, pp. 373-379, (2006); Piguet O., Halliday G.M., Reid W.G., Casey B., Carman R., Huang Y., Et al., Clinical phenotypes in autopsy-confirmed Pick disease, Neurology, 76, 3, pp. 253-259, (2011); Piguet O., Hornberger M., Mioshi E., Hodges J.R., Behavioural-variant frontotemporal dementia: Diagnosis, clinical staging, and management, Lancet Neurology, 10, 2, pp. 162-172, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Et al., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 134, 9, pp. 2456-2477, (2011); Rosen H.J., Allison S.C., Schauer G.F., Gorno-Tempini M.L., Weiner M.W., Miller B.L., Neuroanatomical correlates of behavioural disorders in dementia, Brain, 128, pp. 2612-2625, (2005); Salmon E., Garraux G., Delbeuck X., Collette F., Kalbe E., Zuendorf G., Et al., Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia, NeuroImage, 20, 1, pp. 435-440, (2003); Salmon E., Kerrouche N., Herholz K., Perani D., Holthoff V., Beuthien-Baumann B., Et al., Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia, NeuroImage, 30, 3, pp. 871-878, (2006); Schroeter M.L., Raczka K., Neumann J., von Cramon D.Y., Neural networks in frontotemporal dementia–A meta-analysis, Neurobiology of Aging, 29, 3, pp. 418-426, (2008); Schroeter M.L., Vogt B., Frisch S., Becker G., Seese A., Barthel H., Et al., Dissociating behavioral disorders in early dementia – An FDG-PET study, Psychiatry Research, 194, pp. 235-244, (2011); Seeley W.W., Crawford R., Rascovsky K., Kramer J.H., Weiner M., Miller B.L., Et al., Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia, Archives of Neurology, 65, pp. 249-255, (2008); Seeley W.W., Zhou J., Kim E.J., Frontotemporal dementia: What can the behavioral variant teach us about human brain organization?, The Neuroscientist, 18, 4, pp. 373-385, (2012); Serafin M., Surian L., Il Test degli Occhi: uno strumento per valutare la “teoria della mente”, Giornale italiano di psicologia, 31, pp. 839-862, (2004); Snowden J.S., Adams J., Harris J., Thompson J.C., Rollinson S., Richardson A., Et al., Distinct clinical and pathological phenotypes in frontotemporal dementia associated with MAPT, PGRN and C9orf72 mutations, Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, 16, 7-8, pp. 497-505, (2015); Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Et al., Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain, NeuroImage, 15, pp. 273-289, (2002); Varrone A., Asenbaum S., Vander Borght T., Booij J., Nobili F., Nagren K., Et al., European association of nuclear medicine neuroimaging committee. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2, European Journal of Nuclear Medicine and Molecular Imaging, 36, 12, pp. 2103-2110, (2009); Venturini R., Lombardo Radice M., Imperiali M.G., Il color-word test o test di Stroop, (1983); Warmus B.A., Sekar D.R., McCutchen E., Schellenberg G.D., Roberts R.C., McMahon L.L., Et al., Tau-mediated NMDA receptor impairment underlies dysfunction of a selectively vulnerable network in a mouse model of frontotemporal dementia, The Journal of Neuroscience, 34, 49, pp. 16482-16495, (2014); Whitwell J.L., Jack C.R., Parisi J.E., Knopman D.S., Boeve B.F., Petersen R.C., Et al., Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia, Journal of Molecular Neuroscience: MN, 45, 3, pp. 372-378, (2011); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Et al., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: A cluster analysis study, Brain, 132, pp. 2932-2946, (2009); Whitwell J.L., Weigand S.D., Boeve B.F., Senjem M.L., Gunter J.L., DeJesus-Hernandez M., Et al., Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics, Brain, 135, pp. 794-806, (2012); Whitwell J.L., Xu J., Mandrekar J., Boeve B.F., Knopman D.S., Parisi J.E., Et al., Frontal asymmetry in behavioral variant frontotemporal dementia: Clinicoimaging and pathogenetic correlates, Neurobiology of Aging, 34, 2, pp. 636-639, (2013); Zamboni G., Huey E.D., Krueger F., Nichelli P.F., Grafman J., Apathy and disinhibition in frontotemporal dementia: Insights into their neural correlates, Neurology, 71, pp. 736-742, (2008)","2-s2.0-84982187234"
"Galimberti D.; D'Addario C.; Dell'Osso B.; Fenoglio C.; Marcone A.; Cerami C.; Cappa S.F.; Palazzo M.C.; Arosio B.; Mari D.; MacCarrone M.; Bresolin N.; Altamura A.C.; Scarpini E.","Galimberti, Daniela (6701617660); D'Addario, Claudio (6505862291); Dell'Osso, Bernardo (13605549800); Fenoglio, Chiara (8661375900); Marcone, Alessandra (6701496511); Cerami, Chiara (25722905400); Cappa, Stefano F. (7005836132); Palazzo, M. Carlotta (36139731300); Arosio, Beatrice (6701903617); Mari, Daniela (57201756398); MacCarrone, Mauro (7004870192); Bresolin, Nereo (7005827082); Altamura, A. Carlo (6603834887); Scarpini, Elio (57210771033)","6701617660; 6505862291; 13605549800; 8661375900; 6701496511; 25722905400; 7005836132; 36139731300; 6701903617; 57201756398; 7004870192; 7005827082; 6603834887; 57210771033","Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration","2013","Neurological Sciences","34","6","","899","903","4","24","https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879114551&doi=10.1007%2fs10072-012-1151-5&partnerID=40&md5=f969fd7b4fd139c026de2be298d7927f","Mutations in progranulin gene (GRN) are the most common cause of autosomal dominant familial frontotemporal lobar degeneration (FTLD). In addition, GRN variability influences the risk to develop the disease in non-carriers (sporadic FTLD). We evaluated progranulin gene (GRN) promoter methylation levels in peripheral blood mononuclear cells isolated from 38 patients with sporadic FTLD compared with 38 controls, and correlate them with GRN mRNA expression rate. The percentage of methylation of the GRN promoter was increased in patients with FTLD compared with controls (61.5 vs. 46.3 %, P < 0.001). A trend towards decreased GRN relative expression was observed in patients compared with controls (threefold decrease over controls, P > 0.05), together with a negative correlation between the degree of GRN promoter methylation and mRNA GRN levels (ρ = -0.1, P > 0.05). GRN promoter methylation was not correlated with age. In conclusion, the degree of methylation of the GRN promoter is increased in patients with FTLD as compared with controls, likely leading to a decreased expression of GRN. © 2012 Springer-Verlag.","Expression; Frontotemporal lobar degeneration (FTLD); Methylation; Peripheral mononuclear cells (PBMC); Progranulin (GRN)","Adult; DNA Mutational Analysis; Female; Frontotemporal Lobar Degeneration; Humans; Intercellular Signaling Peptides and Proteins; Male; Methylation; Middle Aged; Mutation; Promoter Regions, Genetic; RNA, Messenger; messenger RNA; progranulin; age; aged; article; cell isolation; clinical article; controlled study; DNA methylation; female; frontotemporal dementia; gene expression; gene mutation; genetic association; GRN gene; human; male; peripheral blood mononuclear cell; promoter region; trend study","Boeve B., Hutton M., Refining frontotemporal dementia with Parkinsonism linked to chromosome 17: Introducing FTDP-17 (MAPT) and FTDP-17 (PGRN), Arch Neurol, 65, 4, pp. 460-464, (2008); Rademakers R., Eriksen J.L., Baker M., Robinson T., Ahmed Z., Lincoln S.J., Finch N., Rutherford N.J., Crook R.J., Josephs K.A., Boeve B.F., Knopman D.S., Petersen R.C., Parisi J.E., Caselli R.J., Wszolek Z.K., Uitti R.J., Feldman H., Hutton M.L., MacKenzie I.R., Graff-Radford N.R., Dickson D.W., Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP-43-positive frontotemporal dementia, Human Mol Genet, 17, 23, pp. 3631-3642, (2008); Rollinson S., Rohrer J.D., Van Der Zee J., Sleegers K., Mead S., Engelborghs S., Collinge J., De Deyn P.P., Mann D.M., Van Broeckhoven C., Pickering-Brown S.M., No association of PGRN 3′UTR rs5848 in frontotemporal lobar degeneration, Neurobiol Aging, 32, 4, pp. 754-755, (2011); Galimberti D., Fenoglio C., Cortini F., Serpente M., Venturelli E., Villa C., Clerici F., Marcone A., Benussi L., Ghidoni R., Gallone S., Scalabrini D., Restelli I., Martinelli Boneschi F., Cappa S., Binetti G., Mariani C., Rainero I., Giordana M.T., Bresolin N., Scarpini E., GRN variability contributes to sporadic frontotemporal lobar degeneration, J Alzheimers Dis, 19, 1, pp. 171-177, (2010); Bird A.P., CpG-rich islands and the function of DNA methylation, Nature, 321, pp. 209-213, (1996); Weber M., Hellmann I., Stadler M.B., Ramos L., Paabo S., Rebhan M., Schubeler D., Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome, Nat Genet, 39, 4, pp. 457-466, (2007); Herman J.G., Baylin S.B., Gene silencing in cancer in association with promoter hypermethylation, N Engl J Med, 349, pp. 2042-2054, (2003); Siegmund K.D., Connor C.M., Campan M., Long T.I., Weisenberger D.J., Biniszkiewicz D., Jaenisch R., Laird P.W., Akbarian S., DNA methylation in the human cerebral cortex is dynamically regulated throughout the life span and involves differentiated neurons, PLoS One, 2, 9, (2007); Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., Benson D.F., Frontotemporal lobar degeneration. A consensus on clinical diagnostic criteria, Neurology, 51, pp. 1546-1554, (2008); McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q., Clinical and pathological diagnosis of frontotemporal dementia, Arch Neurol, 58, pp. 1803-1809, (2001); Villa C., Ghezzi L., Pietroboni A.M., Fenoglio C., Cortini F., Serpente M., Cantoni C., Ridolfi E., Marcone A., Benussi L., Ghidoni R., Jacini F., Arighi A., Fumagalli G.G., Mandelli A., Binetti G., Cappa S., Bresolin N., Scarpini E., Galimberti D., A novel MAPT mutation associated with the clinical phenotype of progressive nonfluent aphasia, J Alzheimers Dis, 26, pp. 19-26, (2011); Carecchio M., Fenoglio C., Cortini F., Comi C., Benussi L., Ghidoni R., Borroni B., De Riz M., Serpente M., Cantoni C., Franceschi M., Albertini V., Monaco F., Rainero I., Binetti G., Padovani A., Bresolin N., Scarpini E., Galimberti D., Cerebrospinal fluid biomarkers in progranulin mutations carriers, J Alzheimers Dis, 27, 4, pp. 781-790, (2011); Pietroboni A.M., Fumagalli G.G., Ghezzi L., Fenoglio C., Cortini F., Serpente M., Cantoni C., Rotondo E., Corti P., Carecchio M., Bassi M., Bresolin N., Galbiati D., Galimberti D., Scarpini E., Phenotypic Heterogeneity of the GRN Asp22fs Mutation in a large Italian kindred, J Alzheimers Dis, 24, 2, pp. 253-259, (2011); Venturelli E., Villa C., Fenoglio C., Clerici F., Marcone A., Benussi L., Ghidoni R., Gallone S., Cortini F., Serpente M., Cantoni C., Fumagalli G., Ridolfi E., Cappa S., Binetti G., Franceschi M., Rainero I., Giordana M.T., Mariani C., Bresolin N., Scarpini E., Galimberti D., BAG1 is a protective factor for sporadic frontotemporal lobar degeneration but not for Alzheimer's disease, J Alzheimers Dis, 23, 4, pp. 701-707, (2011); Dejesus-Hernandez M., MacKenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., Kouri N., Wojtas A., Sengdy P., Hsiung G.Y., Karydas A., Seeley W.W., Josephs K.A., Coppola G., Geschwind D.H., Wszolek Z.K., Feldman H., Knopman D.S., Petersen R.C., Miller B.L., Dickson D.W., Boylan K.B., Graff-Radford N.R., Rademakers R., Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS, Neuron, 72, pp. 245-256, (2011); Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., Van Swieten J.C., Myllykangas L., Kalimo H., Paetau A., Abramzon Y., Remes A.M., Kaganovich A., Scholz S.W., Duckworth J., Ding J., Harmer D.W., Hernandez D.G., Johnson J.O., Mok K., Ryten M., Trabzuni D., Guerreiro R.J., Orrell R.W., Neal J., Murray A., Pearson J., Jansen I.E., Sondervan D., Seelaar H., Blake D., Young K., Halliwell N., Callister J.B., Toulson G., Richardson A., Gerhard A., Snowden J., Mann D., Neary D., Nalls M.A., Peuralinna T., Jansson L., Isoviita V.M., Kaivorinne A.L., Holtta-Vuori M., Ikonen E., Sulkava R., Benatar M., Wuu J., Chio A., Restagno G., Borghero G., Sabatelli M., Heckerman D., Rogaeva E., Zinman L., Rothstein J.D., Sendtner M., Drepper C., Eichler E.E., Alkan C., Abdullaev Z., Pack S.D., Dutra A., Pak E., Hardy J., Singleton A., Williams N.M., Heutink P., Pickering-Brown S., Morris H.R., Tienari P.J., Traynor B.J., A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD, Neuron, 72, pp. 257-268, (2011); Livak K.J., Schmittgen T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method, Methods, 25, pp. 402-408, (2001); Lu L., Katsaros D., De La Longrais I.A., Sochirca O., Yu H., Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis, Cancer Res, 67, 21, pp. 10117-10122, (2007); Gomez-Hernandez A., Sanchez-Galan E., Martin-Ventura J.L., Vidal C., Blanco-Colio L.M., Ortego M., Vega M., Serrano J., Ortega L., Hernandez G., Tunon J., Egido J., Atorvastatin reduces the expression of prostaglandin e2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization, J Cardiovasc Pharmacol, 47, pp. 60-69, (2006); Serpente M., Fenoglio C., Villa C., Cortini F., Cantoni C., Ridolfi E., Clerici F., Marcone A., Benussi L., Ghidoni R., Martinelli Boneschi F., Gallone S., Cappa S., Binetti G., Franceschi M., Rainero I., Giordana M.T., Mariani C., Bresolin N., Scarpini E., Galimberti D., Role of OLR1 and its regulating hsa-miR369-3p in Alzheimer's disease: Genetics and expression analysis, J Alzheimers Dis, 26, 4, pp. 787-793, (2011); Fenoglio C., Galimberti D., Cortini F., Kauwe J.S., Cruchaga C., Venturelli E., Villa C., Serpente M., Scalabrini D., Mayo K., Piccio L.M., Clerici F., Albani D., Mariani C., Forloni G., Bresolin N., Goate A.M., Scarpini E., S5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer's disease, J Alzheimers Dis, 18, pp. 603-612, (2009); Ghidoni R., Benussi L., Glionna M., Franzoni M., Binetti G., Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration, Neurology, 71, 16, pp. 1235-1239, (2008); Carecchio M., Fenoglio C., De Riz M., Guidi I., Comi C., Cortini F., Venturelli E., Restelli I., Cantoni C., Bresolin N., Monaco F., Scarpini E., Galimberti D., Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic mild cognitive impairment converted to Alzheimer's disease, J Neurol Sci, 287, 1-2, pp. 291-293, (2009); Fraga M.F., Esteller M., Epigenetics and aging: The targets and the marks, Trends Genet, 23, pp. 413-418, (2007); Zhang F.F., Cardarelli R., Carroll J., Fulda K.G., Kaur M., Gonzalez K., Vishwanatha J.K., Santella R.M., Morabia A., Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood, Epigenetics, 6, 5, pp. 623-629, (2011)","2-s2.0-84879114551"
"Dodich A.; Crespi C.; Santi G.C.; Luzzi S.; Ranaldi V.; Iannaccone S.; Marcone A.; Zamboni M.; Cappa S.F.; Cerami C.","Dodich, Alessandra (56001713900); Crespi, Chiara (57034303800); Santi, Gaia C. (57217289456); Luzzi, Simona (56264790400); Ranaldi, Valentina (56730976600); Iannaccone, Sandro (7005943171); Marcone, Alessandra (6701496511); Zamboni, Michele (36777386200); Cappa, Stefano F. (7005836132); Cerami, Chiara (25722905400)","56001713900; 57034303800; 57217289456; 56264790400; 56730976600; 7005943171; 6701496511; 36777386200; 7005836132; 25722905400","Diagnostic Accuracy of Affective Social Tasks in the Clinical Classification between the Behavioral Variant of Frontotemporal Dementia and Other Neurodegenerative Disease","2021","Journal of Alzheimer's Disease","80","4","","1401","1411","10","10","https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105069358&doi=10.3233%2fJAD-201210&partnerID=40&md5=d6de5fac500e04555e3e55c03a545d69","Background: Severe socio-emotional impairments characterize the behavioral variant of frontotemporal dementia (bvFTD). However, literature reports social cognition disorders in other dementias. Objective: In this study, we investigated the accuracy of social cognition performances in the early and differential diagnosis of bvFTD. Methods: We included 131 subjects: 32 bvFTD, 26 Alzheimer's disease (AD), 16 primary progressive aphasia (PPA), 17 corticobasal syndrome (CBS), and 40 healthy control (HC). Each subject completed the Ekman 60 faces (Ek-60F) test assessing basic emotion recognition and the Story-based Empathy Task (SET) assessing attribution of intentions/emotions. A combined social measure (i.e., Emotion Recognition and Attribution (ERA) index) was calculated. One-way ANOVA has been used to compare performances among groups, while receiver operating characteristic (ROC) curve tested measures ability to distinguish subjects with and without bvFTD. Results: Ek-60F and ERA index scores were significantly lower in bvFTD versus HC, AD, and PPA groups. ROC analyses significantly distinguished bvFTD from HC (AUC 0.82-0.92), with the Ek-60F test showing the highest performance, followed by the ERA index. These two social measures showed the best accuracy in detecting bvFTD from AD (AUC 0.78-0.74) and PPA (AUC 0.80-0.76). Investigated measures failed in detecting bvFTD from CBS. Conclusion: Accuracy analyses support the advantage of using social cognition tests for bvFTD diagnosis. Short social battery may reduce uncertainties and improve disease identification in clinical settings. We recommend a revision of current clinical criteria considering neuropsychological deficits in emotion recognition and processing tasks as key cognitive markers of this neurodegenerative syndrome.  © 2021 - IOS Press. All rights reserved.","Accuracy; behavioral variant of frontotemporal dementia; cognitive marker; diagnosis; emotion recognition; empathy; frontotemporal dementia; social cognition","Aged; Aged, 80 and over; Alzheimer Disease; Aphasia, Primary Progressive; Basal Ganglia Diseases; Case-Control Studies; Cerebral Cortex; Diagnosis, Differential; Emotions; Female; Frontotemporal Dementia; Humans; Male; Middle Aged; Neuropsychological Tests; ROC Curve; Social Skills; aged; Alzheimer disease; anger; Article; clinical classification; cognition; cognition assessment; controlled study; corticobasal degeneration; degenerative disease; dementia assessment; diagnostic accuracy; diagnostic test accuracy study; differential diagnosis; disease duration; disgust; early diagnosis; Ek-60F; emotion; Eotion Recognition and Attribution Index; executive function; facial expression; fear; female; follow up; frontal variant frontotemporal dementia; happiness; human; major clinical study; male; Mini Mental State Examination; neuroimaging; neuropsychological test; nuclear magnetic resonance imaging; patient; positron emission tomography; primary progressive aphasia; priority journal; sadness; social cognition; Story-based Empathy Task; task performance; Youden index; brain cortex; case control study; emotion; extrapyramidal syndrome; frontotemporal dementia; middle aged; pathology; psychology; receiver operating characteristic; social competence; very elderly","Cerami C., Cappa S.F., The behavioral variant of frontotemporal dementia: Linking neuropathology to social cognition, Neurol Sci, 8, pp. 1267-1274, (2013); Piguet O., Kumfor F., Frontotemporal dementias: Main syndromes and underlying brain changes, Curr Opin Neurol, 2, pp. 215-221, (2020); Seeley W.W., Selective functional, regional, and neuronal vulnerability in frontotemporal dementia, Curr Opin Neurol, 6, pp. 701-707, (2008); Bertoux M., Cruz De Souza L., Sarazin M., Funkiewiez A., Dubois B., Hornberger M., How preserved is emotion recognition in Alzheimer's disease compared with behave ioral variant of frontotemporal dementia?, Alzheimer Dis Assoc Dis, 2, pp. 154-157, (2015); Goodkind M.S., Sturm V.E., Ascher E.A., Shdo S.M., Miller B.L., Rankin K.P., Levenson R.W., Emotion recognition in frontotemporal dementia and Alzheimer's disease:Anew film-based assessment, Emotion, 4, pp. 416-427, (2015); Brioschi Guevara A., Knutson K.M., Wassermann E.M., Pulaski E.M., Grafman J., Krueger F., Theory of mind impairment in patients with behavioural variant frontotemporal dementia (bv-FTD) increases caregiver burden, Age Ageing, 5, pp. 891-895, (2015); Bora E., Walterfang M., Velakoulis D., Theory of mind in behavioural-variant frontotemporal dementia and Alzheimer's disease: A meta-analysis, J Neurol Neurosurg Psychiatry, 7, pp. 714-719, (2015); Carr A.R., Mendez M.F., Affective empathy in behavioral variant frontotemporal dementia: A meta-analysis, Front Neurol, 9, (2018); Baez S., Manes F., Huepe D., Torralva T., Fiorentino N., Richter F., Huepe-Artigas D., Ferrari J., Montanes P., Reyes P., Matallana D., Vigliecca N.S., Decety J., Ibanez A., Primary empathy deficits in frontotemporal dementia, Front Aging Neurosci, 6, (2014); Manes F., Torralva T., Ibanez A., Roca M., Bekinschtein T., Gleichgerrcht E., Decision-making in frontotemporal dementia: Clinical, theoretical and legal implications, Dement Geriatr Cogn Disord, 1, pp. 11-17, (2011); Rascovsky K., Hodges J.R., Knopman D., Mendez M.F., Kramer J.H., Neuhaus J., Van Swieten J.C., Seelaar H., Dopper E.G., Onyike C.U., Hillis A.E., Josephs K.A., Boeve B.F., Kertesz A., Seeley W.W., Rankin K.P., Johnson J.K., Gorno-Tempini M.L., Rosen H., Prioleau-Latham C.E., Lee A., Kipps C.M., Lillo P., Piguet O., Rohrer J.D., Rossor M.N., Warren J.D., Fox N.C., Galasko D., Salmon D.P., Black S.E., Mesulam M., Weintraub S., Dickerson B.C., Diehl-Schmid J., Pasquier F., Deramecourt V., Lebert F., Pijnenburg Y., Chow T.W., Manes F., Grafman J., Cappa S.F., Freedman M., Grossman M., Miller B.L., Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia, Brain, 9, pp. 2456-2477, (2011); Dodich A., Crespi C., Santi G.C., Cappa S.F., Cerami C., Evaluation of discriminative and early detection abilities of social cognition measures for the diagnosis of the behavioral variant of frontotemporal dementia: A systematic review, Neuropsychol Rev, (2020); Dodich A., Cerami C., Crespi C., Canessa N., Lettieri G., Iannaccone S., Marcone A., Cappa S.F., Cacioppo J.T., Differential impairment of cognitive and affective mentalizing abilities in neurodegenerative dementias: Evidence from behavioral variant of frontotemporal dementia, Alzheimer's disease, and mild cognitive impairment, J Alzheimers Dis, 4, pp. 1011-1022, (2016); Diehl-Schmid J., Pohl C., Ruprecht C., Wagenpfeil S., Foerstl H., Kurz A., The Ekman 60 Faces Test as a diagnostic instrument in frontotemporal dementia, Arch Clin Neuropsychol, 4, pp. 459-464, (2007); Ferretti V., Papaleo F., Understanding others: Emotion recognition in humans and other animals, Genes Brain Behav, 1, (2019); De Vignemont F., Singer T., The empathic brain: How, when and why?, Trends Cogn Sci, 10, pp. 435-441, (2006); Schroeter M.L., Laird A.R., Chwiesko C., Deuschl C., Schneider E., Bzdok D., Eickhoff S.B., Neumann J., Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses: The case of behavioral variant frontotemporal dementia, Cortex, 57, pp. 22-37, (2014); Kumfor F., Piguet O., Disturbance of emotion processing in frontotemporal dementia: A synthesis of cognitive and neuroimaging findings, Neuropsychol Rev, 3, pp. 280-297, (2012); Rankin K.P., Gorno-Tempini M.L., Allison S.C., Stanley C.M., Glenn S., Weiner M.W., Miller B.L., Structural anatomy of empathy in neurodegenerative disease, Brain, 11, pp. 2945-2956, (2006); Stietz J., Jauk E., Krach S., Kanske P., Dissociating empathy from perspective-taking: Evidence from intra-and inter-individual differences research, Front Psychiatry, 10, (2019); Hornberger M., Yew B., Gilardoni S., Mioshi E., Gleichgerrcht E., Manes F., Hodges J.R., Ventromedial-frontopolar prefrontal cortex atrophy correlates with insight loss in frontotemporal dementia and Alzheimer's disease, Hum Brain Mapp, 2, pp. 616-626, (2014); Bertoux M., De Souza L.C., O'Callaghan C., Greve A., Sarazin M., Dubois B., Hornberger M., Social cognition deficits: The key to discriminate behavioral variant frontotemporal dementia from Alzheimer's disease regardless of amnesia?, J Alzheimers Dis, 4, pp. 1065-1074, (2016); Cerami C., Dodich A., Lettieri G., Iannaccone S., Magnani G., Marcone A., Gianolli L., Cappa S.F., Perani D., Different FDG-PET metabolic patterns at single-subject level in the behavioral variant of fronto-temporal dementia, Cortex, 83, pp. 101-112, (2016); Whitwell J.L., Przybelski S.A., Weigand S.D., Ivnik R.J., Vemuri P., Gunter J.L., Senjem M.L., Shiung M.M., Boeve B.F., Knopman D.S., Parisi J.E., Dickson D.W., Petersen R.C., Jack C.R., Josephs K.A., Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia:Acluster analysis study, Brain, 11, pp. 2932-2946, (2009); Dodich A., Cerami C., Cappa S.F., Marcone A., Golzi V., Zamboni M., Giusti M.C., Iannaccone S., Combined socio-behavioral evaluation improves the differential diagnosis between the behavioral variant of frontotemporal dementia and Alzheimer's disease: In search of neuropsychological markers, J Alzheimers Dis, 2, pp. 761-772, (2018); Hutchinson A.D., Mathias J.L., Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: A meta-analytic review, J Neurol Neurosurg Psychiatry, 9, pp. 917-928, (2007); Bediou B., Ryff I., Mercier B., Milliery M., Henaff M., D'Amato T., Bonnefoy M., Vighetto A., Krolak-Salmon P., Impaired social cognition in mild Alzheimer disease, J Geriatr Psychiatry Neurol, 2, pp. 130-140, (2009); Rosen H.J., Wilson M.R., Schauer G.F., Allison S., Gorno-Tempini M.L., Pace-Sativsky C., Kramer J.H., Levenson R.W., Weiner M., Miller B.L., Neuroanatomical correlates of impaired recognition of emotion in dementia, Neuropsychologia, 3, pp. 365-373, (2006); Fittipaldi S., Ibanez A., Baez S., Manes F., Sedeno L., Garcia A.M., More than words: Social cognition across variants of primary progressive aphasia, Neurosci Biobehav Rev, 100, pp. 263-284, (2019); Kumfor F., Leyton C.E., Burrell J.R., Hodges J.R., Piguet O., Degradation of emotion processing ability in corticobasal syndrome and Alzheimer's disease, Brain, 11, pp. 3061-3072, (2014); Duval C., Bejanin A., Piolino P., Laisney M., De La Sayette V., Belliard S., Eustache F., Desgrandes B., Theory of mind impairments in patients with semantic dementia, Brain, 1, pp. 228-241, (2012); Couto B., Manes F., Montanes P., Matallana D., Reyer P., Velasquez M., Yoris A., Baez S., Inanez A., Structural neuroimaging of social cognition in progressive non-fluent aphasia and behavioral variant of frontotemporal dementia, Front Hum Neurosci, 7, (2013); Cerami C., Dodich A., Iannaccone S., Marcone A., Lettieri G., Crespi C., Gianolli L., Cappa S.F., Perani D., Right limbic FDG-PET hypometabolism correlates with emotion recognition and attribution in probable behavioral variant of frontotemporal dementia patients, PLoS One, 10, (2015); Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 3, pp. 270-299, (2011); McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H., The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease, Alzheimers Dement, 3, pp. 263-269, (2011); Gorno-Tempini M.L., Hillis A.E., Weintraub S., Kertesz A., Mendez M., Cappa S.F., Ogar J.M., Rohrer J.D., Black S., Boeve B.F., Manes F., Dronkers N.F., Vandenberghe R., Rascovsky K., Patterson K., Miller B.L., Knopman D.S., Hodges J.R., Mesulam M.M., Grossman M., Classification of primary progressive aphasia and its variants, Neurology, 11, pp. 1006-1014, (2011); Armstrong M.J., Litvan I., Lang A.E., Bak T.H., Bhatia K.P., Borroni B., Boxer A.L., Dickson D.W., Grossman M., Hallett M., Josephs K.A., Kertesz A., Lee S.E., Miller B.L., Reich S.G., Riley D.E., Tolosa E., Troster A.I., Vidailhet M., Weiner W.J., Criteria for the diagnosis of corticobasal degeneration, Neurology, 5, pp. 496-503, (2013); Dodich A., Cerami C., Canessa N., Crespi C., Marcone A., Arpone M., Realmuto S., Cappa D.F., Emotion recognition from facial expressions: A normative study of the Ekman 60-Faces Test in the Italian population, Neurol Sci, 7, pp. 1015-1021, (2014); Dodich A., Cerami C., Canessa N., Crespi C., Iannaccone S., Marcone A., Realmuto S., Lettieri G., Perani D., Cappa S.F., A novel task assessing intention and emotion attribution: Italian standardization and normative data of the Story-based Empathy Task, Neurol Sci, 10, pp. 1907-1912, (2015); Ekman P., Friesen W.V., Pictures of Facial Affect, (1976); Billeke P., Zamorano F., Cosmelli D., Aboitiz F., Oscillatory brain activity correlates with risk perception and predicts social decisions, Cereb Cortex, 12, pp. 2872-2883, (2013); Van Overwalle F., Baetens K., Understanding others' actions and goals by mirror and mentalizing systems: A meta-analysis, Neuroimage, 3, pp. 564-584, (2009); Le Bouc R., Lenfant P., Delbeuck X., Ravasi L., Lebert F., Semah F., Pasquier F., My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease, Brain, 10, pp. 3026-3038, (2012); Landin-Romero R., Kumfor F., Leyton C.E., Irish M., Hodges J.R., Piguet O., Disease-specific patterns of cortical and subcortical degeneration in a longitudinal study of Alzheimer's disease and behavioural-variant frontotemporal dementia, Neuroimage, 151, pp. 72-80, (2017); Henry J.D., Von Hippel W., Molenberghs P., Lee T., Sachdev P.S., Clinical assessment of social cognitive function in neurological disorders, Nat Rev Neurol, 1, pp. 28-39, (2016); Harciarek M., Cosentino S., Language executive function and social cognition in the diagnosis of frontotemporal dementia syndromes, Int Rev Psychiatry, 2, pp. 178-196, (2013); Cerami C., Dodich A., Canessa N., Crespi C., Marcone A., Cortese F., Chierchia G., Scola E., Falini A., Cappa S.F., Neural correlates of empathic impairment in the behavioral variant of frontotemporal dementia, Alzheimers Dement, 6, pp. 827-834, (2014); Caminiti S.P., Canessa N., Cerami C., Dodich A., Crespi C., Iannaccone S., Marcone A., Falini A., Cappa S.F., Affective mentalizing and brain activity at rest in the behavioral variant of frontotemporal dementia, Neuroimage Clin, 9, pp. 484-497, (2015); Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Pelagallo E., Santangelo R., Cappa S.F., Perani D., The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia, J Alzheimers Dis, 1, pp. 183-197, (2017); Adolphs R., Baron-Cohen S., Tranel D., Impaired recognition of social emotions following amygdala damage, J Cogn Neurosci, 8, pp. 1264-1274, (2002); Burrell J.R., Hodges J.R., Rowe J.B., Cognition in corticobasal syndrome and progressive supranuclear palsy: A review, Mov Disord, 5, pp. 684-693, (2014); Spinelli E.G., Mandelli M.L., Miller Z.A., Santos-Santos M.A., Wilson S.M., Agosta F., Grinberg L.T., Huang E.J., Trojanowski J.Q., Meyer M., Henry M.L., Comi G., Rabinovici G., Rosen H.J., Filippi M., Miller B.L., Seeley W.W., Gorno-Tempini M.L., Typical and atypical pathology in primary progressive aphasia variants, Ann Neurol, 3, pp. 430-443, (2017); Cerami C., Dodich A., Iannaccone S., Magnani G., Marcone A., Guglielmo P., Vanoli G., Cappa S.F., Perani D., Individual brain metabolic signatures in corticobasal syndrome, J Alzheimers Dis, 2, pp. 517-528, (2020); Pardini M., Huey E.D., Spina S., Kreisl W.C., Morbelli S., Wassermann E.M., Nobili F., Ghetti B., Grafman J., FDG-PET patterns associated with underlying pathology in corticobasal syndrome, Neurology, 10, pp. 1121-1135, (2019); Poletti M., Enrici I., Adenzato M., Cognitive and affective Theory of Mind in neurodegenerative diseases: Neuropsychological, neuroanatomical and neurochemical levels, Neurosci Biobehav Rev, 9, pp. 2147-2164, (2012)","2-s2.0-85105069358"
